Document:

EX-10.3

 Exhibit 10.3 

INVESTOR AGREEMENT 
 BY
AND BETWEEN 
 GENZYME CORPORATION 

AND 
 ALNYLAM
PHARMACEUTICALS, INC. 
 DATED AS OF FEBRUARY 27, 2014 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY
WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
	 1. Definitions
	  	 	1	  
		
	 2. Registration Rights
	  	 	9	  
	 2.1 Required Registration
	  	 	9	  
	 2.2 Company Registration
	  	 	10	  
	 2.3 Underwritten Required Registration Required; Priority in Underwritten Offering
	  	 	11	  
	 2.4 Priority in Required Registration
	  	 	12	  
	 2.5 Revocation of Required Registration
	  	 	13	  
	 2.6 Effective Required Registrations
	  	 	13	  
	 2.7 Continuous Effectiveness of Registration Statement
	  	 	13	  
	 2.8 Obligations of the Company
	  	 	14	  
	 2.9 Furnish Information
	  	 	17	  
	 2.10 Expenses
	  	 	17	  
	 2.11 Indemnification
	  	 	17	  
	 2.12 SEC Reports
	  	 	19	  
	 2.13 Assignment of Registration Rights
	  	 	20	  
		
	 3. Restrictions on Beneficial Ownership
	  	 	20	  
	 3.1 Standstill
	  	 	20	  
	 3.2 Company Agreements
	  	 	22	  
		
	 4. Restrictions on Dispositions
	  	 	24	  
	 4.1 Lock-Up
	  	 	24	  
	 4.2 Limitations Following Lock-Up Term
	  	 	25	  
	 4.3 Certain Tender Offers
	  	 	25	  
	 4.4 Offering Lock-Up
	  	 	26	  
		
	 5. Voting Agreement
	  	 	26	  
	 5.1 Voting of Securities
	  	 	26	  
	 5.2 Certain Extraordinary Matters
	  	 	28	  
		
	 6. Right of First Offer
	  	 	28	  
	 6.1 Right of First Offer
	  	 	28	  
	 6.2 Limitations
	  	 	28	  
	 6.3 Expiration
	  	 	30	  
		
	 7. Designated Director
	  	 	30	  
	 7.1 Designated Director
	  	 	30	  
	 7.2 Notice and Information Rights
	  	 	32	  
	 7.3 Freedom to Pursue Opportunities
	  	 	32	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 i 

					
	 8. Information Rights
	  	 	33	  
	 8.1 Information Rights
	  	 	33	  
	 8.2 Financial Information and Reporting
	  	 	33	  
	 8.3 Confidentiality
	  	 	33	  
		
	 9. Termination of Certain Rights and Obligations
	  	 	33	  
	 9.1 Termination of Registration Rights
	  	 	33	  
	 9.2 Termination of Standstill Agreement
	  	 	34	  
	 9.3 Termination of Restrictions on Dispositions
	  	 	34	  
	 9.4 Termination of Voting Agreement and Offering Lock-Up
	  	 	35	  
	 9.5 Termination of Right of First Offer
	  	 	35	  
	 9.6 Effect of Termination
	  	 	35	  
		
	 10. Miscellaneous
	  	 	36	  
	 10.1 Governing Law; Submission to Jurisdiction
	  	 	36	  
	 10.2 Waiver
	  	 	36	  
	 10.3 Notices
	  	 	36	  
	 10.4 Entire Agreement
	  	 	37	  
	 10.5 Amendments
	  	 	37	  
	 10.6 Headings; Nouns and Pronouns; Section References
	  	 	37	  
	 10.7 Severability
	  	 	37	  
	 10.8 Assignment
	  	 	37	  
	 10.9 Successors and Assigns
	  	 	37	  
	 10.10 Counterparts
	  	 	37	  
	 10.11 Third Party Beneficiaries
	  	 	37	  
	 10.12 No Strict Construction
	  	 	38	  
	 10.13 Remedies
	  	 	38	  
	 10.14 Specific Performance
	  	 	38	  
	 10.15 No Conflicting Agreements
	  	 	38	  
	 10.16 Rule 16b-3
	  	 	38	  
	 10.17[***]
	  	 	38	  

 Exhibit A – Form of Irrevocable Proxy 

Exhibit B – Notices 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 ii 

 INVESTOR AGREEMENT 

THIS INVESTOR AGREEMENT (this “Agreement”) is made as of February 27, 2014, by and among Genzyme Corporation
(“Investor”), a Massachusetts corporation with its principal place of business at 500 Kendall Street, Cambridge, MA 02142, and Alnylam Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal
place of business at 300 Third Street, Cambridge, MA 02142. 
 WHEREAS, the Stock Purchase Agreement, dated as of January 11, 2014, by
and between the Investor and the Company (the “Purchase Agreement”) provides for the issuance and sale by the Company to the Investor, and the purchase by the Investor, of a number of shares of the Company’s common stock, par
value $.01 per share (the “Common Stock”), equal to the Share Amount (as defined in the Purchase Agreement) (the “Purchased Shares”); and 

WHEREAS, as a condition to consummating the transactions contemplated by the Purchase Agreement, the Investor and the Company have agreed upon
certain rights and restrictions as set forth herein with respect to the Purchased Shares and other securities of the Company beneficially owned by the Investor and its Affiliates, and it is a condition to the closing under the Purchase Agreement
that this Agreement be executed and delivered by the Investor and the Company. 
 NOW, THEREFORE, in consideration of the premises and
mutual agreements hereinafter set forth, and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1. Definitions. As used in this Agreement, the following terms shall have the following meanings: 

(a) “Acquisition Proposal” shall have the meaning set forth in Section 3.1(c). 

(b) “Affiliate” shall mean, with respect to a Person, any other Person which controls, is controlled by or is under common
control with the applicable Person. For purposes of this definition, “control” shall mean: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to
vote for the election of directors, or otherwise having the power to control or direct the affairs of such Person; and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity
interest or the power to direct the management and policies of such non-corporate entities. 
 (c) “Affiliate Irrevocable
Proxy” shall have the meaning set forth in Section 5.1. 
 (d) “Agreement” shall have the meaning set forth in
the Preamble to this Agreement, including all Exhibits attached hereto. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  

 (e) “ALN-TTRsc” shall have the meaning set forth in the Master Agreement. 

(f) “beneficial owner,” “beneficially owns,” “beneficial ownership” and terms of similar
import used in this Agreement shall, with respect to a Person, have the meaning set forth in Rule 13d-3 under the Exchange Act (i) assuming the full conversion into, and exercise and exchange for, shares of Common Stock of all Common Stock
Equivalents beneficially owned by such Person and (ii) determined without regard for the number of days in which such Person has the right to acquire such beneficial ownership. 

(g) “Business Day” shall mean a day on which commercial banking institutions in New York, New York are open for business. 

(h) “Change of Control” shall mean, with respect to the Company, any of the following events: (i) any Person is or
becomes the beneficial owner (except that a Person shall be deemed to have beneficial ownership of all shares that any such Person has the right to acquire, whether such right which may be exercised immediately or only after the passage of time),
directly or indirectly, of a majority of the total voting power represented by all Shares of Then Outstanding Common Stock; (ii) the Company consolidates with or merges into another corporation or entity, or any corporation or entity
consolidates with or merges into the Company, other than (A) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by
remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) a majority of the combined voting power of the voting securities of the Company or such surviving entity or any parent thereof
outstanding immediately after such merger or consolidation, (B) a merger or consolidation which would result in a majority of the board of directors of the combined entity being comprised of members of the board of directors of the
pre-transaction Company and the chief executive officer of the combined entity being the chief executive officer of the pre-transaction Company, in each case immediately following the consummation of such merger or consolidation, or (C) a
merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person becomes the beneficial owner, directly or indirectly, of a majority of the total voting power of all Shares of Then
Outstanding Common Stock or (iii) the Company conveys, transfers or leases all or substantially all of its assets to any Person other than a wholly owned Affiliate of the Company. 

(i) “Clinical Study” shall have the meaning set forth in the Master Agreement. 

(j) “Closing Date” shall have the meaning set forth in the Purchase Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 2 

 (k) “Co-Co License Terms” shall mean the Co-Commercialization License and
Collaboration Terms attached to the Master Agreement as Appendix C. 
 (l) “Collaboration Agreement” shall mean the
Master Agreement, the Co-Co License Terms, the Global License Terms and the Regional License Terms. 
 (m) “Common Stock”
shall have the meaning set forth in the Preamble to this Agreement. 
 (n) “Common Stock Equivalents” shall mean any
options, warrants or other securities or rights convertible into or exercisable or exchangeable for, whether directly or following conversion into or exercise or exchange for other options, warrants or other securities or rights, shares of Common
Stock. 
 (o) “Company” shall have the meaning set forth in the Preamble to this Agreement. 

(p) “Demand Request” shall have the meaning set forth in Section 2.1. 

(q) “Designated Director” shall have the meaning set forth in Section 7.1. 

(r) “Dilutive Event” shall have the meaning set forth in Section 3.2(c). 

(s) “Director Information” shall have the meaning set forth in Section 7.2. 

(t) “Disposition” or “Dispose of” shall mean any (i) pledge, sale, contract to sell, sale of any option
or contract to purchase, purchase of any option or contract to sell, grant of any option, right or warrant for the sale of, or other disposition of or transfer of any shares of Common Stock, or any Common Stock Equivalents, including, without
limitation, any “short sale” or similar arrangement, or (ii) swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of shares of Common Stock,
whether any such swap or transaction is to be settled by delivery of securities, in cash or otherwise. 
 (u) “Election Notice
Date” shall have the meaning set forth in Section 3.2(c). 
 (v) “Excepted Compensatory Issuance” shall have
the meaning set forth in Section 6.2. 
 (w) “Excepted Transactional Issuance” shall have the meaning set forth in
Section 6.2. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 3 

 (x) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended,
and the rules and regulations of the SEC promulgated thereunder. 
 (y) “Exercise Period” shall have the meaning set forth
in Section 6.1. 
 (z) “Extraordinary Matter” shall have the meaning set forth in Section 5.2. 

(aa) “Filing Date” shall mean (i) with respect to any Registration Statement to be filed on Form S-1 (or any applicable
successor form), ninety (90) days after receipt by the Company of a Demand Request for such Registration Statement and (ii) with respect to any Registration Statement to be filed on Form S-3 (or any applicable successor form), thirty
(30) days after receipt by the Company of a Demand Request for such Registration Statement. 
 (bb) “Funds” shall have
the meaning set forth in Section 4.2. 
 (cc) “Global License Terms” shall mean the Global Product License and
Collaboration Terms attached to the Master Agreement as Appendix B. 
 (dd) “Global Licensed Product” shall have the
meaning set forth in the Master Agreement. 
 (ee) “Governmental Authority” shall mean any court, agency, authority,
department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or country or any supranational
organization of which any such country is a member. 
 (ff) “Holders” shall mean (but, in each case, only for so long as
such Person remains an Affiliate of the Investor) the Investor and any Permitted Transferee thereof, if any, in accordance with Section 2.13. 

(gg) “Initiating Holder” shall have the meaning set forth in Section 2.3. 

(hh) “Interference” shall have the meaning set forth in Section 2.6. 

(ii) “Investor” shall have the meaning set forth in the Preamble to this Agreement. 

(jj) “Irrevocable Proxy” shall have the meaning set forth in Section 5.1. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 4 

 (kk) “Law” or “Laws” shall mean all laws, statutes, rules,
regulations, orders, judgments, injunctions and/or ordinances of any Governmental Authority. 
 (ll) “License Terms” shall
mean the Regional License Terms, the Co-Co License Terms and the Global License Terms. 
 (mm) “Lock-Up Term” shall have the
meaning set forth in Section 4.1. 
 (nn) “Master Agreement” shall mean that certain Master Collaboration Agreement
between Investor and Company, dated as of January 11, 2014. 
 (oo) “Modified Clause” shall have the meaning set forth
in Section 10.7. 
 (pp) “New Securities” shall have the meaning set forth in Section 6.1. 

(qq) “Offer Notice” shall have the meaning set forth in Section 6.1. 

(rr) “Offeror” shall have the meaning set forth in Section 3.1(c). 

(ss) “Other Holders” shall mean any Person having rights to participate in a registration of the Company’s securities.

 (tt) “Ownership Threshold” shall have the meaning set forth in Section 7.1 

(uu) “Permitted Transferee” shall mean (i) a controlled Affiliate of the Investor that is wholly owned, directly or
indirectly, by the Investor, or (ii) a controlling Affiliate of the Investor (or any controlled Affiliate of such controlling Affiliate) that wholly owns, directly or indirectly, the Investor; it being understood that for purposes of this
definition “wholly owned” shall mean an Affiliate in which the Investor owns, directly or indirectly, at least ninety-nine percent (99%) of the outstanding capital stock of such Affiliate. 

(vv) “Person” shall mean any individual, limited liability company, partnership, firm, corporation, association, trust,
unincorporated organization, government or any department or agency thereof or other entity, as well as any syndicate or group that would be deemed to be a Person under Section 13(d)(3) of the Exchange Act. 

(ww) “Potential Standstill Term Expiration Date” shall have the meaning set forth in Section 3.2(c). 

(xx) “Prospectus” shall mean the prospectus forming a part of any Registration Statement, as supplemented by any and all
prospectus supplements and as amended by any and all amendments (including post-effective amendments) and including all material incorporated by reference or explicitly deemed to be incorporated by reference in such prospectus. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 5 

 (yy) “Purchase Agreement” shall have the meaning set forth in the Preamble to
this Agreement, and shall include all Exhibits attached thereto. 
 (zz) “Purchased Shares” shall have the meaning set forth
in the Preamble to this Agreement, and shall be adjusted for (i) any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization and (ii) any Common Stock issued as (or issuable upon the exercise of any
warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange or in replacement of, the Purchased Shares. 

(aaa) “Regional License Terms” shall mean the Regional Product License and Collaboration Terms attached to the Master
Agreement as Appendix A. 
 (bbb) “registers,” “registered,” and “registration”
refer to a registration effected by preparing and filing a Registration Statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such Registration Statement or document by the SEC. 

(ccc) “Registrable Securities” shall mean (i) the Purchased Shares, together with any shares of Common Stock issued in
respect thereof as a result of any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization and (ii) any Common Stock issued as (or issuable upon the exercise of any warrant, right or other security that is
issued as) a dividend or other distribution with respect to, or in exchange or in replacement of, the shares of Common Stock described in clause (i) of this definition, excluding in all cases, however, (A) any Registrable Securities if and
after they have been transferred to a Permitted Transferee in a transaction in connection with which registration rights granted hereunder are not assigned, or (B) any Registrable Securities sold to or through a broker or dealer or underwriter
in a public distribution or a public securities transaction. 
 (ddd) “Registration Expenses” shall mean all expenses
incurred by the Company in connection with any Required Registration pursuant to Section 2.1 or the Company’s compliance with Section 2.8, including, without limitation, all registration and filing fees, fees and expenses of
compliance with securities or blue sky Laws (including reasonable fees and disbursements of counsel in connection with blue sky qualifications of any Registrable Securities), expenses of printing (i) certificates for any Registrable Securities
in a form eligible for deposit with the Depository Trust Company or (ii) Prospectuses if the printing of Prospectuses is requested by Holders, messenger and delivery expenses, fees and disbursements of counsel for the Company and its
independent certified public accountants (including the expenses of any management review, cold comfort letters or any special audits required by or incident to such performance and compliance), Securities Act liability insurance (if the Company
elects to obtain such insurance), the reasonable fees and expenses of any special experts retained 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 6 

 
by the Company in connection with such registration, fees and expenses of other Persons retained by the Company and the reasonable fees and expenses of one (1) counsel for the Holders of
Registrable Securities in each Required Registration, selected by the Holders of a majority of the Registrable Securities to be included in such Required Registration. In addition, the Company will pay its internal expenses (including, without
limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Purchased Shares to be registered on
each securities exchange, if any, on which equity securities issued by the Company are then listed or the quotation of such securities on any national securities exchange on which equity securities issued by the Company are then quoted. 

(eee) “Registration Rights Term” shall have the meaning set forth in Section 2.1. 

(fff) “Registration Statement” shall mean any registration statement of the Company under the Securities Act that covers any
of the Registrable Securities pursuant to the provisions of this Agreement, including the related Prospectus, all amendments and supplements to such registration statement (including post-effective amendments), and all exhibits and all materials
incorporated by reference or explicitly deemed to be incorporated by reference in such Registration Statement. 
 (ggg) “Required
Period” with respect to a Required Registration shall mean the earlier of (i) the date on which all Registrable Securities covered by such Required Registration are sold pursuant thereto and (ii) one hundred twenty (120) days
following the first day of effectiveness of the Registration Statement for such Required Registration, in each case subject to extension as set forth herein; provided, however, that in no event will the Required Period expire prior to the expiration
of the applicable period referred to in Section 4(3) of the Securities Act and Rule 174 promulgated thereunder. 
 (hhh)
“Required Registration” shall have the meaning set forth in Section 2.1. 
 (iii) “Rights Plan” shall
have the meaning set forth in Section 3.2(a). 
 (jjj) “SEC” shall mean the United States Securities and Exchange
Commission. 
 (kkk) “Securities Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations of
the SEC promulgated thereunder. 
 (lll) “Selling Expenses” shall mean all underwriting discounts and selling commissions
applicable to the sale of Registrable Securities pursuant to this Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 7 

 (mmm) “Shares of Then Outstanding Common Stock” shall mean, at any time, the
issued and outstanding shares of Common Stock at such time, as well as all capital stock issued and outstanding as a result of any stock split, stock dividend, or reclassification of Common Stock distributable, on a pro rata basis, to all holders of
Common Stock. 
 (nnn) “Standstill Limit” shall mean thirty percent (30%) of the Shares of Then Outstanding Common
Stock. 
 (ooo) “Standstill Parties” shall have the meaning set forth in Section 3.1. 

(ppp) “Standstill Term” shall mean the period from and after the date of this Agreement until the earlier of (i) the
fifth (5th) anniversary of the earlier of (a) the expiration of the Term and (b) the termination of the Collaboration Agreement and (ii) the date on which (x) the beneficial ownership of the Investor and its Affiliates no
longer represents at least 5% of the Shares of Then Outstanding Common Stock and (y) Investor delivers a written notice to the Company electing to terminate Section 3.1 (provided, however, that if the Investor and its Affiliates acquire
beneficial ownership representing at least 5% of the Shares of Then Outstanding Common Stock at any time within one year after the beneficial ownership of the Investor and its Affiliates ceasing to represent at least 5% of the Shares of Then
Outstanding Common Stock, the Standstill Term shall be automatically reinstated). 
 (qqq) “Term” shall mean the period
beginning on the Closing Date and ending on the expiration of the last to expire of the Option Period (as defined in the Master Agreement) or any Royalty Term (as defined in any of the following License Terms) under the Regional License Terms, the
Co-Co License Terms or the Global License Terms. 
 (rrr) “Third Party” shall mean any Person other than the Investor, the
Company or any of their respective Affiliates. 
 (sss) “Underwritten Registration” or “Underwritten
Offering” shall mean a registration in which Registrable Securities are sold to an underwriter for reoffering to the public. 

(ttt) “Violation” shall have the meaning set forth in Section 2.11(a). 

(uuu) “Voting-Restricted Shares” shall mean all shares of Common Stock held by the Investor and its Affiliates; however, if
the shares of Common Stock held by the Investor and its Affiliates comprise or exceed twenty percent (20%) of the Shares of Then Outstanding Common Stock, the term “Voting-Restricted Shares” shall only apply to the number of shares of
Common Stock held by the Investor and its Affiliates that is equal to 19.99% of the Shares of Then Outstanding Common Stock. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 8 

	2.	Registration Rights. 

 2.1 Required Registration. If, at any time after the
expiration of the Lock-Up Term but no later than the tenth (10th) anniversary of such expiration (the “Registration Rights Term”), the Company receives from any Holder
or Holders a written request or requests (each, a “Demand Request”) that the Company file a Registration Statement under the Securities Act to effect the registration (a “Required Registration”) of Registrable
Securities, the Company shall use all reasonable efforts to file a Registration Statement covering such Holders’ Registrable Securities as soon as practicable (and by the applicable Filing Date) and shall use all reasonable efforts to, as soon
as practicable thereafter, effect the registration of the Registrable Securities to permit or facilitate the sale and distribution in an Underwritten Offering of all or such portion of such Holder’s or Holders’ Registrable Securities as
are specified in such Demand Request, subject however, to the conditions and limitations set forth herein; provided, however, that the Company shall not be obligated to effect any registration of Registrable Securities upon receipt of
a Demand Request pursuant to this Section 2.1 if: 
 (i) the Company has already completed three (3) Required
Registrations; 
 (ii) (A) in the event that the market value of all Registrable Securities outstanding is equal to or
greater than fifty million dollars ($50,000,000), the market value of the Registrable Securities proposed to be included in the registration, based on the average closing price during the ten (10) consecutive trading days period prior to the
making of the Demand Request, is less than fifty million dollars ($50,000,000) or (B) in the event that the market value of all Registrable Securities outstanding is less than fifty million dollars ($50,000,000), the market value of the
Registrable Securities proposed to be included in the registration, based on the average closing price during the ten (10) consecutive trading days period prior to the making of the Demand Request, is less than the lesser of
(x) twenty-five million dollars ($25,000,000) or (y) the total market value of Registrable Securities outstanding. 

(iii) the Company furnishes to the Holders a certificate signed by an authorized officer of the Company stating that
(A) within ninety (90) days after receipt of the Demand Request under this Section 2.1, the Company will file a registration statement for the public offering of securities for the account of the Company (other than a registration of
securities (x) issuable pursuant to an employee stock option, stock purchase or similar plan, (y) issuable pursuant to a merger, exchange offer or a transaction of the type specified in Rule 145(a) under the Securities Act or (z) in
which the only securities being registered are securities issuable upon conversion of debt securities which are also being registered), or (B) the Company is engaged in a material transaction or has an undisclosed material corporate
development, in either case, which would be required to be disclosed in the Registration Statement, and in the good faith judgment of the Company’s Board of Directors, such disclosure would be materially detrimental to the Company and its
stockholders at such time (in which case, the Company shall disclose the matter as promptly as reasonably practicable and thereafter 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 9 

 
file the Registration Statement, and each Holder agrees not to disclose any information about such material transaction to Third Parties until such disclosure has occurred or such information has
entered the public domain other than through breach of this provision by such Holder), provided, however, that the Company shall have the right to only defer the filing of the Registration Statement pursuant to this subsection once in
any twelve (12) month period and, such deferral may not exceed a period of more than one-hundred twenty (120) days after receipt of a Demand Request; 

(iv) the Company has, within the twelve (12) month period preceding the date of the Demand Request, already effected one
(1) Required Registration for any Holder pursuant to this Section 2.1; or 
 (v) at any time during the period
between the Company’s receipt of the Demand Request and the completion of the Required Registration, any Holder is in breach of or has failed to cause its Affiliates to comply with the obligations and restrictions of Sections 3, 4 or 5 of this
Agreement, the Company has provided notice of such breach to a Holder and such breach or failure is ongoing and has not been remedied; it being understood that (A) a one-time, inadvertent and de minimis breach of Section 4 shall not be
deemed to be a breach of the obligations and restrictions under Section 4 for purposes of this Section 2.1(v) and (B) a de minimis breach of Section 3.1(a) hereof, or an inadvertent breach of Section 3.1(g) hereof arising
from informal discussions covering general corporate or other business matters the purpose of which is not intended to effectuate or lead to any of the actions referred to in paragraphs (a) through (e) of Section 3.1, shall not be
deemed to be a breach of the obligations and restrictions under Section 3.1 for purposes of this Section 2.1(v). 
 2.2 Company
Registration. Effective from the expiration of the Lock-Up Term until the earlier of (a) the tenth (10th) anniversary of such expiration and (b) the date on which the Holders no
longer beneficially own at least five percent (5%) of the Shares of Then Outstanding Common Stock, (provided, however, if the Holders reacquire beneficial ownership representing at least 5% of the Shares of Then Outstanding Common Stock at any
time within ten (10) year period set forth in clause (a) of this Section 2.2, the provisions of this Section 2.2 shall automatically again become applicable to the Holders) the Company shall notify the Holders in writing at least
ten (10) days prior to the filing of any Registration Statement including shares of Common Stock by one or more selling stockholders (other than the Holders) (“Registration Notice”) and will afford each Holder an opportunity,
subject to the terms and conditions of this Agreement, to include in such Registration Statement the number of Registrable Securities then held by such Holder that such Holder wishes to include in such Registration Statement. Each Holder desiring to
include in any such Registration Statement all or any part of the Registrable Securities held by such Holder shall, within five (5) days after receipt of the Registration Notice, so notify the Company in writing, and in such notification,
inform the Company of the number of Registrable Securities such Holder wishes to include in such Registration Statement. If a Holder decides not to include Registrable Securities in any 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 10 

 
Registration Statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include Registrable Securities in any subsequent Registration Statement or
Registration Statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. Each Holder shall keep confidential and not disclose to any third party (i) its receipt of
any Registration Notice and (ii) any information regarding the proposed offering as to which such notice is delivered, except as required by law, regulation or as compelled by subpoena. If a registration pursuant to this Section 2.2 is an
Underwritten Offering, the right of any such Holder to include Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities
in the underwriting to the extent provided herein. The Company and all Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the managing underwriter
or underwriters selected for such underwriting. Notwithstanding any other provision of this Section 2, if the managing underwriter for the Underwritten Offering determines in good faith that marketing factors require a limitation of the number
of shares of Registrable Securities to be included in such Underwritten Offering, then the managing underwriter may exclude shares (including up to 100% of the Registrable Securities) from the registration and the underwriting, with the number of
Registrable Securities, if any, included in the registration and the underwriting being allocated to each of the Holders requesting inclusion of their Registrable Securities in such Registration Statement and all other Persons selling shares of
Common Stock pursuant to such Registration Statement on a pro rata basis based on the total number of shares of Common Stock then held by each such Holder or other stockholder. Notwithstanding the foregoing, the Company shall have the right to
terminate or withdraw any registration initiated by it under this Section 2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. 

2.3 Underwritten Required Registration Required; Priority in Underwritten Offering. The underwriter for any Underwritten Offering
requested pursuant to Section 2.1 shall be selected by a majority in interest of the Holders initiating the Required Registration hereunder (such Holder(s) initiating the registration request, the “Initiating Holders”) and
shall be acceptable to the Company, such acceptance not to be unreasonably withheld, conditioned or delayed. The right of any Holder to include its Registrable Securities in the Underwritten Offering shall be conditioned upon such Holder’s
participation in such Underwritten Offering and the inclusion of such Holder’s Registrable Securities to the extent provided herein. All Holders requesting the inclusion of their Registrable Securities in such Underwritten Offering shall
(together with the Company as provided in Section 2.8(h)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such Underwritten Offering. Notwithstanding any other provision of this
Section 2, if the managing underwriter for the Underwritten Offering determines in good faith that marketing factors require a limitation of the number of shares of Registrable Securities to be included in such Underwritten Offering, then the
Company shall so advise all Holders which requested inclusion of their Registrable Securities in such Underwritten Offering, and the number of shares of Registrable 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 11 

 
Securities that may be included in such Underwritten Offering shall be allocated among the Holders in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company
owned by each Holder; provided, however, that the number of shares of Registrable Securities to be included in such Underwritten Offering shall not be reduced unless all other securities are first entirely excluded from such
Underwritten Offering. In the event the Company advises the Holders of its intent to decrease the total number of Registrable Securities that may be included by the Holders in such Required Registration such that the number of Registrable Securities
included in such Required Registration would be less than seventy-five percent (75%) of all Registrable Securities which the Holders requested be included in such Required Registration, then Holders representing a majority of the Registrable
Securities requested to be included in such Required Registration will have the right to withdraw, on behalf of all Holders of all Registrable Securities requested to be so included, such Required Registration, in which case, such Required
Registration will not count as a Required Registration for the purposes of Section 2.1(i), and the Company shall bear all Registration Expenses in connection therewith; provided, that, the right to withdraw a registration and have
it not count as a Required Registration may only be exercised once by the Holders (taken collectively). 
 2.4 Priority in Required
Registration. With respect to any Required Registration of Registrable Securities requested pursuant to Section 2.1, the Company may also (i) propose to sell shares of Common Stock on its own behalf and (ii) provide written notice
of such Required Registration to Other Holders and permit all such Other Holders who request to be included in the Required Registration to include any or all Company securities held by such Other Holders in such Required Registration on the same
terms and conditions as the Registrable Securities. Notwithstanding the foregoing, if the managing underwriter or underwriters of the Underwritten Offering to which any Required Registration relates advise the Company and the Holders of Registrable
Securities that, in its good faith determination, the total amount of securities that such Holders, Other Holders, and the Company intend to include in such Required Registration is in an amount in the aggregate which would adversely affect the
success of such Underwritten Offering, then such Required Registration shall include (i) first, all Registrable Securities of the Holders allocated, if the amount is less than all the Registrable Securities requested to be sold, pro rata
on the basis of the total number of Registrable Securities held by such Holders; and (ii) second, as many other securities proposed to be included in the Required Registration by the Company and any Other Holders, allocated pro rata
among the Company and such Other Holders, on the basis of the amount of securities requested to be included therein by the Company and each such Other Holder so that the total amount of securities to be included in such Underwritten Offering is the
full amount that, in the written opinion of such managing underwriter, can be sold without materially and adversely affecting the success of such Underwritten Offering. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 12 

 2.5 Revocation of Required Registration. With respect to one (1) Required
Registration only, the Holders of at least a majority of the Registrable Securities to be included in a Registration Statement with respect to such Required Registration may, at any time prior to the effective date of such Registration Statement, on
behalf of all Holders of all Registrable Securities requested to be included therein, revoke the request to have Registrable Securities included therein and revoke the request for such Required Registration by providing a written notice to the
Company, in which case such Required Registration that has been revoked will be deemed not to have been effected and will not count as a Required Registration for purposes of Section 2.1(i) if, and only if, the Holders of Registrable Securities
which had requested inclusion of Registrable Securities in such Required Registration promptly reimburse the Company for all Registration Expenses incurred by the Company in connection with such Required Registration. Notwithstanding the foregoing
sentence, the parties agree and acknowledge that the Holders may revoke any Required Registration (without any obligation to reimburse the Company for Registration Expenses incurred in connection therewith) if such revocation is based on (i) a
material adverse change in circumstances with respect to the Company and its subsidiaries, taken as a whole, caused by an act or failure to act by the Company or any of its subsidiaries and not known to any Holder at the time the Required
Registration was first made or (ii) the Company’s failure to comply in any material respect with its obligations hereunder, and any such revocation based on an event described in (i) or (ii) above shall be exercisable at any time
and shall not be counted as the one (1) revocation of a Required Registration permitted by the first sentence of this Section 2.5. 

2.6 Effective Required Registrations. A Required Registration will not be deemed to be effected for purposes of Section 2.1(i) if
the Registration Statement for such Required Registration has (a) not been declared effective by the SEC or (b) become effective in accordance with the Securities Act and the rules and regulations thereunder and not been kept effective for
the Required Period. In addition, if after such Registration Statement has been declared or becomes effective, (i) the offering of Registrable Securities pursuant to such Registration Statement is interfered with by any stop order, injunction,
or other order or requirement of the SEC or other governmental agency or court such that the continued offer and sale of Registrable Securities being offered pursuant to such Registration Statement would violate applicable Law and such stop order,
injunction or other order or requirement of the SEC or other governmental agency or court does not result from any act or omission of any Holder whose Registrable Securities are registered pursuant to such Registration Statement (an
“Interference”) and (ii) any such Interference is not cured within sixty (60) days thereof, such Required Registration will be deemed not to have been effected and will not count as a Required Registration. In the event
such Interference occurs and is cured, the Required Period relating to such Registration Statement will be extended by the number of days of such Interference, including the date such Interference is cured. 

2.7 Continuous Effectiveness of Registration Statement. The Company will use all reasonable efforts to cause each Registration Statement
filed pursuant to this Section 2 to be declared effective by the SEC or to become effective under the Securities Act as promptly as practicable and to keep each such Registration Statement that has been declared or becomes effective
continuously effective for the Required Period. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 13 

 2.8 Obligations of the Company. Whenever required under Section 2.1 to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC
a Registration Statement with respect to such Registrable Securities sought to be included therein; provided that at least five (5) Business Days prior to filing any Registration Statement or Prospectus or any amendments or supplements thereto,
the Company shall furnish to the Holders of the Registrable Securities covered by such Registration Statement, their counsel and the managing underwriter copies of all such documents proposed to be filed, and any such Holder shall have the
opportunity to comment on any information pertaining solely to such Holder and its plan of distribution that is contained therein and the Company shall make the corrections reasonably requested by such Holder or the managing underwriter with respect
to such information prior to filing any such Registration Statement or amendment; 
 (b) prepare and file with the SEC such amendments and
post-effective amendments to any Registration Statement and any Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective for the Required Period, and cause the Prospectus to be supplemented by any
required prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 under the Securities Act, to comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities covered by such
registration statement for the Required Period; provided that at least five (5) Business Days prior to filing any such amendments and post effective amendments or supplements thereto, the Company shall furnish to the Holders of the Registrable
Securities covered by such Registration Statement, their counsel and the managing underwriter copies of all such documents proposed to be filed, and any such Holder or managing underwriter shall have the opportunity to comment on any information
pertaining solely to such Holder and its plan of distribution that is contained therein and the Company shall make the corrections reasonably requested by such Holder and the managing underwriter with respect to such information prior to filing any
such Registration Statement or amendment; 
 (c) furnish to the Holders of Registrable Securities covered by such Registration Statement and
the managing underwriter such numbers of copies of such Registration Statement, each amendment and supplement thereto, the Prospectus included in such Registration Statement (including each preliminary prospectus or free writing prospectus) in
conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them; 

(d) notify the Holders of Registrable Securities covered by such Registration Statement, promptly after the Company shall receive notice
thereof, of the time when such Registration Statement becomes or is declared effective or when any amendment or supplement or any Prospectus forming a part of such Registration Statement has been filed; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 14 

 (e) notify the Holders of Registrable Securities covered by such Registration Statement promptly
of any request by the SEC for the amending or supplementing of such Registration Statement or Prospectus or for additional information and promptly deliver to such Holders copies of any comments received from the SEC; 

(f) notify the Holders promptly of any stop order suspending the effectiveness of such Registration Statement or Prospectus or the initiation
of any proceedings for that purpose, and use all reasonable efforts to obtain the withdrawal of any such order or the termination of such proceedings; 

(g) use all reasonable efforts to register and qualify the Registrable Securities covered by such Registration Statement under such other
securities or blue sky Laws of such jurisdictions as shall be reasonably requested by the Holders, use all reasonable efforts to keep each such registration or qualification effective, including through new filings, or amendments or renewals, during
the Required Period, and notify the Holders of Registrable Securities covered by such Registration Statement of the receipt of any written notification with respect to any suspension of any such qualification; provided, however, that
the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions; 

(h) enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of the
Underwritten Offering pursuant to which such Registrable Securities are being offered; 
 (i) use all reasonable efforts to obtain:
(A) at the time of effectiveness of the Registration Statement covering such Registrable Securities, a “cold comfort letter” from the Company’s independent certified public accountants covering such matters of the type
customarily covered by “cold comfort letters” as the underwriters may reasonably request; and (B) at the time of any underwritten sale pursuant to such Registration Statement, a “bring-down comfort letter,” dated as of the
date of such sale, from the Company’s independent certified public accountants covering such matters of the type customarily covered by “bring-down comfort letters” as the underwriters may reasonably request. 

(j) promptly notify each Holder of Registrable Securities covered by such Registration Statement at any time when a Prospectus relating
thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the Prospectus included in such Registration Statement or any offering memorandum or other offering document includes an untrue statement
of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing, and promptly prepare a supplement or amendment to such
Prospectus or file any other required document so that, as thereafter delivered to the purchasers of such Registrable Securities, such Prospectus will not contain an untrue statement of material fact or omit to state any fact necessary to make the
statements therein not misleading; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 15 

 (k) permit any Holder of Registrable Securities covered by such Registration Statement, which
Holder in its reasonable judgment could reasonably be deemed to be an underwriter with respect to the Underwritten Offering pursuant to which such Registrable Securities are being offered, or to be a controlling Person of the Company, to reasonably
participate in the preparation of such Registration Statement and to require the insertion therein of information to the extent concerning such Holder, furnished to the Company in writing, which in the reasonable judgment of such Holder and its
counsel should be included; 
 (l) in connection with any Underwritten Offering, use all reasonable efforts to obtain an opinion or opinions
addressed to the underwriter or underwriters in customary form and scope from counsel for the Company; 
 (m) upon reasonable notice and
during normal business hours, subject to the Company receiving customary confidentiality undertakings or agreements from any Holder of Registrable Securities covered by such Registration Statement or other person obtaining access to Company records,
documents, properties or other information pursuant to this subsection (m), make available for inspection by a representative of such Holder and any underwriter participating in any disposition of such Registrable Securities and any attorneys or
accountants retained by any such Holder or underwriter, relevant financial and other records, pertinent corporate documents and properties of the Company, and use all reasonable efforts to cause the officers, directors and employees of the Company
to supply all information reasonably requested by any such representative, underwriter, attorneys or accountants in connection with the Registration Statement; 

(n) with respect to one (1) Required Registration which includes Registrable Securities the market value of which is at least one hundred
million United States dollars ($100,000,000), participate, to the extent requested by the managing underwriter, in efforts extending for no more than three (3) days scheduled by such managing underwriter and reasonably acceptable to the
Company’s senior management, to sell the Registrable Securities being offered pursuant to such Required Registration (including participating during such period in customary “roadshow” meetings with prospective investors); 

(o) use all reasonable efforts to comply with all applicable rules and regulations of the SEC relating to such registration and make generally
available to its security holders earning statements satisfying the provisions of Section 11(a) of the Securities Act, provided that the Company will be deemed to have complied with this Section 2.8(o) with respect to such earning
statements if it has satisfied the provisions of Rule 158; 
 (p) if requested by the managing underwriter or any selling Holder, promptly
incorporate in a prospectus supplement or post-effective amendment such information as the managing underwriter or any selling Holder reasonably requests to be included therein, with respect to the Registrable Securities being sold by such selling
Holder, including, without limitation, the purchase price being paid therefor by the underwriters and with respect to any other terms of the Underwritten Offering of Registrable Securities to be sold in such offering, and promptly make all required
filings of such prospectus supplement or post-effective amendment; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 16 

 (q) cause the Registrable Securities covered by such Registration Statement to be listed on each
securities exchange, if any, on which equity securities issued by the Company are then listed; and 
 (r) reasonably cooperate with each
selling Holder and each underwriter participating in the disposition of such Registrable Securities and their respective counsel in connection with filings required to be made with the Financial Industry Regulatory Authority, Inc., if any. 

2.9 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself and the Registrable Securities held by it as shall be reasonably necessary to effect the
registration of such Holder’s Registrable Securities. 
 2.10 Expenses. Except as specifically provided herein, all Registration
Expenses shall be borne by the Company. All Selling Expenses incurred in connection with any registration hereunder shall be borne by the Holders of Registrable Securities covered by a Registration Statement, pro rata on the basis of the number of
Registrable Securities registered on their behalf in such Registration Statement. 
 2.11 Indemnification. In the event any
Registrable Securities are included in a Registration Statement under this Agreement: 
 (a) The Company shall indemnify and hold harmless
each Holder including Registrable Securities in any such Registration Statement, any underwriter (as defined in the Securities Act) for such Holder and each Person, if any, who controls such Holder or underwriter within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act and the officers, directors, owners, agents and employees of such controlling Persons, against any and all losses, claims, damages or liabilities (joint or several) to
which they may become subject under any securities Laws including, without limitation, the Securities Act, the Exchange Act, or any other statute or common law of the United States or any other country or political subdivision thereof, or otherwise,
including the amount paid in settlement of any litigation commenced or threatened (including any amounts paid pursuant to or in settlement of claims made under the indemnification or contribution provisions of any underwriting or similar agreement
entered into by such Holder in connection with any offering or sale of securities covered by this Agreement), and shall promptly reimburse them, as and when incurred, for any legal or other expenses incurred by them in connection with investigating
any claims and defending any actions, insofar as any such losses, claims, damages or liabilities (or actions in 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 17 

 
respect thereof) arise out of or are based upon any of the following statements, omissions or violations (each, a “Violation”): (i) any untrue statement or alleged untrue
statement of a material fact contained in or incorporated by reference into such Registration Statement, including any preliminary prospectus or final prospectus contained therein or any free writing prospectus or any amendments or supplements
thereto, or in any offering memorandum or other offering document relating to the offering and sale of such securities or (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make
the statements therein not misleading; provided, however, the Company shall not be liable in any such case for any such loss, claim, damage, liability or action to the extent that it (A) arises out of or is based upon a Violation
which occurs solely in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder; or (B) is caused by such Holder’s disposition of Registrable Shares during any
period during which such Holder is obligated to discontinue any disposition of Registrable Shares as a result of any stop order suspending the effectiveness of any registration statement or prospectus with respect to Registrable Securities of which
such Holder has received written notice. 
 (b) Each Holder including Registrable Securities in a registration statement shall indemnify and
hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each Person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act and the officers, directors, owners, agents and employees of such controlling Persons, any underwriter, any other Holder selling securities in such registration statement and any controlling Person of any such underwriter or other
Holder, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing Persons may become subject, under liabilities (or actions in respect thereto) which arise out of or are based upon any Violation, in each
case to the extent (and only to the extent) that such Violation: (i) arises out of or is based upon a Violation which occurs solely in reliance upon and in conformity with written information furnished expressly for use in connection with such
registration by such Holder; or (ii) is caused by such Holder’s disposition of Registrable Shares during any period during which such Holder is obligated to discontinue any disposition of Registrable Shares as a result of any stop order
suspending the effectiveness of any registration statement or prospectus with respect to Registrable Securities of which such Holder has received written notice. Each such Holder shall pay, as incurred, any legal or other expenses reasonably
incurred by any Person intended to be indemnified pursuant to this Section 2.11(b), in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement
contained in this Section 2.11(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without consent of the Holder, which consent shall not be unreasonably withheld.

 (c) Promptly after receipt by an indemnified party under this Section 2.11 of notice of the commencement of any action (including
any action by a Governmental Authority), such indemnified party shall, if a claim in respect thereof is to be made against any 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 18 

 
indemnifying party under this Section 2.11, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in,
and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified
party shall have the right to retain its own counsel, with the reasonable fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate
due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the
commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.11, but the omission so to deliver written notice to the
indemnifying party shall not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.11. 

(d) In order to provide for just and equitable contribution to joint liability in any case in which a claim for indemnification is made
pursuant to this Section 2.11 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such
indemnification may not be enforced in such case notwithstanding the fact that this Section 2.11 provided for indemnification in such case, the Company and each Holder of Registrable Securities shall contribute to the aggregate losses, claims,
damages or liabilities to which they may be subject (after contribution from others) in proportion to the relative fault of the Company, on the one hand, and such Holder, severally, on the other hand; provided, however, that in any
such case, no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; provided
further, however, that in no event shall any contribution under this Section 2.11(d) on the part of any Holder exceed the net proceeds received by such Holder from the sale of Registrable Securities giving rise to such
contribution obligation, except in the case of willful misconduct or fraud by such Holder. 
 (e) The obligations of the Company and the
Holders under this Section 2.11 shall survive the completion of any offering of Registrable Securities in a registration statement under this Agreement and otherwise. 

2.12 SEC Reports. With a view to making available to the Holders the benefits of Rule 144 under the Securities Act and any other rule or
regulation of the SEC that may at any time permit a Holder to sell Registrable Securities of the Company to the public without registration, the Company agrees to at any time that it is a reporting company under Section 13 or 15(d) of the
Exchange Act: 
 (a) file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act;
and 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 19 

 (b) furnish to any Holder, so long as such Holder owns any Registrable Securities, forthwith
upon request (i) a written statement by the Company that it has complied with the reporting requirements of the Exchange Act, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so
filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC (exclusive of Rule 144A) which permits the selling of any Registrable Securities without
registration. 
 2.13 Assignment of Registration Rights. The rights to cause the Company to register any Registrable Securities
pursuant to this Agreement may be assigned in whole or in part (but only with all restrictions and obligations set forth in this Agreement) by a Holder to a Permitted Transferee which acquires Registrable Securities from such Holder;
provided, however, (a) such Holder shall, within five (5) days prior to such transfer, furnish to the Company written notice of the name and address of such Permitted Transferee, details of its status as a Permitted
Transferee and details of the Registrable Securities with respect to which such registration rights are being assigned, (b) the Permitted Transferee, prior to or simultaneously with such transfer or assignment, shall agree in writing to be
subject to and bound by all restrictions and obligations set forth in this Agreement, (c) the Investor shall continue to be bound by all restrictions and obligations set forth in this Agreement and (d) such transfer or assignment shall be
effective only if immediately following such transfer or assignment the further disposition of such Registrable Securities by the Permitted Transferee is restricted under the Securities Act and other applicable securities Law. 

3. Restrictions on Beneficial Ownership. 

3.1 Standstill. During the Standstill Term, neither the Investor nor any of its Affiliates (collectively, the “Standstill
Parties”) shall (and the Investor shall cause its Affiliates not to), except as expressly approved or invited in writing by the Company: 

(a) directly or indirectly, acquire beneficial ownership of Shares of Then Outstanding Common Stock and/or Common Stock Equivalents, or make a
tender, exchange or other offer to acquire Shares of Then Outstanding Common Stock and/or Common Stock Equivalents, if after giving effect to such acquisition, the Standstill Parties would beneficially own more than the Standstill Limit;
provided, however, that notwithstanding the provisions of this Section 3.1(a), if the number of shares constituting Shares of Then Outstanding Common Stock is reduced or if the aggregate ownership of the Standstill Parties is
increased as a result of a repurchase by the Company of Shares of Then Outstanding Common Stock, stock split, stock dividend or a recapitalization of the Company, the Standstill Parties shall not be required to dispose of any of their holdings of
Shares of Then Outstanding Common Stock even though such action resulted in the Standstill Parties’ beneficial ownership totaling more than the Standstill Limit; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 20 

 (b) directly or indirectly, (i) seek to have called any meeting of the stockholders of the
Company, (ii) propose or nominate for election to the Company’s Board of Directors any person whose nomination has not been approved by a majority of the Company’s Board of Directors (excluding the Designated Director, if any) or
(iii) unless a person referred to in the foregoing clause (ii) is nominated by a third party in connection with such party’s publicly announced and not withdrawn Acquisition Proposal (in which case the provisions of Section 5.1
shall apply to permit the Standstill Parties to either vote in accordance with the recommendation of the Company’s Board of Directors or in the same proportion as the votes cast by all other holders of all classes of voting securities of the
Company), fail to cause to be voted in accordance with the recommendation of the Company’s Board of Directors with respect to such person for election to the Company’s Board of Directors any Shares of Then Outstanding Common Stock; 

(c) directly or indirectly, encourage or support a tender, exchange or other offer or proposal by any other Person or group (an
“Offeror”) the consummation of which would result in a Change of Control of the Company (an “Acquisition Proposal”); provided, however, that from and after the filing of a Schedule 14D-9 (or successor form of Tender
Offer Solicitation/Recommendation Statement under Rule 14d-9 of the Exchange Act) by the Company recommending that stockholders accept any such offer, Investor shall not be prohibited from taking any of the actions otherwise prohibited by this
Section 3.1(c) for so long as the Company maintains and does not withdraw such recommendation; 
 (d) directly or indirectly, solicit
proxies or consents or become a participant in a solicitation (as such terms are defined in Regulation 14A under the Exchange Act) in opposition to the recommendation of a majority of the Company’s Board of Directors with respect to any matter,
or seek to advise or influence any Person, with respect to voting of any Shares of Then Outstanding Common Stock of the Company; 
 (e)
deposit any Shares of Then Outstanding Common Stock in a voting trust or subject any Shares of Then Outstanding Common Stock to any arrangement or agreement with respect to the voting of such Shares of Then Outstanding Common Stock; 

(f) propose (i) any merger, consolidation, business combination, tender or exchange offer, purchase of the Company’s assets or
businesses, or similar transaction involving the Company or (ii) any recapitalization, restructuring, liquidation or other extraordinary transaction with respect to the Company; 

(g) act in concert with any Third Party to take any action in clauses (a) through (f) above, or form, join or in any way participate
in a “partnership, limited partnership, syndicate, or other group” within the meaning of Section 13(d)(3) of the Exchange Act; 

(h) enter into discussions, negotiations, arrangements or agreements with any Person relating to the foregoing actions referred to in
(a) through (g) above; or 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 21 

 (i) request or propose to the Company’s Board of Directors, any member(s) thereof or any
officer of the Company that the Company amend, waive, or consider the amendment or waiver of, any provisions set forth in this Section 3.1 (including this clause (i)); 

provided, however, that (A) nothing contained in this Section 3.1 shall prohibit the Investor from making confidential, non-public
proposals to, or entering into confidential, non-public discussions, negotiations, arrangements or agreements with, the Company and with third parties with the express authorization of the Company, which the Investor or any Affiliate may request in
a confidential, non-public manner, regarding a transaction or matter of the type described in the foregoing clauses (a) and (f), (B) the mere voting in accordance with Section 5 hereof of any voting securities of the Company held by
the Investor or its Affiliates shall not constitute a violation of any of clauses (a) through (h) above, and (C) nothing in the foregoing clause (b) shall prohibit the Investor from proposing to the Company’s Nominating and
Corporate Governance Committee (and not pursuant to the advance notice provisions set forth in the Company’s bylaws), in a confidential, non public manner, potential director candidates for consideration by the Company’s Nominating and
Corporate Governance Committee, which candidates the Investor believes would be in the best interest of the Company and its stockholders. 

3.2 Company Agreements. 

(a) During the Standstill Term, the Company shall not take any action or omit to take any action that would prevent or impede the Investor or
its Affiliates from acquiring beneficial ownership of Shares of Then Outstanding Common Stock and/or Common Stock Equivalents to the extent that, after giving effect to such acquisition, the Standstill Parties would beneficially own less than the
Standstill Limit, including by adopting a shareholder rights plan applicable to the Standstill Parties that contains a threshold below the Standstill Limit if such shareholder rights plan does not otherwise permit the Investor to beneficially own up
to the Standstill Limit, provided, however, that nothing contained in this Section 3.2(a) or elsewhere in this Agreement shall affect the Company’s ability to (i) take and disclose a position in accordance with Rule
14d-9, Rule 14e-2(a) or Item 1012(a) of Regulation M-A promulgated under the Exchange Act or (ii) make any disclosure to the Company’s stockholders, in each case if, in the good faith judgment of the Company’s Board of Directors,
the failure to take such position and/or make such disclosure would be inconsistent with the directors’ fiduciary duties under applicable law or any disclosure requirements under applicable law. During the Standstill Term and notwithstanding
the provisions of Section 5.1, Investor shall, and shall cause its Affiliates to, not take any action or omit to take any action that would prevent or impede the Company or its Affiliates from maintaining and enforcing the provisions of the
Rights Agreement, dated July 13, 2005, by and between the Company and EquiServe Trust Company, N.A. (the “Rights Plan”) as in effect on the date hereof, as amended as contemplated by the Purchase Agreement, including without
limitation, by voting (or, if applicable, by executing a written consent with respect to) all of its and their Shares of Then Outstanding Common Stock in favor of any renewal of such shareholder rights plan or adoption of a replacement shareholder

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 22 

 
rights plan in each case that is materially consistent with the Rights Plan as in effect on the date hereof, as amended as contemplated by the Purchase Agreement, should the Company submit such
renewal or adoption to the stockholders of the Company for their approval. 
 (b) Following expiration of the Standstill Term, the Company
shall not take any action or omit to take any action that would force the Investor to dispose of any of its holdings of Shares of Then Outstanding Common Stock. 

(c) Upon the expiration of the Standstill Term (the “Potential Standstill Term Expiration Date”), in the event that the
Standstill Parties beneficially own, in the aggregate, at least twenty percent (20%) of the Shares of Then Outstanding Common Stock, the Investor may deliver to the Company not later than five (5) business days following a Potential
Standstill Term Expiration Date a written notice electing to reinstate the provisions of Section 3 and Section 5 and continue the Standstill Term as provided in this Section 3.2(c) (the “Election Notice Date”). If
such election is made, the provisions of Section 3 and Section 5 shall be reinstated and the provisions of such sections, including the Standstill Term, shall be deemed to have remained in effect at all times without interruption or
tolling notwithstanding the occurrence of a Potential Standstill Term Expiration Date; provided, however, that the “Standstill Limit” shall instead be the percentage of Shares of Then Outstanding Common Stock beneficially
owned, in the aggregate, by the Standstill Parties as of the Potential Standstill Term Expiration Date. Following the Election Notice Date, the “Standstill Term” shall terminate on the date on which the Standstill Parties beneficially own,
in the aggregate, less than twenty percent (20%) of the Shares of Then Outstanding Common Stock; provided, however, that if the beneficial ownership of the Investor and its Affiliates in the aggregate is reduced below such
threshold as a direct result of dilution suffered upon an issuance of securities by the Company pursuant to an Excepted Transactional Issuance (a “Dilutive Event”), the Standstill Term shall instead terminate upon the earliest of
(x) Investor’s failure to provide written notice to the Company of its election to purchase additional securities within the five (5) business day period set forth in Section 6.2 related to the applicable Dilutive Event,
(y) Investor’s failure to consummate such purchase of additional securities of the Company pursuant to Section 6.2 within the time period set forth therein related to the applicable Dilutive Event or (z) the date of
Investor’s purchase of additional securities of the Company pursuant to Section 6.2 related to the applicable Dilutive Event if, immediately following the consummation of such purchase, the Investor and its Affiliates beneficially own, in
the aggregate, less than twenty percent (20%) of the Shares of Then Outstanding Common Stock. 
 (d) If the Company (i) permits
any other Person or group to own Shares of Then Outstanding Common Stock and/or Common Stock Equivalents in the aggregate exceeding the Standstill Limit or (ii) executes a transaction with any other Person or group that (i) results in said
Person or group becoming the beneficial owner of Shares of Then Outstanding Common Stock and/or Common Stock Equivalents in an amount equal to or greater than the percentage ownership represented by the Purchased Shares on the date hereof and
(ii) is a collaboration or other license agreement with the Company, the Company shall offer to the 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 23 

 
Investor an opportunity to amend Sections 3 and 5 of this Agreement in a manner such that such provisions would be consistent with the “standstill” terms and conditions upon which the
Company permitted such other Person or group to own and act (or fail to act) with respect to the Company and the Company’s Shares of Then Outstanding Common Stock and/or Common Stock Equivalents. This Section 3.2(d) shall terminate and be
of no further force or effect on the date on which the Investor and its Affiliates beneficially own, in the aggregate, less than seven and a half percent (7.5%) of the Shares of Then Outstanding Common Stock; provided, however, that if the
beneficial ownership of the Investor and its Affiliates in the aggregate is reduced below such threshold as a direct result of dilution suffered upon a Dilutive Event, this Section 3.2(d) shall instead terminate upon the earliest of
(x) Investor’s failure to provide written notice to the Company of its election to purchase additional securities within the five (5) business day period set forth in Section 6.2 related to the applicable Dilutive Event,
(y) Investor’s failure to consummate the purchase of additional securities of the Company pursuant to Section 6.2 within the time period set forth therein related to the applicable Dilutive Event or (z) the date of
Investor’s purchase of additional securities of the Company pursuant to Section 6.2 related to the applicable Dilutive Event if, immediately following the consummation of such purchase, the Investor and its Affiliates beneficially own, in
the aggregate, less than seven and a half percent (7.5%) of the Shares of Then Outstanding Common Stock. 
 4. Restrictions on
Dispositions. 
 4.1 Lock-Up. From and after the date of this Agreement and until the earlier of (i) December 31, 2019,
plus the amount of time by which either the Regional Option Outside Date (as defined in the Master Agreement) or the Global Option Outside Date (as defined in the Master Agreement) is extended beyond December 31, 2019 and (ii) six
(6) months after the earlier of (a) the expiration of the Term and (b) the termination of the Collaboration Agreement (the “Lock-Up Term”), without the prior approval of the Company, the Investor shall not, and shall
cause its Affiliates not to, Dispose of (x) any of the Purchased Shares or any shares of Common Stock beneficially owned by any Standstill Party as of the date of this Agreement, together with any shares of Common Stock issued in respect
thereof as a result of any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization, and (y) any Common Stock issued as (or issuable upon the exercise of any warrant, right or other security that is issued
as) a dividend or other distribution with respect to, or in exchange or in replacement of, the shares of Common Stock described in clause (x) of this sentence; provided, however, that the foregoing shall not prohibit the Investor
from (A) transferring any of the foregoing to a Permitted Transferee, (B) Disposing of any of the foregoing in order to reduce the beneficial ownership of the Standstill Parties to 19.9% or other level, as advised in good faith and in
writing by Sanofi’s certified public accountants, that would not require the Investor to include in its financial statements its portion of the Company’s financial results, of the Shares of Then Outstanding Common Stock, provided that any
Disposition referred to in this clause (B) shall be subject to the restrictions and requirements set forth in Section 4.2, and (C) effective on or after the second anniversary of the date hereof, Disposing of up to twenty-five percent
(25%) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 24 

 
of the foregoing if the market value of the Common Stock, based on the average closing price during the ten (10) consecutive trading days period prior to the Investor’s election to
exercise this clause (C), is at least one-hundred percent (100%) higher than the market value of the Common Stock, based on the average closing price during the ten (10) consecutive trading days period prior to the date hereof, provided
that any Disposition referred to in this clause (C) shall be subject to the restrictions and requirements set forth in Section 4.2. 

4.2 Limitations Following Lock-Up Term. Except for any transfer of Registrable Securities by the Investor to a Permitted Transferee, the
Investor shall not, and shall cause its Affiliates not to, Dispose of any Purchased Shares at any time after the expiration of the Lock-Up Term except (i) pursuant to a registered underwritten public offering in accordance with Section 2,
(ii) in a manner consistent with the volume limitations set forth in Rule 144 under the Securities Act (whether or not such limitations would by their terms apply to such sales), (iii) pursuant to privately negotiated sales in transactions
exempt from the registration requirements under the Securities Act to mutual funds or pension funds, each of which will not be required, based on its ownership of Shares of Then Outstanding Common Stock immediately following the contemplated
transaction, to file a Schedule 13D with respect to its ownership of the Shares of Then Outstanding Common Stock disclosing in response to Item 4 of such filing any plans or proposals described in clauses (a) through (j) of such Item
(the “Funds”), or to which the Company has no reasonable objection with respect to (x) the nature of the transferee or (y) the ability of the transferee to subsequently sell such Shares of Then Outstanding Common Stock
and/or Common Stock Equivalents into the market without having a material and adverse impact on the market price of the Company’s Common Stock; provided that, in the case of this clause (iii), other than with respect to the Funds, any
transferee that acquires more than five percent (5%) of the Shares of Then Outstanding Common Stock shall agree to be bound by the transfer limitations set forth in this Section 4.2 and the standstill limitations set forth in
Section 3.1, or (iv) in any transaction approved by the Company; provided, however, that in any Underwritten Offering in accordance with Section 2.1, the Holders whose Registrable Securities are included in such
Underwritten Offering shall request that the underwriter for such Underwritten Offering, and shall require that the underwriter for such Underwritten Offering shall agree in writing to, use all reasonable efforts to make as broad a distribution as
reasonably practical and to prevent any Person, or Affiliates of such Person, other than the Funds, from purchasing in such offering Registrable Securities which would constitute, or result in such Person, together with such Person’s
Affiliates, having beneficial ownership of, five percent (5%) or more of the total shares of Common Stock then outstanding. 
 4.3
Certain Tender Offers. Notwithstanding any other provision of this Section 4, this Section 4 shall not prohibit or restrict any Disposition of Purchased Shares by the Standstill Parties into (a) a tender offer by a Third Party
which is not opposed by the Company’s Board of Directors (but only after the Company’s filing of a Schedule 14D-9, or any amendment thereto, with the SEC disclosing the recommendation of the Company’s Board of Directors with respect
to such tender offer), unless Investor is then in breach of its obligations pursuant to Section 3.1 with respect to the tender offer or (b) an issuer tender offer by the Company. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 25 

 4.4 Offering Lock-Up. If the Holders together beneficially own at least five percent
(5%) of the Shares of Then Outstanding Common Stock, the Holders shall, if requested by the Company and an underwriter of Common Stock of the Company, agree not to Dispose of any Purchased Shares for a specified period of time, such period of
time not to exceed ninety (90) days. Such agreement shall be in writing in a form satisfactory to the Company, the underwriter(s) in such offering and shall contain customary exceptions to the restrictions set forth therein. The Company may
impose stop transfer instructions with respect to the Purchased Shares to the extent consistent with any such agreement until the end of the specified period of time. The foregoing provisions of this Section 4.4 shall apply to the Holders only
if the Company’s directors, officers and any holders of an equal or greater number of Shares of Then Outstanding Common Stock that are party to a collaboration, license or similar agreement with the Company are subject to similar lock-up
restrictions. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to
such agreements. 
 5. Voting Agreement. 

5.1 Voting of Securities. From and after the date of this Agreement, other than as permitted by Section 5.2 with respect to
Extraordinary Matters or as required by Section 3.1(b) or 3.2(a), in any vote or action by written consent of the stockholders of the Company (including, without limitation, with respect to the election of directors), the Investor shall, and
shall cause its respective Affiliates to, vote or execute a written consent with respect to the Voting-Restricted Shares, in the sole discretion of the Investor, either (a) in accordance with the recommendation of the Company’s Board of
Directors or (b) in the case of a meeting of stockholders, if the Investor or an Affiliate of the Investor has delivered written notice to the Company at any time prior to the vote on any given matter (but in any event not less than five
(5) Business Days prior to such vote), setting forth its intent to vote pursuant to this Section 5.1(b), in the same proportion as the votes cast by all other holders of all classes of voting securities of the Company (as estimated by the
inspector of election immediately prior to the closing of the polls with respect to the vote on any given matter, subject to adjustment for the inspector of election’s final tabulation of votes cast). In the event that the Investor or an
Affiliate of the Investor does not deliver timely written notice to the Company as provided in Section 5.1(b), such Person shall be deemed to have elected to vote the Voting-Restricted Shares of the Company as to which it is entitled to vote as
provided in Section 5.1(a). In furtherance of this Section 5.1, the Investor hereby irrevocably appoints the Company and any individuals designated by the Company, and each of them individually, as the attorneys, agents and proxies, with
full power of substitution and re-substitution in each of them, for the Investor, and in the name, place and stead of the Investor, to vote (or cause to be voted) in such manner as set forth in this Section 5.1 (but in any case, (i) in
accordance with any written instruction from the 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 26 

 
Investor, properly delivered under this Section 5.1, to vote as contemplated by clause (b) above, and (ii) excluding any matter that is an Extraordinary Matter described in
Section 5.2) with respect to the Voting-Restricted Shares, and Section 3.1(b) and Section 3.2(a) with respect to all Shares of Then Outstanding Common Stock beneficially owned by Investor and its Affiliates, with respect to which the
Investor is or may be entitled to vote at any meeting of the Company held after the date hereof, whether annual or special and whether or not an adjourned meeting (the “Irrevocable Proxy”). This Irrevocable Proxy is coupled
with an interest, shall be irrevocable and binding on any successor in interest of the Investor and shall not be terminated by operation of law upon the occurrence of any event. This Irrevocable Proxy shall operate to revoke and render void any
prior proxy as to any securities of the Company heretofore granted by the Investor which is inconsistent herewith. Notwithstanding the foregoing, the Irrevocable Proxy shall be effective if, at any annual or special meeting of the stockholders of
the Company and at any adjournments or postponements of any such meetings, the Investor (A) fails to appear or otherwise fails to cause the Voting-Restricted Shares (in the case of matters referred to in this Section 5.1) and any
securities of the Company (in the case of the matters referred to in Section 3) to be counted as present for purposes of calculating a quorum, or (B) fails to vote such securities of the Company in accordance with this Section 5.1,
Section 3.1(b) and Section 3.2(a), in each case at least five (5) business days prior to the date of such stockholders’ meeting. The Irrevocable Proxy shall terminate upon the earlier of the expiration or termination of the
voting agreement set forth in this Section 5.1. The Investor shall cause any Affiliate of the Investor that may from time to time own of record (or the record holder holding on behalf of such Affiliate if owned beneficially)
Voting-Restricted Shares (in the case of matters referred to in this Section 5.1) and any securities of the Company (in the case of the matters referred to in Section 3.1(b) and 3.2(a)), if and when requested by the Company from time to
time, to promptly execute and deliver to the Company an irrevocable proxy, substantially in the form of Exhibit A attached hereto, and irrevocably appoint the Company and any individuals designated by the Company, and each of them individually, with
full power of substitution and resubstitution, as its attorney, agent and proxy to vote (or cause to be voted) such securities of the Company as to which such Affiliate is entitled to vote, in such manner as each such attorney, agent and proxy or
his substitute shall in its, his or her sole discretion deem appropriate or desirable with respect to the matters set forth in this Section 5.1, Section 3.1(b) and Section 3.2(a) (the “Affiliate Irrevocable Proxy”).
The Investor acknowledges, and shall cause its Affiliates to acknowledge, that any such proxy executed and delivered shall be coupled with an interest, shall constitute, among other things, an inducement for the Company to enter into this Agreement,
shall be irrevocable and binding on any successor in interest of such Affiliate and shall not be terminated by operation of Law upon the occurrence of any event. Such proxy shall operate to revoke and render void any prior proxy as to any securities
of the Company heretofore granted by such Affiliate, to the extent it is inconsistent herewith. The Investor acknowledges and agrees that it shall be a condition to any proposed transfer of any securities of the Company by the Investor to such
Affiliate that such Affiliate execute and deliver to the Company an Affiliate Irrevocable Proxy, and that any purported transfer shall be void and of no force or effect if such Affiliate Irrevocable Proxy is not so executed and delivered at the
closing of such transfer. Such proxy 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 27 

 
shall terminate upon the earlier of the expiration or termination of this Section 5.1. For the avoidance of doubt, this Section 5 does not apply to any Shares of Then Outstanding Common
Stock other than the Voting-Restricted Shares, except as otherwise expressly contemplated by Section 3.1(b) and Section 3.2(a). In the event the Company’s stockholders are permitted to act by written consent, the Company and the
Investor shall each negotiate in good faith with the other provisions as consistent as possible with the foregoing to govern the voting of the Investor’s and its Affiliates’ Voting-Restricted Shares and Shares of Then Outstanding Common
Stock as closely as practicable to the foregoing. 
 5.2 Certain Extraordinary Matters. The Investor and its Affiliates may vote, or
execute a written consent with respect to, any or all of the Voting-Restricted Shares of the Company as to which they are entitled to vote or execute a written consent, as they may determine in their sole discretion, with respect to the following
matters (each such matter being an “Extraordinary Matter”): 
 (a) any transaction which would result in a Change of
Control; and 
 (b) any liquidation or dissolution of the Company 

6. Right of First Offer. 

6.1 Right of First Offer. Subject to the terms and conditions of this Section 6 and applicable securities laws, if the Company
proposes to offer or sell any shares of Common Stock or any Common Stock Equivalents (the “New Securities”), the Company shall give written notice (the “Offer Notice”) to the Investor stating (a) its bona fide
intention to offer such New Securities, (b) the number of such New Securities to be offered, and (c) the structure of the proposed offering or sale. By written notification to the Company within five (5) days after the date of the
Offer Notice (the “Exercise Period”, the Investor may elect to purchase, upon the same terms and conditions as other purchasers in the offering or sale of the New Securities, up to that portion of such New Securities that would
allow the Investor to maintain its percentage ownership of Shares of Then Outstanding Common Stock after the offering or sale of the New Securities. The Investor shall be entitled to apportion the right of first offer hereby granted to it in such
proportions as it deems appropriate, among itself and its Permitted Transferees that are “accredited investors” within the meaning of Rule 501(a) under the Securities Act. 

6.2 Limitations. The right of first offer in Section 6.1 shall not be applicable to: 

(a) securities issued or issuable in exchange and as consideration for the bona fide acquisition of another corporation or entity by
the Company by consolidation, merger, purchase of all or substantially all of the assets, or other bona fide reorganization in which the Company acquires, in a single transaction or series of related transactions, all or substantially all of
the assets of such other corporation or entity or fifty percent (50%) or more of the voting power of such other corporation or entity or fifty percent (50%) or more of the equity ownership of such other entity; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 28 

 (b) securities issued or issuable in exchange and as consideration for the rights obtained in
research, collaboration, license, development, strategic alliance or other similar agreements or strategic partnerships; 
 (c) securities
issuable upon conversion of or with respect to any then previously-issued or outstanding securities; 
 (d) securities issued pursuant to
arms’ length bank financings; 
 (e) shares of Common Stock and/or Common Stock Equivalents issued or issuable for compensatory
purposes to employees, officers, directors, contractors, vendors, advisors or consultants of the Company or any of its subsidiaries (whether or not issued pursuant to a Company equity incentive plan); 

(f) securities issued as a dividend, stock split or distribution on the Common Stock; and 

(g) any right, option or warrant to acquire any securities set forth in Section 6.2(a)-(f) above. 

provided, however, in the event the Company issues New Securities in a transaction to which the right of first offer in Section 6.1 shall not apply
pursuant to Sections 6.2(a), 6.2(b) or 6.2(d) (an “Excepted Transactional Issuance”) or Section 6.2(e) (an “Excepted Compensatory Issuance”), the Company shall grant the Investor the right, upon the terms and
conditions set forth in this paragraph, (i) to purchase a number of securities of the same type as the New Securities issued in the Excepted Transactional Issuance (except that securities purchased by the Investor in connection with an Excepted
Transactional Issuance involving a public offering shall be registered under the Securities Act only to the extent permitted by applicable law) such that the percentage of Common Stock or any Common Stock Equivalents of the Company held by the
Investor immediately after giving effect to the issuance of such New Securities and the issuance and purchase by the Investor of such securities pursuant to this Section 6.2 shall equal the percentage of Common Stock or any Common Stock
Equivalents of the Company held by the Investor immediately prior to the Excepted Transactional Issuance and (ii) to purchase a number of securities of the same type as the New Securities issued in Excepted Compensatory Issuances during the
previous calendar year such that the percentage of Common Stock or any Common Stock Equivalents of the Company held by the Investor immediately after giving effect to the issuance of such New Securities in such Excepted Compensatory Issuances and
the issuance and purchase by the Investor of such securities pursuant to this Section 6.2 shall equal the percentage of Common Stock or any Common Stock Equivalents of the Company that would have been held by the Investor had the applicable
Excepted Compensatory Issuances not been 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 29 

 
made. The Company shall, within five (5) business days after the consummation of an Excepted Transactional Issuance and within ten (10) business days after the end of each calendar year
in respect of Excepted Compensatory Issuances, provide written notice to the Investor of the offer described in this clause. The Investor shall have five (5) business days from the date of such notice to provide the Company with written notice
of its election to exercise all or a portion of its purchase right under this clause, and such purchase shall be consummated within five (5) business days after the date of the Investor’s written election. The price per security for the
offer related to an Excepted Transactional Issuance shall be the greater of (x) the per security price of the New Securities issued in the Excepted Transactional Issuance and (y) the closing price, if any, of the New Securities on the date
of purchase by the Investor pursuant to this Section 6.2; provided, however, that if the price per security of the New Securities issued in the Excepted Transactional Issuance is greater than the closing market price of the New Securities on
the date of the definitive agreement for such Excepted Transactional Issuance, the foregoing price formula shall not apply, and the price per security shall be the closing market price of the New Securities on the date of purchase by the Investor
pursuant to this Section 6.2. The price per security for the offer related to Excepted Compensatory Issuances shall be the closing market price of the New Securities on the date of purchase by the Investor pursuant to this Section 6.2.

 6.3 Expiration. In the event the Investor fails to exercise its right of first refusal within the Exercise Period for the entire
amount of New Securities offered pursuant to Section 6.1 above, the Company shall have forty-five (45) days thereafter to it to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed,
if at all, within thirty (30) days from the date of such agreement) to sell the New Securities respecting which the Investor’s right of first refusal set forth in Section 6.1 was not exercised, at a price and upon terms no more
favorable to the purchasers thereof than specified in the Offer Notice. In the event the Company has not sold within such forty-five (45) day period or entered into an agreement to sell the New Securities in accordance with the foregoing within
such thirty (30) days, the Company shall not thereafter issue or sell any New Securities without first again offering such securities to the Investor in the manner provided in this Section 6. If the Investor fails to exercise its right to
purchase New Securities within the Exercise Period for the entire amount of New Securities offered pursuant to Section 6.1 above, but nevertheless expresses thereafter an interest in participating in such offering prior to such offering having
been effected, the Company will use commercially reasonable efforts to include the Investor in such offering if the Company, in its reasonable discretion, determines that the inclusion of the Investor at such later time will not adversely affect the
success of such offering. 
 7. Designated Director. 

7.1 Designated Director. In the event the Investor and its Affiliates acquire beneficial ownership, in the aggregate, of at least twenty
percent (20%) of the Shares of Then Outstanding Common Stock (the “Ownership Threshold”), the Investor may, upon written notice to the Company elect to cause, and the Company shall cause, one individual selected by the Investor
(the “Designated Director”) to be appointed as a member of the Company’s Board 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 30 

 
of Directors within thirty (30) days after the Company’s receipt of such written notice. The Company will not require the Designated Director to personally enter into any non-disclosure
agreement, and to the extent other directors of the Company enter into such agreements, the Company agrees that it will accept the Investor’s non-disclosure covenant in lieu of any such covenant from the Designated Director. In connection with
each subsequent meeting of the stockholders of the Company at which the Designated Director’s term of service as a director is expiring, the Company shall cause the Designated Director to be nominated for re-election at such meeting and
included within the slate of directors contained in the Company’s proxy statement, accompanied by a recommendation by the Company’s Board of Directors that such individual be elected as a director. In the event the Designated Director is
nominated for re-election at a meeting of the stockholders of the Company but is not re-elected by the stockholders, the Company’s obligations pursuant to this Section 7 shall terminate with respect to such individual. Notwithstanding the
foregoing sentence, in the event a Designated Director is not re-elected by the stockholders, the Investor retains the right to appoint a new Designated Director in accordance with this Section 7, and the Company’s obligations pursuant to
this Section 7 remain in effect with respect to such new Designated Director. In the event a vacancy is created at any time by the death, disability, retirement, resignation or removal of a Designated Director, the Investor shall appoint a new
Designated Director to fill the resulting vacancy. In the event a Designated Director is serving on the Company’s Board of Directors and the aggregate beneficial ownership of the Shares of Then Outstanding Common Stock held by the Investor and
its Affiliates decreases below the Ownership Threshold, the Investor shall cause, at the request of the Company, the Designated Director to resign from the Company’s Board of Directors at such time as is deemed advisable by the Company’s
Board of Directors (excluding the Designated Director), but in no event later than the next meeting of the stockholders of the Company at which members of the Company’s Board of Directors are elected; provided, however, that if the beneficial
ownership of the Investor and its Affiliates in the aggregate is reduced below the Ownership Threshold as a direct result of dilution suffered upon an issuance of securities by the Company pursuant to a Dilutive Event, the Investor’s
obligations under clauses (a) and (b) of this sentence shall instead be triggered if the beneficial ownership of the Investor and its Affiliates remains below the Ownership Threshold for the ensuing six (6) months and fifteen
(15) days following the date on which the aggregate beneficial ownership of the Shares of Then Outstanding Common Stock held by the Investor and its Affiliates decreases below the Ownership Threshold. Notwithstanding the foregoing, this
Section 7.1 shall terminate, and the Investor shall cause, upon delivery of written notice by the Company to the Investor within ten (10) business days after the occurrence of the applicable event (or, for purposes of clause
(iii) below, within ten (10) business days after the Company’s knowledge of such event), the Designated Director to resign from the Company’s Board of Directors no later than at such time as is deemed advisable by the
Company’s Board of Directors (excluding the Designated Director) and set forth in the notice referenced above, upon the earliest of (i) the date of termination of the Master Agreement by the Company pursuant to Section 12.2.3
(Termination of this Master Agreement for Cause) or Section 12.2.4 (Challenges of Patent Rights) of the Master Agreement, (ii) the date of termination of the Master Agreement by the Investor pursuant to Section 12.2.1 (Termination for
Convenience) of the Master Agreement and (iii) material breach by the Investor or any of its Affiliates of Section 3.1 of this Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 31 

 7.2 Notice and Information Rights. The Company shall notify the Designated Director of all
regular and special meetings of the Company’s Board of Directors or any committee thereof of which the Designated Director is a member. Subject to the following sentence, the Company shall provide the Designated Director with copies of all
notices, minutes, consents and other materials provided to all other directors (the “Director Information”) concurrently as such materials are provided to the other directors. The Designated Director will be afforded no less
favorable treatment than any other member of the Company’s Board of Directors with respect to all matters, including, without limitation, expense reimbursement and indemnification consistent with those offered to all other members of the
Company’s Board of Directors (including with respect to expense reimbursement and domestic travel unless and until the Company invites a non-U.S. person to join the Company’s Board of Directors) and reasonable access to Company information
and management, except that (i) the Designated Director may be excluded from participation or deliberation by the Company’s Board of Directors or committees thereof in connection with issues involving: (a) the Collaboration Agreement
or any other agreements between the Company and the Investor (as reasonably determined by the Company’s Board of Directors or relevant committee thereof), (b) matters of conflict or dispute between the Company and the Investor, or
(c) any other matter which is confidential and in the reasonable determination of the Company’s Board of Directors, would be compromised by the presence of the Designated Director due to such Designated Director’s affiliation with the
Investor and (ii) the Designated Director shall not have the right to receive Director Information with respect to the matters noted in clause (i) of this sentence. 

7.3 Freedom to Pursue Opportunities. Each of the parties hereto expressly acknowledges and agrees that: (i) the Investor, its
Affiliates and any Designated Director that is an employee of the Investor or any of its Affiliates have the right to, and shall have no duty (contractual or otherwise) not to, directly or indirectly engage in the same or similar business activities
or lines of business as the Company or any of its subsidiaries, including those deemed to be competing with the Company or any of its subsidiaries; and (ii) in the event that the Investor, its Affiliates or any Designated Director that is an
employee of the Investor or any of its Affiliates acquire knowledge of a potential transaction or matter (other than in the case of a Designated Director where knowledge of such transaction or matter was acquired by the Designated Director solely in
his or her capacity as a Designated Director) that may be a corporate opportunity for each of the Company and the Investor, such Person shall have no duty (contractual or otherwise) to communicate or present such corporate opportunity to the Company
or any of its subsidiaries, as the case may be, and, notwithstanding any provision of this Agreement to the contrary, shall not be liable to the Company or its Affiliates for any breach of any duty (contractual or otherwise) by reason of the fact
that the Investor, its Affiliates or any Designated Director, directly or indirectly, pursues or acquires such opportunity for itself or another Person, directs such opportunity to another Person, or does not present such opportunity to the Company.
Each Designated Director is an intended third party beneficiary of this provision, entitled to enforce it directly against the Company. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 32 

 8. Information Rights. 

8.1 Information Rights. During such time that a Designated Director is a member of the Company’s Board of Directors, the Investor
and its Affiliates will be entitled to receive any information which the Designated Director receives or is entitled to receive; provided, however, that the Investor and its Affiliates may make such information available only to individuals who have
a need to know such information for purposes of the Collaboration Agreement or the Investor’s or any Affiliate’s investment in the Company, including any outside service providers subject to a duty of confidentiality to the Investor or any
Affiliate, such as auditors and legal counsel. 
 8.2 Financial Information and Reporting. The Company will provide to Investor or its
designated Affiliate the financial information described in this Section 8.2 as well as any financial information reasonably requested by Investor so that Investor can manage and account for its investment in the Company, including to determine
the fair value of the Company’s investment or assess whether the Company needs to account for the investment using the equity method of accounting or otherwise, including making its management available to Investor for reasonable inquiries
regarding its financial statements and performance. If the Investor or its Affiliate (a) determines in good faith that such financial information is reasonably likely to be necessary with respect to the financial reporting of the Investor or
its Affiliates and (b) provides the Company with written notice to such effect, then beginning as promptly as reasonably practicable but in no event later than the 120th day following such
notice, the Company will deliver via overnight delivery and electronic mail to the Investor or its Affiliate the information described in Exhibit C hereto by the dates indicated on Exhibit C (as such Exhibit C may be updated by the Investor from
time to time to reflect changes in the financial reporting requirements of the Investor or its Affiliates). 
 8.3 Confidentiality.
All confidential or proprietary information and data relating to the Company and its subsidiaries provided by the Company to either the Investor pursuant to this Section 8 or the Designated Director pursuant to Section 7 shall be deemed
“Confidential Information” under the Master Agreement and accordingly shall be subject to the terms and conditions of the Master Agreement governing “Confidential Information.” 

9. Termination of Certain Rights and Obligations. 

9.1 Termination of Registration Rights. Except for Section 2.11, which shall survive until the expiration of any applicable
statutes of limitation, Section 2 shall terminate automatically and have no further force or effect upon the earliest to occur of: 

(a) the expiration of the Registration Rights Term; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 33 

 (b) the date on which the Common Stock ceases to be registered pursuant to Section 12 of
the Exchange Act; and 
 (c) a liquidation or dissolution of the Company. 

9.2 Termination of Standstill Agreement. Section 3, other than Sections 3.2(b) and (c), shall terminate and have no further force
or effect, upon the earliest to occur of: 
 (a) provided that none of the Standstill Parties has violated Section 3.1(c), (d) or
(f) with respect to the Offeror referred to in this clause (a), the public announcement by the Company or any Offeror of any definitive agreement between the Company and such Offeror and/or any of its Affiliates providing for a Change of
Control of the Company; 
 (b) the expiration of the Standstill Term (subject to revival as set forth in the definition of such term); 

(c) the date on which the Common Stock ceases to be registered pursuant to Section 12 of the Exchange Act; and 

(d) a liquidation or dissolution of the Company; 

provided, however, that if Section 3 terminates due to clause (a) above and such agreement is abandoned and no other similar
transaction has been announced and not abandoned or terminated within ninety (90) days thereafter, the restrictions contained in Section 3 shall again be applicable until otherwise terminated pursuant to this Section 9.2. 

9.3 Termination of Restrictions on Dispositions. Section 4 (other than Section 4.4) shall terminate and have no further force
or effect upon the earliest to occur of: 
 (a) the consummation by an Offeror of a Change of Control of the Company; 

(b) a liquidation or dissolution of the Company; 

(c) the date on which the Common Stock ceases to be registered pursuant to Section 12 of the Exchange Act; and 

(d) if there has been a period of at least [***] months during which [***], the date that is the first day after the end of such [***] month
period. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 34 

 9.4 Termination of Voting Agreement and Offering Lock-Up. Section 5 and
Section 4.4 shall terminate and have no further force or effect upon the earliest to occur of: 
 (a) the consummation by an Offeror of
a Change of Control of the Company; 
 (b) a liquidation or dissolution of the Company; 

(c) the date on which the Common Stock ceases to be registered pursuant to Section 12 of the Exchange Act; and 

(d) the expiration or termination of the Standstill Term. 

9.5 Termination of Right of First Offer. Section 6 shall terminate and have no further force or effect upon the earliest to occur
of: 
 (a) the date on which the Investor and its Affiliates beneficially own, in the aggregate, less than seven and a half percent
(7.5%) of the Shares of Then Outstanding Common Stock; provided, however, that if the beneficial ownership of the Investor and its Affiliates in the aggregate is reduced below such threshold as a direct result of dilution suffered upon a
Dilutive Event, Section 6 shall instead terminate upon the earliest of (x) Investor’s failure to provide written notice to the Company of its election to purchase additional securities within the five (5) business day period set
forth in Section 6.2 related to the applicable Dilutive Event, (y) Investor’s failure to consummate the purchase of additional securities of the Company pursuant to Section 6.2 within the time period set forth therein related to
the applicable Dilutive Event or (z) the date of Investor’s purchase of additional securities of the Company pursuant to Section 6.2 related to the applicable Dilutive Event if, immediately following the consummation of such purchase,
the Investor and its Affiliates beneficially own, in the aggregate, less than seven and a half percent (7.5%) of the Shares of Then Outstanding Common Stock. 

(b) the consummation by an Offeror of a Change of Control of the Company; 

(c) a liquidation or dissolution of the Company; and 

(d) the date on which the Common Stock ceases to be registered pursuant to Section 12 of the Exchange Act. 

9.6 Effect of Termination. No termination pursuant to any of Sections 9.1, 9.2, 9.3, 9.4 or 9.5 shall relieve any of the parties (or the
Permitted Transferee, if any) for liability for breach of or default under any of their respective obligations or restrictions under any terminated provision of this Agreement, which breach or default arose out of events or circumstances occurring
or existing prior to the date of such termination. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 35 

 10. Miscellaneous. 

10.1 Governing Law; Submission to Jurisdiction. This Agreement shall be governed by and construed in accordance with the Laws of the
State of Delaware, without regard to the conflict of laws principles thereof that would require the application of the Law of any other jurisdiction. Any action brought, arising out of, or relating to this Agreement shall be brought in the Court of
Chancery of the State of Delaware. Each party hereby irrevocably submits to the exclusive jurisdiction of said Court in respect of any claim relating to the validity, interpretation and enforcement of this Agreement, and hereby waives, and agrees
not to assert, as a defense in any action, suit or proceeding in which any such claim is made that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in such courts, or that the venue thereof
may not be appropriate or that this agreement may not be enforced in or by such courts. The parties hereby consent to and grant the Court of Chancery of the State of Delaware jurisdiction over such parties and over the subject matter of any such
claim and agree that mailing of process or other papers in connection with any such action, suit or proceeding in the manner provided in Section 10.3 or in such other manner as may be permitted by law, shall be valid and sufficient thereof.

 10.2 Waiver. Waiver by a party of a breach hereunder by another party shall not be construed as a waiver of any subsequent breach
of the same or any other provision. No delay or omission by a party in exercising or availing itself of any right, power or privilege hereunder shall preclude the later exercise of any such right, power or privilege by such party. No waiver shall be
effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the party granting the waiver. 

10.3 Notices. All notices, instructions and other communications hereunder or in connection herewith shall be in writing, shall be sent
to the address of the relevant party set forth on Exhibit B attached hereto and shall be (a) delivered personally, (b) sent by registered or certified mail, return receipt requested, postage prepaid, (c) sent via a reputable
nationwide overnight courier service or (d) sent by facsimile transmission, with a confirmation copy to be sent by registered or certified mail, return receipt requested, postage prepaid. Any such notice, instruction or communication shall be
deemed to have been delivered upon receipt if delivered by hand, three (3) Business Days after it is sent by registered or certified mail, return receipt requested, postage prepaid, one (1) Business Day after it is sent via a reputable
nationwide overnight courier service or when transmitted with electronic confirmation of receipt, if transmitted by facsimile (if such transmission is made during regular business hours of the recipient on a Business Day; or otherwise, on the next
Business Day following such transmission). Any party may change its address by giving notice to the other parties in the manner provided above. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 36 

 10.4 Entire Agreement. This Agreement and the Purchase Agreement contain the entire
agreement among the parties with respect to the subject matter hereof and thereof and supersede all prior and contemporaneous arrangements or understandings, whether written or oral, with respect hereto and thereto. 

10.5 Amendments. No provision in this Agreement shall be supplemented, deleted or amended except in a writing executed by an authorized
representative of each of the parties hereto. 
 10.6 Headings; Nouns and Pronouns; Section References. Headings in this Agreement are
for convenience of reference only and shall not be considered in construing this Agreement. Whenever the context may require, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of
names and pronouns shall include the plural and vice-versa. References in this Agreement to a section or subsection shall be deemed to refer to a section or subsection of this Agreement unless otherwise expressly stated. 

10.7 Severability. If, under applicable Laws, any provision hereof is invalid or unenforceable, or otherwise directly or indirectly
affects the validity of any other material provision(s) of this Agreement in any jurisdiction (“Modified Clause”), then, it is mutually agreed that this Agreement shall endure and that the Modified Clause shall be enforced in such
jurisdiction to the maximum extent permitted under applicable Laws in such jurisdiction; provided that the parties shall consult and use all reasonable efforts to agree upon, and hereby consent to, any valid and enforceable modification of this
Agreement as may be necessary to avoid any unjust enrichment of either party and to match the intent of this Agreement as closely as possible, including the economic benefits and rights contemplated herein. 

10.8 Assignment. Neither this Agreement nor any rights or duties of a party hereto may be assigned by such party, in whole or in part,
without (a) the prior written consent of the Company in the case of any assignment by the Investor, except as provided by Section 2.13 with respect to the Investor’s assignment to a Permitted Transferee; or (b) the prior written
consent of the Investor in the case of an assignment by the Company. 
 10.9 Successors and Assigns. This Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. 
 10.10 Counterparts. This
Agreement may be executed in counterparts, each of which shall be deemed an original but which together shall constitute one and the same instrument. 

10.11 Third Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party
other than a Designated Director and any Affiliate of the Investor. No Third Party with the exception of any Designated Director and any Affiliate of the Investor shall obtain any right under any provision of this Agreement or shall by reason of any
such provision make any claim in respect of any debt, liability or obligation (or otherwise) against any party hereto. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 37 

 10.12 No Strict Construction. This Agreement has been prepared jointly and will not be
construed against any party. 
 10.13 Remedies. The rights, powers and remedies of the parties under this Agreement are cumulative and
not exclusive of any other right, power or remedy which such parties may have under any other agreement or Law. No single or partial assertion or exercise of any right, power or remedy of a party hereunder shall preclude any other or further
assertion or exercise thereof. 
 10.14 Specific Performance. The Company and the Investor hereby acknowledge and agree that the
rights of the parties hereunder are special, unique and of extraordinary character, and that if any party refuses or otherwise fails to act, or to cause its Affiliates to act, in accordance with the provisions of this Agreement, such refusal or
failure would result in irreparable injury to the Company or the Investor, as the case may be, the exact amount of which would be difficult to ascertain or estimate and the remedies at law for which would not be reasonable or adequate compensation.
Accordingly, if any party refuses or otherwise fails to act, or to cause its Affiliates to act, in accordance with the provisions of this Agreement, then, in addition to any other remedy which may be available to any damaged party at law or in
equity, such damaged party will be entitled to seek specific performance and injunctive relief, without posting bond or other security, and without the necessity of proving actual or threatened damages, which remedy such damaged party will be
entitled to seek in any court of competent jurisdiction. 
 10.15 No Conflicting Agreements. The Investor hereby represents and
warrants to the Company that neither it nor any of its Affiliates is, as of the date of this Agreement, a party to, and agrees that neither it nor any of its Affiliates shall, on or after the date of this Agreement, enter into any agreement that
conflicts with the rights granted to the Company in this Agreement. The Company hereby represents and warrants to each Holder that it is not, as of the date of this Agreement, a party to, and agrees that it shall not, on or after the date of this
Agreement, enter into, any agreement or approve any amendment to its Organizational Documents (as defined in the Purchase Agreement) with respect to its securities that conflicts with the rights granted to the Holders in this Agreement. The Company
further represents and warrants that the rights granted to the Holders hereunder do not in any way conflict with the rights granted to any other holder of the Company’s securities under any other agreements. 

10.16 Rule 16b-3. If at any time in the future the Investor determines that Rule 16b-3 promulgated under the Exchange Act may be
available to exempt from Section 16(b) of the Exchange Act a transaction between the Investor and the Company, the Company shall cooperate and use commercially reasonable efforts to take such actions, including by adopting appropriate
resolutions of the Board of Directors of the Company, to permit the Investor to rely on such exemption.
 10.17 [***]. [***]. 

(Signature Page Follows) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  
 38 

 IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first
above written. 
  

			
	GENZYME CORPORATION
		
	By:	 	/s/ David Meeker
		 	Name: David Meeker, M.D.
		 	Title: President and Chief Executive Officer
	
	ALNYLAM PHARMACEUTICALS, INC.
		
	By:	 	/s/ John M. Maraganore
		 	Name: John M. Maraganore, Ph.D.
		 	Title: Chief Executive Officer

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  

 EXHIBIT A 

FORM OF IRREVOCABLE PROXY 

In order to secure the performance of the duties of the undersigned pursuant to Section 5.1 of the Investor Agreement, dated as of
February 27, 2014 (the “Agreement”), by and between Genzyme Corporation and Alnylam Pharmaceuticals, Inc. (the “Company”), the undersigned hereby irrevocably appoints the Company and any individual designated by the
Company, and each of them individually, as the attorneys, agents and proxies, with full power of substitution and resubstitution in each of them, for the undersigned, and in the name, place and stead of the undersigned, to vote (or cause to be
voted) in such manner as set forth in Section 5.1 of the Agreement (but in any case, (i) in accordance with any written instruction from the undersigned, properly delivered under Section 5.1 of the Agreement, to vote as contemplated
by Section 5.1(b) of the Agreement and (ii) excluding any matter that is an Extraordinary Matter described in Section 5.2) with respect to all Voting-Restricted Shares (in the case of matters referred to in Section 5.1) and all
securities of the Company (in the case of the matters referred to in Section 3.1(b) and Section 3.2(a)), which the undersigned is or may be entitled to vote at any meeting of the Company held after the date hereof, whether annual or
special and whether or not an adjourned meeting. This proxy is coupled with an interest, shall be irrevocable and binding on any successor in interest of the undersigned and shall not be terminated by operation of law upon the occurrence of any
event. This proxy shall operate to revoke and render void any prior proxy as to securities of the Company heretofore granted by the undersigned which is inconsistent herewith. Notwithstanding the foregoing, this irrevocable proxy shall be effective
if, at any annual or special meeting of the stockholders of the Company (or any consent in lieu thereof) and at any adjournments or postponements of any such meetings, the undersigned (A) fails to appear or otherwise fails to cause its voting
securities of the Company to be counted as present for purposes of calculating a quorum, or (B) fails to vote such voting securities in accordance with Sections 3.1(b), 3.2(a) or 5.1 of the Agreement, in each case at least five
(5) business days prior to the date of such stockholders’ meeting. This proxy shall terminate upon the earlier of the expiration or termination of the voting agreement set forth in Section 5.1 of the Agreement. 

 

			
	[                                   
                             ]
		
	By:	 	 
		 	Name:
		 	 Title:

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 A-1 

 EXHIBIT B 

NOTICES 
  

	(a)	If to Genzyme Corporation: 

 Genzyme Corporation 

500 Kendall Street 
 Cambridge, MA
02142 
 Attention: President of Rare Disease 

Facsimile No.: (617) 374-2424 

with a copy to: 
 Genzyme
Corporation 
 500 Kendall Street 

Cambridge, MA 02142 
 Attention:
General Counsel 
 Facsimile: (617) 252-7553 

and to: 
 Ropes & Gray
LLP 
 Prudential Tower 
 800
Boylston Street 
 Boston, MA 02199-3600 

Attention: Christopher D. Comeau, Esq. 

Facsimile: (617) 235-0507 
  

	(b)	If to the Company: 

 Alnylam Pharmaceuticals, Inc. 

300 Third Street 
 Cambridge, MA
02142 
 Attention: Vice President – Legal 

Facsimile: (617) 551-8101 

with a copy to: 
 Goodwin Procter
LLP 
 53 State Street 
 Boston,
MA 02109 
 Attention: Mitchell S. Bloom, Esq, 

Facsimile: (617) 523-1231 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 B-1 

 EXHIBIT C 

The below chart summarizes the type of information needed to apply the at equity method for an associate that is disclosing its financial
statements under another referential than IFRS. 
  

									
	 INFORMATION
	  	 Ref
	  	 PERIOD
	  	 TIMING
	  	 COMMENT

	 Issued and outstanding shares by classes

(Common, Preferred...)
	  		  	Quarter	  	D+5	  	Rights attached to each class of shares is also needed in order to determine the appropriate ownership interest
	 Outstanding potential rights
 (Options,
Convertible rights)
	  		  	Quarter	  	D+5	  	
	 YTD consolidated income statement

(USGAAP)
	  	A	  	Month	  	D+7	  	Estimate could be used at this deadline – (final numbers required at D+11)
	 YTD statement of comprehensive income

(USGAAP)
	  	B	  	Quarter	  	D+7	  	Same
	 Equity Roll forward including detail of equity transactions

(USGAAP)
	  	C	  	Quarter	  	D+7	  	Same
	Summarized balance sheet (USGAAP)	  	D	  	Quarter	  	D+7	  	Same
	Main USGAAP/IFRS differences	  	E	  	Quarter	  	D+7	  	>5M$
	Transactions between Sanofi & the Company	  	F	  	Quarter	  	D+7	  	P&L, OCI and Balance Sheet
	Transactions between Sanofi & the Company	  		  	Half-year	  	D+7	  	Off balance sheet
	List of the Company’s subsidiaries	  		  	Annual	  	D+7	  	

 Other information needed as part of a first application of the equity method: 

- Detailed programs of share based payment awards as of 31 December 20Y-2, 31 December 20Y-1 and equity method date 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 C-1 

 The financial reporting schedules (referenced from A to F) to be obtained from the Company are presented below:

 A/ YTD CONSOLIDATED INCOME STATEMENT (USGAAP) 
  

					
	 Amounts in K$ (1)
	  	YTD as of XX	  	 
	 	  	Total	  	Transactions
with Sanofi
	 Net Sales
	  		  	
	 Other Revenue
	  		  	
	 Cost of goods sold
	  		  	
	 Gross profit
	  		  	
	 Research and development expense
	  		  	
	 Selling and general expenses
	  		  	
	 Other operating income & expense
	  		  	
	 Amortization of intangible assets
	  		  	
	 Impairment of intangible assets
	  		  	
	 Fair value re-measurement of contingent consideration liabilities
	  		  	
	 Operating income
	  		  	
	 Financial expense
	  		  	
	 Financial income
	  		  	
	 Income before tax and associates & JV
	  		  	
	 Income tax expense
	  		  	
	 Share of profit/(loss) of associates and JV
	  		  	
	 Net income
	  		  	
	 Attributable to non-controlling interests
	  		  	
	 Net income attributable to equity holders of the Company
	  		  	

  

	(1)	Positive amount = income 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 C-2 

 B/ YTD CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME/LOSS (USGAAP) 

 

							
	 Amounts in K$ (1)
	  	Beginning
period as
of XX	  	Change in
the period	  	Ending
period as
of XX
	 Net income
	  		  		  	
	 Other comprehensive income:
	  		  		  	
	 Actuarial gains (losses)
	  		  		  	
	 Tax effect on actuarial gains and losses
	  		  		  	
	 Unrealized gains & losses on available-for-sale financial assets
	  		  		  	
	 Tax effect on unrealized gains & losses on AFS
	  		  		  	
	 Cash flow hedge
	  		  		  	
	 Tax effect on cash flow hedge
	  		  		  	
	 Net investment hedge
	  		  		  	
	 Tax effect on net investment hedge
	  		  		  	
	 Change in currency translation difference
	  		  		  	
	 Other comprehensive income for the period, net of taxes
	  		  		  	
	 Total comprehensive income
	  		  		  	
	 Of which attributable to non-controlling interests
	  		  		  	

  

	(1)	Positive amount = income 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 C-3 

 C/ EQUITY ROLL FORWARD (USGAAP) 
  

															
	 Amounts in K$ (1)
	  	Number
of
Shares	  	Capital	  	Additional
Paid in
Capital	  	Accumulated
retained
earnings	  	Other
Comprehensive
income (loss)	  	Non-controlling
interests	  	Total
Equity
	 Beginning balance as of XX
	  		  		  		  		  		  		  	
	 Net income for the period
	  		  		  		  		  		  		  	
	 Other comprehensive income for the period
	  		  		  		  		  		  		  	
	 Payment of dividends
	  		  		  		  		  		  		  	
	 Increase in capital (2)
	  		  		  		  		  		  		  	
	 Decrease in capital
	  		  		  		  		  		  		  	
	 Repurchase of Shares
	  		  		  		  		  		  		  	
	 Equity component of convertible notes
	  		  		  		  		  		  		  	
	 Purchase of convertible note
	  		  		  		  		  		  		  	
	 Warrants in connection of convertible notes
	  		  		  		  		  		  		  	
	 Share-based payments:
	  		  		  		  		  		  		  	
	 Increase in capital in connection with exercise of stock options
	  		  		  		  		  		  		  	
	 Increase in capital in connection with restricted shares
	  		  		  		  		  		  		  	
	 Share-based payment expense
	  		  		  		  		  		  		  	
	 Excess tax benefit from share-based payment expense
	  		  		  		  		  		  		  	
	 Other changes (3)
	  		  		  		  		  		  		  	
	 Ending balance as of XX
	  		  		  		  		  		  		  	

  

	(1)	Positive amount = credit 

	(2)	Other than share-based payments 

	(3)	To be detailed 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 C-4 

 D/ SUMMARIZED BALANCE SHEET (USGAAP) 

 

							
	 Amounts in K$ (1)
	  	YTD as of XX	  	 	 
	 	  	Total	  	Transactions
with Sanofi	 
	 ASSETS
	  		  			
	 Non-current assets
	  		  	 	(2	) 
	 Accounts receivable
	  		  			
	 Deferred tax assets – current portion
	  		  			
	 Other current assets
	  		  	 	(2	) 
	 TOTAL ASSETS
	  		  			

  

	(1)	Positive amount = debit balance 

	(2)	To be detailed 

  

							
	 Amounts in K$ (1)
	  	YTD as of XX	  	 	 
	 	  	Total	  	Transactions
with Sanofi	 
	 LIABILITIES AND EQUITY
	  		  			
	 Equity
	  		  			
	 Deferred revenue non-current portion
	  		  			
	 Other non-current liabilities
	  		  	 	(2	) 
	 Accounts payable
	  		  			
	 Deferred revenue current portion
	  		  			
	 Other current liabilities
	  		  	 	(2	) 
	 TOTAL LIABILITIES AND EQUITY
	  		  			

  

	(1)	Positive amount = credit balance 

	(2)	To be detailed 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 C-5 

 E/IFRS-USGAAP differences 
  

																	
	 Amounts in K$
	  	Note	 	 	Beginning
period as
of XX	  	Net
income	  	OCI	  	Other
Equity	  	Ending
period
as of
XX	  	Income
Statement
line
affected
	 R&D expense resulting from payments of rights to a product or technology (before regulatory approval)
	  	 	(1	) 	 		  		  		  		  		  	
	 Amortization expense related to acquired R&D previously capitalized
	  	 	(1	) 	 		  		  		  		  		  	
	 Impairment loss related to acquired R&D previously capitalized
	  	 	(1	) 	 		  		  		  		  		  	
	 Lease classification including land
	  	 	(2	) 	 		  		  		  		  		  	
	 Asset retirement obligations
	  	 	(3	) 	 		  		  		  		  		  	
	 Inventory capitalized prior regulatory approval
	  	 	(4	) 	 		  		  		  		  		  	
	 Reversal of inventory written off upon regulatory approval
	  	 	(5	) 	 		  		  		  		  		  	
	 Inventory samples
	  	 	(6	) 	 		  		  		  		  		  	
	 Deferred tax on intragroup inventory margin
	  	 	(7	) 	 		  		  		  		  		  	
	 Executive Stock Purchase Plan
	  	 	(8	) 	 		  		  		  		  		  	
	 Share based payments (Income tax)
	  	 	(9	) 	 		  		  		  		  		  	
	 Actuarial gains & losses on postretirement benefits
	  	 	(10	) 	 		  		  		  		  		  	
	 Prior service costs on postretirement employee benefits
	  	 	(11	) 	 		  		  		  		  		  	

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 C-6 

																	
	 Expected return on plan asset
	  	 	(12	) 	 		  		  		  		  		  	
	 Asset ceiling (net pension asset)
	  	 	(13	) 	 		  		  		  		  		  	
	 Provision recognition – measurement
	  	 	(14	) 	 		  		  		  		  		  	
	 Long term provision discounting
	  	 	(15	) 	 		  		  		  		  		  	
	 Revenue recognition (TBD)
	  				 		  		  		  		  		  	
	 TOTAL
	  				 		  		  		  		  		  	

  

	(1)	Capitalized under IFRS 

	(2)	Classification Operating versus Finance lease depending on criteria (IFRS/USGAAP) 

	(3)	Recognition criteria & measurement differences between IFRS and USGAAP 

	(4)	Fully written down under Sanofi’s accounting policy 

	(5)	Reversal permitted under IFRS 

	(6)	Net Residual Value is zero under Sanofi’s accounting policy 

	(7)	Based on the buyer’s rate under IFRS versus seller’s rate under USGAAP 

	(8)	Compensation expense under IFRS 

	(9)	Deferred tax based on intrinsic value at each balance sheet date under IFRS – Only tax expected above tax effect of cumulative expense is recognized through equity 

	(10)	Recognized immediately in OCI under IFRS 

	(11)	Recognized as expense in the period of plan amendments under IFRS 

	(12)	Expected return on plan assets determined by applying the discount rate under IFRS (market yields on high quality corporate bonds) 

	(13)	Limitation required under IFRS 

	(14)	Present obligation exists under IFRS and best estimate approach 

	(15)	Discounted required under IFRS when the effect is material (>5M€) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 C-7 

 F/ TRANSACTIONS WITH SANOFI – 

UPFRONT AND MILESTONE PAYMENTS: 
  

													
	 Upfronts &
Milestones paid

by Sanofi
	  	Amount in K$	  	Payment date	  	Deferred Revenue
Beginning period
as of XX(1)	  	Payment during
the period	  	Amount
recognized
as Revenue
during the
period (1)	  	Deferred
Revenue
Ending
period as
of XX (1)

 

	(1)	Positive amount = credit amount in the balance sheet and income statement 

 OTHER ITEMS WITH P&L IMPACT:

  

					
	 	  	Amount in K$
(1)	  	Line impacted
in the
consolidated
P&L
	 Product sales to Sanofi
	  		  	
	 Royalties paid by Sanofi
	  		  	
	 R&D expense incurred by the Company funded by Sanofi
	  		  	

  

	(1)	Positive amount = income; Negative amount = expense 

 OTHER GAINS & LOSSES RELATING TO TRANSACTIONS
WITH SANOFI 
 (Amounts >5M$) – to be detailed 

Example: Gain or loss on non-current asset disposals to Sanofi. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 C-8EX-10.4

 EXHIBIT 10.4 

MASTER COLLABORATION AGREEMENT 

by and between 
 ALNYLAM
PHARMACEUTICALS, INC. 
 and 

GENZYME CORPORATION 
 The Master
Collaboration Agreement is not intended to provide any factual information about Alnylam. The Master Collaboration Agreement contains representations, warranties and covenants that Alnylam and Genzyme made to each other as of specific dates. The
assertions embodied in those representations, warranties and covenants were made solely for purposes of the Master Collaboration Agreement between Alnylam and Genzyme and may be subject to important qualifications and limitations agreed to by
Alnylam and Genzyme in connection with negotiating its terms, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Master Collaboration Agreement. Moreover, the representations
and warranties may be subject to a contractual standard of materiality that may be different from what may be viewed as material to investors or security holders, or may have been used for the purpose of allocating risk between Alnylam and Genzyme
rather than establishing matters as facts. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Master Collaboration Agreement, which subsequent information concerning the subject
matter of the representations and warranties may change after the date of the Master Collaboration Agreement, which subsequent information may or may not be fully reflected in Alnylam’s public disclosures. For the foregoing reasons, no person
should rely on the representations and warranties as statements of factual information at the time they were made or otherwise. 
 CERTAIN CONFIDENTIAL
PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL
TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

TABLE OF CONTENTS 
  

					
	 	  	Page	 
	 1. OVERVIEW; DEFINITIONS
	  	 	2	  
		
	 1.1. Overview of Transactions
	  	 	2	  
		
	 1.2. Definitions
	  	 	4	  
		
	 2. EFFECTIVENESS OF AGREEMENTS AND LICENSES
	  	 	27	  
		
	 2.1. Effective Date
	  	 	27	  
		
	 2.2. Effectiveness of Licenses to Collaboration Products
	  	 	31	  
		
	 2.3. Cooperation
	  	 	32	  
		
	 2.4. No Antitrust Undertakings
	  	 	32	  
		
	 2.5. No Effect
	  	 	32	  
		
	 3. GRANT AND EXERCISE OF OPTIONS
	  	 	33	  
		
	 3.1. Alnylam Programs
	  	 	33	  
		
	 3.2. Option Grants
	  	 	37	  
		
	 3.3. Option Exercise Period
	  	 	41	  
		
	 3.4. Exercise of an Option
	  	 	45	  
		
	 3.5. Option Not Exercised
	  	 	48	  
		
	 3.6. Exclusivity during Option Period
	  	 	49	  
		
	 4. DEVELOPMENT AND PHARMACOVILIGANCE
	  	 	51	  
		
	 4.1. Overview
	  	 	51	  
		
	 4.2. Diligence
	  	 	51	  
		
	 4.3. Scientific Records
	  	 	52	  
		
	 4.4. Third Parties
	  	 	52	  
		
	 4.5. Oversight
	  	 	52	  
		
	 4.6. Pharmacovigilance
	  	 	52	  
		
	 5. COLLABORATION MANAGEMENT
	  	 	52	  
		
	 5.1. Alliance Joint Steering Committee
	  	 	52	  
		
	 5.2. Pipeline Advisory Committee
	  	 	57	  
		
	 5.3. IP Committee
	  	 	58	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -i- 

 MASTER AGREEMENT 

 

					
	 5.4. Manufacturing Committee
	  	 	59	  
		
	 5.5. Product Joint Steering Committees
	  	 	61	  
		
	 5.6. No Power to Amend
	  	 	61	  
		
	 5.7. Confidentiality
	  	 	61	  
		
	 5.8. Modifications
	  	 	61	  
		
	 5.9. Other Governance Terms
	  	 	61	  
		
	 6. MANUFACTURE AND SUPPLY OF THE COLLABORATION PRODUCTS
	  	 	61	  
		
	 6.1. ALN-TTR02 Supply Agreements
	  	 	61	  
		
	 6.2. Collaboration Product Supply Agreements
	  	 	62	  
		
	 6.3. General Supply Agreement Requirements
	  	 	62	  
		
	 6.4. Disputed Supply Agreement Terms
	  	 	62	  
		
	 6.5. Transfer of Manufacturing Know-How
	  	 	63	  
		
	 6.6. Establishment of Second Source and Back-Up Sources
	  	 	63	  
		
	 6.7. Third Party Manufacturers and Subcontracting
	  	 	63	  
		
	 6.8. Waivers
	  	 	64	  
		
	 7. CONFIDENTIALITY AND PUBLICATION
	  	 	64	  
		
	 7.1. Nondisclosure Obligation
	  	 	64	  
		
	 7.2. Publication and Publicity
	  	 	66	  
		
	 7.3. Press Release
	  	 	67	  
		
	 8. REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	68	  
		
	 8.1. Mutual Representations and Warranties as of the Execution Date
	  	 	68	  
		
	 8.2. Representations and Warranties of Alnylam
	  	 	69	  
		
	 8.3. Warranty Disclaimer
	  	 	71	  
		
	 8.4. Certain Covenants
	  	 	72	  
		
	 9. ROYALTY REPORTS; PAYMENTS; AUDIT
	  	 	74	  
		
	 9.1. Reports; Payment of Royalty
	  	 	74	  
		
	 9.2. Audits
	  	 	74	  
		
	 9.3. Payment Exchange Rate
	  	 	75	  
		
	 9.4. Late Payments
	  	 	75	  
		
	 9.5. Blocked Payments
	  	 	75	  
		
	 9.6. Taxes
	  	 	76	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - ii - 

 MASTER AGREEMENT 

 

					
	 10. INDEMNIFICATION; LIMITATION OF LIABILITY; INSURANCE
	  	 	76	  
		
	 10.1. General Indemnification by Genzyme
	  	 	76	  
		
	 10.2. General Indemnification by Alnylam
	  	 	77	  
		
	 10.3. Product Liability
	  	 	77	  
		
	 10.4. Indemnification Procedure
	  	 	77	  
		
	 10.5. Limitation of Liability
	  	 	78	  
		
	 10.6. Insurance
	  	 	78	  
		
	 11. INTELLECTUAL PROPERTY
	  	 	79	  
		
	 11.1. Prosecution and Maintenance of Patent Rights
	  	 	79	  
		
	 11.2. Patent Prosecution Information Sharing
	  	 	79	  
		
	 11.3. In-Licenses
	  	 	79	  
		
	 11.4. Common Interest
	  	 	82	  
		
	 12. TERM AND TERMINATION
	  	 	83	  
		
	 12.1. Term
	  	 	83	  
		
	 12.2. Termination Rights
	  	 	83	  
		
	 12.3. Effect of Termination
	  	 	84	  
		
	 13. MISCELLANEOUS
	  	 	86	  
		
	 13.1. Assignment
	  	 	86	  
		
	 13.2. Governing Law
	  	 	86	  
		
	 13.3. Jurisdiction
	  	 	86	  
		
	 13.4. Venue
	  	 	86	  
		
	 13.5. Entire Agreement; Amendments
	  	 	87	  
		
	 13.6. Severability
	  	 	87	  
		
	 13.7. Headings
	  	 	87	  
		
	 13.8. Waiver of Rule of Construction
	  	 	87	  
		
	 13.9. Interpretation
	  	 	87	  
		
	 13.10. No Implied Waivers; Rights Cumulative
	  	 	88	  
		
	 13.11. Notices
	  	 	88	  
		
	 13.12. Compliance with Export Regulations
	  	 	89	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - iii - 

 MASTER AGREEMENT 

 

							
			
	 13.13.
	  	Force Majeure	  	 	89	  
			
	 13.14.
	  	Independent Parties	  	 	90	  
			
	 13.15.
	  	Counterparts	  	 	90	  
			
	 13.16.
	  	Performance by Affiliates	  	 	90	  
			
	 13.17.
	  	Binding Effect; No Third Party Beneficiaries	  	 	90	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - iv - 

 MASTER AGREEMENT 

 

 SCHEDULES 
  

			
	Schedule 1.2.7	  	Additional Alnylam In-Licenses
		
	Schedule 1.2.21	  	ALN-AT3
		
	Schedule 1.2.22	  	ALN-TTR Core Technology Patents
		
	Schedule 1.2.24	  	ALN-TTR Product-Specific Patents
		
	Schedule 1.2.26	  	ALN-TTR02
		
	Schedule 1.2.29	  	ALN-TTRsc
		
	Schedule 1.2.34	  	[***]
		
	Schedule 1.2.71	  	Core Pipeline Program List
		
	Schedule 1.2.80	  	Form of Exercise Notice
		
	Schedule 1.2.82	  	Existing Alnylam In-Licenses
		
	Schedule 1.2.88	  	Final Option Data Package
		
	Schedule 1.2.116	  	Human POP Proposed Studies
		
	Schedule 1.2.123	  	Initial Option Data Package
		
	Schedule 1.2.134	  	Locked Core Pipeline Program List
		
	Schedule 1.2.135	  	Locked Non-Core Pipeline Program List
		
	Schedule 1.2.146	  	Named Pipeline Programs
		
	Schedule 1.2.149	  	Non-Core Pipeline Program List
		
	Schedule 1.2.159	  	Option Product Core Technology Patents
		
	Schedule 1.2.162	  	Option Product-Specific Patents
		
	Schedule 1.2.178	  	Potential Alnylam In-Licenses
		
	Schedule 2.1.3.3	  	Exempted Third Party CNS Agreements

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - v - 

 MASTER AGREEMENT 

 

			
		
	Schedule 6.1	  	ALN-TTR02 Supply Agreement Terms
		
	Schedule 6.2	  	Supply Agreement Terms
		
	Schedule 7.3	  	Press Release
		
	Schedule 8.2	  	Disclosure Schedule
		
	Schedule 10.2	  	Identified Patent Rights

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - vi - 

 MASTER AGREEMENT 

 

 APPENDICES 
  

			
	Appendix A	  	Regional License Terms
		
	Appendix B	  	Global License Terms
		
	Appendix C	  	Co-Co License Terms

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - vii - 

 MASTER AGREEMENT 

 

 MASTER COLLABORATION AGREEMENT 

THIS MASTER COLLABORATION AGREEMENT (this “Master Agreement”), entered into as of January 11, 2014 (the
“Execution Date”), is entered into by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and, Genzyme Corporation, a corporation
organized and existing under the laws of the Commonwealth of Massachusetts (“Genzyme”). 
 RECITALS: 

WHEREAS, Alnylam, among other things, conducts programs to discover, to characterize and to develop siRNAs targeting human genes;

 WHEREAS, the Parties have entered into that certain License and Collaboration Agreement dated as of October 18, 2012 (the
“Historical TTR Agreement”) pursuant to which Alnylam granted Genzyme certain exclusive licenses and other rights with respect to the siRNAs known as ALN-TTR02 and ALN-TTRsc (and certain back-up and improvement products) in certain
Asian countries; 
 WHEREAS, Alnylam and Genzyme desire to enter into the transactions contemplated by this Master Agreement, which
will supersede and replace the Historical TTR Agreement and under which, among other things, (1) Genzyme shall have certain exclusive licenses and other rights with respect to ALN-TTR02 and ALN-TTRsc, including the exclusive right to Develop
and Commercialize ALN-TTR02 and ALN-TTRsc on a regional basis outside North America and western Europe and the further right to co-Commercialize ALN-TTRsc with Alnylam in North America and western Europe, and (2) Genzyme shall have certain
Options to obtain from Alnylam exclusive licenses and other rights to certain of Alnylam’s other siRNAs targeting human genes as potential treatments for Orphan Diseases (a) on a regional basis outside North America and western Europe,
(b) with respect to certain siRNAs, on a global basis, or (c) with respect to a certain other siRNA on a regional basis outside North America and western Europe with the right to co-Commercialize such siRNA in North America and western
Europe, in each case on terms and conditions set forth in this Master Agreement and the License Terms attached to this Master Agreement as Appendix A (Regional License Terms), Appendix B (Global License Terms) and Appendix C
(Co-Co License Terms); 
 WHEREAS, Alnylam and Genzyme desire to enter into exclusive discussions and negotiations to potentially
enter into an agreement under which the Parties would collaborate to advance new technology for the delivery of siRNA to the CNS with the objective of enabling the discovery of siRNAs for the treatment of CNS disorders, and Genzyme would obtain
certain rights to the technology and products discovered in such collaboration; 
 WHEREAS, as partial consideration for
Alnylam’s grant of the Options, licenses and other rights to Genzyme under the Collaboration Agreement, Genzyme desires to subscribe for and purchase from Alnylam, and Alnylam desires to issue and sell to Genzyme, certain shares of Common Stock
pursuant to the terms and subject to the conditions set forth in the Stock Purchase Agreement; and 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  

 MASTER AGREEMENT 

 

 WHEREAS, a more detailed overview of the transactions contemplated by this Master
Agreement is set forth in Section 1.1 (Overview of Transactions) below. 
 NOW, THEREFORE, in consideration of the
foregoing premises and the mutual covenants herein contained, the Parties hereby agree as follows: 
 1. OVERVIEW; DEFINITIONS

 1.1. Overview of Transactions. This Master Agreement is part of the Collaboration Agreement between Genzyme and Alnylam
under which the Parties are Developing and Commercializing ALN-TTR02 and ALN-TTRsc and under which Alnylam has granted Genzyme various Options to obtain licenses to Develop and Commercialize siRNAs generated by Alnylam’s Core Pipeline Programs,
subject to the terms and conditions of this Master Agreement. As of the Effective Date, the Collaboration Agreement shall supersede and replace the Historical TTR Agreement pursuant to which Alnylam granted Genzyme certain exclusive licenses and
other rights with respect to ALN-TTR02 and ALN-TTRsc in certain Asian countries. The Collaboration Agreement consists of: (a) this Master Agreement; (b) the Regional License Terms, which are attached to this Master Agreement as Appendix
A; (c) the Co-Co License Terms, which are attached to this Master Agreement as Appendix B; (d) the Global License Terms, which are attached to this Master Agreement as Appendix C; and (e) the schedules and exhibits
attached to each of the foregoing. As of the Effective Date, ALN-TTR02 shall be a Regional Licensed Product and, as such, shall be governed by this Master Agreement and the Regional License Terms. As of the Effective Date, ALN-TTRsc shall be a Co-Co
Licensed Product and, as such, shall be governed by this Master Agreement and the Co-Co License Terms. 
 This Master Agreement includes, among other
things, the terms of the various Options granted to Genzyme (i.e., the Regional Option, the 2019 Trailing Regional Option, the 2021 Trailing Regional Option, the Co-Co/Global Option, the Global Option, the Additional Global Option and the
Trailing Global Option), and the process for exercising such Options. The Master Agreement sets forth, among other things, the Parties’ obligations to one another with respect to the Core Pipeline Programs during the period when Genzyme may
exercise such Options. 
 This Master Agreement also contains certain terms and conditions that are applicable to all of the “Collaboration
Products” (i.e., siRNAs with respect to which Genzyme exercises one of its Options) after Genzyme exercises an Option with respect to any such Collaboration Product. For example, the Master Agreement describes portions of the overall
governance structure for the Collaboration and also includes manufacture and supply terms, payment terms, confidentiality and publication provisions, indemnification, limitations of liability, insurance requirements, provisions regarding
intellectual property and in-licenses, and miscellaneous provisions that are applicable to the Collaboration Products, subject to the terms and conditions of this Master Agreement and the applicable License Terms.

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 2 - 

 MASTER AGREEMENT 

 

 
Following Genzyme’s exercise of an Option for an siRNA generated by an Alnylam Core Pipeline Program (or, with respect to ALN-TTR02 and ALN-TTRsc, following the Effective Date of the
Collaboration Agreement), the Development and Commercialization of the applicable siRNA will be governed by this Master Agreement and one of the 3 Appendices attached to the Master Agreement as follows: 

(1) The Regional License Terms will govern the Parties’ joint Development and Commercialization of ALN-TTR02 and any siRNA for which
Genzyme exercises a Regional Option, including the 2019 Trailing Regional Option or a 2021 Trailing Regional Option. Any such siRNA is referred to as a “Regional Licensed Product.” Under the Regional License Terms, Genzyme shall acquire a
license to Develop and Commercialize Regional Licensed Products in only the Genzyme Territory. 
 (2) The Co-Co License Terms will govern the
Parties’ joint Development and Commercialization of ALN-TTRsc, and will also govern the Parties’ joint Development and Commercialization of ALN-AT3 if Genzyme exercises the Co-Co/Global Option to acquire a license to Develop and
Commercialize ALN-AT3 in the Genzyme Territory and to co-Commercialize ALN-AT3 in the Alnylam Territory. Each such siRNA is referred to as a “Co-Co Licensed Product.” Subject to the specific terms in this Master Agreement and to the Co-Co
License Terms, the Co-Co License Terms are largely identical to the Regional License Terms with respect to the Genzyme Territory, but provide for additional terms governing the co-Commercialization of Co-Co Licensed Products in the Alnylam
Territory. 
 (3) The Global License Terms will govern Genzyme’s Development and Commercialization of ALN-AS1 if Genzyme exercises the
Co-Co/Global Option for ALN-AS1, and any siRNA for which Genzyme exercises the Global Option, the Additional Global Option or the Trailing Global Option. Each such siRNA is referred to as a “Global Licensed Product.” Under the Global
License Terms, Genzyme shall acquire the exclusive right to Develop and Commercialize Global Licensed Products worldwide. 
 Unlike the Master Agreement,
which contains terms that apply to all Collaboration Products, the License Terms include only terms that apply to the specific type of Collaboration Product to which the License Terms relate, such as economic terms, license grants, product-specific
governance provisions, Development and Commercialization provisions, intellectual property provisions, and provisions relating to term and termination, including termination on a product-by-product basis, in each case subject to the specific terms
of the License Terms. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 3 - 

 MASTER AGREEMENT 

 

 1.2. Definitions.  

Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective
meanings set forth below: 
 1.2.1. “2019 Trailing Regional Option” has the meaning set forth in
Section 3.2.1.2 (2019 Trailing Regional Option Grant). 
 1.2.2. “2021 Trailing Regional Option” has
the meaning set forth in Section 3.2.1.3 (2021 Trailing Regional Option Grant). 
 1.2.3. “Acquirer”
has the meaning set forth in Section 13.16.2 (Future Acquisition of a Party or its Business). 
 1.2.4.
“Action” has the meaning set forth in Section 13.3 (Jurisdiction). 
 1.2.5. “Active Alnylam
Program” means an Alnylam Program that has generated an siRNA (i) that achieved Clinical Success, (ii) that was administered to a patient in a Phase III Study, (iii) for which Development activities have not been terminated
and (iv) in which Alnylam has retained commercial rights anywhere in the world. 
 1.2.6. “Additional Global
Option” has the meaning set forth in Section 3.2.3.2 (Additional Global Option Grant). 
 1.2.7.
“Additional Alnylam In-Licenses” means (a) with respect to ALN-TTR02, ALN-TTRsc and each Co-Co/Global Option Product, the Third Party agreements set forth on Schedule 1.2.7; and (b) with respect to each Option Product,
the additional Third Party agreements that are identified in the applicable Option Data Package as “Additional Alnylam In-Licenses” for such Option Product (which, for clarity, shall include any of the Third Party agreements described in
clause (a) if the Patent Rights licensed to Alnylam under such agreements, if issued, could be infringed by the Development, Manufacture or Commercialization of such Option Product in the Genzyme Territory). 

1.2.8. “AF11 Lipid Nanoparticle Formulation” [***]. 

1.2.9. “Affiliate” means, with respect to a Person, any other Person which controls, is controlled by, or is
under common control with the applicable Person. For purposes of this definition, “control” shall mean: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares
entitled to vote for the election of directors, or otherwise having the power to control or direct the affairs of such Person; and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of
the equity interest or the power to direct the management and policies of such non-corporate entities. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 4 - 

 MASTER AGREEMENT 

 

 1.2.10. “ALAS-1” means the human ALAS-1 gene (also known as
ALAS, ALAS3, ALASH, aminolevulinate delta-synthase, Delta-ALA synthase, Delta-Aminolevulinate synthase 1, 5-aminolevulinic acid synthase 1, ALAS-H, 5-aminolevulinate synthase, MIG4, aminolevulinate synthase-1). As of the Execution Date, an example
of an identifier for the ALAS-1 gene is NCBI RefSeq code NM_000688 and an example of an identifier for the ALAS-1 protein product is NCBI RefSeq code NP_000679. 

1.2.11. “Alliance Joint Steering Committee” or “AJSC” means the Alliance Joint Steering
Committee as more fully described in Section 5.1(Alliance Joint Steering Committee). 
 1.2.12. “Alliance
Manager” has the meaning set forth in Section 5.1.3 (Alliance Managers). 
 1.2.13. “Alnylam
Indemnitees” has the meaning set forth in Section 10.1 (General Indemnification by Genzyme). 
 1.2.14.
“Alnylam In-Licenses” means any Existing Alnylam In-License or any Collaboration In-License to which Alnylam is a party. 

1.2.15. “Alnylam Manufacturing Know-How” means any Know-How related to the Manufacture of Option Products or
Collaboration Products (or oligonucleotides generally) Controlled by Alnylam at any time during the Term, to the extent such Know-How is disclosed or made available to Genzyme by or on behalf of Alnylam. 

1.2.16. “Alnylam Program” means any Development program conducted by Alnylam or, subject to
Section 13.16.2 (Future Acquisition of a Party or its Business), any of its Related Parties to Develop an siRNA targeting a human gene. 

1.2.17. “Alnylam Supply Agreements” means the ALN-TTR02 Clinical Supply Agreement, the ALN-TTR02 Commercial
Supply Agreement, each Clinical Supply Agreement and each Commercial Supply Agreement. 
 1.2.18. “Alnylam
Territory” means with respect to any Regional Licensed Product or Co-Co Licensed Product, the countries of the United States, Canada, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands,
Portugal, Spain, Sweden, the United Kingdom, Norway, Switzerland, Liechtenstein, Andorra, Iceland and Greenland. 

1.2.19. “Alnylam Territory MMC” means [***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 5 - 

 MASTER AGREEMENT 

 

 1.2.20. “ALN-AS1” means (i) the first siRNA that
targets ALAS-1 that is generated by a Core Pipeline Program that achieves Human POP Study Completion or (ii) if the siRNA described in clause (i) fails to achieve Clinical Success, the next siRNA that is generated by a Core Pipeline
Program and that targets ALAS-1. 
 1.2.21. “ALN-AT3” means (i) an siRNA Controlled by Alnylam,
comprising the siRNA (#ALN-[***]) conjugated to a GalNAc Conjugate, as further described on Schedule 1.2.21 or (ii) if the siRNA described in clause (i) fails to achieve Clinical Success, the next siRNA that is generated by a Core
Pipeline Program and that targets Antithrombin. 
 1.2.22. “ALN-TTR Core Technology Patents” means the
Alnylam Core Technology Patents for ALN-TTR02 and the Alnylam Core Technology Patents for ALN-TTRsc. The TTR Core Technology Patents existing as of the Execution Date are those Patent Rights identified on Schedule 1.2.22. 

1.2.23. “ALN-TTR Patents” means the Alnylam Patents for ALN-TTR02 and the Alnylam Patents for ALN-TTRsc. 

1.2.24. “ALN-TTR Product-Specific Patents” means the Alnylam Product-Specific Patents for ALN-TTR02 and the
Alnylam Product-Specific Patents for ALN-TTRsc. The TTR Product-Specific Patents existing as of the Execution Date are those Patent Rights identified on Schedule 1.2.24. 

1.2.25. “ALN-TTR Technology” means the Alnylam Technology for ALN-TTR02 and the Alnylam Technology for
ALN-TTRsc. 
 1.2.26. “ALN-TTR02” means an siRNA Controlled by Alnylam, comprising the siRNA (#AD[***])
formulated in an AF11 Lipid Nanoparticle Formulation, as further described on Schedule 1.2.26. 
 1.2.27.
“ALN-TTR Clinical Supply Agreement” has the meaning set forth in Section 6.1 (ALN-TTR02 Supply Agreements). 

1.2.28. “ALN-TTR Commercial Supply Agreement” has the meaning set forth in Section 6.1 (ALN-TTR02 Supply
Agreements). 
 1.2.29. “ALN-TTRsc” means an siRNA Controlled by Alnylam, comprising the siRNA (#AD[***])
conjugated to a Ga1NAc Conjugate, as further described on Schedule 1.2.29. For the sake of clarity (but not for purposes of interpretation of the Collaboration Agreement), even though ALN-TTRsc will be a Co-Co Licensed Product that is subject
to the Co-Co License Terms as of the Effective Date, ALN-TTRsc will be exclusively licensed to Genzyme in the Genzyme Territory in much the same way that ALN-TTR02 will be exclusively licensed to Genzyme in the Genzyme Territory under the Regional
License Terms. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 6 - 

 MASTER AGREEMENT 

 

 1.2.30. “Antithrombin” means the human antithrombin gene and
its protein product, antithrombin (also known as SERPINC1, antithrombin3, AT3 and ATIII). As of the Execution Date, an example of an identifier for the antithrombin gene is NCBI RefSeq code NM_000488 and an example of an identifier for the
antithrombin protein product is NCBI RefSeq code NP_000479. 
 1.2.31. “Antitrust Laws” means any federal,
state or foreign law, regulation or decree, including the HSR Act, designed to prohibit, restrict or regulate actions for the purpose or effect of monopolization or restraint of trade. 

1.2.32. “Available Third Party Right” has the meaning set forth in Section 3.6.3 (ROFN for Available
Third Party Rights). 
 1.2.33. “Back-Up Source” has the meaning set forth in Section 6.6 (Obligation
to Establish). 
 1.2.34. [***]. 

1.2.35. “Blocking Patent Right” means a Patent Right Controlled by a Third Party that Covers a Collaboration
Product. 
 1.2.36. “Bulk Drug Product” has the meaning set forth in Schedule 6.1 or Schedule
6.2, as applicable. 
 1.2.37. “Bulk Drug Substance” has the meaning set forth in Schedule 6.1 or
Schedule 6.2, as applicable. 
 1.2.38. “Calendar Quarter” means the respective periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 and December 31 of each calendar year. 

1.2.39. “Carbohydrate Conjugate” means a carbohydrate ligand covalently linked to the 3’ end of the sense
strand of an siRNA via a linker. 
 1.2.40. “cGMP” or “current Good Manufacturing
Practices” means the then-current standards for manufacturing activities for pharmaceuticals, as set forth in the United States Federal Food, Drug, and Cosmetic Act, as amended, and applicable regulations promulgated thereunder, as amended
from time to time, and such standards of good manufacturing practice as are required by other Governmental Authorities in countries in which Option Products or Collaboration Products are intended to be manufactured or sold. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 7 - 

 MASTER AGREEMENT 

 

 1.2.41. “Clinical Study” means a Phase I Study, Phase II
Study, Phase III Study, Post-Marketing Study, Secondary Indication Study or other study (including a non-interventional study) in humans to obtain information regarding the product, including information relating to the safety, tolerability,
pharmacological activity, pharmacokinetics, dose ranging or efficacy of the product. 
 1.2.42. “Clinical
Success” means [***]. 
 1.2.43. “Clinical Supply Agreement” has the meaning set forth in
Section 6.2 (Collaboration Product Supply Agreements). 
 1.2.44. “CNS” has the meaning set forth in
Section 2.1.3.1 (CNS Exploration Period). 
 1.2.45. “CNS Collaboration and License Agreement” has the
meaning set forth in Section 2.1.3.1 (CNS Exploration Period). 
 1.2.46. “CNS Exploration Period” has
the meaning set forth in Section 2.1.3.1 (CNS Exploration Period). 
 1.2.47. “CNS ROFN Exercise
Notice” has the meaning set forth in Section 2.1.3.4 (ROFN for CNS). 
 1.2.48. “CNS ROFN Negotiation
Period” has the meaning set forth in Section 2.1.3.4 (ROFN for CNS). 
 1.2.49. “CNS ROFN Non-Binding
Offer” has the meaning set forth in Section 2.1.3.4 (ROFN for CNS). 
 1.2.50. “CNS ROFN Offer
Period” has the meaning set forth in Section 2.1.3.4 (ROFN for CNS). 
 1.2.51. “CNS ROFN
Period” has the meaning set forth in Section 2.1.3.4 (ROFN for CNS). 
 1.2.52. “Co-Co License
Terms” means the Co-Commercialization License and Collaboration Terms attached hereto as Appendix C, under which (i) Alnylam and Genzyme shall amend, restate and supersede the Historical TTR Agreement in respect of
ALN-TTRsc effective as of the Effective Date, and (ii) Alnylam may grant Genzyme a license to ALN-AT3 effective as of the applicable Option Exercise Date. For the sake of clarity (but not for purposes of interpretation of the Collaboration
Agreement), each Co-Co Licensed Product that becomes subject to the Co-Co License Terms will be exclusively licensed to Genzyme in the Genzyme Territory in much the same way that each Regional Licensed Product will be exclusively licensed to Genzyme
in the Genzyme 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 8 - 

 MASTER AGREEMENT 

 

 
Territory under the Regional License Terms, and will be licensed to Genzyme in the Alnylam Territory to the extent necessary to enable Genzyme to co-Commercialize such Co-Co Licensed Product in
the Alnylam Territory as contemplated by the Co-Co License Terms. 
 1.2.53. “Co-Co Licensed Product” means
(i) ALN-TTRsc as of the Effective Date and (ii) if Genzyme exercises the Co-Co/Global Option for ALN-AT3, then ALN-AT3 as of the applicable Option Exercise Date, in each case, for as long as the Co-Co License Terms apply to ALN-TTRsc or
ALN-AT3. For the sake of clarity (but not for purposes of interpretation of the Collaboration Agreement), each Co-Co Licensed Product that becomes subject to the Co-Co License Terms will be exclusively licensed to Genzyme in the Genzyme Territory in
much the same way that each Regional Licensed Product will be exclusively licensed to Genzyme in the Genzyme Territory under the Regional License Terms, and will be licensed to Genzyme in the Alnylam Territory to the extent necessary to enable
Genzyme to co-Commercialize such Co-Co Licensed Product in the Alnylam Territory as contemplated by the Co-Co License Terms. 

1.2.54. “Co-Co/Global Option” has the meaning set forth in Section 3.2.2 (Co-Co/Global Option Grant).

 1.2.55. “Co-Co/Global Option Product” means either
(i) ALN-AT3 or (ii) ALN-AS1. 
 1.2.56. “Co-Co/Global Option
Trigger Notice” has the meaning set forth in Section 3.2.2.4 (Discontinuation of Second Co-Co/Global Option Product). 

1.2.57. “Collaboration” means the collaboration of the Parties under the Collaboration Agreement. 

1.2.58. “Collaboration Agreement” means this Master Agreement and each of the License Terms. 

1.2.59. “Collaboration In-License” has the meaning set forth in Section 11.3.3.1 (Proposed In-Licenses).

 1.2.60. “Collaboration Product” means any Regional Licensed Product, Co-Co Licensed Product or
Global Licensed Product, after exercise of the applicable Option by Genzyme and the occurrence of the applicable Option Exercise Date and effectiveness of the applicable License Terms, following which any such Option Product shall cease to be an
Option Product. 
 1.2.61. “Collaboration Product-Specific Payment” has the meaning set forth in
Section 11.3.4.2 (Collaboration In-Licenses). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 9 - 

 MASTER AGREEMENT 

 

 1.2.62. “Commercial Indication” means [***]. 

1.2.63. “Commercial Supply Agreement” has the meaning set forth in Section 6.2 (Collaboration Product
Supply Agreements). 
 1.2.64. “Commercialization” or “Commercialize” means any and all activities
directed to marketing, promoting, distributing, importing, exporting, using, offering to sell and/or selling a product, and activities directed to obtaining pricing and reimbursement approvals, as applicable. 

1.2.65. “Commercialization Plan” means (i) with respect a Regional Licensed Product, the Alnylam
Territory Commercialization Plan and the Genzyme Territory Commercialization Plan, as such terms are defined under the Regional License Terms, and (ii) with respect to a Co-Co Licensed Product, the Co-Co Territory Commercialization Plan and the
Genzyme Territory Commercialization Plan, as such terms are defined under the Co-Co License Terms. 
 1.2.66. “Common
Stock” means shares of common stock, par value $.01 per share, of Alnylam. 
 1.2.67. “Confidential
Information” means any and all confidential or proprietary information and data (including Option Product Technology, ALN-TTR Technology, Alnylam Technology (as defined in the License Terms), Genzyme Technology (as defined in the License
Terms), Genzyme Manufacturing IP and Genzyme Disclosed Manufacturing Know-How (each as defined in the License Terms), Alnylam Manufacturing Know-How and Joint Collaboration IP (as defined in the License Terms)) and all other scientific,
pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method, which is or has been provided by one Party to the other Party in connection
with the Collaboration Agreement, Stock Purchase Agreement, Investor Agreement or the Historical TTR Agreement. Option Product Technology, Alnylam Manufacturing Know-How and Alnylam Technology are the Confidential Information of Alnylam. Genzyme
Technology, Genzyme Manufacturing IP and Genzyme Disclosed Manufacturing Know-How are the Confidential Information of Genzyme. Joint Collaboration IP and the terms of the Collaboration Agreement, Stock Purchase Agreement, Investor Agreement and the
Historical TTR Agreement are the Confidential Information of both Parties, subject to Section 7.1 (Nondisclosure Obligation). 

1.2.68. “Control”, “Controls” or “Controlled by” means, with
respect to any Know-How, Patent Rights or other intellectual property right, the possession of (whether by ownership or license, other than pursuant to the Collaboration Agreement), the ability of a Person or its Affiliates to assign, transfer, or
grant access to, or to grant a license or sublicense of, such item or right as provided for herein without violating the terms of any 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 10 - 

 MASTER AGREEMENT 

 

 
agreement or other arrangement with any Third Party existing at the time such Person would be required hereunder to assign, transfer or grant another Person such access or license or sublicense,
provided that with respect to rights to any Third Party Know-How, Patent Rights or other intellectual property right that are licensed to, or otherwise obtained by, a Party pursuant to an agreement entered into by such Party, such Third Party
Know-How, Patent Rights or other intellectual property right shall be deemed not to be under the Control of such Party unless the agreement pursuant to which such rights are obtained is an In-License. 

1.2.69. “Core Pipeline Dispute” has the meaning set forth in Section 5.1.8.2 (Escalation). 

1.2.70. “Core Pipeline Program” means an Alnylam Program, existing as of the Execution Date or initiated
thereafter during the Option Period, to Develop an siRNA targeting a human gene, where [***]. Core Pipeline Programs include as of the Execution Date, without limitation, the Alnylam Programs identified on the Core Pipeline Program List. 

1.2.71. “Core Pipeline Program List” means the non-limiting list of Core Pipeline Programs, attached hereto as
Schedule 1.2.71, as the same may be updated from time to time in accordance with Section 3.1.1 (Program Identification). The Core Pipeline Programs as of the Execution Date are listed on Schedule 1.2.71. 

1.2.72. “Cost of Goods” means, with respect to the supply of a Product: (a) where Alnylam or its
Affiliates Manufacture such Product, the reasonable internal and external costs incurred by Alnylam and its Affiliates in Manufacturing such Product, including the fully allocated cost of Manufacture of such Product, consisting of direct material
and direct labor costs (including direct material and labor costs incurred for facility start-up), plus overhead directly attributable to the Manufacture of such Product (including all directly incurred Manufacturing variances and a reasonable
allocation of related Manufacturing administrative, facilities operations and facilities depreciation costs for such Product, but in all cases excluding corporate administrative overhead and/or costs associated with excess capacity), all calculated
strictly in accordance with GAAP, and (b) where such Product is Manufactured by a Third Party manufacturer, the actual fees paid by Alnylam to the Third Party for the Manufacture and supply of such Product. Any CMC costs that can be classified
under Costs of Goods pursuant to GAAP will be classified as such for the purposes of calculation of R&D Costs (as defined in the License Terms). 

1.2.73. “Cover,” “Covering” or “Covers” means, as to a product and Patent Rights,
that, in the absence of a license granted under, or ownership of, such Patent Rights, the manufacture, use, offer for sale, sale or importation of such product would infringe such Patent Rights or, as to a pending claim included in such Patent
Rights, the manufacture, use, offer for sale, sale or importation of such product would infringe such Patent Rights if such pending claim were to issue in an issued patent. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 11 - 

 MASTER AGREEMENT 

 

 1.2.74. “CRO” means a contract research organization. 

1.2.75. “Development,” “Developing” or “Develop” means under the Collaboration Agreement,
with respect to Option Products, Collaboration Products and other siRNA, the research and development activities related to the generation, characterization, optimization, construction, use and production of Option Products, Collaboration Products
or other siRNA, any other non-clinical, pre-clinical or clinical research and development activities related to the testing and qualification of Option Products, Collaboration Products or other siRNA, as applicable, including toxicology studies,
statistical analysis and report writing, pre-clinical testing, formulation development, CMC activities, Clinical Studies, regulatory affairs and registration activities, and all other activities necessary to prepare and file applications for
Regulatory Approval and to seek, obtain and maintain Regulatory Approval. 
 1.2.76. “Development Plan”
means (i) with respect a Regional Licensed Product, the Global Development Plan, Alnylam Territory Development Plan and the Genzyme Territory Development Plan, as such terms are defined under the Regional License Terms, and (ii) with
respect to a Co-Co Licensed Product, the Global Development Plan and the Genzyme Territory Development Plan, as such terms are defined under the Co-Co License Terms. 

1.2.77. “DOJ” means the U.S. Department of Justice. 

1.2.78. “Effective Date” has the meaning set forth in Section 2.1.1 (Effectiveness of Collaboration
Agreement). 
 1.2.79. “EMA” means the European Medicines Agency and any successor Governmental
Authority having substantially the same function. 
 1.2.80. “Exercise Notice” means the written
notice Genzyme delivers to Alnylam to exercise an Option with respect to an Option Product, in the form set forth on Schedule 1.2.80, containing the information set forth in such form. 

1.2.81. “Existing Core Option Products” means the Option Products of the following Core Pipeline
Programs existing as of the Execution Date and listed on the following referenced Schedule as of the Execution Date: (i) the Named Pipeline Programs listed on Schedule 1.2.146, (ii) the Core Pipeline Programs on the Locked Core
Pipeline Program List set forth on Schedule 1.2.134, and (iii) the Core Pipeline Programs listed in Section A (but not Section B) of Schedule 1.2.71. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 12 - 

 MASTER AGREEMENT 

 

 1.2.82. “Existing Alnylam In-Licenses” means
(a) with respect to ALN-TTR02, ALN-TTRsc and any Co-Co/Global Option Product for which Genzyme exercises an Option, the Third Party agreements set forth on Schedule 1.2.82 as of the Execution Date; (b) with respect to each
Option Product, additional Third Party agreements that are identified in the applicable Option Data Package as “Existing Alnylam In-Licenses” for such Option Product (which, for clarity, shall include any of the Third Party agreements
described in clause (a) if the Patent Rights and Know-How licensed to Alnylam under such agreements are necessary or useful for the Development, Manufacture or Commercialization of such Option Product in the Genzyme Territory); and (c) any
Additional Alnylam In-License which is deemed to be an Existing Alnylam In-License pursuant to Section 11.3.1 (Additional Alnylam In-Licenses), in each case ((a), (b) and (c)) as such agreement may be amended or supplemented from
time-to-time. 
 1.2.83. “Existing Genzyme In-License” means, with respect to a Collaboration
Product, any agreement between Genzyme and a Third Party entered into on or prior to the Option Exercise Date for such Collaboration Product pursuant to which Genzyme Controls Know-How or Patent Rights that are necessary or useful to Develop,
Manufacture or Commercialize such Collaboration Product in the Field under the applicable License Terms. 
 1.2.84.
“Execution Date” has the meaning set forth in the preamble. 
 1.2.85. “Expert”
has the meaning set forth in Section 5.1.8.3 (Resolution of Core Pipeline Disputes). 
 1.2.86.
“FDA” means the United States Food and Drug Administration and any successor Governmental Authority having substantially the same function. 

1.2.87. “Field” means the treatment, diagnosis or prevention of all human diseases. 

1.2.88. “Final Option Data Package” means, with respect to an Option Product: 

 

	 	(a)	[***]. 

  

	 	(b)	[***]. 

 1.2.89. “Finished Product” has the meaning set
forth in Schedule 6.1 or Schedule 6.2, as applicable. 
 1.2.90. “First Co-Co/Global Option
Product” has the meaning set forth in Section 3.2.2.1 (First Co-Co/Global Option Product). 
 1.2.91.
“FTC” means the U.S. Federal Trade Commission. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 13 - 

 MASTER AGREEMENT 

 

 1.2.92. “GAAP” means generally accepted accounting
principles as practiced in the United States or IFRS (International Financial Reporting Standards), in each case, consistently applied. 

1.2.93. “GalNAc Conjugate” means a triantennary N-acetylgalactosamine ligand (GalNAc3) covalently
linked to the 3’ end of the sense strand of the siRNA via a linker. 
 1.2.94. “Genzyme
Indemnitees” has the meaning set forth in Section 10.2 (General Indemnification by Alnylam). 
 1.2.95.
“Genzyme Disclosed Manufacturing Know-How” means Know-How (a) Controlled by Genzyme at any time during the Term that is useful in the Manufacture of a Regional Licensed Product and (b) that Genzyme, in its sole
discretion, discloses in writing to Alnylam in the course of the Collaboration. 
 1.2.96. “Genzyme
In-Licenses” means any Existing Genzyme In-License or any Collaboration In-License to which Genzyme is a party. 

1.2.97. “Genzyme Patent Jurisdictions” means [***]. 

1.2.98. “Genzyme Supply Agreement” has the meaning set forth in Section 6.6.2.1(Qualification). 

1.2.99. “Genzyme Territory” means (i) with respect to any Regional Licensed Product or Co-Co
Licensed Product, all countries and territories of the world other than the Alnylam Territory and (ii) with respect to any Global Licensed Product, worldwide. 

1.2.100. “Genzyme Territory MMC” means [***]. 

1.2.101. “Global Development Plan” has the meaning set forth in the applicable License Terms. 

1.2.102. “Global Development Strategy” has the meaning set forth in the applicable License Terms. 

1.2.103. “Global/Additional Global Option Forfeiture” has the meaning set forth in Section 3.4.2.2
(Exercise of Preserved Option). 
 1.2.104. “Global License Terms” means the Global Product License
and Collaboration Terms attached hereto as Appendix B, under which Alnylam may grant Genzyme a license to (i) ALN-AS1 and/or (ii) a Global Option Product, in each case with such license to be effective as of the applicable
Option Exercise Date. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 14 - 

 MASTER AGREEMENT 

 

 1.2.105. “Global Licensed Product” means (i) if
Genzyme exercises the Co-Co/Global Option for ALN-AS1, then ALN-AS1 as of the applicable Option Exercise Date, and (ii) if Genzyme exercises the Global Option for any Global Option Product, then such Global Option Product as of the applicable
Option Exercise Date, in each case for as long as the Global License Terms apply to such Co-Co/Global Option Product or such Global Option Product. 

1.2.106. “Global Option” has the meaning set forth in Section 3.2.3.1 (Global Option Grant). 

1.2.107. “Global Option Outside Date” means [***]. 

1.2.108. “Global Option Period” means the period beginning on the Effective Date and ending on the
earlier of (i) the occurrence of the Option Exercise Date for the exercise of the Global Option and, if exercisable, the Additional Global Option and (ii) the Global Option Outside Date. 

1.2.109. “Global Option Product” means any siRNA targeting a human gene that is generated by a Core
Pipeline Program, where such Core Pipeline Program is not a Named Pipeline Program. 
 1.2.110. “Global
R&D Costs” has the meaning ascribed thereto in each of the applicable License Terms. 
 1.2.111.
“Global Regulatory Costs” has the meaning ascribed thereto in the Co-Co License Terms. 
 1.2.112.
“GLP” or “Good Laboratory Practices” means, with respect to a particular Development activity or non-clinical study conducted by a Party, that such Development activity or non-clinical study (i) was conducted in
accordance with “good laboratory practices” as set forth in 21 C.F.R. Part 58, the United States Animal Welfare Act, the International Conference on Harmonization’s (“ICH”) Guideline on Nonclinical Safety Studies for
the Conduct of Human Clinical Trials for Pharmaceuticals or the ICH Guideline on Safety Pharmacology Studies for Human Pharmaceuticals or (ii) involved experimental research techniques that were performed for informational purposes only
(whether or not included in a regulatory filing) or could not be performed by a GLP-compliant testing facility (with appropriate notice being given to the FDA in regulatory filings), and such Party employed the procedures and controls generally used
by qualified experts in animal or preclinical studies of products comparable to those being developed by such Party. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 15 - 

 MASTER AGREEMENT 

 

 1.2.113. “Governmental Authority” means any
applicable government authority, court, tribunal, arbitrator, agency, department, legislative body, commission or other instrumentality of (a) any government of any country or territory, (b) any nation, state, province, county, city or
other political subdivision thereof or (c) any supranational body. 
 1.2.114. “Historical TTR
Agreement” has the meaning set forth in the recitals. 
 1.2.115. “HSR Act” means the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 
 1.2.116. “Human POP Study” means
[***]. 
 1.2.117. “Human POP Study Completion” means, with respect to an Option Product or other
siRNA, the [***] day [***]. 
 1.2.118. “IFRS” means International Financial Reporting Standards, as
consistently applied. 
 1.2.119. “Implementation Date,” with respect to a Collaboration Product, has
the meaning set forth in the License Terms applicable to such Collaboration Product. 
 1.2.120.
“IND” means an Investigational New Drug application, Clinical Trial Application or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in
conformance with the requirement of such Regulatory Authority, and any amendments thereto. 
 1.2.121.
“Indemnitee” has the meaning set forth in Section 10.4 (Indemnification Procedure). 
 1.2.122.
“Initial Evaluation Period” means, with respect to Option Product, the [***] day period beginning on the date that Genzyme acknowledges receipt of an Initial Option Data Package, as such period may be extended pursuant to
Section 3.3.4.3 (Extension of Initial Evaluation Period and Option Exercise Period). 
 1.2.123. “Initial
Option Data Package” means, with respect to an Option Product, the information set forth on Schedule 1.2.123. 

1.2.124. “Initial Option Notice” has the meaning set forth in Section 3.3.1 (Initial Option Data
Package). 
 1.2.125. “In-Licenses” means, collectively, all Existing Alnylam In-Licenses, all
Existing Genzyme In-Licenses and all Collaboration In-Licenses. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 16 - 

 MASTER AGREEMENT 

 

 1.2.126. “Investor Agreement” means that certain
Investor Agreement between Genzyme and Alnylam, executed as of the Effective Date, as the same may be amended from time to time. 

1.2.127. “IP Committee” means the intellectual property advisory committee as more fully described in
Section 5.3 (IP Committee). 
 1.2.128. “Know-How” means all chemical or biological materials
and other tangible materials, inventions, improvements, practices, discoveries, developments, data, information, technology, methods, protocols, formulas, knowledge, know-how, trade secrets, processes, assays, skills, experience, techniques and
results of experimentation and testing, including pharmacological, toxicological and pre-clinical and clinical data and analytical and quality control data; provided, however, excluding in any event any Patent Right and Trademarks.

 1.2.129. “KPIs” has the meaning set forth in Section 6.3 (General Supply Agreement
Requirements). 
 1.2.130. “Laws” means all applicable laws, statutes, rules, regulations, orders,
judgments, injunctions, ordinances or other pronouncements having the binding effect of law of any Governmental Authority, including if either Party is or becomes subject to a legal obligation to a Regulatory Authority or other Governmental
Authority (such as a corporate integrity agreement or settlement agreement with a Governmental Authority). 
 1.2.131.
“License Terms” means the Regional License Terms, the Co-Co License Terms or the Global License Terms, as applicable. 

1.2.132. “Licensed Target” means, for each Collaboration Product, the human gene that is targeted by
such Collaboration Product. 
 1.2.133. “Lipid Nanoparticle Formulation” means a lipid-based
nanoparticle comprising more than one lipid species designed to enable delivery of siRNAs to mammalian cells. 

1.2.134. “Locked Core Pipeline Program List” means the list of Core Pipeline Programs, as the same may
be updated from time to time in accordance with Section 3.1.1 (Program Identification), identifying those Core Pipeline Programs that shall remain Core Pipeline Programs for all purposes under the Collaboration Agreement, except as the Parties,
each acting in its sole discretion, may later mutually agree in writing. The Core Pipeline Programs that exist as of the Execution Date and shall be included on the Locked Core Pipeline Program List are identified on Schedule 1.2.134. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 17 - 

 MASTER AGREEMENT 

 

 1.2.135. “Locked Non-Core Pipeline Program List”
means the list of Non-Core Pipeline Programs, as the same may be updated from time to time in accordance with Section 3.1.1 (Program Identification), identifying those Non-Core Pipeline Programs that shall remain Non-Core Pipeline Programs for
all purposes under the Collaboration Agreement, except as the Parties, each acting in its sole discretion, may later mutually agree in writing. The Non-Core Pipeline Programs that exist as of the Execution Date and shall be included on the Locked
Non-Core Pipeline Program List are identified on Schedule 1.2.135. 
 1.2.136. “Losses” has
the meaning set forth in Section 10.1 (General Indemnification by Genzyme). 
 1.2.137.
“Manufacturing” or “Manufacture” means, as applicable, all activities associated with the production, manufacture, process of formulating, processing, filling, finishing, packaging, labeling, shipping, importing
and storage of Collaboration Products or Option Products (including Bulk Drug Product, Bulk Drug Substance and Finished Product) including process development, process validation, stability testing, manufacturing scale-up, pre-clinical, clinical and
commercial manufacture and analytical development, product characterization, quality assurance and quality control development, testing and release. 

1.2.138. “Manufacturing Committee” means the manufacturing advisory committee as more fully described
in Section 5.4 (Manufacturing Committee). 
 1.2.139. “Manufacturing FTE” means [***] hours of
work per annum devoted to or in support of the Development or Manufacture of a Collaboration Product that is carried out by one or more qualified scientific or technical employees of a Party or its Affiliates. 

1.2.140. “Manufacturing FTE Rate” means [***] per Manufacturing FTE, increased annually beginning,
for the first time, on January 1, 2015 and thereafter on January 1 of each succeeding year by the percentage increase in the CPI as of December 31 of the then most recently ended calendar year over the level of the CPI on
December 31, 2013. 
 1.2.141. “Merger Control Authorities” means all relevant Governmental
Authorities under applicable Antitrust Laws, including the FTC and DOJ. 
 1.2.142. “MicroRNA” or
“miRNA” means a structurally defined functional RNA molecule usually between nineteen (19) and twenty-five (25) nucleotides in length, which is derived from an endogenous, genetically-encoded non-coding RNA which is
predicted to be processed into a hairpin RNA structure that is a substrate for the double-stranded RNA-specific ribonuclease Drosha and subsequently is predicted to serve as a substrate for the enzyme Dicer, a member of the RNase III enzyme family.

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 18 - 

 MASTER AGREEMENT 

 

 1.2.143. “MicroRNA Mimic” means a single-stranded or
double-stranded oligonucleotide with the same or substantially similar-base composition and sequence (including chemically modified bases) as a particular natural miRNA and which is designed to mimic the activity of such miRNA. For clarity, miRNA
Mimic excludes a double-stranded oligonucleotide which functions or is designed to function as an siRNA. 
 1.2.144.
“Minimum Annual Investment” means [***], 
 1.2.145. “MMC” means any Alnylam
Territory MMC or Genzyme Territory MMC. 
 1.2.146. “Named Pipeline Programs” means those Alnylam
Programs listed on Schedule 1.2.146. 
 1.2.147. “NDA” means a New Drug Application,
Biologics License Application, Marketing Authorization Application or similar application or submission filed with a Regulatory Authority in a country or group of countries to obtain Regulatory Approval to market a product in that country or in that
group of countries, and any amendments thereto. 
 1.2.148. “Negotiation Period” has the meaning set
forth in Section 6.6.2.2 (Negotiating Period). 
 1.2.149. “New Information” has the meaning set
forth in Section 3.4.2.3 (Exercise of Preserved Option). 
 1.2.150. “Non-Core Pipeline Program
List” means the non-limiting list of Non-Core Pipeline Programs, attached hereto as Schedule 1.2.149, as the same may be updated from time to time by Alnylam in accordance with
Section 3.1.1 (Program Identification). The Non-Core Pipeline Programs as of the Execution Date are listed on Schedule 1.2.149. 

1.2.151. “Non-Sales-Based Payment” means any Third Party License Payment that is not a Sales-Based
Payment. 
 1.2.152. “Option” means any Regional Option, the Co-Co/Global Option, the Global Option,
the Additional Global Option, the 2019 Trailing Regional Option, any 2021 Trailing Regional Option or any Trailing Global Option, as applicable. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 19 - 

 MASTER AGREEMENT 

 

 1.2.153. “Option Data Package” means, with respect to
an Option Product, the Initial Option Data Package or, if applicable, the Final Option Data Package for such Option Product. 

1.2.154. “Option Exercise Date” means the date on which an Exercise Notice is deemed to have been given
by Genzyme to Alnylam pursuant to Section 13.11 (Notices) or such later date as may be required pursuant to Section 2.2.2 (Effectiveness of Licenses to Collaboration Products). 

1.2.155. “Option Exercise Period” means: 

(a) with respect to any Regional Option Product or ALN-AT3, the period [***]; 

(b) with respect to ALN-AS1 or any Global Option Product, the period [***]; or 

(c) if Alnylam delivers a Co-Co/Global Option Trigger Notice under Section 3.2.2.4 (Discontinuation of Second Co-Co/Global
Option Product) for the First Co-Co/Global Option Product, the [***] day period following Genzyme’s acknowledgement of receipt of such notice, as such period may be extended pursuant to 3.3.4.3 (Extension of Initial Evaluation Period and Option
Exercise Period). 
 1.2.156. “Option Period” means the period beginning on the Effective Date and
ending on the date that no Option remains exercisable. 
 1.2.157. “Option Preservation Notice” has
the meaning set forth in Section 3.3.2 (Initial Evaluation Period). 
 1.2.158. “Option Product”
means any Regional Option Product (including any Trailing Regional Option Product), Co-Co/Global Option Product or Global Option Product (including any Trailing Global Option Product). 

1.2.159. “Option Product Core Technology Patents” means Patent Rights Controlled by Alnylam during the
Option Period that are reasonably necessary or useful to Develop, Commercialize, and/or Manufacture Option Products, other than Option Product-Specific Patents. Option Product Core Technology Patents include Patent Rights Controlled by Alnylam that
claim [***]. The Option Product Core Technology Patents existing as of the Execution Date, solely in respect of the Existing Core Option Products, are those Patent Rights identified on Schedule 1.2.159. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 20 - 

 MASTER AGREEMENT 

 

 1.2.160. “Option Product Know-How” means Know-How
Controlled by Alnylam during the Term that is reasonably necessary or useful for Genzyme to Develop, Manufacture and/or Commercialize Option Products in the Field. 

1.2.161. “Option Product Patents” means Option Product Core Technology Patents and Option
Product-Specific Patents. 
 1.2.162. “Option Product-Specific Patents” means Patent Rights
Controlled by Alnylam during the Term that claim [***]. The Option Product-Specific Patents existing as of the Execution Date, solely in respect of the Existing Core Option Products, are those Patent Rights identified on Schedule 1.2.162.

 1.2.163. “Option Product Technology” means, collectively, Option Product Know-How and Option
Product Patents. 
 1.2.164. “Optioned Target” means, for each Option Product, the human gene that is
intended to be targeted by the Option Product. 
 1.2.165. “Orphan Disease” means [***]. 

1.2.166. “Out-of-Pocket Costs” means, with respect to certain activities hereunder, direct expenses
paid or payable by either Party or its Affiliates to Third Parties and specifically identifiable and incurred (and invoiced) to conduct such activities for an Option Product or a Collaboration Product, as applicable, including payments to contract
personnel. 
 1.2.167. “Party” means Genzyme or Alnylam. 

1.2.168. “Patent Challenge” has the meaning set forth in Section 12.2.4 (Challenges of Patent
Rights). 
 1.2.169. “Patent Rights” means (a) all issued patents (including any extensions,
restorations by any existing or future extension or registration mechanism (including patent term adjustments, patent term extensions, supplemental protection certificates or the equivalent thereof), substitutions, confirmations, re-registrations,
re-examinations, and patents of addition); (b) patent applications (including all provisional applications, substitutions, requests for continuation, continuations, continuations-in-part, divisionals and renewals); (c) inventor’s
certificates; and (d) all equivalents of the foregoing in any country of the world. 
 1.2.170. “Paying
Party” has the meaning set forth in Section 9.6 (Taxes). 
 1.2.171. “Permitted Third Party
Agreement” has the meaning set forth in Section 3.6.3 (ROFN for Available Third Party Rights). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 21 - 

 MASTER AGREEMENT 

 

 1.2.172. “Person” means any natural person,
corporation, unincorporated organization, partnership, association, sole proprietorship, joint stock company, joint venture, limited liability company, trust or government, or Governmental Authority, or any other similar entity. 

1.2.173. “Phase I Study” means a study in humans which provides for the introduction into humans of a
product, conducted in healthy volunteers or patients, to obtain initial information on product safety, tolerability, pharmacological activity or pharmacokinetics, as further defined in 21 C.F.R. § 312.21(a) (or the equivalent thereof outside
the United States). 
 1.2.174. “Phase II Study” means a study in humans of the safety, dose ranging
or efficacy of a product, as further defined in 21 C.F.R. § 312.21(b) (or the equivalent thereof outside the United States). 

1.2.175. “Phase III Study” means a study in humans of the efficacy and safety of a product, which is
prospectively designed to demonstrate statistically whether such product is effective and safe for use in a particular indication in a manner sufficient (alone or together with one or more other such studies) to file an application for Regulatory
Approval for the product. For the avoidance of doubt, the Parties acknowledge that, because of the nature of the diseases which the Collaboration Products are anticipated to treat, a Phase III Study for a Collaboration Product may not include
all of the elements that a Phase III Study for other kinds of drug products may include (e.g., a Phase III Study for a Collaboration Product may be a single study and there may be no prospective plan to run a second pivotal clinical trial
independent of such Phase III Study). 
 1.2.176. “Pipeline Advisory Committee” or “PAC”
means the pipeline advisory committee as more fully described in Section 5.2 (Pipeline Advisory Committee). 

1.2.177. “Post-Marketing Study” means a non-human or human clinical study of a Collaboration Product
initiated after receipt of Regulatory Approval for such Collaboration Product in a country or territory, that is required by the Regulatory Authority in such country or territory to maintain the Regulatory Approval for such Collaboration Product in
such country or territory, but excluding any Secondary Indication Study. 
 1.2.178. “Potential Alnylam
In-Licenses” means, with respect to ALN-TTR02, ALN-TTRsc and each Option Product, the potential future Third Party agreements described on Schedule 1.2.178. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 22 - 

 MASTER AGREEMENT 

 

 1.2.179. “Product” means a given quantity of
Collaboration Product in one of Bulk Drug Substance, Bulk Drug Product or Finished Product form. 
 1.2.180.
“Proposed CNS Terms” has the meaning set forth in Section 2.1.3.4 (ROFN for CNS). 
 1.2.181.
“Proposed In-License” has the meaning set forth in Section 11.3.3.1 (Proposed In-Licenses). 

1.2.182. “Proposed In-License Notice” has the meaning set forth in Section 11.3.3.1 (Proposed
In-Licenses). 
 1.2.183. “Receiving Party” has the meaning set forth in Section 9.6 (Taxes).

 1.2.184. “Regional License Terms” means those certain Regional Product License and Collaboration
Terms between Genzyme and Alnylam, in the form of Appendix A attached hereto, under which (i) Alnylam and Genzyme shall amend, restate and supersede the Historical TTR Agreement in respect of ALN-TTR02, effective as of the Effective
Date, and (ii) Alnylam may grant Genzyme a license to one or more Regional Licensed Products, effective as of the applicable Option Exercise Date. 

1.2.185. “Regional Licensed Product” means (i) ALN-TTR02 as of the Effective Date, and
(ii) if Genzyme exercises a Regional Option for any Regional Option Product, then such Regional Option Product as of the applicable Option Exercise Date, in each case for as long as the Regional License Terms applies to ALN-TTR02 or any such
Regional Option Product. 
 1.2.186. “Regional Option” has the meaning set forth in
Section 3.2.1.1 (Regional Option Grants). 
 1.2.187. “Regional Option Outside Date” means
[***]. 
 1.2.188. “Regional Option Period” means the period beginning on the Effective Date and
ending on the Regional Option Outside Date. 
 1.2.189. “Regional Option Product” means an siRNA that
is generated by a Core Pipeline Program. For clarity, any such siRNA shall constitute a Regional Option Product even if any such Regional Option Product is also a Co-Co/Global Option Product or a Global Option Product. 

1.2.190. “Regulatory Approval” means any and all approvals, licenses, registrations or authorizations
of any Regulatory Authority that are necessary for the marketing and sale of a product in a country or group of countries. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 23 - 

 MASTER AGREEMENT 

 

 1.2.191. “Regulatory Authority” means any
Governmental Authority involved in granting approvals for the Development, Manufacturing, Commercialization, reimbursement or pricing of Option Products or Collaboration Products, including the FDA, the EMA, the Japanese Ministry of Health, Labour
and Welfare (“MHLW”) and the Pharmaceuticals and Medical Devices Agency in Japan (“PMDA”). 

1.2.192. “Regulatory Briefing Document” has the meaning set forth in Section 3.3.3.1 (Final Option
Data Package). 
 1.2.193. “Related Party” means a Party’s Affiliates and permitted Sublicensees
(as defined in any of the License Terms). 
 1.2.194. “Residual Knowledge” means knowledge,
techniques, experience and Know-How that (a) are, or are based on any Confidential Information of the disclosing Party and (b) are retained in the unaided memory of any authorized representative of the receiving Party after having access
to such Confidential Information. An individual’s memory shall be considered to be unaided if the individual has not intentionally memorized the Confidential Information for the purpose of retaining and subsequently using or disclosing it. In
no event, however, shall Residual Knowledge include (i) any Genzyme Disclosed Manufacturing Know-How, (ii) any Alnylam Manufacturing Know-How or (iii) any Know-How to the extent (at any time, for such time) it is within the scope of
any issued, valid and enforceable Patent Right Controlled by the disclosing Party under any License Terms. 
 1.2.195.
“ROFN Exercise Notice” has the meaning set forth in Section 3.6.3 (ROFN for Available Third Party Rights). 

1.2.196. “ROFN Negotiation Period” has the meaning set forth in Section 3.6.3 (ROFN for Available
Third Party Rights) 
 1.2.197. “ROFN Non-Binding Offer” has the meaning set forth in
Section 3.6.3 (ROFN for Available Third Party Rights) 
 1.2.198. “ROFN Offer Notice” has the
meaning set forth in Section 3.6.3 (ROFN for Available Third Party Rights) 
 1.2.199. “Safety
Concern” means (a) any safety concern required to be reported under 21 C.F.R. § 312.32(c)(1)(iii) (“Findings from animal or in vitro testing”) if an IND with respect to such Option Product was open at the time of the
observation or (b) a material toxicity or material drug safety issue or a Serious Adverse Event reasonably related to an Option Product. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 24 - 

 MASTER AGREEMENT 

 

 1.2.200. “Sales-Based Payment” means any Third Party
License Payment that is calculated based on sales of a product (e.g., royalties and sales milestones). 
 1.2.201.
“SDEA” has the meaning set forth in Section 4.6 (Pharmacovigilance). 
 1.2.202.
“Second Co-Co/Global Option Product” has the meaning set forth in Section 3.2.2.2 (Second Co-Co/Global Option Product). 

1.2.203. “Second Source” has the meaning set forth in Section 6.6 (Establishment of Second
Source). 
 1.2.204. “Secondary Indication” means a use of a Collaboration Product or Option Product
for an indication that is not the first indication of such Collaboration Product or Option Product to receive Regulatory Approval, but is intended to be the subject of a supplemental application submitted to a Regulatory Authority that includes
clinical trial data from a Clinical Study seeking Regulatory Approval to market the Collaboration Product or Option Product for such use. 

1.2.205. “Secondary Indication Study” means a human clinical study of a Collaboration Product or Option
Product that is not necessary for receipt of the first anticipated Regulatory Approval for such Collaboration Product or Option Product in a country or territory but is intended to support receipt of Regulatory Approval for a Secondary Indication.

 1.2.206. “Serious Adverse Event” means an adverse drug experience or circumstance that results in
any of the following outcomes (a) death, (b) life-threatening condition, (c) inpatient hospitalization or a significant prolongation of existing hospitalization, (d) persistent or significant disability or incapacity or
substantial disruption of the ability to conduct normal life functions, (e) or a congenital anomaly/birth defect or (f) significant intervention required to prevent permanent impairment or damage. 

1.2.207. “siRNA” means an oligonucleotide composition of native or chemically modified RNA that targets
a gene through activation of the RNA interference pathway, and that is not a MicroRNA, MicroRNA antagonist or MicroRNA Mimic. 

1.2.208. “Stock Purchase Agreement” means that certain Stock Purchase Agreement between Genzyme and
Alnylam, executed as of the Execution Date, as the same may be amended from time to time. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 25 - 

 MASTER AGREEMENT 

 

 1.2.209. “Supply Agreements” means the Clinical
Supply Agreements, the Commercial Supply Agreements, the ALN-TTR Clinical Supply Agreement and the ALN-TTR Commercial Supply Agreement. 

1.2.210. “Supply Expert” has the meaning set forth in Section 6.3 (Disputed Supply Agreement
Terms). 
 1.2.211. “Supply Source Notice” has the meaning set forth in Section 6.6.2.2
(Negotiating Period). 
 1.2.212. “Technology Transfer” has the meaning set forth in Section 6.5
(Transfer of Manufacturing Know-How). 
 1.2.213. “Tentative Core Pipeline Program” has the meaning
set forth in Section 3.1.1.3(b) (Pipeline Programs Lists). 
 1.2.214. “Tentative Core Pipeline Program
List” has the meaning set forth in Section 3.1.1.3(b) (Pipeline Programs Lists). 
 1.2.215.
“Term” has the meaning set forth in Section 12.1 (Term). 
 1.2.216.
“Territory” means (i) with respect to Alnylam, the Alnylam Territory and (ii) with respect to Genzyme, the Genzyme Territory. 

1.2.217. “Third Party” means an entity other than a Party and its Affiliates. 

1.2.218. “Third Party CNS Agreement” has the meaning set forth in Section 2.1.3.2 (CNS
Exclusivity). 
 1.2.219. “Third Party License Payment” means royalties, upfront fees, milestones or
other amounts payable under an In-License in consideration for the rights granted under such In-License with respect to a Patent Right. 

1.2.220. “Third Party Pricing Terms” means, in respect of the supply of a Product, (i) the cost
per unit of Product, (ii) minimum order quantities (per batch and annually), (iii) firm order forecast requirements, (iv) cost, if any, for reserving capacity including any costs required to maintain compliance, and (v) capital
costs, if any, to enable manufacturing. 
 1.2.221. “Third Party Supply Agreement” has the meaning
set forth in Section 6.7 (Third Party Manufacturer as Second Source). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 26 - 

 MASTER AGREEMENT 

 

 1.2.222. “Trademark” means any trademark, trade name,
service mark, service name, brand, domain name, trade dress, logo, slogan or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing. 

1.2.223. “Trailing Global Option Product” means a Global Option Product (i) [***]. 

1.2.224. “Trailing Global Option” has the meaning set forth in 3.2.3.3 (Trailing Global Option Grant).

 1.2.225. “Trailing Regional Option Product” means a Regional Option Product [***]. 

1.2.226. “Transition Period” means the period beginning on Alnylam’s receipt of an Option
Preservation Notice with respect to an Option Product and ending on the earlier of (x) the Option Exercise Date for such Option Product or (y) the expiration of the Option Exercise Period for such Option Product. 

1.2.227. [***]. 

1.2.228. “TTR” means the human TTR gene and its protein product, transthyretin. As of the Execution
Date, an example of an identifier for the human TTR gene is the NCBI RefSeq code NM_000371.3 and an example of an identifier for the human TTR gene protein product NCBI RefSeq code NP_000362.1. 

1.2.229. “Un-Blocking Genzyme In-License” means, with respect to a Collaboration Product, any
Collaboration In-License that Genzyme enters into in accordance with Section 11.3.3 (Collaboration In-Licenses) and pursuant to which Genzyme has a license to any Blocking Patent Right with respect to such Collaboration Product. 

1.2.230. “United States” means the United States of America and its territories, possessions and
commonwealths. 
 Capitalized terms used, but not defined, herein shall have the meanings ascribed to those terms in the License Terms. 

2. EFFECTIVENESS OF AGREEMENTS AND LICENSES 

2.1. Effective Date.  

2.1.1. Effectiveness of Collaboration Agreement. Upon the occurrence of the Closing Date under the Stock Purchase
Agreement (the “Effective Date”), the Collaboration Agreement, which consists of this Master Agreement and the License 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 27 - 

 MASTER AGREEMENT 

 

 
Terms listed below, shall automatically, with no further action by any Party, go into full force and effect and all of the obligations of the applicable Party set forth therein (including in this
Master Agreement) shall become the binding obligations of the applicable Party thereto: 
  

	 	(a)	Regional License Terms; 

  

	 	(b)	Global License Terms; and 

  

	 	(c)	Co-Co License Terms. 

 2.1.2. Termination of Historical TTR Agreement.
Simultaneous with the Collaboration Agreement going into full force and effect on the Effective Date, the Historical TTR Agreement shall be terminated in its entirety and superseded in its entirety by the Collaboration Agreement on the Effective
Date, provided that all rights and obligations accrued under the Historical TTR Agreement shall continue for and against the Parties under the terms of the Collaboration Agreement. 

2.1.3. CNS Collaboration.  

2.1.3.1. CNS Exploration Period. During the [***] year period beginning on the Effective Date (the “CNS
Exploration Period”), the Parties will use commercially reasonable efforts to assess the state of the art in the area of delivery of siRNAs to the central nervous system (“CNS”), including identifying Third Parties with
relevant expertise and technology and, at Genzyme’s request, (a) develop a plan to jointly undertake research and development of siRNAs for delivery to the CNS and (b) negotiate in good faith and enter into a mutually agreeable
collaboration and license agreement pursuant to which the Parties will conduct the research and development activities set forth in such plan (the “CNS Collaboration and License Agreement”), which CNS Collaboration and License
Agreement shall contain customary and reasonable provisions for agreements of its type that may be agreed by the Parties, including provisions relating to governance, intellectual property ownership, prosecution and enforcement, regulatory
interactions and approvals, term and termination, representations and warranties, indemnification, and confidentiality. Each Party will dedicate employees within its organization with appropriate expertise in CNS and/or rare diseases to conducting
the activities described in this Section 2.1.3. 
 2.1.3.2. CNS Exclusivity. Subject to Section 2.1.3.3
(Exceptions to CNS Exclusivity), during the CNS Exploration Period, neither Party shall enter into any agreement with a Third Party regarding the development or commercialization of siRNAs delivered to the CNS (a “Third Party CNS
Agreement”) without the prior written consent of the other Party, provided that Genzyme may terminate the CNS Exploration Period at any time upon written notice to Alnylam. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 28 - 

 MASTER AGREEMENT 

 

 2.1.3.3. Exceptions to CNS Exclusivity. 

(a) Existing Third Party Agreements. None of the following agreements in existence or being negotiated on the Execution
Date shall constitute a “Third Party CNS Agreement” for purposes of this Master Agreement: (i) the agreements between Genzyme and a Third Party that will be identified by Genzyme by the Effective Date and added to Schedule
2.1.3.3 and (ii) the agreements between Alnylam and a Third Party, listed on Schedule 2.1.3.3, in each case ((i) and (ii)) as such agreements may be amended or restated in the future so long as such amendment or restatement does not
expand the field of such agreement, and the activities thereunder and discussions with such Third Party in relation thereto. 

(b) Future Third Party Agreements. The following shall not constitute “Third Party CNS Agreements” for
purposes of this Master Agreement: (i) any agreement between a Party and a contractor, contract research organization, contract manufacturer or other Third Party, under which such Third Party only performs contract services on behalf of such
Party, for the research, development or manufacture of siRNAs delivered to the CNS and for which no product-related commercial rights are granted or (ii) any agreement between a Party and an academic institution or non-profit institution, under
which such Party and such institution collaborate with respect to the research, development or manufacture of siRNAs delivered to the CNS and for which no product-related commercial rights are granted. 

(c) Internal Activities. Notwithstanding anything in this Section 2.1.3 (CNS Collaboration), either Party may
conduct internal programs and other activities regarding the research, development, manufacture and commercialization of siRNAs to be delivered to the CNS. 

2.1.3.4. ROFN for CNS. 

(a) ROFN Process. If Genzyme makes a request to negotiate under Section 2.1.3.1, but the Parties do not enter into,
a CNS Collaboration and License Agreement during the CNS Exploration Period and Genzyme does not terminate the CNS Exploration Period prior to its expiration, then, if at any time during the [***] year period following the CNS Exploration Period
(the “CNS ROFN  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 29 - 

 MASTER AGREEMENT 

 

 
Period”), Alnylam desires to enter into a Third Party CNS Agreement, Alnylam shall so notify Genzyme in writing, which notice shall describe the proposed terms of such Third Party CNS
Agreement (the “Proposed CNS Terms”). Upon receipt of such notice from Alnylam, Genzyme shall have [***] days from receipt of such written notice to notify Alnylam in writing as to whether Genzyme desires to negotiate an agreement
with Alnylam with respect to the Proposed CNS Terms (a “CNS ROFN Exercise Notice”). If Genzyme delivers a CNS ROFN Exercise Notice prior to the expiration of such [***] day period, Genzyme shall have the exclusive right [***] days
following the date that Genzyme delivers a CNS ROFN Exercise Notice (the “CNS ROFN Offer Period”) to negotiate with Alnylam and to make one or more written non-binding offers to Alnylam concerning the terms on which Genzyme would
enter into an agreement with respect to the Proposed CNS Terms (the “CNS ROFN Non-Binding Offer”). If Genzyme delivers a CNS ROFN Non-Binding Offer to Alnylam prior to the expiration of the CNS ROFN Offer Period, Genzyme shall
thereafter have the exclusive right for [***] days (or such longer period as may be mutually agreed by the Parties) (the “CNS ROFN Negotiation Period”), to finalize and enter into a definitive agreement with Alnylam with respect to
the Proposed CNS Terms. 
 (b) Post-ROFN MFN. Alnylam shall not, during the CNS ROFN Offer Period or CNS ROFN
Negotiation Period, enter into discussions, exchange information, or otherwise negotiate with any Third Party with respect to the Proposed CNS Terms. If (i) Genzyme does not provide a CNS ROFN Exercise Notice within [***] days of receiving
notice of the Proposed CNS Terms, (ii) Genzyme does not provide a CNS ROFN Non-Binding Offer prior to the expiration of the CNS ROFN Offer Period prior to the expiration of the CNS ROFN Offer Period, or (iii) the Parties do not enter into
a definitive agreement with respect to the Proposed CNS Terms prior to the expiration of the CNS ROFN Negotiation Period, then Alnylam shall be free to enter into an agreement with any Third Party with respect to such Proposed CNS Terms,
provided that, for the remainder of the CNS ROFN Period, Alnylam shall not enter into an agreement with respect to such Proposed CNS Terms that are, in the aggregate, materially more favorable to such Third Party than the last terms offered
in writing by Genzyme to Alnylam during the CNS ROFN Offer Period or CNS ROFN Negotiation Period, as applicable, unless Alnylam first re-offers to enter into an agreement with Genzyme on such more favorable terms and Genzyme does not accept such
offer and enter into such agreement with Alnylam within [***] days after such re-offer. For clarity, prior to the CNS ROFN Offer Period and CNS ROFN Exercise Period, Alnylam shall be free to engage in discussions and exchange information with Third
Parties with respect to development or commercialization of siRNAs delivered to the CNS, but shall not enter into any binding agreement with any Third Party with respect to such rights. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 30 - 

 MASTER AGREEMENT 

 

 (c) Notwithstanding the foregoing, in the event that Genzyme enters into any
Third Party CNS Agreement following the Execution Date without the prior written consent of Alnylam, Genzyme’s exclusive rights under this Section 2.1.3 shall automatically convert to non-exclusive rights and the proviso set forth in
Section 2.1.3.4(b) (Post-ROFN MFN) shall automatically no longer apply. The foregoing shall be Alnylam’s sole and exclusive remedy with respect to any breach of Section 2.1.3.2 (CNS Exclusivity) by Genzyme. 

2.2. Effectiveness of Licenses to Collaboration Products. As promptly as practicable following Alnylam’s delivery of a Final
Option Data Package to Genzyme, but not later than the applicable Option Exercise Date, Genzyme shall determine whether any filing or notification is necessary or advisable under any applicable Antitrust Law if Genzyme were to exercise the
respective Option to take a license from Alnylam to Genzyme in respect of the corresponding Option Product pursuant to the applicable License Terms. 

2.2.1. If Genzyme determines that a filing or notification under any applicable Antitrust Law is not necessary or
advisable, then Genzyme shall indicate the same in the respective Exercise Notice for such Option. 
 2.2.2. If
Genzyme determines that a filing or notification under any applicable Antitrust Law is necessary or advisable, then Genzyme shall indicate the same in the respective Exercise Notice for such Option and each of Genzyme and Alnylam shall make or cause
to be made such notifications and filings as promptly as practicable (but in any event within [***] business days). Each Party shall be responsible for its own costs and expenses associated with such notifications and filings, and Genzyme shall pay
any applicable premerger filing fee under the HSR Act. Each Party shall use its commercially reasonable efforts to obtain the expiration or termination of the applicable waiting period under the HSR Act, and to obtain the termination or expiration
of any other applicable waiting periods or any necessary approvals or consents under any other applicable Antitrust Law, at the earliest possible date after the date of filing. Immediately following the later of the expiration or termination of the
last such waiting period, or receipt of any necessary approvals or consents under any other applicable Antitrust Law, Genzyme shall send Alnylam written notice that all waiting periods under any applicable Antitrust Law have expired or been
terminated and any necessary approvals or consents under any applicable Antitrust Law have been obtained. The effectiveness of the Option Exercise Date for the corresponding Collaboration Product, which will be the Implementation Date under the
applicable License Terms, shall be deemed to be delayed until the date on which the last waiting period under any applicable Antitrust Law has expired or been terminated or on which the last approval or consent under such Antitrust Law is granted.

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 31 - 

 MASTER AGREEMENT 

 

 2.3. Cooperation. Each of Genzyme and Alnylam shall: (i) reasonably
cooperate with each other in connection with any investigation or other inquiry relating to the transactions contemplated by an Exercise Notice for an Option; (ii) reasonably keep the other Party informed of any communication received by such
Party from, or given by such Party to, the FTC, the DOJ or any other Merger Control Authority and of any communication received or given in connection with any proceeding by a private party, in each case regarding the transactions contemplated by an
Exercise Notice for an Option; (iii) promptly respond to and certify substantial compliance with any inquiries or requests received from the FTC, the DOJ or any other Merger Control Authorities for additional information or documentation;
(iv) reasonably consult with each other in advance of any meeting or conference with the FTC, the DOJ or any other Merger Control Authority, and to the extent permitted by the FTC, the DOJ or such other Merger Control Authority and reasonably
determined by such Party to be appropriate under the circumstances, give the other Parties or their counsel the opportunity to attend and participate in such meetings and conferences; and (v) permit the other Parties or their counsel to the
extent reasonably practicable to review in advance, and in good faith consider the views of the other Parties or their counsel concerning, any submission, filing or communication (and documents submitted therewith) intended to be given by it to the
FTC, the DOJ or any other Merger Control Authority; provided, however, such Party shall be under no obligation to reschedule any meetings or conferences with the FTC, the DOJ or any other Merger Control Authority to enable the other
Party to attend. 
 2.4. No Antitrust Undertakings. Notwithstanding anything to the contrary in this Section 2, the term
“commercially reasonable efforts” as used in this Section 2 does not require that either Party (i) offer, negotiate, commit to or effect, by consent decree, hold separate order, trust or otherwise, the sale, divestiture, license
or other disposition of any capital stock, assets, rights, products or businesses of Genzyme, Alnylam or their respective Affiliates, (ii) agree to any restrictions on the activities of Genzyme, Alnylam or their respective Affiliates, or
(iii) pay any material amount or take any other action to prevent, effect the dissolution of, vacate, or lift any decree, order, judgment, injunction, temporary restraining order, or other order in any suit or proceeding that would otherwise
have the effect of preventing or delaying any of the transactions contemplated by an Exercise Notice for an Option. 
 2.5. No
Effect.  
 2.5.1. Transaction Agreements. The Collaboration Agreement shall (i) not take effect
until the occurrence of the Closing (as defined in the Stock Purchase Agreement) in accordance with its terms and (ii) become null and void and have no further force or effect in the event the Stock Purchase Agreement is terminated prior to the
Closing in accordance with its terms. 
 2.5.2. License to an Option Product. At the election of either Party,
immediately upon notice to the other Party, Genzyme’s exercise of an Option shall become null and void and have no further force or effect (i) in the event that the FTC or DOJ obtains a preliminary injunction against the Parties to enjoin
the transactions contemplated by the Exercise Notice for such Option or (ii) in the event any applicable 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 32 - 

 MASTER AGREEMENT 

 

 
waiting periods shall not have expired or been terminated, or any necessary approvals or consents shall not have been obtained, under any applicable Antitrust Law on or prior to [***] months
after the effectiveness of the filings and notifications contemplated by Section 2.2.2 (Effectiveness of Licenses to Collaboration Products). In addition, beginning on the [***] day following Genzyme’s delivery of an Exercise Notice with
respect to an Option Product but prior to the Option Exercise Date for the corresponding Collaboration Product, Genzyme shall have the right to nullify its exercise of such Option by providing written notice to Alnylam. Following the voiding or
nullification of Genzyme’s exercise of an Option for any reason under this Section 2.5, the Option Product previously subject to such Option shall be treated for all purposes under this Master Agreement, including Section 3.5, as an
Option Product in respect of which Genzyme did not deliver an Exercise Notice to Alnylam. 
 3. GRANT AND EXERCISE OF OPTIONS 

3.1. Alnylam Programs.  

3.1.1. Program Identification. 

3.1.1.1. Alnylam Development Updates. At each regularly scheduled meeting of the PAC during the Option Period,
Alnylam shall advise the PAC of any Alnylam Program with respect to which, since the last PAC meeting, either (i) the existence of such Alnylam Program (and the target thereof) has been publicly disclosed by Alnylam, including as a result of
the filing of an IND for such siRNA or (ii) [***]. In addition, Alnylam may elect to advise the PAC of any Alnylam Program at any time. The PAC shall discuss the selection of new targets for new Core Pipeline Programs and the research and
development strategy for Option Products. Alnylam shall consider in good faith recommended new targets proposed by Genzyme. 

3.1.1.2. PAC Categorization of Alnylam Programs. The PAC, acting reasonably, shall seek to determine whether such
Alnylam Program is a Core Pipeline Program or a Non-Core Pipeline Program and advise the Parties of its consensus view (if any). 

3.1.1.3. Pipeline Programs Lists. 

(a) If the PAC recommends to the AJSC and to the Parties that any Alnylam Program is a Core Pipeline Program or a Non-Core
Pipeline Program, then the Parties may agree that such Alnylam Program shall be identified on the Core Pipeline Program List or the Non-Core Program Pipeline List, respectively. Any Alnylam Program and the corresponding human gene and siRNA, for as
long as listed on the Core Pipeline Program List or Non-Core Pipeline Program List, shall be treated as a Core Pipeline Program or Non-Core Pipeline Program, as applicable, for all purposes of this Master Agreement, subject to this
Section 3.1.1. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 33 - 

 MASTER AGREEMENT 

 

 (b) If, within [***] days of the PAC meeting referred to in
Section 3.1.1.2 (PAC Categorization of Alnylam Programs), the Parties, acting reasonably, are unable to agree on whether any such Alnylam Program is a Core Pipeline Program or a Non-Core Pipeline Program, then such Alnylam Program shall be
deemed to be a “Tentative Core Pipeline Program” and shall be identified on a list of such Tentative Core Pipeline Programs (the “Tentative Core Pipeline Program List”) and, for the sake of clarity, except as
provided in Section 3.1.1.5 (Requested Dispute Resolution), such disagreement shall not be subject to resolution pursuant to Section 5.1.8 (Decision-Making). Any Alnylam Program and the corresponding human gene and siRNA, for as long as
listed on the Tentative Core Pipeline Program List, shall be treated as a Core Pipeline Program for purposes of Section 3.1.2.1 (Information Sharing for Core Pipeline Programs), Section 3.1.2.2 (Meetings with Regulatory Authorities),
Section 3.1.2.3 (Design of Human POP Studies), Section 3.6 (Exclusivity during Option Period), Section 5.3.3 (IP Committee Responsibilities) and Section 11 (Intellectual Property), subject to Section 3.1.1 (Program
Identification). 
 3.1.1.4. Locking of Alnylam Programs. Alnylam shall notify the PAC promptly after the first
IND with respect to an Alnylam Program becomes, or is deemed to be, effective and (i) if such Alnylam Program is on the Core Pipeline Program List or Non-Core Pipeline Program List, it will automatically be moved to the Locked Core Pipeline
Program List or the Locked Non-Core Pipeline Program List, as applicable, upon delivery of such notice; or (ii) if such Alnylam Program is on the Tentative Core Pipeline Program List, then the Parties will seek to reach consensus as to whether
such Alnylam Program is a Core Pipeline Program or Non-Core Pipeline Program within [***] days after delivery of such notice. If the Parties agree on the categorization of such Tentative Core Pipeline Program within such [***] day period, such
Alnylam Program will automatically be moved to the Locked Core Pipeline Program List or the Locked Non-Core Pipeline Program List, as applicable. If the Parties cannot agree within such [***] day period, either Party may submit the categorization of
such Alnylam Program to the AJSC for resolution pursuant to Section 5.1.8 (Decision-Making) and, following any such resolution of such categorization, such Alnylam Program will automatically be moved to the Locked Core Pipeline Program List or
the Locked Non-Core Pipeline Program List, as applicable. Once an Alnylam Program has been moved to the Locked Core Pipeline Program List or the Locked Non-Core Pipeline Program List, such Core Pipeline Programs shall remain Core Pipeline Programs
and such Non-Core Pipeline Programs shall remain Non-Core 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 34 - 

 MASTER AGREEMENT 

 

 Pipeline Programs, respectively, for all purposes under the Collaboration Agreement, except
as the Parties, each acting in its sole discretion, may later mutually agree in writing. Notwithstanding the foregoing, if Alnylam enters into an agreement with a Third Party granting such Third Party any rights or options to a Non-Core Pipeline
Program (or any siRNA arising therefrom) prior to the first IND with respect to such Non-Core Pipeline Program becoming effective, Alnylam shall notify the PAC of the existence of such an agreement (but not the counterparty thereto or any terms
thereof) and the human gene(s) targeted by such Non-Core Pipeline Program (or any siRNA arising therefrom) and such Non-Core Pipeline Program will automatically then be moved to the “Locked Non-Core Pipeline Program List” as of the date of
such agreement, [***]. 
 3.1.1.5. Requested Dispute Resolution. If an Alnylam Program is not listed on the
Locked Core Pipeline Program List or the Locked Non-Core Pipeline Program List and the Parties, at any time, are unable to agree on whether any such Alnylam Program is a Core Pipeline Program or a Non-Core Pipeline Program then, upon the request of
either Party, such categorization of such Alnylam Program shall be submitted to the AJSC for resolution pursuant to Section 5.1.8 (Decision-Making), and, following resolution, such Alnylam Program will automatically be moved to the Locked Core
Pipeline Program List or the Locked Non-Core Pipeline Program List, as applicable. 
 3.1.1.6. Updating Program
Lists. Solely as an administrative manner, Alnylam shall be responsible for updating the Core Pipeline Program List, the Locked Core Pipeline Program List, the Non-Core Pipeline Program List, the Locked Non-Core Pipeline Program List and the
Tentative Core Pipeline Program List from time to time, in all cases in accordance with this Section 3.1.1. Promptly following any such update, Alnylam shall provide a copy of the applicable list to each of the PAC representatives. 

3.1.2. Core Pipeline Programs. 

3.1.2.1. Information Sharing for Core Pipeline Programs. 

(a) During the Option Period, Alnylam shall update the PAC, at each regularly scheduled meeting thereof, on the status of the
Core Pipeline Programs, which update shall include a summary of the Development activities undertaken by Alnylam with respect to such Core Pipeline Programs since the last update provided to the PAC or planned to be undertaken by Alnylam. [***]. In
addition, in connection with each regularly scheduled meeting of the PAC during the Option Period, Alnylam will provide to the PAC and Genzyme copies of all then-available preclinical, clinical, regulatory and supporting reports and material
correspondence with Regulatory Authority with respect to any Core Pipeline 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 35 - 

 MASTER AGREEMENT 

 

 
Program and, if available, a copy of any Development plan for each Core Pipeline Program. Notwithstanding the foregoing, Alnylam shall not be obligated pursuant to the foregoing to provide
information the disclosure of which would: (a) in the reasonable opinion of Alnylam’s counsel, adversely affect the attorney-client privilege between Alnylam and its counsel; or (b) violate or cause a breach by Alnylam of any
confidentiality or non-disclosure agreement with any Third Party. Once Alnylam delivers an Initial Option Data Package for an Option Product, Alnylam will provide information related to such Option Product solely pursuant to Section 3.3 (Option
Exercise Period), including Section 3.3.3.2 (Governance) if Genzyme delivers an Option Preservation Notice for such Option Product to Alnylam, and Alnylam shall not have any obligations related to such Option Product and its related Core
Pipeline Program under Sections 3.1.1 (Program Identification), 4.5 (Oversight), 5 (Collaboration Management) or 11.2 (Patent Prosecution Information Sharing). 

(b) Following the filing of an IND with respect to a Core Pipeline Program, Alnylam shall (x) promptly provide
(i) any patent, regulatory or CMC information, (ii) any material, complete sets of preclinical or clinical data and (iii) raw data tables, in each case ((i), (ii) and (iii)) then available to Alnylam that Genzyme may reasonably
request, to the extent that such information was not previously provided by Alnylam to Genzyme and subject to customary and reasonable due diligence procedures to preserve the confidential nature of any such information, regarding such Option
Product to assist Genzyme in deciding whether to exercise an Option for such Option Product if and when any such Option becomes exercisable; and (y) afford to Genzyme and its representatives, reasonable access during normal business hours to
Alnylam’s personnel that Genzyme may reasonably request regarding such Option Product to assist Genzyme in deciding whether to exercise an exercisable Option for such Option Product. 

3.1.2.2. Meetings with Regulatory Authorities. Alnylam shall provide Genzyme with reasonable advance notice of
any pre-IND meetings with any Regulatory Authority with respect to any Core Pipeline Program, or with as much advance notice as practicable under the circumstances. [***]. 

3.1.2.3. Design of Human POP Studies. During the Option Period, Alnylam shall reasonably consult with the AJSC
regarding the design of each Human POP Study proposed to be conducted for any siRNA generated by a Core Pipeline Program. In addition, at least [***] days prior to submitting a final protocol for such Human POP Study to a Regulatory Authority as
part of an IND, Alnylam shall submit a draft of such protocol (or, if a draft protocol is not available, a full protocol concept sheet) to the AJSC for review and comment. If a draft protocol was not available, Alnylam shall provide the draft
protocol to the 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 36 - 

 MASTER AGREEMENT 

 

 
AJSC as soon as it becomes available. Alnylam shall reasonably consider in good faith any comments provided by the AJSC (or its members) within [***] days of the submission of such draft protocol
or full protocol concept sheet to the AJSC; provided, however, in any event, the AJSC shall have at least [***] days to review and comment on the draft protocol. [***]. 

3.1.2.4. Improperly Designated Programs. In the event that (i) it is determined [***] and (iii) Alnylam
continues to conduct such Alnylam Program following such [***] determination as a Non-Core Pipeline Program, but does not initiate a Phase II Study for any siRNA generated by such Non-Core Pipeline Program in a non-Orphan Disease or any cancer or infectious disease within [***] following the date on which such siRNA received Regulatory Approval in respect of an Orphan Disease, then Alnylam
and Genzyme shall in good faith negotiate together the terms under which such siRNA could be deemed a Regional Option Product (even if such [***] year period ends after the expiration of the Regional Option Period), including [***]. Following
agreement on such terms, Alnylam shall provide Genzyme with an Initial Option Notice with respect to the applicable siRNAs as soon as reasonably practicable. If the Parties are unable to agree upon the terms under which such siRNA could be deemed a
Regional Option Product during the first [***] days of such negotiation, [***]. 
 3.2. Option Grants.  

3.2.1. Regional Option Grants. 

3.2.1.1. Regional Option Grants. Alnylam hereby grants Genzyme a series of exclusive options (each,
a “Regional Option”), under each of which Genzyme shall have the right, but not the obligation, to take a license on the terms set forth in the Regional License Terms to any Regional Option Product that achieves Human POP Study
Completion during the Regional Option Period. Each Regional Option may be exercised by Genzyme at any time during the applicable Option Exercise Period for a Regional Option Product that achieves Human POP Study Completion in accordance with the
terms and conditions set forth in Sections 3.3 (Option Exercise Period) and 3.4 (Exercise of an Option). 
 3.2.1.2.
[***]. 
 3.2.1.3. [***]. 

3.2.2. Co-Co/Global Option Grant. Alnylam hereby grants Genzyme one (1) exclusive option (the “Co-Co/Global
Option”) under which Genzyme shall have the right, but not the obligation, to either (i) take a license on the terms set forth in the Global License Terms to ALN-AS1 or (ii) take a license on the terms set forth in the Co-Co 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 37 - 

 MASTER AGREEMENT 

 

 
License Terms to ALN-AT3. Genzyme may wait to exercise such Co-Co/Global Option until both ALN-AS1 and ALN-AT3 achieve Human POP Study Completion as described below in this Section 3.2.2, or
may terminate such Co-Co/Global Option prior to both ALN-AS1 and ALN-AT3 achieving Human POP Study Completion (in which case, the Additional Global Option will become exercisable pursuant to Section 3.2.3.2 (Additional Global Option Grant)).
The Co-Co/Global Option may be exercised by Genzyme at any time during the applicable Option Exercise Period for a Co-Co/Global Option Product in accordance with the terms and conditions set forth in Sections 3.3 (Option Exercise Period) and 3.4
(Exercise of an Option), subject to the conditions set forth in this Section 3.2.2. 
 3.2.2.1. First
Co-Co/Global Option Product. For the first Co-Co/Global Option Product to achieve Human POP Study Completion (the “First Co-Co/Global Option Product”), Genzyme may do any of the following: 

(a) exercise a Regional Option (or 2019 Trailing Regional Option or 2021 Trailing Regional Option, if and as applicable) for
such First Co-Co/Global Option Product, in which case the Co-Co/Global Option shall remain exercisable with respect to the First Co-Co/Global Option Product on the terms set forth in Sections 3.2.2.2(a) (Second Co-Co/Global Option Product) and
3.2.2.4 (Discontinuation of Second Co-Co/Global Option Product); 
 (b) exercise the Co-Co/Global Option for the First
Co-Co/Global Option Product, in which case the Co-Co/Global Option shall be fully exercised; or 
 (c) not exercise any
Option for the First Co-Co/Global Option Product, in which case the Co-Co/Global Option shall cease to be exercisable with respect to the First Co-Co/Global Option Product but shall remain exercisable for the Second Co-Co/Global Option Product. 

3.2.2.2. Second Co-Co/Global Option Product. For the second Co-Co/Global Option Product (i.e., if the
First Co-Co/Global Option Product is ALN-AT3, then ALN-AS1 or, if the First Co-Co/Global Option Product is ALN-AS1, then ALN-AT3) to achieve Human POP Study Completion (the “Second Co-Co/Global Option Product”), Genzyme may do any
of the following: 
 (a) exercise the Co-Co/Global Option for the First Co-Co/Global Option Product, in which case the
Co-Co/Global Option shall be fully exercised; 
 (b) exercise the Co-Co/Global Option for the Second Co-Co/Global Option
Product, in which case the Co-Co/Global Option shall be fully exercised; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 38 - 

 MASTER AGREEMENT 

 

 (c) exercise a Regional Option (or 2019 Trailing Regional Option or 2021
Trailing Regional Option, if and as applicable) for the Second Co-Co/Global Option Product, in which case, the Co-Co/Global Option shall be terminated in full and the Additional Global Option will become exercisable pursuant to Section 3.2.3.2
(Additional Global Option Grant) (for clarity, Genzyme may do both (a) and (c) of this Section 3.2.2.2); or 

(d) not exercise any Option for the Second Co-Co/Global Option Product, in which case 

(i) if the Second Co-Co/Global Option Product achieved Clinical Success (and Genzyme does not exercise the Co-Co/Global Option for the First
Co-Co/Global Option Product or the Second Co-Co/Global Option Product or Genzyme has terminated the Co-Co/Global Option pursuant to Section 3.2.2.5 (Genzyme Elective Termination of Co-Co/Global Option)), the Co-Co/Global Option shall terminate
in full at the end of the Option Exercise Period for the Second Co-Co/Global Option Product and the Additional Global Option will become exercisable pursuant to Section 3.2.3.2 (Additional Global Option Grant); 

(ii) if the Second Co-Co/Global Option Product did not achieve Clinical Success, but the First Co-Co/Global Option Product did achieve
Clinical Success (and Genzyme does not exercise the Co-Co/Global Option for the First Co-Co/Global Option Product or the Second Co-Co/Global Option Product or Genzyme has terminated the Co-Co/Global Option pursuant to Section 3.2.2.5 (Genzyme
Elective Termination of Co-Co/Global Option)), then the Co-Co/Global Option shall terminate in full at the end of the Option Exercise Period for the Second Co-Co/Global Option Product and the Additional Global Option will become exercisable pursuant
to Section 3.2.3.2 (Additional Global Option Grant); 
 (iii) if both the Second Co-Co/Global Option Product and the First Co-Co/Global
Option Product failed to achieve Clinical Success, then the Co-Co/Global Option shall remain exercisable but only with respect to the next Co-Co/Global Option Product, if any, to achieve Clinical Success (the “Back-Up Co-Co/Global Option
Product”). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 39 - 

 MASTER AGREEMENT 

 

 3.2.2.3. Back-Up Co-Co/Global Option Product. If the
Co-Co/Global Option is exercisable with respect to the Back-Up Co-Co/Global Option Product pursuant to Section 3.2.2.2(d)(iii), Genzyme may do any of the following: 

(a) exercise the Co-Co/Global Option for the Back-Up Co-Co/Global Option Product, in which case the Co-Co/Global Option shall
be fully exercised; or 
 (b) not exercise the Co-Co/Global Option for the Back-Up Co-Co/Global Option Product, in which case
the Co-Co/Global Option shall terminate in full at the end of the Option Exercise Period for the Back-Up Co-Co/Global Option Product and the Additional Global Option will become exercisable pursuant to Section 3.2.3.2 (Additional Global Option
Grant). 
 3.2.2.4. Discontinuation of Second Co-Co/Global Option Product. If Genzyme exercises a Regional
Option for the First Co-Co/Global Option Product and Alnylam decides to abandon or terminate Development of the other Co-Co/Global Option Product prior to achieving Human POP Study Completion, then Alnylam shall promptly deliver written notice of
such abandonment or termination to Genzyme (any such notice, the “Co-Co/Global Option Trigger Notice”) and Genzyme may do either of the following: 

(a) exercise the Co-Co/Global Option for the First Co-Co/Global Option Product, in which case the Co-Co/Global Option shall be
fully exercised and the First Co-Co/Global Option Product shall cease to be a Regional Licensed Product; or 
 (b) not
exercise the Co-Co/Global Option for the First Co-Co/Global Option Product, in which case the Co-Co/Global Option shall terminate in full at the end of the applicable Option Exercise Period, the First Co-Co/Global Option Product shall continue to be
a Regional Licensed Product and the Additional Global Option will become exercisable pursuant to Section 3.2.3.2 (Additional Global Option Grant). 

3.2.2.5. Genzyme Elective Termination of Co-Co/Global Option. At any time prior to the exercise of the
Co-Co/Global Option, Genzyme may, in its sole discretion, terminate the Co-Co/Global Option by providing written notice of termination to Alnylam and, upon delivery of such notice, the Co-Co/Global Option shall irrevocably and perpetually terminate
in full, the Option Exercise Period for the Co-Co/Global Option shall expire, and the Additional Global Option will become exercisable pursuant to Section 3.2.3.2 (Additional Global Option Grant). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 40 - 

 MASTER AGREEMENT 

 

 3.2.3. Global Option Grants. 

3.2.3.1. Global Option Grant. Alnylam hereby grants Genzyme one (1) exclusive option (the “Global
Option”), under which Genzyme shall have the right, but not the obligation, to take a license on the terms set forth in the Global License Terms to any Global Option Product for which it is anticipated that Human POP Study Completion will
be achieved during the Global Option Period. The Global Option may be exercised by Genzyme at any time during the applicable Option Exercise Period for a Global Option Product for which a Human POP Study is conducted during the Global Option Period
in accordance with the terms and conditions set forth in Sections 3.3 (Option Exercise Period) and 3.4 (Exercise of an Option). The Global Option shall terminate in full upon the Option Exercise Date for any Global Option Product with respect to
which Genzyme exercises the Global Option. 
 3.2.3.2. [***]. 

3.2.3.3. [***]. 

3.3. Option Exercise Period.  

3.3.1. Initial Option Data Package. As soon as is reasonably practicable on or after [***] (i) any Option Product
that achieves Human POP Study Completion during the applicable Option Period or (ii) any Trailing Regional Option Product or Trailing Global Option Product that achieves Human POP Study Completion after the end of the applicable Option Period;
(y) Genzyme notifies Alnylam that it desires to exercise the Co-Co/Global Option with respect to ALN-AS1 prior to the achievement of Human POP Study Completion; or (z) Genzyme notifies Alnylam that it desires to exercise the Global Option
or the Additional Global Option with respect to a Global Option Product prior to the achievement of Human POP Study Completion, Alnylam shall complete all activities necessary for Alnylam to prepare a complete Initial Option Data Package for the
applicable Option Product and provide a written notice to Genzyme (such notice, an “Initial Option Notice”). Alnylam shall include in each such Initial Option Notice:: 

(a) a letter indicating which Option(s) is(are) applicable to the Option Product; 

(b) the Initial Option Data Package for the Option Product (and all such data therein shall be made available to Genzyme
through an electronic data room promptly following the date that such Initial Option Notice is delivered); and 
 (c) a
certification of an officer of Alnylam as to the accuracy and completeness of the provided information. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 41 - 

 MASTER AGREEMENT 

 

 Within [***] days after Genzyme’s receipt of an Initial Option Notice, Genzyme shall
acknowledge receipt of such Initial Option Notice in writing to Alnylam or be deemed to have acknowledged such receipt as of such date. For clarity, if Genzyme requests the delivery of an Initial Option Notice with respect to ALN-AS1 or a Global
Option Product prior to the time determined in accordance with clause (x) of this Section 3.3.1, Alnylam shall only be obligated to provide such information in the Initial Option Data Package as is available to Alnylam as of the date of
such request from Genzyme. 
 3.3.2. Initial Evaluation Period. If an Initial Option Notice is delivered by Alnylam to
Genzyme pursuant to clause (x) of Section 3.3.1 (Initial Option Package) (i.e., after an Option Product achieves Human POP Completion), then, if Genzyme desires to preserve its right to exercise an Option for such
Option Product, Genzyme shall notify Alnylam in writing of Genzyme’s desire to exercise an Option and the type of Option that Genzyme desires to exercise (an “Option Preservation Notice”) prior to the expiration of the Initial
Evaluation Period with respect to such Option Product. If Genzyme delivers an Option Preservation Notice to Alnylam prior to the expiration of the Initial Evaluation Period for an Option Product, then Section 3.3.3 (Effect of Option
Preservation) shall apply. If Genzyme does not deliver an Option Preservation Notice to Alnylam prior to the expiration of the Initial Evaluation Period for an Option Product, then such Option Product shall be treated for all purposes under this
Master Agreement, including Section 3.5 (Option Not Exercised), as an Option Product in respect of which Genzyme did not deliver an Exercise Notice to Alnylam.  

3.3.3. Effects of Option Preservation. If Genzyme delivers an Option Preservation Notice prior to the expiration of the
Initial Evaluation Period for an Option Product pursuant to Section 3.3.2 (Initial Evaluation Period), then the provisions of this Section 3.3.3 shall apply. 

3.3.3.1. Final Option Data Package. Within [***] days after the earlier of [***], Alnylam shall complete all
activities necessary for Alnylam to prepare a complete Final Option Data Package for the applicable Option Product and deliver such Final Option Data Package to Genzyme. Within [***] days after Genzyme’s receipt of a Final Option Data Package,
Genzyme shall acknowledge receipt of such Final Option Data Package in writing to Alnylam or be deemed to have acknowledged such receipt as of such date. Notwithstanding the foregoing, Alnylam shall not deliver a Final Option Data Package to Genzyme
unless and until all of the activities necessary to generate the information to be included in such Final Option Data Package have been completed.  

3.3.3.2. Governance. At Genzyme’s request following the delivery of an Option Preservation Notice for an
Option Product, the Parties shall form the committee that would be responsible for facilitating the Collaboration with respect to such Option Product under the applicable License Terms if Genzyme  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 42 - 

 MASTER AGREEMENT 

 

 exercised the Option identified in such Option Preservation Notice (i.e. if the
identified Option is the Global Option, the Parties will form the JTT described in Section 5.1 (Joint Transition Team) of the Global License Terms; and if the identified Option is the Co-Co/Global Option, the Regional Option, the 2019 Trailing
Regional Option or the 2021 Trailing Regional Option, the Parties will form the PJSC described in Section 5.1 (Product Joint Steering Committee) of the Co-Co License Terms or Section 5.1 (Product Joint Steering Committee) of the Regional
License Terms, as applicable). Such committee shall have the responsibilities allocated to such committee under the applicable License Terms, except that such committee shall serve solely in an advisory committee and shall not have any
decision-making authority with respect to the applicable Option Product unless and until Genzyme exercises an Option with respect to such Option Product. Such committee shall be disbanded if Genzyme does not exercise an Option with respect to the
applicable Option Product prior to the end of the Option Exercise Period for such Option Product.  
 3.3.3.3.
[***] 
 (a) [***] 

(b) [***] 

(c) [***] 

3.3.3.4. No Rights. Except for the right to exercise an Option in respect of an Option Product following receipt
of a Final Option Data Package in respect thereof, Genzyme shall not obtain any ownership interest or other right to Develop or Commercialize (or to compel Alnylam Develop or Commercialize) such Option Product during the Transition Period,
provided that the foregoing shall not relieve Alnylam of any of its obligations under this Master Agreement in respect of such Option Product during the Transition Period. 

3.3.4. Updates to Option Data Packages. 

3.3.4.1. Incomplete Option Data Package. 

(a) Notice of Missing Information. Following receipt of an Option Data Package, Genzyme shall have [***] days to notify
Alnylam if such Option Data Package is missing any information, which notice shall describe the information that is missing. Alnylam shall provide Genzyme with such missing information identified in such notice as soon as reasonably practicable (if
and to the extent that such information is available to Alnylam). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 43 - 

 MASTER AGREEMENT 

 

 (b) Disputed Missing Information. If, notwithstanding any information
subsequently delivered by Alnylam pursuant to Section 3.3.4.1(a) (Notice of Missing Information), Genzyme, acting in good faith, still believes that the Option Data Package is missing material information, then Genzyme shall have the right to
request that the AJSC review the Option Data Package (including any information subsequently delivered by Alnylam pursuant to Section 3.3.4.1(a) (Notice of Missing Information) or Section 3.3.4.2 (Supplements to Option Data Package))
within [***] days and determine whether material information is then missing from such Option Data Package. The AJSC is hereby empowered to compel Alnylam to produce any missing material information (if and to the extent that such information is
available to Alnylam) within [***] days of such order. 
 3.3.4.2. Supplements to Option Data Package.
Following delivery of an Option Data Package, Alnylam shall have the right to provide supplemental updates to any of the information included in such Option Data Package. In addition, Alnylam shall be required to promptly provide supplemental
update(s) to Genzyme if [***]. In either such case, any such supplemental information shall be deemed to constitute a part of such Option Data Package for all purposes of this Collaboration Agreement (and to supersede previously provided
information, to the extent such supplement information is identified, or would reasonably be apparent to Genzyme, as superseding previously provided information [***]. 

3.3.4.3. Information Sharing during Initial Evaluation Period and Option Exercise Period. During the Option
Exercise Period (including, if applicable, the Initial Evaluation Period) for an Option Product, Alnylam shall (a) promptly provide to Genzyme (i) any patent, regulatory or CMC information, (ii) any material, complete sets of
preclinical or clinical data and (iii) raw data tables, in each case ((i), (ii) and (iii)) then available to Alnylam that Genzyme may reasonably request, to the extent that such information was not previously provided by Alnylam to Genzyme
and subject to customary and reasonable due diligence procedures to preserve the confidential nature of any such information, regarding such Option Product to assist Genzyme in deciding whether to exercise an Option for such Option Product if and
when any such Option becomes exercisable, and (b) afford to Genzyme and its representatives reasonable access during normal business hours to Alnylam’s personnel, in each case ((a) and (b)) that Genzyme may reasonably request regarding
such Option Product to assist Genzyme in deciding whether to exercise the Option for such Option Product, to the extent that such information was not previously provided by Alnylam to Genzyme.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 44 - 

 MASTER AGREEMENT 

 

 3.3.4.4. Extension of Initial Evaluation Period and Option Exercise
Period. If any information is provided to Genzyme following the receipt of an Option Data Package pursuant to Section 3.3.4.1 (Incomplete Data Option Package), 3.3.4.2 (Supplements to Option Data Package) or 3.3.4.3 (Information Sharing
During Option Exercise Period) and such information is, in Genzyme’s reasonable discretion, material information not previously provided to Genzyme relating to the applicable Option Product, the Initial Evaluation Period or Option Exercise
Period, as applicable, shall, if necessary and upon notice from Genzyme to Alnylam, be extended such that there is at least [***] days between Genzyme’s receipt of such material information and the expiration of such Initial Evaluation Period
or Option Exercise Period, provided that in no event shall any Initial Evaluation Period or Option Exercise Period be extended by more than [***] days in the aggregate. 

3.3.5. Information Excluded from Option Data Packages. Notwithstanding anything in this Master Agreement to the
contrary, Alnylam shall not be obligated to include in any Option Data Package or to disclose pursuant to Section 3.3.4 (Updates to Option Data Packages) any information the disclosure of which would (i) in the reasonable opinion of
Alnylam’s counsel, adversely affect the attorney-client privilege between Alnylam and its counsel or (ii) [***], and the exclusion of such information from any Option Data Package, as applicable, shall not constitute missing information
for purposes of Section 3.3.4.1 (Incomplete Option Data Package), render the Option Data Package deficient in any respect or otherwise result in Genzyme having any right or claim against Alnylam. If material information may be excluded from any
Option Data Package pursuant to clause (i) in the immediately preceding sentence, the Parties will enter into a common interest agreement designed to preserve such privilege and, after execution of such agreement, Alnylam will provide Genzyme
with access to such information. 
 3.4. Exercise of an Option. Genzyme shall exercise an Option, if at all, by properly
delivering a complete Exercise Notice in respect of such Option to Alnylam at any time during the respective Option Exercise Period for such Option. 

3.4.1. [***].  

3.4.2. Exercise of Preserved Option.  

3.4.2.1. Except as provided in Section 3.4.2.3, in the event that Genzyme exercises an Option for an Option Product
for which an Option Preservation Notice was delivered pursuant to Section 3.3.2 (Initial Evaluation Period), then Genzyme may only exercise the Option identified in such Option Preservation Notice for such Option Product.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 45 - 

 MASTER AGREEMENT 

 

 3.4.2.2. Except as provided in Section 3.4.2.3, if Genzyme
identified the Global Option or the Additional Global Option as the Option it was preserving in an Option Preservation Notice and Genzyme does not deliver to Alnylam an Exercise Notice with respect to the exercise of such Option prior to the
expiration of the applicable Option Exercise Period, then such Option shall terminate in full at the end of the Option Exercise Period and Genzyme shall not thereafter be permitted to exercise such unexercised Global Option or Additional Global
Option, as applicable (such failure to deliver an Exercise Notice, a “Global/Additional Global Option Forfeiture”). 

3.4.2.3. Notwithstanding the foregoing, if prior to the expiration of the Option Exercise Period for an Option Product
(i) Genzyme receives material (a) clinical, GLP toxicology or nonclinical data or (b) regulatory guidance or a regulatory determination involving such Option Product, including in the Final Option Data Package, that was not included
in (or, in the case of clause b, reasonably ascertainable from) the Initial Option Data Package or information presented to the AJSC or the PAC (and reflected in the written meeting minutes thereof) (such new data, regulatory guidance or a
regulatory determination, “New Information”) and (ii) such New Information is adversely material to the expected clinical or commercial success of such Option Product such that Genzyme would not have exercised the Global Option
or Additional Global Option if it possessed such New Information at the time it delivered such Option Preservation Notice, then Genzyme shall have the right (but not the obligation) to deliver an Option Exercise Notice to exercise a Regional Option
during the applicable Option Exercise Period or it may elect not to exercise any Option with respect to such Option Product and, in either such case, Genzyme’s failure to exercise the Global Option or the Additional Global Option, as
applicable, shall not constitute a Global/Additional Global Option Forfeiture and the Global Option or Additional Global Option, as applicable shall remain exercisable.  

3.4.2.4. If development milestone(s) become payable under any License Terms, including because an Option Product is
dosed in a patient in a Phase III Study, prior to the expiration of the Option Exercise Period for such Option Product and Genzyme exercises an Option in respect of such Option Product and such Option Product becomes a Collaboration Product, then
Genzyme shall promptly, and in any event within [***] days following receipt of an invoice, pay such development milestone(s) to Alnylam as though such Option Product was a Collaboration Product at the time such development milestone(s) became
payable Alnylam. 
 3.4.3. Regional Options. On the applicable Option Exercise Date for the exercise of any
Regional Option, 2019 Trailing Regional Option or 2021 Trailing Regional Option, the applicable Regional Option Product or Trailing Regional Option 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 46 - 

 MASTER AGREEMENT 

 

 Product shall automatically be deemed to be a Regional Licensed Product for all purposes
under the Collaboration Agreement and the license from Alnylam to Genzyme for such Regional Licensed Product shall automatically, with no further action by any Party, go into full force and effect and all of the obligations of Alnylam and Genzyme
set forth in the Regional License Terms, including the payment obligations set forth therein, shall become the binding obligations of the applicable Party in respect of such Regional Licensed Product. As part of the effectiveness of such license,
the Regional License Terms shall automatically, with no further action by any Party, be deemed to be amended to incorporate the human gene target for such Regional Licensed Product as a Licensed Target under the Regional License Terms and to
incorporate as part of the Regional License Terms or this Master Agreement the schedules, appendices and exhibits in respect of such Regional Licensed Product that were included in the last Option Data Package delivered by Alnylam for such Regional
Licensed Product or, in the case of the Global Development Strategy for such Regional Licensed Product, mutually agreed upon by the Parties prior to the Option Exercise Date. The Parties may, at their option, prepare an updated version of the
Regional License Terms and this Master Agreement that includes such schedules, appendices and exhibits. 
 3.4.4.
Co-Co/Global Option. 
 3.4.4.1. ALN-AT3. If Genzyme exercises the Co-Co/Global Option for ALN-AT3, then on
the applicable Option Exercise Date, ALN-AT3 shall automatically be deemed to be Co-Co Licensed Product for all purposes under the Collaboration Agreement and the license from Alnylam to Genzyme to such Co-Co Licensed Product shall automatically,
with no further action by any Party, go into full force and effect and all of the obligations of Alnylam and Genzyme set forth in the Co-Co License Terms, including the payment obligations set forth therein, shall become the binding obligations of
the applicable Party in respect of ALN-AT3. As part of the effectiveness of such license, the Co-Co License Terms shall automatically, with no further action by any Party, be deemed to be amended to incorporate AT3 as a Licensed Target under the
Co-Co License Terms and to incorporate as part of the Co-Co License Terms or this Master Agreement the schedules, appendices and exhibits in respect of such Co-Co Licensed Product that were included in the last Option Data Package delivered by
Alnylam or, in the case of the Global Development Strategy for such Co-Co Licensed Product, mutually agreed upon by the Parties prior to the Option Exercise Date. The Parties may, at their option, prepare an updated version of the Co-Co License
Terms and this Master Agreement that includes such schedules, appendices and exhibits. 
 3.4.4.2. ALN-AS1. If
Genzyme exercises the Co-Co/Global Option for ALN-AS1, then on the applicable Option Exercise Date, the applicable Co-Co/Global Option Product shall automatically be deemed to be a Global Licensed 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 47 - 

 MASTER AGREEMENT 

 

 
Product for all purposes under the Collaboration Agreement and the license from Alnylam to Genzyme to such Global Licensed Product shall automatically, with no further action by any Party, go
into full force and effect and all of the obligations of Alnylam and Genzyme set forth in the Global License Terms, including the payment obligations set forth therein, shall become the binding obligations of the applicable Party in respect of such
Global Licensed Product. As part of the effectiveness of such license, the Global License Terms shall automatically, with no further action by any Party, be deemed to be amended to incorporate ALN-AS1 as a Licensed Target under the Global License
Terms and to incorporate as part of the Global License Terms or this Master Agreement the schedules, appendices and exhibits in respect of such Global Licensed Product that were included in the last Option Data Package delivered by Alnylam for such
Global Licensed Product. The Parties may, at their option, prepare an updated version of the Global License Terms and this Master Agreement that includes such schedules, appendices and exhibits. 

3.4.5. Global Options. On the applicable Option Exercise Date for the exercise of a Global Option or Trailing Global
Option, the applicable Global Option Product or Trailing Global Option Product shall automatically be deemed to be a Global Licensed Product for all purposes under the Collaboration Agreement and the license from Alnylam to Genzyme to such Global
Licensed Product shall automatically, with no further action by any Party, go into full force and effect and all of the obligations of Alnylam and Genzyme set forth in the Global License Terms, including the payment obligations set forth therein,
shall become the binding obligations of the applicable Party in respect of such Global Licensed Product. As part of the effectiveness of such license, the Global License Terms shall automatically, with no further action by any Party, be deemed to be
amended to incorporate the human gene target for such Global Licensed Product as a Licensed Target under the Global License Terms and to incorporate as part of the Global License Terms or this Master Agreement the schedules, appendices and exhibits
in respect of such Global Licensed Product that were included in the last Option Data Package delivered by Alnylam for such Global Licensed Product. The Parties may, at their option, prepare an updated version of the Global License Terms and this
Master Agreement that includes such schedules, appendices and exhibits. 
 3.4.6. Development and Commercialization
Following Option Exercise. Following the Option Exercise Date for a Collaboration Product, the Development and Commercialization of such Collaboration Product shall thereafter be governed by the applicable License Terms. 

3.5. Option Not Exercised. If Genzyme does not deliver to Alnylam an Exercise Notice, or if Genzyme elects and delivers written
notice to Alnylam to terminate an Option, with respect to an Option Product prior to the expiration of the applicable Option Exercise Period, then Genzyme’s Option with respect to such Option Product shall expire, Genzyme’s other rights
 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 48 - 

 MASTER AGREEMENT 

 

 with respect to such Option Product (including any rights under Section 4 (Development and
Pharmacovigilance) and Section 5 (Collaboration Management)), shall lapse, and Alnylam shall thereafter be free to Develop, Manufacture or Commercialize, alone or with one or more Third Parties, such Option Product, in each case without any
further obligation to Genzyme. In addition, so long as Alnylam continues to actively Develop an Option Product following the expiration of Genzyme’s Option or Alnylam grants any rights to an Option Product to a Third Party, then other siRNAs
Developed by Alnylam or any such Third Party (or its licensees or sublicensees, through multiple tiers) that target the same human gene as such Option Product (except for siRNAs described in clause (ii) of Section 1.2.21 (ALN-AT3) or
clause (ii) of Section 1.2.20 (ALN-AS1) if any such siRNA is potentially subject to the Co-Co/Global Option) shall not be considered Option Products for purposes of this Master Agreement and Genzyme shall not have any Option hereunder with
respect to such other siRNAs; provided, however, that if Alnylam ceases active Development of such Option Product, then the other siRNAs that target the same human gene as such Option Product shall again be considered Option Products
for the purposes of this Master Agreement. [***]. 
 3.6. Exclusivity during Option Period.  

3.6.1. Exclusivity for Core Pipeline Programs. Subject to Section 13.16.2 (Future Acquisition of a Party or its
Business), during the Option Period, Alnylam and its Affiliates shall not enter into any agreement with any Third Party that grants such Third Party any rights with respect to any Core Pipeline Program that would be in conflict with the
Collaboration Agreement following an siRNA becoming a Collaboration Product under the Collaboration Agreement, provided that this restriction shall not apply to: 

3.6.1.1. following the expiration of the Option Exercise Period for an Option Product, an agreement with a Third Party
that grants such Third Party rights with respect to such Option Product and other siRNAs that target the same human gene as such Option Product; 

3.6.1.2. an agreement with a Third Party that grants such Third Party rights with respect to any Named Pipeline Program
(excluding ALN-TTR02, ALN-TTRsc, ALN-AT3 and ALN-AS1) solely in the Alnylam Territory, provided that Alnylam complies with the provisions of Section 3.6.3 (ROFN for Available Third Party Rights) and 3.6.4 (Permitted Third Party
Agreements); 
 3.6.1.3. following the exercise of the Co-Co/Global Option with respect to either Co-Co/Global
Option Product, an agreement with a Third Party that grants such Third Party rights with respect to the other Co-Co/Global Option Product solely in the Alnylam Territory, provided that Alnylam complies with the provisions of
Section 3.6.3 (ROFN for Available Third Party Rights) and 3.6.4 (Permitted Third Party Agreements); or 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 49 - 

 MASTER AGREEMENT 

 

 3.6.1.4. following the exercise of the Global Option, an agreement
with a Third Party that grants such Third Party rights with respect to any Core Pipeline Program solely in the Alnylam Territory, provided that Alnylam complies with the provisions of Section 3.6.3 (ROFN for Available Third Party Rights)
and 3.6.4 (Permitted Third Party Agreements). 
 3.6.2. Other Exclusivity Requirements in License Terms. Upon
the exercise of any Option (which will cause an Option Product to become a Collaboration Product), the exclusivity provisions set forth in the applicable License Terms will go into effect with respect to such Collaboration Product. 

3.6.3. ROFN for Available Third Party Rights. If Alnylam desires to enter into an agreement described in
Section 3.6.1.2, 3.6.1.3 or 3.6.1.4, other than in accordance with Section 4.4 (Third Parties), then Alnylam shall so notify Genzyme in writing, which notice shall describe the rights that Alnylam intends to grant to a Third Party pursuant
to such agreement (the “Available Third Party Rights”). Genzyme shall have [***] days from receipt of such written notice to notify Alnylam in writing as to whether Genzyme desires to negotiate for such Available Third Party Rights
(a “ROFN Exercise Notice”). If Genzyme delivers a ROFN Exercise Notice prior to the expiration of such [***]-day period, Genzyme shall have the exclusive right for [***] days following the date that Genzyme delivers a ROFN Exercise
Notice (the “ROFN Offer Period”) to negotiate with Alnylam and to make one or more written non-binding offers to Alnylam concerning the terms on which Genzyme would enter into an agreement to acquire the Available Third Party Rights
(a “ROFN Non-Binding Offer”). If Genzyme delivers a ROFN Non-Binding Offer to Alnylam prior to the expiration of the ROFN Offer Period, Genzyme shall thereafter have the exclusive right for [***] days (or such longer period as may
be mutually agreed by the Parties) (the “ROFN Negotiation Period”), to finalize and enter into a definitive agreement with Alnylam for the acquisition of such Available Third Party Rights. Alnylam shall not, during the ROFN Offer
Period or Negotiation Period, enter into discussions, exchange information, or otherwise negotiate with any Third Party with respect to any of the Available Third Party Rights. If (i) Genzyme does not provide a ROFN Exercise Notice within [***]
days of receiving notice of Available Third Party Rights, (ii) Genzyme does not provide a ROFN Non-Binding Offer prior to the expiration of the ROFN Offer Period, or (iii) the Parties do not execute a definitive agreement with respect to
the Available Third Party Rights prior to the expiration of the ROFN Negotiation Period, then Alnylam shall be free to enter into an agreement with any Third Party with respect to such Available Third Party Rights (any such agreement, a
“Permitted Third Party Agreement”), provided that, during the period of [***] months after the later of the expiration of the ROFN Offer Period or expiration of the ROFN Negotiation Period, Alnylam shall not enter into a
Permitted Third Party Agreement with respect to such Available Third Party Rights on terms that are, in the aggregate, materially more favorable to such Third Party than the  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 50 - 

 MASTER AGREEMENT 

 

 
last terms offered in writing by Genzyme to Alnylam during the ROFN Offer Period or ROFN Negotiation Period, as applicable, unless (a) Alnylam first re-offers to enter into an agreement with
Genzyme on such more favorable terms and Genzyme does not accept such offer and enter into such agreement with Alnylam within [***] days after such re-offer. For clarity, prior to the ROFN Offer Period and ROFN Exercise Period with respect to any
Available Third Party Rights, Alnylam shall be free to engage in discussions and exchange information with Third Parties with respect to such Available Third Party Rights, but shall not enter into any binding agreement with any Third Party with
respect to such Available Third Party Rights. 
 3.6.4. Permitted Third Party Agreements. If Alnylam enters into a
Permitted Third Party Agreement pursuant to Section 3.6.3 (ROFN For Available Third Party Rights) with respect to any Regional Option Product, such Permitted Third Party Agreement shall be compliant with Alnylam’s obligations under, and
consistent with the terms of, the Regional License Terms. 
 3.6.5. Gate-Keeping. Promptly following the
Effective Date, Alnylam shall establish a commercially reasonable mechanism to ensure that it does not grant any Third Party any rights with respect to a Core Pipeline Program in violation of Section 3.6.1 (Exclusivity for Core Pipeline
Programs), whether pursuant to a new agreement or an amendment to, or any action or inaction pursuant to, any agreement between a Third Party and Alnylam that is in effect on the Effective Date. 

4. DEVELOPMENT AND PHARMACOVILIGANCE 

4.1. Overview. Alnylam shall control and be responsible for the Development of its Core Pipeline Programs. In connection
therewith, Alnylam shall be responsible for all communications, interactions and filings with, submissions to, and other actions related to, each Regulatory Authority regarding the Core Pipeline Programs.  

4.2. Diligence. Subject to and without limiting any obligation set forth in any License Terms, during the Option Period, Alnylam
shall use commercially reasonable efforts to initiate Core Pipeline Programs and undertake the Development of Option Products from its Core Pipeline Programs through achievement of Human POP Study Completion and thereafter through the end of the
applicable Option Exercise Period in accordance with industry standards in the biotechnology and pharmaceutical industry. During the Transition Period, Alnylam shall use commercially reasonable efforts to Develop the applicable Option Product. In
addition, both Parties shall use commercially reasonable efforts to plan for the transition to Genzyme of any Global Option Product during the applicable Transition Period upon the Implementation Date of the applicable License Terms. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 51 - 

 MASTER AGREEMENT 

 

 4.3. Scientific Records. Alnylam shall maintain scientific records, in
sufficient detail and in sound scientific manner appropriate for patent and regulatory purposes and in compliance with GLP with respect to activities intended to be submitted in regulatory filings (including INDs), which shall fully and properly
reflect all work done and results achieved in the performance of the Development activities with respect to potential Option Products by Alnylam. 

4.4. Third Parties. Alnylam shall be entitled to utilize the services of Third Parties to perform the Development activities with
respect to Option Products under this Master Agreement, provided that (a) Alnylam shall require that such Third Party operates in a manner consistent with the terms of the Collaboration Agreement and (b) Alnylam shall remain at all times
fully liable for its responsibilities and (c) the Parties will make reasonable efforts to share through the PAC information regarding any prior experience with specific CROs that are anticipated to be engaged to perform work for any Core
Pipeline Program. Alnylam shall require, however, that any such Third Party agreement (other than an agreement with an academic institution) include commercially reasonable confidentiality and non-use provisions that are, in the aggregate, not
materially less stringent than those included in the Collaboration Agreement. Lastly, Alnylam shall use commercially reasonable efforts to obtain ownership of, and/or a fully sublicensable license under and to, any Know-How and Patent Rights that
are developed by such Third Party in the performance of such agreement and are reasonably expected to be necessary or useful to Develop, Manufacture and/or Commercialize Option Products. 

4.5. Oversight. The Collaboration shall be conducted under the oversight of the Alliance Joint Steering Committee which shall
have the responsibilities outlined in the Collaboration Agreement. 
 4.6. Pharmacovigilance. At least [***], the
Parties will negotiate in good faith and enter into a Safety Data Exchange Agreement (“SDEA”), which will define the pharmacovigilance responsibilities of the Parties and include safety data exchange procedures governing the
coordination of collection, investigation, reporting and exchange of information concerning any adverse experiences, and any product quality and product complaints associated with adverse experiences, related to such Collaboration Product sufficient
to enable each Party (and their respective Related Parties, if any) to comply with its legal and regulatory obligations. In addition, as appropriate, such SDEAs will include the safety data exchange procedures governing the exchange of information
affecting the class (e.g., serious adverse events, emerging safety issues).  
 5. COLLABORATION
MANAGEMENT 
 5.1. Alliance Joint Steering Committee.  

5.1.1. Composition. The AJSC shall be comprised of three (3) representatives who are employees of each Party. Each
Party shall appoint its respective representatives to the AJSC as of the Effective Date and may substitute one or more of its  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 52 - 

 MASTER AGREEMENT 

 

 
representatives, in its sole discretion, effective upon notice to the other Party of such change. Each Party shall have at least two (2) AJSC representatives who are executive level
employees (vice president or above), and all AJSC representatives shall have appropriate expertise, seniority, decision-making authority and ongoing familiarity with the Collaboration. Additional representatives or consultants may from time to time,
by mutual consent of the Parties, be invited to attend AJSC meetings, subject to such representatives and consultants (or the representative’s or consultant’s employer) undertaking confidentiality obligations, whether in a written
agreement or by operation of law, no less stringent than the requirements of Section 7.1 (Nondisclosure Obligation). 
 5.1.2. AJSC
Chairperson. The AJSC shall be co-chaired, with one chairperson designated by Alnylam and one chairperson designated by Genzyme, whose responsibilities shall include conducting meetings, including, when feasible, ensuring that objectives for
each meeting are set and achieved. Responsibility for running each meeting of the AJSC will alternate between the chairpersons from meeting-to-meeting, with Alnylam’s chairperson running the first meeting.  

5.1.3. Alliance Managers. 

5.1.3.1. Each Party shall appoint an alliance manager who is an employee of such Party (each, an “Alliance
Manager”). Each Alliance Manager will be responsible to ensure a collaborative work environment between the Parties to ensure that the alliance is run smoothly, professionally and productively. Each Alliance Manager shall act in his or her
discretion to facilitate the execution of the Collaboration throughout their organization and will oversee and support implementation plans; promote effectiveness of the governance model and implementation of contractual provisions and lead any
changes to enhance the alliance; and facilitate the AJSC (and other bodies) for effective decision making in a timely manner. The Alliance Managers will serve as a primary point of contact for the other Party under the Collaboration and will
undertake such other tasks as are detailed in the Collaboration Agreement or as may be assigned by the AJSC. Each Alliance Manager shall attend each meeting of the AJSC. Each Party may change its Alliance Manager at any time in its sole discretion
with written notice to the other Party.  
 5.1.3.2. The Alliance Managers shall be responsible for
(i) scheduling meetings of the AJSC, (ii) setting agendas for meetings with solicited input from other members and (iii) for acting as secretary at each meeting and preparing the draft minutes of such meeting, which shall provide a
description in reasonable detail of the discussions held at the meeting and a list of any actions, decisions or determinations approved by the AJSC. [***] days after each meeting, the drafting Alliance Manager shall provide the draft minutes to the
other Alliance Manager for review and comment. The drafting Alliance Manager  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 53 - 

 MASTER AGREEMENT 

 

 
shall reasonably consider all comments from the other Alliance Manager that are provided within [***] days. The drafting Alliance Manager shall prepare and submit revised minutes for approval
within [***] days after receipt of such comments or upon the expiration of such [***] day comment period. Beginning with Alnylam’s Alliance Manager, such responsibilities shall alternate between the Alliance Managers on a meeting-by-meeting
basis after each meeting of the applicable committee. 
 5.1.4. Meetings. The AJSC shall meet in accordance with a
schedule established by mutual written agreement of the Parties, but no less frequently than once per Calendar Quarter during the Term, provided that either Party may from time to time reasonably request that the AJSC meet to undertake its
duties under Section 5.1.7(c), 5.1.7(d), 5.1.7(e), 5.1.7(f), 5.1.7(h) or 5.1.7(i). The location for any such meetings shall alternate between Alnylam and Genzyme facilities (or such other locations as are mutually agreed by the Parties).
Alternatively, the AJSC may meet by means of teleconference, videoconference or other similar communications equipment. All meetings and proceedings for the AJSC or its subcommittees shall take place in English. Each Party shall bear its own
expenses relating to attendance at such meetings by its representatives. 
 5.1.5. Subcommittee Minutes. For each
subcommittee created pursuant to Section 5.1.6 (Subcommittees), each Party shall designate a secretary, who may be such Party’s Alliance Manager, to prepare draft minutes of each meeting, which shall provide a description in reasonable
detail of the discussions held at the meeting and a list of any actions, decisions or determinations approved by such committee. Beginning with the Alnylam secretary, the responsibility for preparing the minutes shall alternate between the
secretaries on a meeting-by-meeting basis after each meeting of such subcommittee. Within [***] days after each meeting, the drafting secretary shall provide the draft minutes to the other secretary for review and comment. The drafting secretary
shall reasonably consider all comments from the other secretary that are provided within [***] days. The drafting secretary shall prepare and submit revised minutes for approval within [***] days after receipt of such comments or upon the expiration
of such [***] day comment period.  
 5.1.6. Subcommittees. 

5.1.6.1. The Parties or the AJSC shall have the right to create such subcommittees of the AJSC as they or it may deem
appropriate or necessary (such as a finance subcommittee, or other appropriate subcommittees). Each such subcommittee shall report to the AJSC, which shall have authority to approve or reject recommendations or actions proposed thereby, subject to
the terms of the Collaboration Agreement. Each Party shall bear its own expenses relating to attendance at any meetings of such subcommittees by its representatives. Each such subcommittee shall have a chairperson, designated by Alnylam, whose
responsibilities shall include conducting meetings, including ensuring that objectives for each meeting are set and achieved. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 54 - 

 MASTER AGREEMENT 

 

 5.1.6.2. The Parties hereby establish a Pipeline Advisory Committee
and an IP Committee as subcommittees of the AJSC, each of which shall have the responsibilities outlined in the Collaboration Agreement. 

5.1.6.3. Each PJSC established pursuant to the License Terms will be a subcommittee of the AJSC; provided,
however, that the membership, operation and responsibilities of each PJSC shall be governed by the applicable License Terms and not this Section 5.1.6. As a general matter, the Parties expect that the representatives on the AJSC will be
more senior than the representatives on the PJSC(s). 
 5.1.7. AJSC Responsibilities. The AJSC shall have the
following responsibilities with respect to the Development, Manufacturing and Commercialization of Option Products from the Core Pipeline Programs and Collaboration Products pursuant to the Collaboration:  

(a) coordinating the activities of the Parties under the Collaboration, including budget matters; 

(b) overseeing the AJSC’s subcommittees and ensuring effective participation in each such committee’s operations by
any of its members; 
 (c) considering (but not deciding) whether any Clinical Study, or protocol therefor, will satisfy the
criteria of a Human POP Study in accordance with Section 3.1.2.3 (Design of Human POP Studies), [***]; 
 (d) attempting
to resolve disputes as to whether an Alnylam Program should be categorized as a Core Pipeline Program or a Non-Core Pipeline Program; 

(e) resolving whether an Option Data Package is missing information pursuant to Section 3.3.4.1(b) (Disputed Missing
Information); 
 (f) resolving any disputed terms of any Supply Agreement under Section 6.3 (Disputed Supply Agreement
Terms); 
 (g) reviewing the status of Collaboration Products, including material Development and Commercialization matters;

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 55 - 

 MASTER AGREEMENT 

 

 (h) resolving disputes on behalf of each PJSC in accordance with, and subject
to the limitations set forth in, the applicable License Terms; 
 (i) addressing any other matters referred to the AJSC by
the terms of the Collaboration Agreement; and 
 (j) performing such other activities as the Parties agree in writing shall
be the responsibility of the AJSC. 
 5.1.8. Decision-Making. 

5.1.8.1. Voting. With respect to decisions of the AJSC, the representatives of each Party shall have collectively
one vote on behalf of such Party. For each meeting of the AJSC, at least two (2) representatives of each Party shall constitute a quorum. Action on any matter may be taken at a meeting, by teleconference, by videoconference or by written
agreement. 
 5.1.8.2. Escalation. The AJSC shall attempt to resolve any and all disputes before it for
decision by consensus. 
 (a) If the AJSC is unable to reach consensus with respect to a dispute arising under this Master
Agreement for a period in excess of [***] days, then the dispute shall be submitted to [***] for resolution. If such dispute cannot be resolved for a period in excess of [***] days following escalation (or such other period as the Parties may
agree), then [***]. 
 (b) If the AJSC is unable to reach consensus with respect to a dispute related to any Collaboration
Product or otherwise arising under any of the License Terms, then the dispute shall be resolved as set forth in the applicable License Terms [***]. 

5.1.8.3. Resolution of Core Pipeline Disputes. [***]. 

5.1.9. Term. Either Party shall have the right to terminate the AJSC upon the expiration of the later to expire of
(i) the Option Periods and (ii) all of the License Terms. Notwithstanding the foregoing, on a Regional Licensed Product-by-Regional Licensed Product basis and on a Global Licensed Product-by-Global Licensed Product basis, Alnylam shall
have the right (but not the obligation) to continue to participate in the AJSC in relation to any such Collaboration Product following the earlier of (i) the [***] anniversary of the Option Exercise Date for such Collaboration Product and
(ii) the termination of the Product Joint Steering Committee (as such term is defined in the Regional License Terms) or the Joint Transition Team (as such term is defined in the Global License Terms), as applicable, for such Collaboration
Product. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 56 - 

 MASTER AGREEMENT 

 

 5.2. Pipeline Advisory Committee.  

5.2.1. Composition. The Pipeline Advisory Committee shall be comprised of three (3) representatives who are
employees of each Party. Each Party shall appoint its respective representatives to the PAC within thirty (30) days of the Effective Date, and from time to time may substitute one or more of its representatives, in its sole discretion,
effective upon notice to the other Party of such change. Each Party shall have at least one PAC representative who is a senior level (vice president or above) employee. All PAC representatives shall have appropriate expertise, seniority,
decision-making authority and ongoing familiarity with the Collaboration and each Party’s representatives collectively shall have relevant expertise in research, development and commercial matters. Additional representatives or consultants may
from time to time, by mutual consent of the Parties, be invited to attend PAC meetings, subject to such representatives and consultants (or the representative’s or the consultant’s employer) undertaking confidentiality obligations, whether
in a written agreement or by operation of law, no less stringent than the requirements of Section 7.1 (Nondisclosure Obligation). 

5.2.2. Meetings. The PAC shall meet in person once per Calendar Quarter at Alnylam, provided that either Party
may from time to time reasonably request that the PAC meet to undertake its duties under Section 3.1.1 (Program Identification) at a location mutually agreed by the Parties. 

5.2.3. PAC Development Responsibilities. The PAC shall provide input to Alnylam and the AJSC regarding the following
with respect to the Development of Option Products from the Core Pipeline Programs prior to their achieving Human POP Study Completion and pursuant to the Collaboration:  

(a) the selection of targets for new Core Pipeline Programs; 

(b) the inclusion of Alnylam Programs on the Tentative Core Pipeline Program List, Core Pipeline Program List and the Non-Core
Pipeline Program List pursuant to Section 3.1.1 (Program Identification); 
 (c) reviewing and discussing periodic
updates from Alnylam to the PAC regarding the development status of potential Option Products; and 
 (d) such other matters
as the Parties agree in writing shall be the responsibility of the PAC. 
 5.2.4. Decision-Making. The PAC shall be an
advisory committee for the Collaboration and to the AJSC. The PAC shall not have any final decision making power.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 57 - 

 MASTER AGREEMENT 

 

 5.2.5. Term. Either Party shall have the right to terminate the PAC
upon the expiration of the last to expire of the Option Periods. 
 5.3. IP Committee.  

5.3.1. Composition. The IP Committee shall be comprised of at least one (1) representative who is an
employee of each Party. Each Party shall appoint its respective representatives to the IP Committee within thirty (30) days of the Effective Date, and from time to time, may substitute one or more of its representatives, in its sole discretion,
effective upon notice to the other Party of such change. All IP Committee representatives shall have appropriate expertise, seniority, decision-making authority and ongoing familiarity with the Collaboration and each Party’s representatives
collectively shall have relevant expertise in intellectual property portfolio management and licensing matters. Additional representatives or consultants may from time to time, by mutual consent of the Parties, be invited to attend IP Committee
meetings, subject to such representatives and consultants (or the representative’s or consultant’s employer) undertaking confidentiality obligations, whether in a written agreement or by operation of law, no less stringent than the
requirements of Section 7.1 (Nondisclosure Obligation). 
 5.3.2. Meetings. The IP Committee shall meet as
necessary to carry out its duties under Section 5.3.3 (IP Committee Responsibilities), but no more often than once per Calendar Quarter, unless otherwise agreed by its members. The IP Committee shall meet in-person at Alnylam or Genzyme or,
alternatively, by means of teleconference, videoconference or other similar communications equipment. 
 5.3.3. IP
Committee Responsibilities. The IP Committee shall provide input to Alnylam regarding the following with respect to Option Products from the Core Pipeline Programs and as indicated in the Global License Terms, the Regional License Terms and the
Co-Co License Terms: 
 (a) strategies for managing certain Patents Rights pursuant to Section 11.2 (Patent
Prosecution Information Sharing); 
 (b) the necessity and terms of any Proposed In-License pursuant to Section 11.3.3.1
(Proposed In-Licenses); and 
 (c) such other matters as the Parties agree in writing shall be the responsibility of the IP
Committee. 
 5.3.4. Decision-Making. The IP Committee shall be an advisory committee for the Collaboration and to
Alnylam and shall make recommendations by consensus. The IP Committee shall not have any final decision making power. If there is a disagreement between the Parties’ representatives on the IP Committee, at either Party’s request, the
General Counsel or other Senior Counsel of each Party will attend a follow-up meeting of the IP Committee to discuss the matter further. The IP Committee may escalate matters to the AJSC as it deems appropriate. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 58 - 

 MASTER AGREEMENT 

 

 5.3.5. Term. Either Party shall have the right to terminate the IP
Committee upon the expiration of the last to expire of the Option Periods, except that no Party shall have the right to terminate the IP Committee in respect of the Collaboration Product(s) prior to the termination of the License Terms, as
applicable. Notwithstanding the foregoing, on a Collaboration Product-by-Collaboration Product basis , Alnylam shall have the right (but not the obligation) to continue to participate in the IP Committee in relation to any such Collaboration Product
following the [***] anniversary of the Option Exercise Date for such Collaboration Product.  
 5.4. Manufacturing
Committee.  
 5.4.1. Composition. The Manufacturing Committee shall be comprised of at least one
(1) representative who is an employee of each Party. Each Party shall appoint its respective representative to the Manufacturing Committee within thirty (30) days of the Effective Date, and from time to time, may substitute one or more of
its representatives, in its sole discretion, effective upon notice to the other Party of such change. All Manufacturing Committee representatives shall have appropriate expertise, seniority, decision-making authority and ongoing familiarity with the
Collaboration and each Party’s representatives collectively shall have relevant expertise in matters related to the Manufacturing and supply of human therapeutic products. Additional representatives or consultants may from time to time, by
mutual consent of the Parties, be invited to attend Manufacturing Committee meetings, subject to such representatives and consultants (or the representative’s or consultant’s employer) undertaking confidentiality obligations, whether in a
written agreement or by operation of law, no less stringent than the requirements of Section 7.1 (Nondisclosure Obligation). 

5.4.2. Meetings. The Manufacturing Committee shall meet as necessary to carry out its duties under Section 5.4.3
(Manufacturing Committee Responsibilities), but no more often than once per Calendar Quarter, unless otherwise agreed by its members. The Manufacturing Committee shall meet in-person at Alnylam or Genzyme or, alternatively, by means of
teleconference, videoconference or other similar communications equipment. 
 5.4.3. Manufacturing Committee
Responsibilities. The Manufacturing Committee shall provide a forum for the discussion and review of matters related to the Manufacturing and supply of Collaboration Products, including the following: 

(a) worldwide Manufacturing and sourcing strategies in support of the Development and Commercialization of Collaboration
Products, including the strategic aspects of Manufacture and release of finished Collaboration Product; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 59 - 

 MASTER AGREEMENT 

 

 (b) use of Third Parties to Manufacture and supply any Collaboration Product;

 (c) logistical strategies, capacity planning and inventory levels for each Collaboration Product for consistency with the
then-current Development Plans and Commercialization Plans for such Collaboration Product; 
 (d) results of regulatory
inspections related to Collaboration Products and reviewing steps to be taken by the Parties to address any deficiencies noted; 

(e) capacity planning and supply continuity plans for each Collaboration Product for consistency with the then-current
Development Plan and Commercialization Plan for such Collaboration Product; regulatory compliance related to the Manufacture of Collaboration Products; 

(f) material quality-related issues concerning the Collaboration Products; 

(g) costs of Manufacture; 

(h) providing updates to the AJSC or a PJSC, as applicable, upon request relating to Manufacturing issues; and 

(i) such other matters as the Parties agree in writing shall be the responsibility of the Manufacturing Committee. 

5.4.4. Decision-Making. The Manufacturing Committee shall be an advisory committee for the Collaboration and shall make
recommendations by consensus. The Manufacturing Committee shall not have any final decision making power. 
 5.4.5.
Term. Either Party shall have the right to terminate the Manufacturing Committee upon the expiration of the last to expire of the (i) Option Periods, and (ii) all of the License Terms. Notwithstanding the foregoing, on a Regional
Licensed Product-by-Regional Licensed Product basis and on a Global Licensed Product-by-Global Licensed Product basis, Alnylam shall have the right (but not the obligation) to continue to participate in the Manufacturing Committee in relation to any
such Collaboration Product following the earlier of (i) the [***] anniversary of the Option Exercise Date for such Collaboration Product and (ii) the termination of the Product Joint Steering Committee (as such term is defined in the
Regional License Terms) or the Joint Transition Team (as such term is defined in the Global License Terms), as applicable, for such Collaboration Product. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 60 - 

 MASTER AGREEMENT 

 

 5.5. Product Joint Steering Committees. Pursuant to the License Terms, the
Parties will form a PJSC (as defined in each of the License Terms) that has certain responsibilities with respect to the Development and Commercialization of each Collaboration Product as set forth in the License Terms for such Collaboration
Product. For the avoidance of doubt, the same representatives from each Party may serve on the PJSC for more than one Collaboration Product and, where membership of a PJSC for a Collaboration Product is the same as one or more other PJSCs for other
Collaboration Product(s), such PJSCs may have a single meeting to discuss each Collaboration Product for which they have responsibility. 

5.6. No Power to Amend. Unless otherwise agreed to by the Parties in writing, the AJSC, PAC, IP Committee, Manufacturing
Committee and each PJSC will have only the powers expressly assigned to it in the Collaboration Agreement. In no event will any of them have any power to amend, modify, or waive compliance with this Agreement. 

5.7. Confidentiality. All information disclosed by either Party or its representatives to the other Party or its representatives
under this Section 5 shall be deemed to be Confidential Information of the disclosing Party and maintained in accordance with Section 7 (Confidentiality and Publication). 

5.8. Modifications. The Parties shall meet from time to time to discuss whether any changes to the governance structure for the
Collaboration are necessary or advisable. 
 5.9. Other Governance Terms. Governance provisions related to each
Collaboration Product are located in the applicable License Terms. 
 6. MANUFACTURE AND SUPPLY OF THE COLLABORATION PRODUCTS

 6.1. ALN-TTR02 Supply Agreements. Subject to the terms and conditions of this Section 6 (Manufacture and Supply of the
Collaboration Products), within [***] days after receiving written notice from Genzyme requesting such negotiations, the Parties will negotiate in good faith and enter into a supply agreement (and any other necessary ancillary agreements) for
clinical supply of ALN-TTR02 by Alnylam (or for Alnylam by Alnylam’s Third Party manufacturer) (the “ALN-TTR02 Clinical Supply Agreement”), which will be consistent with the terms set forth on Schedule 6.1. In
addition, at the request of Genzyme at least [***] months in advance of the first Regulatory Approval of ALN-TTR02 in the Genzyme Territory, the Parties will negotiate in good faith and enter into a supply agreement (and any other necessary
ancillary agreements), before such [***]-month date, for commercial supply of ALN-TTR02 by Alnylam (or for Alnylam, by Alnylam’s Third Party manufacturer) (the “ALN-TTR02 Commercial Supply Agreement”), which will also be
consistent with the terms set forth on Schedule 6.1. Notwithstanding the foregoing, the breach of any such Manufacturing terms as applied to a Collaboration Product shall be treated as a breach under the Regional License Terms, and not under
this Master Agreement. When the Parties enter into an ALN-TTR02 Clinical Supply Agreement or ALN-TTR02 Commercial Supply agreement, such agreement will supersede the terms set forth in Schedule 6.1 with respect to Manufacture and supply of
ALN-TTR02.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 61 - 

 MASTER AGREEMENT 

 

 6.2. Collaboration Product Supply Agreements. Subject to the terms and
conditions of this Section 6 (Manufacture and Supply of the Collaboration Products), following the Implementation Date with respect to any given Collaboration Product other than ALN-TTR02, and within [***] days following a written notice by
Genzyme requesting such negotiation, the Parties will negotiate in good faith and enter into a supply agreement (and any other necessary ancillary agreements) for clinical supply of such Collaboration Product by Alnylam (or for Alnylam by
Alnylam’s Third Party manufacturer) (each, a “Clinical Supply Agreement”), which will be consistent with the terms set forth on Schedule 6.2. In addition, at least [***] months in advance of the first Regulatory
Approval of each Collaboration Product (other than ALN-TTR02) the Parties will negotiate in good faith and enter into a supply agreement (and any other necessary ancillary agreements), before such [***]-month date, for commercial supply of such
Collaboration Product by Alnylam (or for Alnylam by Alnylam’s Third Party manufacturer) (each, a “Commercial Supply Agreement”), which will also be consistent with the terms set forth on Schedule 6.2;
provided, however, in the case of any Global Licensed Product, the Parties shall only negotiate and enter into a Commercial Supply Agreement at the request of Genzyme. Notwithstanding the foregoing, the breach of any such Manufacturing
terms as applied to a Collaboration Product shall be treated as a breach under its respective License Terms, and not under this Master Agreement. When the Parties enter into a Clinical Supply Agreement or Commercial Supply Agreement, such agreement
will supersede the terms set forth in Schedule 6.2 with respect to the Manufacture and supply of the applicable Collaboration Product. 

6.3. General Supply Agreement Requirements. In addition to reflecting terms consistent with those set forth on Schedule
6.1 or Schedule 6.2, as applicable, each Alnylam Supply Agreement will include key performance indicators for Alnylam (including criteria regarding Manufacturing capacity, quantity, timeliness of delivery, quality and cost that are
consistent with prevailing industry standards for Third Party contract manufacturing agreements) (collectively, the “KPIs”). Further, for each Alnylam Supply Agreement for a given Collaboration Product, the Parties shall also enter
into a quality technical agreement, which will be designed to ensure sufficient oversight by Genzyme of quality matters related to the Manufacture and testing of such Collaboration Product by Alnylam and its Third Party manufacturers and will set
forth the quality responsibilities and obligations of both Genzyme and Alnylam. 
 6.4. Disputed Supply Agreement Terms. If the
Parties are unable to reach agreement on any terms of any of the Alnylam Supply Agreements, as required by Sections 6.1 (ALN-TTR02 Supply Agreements), 6.2 (Collaboration Product Supply Agreements) and 6.3 (General Supply Agreement
Requirements), then any such disputed terms shall be submitted to the AJSC for resolution pursuant to Section 5.1.8 (Decision-Making). If the AJSC is unable to resolve any such disputed terms, then those unresolved disputed terms shall be
[***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 62 - 

 MASTER AGREEMENT 

 

 6.5. Transfer of Manufacturing Know-How. [***]. 

6.6. Establishment of Second Source and Back-Up Sources.  

6.6.1. [***]. 

6.6.2. [***]. 

6.6.2.1. [***]. 

6.6.2.2. [***]. 

6.6.2.3. [***]. 

6.6.2.4. [***]. 

6.6.2.5. [***]. 
 6.7.
Third Party Manufacturers and Subcontracting. If, following the Effective Date, either Party desires to enter into an agreement with a Third Party manufacturer for the supply of Product, then (a) the other Party shall have the right
to review and approve (such approval not unreasonably withheld, conditioned or delayed) such Third Party manufacturer and (b) each Party shall keep the other Party reasonably informed through the Manufacturing Committee of the status of any
proposed supply agreement to be entered into with any such Third Party manufacturer with respect to the Manufacture and supply of such Product (a “Third Party Supply Agreement”) and submit any such Third Party Supply Agreement to
the Manufacturing Committee for review and good faith discussion prior to its execution. For the avoidance of doubt, if a Party is subject to an existing binding agreement with a Third Party manufacturer for the supply of Product as of the Effective
Date (each an “Existing Third Party Supply Agreement”), then, provided that such existing binding agreement is not materially amended at any time following the Effective Date (i) such existing binding agreement shall be deemed
a Third Party Supply Agreement and (ii) the provisions of clauses a and b (immediately above) shall not apply to such existing binding agreement or the Third Party manufacturer party thereto. Without the consent of the other Party, but subject
to the terms of this Section 6, either Party may subcontract (in whole or in part) its Manufacturing obligations under any Alnylam Supply Agreement or Genzyme Supply Agreement, as applicable, to a qualified Third Party manufacturer
pursuant to a binding Third Party Supply Agreement; provided, however, that (A) the subcontracting Party shall remain solely responsible to the other Party for the performance of the subcontracting Party’s obligations under
each Alnylam Supply Agreement or Genzyme Supply Agreement, as applicable and (B) the terms and/or conditions of any Third Party Supply 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 63 - 

 MASTER AGREEMENT 

 

 
Agreement shall not in any way amend, modify or diminish the subcontracting Party’s obligations to the other Party under any Alnylam Supply Agreement or Genzyme Supply Agreement, as
applicable. If the forecasting or order timing/method provisions of a Third Party Supply Agreement do not align with the corresponding provisions of a relevant Alnylam Supply Agreement or Genzyme Supply Agreement, as applicable, then, at the request
of the subcontracting Party, the Parties shall discuss in good faith appropriate modifications to such Alnylam Supply Agreement or Genzyme Supply Agreement, as applicable, to bring the relevant provisions into alignment with such Third Party Supply
Agreement, provided, however, that the non-subcontracting Party shall have no obligation to agree to any amendment to such Alnylam Supply Agreement or Genzyme Supply Agreement that can reasonably be expected to materially disadvantage
the non-subcontracting Party. 
 6.8. Waivers. In the event that any Collaboration Product must be substantially Manufactured
in the United States pursuant to applicable Law, then, at Genzyme’s request, Alnylam will use commercially reasonable efforts, at Genzyme’s expense, to secure a waiver of such requirement for such Collaboration Product under 35 U.S.C.
§ 204 or any analogous applicable Law outside the United States. If a waiver of the substantially manufactured requirement is obtained, then such Collaboration Product used or sold in the United States may be Manufactured as such waiver
permits. 
 7. CONFIDENTIALITY AND PUBLICATION 

7.1. Nondisclosure Obligation.  

7.1.1. All Confidential Information disclosed by one Party to the other Party under the Collaboration Agreement, Stock
Purchase Agreement and Investor Agreement shall be maintained in confidence by the receiving Party and shall not be disclosed to a Third Party or used for any purpose except as set forth herein without the prior written consent of the disclosing
Party, except to the extent that such Confidential Information: 
 (a) is known by the receiving Party at the time of
its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s business records; 

(b) is known to the public before its receipt from the disclosing Party, or thereafter becomes generally known to the public
through no breach of the Collaboration Agreement, Stock Purchase Agreement or Investor Agreement by the receiving Party; 

(c) is subsequently disclosed to the receiving Party by a Third Party who is not known by the receiving Party to be under an
obligation of confidentiality to the disclosing Party; or 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 64 - 

 MASTER AGREEMENT 

 

 (d) is developed by the receiving Party independently of Confidential
Information received from the disclosing Party, as documented by the receiving Party’s business records. 
 7.1.2.
Notwithstanding the obligations of confidentiality and non-use set forth above and in Section 7.1.3 below, a receiving Party may provide Confidential Information disclosed to it, and disclose the existence and terms of the Collaboration
Agreement, Stock Purchase Agreement or Investor Agreement as may be reasonably required in order to perform its obligations and to exploit its rights under the Collaboration Agreement, Stock Purchase Agreement or Investor Agreement, and specifically
to (i) Related Parties, and their employees, directors, agents, consultants, advisors or other Third Parties for the performance of its obligations hereunder (or for such entities to determine their interest in performing such activities) in
accordance with the Collaboration Agreement, Stock Purchase Agreement or Investor Agreement in each case who are under an obligation of confidentiality with respect to such information that is no less stringent than the terms of this
Section 7.1; (ii) governmental or other Regulatory Authorities in order to obtain patents or perform its obligations or exploit its rights under the Collaboration Agreement, Stock Purchase Agreement or Investor Agreement, provided
that such Confidential Information shall be disclosed only to the extent reasonably necessary to do so; (iii) the extent required by Law, including by the rules or regulations of the United States Securities and Exchange Commission or similar
regulatory agency in a country other than the United States or of any stock exchange or listing entity; (iv) any bona fide actual or prospective acquirers, underwriters, investors, lenders or other financing sources and any bona fide actual or
prospective collaborators or strategic partners and to consultants and advisors of such Party, in each case who are under an obligation or confidentiality with respect to such information that is no less stringent than the terms of this
Section 7.1; and (v) to Third Parties to the extent a Party is required to do so pursuant to the terms of an In-License. If a Party is required by Law to disclose Confidential Information that is subject to the non-disclosure provisions of
this Section 7.1, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure. Notwithstanding Section 7.1.1, Confidential
Information that is required to be disclosed by Law shall remain otherwise subject to the confidentiality and non-use provisions of this Section 7.1. If either Party concludes that a copy of any of the Collaboration Agreement, Stock Purchase
Agreement or Investor Agreement must be filed with the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States, such Party shall provide the other Party with a copy of such agreement
showing any provisions hereof as to which the Party proposes to request confidential treatment, shall provide the other Party with an opportunity to comment on any such proposed redactions and to suggest additional redactions, and shall take such
Party’s reasonable comments into consideration before filing such agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 65 - 

 MASTER AGREEMENT 

 

 7.1.3. Alnylam acknowledges that Genzyme may use Confidential
Information of Alnylam for purposes of making investment and voting decisions with respect to the shares of Common Stock owned by Genzyme, provided that (i) Genzyme hereby acknowledges to Alnylam that Genzyme is aware that the United
States securities laws prohibit any Person who has material, non-public information concerning a company from purchasing or selling securities of such company or from communicating such information to any other Person under circumstances in which it
is reasonably foreseeable that such Person is likely to purchase or sell such securities and (ii) Genzyme hereby acknowledges that it is are aware of the sanctions under the United States securities laws attaching to misuse or such improper
disclosure of any material, non-public information relating to Alnylam. 
 7.1.4. Each Party recognizes that
the value to the other Party of the transactions under the Collaboration Agreement, Stock Purchase Agreement and Investor Agreement depend, in part, on each Party protecting the secrecy of its Know-How. Therefore, without limiting any Party’s
right’s right to license its Know-How, subject to the terms of the Collaboration Agreement, Stock Purchase Agreement or Investor Agreement, in any way it chooses, each Party shall use commercially reasonable efforts to protect the
confidentiality of its Know-How as determined in such Party’s reasonable business judgment. 
 7.1.5.
Notwithstanding any provision of the Collaboration Agreement to the contrary but subject to the occurrence of the Effective Date, Residual Knowledge shall not be considered Confidential Information for purposes of this Section 7.1. 

7.2. Publication and Publicity.  

7.2.1. Publication. Genzyme and Alnylam each acknowledge the other Party’s interest in publishing certain key
results of the Collaboration. Each Party also recognizes the mutual interest in obtaining valid patent protection and in protecting trade secret information. Consequently, except for disclosures permitted pursuant to Section 7.1 (Nondisclosure
Obligation) and 7.2.2 (Publicity), either Party wishing to make a publication or public presentation that contains the Confidential Information of the other Party shall deliver to the other Party a copy of the proposed written publication or
presentation at least [***] days prior to submission for publication or presentation. The reviewing Party shall have the right (i) to propose modifications to the publication or presentation for patent reasons, trade secret reasons or business
reasons, and the publishing Party shall remove all Confidential Information of the other Party if requested by the reviewing Party, or (ii) to request a reasonable delay in publication or presentation in order to protect patentable information.
If the reviewing Party requests a delay, the publishing Party shall delay submission or presentation for a period of [***] days (or such shorter period as may be mutually agreed by the Parties) to enable the non-publishing Party to file patent
applications protecting such Party’s rights in such  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 66 - 

 MASTER AGREEMENT 

 

 information. With respect to any proposed publications or disclosures by investigators or
academic or non-profit collaborators, such materials shall be subject to review under this Section 7.2.1 to the extent that Genzyme or Alnylam, as the case may be, has the right and ability (after using commercially reasonable efforts to obtain
such right and ability) to do so. 
 7.2.2. Publicity. Except as set forth in Section 7.1 (Nondisclosure
Obligation) and Section 7.2.1 (Publication) above and 7.3.2 (Press Release) below, the terms of any of the Collaboration Agreement, Stock Purchase Agreement or Investor Agreement may not be disclosed by either Party, and neither Party shall use
the name, Trademark, trade name or logo of the other Party or its employees in any publicity, news release or disclosure relating to any of the Collaboration Agreement, Stock Purchase Agreement or Investor Agreement, its subject matter, or the
activities of the Parties hereunder without the prior express written permission of the other Party, except as may be required by Law, including by the rules or regulations of the United States Securities and Exchange Commission, the French
Financial Markets Authority, the French Prudential Supervisory Authority or similar regulatory agency in any country other than the United States or France or of any stock exchange or listing entity, or except as expressly permitted by the terms
hereof. 
 7.3. Press Release.  

7.3.1. Following the execution of the Collaboration Agreement, the Parties shall issue separate press releases in the
forms set forth in Schedule 7.3 or such other forms mutually agreed by the Parties. After such initial press releases, except as provided in Section 7.3.2, neither Party shall issue a press release or public announcement relating to the
Collaboration Agreement without the prior written approval of the other Party, which approval shall not be unreasonably withheld, conditioned or delayed, except that a Party may (i) once a press release or other public statement is approved in
writing by both Parties, make subsequent public disclosure of the information contained in such press release or other written statement without the further approval of the other Party, and (ii) issue a press release or public announcement as
required, in the reasonable judgment of such Party, by Law, including by the rules or regulations of the United States Securities and Exchange Commission, the French Financial Markets Authority, the French Prudential Supervisory Authority or similar
regulatory agency in a country other than the United States or France or of any stock exchange or listing entity. 

7.3.2. Notwithstanding anything in this Section 7.3 to the contrary, either Party may issue a press release or make
a public disclosure relating to (i) the results of any Clinical Studies with respect to an Option Product, (ii) the exercise of an Option, (iii) the payment or receipt of a milestone payment under any License Terms with respect to a
Collaboration Product and (iv) such Party’s Development, Manufacturing or Commercialization activities under any License Terms with respect to Collaboration  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 67 - 

 MASTER AGREEMENT 

 

 
Products in such Party’s Territory, provided that such press release or public disclosure does not disclose Confidential Information of the other Party. Furthermore, either Party may
issue a press release or make a public disclosure relating to the other Party’s Development, Manufacturing or Commercialization activities with respect to the Collaboration Products in the other Party’s Territory, provided that
(i) such press release or public disclosure does not disclose Confidential Information of the other Party and (ii) such press release or public disclosure merely repeats subject matter previously disclosed by the other Party in a manner
that is substantially consistent with such prior disclosure. Prior to making any such disclosure under this Section 7.3.2, however, the Party making the disclosure shall provide the other Party with a draft of such proposed disclosure a
reasonable time (but at least [***] business days) prior to disclosure to allow the other Party to review and comment prior to making any such disclosure, for the other Party’s review and comment, and the disclosing Party shall consider in good
faith any timely comments provided by the other Party. Notwithstanding the foregoing, except as expressly permitted by clause (i), (ii) or (iii) above and subject to clause (ii) of Section 7.3.1, Alnylam may not issue any other
press release or make a public disclosure relating to Genzyme’s activities for any Global Licensed Product without the prior written consent of Genzyme. 

8. REPRESENTATIONS, WARRANTIES AND COVENANTS 

8.1. Mutual Representations and Warranties as of the Execution Date. Each Party represents and warrants to the
other Party that, as of the Execution Date: 
 8.1.1. such Party is a corporation duly organized, validly
existing and in good standing under the laws of its jurisdiction of incorporation or formation;  
 8.1.2. such
Party has all requisite corporate power and corporate authority to enter into the Collaboration Agreement and to carry out its obligations under the Collaboration Agreement;  

8.1.3. all requisite corporate action on the part of such Party, its directors and stockholders required by applicable
Law for the authorization, execution and delivery by such Party of the Collaboration Agreement, and the performance of all obligations of such Party under the Collaboration Agreement, has been taken; 

8.1.4. the execution, delivery and performance of the Collaboration Agreement, and compliance with the provisions of the
Collaboration Agreement, by such Party do not and shall not: (a) violate any provision of applicable Law or any ruling, writ, injunction, order, permit, judgment or decree of any Governmental Authority, (b) constitute a breach of, or
default under (or an event which, with notice or lapse of time or both, would become a default under) or conflict with, or give rise to any right of termination, cancellation or acceleration of, any agreement, arrangement or instrument, whether 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 68 - 

 MASTER AGREEMENT 

 

 
written or oral, by which such Party or any of its assets are bound, or (c) violate or conflict with any of the provisions of such Party’s organizational documents (including any articles or
memoranda of organization or association, charter, bylaws or similar documents), except, in the case of subsections (a) and (b), as would not have or be reasonably likely to have a Material Adverse Effect (as defined in the Stock Purchase
Agreement); 
 8.1.5. no consent, approval, authorization or other order of, or filing with, or notice to, any
Governmental Authority or other Third Party is required to be obtained or made by such Party in connection with the authorization, execution and delivery by the Company of the Collaboration Agreement, except as required pursuant to the HSR Act;
and 
 8.1.6. such Party has not entered into any agreement with any Third Party that grants such Third Party
any rights that would be in conflict with the Collaboration Agreement following an siRNA becoming a Collaboration Product under the Collaboration Agreement. 

8.2. Representations and Warranties of Alnylam. Except as provided in Schedule 8.2, Alnylam represent and warrants to
Genzyme that, as of the Execution Date and, with respect to the representations in Sections 8.2.1, 8.2.2, 8.2.5, 8.2.7, 8.2.9 and 8.2.10 below, as of the Effective Date: 

8.2.1. Alnylam is the sole and exclusive owner of, or otherwise Controls pursuant to an Existing Alnylam In-License, the
Option Product Technology and the ALN-TTR Technology. 
 8.2.2. Alnylam has sufficient legal and/or beneficial title
and ownership of, or sufficient license rights under, the Option Product Technology and ALN-TTR Technology to grant the licenses to such Option Product Technology and ALN-TTR Technology to Genzyme pursuant to the Collaboration Agreement. 

8.2.3. (a) Schedule 1.2.22 (ALN-TTR Core Technology Patents), Schedule 1.2.24 (ALN-TTR Product-Specific
Patents), Schedule 1.2.159 (Option Product Core Technology Patents) and Schedule 1.2.162 (Option Product-Specific Patents) collectively set forth a complete and accurate list of the ALN-TTR Patents and Option Product Patents
owned, either solely or jointly, by Alnylam, and to Alnylam’s knowledge, Schedule 1.2.22 (ALN-TTR Core Technology Patents), Schedule 1.2.24 (ALN-TTR Product-Specific Patents), Schedule 1.2.159 (Option Product Core
Technology Patents) and Schedule 1.2.162 (Option Product-Specific Patents) collectively set forth a complete and accurate list of the ALN-TTR Patents and Option Product Patents licensed, either exclusively or nonexclusively, to Alnylam,
(b) to Alnylam’s knowledge, each issued ALN-TTR Patent and Option Product Patent remains in full force and effect and (c)

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 69 - 

 MASTER AGREEMENT 

 

 
Alnylam or its Affiliates have timely paid all filing and renewal fees payable with respect to such ALN-TTR Patents and Option Product Patents for which Alnylam controls prosecution and
maintenance. Schedule 1.2.22 (ALN-TTR Core Technology Patents), Schedule 1.2.24 (ALN-TTR Product-Specific Patents), Schedule 1.2.159 (Option Product Core Technology Patents) and Schedule 1.2.162 (Option
Product-Specific Patents) indicate whether each ALN-TTR Patent and Option Product Patent is owned exclusively by Alnylam, is owned jointly by Alnylam and one or more Third Parties, or is licensed to Alnylam. For each ALN-TTR Patent and Option
Product Patent that is owned, but not owned exclusively, by Alnylam, or that is licensed to Alnylam, Schedule 1.2.22 (ALN-TTR Core Technology Patents), Schedule 1.2.24 (ALN-TTR Product-Specific Patents), Schedule 1.2.159
(Option Product Core Technology Patents) and Schedule 1.2.162 (Option Product-Specific Patents) identify the Third Party owner(s) and, if applicable, the Existing Alnylam In-License pursuant to which Alnylam Controls such ALN-TTR Patent
or Option Product Patent. For each Option Product Core Technology Patent family (other than Patent Rights licensed from Isis Pharmaceuticals, Inc.) and each ALN-TTR Core Technology Patent family that is licensed, but not exclusively licensed, to
Alnylam, Schedule 1.2.22 (ALN-TTR Core Technology Patents) or Schedule 1.2.159 (Option Product Core Technology Patents), as applicable indicates the non-exclusive nature of the license. For each Option Product-Specific Patent and
ALN-TTR Product-Specific Patent that is licensed, but not exclusively licensed, to Alnylam, Schedule 1.2.24 (ALN-TTR Product-Specific Patents) or Schedule 1.2.162 (Option Product-Specific Patents), as applicable, indicates the
non-exclusive nature of the license. Alnylam is the sole and exclusive owner of all Patent Rights identified in Schedule 1.2.22 (ALN-TTR Core Technology Patents), Schedule 1.2.24 (ALN-TTR Product-Specific Patents),
Schedule 1.2.159 (Option Product Core Technology Patents) and Schedule 1.2.162 (Option Product-Specific Patents) as being owned exclusively by Alnylam and Controls all other Patent Rights identified on such schedules. 

8.2.4. Schedule 1.2.82 (Existing Alnylam In-Licenses) sets forth a complete and accurate list of all agreements
between Alnylam and a Third Party entered into prior to the Execution Date pursuant to which Alnylam Controls Know-How or Patent Rights that are necessary or useful to Develop, Manufacture or Commercialize ALN-TTR02, ALN-TTRsc or any Co-Co/Global
Option Product in the Field, other than Additional Alnylam In-Licenses. [***]. 
 8.2.5. Alnylam has complied with all
applicable Laws, including any duties of candor to applicable patent offices, in connection with the filing, prosecution and maintenance of the ALN-TTR Patents and Option Product Patents. 

8.2.6. To Alnylam’s knowledge, neither Alnylam nor its Affiliates are in breach or default under any Existing
Alnylam In-License, and neither Alnylam nor its Affiliates have received any written notice of breach or default with respect to any Existing Alnylam In-License. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 70 - 

 MASTER AGREEMENT 

 

 8.2.7. Alnylam has obtained from all inventors of ALN-TTR Technology
or Option Product Technology owned by Alnylam valid and enforceable agreements assigning to Alnylam each such inventor’s entire right, title and interest in and to all such ALN-TTR Technology or Option Product Technology, as applicable. 

8.2.8. There is no (a) claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action
of any nature, civil, criminal, regulatory or otherwise, pending or, to Alnylam’s knowledge, threatened against Alnylam or any of its Affiliates or (b) judgment or settlement against or owed by Alnylam or any of its Affiliates, in each
case in connection with the ALN-TTR Technology or Option Product Technology. 
 8.2.9. Alnylam owns or Controls all
Know-How that is or has been used by Alnylam in the Development and Manufacture of ALN-TTR02, ALN-TTRsc and the Option Products, and has sufficient legal or beneficial title and ownership of, or sufficient license rights under such Know-How to
transfer Know-How to Genzyme as provided in Section 6.5 (Transfer of Manufacturing Know-How). 
 8.2.10.
Alnylam has conducted all Development activities with respect to the Core Pipeline Programs currently in existence in compliance with all applicable Laws, including current governmental regulations concerning, GLP, good clinical practices and
cGMP. 
 8.2.11. True and complete copies of the agreements set forth on Schedule 1.2.82 (Existing
Alnylam In-Licenses) and Schedule 1.2.7 (Additional Alnylam In-Licenses), and all of the agreements relating to any Option Product, ALN-TTR02 or ALN-TTRsc have been made available to Genzyme through an electronic data room. 

For purposes of this Section 8.2 and where indicated in Section 8.4 (Certain Covenants), with respect to each instance of Option Product Technology,
Option Product Patents, Option Product Core Technology Patents and Option Product-Specific Patents and Option Products, those definitions shall be limited to the Existing Core Option Products. 

8.3. Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THE COLLABORATION AGREEMENT, STOCK PURCHASE AGREEMENT OR
INVESTOR AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY TECHNOLOGY, COLLABORATION PRODUCT, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF
THE COLLABORATION AGREEMENT AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR
WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY COLLABORATION PRODUCT PURSUANT TO THE COLLABORATION AGREEMENT SHALL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY COLLABORATION PRODUCT SHALL BE
ACHIEVED. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 71 - 

 MASTER AGREEMENT 

 

 8.4. Certain Covenants.  

8.4.1. Compliance. Each Party and its Related Parties shall conduct the Collaboration and the Development, Manufacture
and Commercialization of the Collaboration Products and any Option Products from the Core Pipeline Programs in material compliance with all applicable Laws, including current governmental regulations concerning GLP, good clinical practices and cGMP.
 
 8.4.2. Clarifying Amendments. [***]. For clarity, such amendment will be an Existing Alnylam In-License for
all purposes of the Collaboration Agreement. 
 8.4.3. Retention of Title. During the Option Period, Alnylam
shall retain and maintain sufficient legal and/or beneficial title and ownership of, or sufficient license rights under, any Option Product Technology relating to a Core Pipeline Program to enable Alnylam to grant the licenses and rights to such
Option Product Technology that would be granted to Genzyme under, and as reasonably necessary to practice, such Option Product Technology under the applicable License Terms if Genzyme exercised an Option with respect to such Option Product. Without
limiting the generality of the foregoing, during the Option Period, Alnylam shall not sell, transfer, lease or otherwise dispose of any Option Product Technology, except to the extent expressly permitted under the Collaboration Agreement or to grant
a security interest, lien or other encumbrance in, on or to any Option Product Technology as part of a financing transaction. 

8.4.4. Know-How. Alnylam shall not use any Know-How that it does not Control in the Development or Manufacture of Option
Products from the Core Pipeline Programs. Alnylam shall obtain sufficient legal or beneficial title and ownership of, or beneficial title and ownership of, or sufficient rights under, and as reasonably necessary to practice, any Know-How that is
used by Alnylam in the Development or Manufacture of Option Products from the Core Pipeline Programs to grant the licenses and rights to such Know-How that would be granted to Genzyme pursuant to the applicable License Terms if Genzyme exercised an
Option with respect to an Option Product from the Core Pipeline Programs. 
 8.4.5. In-Licenses. Alnylam shall use
commercially reasonable efforts to maintain Control of all Know-How and Patent Rights licensed to Alnylam under the Existing Alnylam In-Licenses and Additional Alnylam In-Licenses that would be necessary or useful for Genzyme to Develop, Manufacture
and/or Commercialize any Option Product in the Field in the Genzyme Territory pursuant to the License Terms that 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 72 - 

 MASTER AGREEMENT 

 

 
would apply to such Option Product if Genzyme exercised an Option for such Option Product. Alnylam shall use commercially reasonable efforts not to materially breach or be in material default
under any of its obligations under any Alnylam In-License. Alnylam will not voluntarily amend or terminate any Alnylam In-License in a manner that would terminate rights that would be sublicensed to Genzyme if Genzyme exercised an Option with
respect to an Option Product, other than Additional Alnylam In-Licenses. Alnylam will update Schedule 1.2.82 (Existing Alnylam In-Licenses) if, prior to the Effective Date, Alnylam enters into any agreement pursuant to which Alnylam Controls
Patent Rights or Know-How necessary or useful to Develop, Manufacture or Commercialize any Option Product (where such term is limited for these purposes in accordance with the last sentence of Section 8.2), ALN-TTR02 or ALN-TTRsc in the Field
in the Genzyme Territory. 
 8.4.6. No Debarment. Each Party shall commercially reasonable efforts to not use, in any
capacity in connection with the Collaboration or the performance of its obligations under the Collaboration Agreement, any Person that has been debarred pursuant to Section 306 of the United States Federal Food, Drug, and Cosmetic Act, as
amended, or that is the subject of a conviction described in such section. Each Party agrees to inform the other Party in writing immediately if it or any Person that is performing activities in the Collaboration or under the Collaboration
Agreement, is debarred or is subject to debarment or is the subject of a conviction described in Section 306, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of the notifying
Party’s knowledge, is threatened, relating to the debarment or conviction of the notifying Party or any Person or entity used in any capacity by such Party or any of its Affiliates in connection with the Collaboration or the performance of its
other obligations under the Collaboration Agreement. 
 8.4.7. [***]. 

8.4.8. Potential License Agreements. [***]. 

8.4.9. [***]. 

8.4.10. Contractual Obligations. If any ALN-TTR Technology or Option Product Technology is subject to any funding
agreement with any government or Governmental Authority or subject to any other agreement under which requirements and obligations will apply to Genzyme under the Collaboration Agreement, then, at Genzyme’s request, Alnylam will use
commercially reasonable efforts, at Genzyme’s expense, to secure a waiver of any requirements or obligations of Genzyme under such agreements. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 73 - 

 MASTER AGREEMENT 

 

 8.4.11. [***]. 

9. ROYALTY REPORTS; PAYMENTS; AUDIT 

9.1. Reports; Payment of Royalty. During the Term, following the First Commercial Sale of any Collaboration Product by or on
behalf of a Party in such Party’s Territory under the applicable License Terms, such Party shall furnish to the other Party a written report within [***] days after the end of each Calendar Quarter showing, on a Collaboration
Product-by-Collaboration Product and country-by-country basis [***]. Except as expressly provided in the Collaboration Agreement, all payments by one Party to the other Party under the Collaboration Agreement shall be non-refundable and
non-creditable and not subject to set-off. Royalties shown to have accrued by each royalty report shall be due and payable [***] days following the date such royalty report is due. In addition, each Party selling a Collaboration Product shall
prepare and deliver to the other Party any additional reports for sales in such selling Party’s Territory as required under any applicable Existing Genzyme In-Licenses, Existing Alnylam In-Licenses or Collaboration In-Licenses. 

9.2. Audits.  

9.2.1. On a Collaboration Product-by-Collaboration Product basis, upon the written request of a Party and not more than
once in each Calendar Year, the other Party and its Related Parties shall permit an independent certified public accounting firm of internationally-recognized standing selected by the requesting Party and reasonably acceptable to the other Party, at
the requesting Party’s expense except as set forth below, to have access during normal business hours to such of the records of the other Party as may be reasonably necessary to verify the accuracy of the royalty and other amounts payable or
reports under the Collaboration Agreement in respect of such Collaboration Product (including Global R&D Costs (as defined in any of the License Terms) and Cost of Goods but excluding S&M Costs (as defined in the Co-Co License Terms)) for
any year ending not more than [***] years prior to the date of such request for the sole purpose of verifying the basis and accuracy of payments made under the applicable License Terms in respect of such Collaboration Product. Notwithstanding the
foregoing, a Party may not make more than [***] in a Calendar Year, [***].  
 9.2.2. If such accounting firm
identifies a discrepancy made during such period, the appropriate Party shall pay the other Party the amount of the discrepancy, together with late-payment interest in accordance with Section 9.4 (Late Payments), within [***] days after the
date the requesting Party delivers to the other Party such accounting firm’s written report so concluding, or as otherwise agreed by the Parties in writing. The fees charged by such accounting firm shall be paid by the requesting Party, unless
such discrepancy represents an underpayment by the other Party of at least [***], on a Collaboration Product-by-Collaboration Product basis, of the total amounts due in respect of such Collaboration Product in the audited period, in which case such
fees shall be paid by the other Party. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 74 - 

 MASTER AGREEMENT 

 

 9.2.3. Each Party shall comply with all applicable audit requirements
in the In-Licenses and shall include in each sublicense granted by it pursuant to the License Terms a provision requiring any Sublicensee (as defined under the applicable License Terms) to make reports to the Party that is party to such In-License,
to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by the independent accountant of the Party that is party to such In-License to the same extent required of a Party under the Collaboration
Agreement. 
 9.2.4. Unless an audit for such year has been commenced prior to and is ongoing upon the [***]
anniversary of the end of such year, the calculation of royalties, expense reimbursement and other payments payable with respect to such year shall be binding and conclusive upon both Parties, and each Party and its Related Parties shall be released
from any further liability or accountability with respect to such royalties or expense reimbursement for such year. 

9.2.5. Each Party shall treat all financial information subject to review under this Section 9.2 or under any
sublicense agreement in accordance with the confidentiality and non-use provisions of Section 7 (Confidentiality and Publication), and shall cause its accounting firm to enter into a confidentiality agreement with the other Party or its Related
Parties obligating it to retain all such information in confidence pursuant to such confidentiality agreement, which terms shall be no less stringent than the provisions of Section 7 (Confidentiality and Publication). 

9.3. Payment Exchange Rate. All payments to be made under the Collaboration Agreement shall be made in United States dollars and
shall be paid by bank wire transfer in immediately available funds to such bank account in the United States as may be designated in writing by the receiving Party from time to time. In the case of Net Sales made or expenses incurred by a Party and
its Related Parties in currencies other than United States dollars during a Calendar Quarter, the rate of exchange to be used in computing the amount of United States dollars due shall be the rate of exchange utilized by such Party in its worldwide
accounting system and calculated in accordance with GAAP. 
 9.4. Late Payments. Any amount owed by a Party to the other
Party under the Collaboration Agreement that is not paid on or before the date such payment is due shall bear interest at a rate per annum equal to the lesser of (a) [***] or (b) the highest rate permitted by Law, calculated on the number
of days such payments are paid after such payments are due and compounded monthly.  
 9.5. Blocked Payments. If, by
reason of Laws in any jurisdiction in a Party’s Territory, it becomes impossible or illegal for a Party to transfer milestone payments, royalties or other payments under the Collaboration Agreement to the other Party, the payor shall promptly
notify the payee. During any such period described above, the payor shall deposit such payments in local currency in the relevant jurisdiction to the credit of the payee in a recognized banking institution designated by the payee or, if none is
designated by the payee within a period of [***] days, in a recognized banking institution selected by the payor and identified in a written notice given to the payee.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 75 - 

 MASTER AGREEMENT 

 

 9.6. Taxes. If a timely and appropriately completed and executed Internal
Revenue Service Form W-9 is provided by the receiving Party to the paying Party, the Parties acknowledge and agree that no United States tax withholding shall be applied with respect to any milestone payments due under any License Terms. Each Party
shall use reasonable efforts to minimize tax withholding on payments made to the other Party. Notwithstanding such efforts, if such Party concludes that tax withholdings under the Laws of any country are required with respect to payments to the
other Party, such Party shall first notify the other Party and provide such Party with [***] days to determine whether there are actions such receiving Party can undertake to avoid such withholding. During this notice period, the paying Party shall
refrain from making such payment until the receiving Party instructs the paying Party that (a) the receiving Party intends to take actions (satisfactory to both Parties) that shall obviate the need for such withholding, in which case the paying
Party shall make such payment only after it is instructed to do so by the receiving Party, or (b) the paying Party should make such payment and withhold the required amount and pay it to the appropriate Governmental Authority. In such case, the
withholding Party shall promptly provide the other Party with copies of receipts or other evidence reasonably required and sufficient to allow the other Party to document such tax withholdings adequately for purposes of claiming foreign tax credits
and similar benefits. The Parties shall cooperate reasonably in completing and filing documents required under the provisions of any applicable tax laws or under any other applicable Law, in connection with the making of any required tax payment or
withholding payment, or in connection with any claim to a refund of or credit for any such payment. The Parties shall cooperate to minimize such taxes in accordance with applicable Laws, including using reasonable efforts to access the benefits of
any applicable treaties. [***]. 
 10. INDEMNIFICATION; LIMITATION OF LIABILITY; INSURANCE 

10.1. General Indemnification by Genzyme. Genzyme shall indemnify, hold harmless and defend Alnylam, its Related Parties, and
their respective directors, officers, employees and agents (“Alnylam Indemnitees”) from and against any and all Third Party claims, suits, losses, liabilities, damages, costs, fees and expenses (including reasonable attorneys’
fees and litigation expenses) (collectively, “Losses”) arising out of or resulting from, directly or indirectly, (a) any breach of, or inaccuracy in, any representation or warranty made by Genzyme in the Collaboration
Agreement, or any breach or violation of any covenant or agreement of Genzyme in or in the performance of the Collaboration Agreement, or (b) the negligence or willful misconduct by or of Genzyme and its Related Parties, and their respective
directors, officers, employees and agents in the performance of Genzyme’s obligations under the Collaboration Agreement. Genzyme shall have no obligation to indemnify the Alnylam Indemnitees to the extent that the Losses arise out of or result
from, directly or indirectly, any breach of, or inaccuracy in, any representation or warranty made by Alnylam in the  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 76 - 

 MASTER AGREEMENT 

 

 Collaboration Agreement, or any breach or violation of any covenant or agreement of Alnylam in or in the
performance of the Collaboration Agreement, or the negligence or willful misconduct by or of any of the Alnylam Indemnitees, or matters for which Alnylam is obligated to indemnify Genzyme under Section 10.2 (General Indemnification by Alnylam)
or 10.3 (Product Liability). 
 10.2. General Indemnification by Alnylam. Alnylam shall indemnify, hold harmless, and defend
Genzyme, its Related Parties and their respective directors, officers, employees and agents (“Genzyme Indemnitees”) from and against any and all Losses arising out of or resulting from, directly or indirectly, (a) any breach
of, or inaccuracy in, any representation or warranty made by Alnylam in the Collaboration Agreement, or any breach or violation of any covenant or agreement of Alnylam in or in the performance of the Collaboration Agreement, (b) the negligence
or willful misconduct by or of Alnylam and its Related Parties, and their respective directors, officers, employees and agents in the performance of Alnylam’s obligations under the Collaboration Agreement or (c) any infringement (including
induced infringement) of any of the Patent Rights identified on Schedule 10.2 (Identified Patent Rights) arising from the Development, Manufacture or Commercialization of a Collaboration Product by Genzyme or its Affiliates. Alnylam shall
have no obligation to indemnify the Genzyme Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, any breach of, or inaccuracy in, any representation or warranty made by Genzyme in the Collaboration
Agreement, or any breach or violation of any covenant or agreement of Genzyme in or in the performance of the Collaboration Agreement, or the negligence or willful misconduct by or of any of the Genzyme Indemnitees, or matters for which Genzyme is
obligated to indemnify Alnylam under Section 10.1 (General Indemnification by Genzyme) or 10.3 (Product Liability).  
 10.3.
Product Liability. Subject to any Supply Agreements, any Losses arising out of Third Party product liability claims arising from the Development or Commercialization of Collaboration Products shall be (a) borne by Genzyme, to the
extent such Losses were incurred with respect to the Development or Commercialization by or on behalf of Genzyme or its Related Parties of a Regional Licensed Product in or for the Genzyme Territory, a Co-Co Licensed Product in or for the Genzyme
Territory, or a Global Licensed Product anywhere in or for the world by or on behalf of Genzyme and its Related Parties, (b) be borne by Alnylam, to the extent such Losses were incurred with respect to Development or Commercialization of a
Regional Licensed Product in or for the Alnylam Territory by or on behalf of Alnylam and its Related Parties, and (c) be borne fifty percent (50%) by each of Genzyme and Alnylam, to the extent such Losses were incurred with respect to
Development or Commercialization by or on behalf of Alnylam or its Related Parties of a Co-Co Licensed Product in or for the Alnylam Territory. The Party bearing such Losses in accordance with the immediately preceding sentence shall indemnify, hold
harmless and defend the other Party and its Related Parties and their respective directors, officers, employees and agents from and against such Losses. 

10.4. Indemnification Procedure. In the event of any such claim against any Genzyme Indemnitee or Alnylam Indemnitee
(individually, an “Indemnitee”), the indemnified Party shall promptly notify the other Party in writing of the claim and the indemnifying Party  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 77 - 

 MASTER AGREEMENT 

 

 
shall manage and control, at its sole expense, the defense of the claim and its settlement. The Indemnitee shall cooperate with the indemnifying Party and may, at its option and expense, be
represented in any such action or proceeding. The indemnifying Party shall not be liable for any settlements, litigation costs or expenses incurred by any Indemnitee without the indemnifying Party’s written authorization. Notwithstanding the
foregoing, if the indemnifying Party believes that any of the exceptions to its obligation of indemnification of the Indemnitees set forth in Sections 10.1 (General Indemnification by Genzyme), 10.2 (General Indemnification by Alnylam) or 10.3
(Product Liability) may apply, the indemnifying Party shall promptly notify the Indemnitees, which shall then have the right to be represented in any such action or proceeding by separate counsel at their expense, provided that the
indemnifying Party shall be responsible for payment of such expenses if the Indemnitees are ultimately determined to be entitled to indemnification from the indemnifying Party for the matters to which the indemnifying Party notified the Indemnitees
that such exception(s) may apply. 
 10.5. Limitation of Liability. NEITHER PARTY HERETO SHALL BE LIABLE FOR SPECIAL,
INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF THE COLLABORATION AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THE COLLABORATION AGREEMENT, REGARDLESS OF ANY NOTICE
OF SUCH DAMAGES, EXCEPT AS A RESULT OF A PARTY’S WILLFUL MISCONDUCT OR A BREACH OF SECTION 3.6 (EXCLUSIVITY DURING OPTION PERIOD), SECTION 7 (CONFIDENTIALITY AND PUBLICATION), SECTION 10.4.1 OF THE CO-CO LICENSE TERMS (EXCLUSIVITY), SECTION
9.4.1 OF THE GLOBAL LICENSE TERMS (EXCLUSIVITY) OR SECTION 8.4.1 OF THE REGIONAL LICENSE TERMS (EXCLUSIVITY). NOTHING IN THIS SECTION 10.5 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. NOTWITHSTANDING
THE FOREGOING, ALNYLAM SHALL NOT BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF ANY BREACH OF SECTION 3.6 (EXCLUSIVITY DURING OPTION PERIOD) UNLESS GENZYME BRINGS AN ACTION SEEKING SUCH DAMAGES WITHIN SIX
(6) MONTHS AFTER THE EARLIER OF THE DATE ON WHICH THE TRANSACTION BETWEEN ALNYLAM AND A THIRD PARTY ENTERED INTO IN BREACH OF SECTION 3.6 (EXCLUSIVITY DURING OPTION PERIOD) FIRST BECOMES PUBLICLY KNOWN OR THE DATE ON WHICH ALNYLAM NOTIFIES
GENZYME OF SUCH TRANSACTION. 
 10.6. Insurance. Each Party shall maintain insurance during the Term and for a period of
at least two (2) years after the last commercial sale of any Collaboration Product generated under the Collaboration, with a reputable, solvent insurer in an amount appropriate for its business and products of the type that are the subject of
the Collaboration Agreement, and for its obligations under the Collaboration Agreement. Specifically, each Party shall maintain product liability insurance and clinical trial liability insurance with limits of at least [***] per occurrence and in
annual aggregate. Upon request, each Party shall provide the other Party with evidence of the existence and maintenance of such insurance coverage. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 78 - 

 MASTER AGREEMENT 

 

 11. INTELLECTUAL PROPERTY 

11.1. Prosecution and Maintenance of Patent Rights. Alnylam has the sole responsibility to, at Alnylam’s discretion and sole
expense (except as provided below), file, conduct prosecution, and maintain (including the defense of any interference or opposition proceedings), all Patent Rights comprising Option Product Core Technology Patents and Option Product-Specific
Patents, in Alnylam’s name. Notwithstanding the foregoing, Alnylam shall file Option Product-Specific Patents in the Genzyme Patent Jurisdictions and shall use commercially reasonable efforts to prosecute and maintain such Patent Rights in the
Genzyme Patent Jurisdictions and shall timely pay all filing (including during the pendency of any Patent Right) and renewal fees payable with respect thereto [***]. 

11.2. Patent Prosecution Information Sharing. Alnylam shall consult with Genzyme, through the IP Committee, on its strategy for
the preparation, filing, prosecution, and maintenance of the Option Product Patents and shall consider in good faith timely comments from Genzyme thereon. Alnylam shall furnish to Genzyme, through the IP Committee or via electronic mail or such
other method as mutually agreed by the Parties, copies of documents received from outside counsel in the course of filing, prosecution or maintenance of or filed with the relevant national patent offices with respect to the filing, prosecution and
maintenance of all Option Product Core Technology Patents and Option Product-Specific Patents within a reasonable time after filing of such documents.  

11.3. In-Licenses.  

11.3.1. Additional Alnylam In-Licenses. In the event that a Patent Right licensed to Alnylam under an Additional Alnylam
In-License actually is or will be infringed by Genzyme’s Commercialization of a Collaboration Product in the Genzyme Territory or Genzyme’s Manufacture or Development of such Collaboration Product in accordance with the applicable License
Terms, then such Additional Alnylam In-License will thereafter automatically be deemed to be an Existing Alnylam In-License on a Collaboration Product-by-Collaboration Product basis, and all rights granted to Alnylam thereunder will be deemed to be
“Controlled” by Alnylam and sublicensed to Genzyme under the applicable License Terms, effective as of the later of (a) the date the applicable Patent Right issues or (b) the date that Genzyme’s Commercialization of such
Collaboration Product in the Genzyme Territory or Genzyme’s Manufacture of Development of such Collaboration Product in accordance with this Master Agreement and the applicable License Terms would infringe such Patent Right in the absence of a
license thereunder from Alnylam.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 79 - 

 MASTER AGREEMENT 

 

 11.3.2. Existing Alnylam In-Licenses. In the event that Alnylam fails
to identify a Third Party agreement under which Alnylam Controls Know-How or Patent Rights that are necessary or useful to Develop, Manufacture or Commercialize a Collaboration Product, then the Parties will amend the Schedules to the applicable
License Terms to include such agreements within the definition of Existing Alnylam In-License or Additional Alnylam In-License. In any event, any Potential Alnylam In-License under which Alnylam Controls Know-How or Patent Rights that are necessary
or useful to Develop, Manufacture or Commercialize a Collaboration Product will be deemed to be an Existing Alnylam In-License regardless of whether it is entered into before or after the Implementation Date for such Collaboration Product.

 11.3.3. Collaboration In-Licenses. 

11.3.3.1. Proposed In-Licenses. In the event that either Party desires to enter into an agreement with a Third
Party pursuant to which such Party would acquire a license under any Patent Rights that are necessary or useful to Develop, Manufacture or Commercialize any Collaboration Product (a “Proposed In-License”), then such Party shall
deliver a written notice to the other that may include the identity of such Third Party, a description of such Patent Rights and any proposed terms of such Proposed In-License (a “Proposed In-License Notice”) [***]. Within [***]
days of delivery of the Proposed In-License Notice, the IP Committee shall meet to discuss the Proposed In-License and the proposing Party shall consider in good faith comments from the other Party. If the proposing Party enters into the Proposed
In-License, and the non-proposing Party wishes to obtain a sublicense under such Proposed In-License, then the Proposed In-License shall be deemed to be a “Collaboration In-License” for all purposes under the Collaboration
Agreement. For the sake of clarity, if the non-proposing Party does not wish to obtain a sublicense under a Proposed In-License, then none of the rights granted to the proposing Party thereunder will be deemed to be “Controlled” by the
proposing Party and, if the proposing Party (or any of its sublicensees thereunder) has rights to enforce any Patent Rights licensed to the proposing Party thereunder, the proposing Party shall have the right to enforce such Patent Rights against
the non-proposing Party. 
 11.3.3.2. Requirements for Collaboration In-Licenses. In entering into any
Collaboration In-License (or Potential Alnylam In-License, in the case of Alnylam), each Party shall [***]. Any Patent Rights licensed to a Party under a Collaboration In-License shall be deemed to be Controlled by such Party for all purposes under
the License Terms. The Party entering into a Collaboration In-License must notify the other Party promptly and provide the other Party with a copy of such Collaboration In-License. 

11.3.3.3. [***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 80 - 

 MASTER AGREEMENT 

 

 11.3.4. Payments under In-Licenses. 

11.3.4.1. In-Licenses that are not Collaboration In-Licenses. 

(a) Except as provided under the Co-Co License Terms, Alnylam shall bear [***] of any Third Party License Payments that become
payable during the Term under any (i) Existing Alnylam In-License or (ii) Potential Alnylam In-License that is entered into after the Execution Date that becomes an Existing Alnylam In-License pursuant to Section 11.3.2 (Existing
Alnylam In-Licenses). 
 (b) Subject to Section 11.3.5 (Royalty Stacking), Genzyme shall bear [***] of any Third Party
License Payments that become payable under any Existing Genzyme In-License or any Un-Blocking Genzyme In-License during the Term. 

11.3.4.2. Collaboration In-Licenses. Any Third Party License Payment that becomes payable under any Collaboration
In-License (other than a Potential Alnylam In-License) shall be allocated between the Parties as follows: 
 (a) if such
Third Party License Payment becomes payable as a result of a Party’s activities under the License Terms with respect to a Collaboration Product and is either (i) [***] (a “Collaboration Product-Specific Payment”); and 

(b) if such Third Party License Payment is not a Collaboration Product-Specific Payment, then [***]. 

(c) If the Parties cannot agree on whether a Third Party License Payment is a Collaboration Product-Specific Payment or not, or
how to allocate a Third Party License Payment that is not a Collaboration Product-Specific Payment, the Parties shall submit the matter to the AJSC for resolution. If the AJSC cannot resolve the matter within [***] days of it being referred to them,
the Parties shall submit the matter [***]. If the Party that is not a party to the Collaboration In-License disagrees with the allocation of a Third Party License Payment pursuant to this Section 11.3.4.2(c), then such Party may elect not to
take a sublicense under such Collaboration In-License, in which case none of the rights granted to the other Party thereunder will be deemed to be “Controlled” by the other Party and, if the other Party has rights to enforce any Patent
Rights licensed to such other Party thereunder, such other Party (or any of its sublicensees thereunder) shall have the right to enforce such Patent Rights against such Party. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 81 - 

 MASTER AGREEMENT 

 

 11.3.4.3. [***]. 

11.3.4.4. To the extent not otherwise deducted from payments by one Party to the other Party when determining Net Sales
of any Collaboration Product and without duplication of Genzyme’s rights under Section 11.3.5 (Royalty Stacking), either Party that advances any payment for which the other Party is actually responsible under this Section 11.3.4 shall
invoice the other Party for such advanced amount on a quarterly basis. The Party receiving such invoice shall make payment of such amount to the invoicing Party within [***] days of the date of such invoice and otherwise in accordance with
Section 9 (Royalty Reports; Payments; Audits) of this Master Agreement. 
 11.3.5. [***]. 

11.3.6. Amendments to In-Licenses. If a Party amends an In-License to which it is a Party in a manner that increases the
royalty payable by the other Party under such In-License without the prior written consent of the other Party, such Party shall be solely responsible for any such additional payments due under such In-License. 

11.3.7. Stand-by Licenses. Upon Genzyme’s reasonable request during the Term, Alnylam shall reasonably cooperate in
good faith with Genzyme’s efforts to obtain stand-by license agreements related to any Collaboration Product with respect to any Alnylam In-License, pursuant to which, upon termination of the relevant In-License, Genzyme would receive a direct
license from the applicable Third Party licensor under any Patent Rights and Know-How that are sublicensed to Genzyme pursuant to the Collaboration Agreement. Such stand-by license agreement will be in a form approved in advance by Alnylam. Any
costs incurred by Alnylam in cooperating with Genzyme’s efforts to obtain any such stand-by license agreement shall be reimbursed by Genzyme.  

11.3.8. Breach or Termination of In-Licenses. In the event that (a) a Party receives notice of an alleged breach by
such Party under an In-License to which it is a party, or (b) a Party intends to terminate an In-License to which it is a party, then such Party shall promptly, but in no event less than ten (10) days thereafter, provide written notice
thereof to the other Party. 
 11.4. Common Interest. All information exchanged between the Parties representatives
regarding the preparation, filing, prosecution, maintenance, or enforcement of the Patents Rights under this Section 11 will be deemed Confidential Information. In addition, the Parties acknowledge and agree that, with regard to such
preparation, filing, prosecution, maintenance and enforcement of the Patents Rights under this Section 11, the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent protection possible, and as
such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Master Agreement constitutes a waiver of, any legal privilege concerning the Patents Rights under this Section 11,
including privilege under the common interest doctrine and similar or related doctrines. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 82 - 

 MASTER AGREEMENT 

 

 12. TERM AND TERMINATION 

12.1. Term. The Collaboration Agreement shall be effective as of the Execution Date and, unless terminated earlier pursuant to
Section 12.2 (Termination Rights), the Collaboration Agreement shall continue in effect until the later of (i) the expiration of the last to expire of the Option Periods and (ii) the last to expire of the License Terms
(“Term”). 
 12.2. Termination Rights. This Master Agreement may not be terminated by either Party
except as provided in this Section 12.2. 
 12.2.1. Termination for Convenience. Genzyme shall have the right
to terminate the Collaboration Agreement in its entirety at any time after the Execution Date on six (6) months’ prior written notice to Alnylam, provided that any such termination for convenience of the Collaboration Agreement
shall automatically be treated, without any other action or notice required of either Party, as a termination for convenience of each License Terms under Sections 10.2.1, 12.2.1 and 11.2.1 of the Regional License Terms, the Co-Co License Terms
and the Global License Terms, respectively, and provided further that if termination under any such License Terms is not then possible, then Genzyme shall not have any right to terminate under this Section 12.2.1. 

12.2.2. Termination of License Terms for Cause. The rights to a Collaboration Product under the applicable License Terms
may be terminated for cause during the Term on a Collaboration Product-by-Collaboration Product basis pursuant Sections 10.2.2, 12.2.2 and 11.2.2 of the Regional License Terms, the Co-Co License Terms and the Global License Terms, respectively,
as applicable. 
 12.2.3. Termination of this Master Agreement for Cause. This Master Agreement may be
terminated at any time during the Term upon written notice by either Party if the other Party is in material breach of its obligations hereunder and has not cured such breach within thirty (30) days in the case of a payment breach, or within
ninety (90) days in the case of all other breaches, after notice requesting cure of the breach; provided, however, that if any breach other than a payment breach is not reasonably curable within ninety (90) days and if a
Party is making a bona fide effort to cure such breach, such termination shall be delayed for a time period to be agreed by both Parties, not to exceed an additional ninety (90) days, in order to permit such Party a reasonable period of time to
cure such breach; provided, further, that in the event that the breach relates to a dispute between the Parties regarding Alnylam’s obligations to use commercially reasonable efforts to undertake the Development of Option Products
from its Core Pipeline Programs and Alnylam disputes whether it has breached such obligation or whether such breach gives Genzyme the right to terminate this Master Agreement and initiates a legal action against Genzyme to resolve such dispute
within the foregoing ninety (90) day cure period, then this Master Agreement shall not terminate during the pendency of such legal action; provided that if Alnylam is found in an unappealable decision by a court of  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 83 - 

 MASTER AGREEMENT 

 

 competent jurisdiction or an appealable decision of a court of competent jurisdiction that
has not been appealed in the time allowed for an appeal in such legal action to have materially breached this Master Agreement or if Alnylam admits in such legal action or settlement thereof that it has materially breached this Master Agreement then
this Master Agreement shall terminate immediately following the Parties’ receipt of such decision or immediately following such admission, as applicable. 

12.2.4. Challenges of Patent Rights. If, during the Term, Genzyme or any of its Affiliates (a) commences or
participates in any action or proceeding (including any patent opposition or re-examination proceeding), or otherwise asserts any claim, challenging or denying the validity or enforceability of any claim of the Alnylam Core Technology Patents (as
defined in any of the License Terms) that Covers any siRNA in any Option Product or Collaboration Product or is licensed by Genzyme under any License Terms or (b) actively assists any other Person in bringing or prosecuting any action or
proceeding (including any patent opposition or re-examination proceeding) challenging or denying the validity or enforceability of any claim of such Patent Rights (each of (a) and (b), a “Patent Challenge”), then, to the extent
permitted by the applicable Laws, Alnylam shall have the right, exercisable within sixty (60) days following receipt of notice regarding such Patent Challenge, in its sole discretion, to give notice to Genzyme that Alnylam may terminate the
Collaboration Agreement ninety (90) days following such notice (or such longer period as Alnylam may designate in such notice), and, unless Genzyme or such Affiliate withdraws or causes to be withdrawn all such challenge(s) (or in the case of
ex-parte proceedings, multi-party proceedings, or other Patent Challenges that Genzyme or Genzyme’s Affiliates do not have the power to unilaterally withdraw or cause to be withdrawn, Genzyme and Genzyme’s Affiliates
cease actively assisting any other party to such Patent Challenge and, to the extent Genzyme or a Genzyme Affiliate is a party to such Patent Challenge, it withdraws from such Patent Challenge) within such ninety (90)-day period, Alnylam shall have
the right to terminate the Collaboration Agreement by providing written notice thereof to Genzyme. The foregoing sentence shall not apply (i) with respect to any claim of an Alnylam Core Technology Patent that Covers any siRNA in any Option
Product or Collaboration Product or is licensed by Genzyme under any License Terms that Alnylam first asserts against Genzyme or any of its Affiliates where the Patent Challenge is made in defense of such assertion, or (ii) with respect to any
Patent Challenge commenced by a Third Party that after the Execution Date acquires or is acquired by Genzyme or its Affiliates or its or their business or assets, whether by stock purchase, merger, asset purchase or otherwise, but only with respect
to Patent Challenges commenced prior to the closing of such acquisition. 
 12.3. Effect of Termination.  

12.3.1. Termination of Collaboration Agreement for Convenience. Without limiting any other legal or equitable remedies
that either Party may have, if the Collaboration Agreement is terminated by Genzyme pursuant to Section 12.2.1  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 84 - 

 MASTER AGREEMENT 

 

 (Termination for Convenience) then (a) this Master Agreement and all Options granted to
Genzyme hereunder shall terminate and (b) each of the License Terms shall terminate and the consequences of termination of the entire License Terms for convenience set forth in each of the License Terms shall apply. 

12.3.2. Termination of Master Agreement for Cause. Without limiting any other legal or equitable remedies that either
Party may have, if this Master Agreement is terminated by either Party pursuant to Section 12.2.3 (Termination of this Master Agreement for Cause), then (a) each of the License Terms shall survive and (b) this Master Agreement and all
Options granted to Genzyme hereunder shall terminate, provided that any terms of this Master Agreement applicable to any Collaboration Product that is subject to any of the License Terms on the effective date of termination shall survive. 

 12.3.3. Termination of Collaboration Agreement for Patent Challenge. Without limiting any other legal or
equitable remedies that either Party may have, if the Collaboration Agreement is terminated by Alnylam pursuant to Section 12.2.4 (Challenges of Patent Rights) then (a) this Master Agreement and all Options granted to Genzyme hereunder
shall terminate and (b) each of the License Terms shall terminate and the consequences of termination of the entire License Terms for cause by Alnylam set forth in each of the License Terms shall apply. 

12.3.4. Effect of Expiration or Termination; Survival. Expiration or termination of the Collaboration Agreement or this
Master Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Any expiration or termination of the Collaboration Agreement or this Master Agreement shall be without prejudice to the rights of
either Party against the other accrued or accruing under the Collaboration Agreement or this Master Agreement, as applicable, prior to expiration or termination, including the obligation to pay royalties for the Collaboration Product sold prior to
such expiration or termination or other payments under the Collaboration Agreement. The provisions of Sections 1 (Definitions), 7 (Confidentiality and Publication), 9 (Royalty Reports; Payments; Audit), 10 (Indemnification; Limitation of Liability;
Insurance), 12 (Term and Termination) and 13 (Miscellaneous) shall survive any expiration or termination of the Collaboration Agreement and, in addition, the provisions of 2.1.3.3 (ROFN for CNS) and 3.1.2.4 (Improperly Designated Programs) shall
survive any termination of the Collaboration Agreement by Genzyme pursuant to Section 12.2.3 (Termination of this Master Agreement for Cause). Except as otherwise set forth in this Section 12, upon termination or expiration of the
Collaboration Agreement or this Master Agreement all rights and obligations of the Parties under the Collaboration Agreement or this Master Agreement, as applicable, shall cease. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 85 - 

 MASTER AGREEMENT 

 

 13. MISCELLANEOUS 

13.1. Assignment. Except as provided in this Section 13.1, the Collaboration Agreement may not be assigned or otherwise
transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the written consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party’s written consent,
assign the Collaboration Agreement and its rights and obligations hereunder in whole or in part to an Affiliate or to a party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the
business of the assigning Party to which the subject matter of the Collaboration Agreement relates. The assigning Party shall remain responsible for the performance by its assignee of the Collaboration Agreement or any obligations hereunder so
assigned. An assignment to an Affiliate shall terminate, and all rights so assigned shall revert to the assigning Party, if and when such Affiliate ceases to be an Affiliate of the assigning Party. Any purported assignment in violation of this
Section 13.1 shall be void. 
 13.2. Governing Law. The Collaboration Agreement shall be construed and the
respective rights of the Parties determined in accordance with the substantive Laws of the State of New York, notwithstanding any provisions of New York Law or any other Law governing conflicts of laws to the contrary, and the patent Laws of the
relevant jurisdiction without reference to any rules of conflict of laws. 
 13.3. Jurisdiction. Each Party by its
execution hereof, (a) hereby irrevocably submits to the jurisdiction of the United States District Court and state courts located in New York, New York for the purpose of any dispute arising between the Parties in connection with the
Collaboration Agreement (each, an “Action”), except as otherwise expressly provided in the Collaboration Agreement; (b) hereby waives, to the extent not prohibited by applicable Law, and agrees not to assert, by way of motion,
as a defense or otherwise, in any such Action, any claim that (i) it is not subject personally to the jurisdiction of the above-named court, (ii) its property is exempt or immune from attachment or execution, (iii) any such Action
brought in the above-named court should be dismissed on grounds of forum non conveniens, should be transferred or removed to any court other than the above-named court, or should be stayed by reason of the pendency of some other proceeding in any
other court other than the above-named court, or (iv) the Collaboration Agreement or the subject matter hereof may not be enforced in or by such court; and (c) hereby agrees not to commence any such Action other than before the above-named
court. Notwithstanding the previous sentence a Party may commence any Action in a court other than the above-named court solely for the purpose of enforcing an order or judgment issued by the above-named court. 

13.4. Venue. Each Party agrees that for any Action between the Parties arising in whole or in part under or in connection with
the Collaboration Agreement, such Party bring Actions only in the federal courts of the United States of America located in New York, New York and any appellate court having jurisdiction over appeals from such courts. Each Party further waives any
claim and shall not assert that venue should properly lie in any other location within the selected jurisdiction. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 86 - 

 MASTER AGREEMENT 

 

 13.5. Entire Agreement; Amendments. The Collaboration Agreement contains the
entire understanding of the Parties with respect to the subject matter hereof, and supersedes all previous arrangements with respect to the subject matter hereof, whether written or oral, including, effective as of the Effective Date, that Mutual
Confidential Disclosure Agreement between the Parties dated as of August 27, 2009, as amended through the Execution Date (provided that all information disclosed or exchanged under such agreement will be treated as Confidential
Information hereunder). This Master Agreement (other than the Appendices and Schedules attached hereto) may be amended, or any term hereof modified, only by a written instrument duly-executed by authorized representatives of both Parties hereto. The
Appendices and Schedules attached hereto may be amended, or any term hereof modified, only by a written instrument duly-executed by authorized representatives of both Parties hereto, except to the extent expressly provided in the Collaboration
Agreement. 
 13.6. Severability. If any provision hereof should be held invalid, illegal or unenforceable in any
respect in any jurisdiction, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions, which valid provisions in their economic effect are sufficiently similar to the invalid,
illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into the Collaboration Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the invalid, illegal or
unenforceable of one or several provisions of the Collaboration Agreement shall not affect the validity of the Collaboration Agreement as a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance to the
Collaboration Agreement that it is to be reasonably assumed that the Parties would not have entered into the Collaboration Agreement without the invalid, illegal or unenforceable provisions. 

13.7. Headings. The captions to the Sections hereof are not a part of the Collaboration Agreement, but are merely for convenience
to assist in locating and reading the several Sections hereof. 
 13.8. Waiver of Rule of Construction. Each Party has
had the opportunity to consult with counsel in connection with the review, drafting and negotiation of the Collaboration Agreement. Accordingly, the rule of construction that any ambiguity in the Collaboration Agreement shall be construed against
the drafting Party shall not apply. 
 13.9. Interpretation. Except where the context expressly requires otherwise,
(a) the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa); (b) the words “include”, “includes”
and “including” shall be deemed to be followed by the phrase “without limitation” and shall not be interpreted to limit the provision to which it relates; (c) the word “will” shall be construed to have the same
meaning and effect as the word “shall”; (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 87 - 

 MASTER AGREEMENT 

 

 amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or
modifications set forth herein); (e) any reference herein to any Person shall be construed to include the Person’s successors and assigns; (f) the words “herein”, “hereof” and “hereunder”, and words of
similar import, shall be construed to refer to this Master Agreement or any of the License Terms in each of their entirety, as the context requires, and not to any particular provision hereof; (g) all references herein to Sections, Appendices
or Schedules shall be construed to refer to Sections, Appendices or Schedules of this Master Agreement, and references to this Master Agreement include all Schedules hereto (but not Appendices); (h) the word “notice” means notice in
writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under the Collaboration Agreement; (i) provisions that require that a Party, the Parties or any committee
hereunder “agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding
e-mail and instant messaging); (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or
regulation thereof; and (k) the term “or” shall be interpreted in the inclusive sense commonly associated with the term “and/or.” 

13.10. No Implied Waivers; Rights Cumulative. No failure on the part of Alnylam or Genzyme to exercise, and no delay in
exercising, any right, power, remedy or privilege under the Collaboration Agreement, or provided by statute or at Law or in equity or otherwise, shall impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be
construed as a waiver of any breach of the Collaboration Agreement or as an acquiescence therein, nor shall any single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the exercise
of any other right, power, remedy or privilege. 
 13.11. Notices. All notices which are required or permitted hereunder
shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or
certified mail, postage prepaid, return receipt requested, addressed as follows: 
  

			
	If to Alnylam, to:	  	 Alnylam Pharmaceuticals, Inc.
 300 Third
Street
 Cambridge, Massachusetts 02142
 Attention: Vice
President - Legal
 Facsimile No.: (617) 551-8101

		
	With a copy to:	  	 Goodwin Procter LLP
 Exchange Place

53 State Street
 Boston, Massachusetts 02109

Attention: Kingsley L. Taft, Esq.
 Facsimile No.: (617)
523-1231

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 88 - 

 MASTER AGREEMENT 

 

			
		
	If to Genzyme, to:	  	 Genzyme Corporation
 500 Kendall Street

Cambridge, Massachusetts 02142
 Attention: Head of Rare Diseases
Business Unit
 Facsimile No.: (617) 374-2424

		
	With a copy to:	  	 Genzyme Corporation
 500 Kendall Street

Cambridge, Massachusetts 02142
 Attention: General Counsel

Facsimile No.: (617) 252-7553

		
	And to:	  	 Ropes & Gray LLP
 Prudential Tower

800 Boylston Street
 Boston, MA 02199-3600

Attention: David M. McIntosh, Esq.
 Facsimile No.: (617)
235-0507

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. In addition, each Party shall deliver a courtesy copy to the other Party’s Alliance Manager concurrently with such notice. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered
or sent by facsimile on a business day (or if delivered or sent on a non-business day, then on the next business day); (b) on receipt if sent by overnight courier; or (c) on receipt if sent by mail. 

13.12. Compliance with Export Regulations. Neither Party shall export any technology licensed to it by the other Party under the
Collaboration Agreement except in compliance with U.S. export Laws and regulations. 
 13.13. Force
Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached the Collaboration Agreement for failure or delay in performing any obligation under the Collaboration
Agreement to the extent that such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including embargoes, war, acts of war (whether war be declared or not), insurrections, riots,
civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake
all reasonable efforts necessary to cure such force majeure circumstances. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 89 - 

 MASTER AGREEMENT 

 

 13.14. Independent Parties. It is expressly agreed that Alnylam and Genzyme
shall be independent contractors and that the relationship between Alnylam and Genzyme shall not constitute a partnership, joint venture or agency. Alnylam shall not have the authority to make any statements, representations or commitments of any
kind, or to take any action, which shall be binding on Genzyme, without the prior written consent of Genzyme, and Genzyme shall not have the authority to make any statements, representations or commitments of any kind, or to take any action, which
shall be binding on Alnylam without the prior written consent of Alnylam. 
 13.15. Counterparts. The Agreement may be
executed in two or more counterparts, including by facsimile or PDF signature pages, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

13.16. Performance by Affiliates.  

13.16.1. Use of Affiliates. Each Party acknowledges and accepts that the other Party may exercise its rights and perform
its obligations under this Master Agreement either directly or through one or more of its Affiliates. A Party’s Affiliates will have the benefit of all rights (including all licenses) of such Party under this Master Agreement. Accordingly, in
this Master Agreement “Genzyme” will be interpreted to mean “Genzyme and/or its Affiliates” and “Alnylam” will be interpreted to mean “Alnylam and/or its Affiliates” where necessary to give each Party’s
Affiliates the benefit of the rights provided to such Party in this Master Agreement; provided, however, that in any event each Party will remain responsible for the acts and omissions, including financial liabilities, of its
Affiliates. 
 13.16.2. Future Acquisition of a Party or its Business. [***]. 

13.17. Binding Effect; No Third Party Beneficiaries. As of the Execution Date, the Collaboration Agreement shall be binding upon
and inure to the benefit of the Parties and their respective permitted successors and permitted assigns. Except as expressly set forth in the Collaboration Agreement, no Person other than the Parties and their respective Affiliates and permitted
assignees hereunder shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of the Collaboration Agreement. 

[THE REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - 90 - 

 IN WITNESS WHEREOF, the Parties have executed this Master Agreement as of the Execution Date.

  

							
	GENZYME CORPORATION	  	ALNYLAM PHARMACEUTICALS, INC.
				
	BY:	 	 /s/ David Meeker
	  	BY:	  	 /s/ John M. Maraganore

	 NAME: David Meeker, M.D.
 TITLE:
President and Chief Executive Officer
	  		  	 NAME: John M. Maraganore, Ph.D.
 TITLE: Chief
Executive Officer

 Signature page to the Master Collaboration Agreement 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY
WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.7 

ADDITIONAL ALNYLAM IN-LICENSES 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 1 page was omitted. 

[***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.21 

ALN-AT3 
 ALN-AT3 is an investigational
ribonucleic acid interference (RNAi) therapeutic agent that is comprised of active pharmaceutical ingredient ALN-[***] (see sequence and diagram below), [***]. 

[***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.22 

ALN-TTR CORE TECHNOLOGY PATENTS 

[***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.24 

ALN-TTR PRODUCT-SPECIFIC PATENTS 

[***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.26 

ALN-TTR02 
 ALN-TTR02 is an
investigational ribonucleic acid interference (RNAi) therapeutic agent that is comprised of active pharmaceutical ingredient [***]. 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of 2 pages were omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.29 

ALN-TTRsc 
 ALN-TTRsc is an
investigational ribonucleic acid interference (RNAi) therapeutic agent that is comprised of active pharmaceutical ingredient [***]. 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of 2 pages were omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.34 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 1 page was omitted. 

[***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.71 

CORE PIPELINE PROGRAM LIST 

Section A 
  

															
	 Alnylam
siRNA
identifier

(if any)
	  	 Gene

Target
 Name
	  	 Gene

Target
 Symbol
	  	 NCBI

Human
Gene
	  	 NCBI’s

Reference
Sequences

Transcript*
	  	 NCBI’s

Reference
Sequences

Protein*
	  	 Alias(es)
	  	 Description

	ALN-TTR02	  	TTR	  	TTR	  	7276	  	NM_000371	  	NP_000362	  	CTS; CTS1; HsT2651; PALB; TBPA	  	transthyretin
								
	ALN-TTRsc	  	TTR	  	TTR	  	7276	  	NM_000371	  	NP_000362	  	CTS; CTS1; HsT2651; PALB; TBPA	  	transthyretin
								
	ALN-AT3	  	AT3	  	SERPINC1	  	462	  	NM_000488	  	NP_000479	  	AT3; AT3D; ATIII; THPH7	  	serpin peptidase inhibitor, clade C (antithrombin), member 1
								
	ALN-CC5	  	CC5	  	C5	  	727	  	NM_001735	  	NP_001726	  	C5a; C5b; CPAMD4	  	complement component 5
								
	ALN-AS1	  	ALAS1	  	ALAS1	  	211	  	NM_000688	  	NP_000679	  	ALAS; MIG4; ALAS3; ALASH	  	aminolevulinate, delta-, synthase 1
								
	ALN-AAT	  	AAT	  	SERPINA1	  	5265	  	NM_000295	  	NP_000286	  	PI; A1A; AAT; PI1; A1AT; PRO2275; alpha1AT	  	serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
								
	ALN-TMP	  	TMPRSS6	  	TMPRSS6	  	164656	  	NM_153609	  	NP_705837	  	IRIDA	  	transmembrane protease, serine 6
								
	ALN-ANG	  	ANGPTL3	  	ANGPTL3	  	27329	  	NM_014495	  	NP_055310	  	ANL3; ANG-5; FHBL2; ANGPT5	  	angiopoietin-like 3

 Updated as of: the Execution Date 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Confidential Materials omitted and filed separately with the Securities and Exchange
Commission. A total of 1 page was omitted. 
 [***] 
 Updated
as of: the Execution Date 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 Schedule 1.2.80 

FORM OF EXERCISE NOTICE 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 Genzyme Corporation 

500 Kendall Street 

Cambridge, MA 02142 

[                    ,
20    ] 
 Alnylam Pharmaceuticals, Inc. 

300 Third Street 
 Cambridge, MA 02142 

Attn: Vice President - Legal 
 Dear Sir or Madam: 

In accordance with Sections 2.2 and 3.4 of that certain Master Collaboration Agreement by and between Alnylam Pharmaceuticals, Inc.
(“Alnylam”) and Genzyme Corporation (“Genzyme”) executed as of January 11, 2014 (the “Master Agreement”), Genzyme hereby provides written notice exercising the option to acquire the Option
Product(s) set forth in Exhibit A attached hereto, pursuant to the terms of the Master Agreement. Capitalized terms used but not defined herein will have the meanings assigned to them in the Master Agreement. 

Please acknowledge receipt of this option exercise by countersigning this letter and returning it to me. Failure to return the letter
countersigned will not affect the effectiveness of this option exercise by Genzyme. 
  

			
	 Very truly yours,
  

GENZYME CORPORATION

		
	By:	 	 
		 	 Name:
 Title:

  

	cc:	Goodwin Proctor LLP 

	  	Exchange Place 

	  	55 State Street 

	  	Boston, MA 02109 

	  	Attn: Kingsley L. Taft, Esq. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 Accepted and agreed: 

ALNYLAM PHARMACEUTICALS, INC. 
  

			
	
		
	By:	 	 
		 	 Name:
 Title:

 Exhibit A 
  

	 	1.	Option Product:
                                    . 

 

	 	2.	Genzyme is exercising its option to acquire the Option Product(s) listed above, pursuant to: 

  

	 	 ̈	the Regional License Terms 

  

	 	 ̈	the Global License Terms (if applicable) 

  

	 	 ̈	the Co-Co License Terms (if applicable) 

  

	 	3.	Genzyme has determined that: 

  

	 	 ̈	a filing or notification under applicable Antitrust Laws is not necessary. 

  

	 	 ̈	a filing or notification must be made under applicable Antitrust Laws. 

 Summary of any such
filing(s) or notification(s): 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 Schedule 1.2.82 

EXISTING ALNYLAM IN-LICENSES 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 1 page was omitted. 

[***] 

 MASTER AGREEMENT 

 

 Schedule 1.2.88 

FINAL OPTION DATA PACKAGE 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of 1 page was omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.116 

HUMAN POP PROPOSED STUDIES 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of 1 page was omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.123 

INITIAL OPTION DATA PACKAGE 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of 2 pages were omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.134 

LOCKED CORE PIPELINE PROGRAM LIST 
  

															
	 Alnylam
siRNA
identifier

(if any)
	  	 Gene

Target
 Name
	  	 Gene

Target
 Symbol
	  	 NCBI

Human
 Gene
	  	 NCBI’s

Reference
 Sequences

Transcript*
	  	 NCBI’s

Reference
 Sequences

Protein*
	  	 Alias(es)
	  	 Description

	ALN-TTR02	  	TTR	  	TTR	  	7276	  	NM_000371	  	NP_000362	  	CTS; CTS1; HsT2651; PALB; TBPA	  	transthyretin
								
	ALN-TTRsc	  	TTR	  	TTR	  	7276	  	NM_000371	  	NP_000362	  	CTS; CTS1; HsT2651; PALB; TBPA	  	transthyretin
								
	ALN-AT3	  	AT3	  	SERPINC1	  	462	  	NM_000488	  	NP_000479	  	AT3; AT3D; ATIII; THPH7	  	serpin peptidase inhibitor, clade C (antithrombin), member 1
								
	ALN-CC5	  	CC5	  	C5	  	727	  	NM_001735	  	NP_001726	  	C5a; C5b; CPAMD4	  	complement component 5
								
	ALN-AS1	  	ALAS1	  	ALAS1	  	211	  	NM_000688	  	NP_000679	  	ALAS; MIG4; ALAS3; ALASH	  	aminolevulinate, delta-, synthase 1
								
	ALN-AAT	  	AAT	  	SERPINA1	  	5265	  	NM_000295	  	NP_000286	  	PI; A1A; AAT; PI1; A1AT; PRO2275; alpha1AT	  	serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
								
	ALN-TMP	  	TMPRSS6	  	TMPRSS6	  	164656	  	NM_153609	  	NP_705837	  	IRIDA	  	transmembrane protease, serine 6

 Updated as of: the Execution Date 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 Schedule 1.2.135 

LOCKED NON-CORE PIPELINE PROGRAM LIST 
  

															
	 Alnylam
 siRNA

identifier

(if any)
	  	 Gene

Target
 Name
	  	Gene
Target
Symbol	  	NCBI
Human
Gene	  	NCBI’s
Reference
Sequences
Transcript*	  	NCBI’s
Reference
Sequences
Protein*	  	Alias(es)	  	Description
	ALN-VSP	  	VEGF	  	VEGFA	  	7422	  	NM_003376	  	NP_003367	  	VPF;
VEGF;
MVCD1	  	Vacular
endothelial
growth
factor A
								
	ALN-VSP	  	KSP (kinesin spindle protein)	  	KIF11	  	3832	  	NM_004523	  	NP_004514	  	EG5;
HKSP;
KNSL1;
MCLMR;
TRIP5	  	Kinesin
family
member 11
								
	ALN-PCS	  	PCSK9	  	PCSK9	  	255738	  	NM_174936	  	NP_777596	  	FH3; PC9;
NARC1;
LDLCQ1;
NARC-1;
HCHOLA3	  	proprotein
convertase
subtilisin/
kexin type
9
								
	ALN-RSV01	  	RSV genome	  	RSV
genome	  	N/A	  	NC_001803	  	N/A	  		  	RSV
Refseq
Genome
								
	ALN-RSV02	  	RSV genome	  	RSV
genome	  	N/A	  	NC_001803	  	N/A	  		  	RSV
Refseq
Genome
								
	ALN-HTT	  	HTT	  	HTT	  	3064	  	NM_002111	  	NP_002102	  	HD; IT15	  	huntingtin

 [***] 
 Updated as of: the
Execution Date 

 Schedule 1.2.146 

NAMED PIPELINE PROGRAMS 
  

															
	 Alnylam
siRNA
identifier

(if any)
	  	Gene
Target
Name	  	Gene
Target
Symbol	  	NCBI
Human
Gene	  	NCBI’s
Reference
Sequences
Transcript*	  	NCBI’s
Reference
Sequences
Protein*	  	Alias(es)	  	Description
	ALN-TTR02	  	TTR	  	TTR	  	7276	  	NM_000371	  	NP_000362	  	CTS; CTS1;
HsT2651;
PALB; TBPA	  	transthyretin
								
	ALN-TTRsc	  	TTR	  	TTR	  	7276	  	NM_000371	  	NP_000362	  	CTS; CTS1;
HsT2651;
PALB; TBPA	  	transthyretin
								
	ALN-AT3	  	AT3	  	SERPINC1	  	462	  	NM_000488	  	NP_000479	  	AT3; AT3D;
ATIII; THPH7	  	serpin peptidase
inhibitor, clade
C (antithrombin),
member 1
								
	ALN-CC5	  	CC5	  	C5	  	727	  	NM_001735	  	NP_001726	  	C5a; C5b;
CPAMD4	  	complement
component 5
								
	ALN-AS1	  	ALAS1	  	ALAS1	  	211	  	NM_000688	  	NP_000679	  	ALAS;
MIG4; ALAS3;
ALASH	  	aminolevulinate,
delta-, synthase 1
								
	ALN-AAT	  	AAT	  	SERPINA1	  	5265	  	NM_000295	  	NP_000286	  	PI; A1A; AAT;
PI1; A1AT;
PRO2275;
alpha1AT	  	serpin peptidase
inhibitor, clade
A (alpha-1
antiproteinase,
antitrypsin),
member 1

 Updated as of: the Execution Date 

 MASTER AGREEMENT 

 

 Schedule 1.2.149 

NON-CORE PIPELINE PROGRAM LIST 
  

															
	 Alnylam
 siRNA

identifier

(if any)
	  	 Gene

Target
 Name
	  	Gene
Target
Symbol	  	NCBI
Human
Gene	  	NCBI’s
Reference
Sequences
Transcript*	  	NCBI’s
Reference
Sequences
Protein*	  	Alias(es)	  	Description
	ALN-VSP	  	VEGF	  	VEGFA	  	7422	  	NM_003376	  	NP_003367	  	VPF;
VEGF;
MVCD1	  	Vacular
endothelial
growth
factor A
								
	ALN-VSP	  	KSP (kinesin spindle protein)	  	KIF11	  	3832	  	NM_004523	  	NP_004514	  	EG5;
HKSP;
KNSL1;
MCLMR;
TRIP5	  	Kinesin
family
member 11
								
	ALN-PCS	  	PCSK9	  	PCSK9	  	255738	  	NM_174936	  	NP_777596	  	FH3; PC9;
NARC1;
LDLCQ1;
NARC-1;
HCHOLA3	  	proprotein
convertase
subtilisin/
kexin type
9
								
	ALN-RSV01	  	RSV genome	  	RSV
genome	  	N/A	  	NC_001803	  	N/A	  		  	RSV
Refseq
Genome
								
	ALN-RSV02	  	RSV genome	  	RSV
genome	  	N/A	  	NC_001803	  	N/A	  		  	RSV
Refseq
Genome
								
	ALN-HTT	  	HTT	  	HTT	  	3064	  	NM_002111	  	NP_002102	  	HD; IT15	  	huntingtin

 [***] 
 Updated as of: the
Execution Date 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.159 

OPTION PRODUCT CORE TECHNOLOGY PATENTS 

[***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.162 

OPTION PRODUCT-SPECIFIC PATENTS 

[***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 1.2.178 

POTENTIAL ALNYLAM IN-LICENSES 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 1 page was omitted. 

[***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 2.1.3.3 

Exempted Third Party CNS Agreements 

Amended and Restated Collaboration Agreement dated as of July 27, 2007 by and between Alnylam Pharmaceuticals, Inc. and Medtronic, Inc. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 6.1 

ALN-TTR02 SUPPLY AGREEMENT TERMS 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 3 pages were omitted. 

[***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 6.2 

SUPPLY AGREEMENT TERMS 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of 4 pages were omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 7.3 

PRESS RELEASES 
 See attached. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 8.2 

DISCLOSURE SCHEDULE 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of 2 pages were omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 MASTER AGREEMENT 

 

 Schedule 10.2 

IDENTIFIED PATENT RIGHTS 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of 1 page was omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 EXECUTION VERSION 

APPENDIX A 

REGIONAL PRODUCT LICENSE AND COLLABORATION 

TERMS 
 AN
APPENDIX TO THE MASTER COLLABORATION AGREEMENT 
 dated as of January 11, 2014 

by and between 
 ALNYLAM
PHARMACEUTICALS, INC. 
 and 

GENZYME CORPORATION 
 CERTAIN CONFIDENTIAL
PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL
TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 REGIONAL LICENSE TERMS 

 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	PAGE	 
	 1. RELATIONSHIP WITH MASTER AGREEMENT; DEFINITIONS
	  	 	5	  
			
	 1.1.
	 	Relationship with Master Agreement	  	 	5	  
			
	 1.2.
	 	Definitions	  	 	6	  
		
	 2. DEVELOPMENT COLLABORATION
	  	 	22	  
			
	 2.1.
	 	Overview	  	 	22	  
			
	 2.2.
	 	Development Plans	  	 	22	  
			
	 2.3.
	 	Responsibilities for Development Activities and Costs	  	 	30	  
			
	 2.4.
	 	Diligence	  	 	33	  
			
	 2.5.
	 	Records; Reports; Information Sharing	  	 	34	  
			
	 2.6.
	 	Third Parties	  	 	35	  
		
	 3. REGULATORY MATTERS
	  	 	35	  
			
	 3.1.
	 	Regulatory Filings and Interactions	  	 	35	  
			
	 3.2.
	 	EMA Regulatory Strategy	  	 	38	  
			
	 3.3.
	 	Costs of Regulatory Affairs	  	 	38	  
			
	 3.4.
	 	Right of Reference	  	 	38	  
		
	 4. COMMERCIALIZATION OF THE LICENSED PRODUCTS
	  	 	39	  
			
	 4.1.
	 	Responsibility, Cost and Diligence	  	 	39	  
			
	 4.2.
	 	Genzyme Territory Commercialization Plan	  	 	39	  
			
	 4.3.
	 	Alnylam Territory Commercialization Plan	  	 	39	  
			
	 4.4.
	 	Advertising and Promotional Materials	  	 	40	  
			
	 4.5.
	 	Commercialization Reporting Obligations	  	 	40	  
			
	 4.6.
	 	Recalls, Market Withdrawals or Corrective Actions	  	 	42	  
			
	 4.7.
	 	Ex-Territory Sales; Export Monitoring	  	 	42	  
		
	 5. COLLABORATION MANAGEMENT
	  	 	42	  
			
	 5.1.
	 	Product Joint Steering Committee	  	 	42	  
			
	 5.2.
	 	Appointment of Subcommittees, Project Teams and RLP Alliance Managers	  	 	43	  
			
	 5.3.
	 	PJSC Meetings	  	 	44	  
			
	 5.4.
	 	PJSC Minutes	  	 	44	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - i - 

 REGIONAL LICENSE TERMS 

 

							
			
	 5.5.
	 	PJSC Responsibilities	  	 	44	  
			
	 5.6.
	 	PJSC Decision-Making	  	 	46	  
			
	 5.7.
	 	Term of PJSC	  	 	47	  
			
	 5.8.
	 	Alnylam Third Party Partner	  	 	47	  
		
	 6. LICENSES
	  	 	49	  
			
	 6.1.
	 	License Grants to Genzyme	  	 	49	  
			
	 6.2.
	 	License Grants to Alnylam	  	 	51	  
			
	 6.3.
	 	Joint Collaboration IP	  	 	52	  
			
	 6.4.
	 	Compliance with In-Licenses	  	 	52	  
			
	 6.5.
	 	Alnylam Territory Right of First Negotiation	  	 	53	  
			
	 6.6.
	 	Bankruptcy	  	 	53	  
			
	 6.7.
	 	No Other Rights	  	 	54	  
		
	 7. CERTAIN FINANCIAL TERMS
	  	 	54	  
			
	 7.1.
	 	Milestone Fees	  	 	54	  
			
	 7.2.
	 	Royalties	  	 	56	  
		
	 8. REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	58	  
			
	 8.1.
	 	Representations and Warranties of Alnylam	  	 	58	  
			
	 8.2.
	 	Representations and Warranties of Genzyme	  	 	60	  
			
	 8.3.
	 	Warranty Disclaimer	  	 	60	  
			
	 8.4.
	 	Certain Covenants	  	 	60	  
		
	 9. INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS
	  	 	62	  
			
	 9.1.
	 	Inventorship	  	 	62	  
			
	 9.2.
	 	Ownership	  	 	62	  
			
	 9.3.
	 	Prosecution and Maintenance of Patent Rights	  	 	62	  
			
	 9.4.
	 	Third Party Infringement	  	 	65	  
			
	 9.5.
	 	Patent Term Extensions	  	 	67	  
			
	 9.6.
	 	Common Interest	  	 	67	  
			
	 9.7.
	 	Trademarks	  	 	67	  
			
	 9.8.
	 	Cooperative Research and Technology (CREATE) Act Acknowledgment	  	 	68	  
		
	 10. TERM AND TERMINATION
	  	 	69	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - ii - 

 REGIONAL LICENSE TERMS 

 

							
	 10.1.
	 	Term	  	 	69	  
			
	 10.2.
	 	Termination Rights	  	 	69	  
			
	 10.2.4.
	 	Challenges of Patent Rights	  	 	71	  
			
	 10.3.
	 	Effect of Termination	  	 	72	  
			
	 10.4.
	 	Fundamental Breach of Alnylam’s Development Obligations	  	 	77	  
			
	 10.5.
	 	Effect of Expiration or Termination; Survival	  	 	78	  
		
	 11. PERFORMANCE BY AFFILIATES
	  	 	79	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - iii - 

 REGIONAL LICENSE TERMS 

 

 SCHEDULES 
  

			
	 Schedule 1.2.13-1
	  	Alnylam Core Technology Patents for ALN-TTR02
		
	 Schedule 1.2.18-1
	  	Alnylam Product-Specific Patents for ALN-TTR02
		
	 Schedule 2.2.1-1
	  	Global Development Strategy for ALN-TTR02
		
	 Schedule 2.2.2.1-1
	  	Global Development Plan for ALN-TTR02
		
	 Schedule 2.2.2.6(d)-1
	  	Alnylam Territory Development Plan for ALN-TTR02
		
	 Schedule 2.2.4-1
	  	Genzyme Territory Development Plan for ALN-TTR02
		
	 Schedule 8.1
	  	Disclosure Schedule
		
	 Schedule 8.1.12
	  	Existing Alnylam In-Licenses / Additional Alnylam In-Licenses
		
	 Schedule 8.4.1.3(c)
	  	Exceptions to Exclusivity

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 - iv - 

 REGIONAL PRODUCT LICENSE AND COLLABORATION TERMS 

THESE REGIONAL PRODUCT LICENSE AND COLLABORATION TERMS are Appendix A to the Master Agreement, dated as of the Execution Date, by and between
Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of
Massachusetts (“Genzyme”). 
 RECITALS: 

WHEREAS, Alnylam and Genzyme are parties to that certain Master Collaboration Agreement (dated as of the Execution Date) (the
“Master Agreement”) pursuant to which Genzyme has an option to receive licenses and other rights with respect to Regional Licensed Products from Alnylam in the Genzyme Territory; 

WHEREAS, the Parties have agreed that ALN-TTR02 is a Regional Licensed Product; 

WHEREAS, Genzyme may exercise a Regional Option, 2019 Trailing Regional Option or 2021 Trailing Regional Option pursuant to the Master
Agreement for any Regional Option Product thereunder and such Regional Option Product will then be deemed a Regional Licensed Product; 

WHEREAS, the Parties desire for Alnylam to continue to develop such Regional Licensed Products for the Alnylam Territory and the
Genzyme Territory; 
 WHEREAS, Alnylam desires to retain the right to commercialize such Regional Licensed Products in the Alnylam
Territory; and 
 WHEREAS, Alnylam and Genzyme now wish to set forth the terms and conditions under which Genzyme will have the right
to Develop and Commercialize such Regional Licensed Products in the Genzyme Territory. 
 NOW, THEREFORE, in consideration of
the foregoing premises and the mutual covenants herein contained, the Parties hereby agree as follows: 
 1. RELATIONSHIP WITH MASTER
AGREEMENT; DEFINITIONS 
 1.1. Relationship with Master Agreement. These Regional License Terms become effective on a
Regional Licensed Product-by-Regional Licensed Product basis on the Implementation Date in accordance with the Master Agreement. The Master Agreement generally governs the Parties’ relationship with respect to Regional Licensed Products during
the period of time before Genzyme exercises its Regional Option under the Master Agreement (i.e., before such product became a Regional Licensed Product). The Master Agreement also contains terms that are generally applicable to Regional
Licensed Products, Global Licensed Products (as defined in the Master Agreement) and Co-Co Licensed Products (as defined in the Master 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 5 

 REGIONAL LICENSE TERMS 

 

 
Agreement). Accordingly, the following Sections of the Master Agreement are incorporated herein by reference: Section 2.2 (Effectiveness of Licenses to Collaboration Products);
Section 5 (Collaboration Management); Section 6 (Manufacture and Supply of the Collaboration Products); Section 7 (Confidentiality and Publication); Section 9 (Royalty Reports; Payments; Audit); Section 10 (Indemnification;
Limitation of Liability; Insurance); Section 12.2.4 (Challenges of Patent Rights); and Section 13 (Miscellaneous). 
 1.2.
Definitions. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 

1.2.1. “Acquired Business” has the meaning set forth in Section 11.3 (Acquired Programs). 

1.2.2. “Acquirer” has the meaning set forth in Section 11.2 (Future Acquisition of a Party or its Business). 

1.2.3. “Additional Development Activities” has the meaning set forth in Section 2.2.2.6(a) (Additional Development
Proposals). 
 1.2.4. “Additional Development Opt-In Date” has the meaning set forth in Section 2.2.2.6(c)(iii)
(Opt-In for Additional Development Activities). 
 1.2.5. “Additional Development Opt-In Notice” has the meaning set
forth in Section 2.2.2.6(c)(iii) (Opt-In for Additional Development Activities). 
 1.2.6. “Additional Development
Proposal” has the meaning set forth in Section 2.2.2.6(a) (Additional Development Proposals). 
 1.2.7. “AF11
Lipid Nanoparticle Formulation” has the meaning set forth in the Master Agreement. 
 1.2.8. “Affiliate”
means, with respect to a Person, any other Person which controls, is controlled by, or is under common control with the applicable Person. For purposes of this definition, “control” shall mean: (a) in the case of corporate entities,
direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of directors, or otherwise having the power to control or direct the affairs of such Person; and (b) in the case of
non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest or the power to direct the management and policies of such non-corporate entities. 

1.2.9. “AJSC” has the meaning set forth in the Master Agreement. 

1.2.10. “ALN-TTR02” has the meaning set forth in the Master Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 6 

 REGIONAL LICENSE TERMS 

 

 1.2.11. “ALN-TTR02 Clinical Supply Agreement” has the meaning set
forth in the Master Agreement. 
 1.2.12. “ALN-TTR02 Commercial Supply Agreement” has the meaning set forth in the
Master Agreement. 
 1.2.13. “Alnylam Core Technology Patents” means Patent Rights Controlled by Alnylam during the
Term that are [***]. The Alnylam Core Technology Patents existing as of the Effective Date for ALN-TTR02 are those Patent Rights identified on Schedule 1.2.13-1. The Alnylam Core Technology Patents existing as of the Implementation Date for
any other Regional Licensed Product will be identified as the “Alnylam Core Technology Patents” in the Option Data Package for such Regional Licensed Product provided by Alnylam to Genzyme under the Master Agreement and then attached
hereto as Schedules 1.2.13-2, 1.2.13-3, and so forth. 
 1.2.14. “Alnylam Developed siRNA Product”
means an siRNA with respect to which (a) Alnylam Controls Patent Rights Covering such siRNA, provided that once a product first satisfies the criterion set forth in this clause (a) such criterion shall be deemed satisfied at all
times thereafter as to such product, and (b) Alnylam or an Affiliate of Alnylam plays(ed) a material role in the Development. 

1.2.15. “Alnylam In-License” means any Existing Alnylam In-License or any Collaboration In-License to which Alnylam is
a party.
 1.2.16. “Alnylam Know-How” means Know-How Controlled by Alnylam during the Term that is reasonably
necessary or useful for Genzyme to Develop, Manufacture and/or Commercialize Regional Licensed Products in the Field in the Genzyme Territory, other than Alnylam’s interest in Know-How included in Joint Collaboration IP. 

1.2.17. “Alnylam Patents” means Alnylam Core Technology Patents and Alnylam Product-Specific Patents. 

1.2.18. “Alnylam Product-Specific Patents” means Patent Rights Controlled by Alnylam during the Term that claim [***].
The Alnylam Product-Specific Patents existing as of the Effective Date for ALN-TTR02 are those Patent Rights identified on Schedule 1.2.18-1. The Alnylam Product-Specific Patents existing as of the Implementation Date for any other Regional
Licensed Product will be identified as the “Alnylam Product-Specific Patents” in the Option Data Package for such Regional Licensed Product provided by Alnylam to Genzyme under the Master Agreement and then attached hereto as Schedules
1.2.18-2, 1.2.18-3, and so forth. [***]. 
 1.2.19. “Alnylam Technology” means, collectively, Alnylam
Know-How, Alnylam Patents and Alnylam’s interest in Joint Collaboration IP. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 7 

 REGIONAL LICENSE TERMS 

 

 1.2.20. “Alnylam Territory” means the United States, Canada, Austria,
Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden, the United Kingdom, Norway, Switzerland, Liechtenstein, Andorra, Iceland and Greenland. 

1.2.21. “Alnylam Territory Commercialization Plan” has the meaning set forth in Section 4.4 (Alnylam Territory
Commercialization Plan). 
 1.2.22. “Alnylam Territory Development Plan” has the meaning set forth in
Section 2.2.3 (Alnylam Territory Development Plan). 
 1.2.23. “Alnylam Territory MMC” [***]. 

1.2.24. “Alnylam Trademark” has the meaning set forth in Section 9.7(b) (Trademarks). 

1.2.25. “ANDA” means an Abbreviated New Drug Application (or any successor application or procedure) as defined in
regulations promulgated by the FDA under the FDCA, which ANDA is filed with or intended to be filed with the FDA (and, as applicable, any other analogous application filed with a Regulatory Authority in any country other than the U.S. in the Genzyme
Territory) for Regulatory Approval for marketing and selling a Regional Licensed Product in the Genzyme Territory. 
 1.2.26.
“Appendix” means this Appendix A (Regional Product License and Collaboration Terms). 
 1.2.27. “Bankrupt
Party” has the meaning set forth in Section 6.6 (Bankruptcy). 
 1.2.28. “Budget Adjustment Triggers”
has the meaning set forth in Section 2.2.2.3 (Managing and Amending Global Development Plans and Global Development Budgets). 

1.2.29. “Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on
March 31, June 30, September 30 and December 31 of each Calendar Year, provided that (a) the first Calendar Quarter of the Term shall begin on the Effective Date and end on the first to occur of
March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Term shall end on the last day of the Term and (b) the first Calendar Quarter of a Royalty Term for a Regional Licensed
Product in a country shall begin on the First Commercial Sale of a Regional Licensed Product in such country and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last
Calendar Quarter of a Royalty Term shall end on the last day of such Royalty Term. 
 1.2.30. “Calendar Year” means
each successive period of twelve (12) months commencing on January 1 and ending on December 31, provided that (a) the first Calendar Year of the Term shall begin on the Effective Date and end on the first December 31
thereafter and the 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 8 

 REGIONAL LICENSE TERMS 

 

 
last Calendar Year of the Term shall end on the last day of the Term and (b) the first Calendar Year of a Royalty Term for a Regional Licensed Product in a country shall begin on the First
Commercial Sale of a Regional Licensed Product in such country and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of such Royalty Term. 

1.2.31. “Carbohydrate Conjugate” has the meaning set forth in the Master Agreement. 

1.2.32. “Clinical Study” has the meaning set forth in the Master Agreement. 

1.2.33. “Co-Co/Global Option” has the meaning set forth in the Master Agreement. 

1.2.34. “Co-Co License Terms” has the meaning set forth in the Master Agreement. 

1.2.35. “Co-Co Licensed Product” has the meaning set forth in the Master Agreement. 

1.2.36. “Collaboration In-License” has the meaning set forth in the Master Agreement. 

1.2.37. “Commercialization” or “Commercialize” has the meaning set forth in the Master Agreement. 

1.2.38. “Commercially Reasonable Efforts” means [***]. 

1.2.39. “Competing Program” has the meaning set forth in Section 11.3 (Acquired Programs). 

1.2.40. “Competitive Infringement” has the meaning set forth in Section 9.4.1 (Notices). 

1.2.41. “Confidential Information” has the meaning set forth in the Master Agreement. 

1.2.42. “Control”, “Controls” or “Controlled by” has the meaning set forth in the
Master Agreement. 
 1.2.43. “Cost of Goods” has the meaning set forth in the Master Agreement. 

1.2.44. “Cover,” “Covering” or “Covers” has the meaning set forth in the Master
Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 9 

 REGIONAL LICENSE TERMS 

 

 1.2.45. “CPI” shall mean the Consumer Price Index – Urban Wage
Earners and Clerical Workers, U.S. City Average, All Items, 1982-84 = 100, published by the United States Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the United States. 

1.2.46. “CRO” means a contract research organization. 

1.2.47. “Development,” “Developing” or “Develop” has the meaning set forth in the
Master Agreement. 
 1.2.48. “Development Plan” means, with respect to each Regional Licensed Product, (a) with
respect to Alnylam, the Alnylam Territory Development Plan for such Regional Licensed Product, (b) with respect to Genzyme, the Genzyme Territory Development Plan for such Regional Licensed Product, and (c) with respect to both Parties,
the Global Development Plan for such Regional Licensed Product. 
 1.2.49. “Disputing Party” has the meaning set
forth in Section 2.3.1.2 (Global R&D Costs). 
 1.2.50. “Effective Date” means the date that the Master
Agreement becomes effective in accordance with its terms. 
 1.2.51. “EMA” means the European Medicines Agency and
any successor Governmental Authority having substantially the same function. 
 1.2.52. “End of Phase II Package” has
the meaning set forth in Section 2.2.2.4(c)(ii). 
 1.2.53. “EU” means the European Union, as its membership may
be altered from time to time, and any successor thereto. 
 1.2.54. “Excess Global R&D Costs” has the meaning set
forth in Section 2.3.1.2 (Global R&D Costs). 
 1.2.55. “Exclusivity Period” means, on a Regional Licensed
Product-by-Regional Licensed Product and country-by-country basis within the Genzyme Territory, [***]. 
 1.2.56. “Execution
Date” has the meaning set forth in the Master Agreement. 
 1.2.57. “Existing Alnylam In-License” has the
meaning set forth in the Master Agreement. 
 1.2.58. “Existing Genzyme In-License” has the meaning set forth in the
Master Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 10 

 REGIONAL LICENSE TERMS 

 

 1.2.59. “FDA” means the United States Food and Drug Administration
and any successor Governmental Authority having substantially the same function. 
 1.2.60. “FDCA” means the United
States Federal Food, Drug, and Cosmetic Act of 1938, as amended from time to time, and the regulations and guidelines promulgated thereunder. 

1.2.61. “Field” means the treatment, diagnosis and/or prevention of all human diseases. 

1.2.62. “First Commercial Sale” means, with respect to a country, the first sale for end use or consumption of a
Regional Licensed Product in such country, except for compassionate use or patient access programs, after all Regulatory Approvals legally required for such sale have been granted by the Regulatory Authority of such country. 

1.2.63. “First Regulatory Approval by the EMA” means, with respect to a Regional Licensed Product, the earlier of
(i) if Regulatory Approval in the EU is sought through the EMA centralized procedure, receipt of Regulatory Approval for such Regional Licensed Product from the EMA or (ii) if Regulatory Approval in the EU is sought through a national
authorization procedure, receipt of Regulatory Approval for such Regional Licensed Product in the first (1st) MMC country in the EU. 

1.2.64. “First Regulatory Approval in Japan” means, with respect to a Regional Licensed Product, receipt of Regulatory
Approval for such Regional Licensed Product in Japan. 
 1.2.65. “Force Majeure” means embargoes, war, acts of war
(whether war be declared or not), terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God. 

1.2.66. “Fundamental Breach” [***]. 

1.2.67. “GAAP” has the meaning set forth in the Master Agreement. 

1.2.68. “GalNAc Conjugate” has the meaning set forth in the Master Agreement. 

1.2.69. “Generic Competition” means, with respect to a Regional Licensed Product in any country in the Genzyme
Territory in a given Calendar Quarter, that, during such Calendar Quarter, (a) one or more Generic Products with respect to such Regional Licensed Product are commercially available in such country, and (b) Net Sales of such Regional
Licensed Product in such country in such Calendar Quarter equal less than [***] of the average Net Sales of such Regional Licensed Product over the [***] consecutive Calendar Quarters immediately prior to the Calendar Quarter in which one or more
Generic Products first became commercially available in such country. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 11 

 REGIONAL LICENSE TERMS 

 

 1.2.70. “Generic Product” means, on a Regional Licensed
Product-by-Regional Licensed Product and country-by-country basis, a pharmaceutical product that (a) is sold by a Person that is not a Related Party of Genzyme under a marketing authorization granted by a Regulatory Authority in such country to
a Third Party; (b) [***]; and (c) is approved by the Regulatory Authority in such country pursuant to an approval process that relies in part on pivotal safety and/or efficacy data in such Regulatory Authority’s previous grant of
marketing authorization for such Regional Licensed Product. 
 1.2.71. “Genzyme Collaboration IP” means (a) any
Know-How, first identified, discovered or developed solely by employees of Genzyme or its Affiliates or other persons not employed by Alnylam acting on behalf of Genzyme, in the conduct of the Collaboration and (b) any Patent Rights that claim
or Cover such Know-How and are Controlled by Genzyme at any time during the Term. Genzyme Collaboration IP excludes Genzyme’s interest in Joint Collaboration IP, in each case (a) and (b), other than Genzyme Manufacturing IP. 

1.2.72. “Genzyme Disclosed Manufacturing Know-How” means Know-How (a) Controlled by Genzyme at any time during the
Term that is useful in the Manufacture of a Regional Licensed Product and (b) that Genzyme, in its sole discretion, discloses in writing to Alnylam in the course of the Collaboration. 

1.2.73. “Genzyme In-License” means any Existing Genzyme In-License, Un-Blocking Genzyme In-License, or any
Collaboration In-License to which Genzyme is a party. 
 1.2.74. “Genzyme Know-How” means Know-How Controlled by
Genzyme during the Term that is reasonably necessary or useful for Alnylam to Develop, Commercialize and/or Manufacture Regional Licensed Products in the Field in the Alnylam Territory (other than Genzyme’s rights in Joint Collaboration IP,
Genzyme Collaboration IP and Genzyme Manufacturing IP). 
 1.2.75. “Genzyme Manufacturing IP” means (a) any
Know-How related to the Manufacture of Regional Licensed Products (or oligonucleotides generally) Controlled by Genzyme at any time during the Term, and (b) any Patent Rights that claim or cover such Know-How and are Controlled by Genzyme at
any time during the Term, excluding Improvement Manufacturing Patent Rights and Genzyme Disclosed Manufacturing Know-How. 
 1.2.76.
“Genzyme Patent Jurisdiction” has the meaning set forth in the Master Agreement. 
 1.2.77. “Genzyme
Patent Rights” means those Patent Rights Controlled by Genzyme during the Term that are reasonably necessary or useful to Develop, Commercialize and/or Manufacture Regional Licensed Products in the Field in the Alnylam Territory; Genzyme
Patent Rights excludes Patent Rights included in Genzyme Collaboration IP, Genzyme’s interest in Joint Collaboration IP and Genzyme Manufacturing IP. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 12 

 REGIONAL LICENSE TERMS 

 

 1.2.78. “Genzyme Technology” means, collectively, Genzyme Know-How,
Genzyme Patent Rights, Genzyme Collaboration IP and Genzyme’s interest in Joint Collaboration IP, but excluding Genzyme Manufacturing IP. 

1.2.79. “Genzyme Territory” means all countries and territories of the world other than the Alnylam Territory. 

1.2.80. “Genzyme Territory Commercialization Plan” has the meaning set forth in Section 4.3 (Genzyme Territory
Commercialization Plan). 
 1.2.81. “Genzyme Territory Development Plan” has the meaning set forth in
Section 2.2.4 (Genzyme Territory Development Plan). 
 1.2.82. “Genzyme Territory MMC” [***]. 

1.2.83. “Genzyme Trademark” has the meaning set forth in Section 9.7(b) (Trademarks). 

1.2.84. “Global Branding Strategy” has the meaning set forth in Section 4.5.1 (Global Branding). 

1.2.85. “Global Clinical Study” has the meaning set forth in Section 2.2.2.5(b) (Oversight of the Global
Development Plans). 
 1.2.86. “Global Development Activity(ies)” has the meaning set forth in Section 2.2.2.1
(Global Development Plans). 
 1.2.87. “Global Development Budget” has the meaning set forth in Section 2.2.2.2
(Global Development Budgets). 
 1.2.88. “Global Development Plan” has the meaning set forth in Section 2.2.2.1
(Global Development Plans). 
 1.2.89. “Global Development Strategy” has the meaning set forth in Section 2.2.1
(Global Development Strategy). 
 1.2.90. “Global License Terms “has the meaning set forth in the Master Agreement.

 1.2.91. “Global Licensed Product” has the meaning set forth in the Master Agreement. 

1.2.92. “Global R&D Cost Opt-In Date” has the meaning set forth in Section 2.3.1.2 (Global R&D Costs).

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 13 

 REGIONAL LICENSE TERMS 

 

 1.2.93. “Global R&D Costs” means, with respect to a Regional
Licensed Product, R&D Costs incurred in connection with any Global Development Activity for such Regional Licensed Product. 
 1.2.94.
“Global R&D Costs Report” has the meaning set forth in Section 2.3.1.2 (Global R&D Costs). 
 1.2.95.
“Governmental Authority” means any applicable government authority, court, tribunal, arbitrator, agency, department, legislative body, commission or other instrumentality of (a) any government of any country or territory,
(b) any nation, state, province, county, city or other political subdivision thereof or (c) any supranational body. 
 1.2.96.
“Human POP Study” has the meaning set forth in the Master Agreement. 
 1.2.97. “IFRS” has the
meaning set forth in the Master Agreement. 
 1.2.98. “Implementation Date” means, with respect to ALN-TTR02, the
Effective Date and, with respect to each other Regional Licensed Product, the Option Exercise Date for such Regional Licensed Product. 

1.2.99. “Improvement Manufacturing Patent Right” means a Patent Right owned exclusively by Genzyme or its Affiliates
that claims an invention related to the Manufacture of a Regional Licensed Product that was made (a) by Genzyme or its Affiliates after the Effective Date in connection with Manufacturing Regional Licensed Products and (b) using Alnylam
Know-How that, at the time such Alnylam Know-How was disclosed to Genzyme or its Affiliates, constituted Alnylam’s Confidential Information under Section 7 of the Master Agreement (Confidentiality and Publication). 

1.2.100. “IND” has the meaning set forth in the Master Agreement. 

1.2.101. “In-License” has the meaning set forth in the Master Agreement. 

1.2.102. “Infringement Action” has the meaning set forth in Section 9.4.2(a) (Rights to Enforce – Genzyme
Technology). 
 1.2.103. “JCOT” has the meaning set forth in Section 2.2.2.5 (Oversight of the Global
Development Plans). 
 1.2.104. “Joint Collaboration IP” means, collectively, (a) any Know-How first identified,
discovered or developed jointly by employee(s), agent(s) or consultant(s) acting on behalf of Alnylam or its Affiliates, on the one hand, and employee(s), agent(s) or consultant(s) acting on behalf of Genzyme or its Affiliates, on the other hand, in
the conduct of the Collaboration that is Controlled by Alnylam and Genzyme, and (b) any Patent Rights that Cover such Know-How and are Controlled by Alnylam and Genzyme. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 14 

 REGIONAL LICENSE TERMS 

 

 1.2.105. “Know-How” has the meaning set forth in the Master
Agreement. 
 1.2.106. “Laws” has the meaning set forth in the Master Agreement. 

1.2.107. “Licensed Target” means, for ALN-TTR02, TTR, and for each other Regional Licensed Product, the human gene that is
targeted by such Regional Licensed Product, as identified in the Option Data Package for such Regional Licensed Product and then attached hereto as Schedules 1.2.107-1, 1.2.107-2, and so forth. 

1.2.108. “Lipid Nanoparticle Formulation” has the meaning set forth in the Master Agreement. 

1.2.109. “Manufacturing” or “Manufacture” has the meaning set forth in the Master Agreement. 

1.2.110. “Manufacturing Claim” means a claim within a Patent Right directed solely to Manufacturing a Regional Licensed
Product. 
 1.2.111. “MMC” means any Alnylam Territory MMC or Genzyme Territory MMC. 

1.2.112. “NDA” has the meaning set forth in the Master Agreement. 

1.2.113. “Net Sales” means, with respect to a Regional Licensed Product, the aggregate gross invoiced sales prices from
sales of all units of such Regional Licensed Product sold by Genzyme and its Related Parties to independent Third Parties (other than a Sublicensee) after deducting, if not previously deducted, from the amount invoiced or received: 

(a) trade, quantity and cash discounts, credits or allowances actually given; 

(b) returns, rejections or recalls (due to spoilage, damage, expiration of useful life or otherwise); 

(c) Third Party rebates, chargebacks, hospital buying group/group purchasing organization administration fees or managed care
organization rebates actually given; 
 (d) rebates and similar payments made with respect to sales paid for by any
governmental or regulatory authority such as Federal or state Medicaid, Medicare or similar state program; 
 (e)
distribution fees and sales commissions paid to Third Parties; 
 (f) retroactive price reductions or billing corrections;

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 15 

 REGIONAL LICENSE TERMS 

 

 (g) value added, sales and use, excise and other similar taxes and
surcharges, customary transportation and insurance, custom duties, and other governmental charges; and 
 (h) amounts
previously included in Net Sales of such Regional Licensed Product that are adjusted or written-off by Genzyme or its Related Parties as bad debt or otherwise uncollectible in accordance with the standard practices of Genzyme or its Related Parties
for writing off uncollectible amounts consistently applied; provided, however, if any such written-off amounts are subsequently collected, such collected amounts shall be included in Net Sales in the period in which they are
subsequently collected. 
 Such amounts shall be determined from the books and records of Genzyme or its Related Parties, maintained in
accordance with IFRS. 
 In the case of any sale or other disposal for value, such as barter or counter-trade, of a Regional Licensed
Product, or part thereof, other than in an arm’s length transaction exclusively for cash, Net Sales shall be calculated as above on the value of the non-cash consideration received or the fair market price (if higher) of such Regional Licensed
Product in the country of sale or disposal, as determined in accordance with IFRS. 
 Notwithstanding the foregoing, the following will not
be included in Net Sales: (1) sales between or among Genzyme and its Related Parties (but Net Sales shall include sales to the first Third Party (other than a Sublicensee) by Genzyme or its Related Parties); (2) samples of Regional
Licensed Product used to promote additional Net Sales, in amounts consistent with normal business practices of Genzyme; and (3) disposal or use of Regional Licensed Products in Clinical Studies or under compassionate use, patient assistance,
named patient use, or test marketing programs or non-registrational studies or other similar programs or studies where the Regional Licensed Product is supplied without charge or at the actual manufacturing cost thereof (without allocation of
indirect costs or any mark-up). 
 In the case where a Regional Licensed Product is sold as part of a Combination Product in a country in
the Licensed Territory, Net Sales for the Regional Licensed Product included in such Combination Product in such country shall be calculated as follows: 

(i) if the Regional Licensed Product is sold separately in such country and the other active ingredient or ingredients in the Combination
Product are sold separately in such country, Net Sales for the Regional Licensed Product shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the fraction A/(A+B), where A is the invoice price of the
Regional Licensed Product when sold separately in such country and B is the total invoice price of the other active ingredient or ingredients in the Combination Product when sold separately in such country; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 16 

 REGIONAL LICENSE TERMS 

 

 (ii) if the Regional Licensed Product is sold separately in such country but the other active
ingredient or ingredients in the Combination Product are not sold separately in such country, Net Sales for the Regional Licensed Product shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the fraction
A/D, where A is the invoice price of the Regional Licensed Product when sold separately in such country and D is the invoice price of the Combination Product in such country; 

(iii) if the Regional Licensed Product is not sold separately in such country but the other active ingredient or ingredients in the
Combinations Product are sold separately in such country, Net Sales for the Regional Licensed Product shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction 1 – (B/D), where B is the invoice price of the
other active ingredient or ingredients in the Combination Product when sold separately in such country and D is the invoice price of the Combination Product in such country; or 

(iv) if neither the Regional Licensed Product nor the other active ingredient or ingredients in the Combination Product are sold separately in
such country, the Parties shall determine Net Sales for the Regional Licensed Product in such Combination Product by mutual agreement based on the relative contribution of the Regional Licensed Product and each other active ingredient to the
Combination Product, and shall take into account in good faith any applicable allocations and calculations that may have been made for the same period in other countries. 

For purposes of this Section, “Combination Product” means a product that includes at least one active ingredient other than a Regional
Licensed Product. Drug delivery vehicles, adjuvants, and excipients shall not be deemed to be “active ingredients”, except in the case where such delivery vehicle, adjuvant, or excipient is recognized by the FDA as an active
ingredient in accordance with 21 C.F.R. 210.3(b)(7). 
 1.2.114. “Non-Bankrupt Party” has the meaning set forth in
Section 6.6 (Bankruptcy). 
 1.2.115. “Non-Disputing Party” has the meaning set forth in Section 2.3.1.2(d)
(Global R&D Costs). 
 1.2.116. “Non-Proposing Party” has the meaning set forth in Section 2.2.2.6(c)
(Independent Performance of Additional Development Activities). 
 1.2.117. “Option Data Package” has the meaning set
forth in the Master Agreement. 
 1.2.118. “Option Exercise Date” has the meaning set forth in the Master Agreement.

 1.2.119. “Party” means Genzyme and/or Alnylam. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 17 

 REGIONAL LICENSE TERMS 

 

 1.2.120. “Patent Challenge” has the meaning set forth in
Section 10.2.4 (Challenges of Patents). 
 1.2.121. “Patent Rights” has the meaning set forth in the Master
Agreement. 
 1.2.122. “Person” means any natural person, corporation, unincorporated organization, partnership,
association, sole proprietorship joint stock company, joint venture, limited liability company, trust or government, or any Governmental Authority, or any other similar entity. 

1.2.123. “Phase 2 Budget” has the meaning set forth in Section 2.2.2.4 (Budget Caps; Adjustment and Compensation).

 1.2.124. [***]. 

1.2.125. “Phase 3 Budget” has the meaning set forth in Section 2.2.2.4 (Budget Caps; Adjustment and Compensation).

 1.2.126. [***]. 

1.2.127. “Phase I Study” has the meaning set forth in the Master Agreement. 

1.2.128. “Phase II Study” has the meaning set forth in the Master Agreement. 

1.2.129. “Phase III Study” has the meaning set forth in the Master Agreement. 

1.2.130. “Post-Marketing Study” has the meaning set forth in the Master Agreement. 

1.1.2. “Post-Phase 3 Budget” has the meaning set forth in Section 2.2.2.4 (Budget Caps; Adjustment and
Compensation). 
 1.2.131. [***]. 

1.2.132. “Product Joint Steering Committee” or “PJSC” means the joint steering committee as more fully
described in Section 5.1 (Product Joint Steering Committee). 
 1.2.133. “Product Trademark(s)” means the
Trademarks used, or intended for use, in connection with the distribution, marketing, promotion and sale of the Regional Licensed Products. Product Trademarks specifically exclude the corporate names and logos of the Parties and their Affiliates.
Product Trademark includes both the Alnylam Trademarks and the Genzyme Trademarks. 
 1.2.134. “Promotional
Materials” has the meaning set forth in Section 4.5.2 (Alnylam A&P). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 18 

 REGIONAL LICENSE TERMS 

 

 1.2.135. “Proposing Party” has the meaning set forth in
Section 2.2.2.6(a) (Additional Development Proposals). 
 1.2.136. “R&D Costs” means, with respect to a
Regional Licensed Product, costs and expenses incurred in connection with the performance of any Development activity for such Regional Licensed Product, including [***]. 

1.2.137. “R&D FTE” means [***] of work per annum devoted to or in support of the Development or Manufacture of a
Regional Licensed Product that is carried out by one or more qualified scientific or technical employees (excluding Third Party contractors) of a Party or its Affiliates. 

1.2.138. “R&D FTE Cost” means, for any period, the R&D FTE Rate multiplied by the number of R&D FTEs in
such period. 
 1.2.139. “R&D FTE Rate” means [***] per FTE, increased annually beginning on January 1, 2015
and thereafter on January 1 of each succeeding year by the percentage increase in the CPI as of December 31 of the then most recently ended Calendar Year over the level of the CPI on December 31, 2013. 

1.2.140. “Regional Licensed Product” means: (i) ALN-TTR02 as of the Effective Date and (ii) if Genzyme
exercises the Regional Option pursuant to the Master Agreement for any Regional Option Product, then such Regional Option Product as of the applicable Option Exercise Date. For the sake of clarity (but not for purposes of interpretation of the
Collaboration Agreement), although ALN-TTRsc is not a Regional Licensed Product, it is exclusively licensed to Genzyme in the Genzyme Territory in much the same way that Regional Licensed Products are licensed to Genzyme in the Genzyme Territory
under these Regional License Terms. As a Co-Co Licensed Product, however, ALN-TTRsc is licensed to Genzyme under the Co-Co License Terms, which also grant Genzyme a license to co-Commercialize ALN-TTRsc in the Alnylam Territory. 

1.2.141. “Regional Option Period” has the meaning set forth in the Master Agreement. 

1.2.142. “Regional Option Product” has the meaning set forth in the Master Agreement. 

1.2.143. “Regional Option” has the meaning set forth in the Master Agreement. 

1.2.144. “Regional Out-of-Pocket Costs” means, with respect to certain activities hereunder, direct expenses paid or
payable by either Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities for a Regional Licensed Product, including payments to contract personnel; provided, however, that amounts
paid to contract sales and marketing personnel will not be considered Regional Out-of-Pocket Costs. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 19 

 REGIONAL LICENSE TERMS 

 

 1.2.145. “Regulatory Approval” has the meaning set forth in the
Master Agreement. 
 1.2.146. “Regulatory Authority” has the meaning set forth in the Master Agreement. 

1.2.147. “Regulatory Exclusivity” means, with respect to a Regional Licensed Product in a country, any exclusive
marketing right, data exclusivity right, orphan drug designation or other country-wide exclusive right or status conferred by any Governmental Authority with respect to such Regional Licensed Product in such country, other than a Patent Right, that
limits or prohibits a Person from [***]. 
 1.2.148. “Related Party” means a Party’s Affiliates, permitted
Sublicensees and, with respect to Alnylam, licensees in the Alnylam Territory. 
 1.2.149. “Reverted Regional Licensed
Product” has the meaning set forth in Section 10.3.1.3(a) (Effects of Termination of Regional License Terms in Their Entirety by Alnylam for Cause or by Genzyme for Convenience). 

1.2.150. “RLP Alliance Manager” has the meaning set forth in Section 5.2 (Appointment of Subcommittees, Project
Teams and RLP Alliance Managers). 
 1.2.151. “RLP Collaboration” means the collaboration of the Parties in the
Development, Manufacture and Commercialization of Regional Licensed Products under these Regional License Terms. 
 1.2.152. “RLP
Clinical Supply Agreements” means, collectively, the ALN-TTR02 Clinical Supply Agreement and each other clinical supply agreement entered into between Alnylam and Genzyme as described in Section 6.2 of the Master Agreement
(Collaboration Product Supply Agreements) pursuant to which Alnylam will provide clinical supplies of a specified Regional Licensed Product to Genzyme. 

1.2.153. “RLP Commercial Supply Agreements” means, collectively, the ALN-TTR02 Commercial Supply Agreement and each other
commercial supply agreement entered into between Alnylam and Genzyme as described in Section 6.2 of the Master Agreement (Collaboration Product Supply Agreements) pursuant to which Alnylam will provide commercial supplies of a specified
Regional Licensed Product to Genzyme. 
 1.2.154. “RLP Supply Agreements” means, collectively, the RLP Clinical
Supply Agreements and the RLP Commercial Supply Agreements. 
 1.2.155. “Regional License Terms” means this Appendix
and the terms of the Master Agreement to the extent applicable to Regional Licensed Products. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 20 

 REGIONAL LICENSE TERMS 

 

 1.2.156. “Royalty Term” has the meaning set forth in
Section 7.2.2 (Royalty Term). 
 1.2.157. “Safety Concern” has the meaning set forth in the Master Agreement.

 1.2.158. “Secondary Indication” has the meaning set forth in the Master Agreement.

1.2.159. “Secondary Indication Study” has the meaning set forth in the Master Agreement. 

1.2.160. “Serious Adverse Event” has the meaning set forth in the Master Agreement. 

1.2.161. “siRNA” has the meaning set forth in the Master Agreement. 

1.2.162. “SPCs” has the meaning set forth in Section 9.5 (Patent Term Extensions). 

1.2.163. “Sublicensee” means a Third Party to whom a Party grants a sublicense under any Alnylam Technology or Genzyme
Technology, as the case may be, to Develop, Manufacture or Commercialize a Regional Licensed Product in the Field pursuant to Section 6.1.4 (Sublicensing Terms) or Section 6.2.4 (Sublicensing Terms). 

1.2.164. “Term” has the meaning set forth in Section 10.1 (Term). 

1.2.165. “Territory” means (a) with respect to Alnylam, the Alnylam Territory and (b) with respect to
Genzyme, the Genzyme Territory. 
 1.2.166. “Third Party” has the meaning set forth in the Master Agreement. 

1.2.167. “Third Party Collaboration Agreement” has the meaning set forth in Section 5.8 (Alnylam Third Party
Partner). 
 1.2.168. “Third Party License Payment” has the meaning set forth in the Master Agreement. 

1.2.169. “Third Party Partner” has the meaning set forth in Section 5.8 (Alnylam Third Party Partner). 

1.2.170. “Trademark” has the meaning set forth in the Master Agreement. 

1.2.171. “TTR” has the meaning set forth in the Master Agreement. 

1.2.172. “Un-Blocking Genzyme In-License” has the meaning set forth in the Master Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 21 

 REGIONAL LICENSE TERMS 

 

 1.2.173. “United States” means the United States of America and its
territories, possessions and commonwealths. 
 1.2.174. “Valid Claim” means a claim of: (a) an issued and
unexpired patent, which claim has not been withdrawn, cancelled, abandoned, disclaimed, revoked or held unenforceable or invalid by an unappealable decision of a court or other governmental agency of competent jurisdiction, or has not been appealed
within the time allowed for appeal, or by an appealed decision of a court or other governmental agency of competent jurisdiction where the appeal has been pending for more than [***] years (unless and until such decision is subsequently overturned
on appeal) and which has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise; or (b) a patent application that has been pending less than [***] years from
the date of filing of the earliest patent application from which such patent application claims priority, which claim has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be
taken. 
 1.2.175. “[***]” has the meaning set forth in Section 2.2.2.3(a) (Managing and Amending Global
Development Plans and Global Development Budgets). 
 1.2.176. “[***] Budget” has the meaning set forth in
Section 2.2.2.3(a) (Managing and Amending Global Development Plans and Global Development Budgets). 
 1.2.177.
“[***]” has the meaning set forth in Section 2.2.2.3(a) (Managing and Amending Global Development Plans and Global Development Budgets). 

1.2.178. “[***] Budget” has the meaning set forth in Section 2.2.2.3(a) (Managing and Amending Global Development
Plans and Global Development Budgets). 
 2. DEVELOPMENT COLLABORATION 

2.1. Overview. The Parties will collaborate in the Development of each Regional Licensed Product pursuant to the applicable
Global Development Plan, Alnylam Territory Development Plan and Genzyme Territory Development Plan. The PJSC will have primary responsibility for the oversight of the Global Development Plans. Alnylam will have primary responsibility for execution
of those Global Development Plans, and sole responsibility for the Alnylam Territory Development Plans, as described below. Genzyme will have sole responsibility for the Genzyme Territory Development Plans, as described below. 

2.2. Development Plans. 

2.2.1. Global Development Strategy. For each Regional Licensed Product, the key Development principles for such Regional Licensed
Product will be set forth in a written summary of the global Development strategy for such Licensed Product, including the indication(s) (including Secondary Indications), for which Regulatory Approval will be sought (each, a “Global
Development Strategy”). The initial Global Development Strategy for ALN-

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 22 

 REGIONAL LICENSE TERMS 

 

 
TTR02 will be provided by Alnylam to Genzyme within [***] days after the Effective Date, agreed upon by the PJSC within [***] days after the Effective Date, and then attached hereto as
Schedule 2.2.1-1. The initial Global Development Strategy for each subsequent Regional Licensed Product will be included in the Option Data Package for such Regional Licensed Product, mutually agreed upon by the Parties prior to
Genzyme’s exercise of the Regional Option with respect to such Regional Licensed Product in accordance with the Master Agreement, and then attached hereto as Schedules 2.2.1-2, 2.2.1-3 and so forth. Any Global Development Strategy
may be amended from time to time only by the PJSC responsible for the applicable Regional Licensed Product. 
 2.2.2. Global Development
Plan. 
 2.2.2.1. Global Development Plans. For each Regional Licensed Product, the Development activities
that are necessary or useful to be undertaken for such Regional Licensed Product to achieve initial Regulatory Approval for each of the indications to be sought pursuant to the Global Development Strategy in at least all of the MMCs in a proximal
fashion (including the design of necessary or useful Clinical Studies) will be set forth in reasonable detail in a written work plan and time table (each, a “Global Development Plan”). Alnylam will provide a draft of the initial
Global Development Plan for ALN-TTR02 to Genzyme on or before [***], and within [***] days thereafter the PJSC will review, update and approve such Global Development Plan and it will be attached hereto as Schedule 2.2.2.1-1. The initial
Global Development Plan for each subsequent Regional Licensed Product will be included in the Option Data Package for such Regional Licensed Product provided by Alnylam to Genzyme under the Master Agreement, and within [***] days of the
Implementation Date for such Regional Licensed Product the PJSC responsible for such Regional Licensed Product will review, update and approve such Global Development Plan and it will be attached hereto as Schedules 2.2.2.1-2,
2.2.2.1-3 and so forth. Each Global Development Plan must, at all times, be consistent with the Global Development Strategy and include all Development activities that (i) are reasonably necessary to obtain initial Regulatory Approval of
the applicable Regional Licensed Product in each MMC for each of the indications, including Secondary Indications, to be sought pursuant to the Global Development Strategy in a proximal fashion and (ii) Secondary Indication Studies included in
the initial Global Development Plan or added pursuant to Section 2.2.2.6 (Secondary Indications) (all such Development activities collectively, the “Global Development Activities”); provided, however, that, unless
otherwise agreed by the Parties, in no event will any Global Development Plan include (a) any Post-Marketing Study or Secondary Indication Study, except for Secondary Indication Studies included in the initial Global Development Plan or added
to a Global Development Plan pursuant to Section 2.2.2.6 (Secondary Indications), (b) any Development activity solely intended or designed to achieve initial Regulatory Approval in a country other than an MMC or (c) after the last
Regulatory 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 23 

 REGIONAL LICENSE TERMS 

 

 
Approval in all MMCs, any Development activity that is useful solely to achieve initial Regulatory Approval in a country that is not an MMC, except for Secondary Indication Studies included in
the initial Global Development Plan or added to a Global Development Plan pursuant to Section 2.2.2.6 (Secondary Indications). Each Global Development Plan will allocate responsibility for the performance of each Global Development Activity to
one of the Parties. The time table for the completion of the Global Development Activities included in each Global Development Plan will be designed to obtain initial Regulatory Approval of the applicable Regional Licensed Product in each MMC in a
proximal fashion and as soon as reasonably possible. The terms of, and Development activities set forth in, each Global Development Plan will at all times be designed to be in compliance with all applicable Laws and in accordance with professional
and ethical standards customary in the pharmaceutical industry. 
 2.2.2.2. Global Development Budgets. Each
Global Development Plan will contain a [***] year rolling budget for the probable Global Development Activities to be performed during [***], and a forecast of the budgets for each subsequent Calendar Year thereafter through completion of all Global
Development Activities set forth in any such Global Development Plan, provided that each initial Global Development Plan will also include such a budget for the partial Calendar Year commencing as of the date of such Global Development Plan
and ending December 31 of such Calendar Year (each such [***] budget plus any such partial Calendar Year is a “Global Development Budget”). Each Global Development Budget will be updated annually by the PJSC responsible for the
applicable Regional Licensed Product in accordance with Section 2.2.2.3 (Managing and Amending Global Development Plans and Global Development Budgets). The initial Global Development Budget for a Regional Licensed Product, and each update
thereto, will be prepared by the PJSC in accordance with[***] 
 (a) [***]; 

(b) [***] 
 (c) [***]. 

Alnylam will enter such Global Development Budget in a template that the Parties agree is efficient for both Parties to communicate such
information. 
 2.2.2.3. Managing and Amending Global Development Plans and Global Development Budgets. The
PJSC responsible for a Regional Licensed Product will update and amend the applicable Global Development Plan from time-to-time as it deems necessary and, until such time as no further Global Development Activities are occurring or expected to occur
with respect to such Regional Licensed Product, the PJSC will update such Global Development Plan annually as follows: 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 24 

 REGIONAL LICENSE TERMS 

 

 (a) No later than [***] of each Calendar Year, the applicable PJSC will
prepare an updated draft of the Global Development Plan, which shall contain a proposed Global Development Budget covering [***]. 

(b) No later than [***] of each Calendar Year, the applicable PJSC will review and tentatively approve an updated Global
Development Plan and Global Development Budget, and such updated Global Development Plan and Global Development Budget will become effective upon such tentative approval by the PJSC, provided that the Parties acknowledge and agree that each
Party’s internal process for receiving final approval of such Global Development Plan and Global Development Budget from its Board of Directors and/or senior management may occur after [***] (but, in any event, before [***]) and such Global
Development Plan and Global Development Budget will not become final unless and until such approvals are obtained [***]. 

2.2.2.4. [***] Adjustments and Compensation. In addition to the Global Development Budget for each Regional
Licensed Product, Alnylam shall prepare, and submit to the PJSC for approval, three Development budget(s) for each Regional Licensed Product, the first of which shall cover the period commencing as of the Implementation Date for such Regional
Licensed Product and ending on the anticipated date of initiation of the first Phase III Study for such Regional Licensed Product (as further described below, each a “Phase 2 Budget”), the second of which shall cover the period
commencing as of the anticipated date of initiation of the first Phase III Study for such Regional Licensed Product and ending on the anticipated date of filing of an application for Regulatory Approval of such Regional Licensed Product in the first
MMC (as further described below, each a “Phase 3 Budget”), and the third of which shall cover the period commencing as of the anticipated date of filing of an application for Regulatory Approval for such Regional Licensed Product in
the first MMC and ending on the date that there are no further Development activities to performed under the Global Development Plan for such Regional Licensed Product (as further described below, each a “Post-Phase 3 Budget”),
provided that if the period covered by the Post-Phase 3 Budget is longer than three (3) years, Alnylam shall prepare a new Post-Phase 3 Budget to cover each subsequent three (3) year period. Each Phase 2 Budget, Phase 3 Budget and
Post-Phase 3 Budget shall be [***]. 
 (a) Preparation of Phase 2 Budget, Phase 3 Budget and Post-Phase 3 Budget. Each
Phase 2 Budget, Phase 3 Budget and Post-Phase 3 Budget submitted to the PJSC will be prepared by Alnylam in accordance with [***]. 

(b) [***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 25 

 REGIONAL LICENSE TERMS 

 

 (c) Delivery and Effectiveness of Phase 2 Budget, Phase 3 Budget and
Post-Phase 3 Budget. 
 (i) Alnylam shall include a Phase 2 Budget [***] with the initial Global Development Plan for each Regional
Licensed Product. Such Phase 2 Budget [***] shall become effective, subject to adjustment in accordance with the foregoing Section 2.2.2.4(b), upon the Implementation Date for the relevant Regional Licensed Product. 

(ii) Alnylam shall provide to the PJSC for approval a Phase 3 Budget [***] for each Regional Licensed Product no less than [***] days prior to
the anticipated initiation of the first Phase III Study for each Regional Licensed Product, along with top line data and data tables from any completed Phase II Studies and other completed non-clinical studies (including all Serious Adverse Event
and Safety Concern data), as well as a draft of the end of Phase II briefing package, in each case to the extent not previously provided or made available to Genzyme (such budget, data and draft, collectively the “End of Phase II
Package”). Such Phase 3 Budget [***] shall become effective at the end of such [***] day period. 
 (iii) Alnylam shall provide to
the PJSC for approval a Post-Phase 3 Budget [***] for each Regional Licensed Product no less than [***] days prior to the anticipated completion of the first Phase III Study for each Regional Licensed Product. Such Post-Phase 3 Budget [***] shall
become effective upon approval by the PJSC. 
 (d) [***]. 

2.2.2.5. Oversight of the Global Development Plans. The PJSC for ALN-TTR02 shall create a Joint Clinical
Operations Team (“JCOT”), with two (2) representatives from each Party, to review, coordinate and provide such PJSC with feedback regarding: 

(a) the implementation of the Global Development Plan for ALN-TTR02, including the implementation and management of the Global
Development Activities set forth in such Global Development Plan; 
 (b) the performance of any Clinical Study included in
such Global Development Activities (a “Global Clinical Study”) by any CRO retained by a Party to perform such Global Clinical Study, against the criteria and timelines in such Global Development Plan; and 

(c) such other activities as the PJSC deems shall be the responsibility of the JCOT. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 26 

 REGIONAL LICENSE TERMS 

 

 Unless otherwise agreed by the Parties, each Party’s representatives on the JCOT must be
employees of such Party. The JCOT shall meet from time-to-time, in person or via teleconference, as it shall reasonably determine. 

2.2.2.6. Secondary Indications. 

(a) Additional Development Proposals. If a Party desires to conduct a Secondary Indication Study of a Regional Licensed
Product for the purpose of seeking Regulatory Approval to market such Regional Licensed Product for a Secondary Indication, such Party (the “Proposing Party”) will submit to the PJSC responsible for such Regional Licensed Product a
proposal to add such Secondary Indication Study to the applicable Global Development Plan (an “Additional Development Proposal”). Each Additional Development Proposal will describe in reasonable detail the Secondary Indication
Study(ies) that the Proposing Party desires to conduct, including a synopsis of the trial, the proposed enrollment criteria, number of patients to be included, endpoints to be measured, and statistical design and powering (the “Additional
Development Activities”), as well as a proposed timeline and budget and an analysis of the business opportunity and revenue potential for such Additional Development Activities and Secondary Indication. 

(b) PJSC Decision Regarding Additional Development Activities. The PJSC shall approve or reject an Additional
Development Proposal within [***] days after receipt thereof from the Proposing Party as set forth in this Section 2.2.2.6. 
 (i) If
the PJSC approves an Additional Development Proposal, upon such an approval, the applicable Global Development Plan will be amended to include the Additional Development Activities, including the proposed timeline and budget for such Additional
Development Activities, set forth in such Additional Development Proposal (as may be amended by the PJSC) upon such approval. Any Additional Development Activities included in a Global Development Plan pursuant to this Section 2.2.2.6(b) shall
be deemed to be Global Development Activities for all purposes under these Regional License Terms (including the definition of Global R&D Costs). 

(ii) If the PJSC fails to approve an Additional Development Proposal, upon such a failure, the Secondary Indication Study proposed in the
Additional Development Proposal will not be deemed a Global Development Activity for any purpose under these Regional License Terms, and Sections 2.2.2.6(c) (Independent Performance of Additional Development Activities) and 2.2.2.6(d) (Opt-In for
Additional Development Activities) shall apply. 
 (c) Independent Performance of Additional Development Activities.

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 27 

 REGIONAL LICENSE TERMS 

 

 (i) If the PJSC fails to approve for inclusion in the Global Development Plan an Additional
Development Proposal proposed by Alnylam for a Secondary Indication Study(ies) in the Alnylam Territory for a Regional Licensed Product, Alnylam may, upon notice to Genzyme, conduct the proposed Secondary Indication Study(ies) at its own expense;
[***]. 
 (ii) If, after receipt of Regulatory Approval for a Regional Licensed Product in an Alnylam Territory MMC, the PJSC fails to
approve for inclusion in the Global Development Plan an Additional Development Proposal proposed by Genzyme for a Secondary Indication Study(ies) in the Genzyme Territory for such Regional Licensed Product, Genzyme may, upon notice to Alnylam,
conduct the proposed Secondary Indication Study(ies) at its own expense [***]. 
 (iii) Notwithstanding anything in Section 3.4 (Right
of Reference) to the contrary, if the PJSC does not approve an Additional Development Proposal, unless and until the Non-Proposing Party delivers an Additional Development Opt-In Notice with respect to such Additional Development Activity, as
described in Section 2.2.2.6(c)(iii) (Opt-In for Additional Development Activities), the Non-Proposing Party will not have any rights under Section 3.4 (Right of Reference) with respect to any information or data generated from any
Secondary Indication Study that was the subject of the unapproved Additional Development Proposal. For avoidance of doubt, if the PJSC rejects for inclusion in all Development Plans an Additional Development Proposal for a Secondary Indication
Study(ies) proposed by Genzyme prior to receipt of Regulatory Approval for a Regional Licensed Product in an MMC in the Alnylam Territory, then Genzyme shall not have any right to proceed with the Secondary Indication Study(ies) described therein
unless and until the PJSC determines that such Additional Development Activities should be permitted or until otherwise permitted under this Section 2.2.2.6(c)(iii). 

(d) Opt-In for Additional Development Activities. In the event that the Proposing Party conducts Secondary Indication
Study(ies) pursuant to Section 2.2.2.6(c) (Independent Performance of Additional Development Activities), the Non-Proposing Party may elect, in its discretion and upon written notice to the Proposing Party no later than [***] days after the
date on which the [***] (an “Additional Development Opt-In Notice”), to opt in with respect to any Secondary Indication Study that was the subject of such Additional Development Proposal that the Proposing Party elected to conduct
in accordance with Section 2.2.2.6(c) (Independent Performance of Additional Development Activities), and then (i) such Secondary Indication Study shall be deemed to be a Global Development Activity under the Global Development Plan for
the applicable Regional Licensed Product from and after the date on which such Additional Development Opt-In Notice is received by the Proposing Party (the “Additional Development Opt-In Date”); (ii) the then-current plan and
budget of the Proposing Party with respect to such Secondary Indication Study shall be deemed to be included within, and part of, the Global Development Plan for such Regional Licensed Product as of the Additional Development Opt-In Date, and shall
control with respect to such 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 28 

 REGIONAL LICENSE TERMS 

 

 
Secondary Indication Study unless and until an amendment to the Global Development Plan providing for a different or modified plan and budget is approved by the applicable PJSC; and
(iii) the Non-Proposing Party will have all rights granted to it under Section 3.4 (Right of Reference) with respect to the information and data generated from such Secondary Indication Study as if such Secondary Indication Study was
conducted under the Global Development Plan for such Regional Licensed Product [***]. 
 2.2.2.7. Additional
Clinical Study Sites in Genzyme Territory. With respect to any Clinical Study in a Global Development Plan, at Genzyme’s request, Alnylam will add a study site in a country in the Genzyme Territory, [***]. If Alnylam adds such a
study site at Genzyme’s request, Genzyme will reimburse Alnylam for any incremental R&D FTE Costs or Regional Out-of-Pocket Costs required as a result of adding such study site. Genzyme will pay Alnylam such reimbursement within [***] days
of receipt of an invoice from Alnylam. 
 2.2.3. Alnylam Territory Development Plan. The Development activities other than Global
Development Activities to be undertaken with respect to each Regional Licensed Product by or on behalf of Alnylam with respect to the Alnylam Territory, including Secondary Indication Studies and Post-Marketing Studies, will be set forth in a
written work plan and time table (each, an “Alnylam Territory Development Plan”). Each Alnylam Territory Development Plan shall be consistent with the requirements of the Global Development Strategy. Alnylam will prepare the Alnylam
Territory Development Plan for ALN-TTR02 and then promptly thereafter will submit it to the PJSC for review and approval. Following approval by the PJSC, it will then be attached to the PJSC meeting minutes and deemed to be attached hereto as
Schedule 2.2.2.6(d)-1. The initial Alnylam Development Plan for each subsequent Regional Licensed Product will be prepared by Alnylam and following review and approval by the PJSC, will then be attached to the PJSC meeting minutes and deemed
to be attached hereto as Schedules 2.2.2.6(d)-2, 2.2.2.6(d)-3 and so forth on the Implementation Date for such Regional Licensed Product. Each Alnylam Territory Development Plan will set forth a rolling written work plan and time table
with respect to the Development of and Secondary Indication Studies for the applicable Regional Licensed Product from the Implementation Date until the later of (a) two (2) years from date of such plan, and (b) receipt of Regulatory
Approval for such Regional Licensed Product. Each Alnylam Territory Development Plan shall subsequently be updated by Alnylam from time-to-time at least once each Calendar Year not later than September 1 until such time as no further
Development or Secondary Indication Studies are occurring or expected to occur with respect to the applicable Regional Licensed Product. Alnylam will present each Alnylam Territory Development Plan and any proposed amendments thereto to the
applicable PJSC at least [***] days in advance of implementation of the Alnylam Territory Development Plan, and following review and approval by the PJSC, will then be attached to the PJSC meeting minutes and deemed to be attached hereto as the
applicable Schedule. In addition, notwithstanding anything to the contrary in these Regional License Terms, Alnylam shall not conduct any Clinical Study for a Regional Licensed Product in a country in the Genzyme Territory after receipt of initial
Regulatory Approval of such Regional Licensed Product in such country in the Genzyme Territory. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 29 

 REGIONAL LICENSE TERMS 

 

 2.2.4. Genzyme Territory Development Plan. Other than Global Development Activities,
all Development activities to be undertaken with respect to each Regional Licensed Product by or on behalf of Genzyme with respect to the Genzyme Territory, including Secondary Indication Studies and Post-Marketing Studies, will be set forth in a
written work plan and time table (each, a “Genzyme Territory Development Plan”). Each Genzyme Territory Development Plan shall be consistent with the requirements of the then-current Global Development Strategy (provided that
Alnylam did not exercise its deciding vote with respect thereto pursuant to Section 5.6.3 ([***]). Prior to [***], Genzyme will prepare the Genzyme Territory Development Plan for ALN-TTR02 and then promptly thereafter will submit it to the PJSC
for review and approval. Following review and approval by the PJSC, it will then be attached to the PJSC meeting minutes and deemed to be attached hereto as Schedule 2.2.4-1. The initial Genzyme Territory Development Plan for each subsequent
Regional Licensed Product will be prepared by Genzyme and following review and approval by the PJSC, will then be attached to the PJSC meeting minutes and deemed to be and attached hereto as Schedules 2.2.4-2, 2.2.4-3 and so forth. Each
Genzyme Territory Development Plan will set forth a rolling written work plan and time table with respect to the Development of and Secondary Indication Studies for the applicable Regional Licensed Product from the Implementation Date until the
later of (a) two (2) years from date of such plan, and (b) receipt of Regulatory Approval for such Regional Licensed Product. Each Genzyme Territory Development Plan shall subsequently be updated by Genzyme from time-to-time at least
once each Calendar Year not later than [***] until such time as no further Development or Secondary Indication Studies are occurring or expected to occur with respect to the applicable Regional Licensed Product. Genzyme will present each Genzyme
Territory Development Plan and any proposed amendments thereto to the applicable PJSC at least [***] days in advance of implementation of the Genzyme Territory Development Plan, and following review and approval by the PJSC, will then be attached to
the PJSC meeting minutes and deemed to be attached hereto as the applicable Schedule. In addition, notwithstanding anything to the contrary in these Regional License Terms, Genzyme shall not conduct any Clinical Study for a Regional Licensed Product
in a country in the Alnylam Territory after receipt of initial Regulatory Approval of such Regional Licensed Product in such country in the Alnylam Territory. 

2.3. Responsibilities for Development Activities and Costs. 

2.3.1. Global Development. 

2.3.1.1. Generally. With respect to each Regional Licensed Product, except to the extent that the Global
Development Plan for such Regional Licensed Product allocates responsibility for any Global Development Activities to Genzyme, Alnylam shall be primarily responsible for the global Development of such Regional Licensed Product and all Development
activities under such Global Development Plan. Each Party and its Affiliates shall conduct each 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 30 

 REGIONAL LICENSE TERMS 

 

 
Global Development Activity for which it is responsible in sound scientific manner and in compliance with applicable Law. Notwithstanding anything to the contrary in these Regional License Terms,
neither Party will be obligated to undertake or continue any Global Development Activity if (a) such Party reasonably determines that performance of such Global Development Activity would violate applicable Law; or (b) with respect to any
Global Clinical Study, (i) a Regulatory Authority or independent safety data review board for such Global Clinical Study has required or recommended termination or suspension of such Global Clinical Study or (ii) such Party believes in
good faith that termination or suspension of such Global Clinical Study is warranted because of safety or tolerability risks or the lack of suitable risk benefit ratio to the study subjects. In the event that a Party determines not to undertake or
continue any Global Development Activity in accordance with the immediately preceding sentence, such Party shall promptly notify the other Party of such determination, and shall use all reasonable efforts to notify and consult with the other Party
prior to making such determination. 
 2.3.1.2. Global R&D Costs. 

(a) With respect to ALN-TTR02, Alnylam shall be responsible for eighty percent (80%) of all Global R&D Costs and
Genzyme shall be responsible for twenty percent (20%) of all Global R&D Costs, in each case for Global Development Activities that occur on or after [***], and amounts specified in clauses (ii) and (iii) of Section 2.3.1.2(c)
below, if any. Alnylam shall be responsible for one-hundred percent (100%) of Global R&D Costs for Global Development Activities for ALN-TTR02 that occur prior to [***], except for amounts specified in clauses (ii) and (iii) of
Section 2.3.1.2(c) below, if any. 
 (b) With respect to each other Regional Licensed Product, Alnylam shall be
responsible for eighty percent (80%) of all Global R&D Costs and Genzyme shall be responsible for twenty percent (20%) of all Global R&D Costs, in each case for Global Development Activities that occur after the later of
(i) [***] and (ii) the earlier of (A) the Implementation Date for such Regional Licensed Product and (B) the date of the dosing of the first patient in the first Clinical Study initiated subsequent to the Human POP Study for such
Regional Licensed Product (such later date, the “Global R&D Cost Opt-In Date”), and amounts specified in clauses (ii) and (iii) of Section 2.3.1.2(c) below, if any. Alnylam shall be responsible for one-hundred percent
(100%) of Global R&D Costs for Global Development Activities for any such Regional Licensed Product that occur prior to the Global R&D Cost Opt-In Date, except for amounts specified in clauses (ii) and (iii) of
Section 2.3.1.2(c) below, if any. 
 (c) The Global R&D Costs to be shared by the Parties pursuant to Sections
2.3.1.2(a) and 2.3.1.2(b) above shall only include amounts that are within one or more of the following four (4) categories: 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 31 

 REGIONAL LICENSE TERMS 

 

 (i) [***]; 

(ii) [***]; 

(iii) [***] 

(iv) [***]. 

(d) For clarity, Global R&D Costs to be shared by the Parties pursuant to 2.3.1.2(a) and 2.3.1.2(b) shall exclude any
amounts paid after the Global R&D Cost Opt-In Date to Third Parties with respect to services rendered or materials procured in connection with the conduct of any Clinical Study or other Development activities, in either case, that is completed
prior to the Global R&D Cost Opt-In Date. 
 (e) Global R&D Costs for each Regional Licensed Product shall initially
be borne by the Party incurring the cost or expense. Each Party will calculate and maintain records of Global R&D Costs incurred by it and its Affiliates with respect to a Regional Licensed Product and, within [***] days following the end of
each Calendar Quarter, each Party shall submit to the other a report detailing the Global R&D Costs incurred by it and its Affiliates during such Calendar Quarter, and, if requested, reasonable supporting documentation will be provided (a
“Global R&D Costs Report”). In addition, each Party shall use good faith efforts to notify the other Party of any material Global R&D Costs incurred by such Party during such Calendar Quarter within [***] days after the end of such
Calendar Quarter. The Party that incurs more than its share of the total actual Global R&D Costs with respect to a Regional Licensed Product during any Calendar Quarter shall be paid by the other Party an amount of cash sufficient to reconcile
to its agreed percentage of Global R&D Costs for such Regional Licensed Product, which payment shall be made within [***] days after delivery of the Global R&D Cost Reports for such Calendar Quarter. Notwithstanding the foregoing, if
following receipt of a Global R&D Costs Report a Party (the “Disputing Party”) disputes any Global R&D Costs under such Global R&D Costs Report, it shall have [***] days to notify the other Party (the “Non-Disputing
Party”). Upon receiving such notice from the Disputing Party, the Non-Disputing Party shall, at the reasonable request of the Disputing Party, provide to the Disputing Party supporting documentation relating to any such disputed Global R&D
Costs. The Parties agree to use reasonable efforts to resolve any such dispute as soon as reasonably practicable, and any undisputed portion of Global R&D Costs in such Global R&D Costs Report shall be paid within [***] days after delivery
of such Global R&D Costs Report. Once the Parties have resolved such dispute, any disputed amounts still owed by either Party will be paid within [***] days of resolution of such dispute. 

(f) [***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 32 

 REGIONAL LICENSE TERMS 

 

 (g) Notwithstanding anything to the contrary in these Regional License Terms,
the Parties shall not share Global R&D Costs incurred in a Calendar Year with respect to Global Development Activities for a Regional Licensed Product to the extent such Global R&D Costs exceed [***] of the amounts included in the final
[***] Budget that was applicable to such Current Calendar Year (the amount in excess of such [***] limit is the “Excess Global R&D Costs”). One hundred percent (100%) of any Excess Global R&D Costs for such Regional
Licensed Product will be borne by the Party that incurred such Excess Global R&D Costs. 
 2.3.2. Genzyme Development. Except with
respect to Global R&D Costs (which shall be shared by the Parties in accordance with Section 2.3.1.2 (Global R&D Costs)), Genzyme shall be responsible for one hundred percent (100%) of all costs and expenses incurred with respect
to Development activities that are conducted by Genzyme pursuant to any Genzyme Territory Development Plan. Genzyme will conduct all Development of each Regional Licensed Product for the Genzyme Territory solely in accordance with the applicable
Global Development Plan and Genzyme Territory Development Plan, as such Global Development Plan and Genzyme Territory Development Plan may be amended in accordance with these Regional License Terms, and in sound scientific manner and in compliance
with applicable Law. 
 2.3.3. Alnylam Development. Except with respect to Global R&D Costs (which shall be shared by the Parties
in accordance with Section 2.3.1.2 (Global R&D Costs)), Alnylam shall be responsible for one hundred percent (100%) of all costs and expenses incurred with respect to Development activities that are conducted by Alnylam pursuant to any
Alnylam Territory Development Plan. Alnylam will conduct all Development of each Regional Licensed Product for the Alnylam Territory solely in accordance with the applicable Global Development Plan and Alnylam Territory Development Plan, as such
Global Development Plan and Alnylam Territory Development Plan may be amended in accordance with these Regional License Terms, and in sound scientific manner and in compliance with applicable Law. 

2.4. Diligence. 

2.4.1. Genzyme Diligence. With respect to each Regional Licensed Product, Genzyme will use Commercially Reasonable Efforts to [***].

 2.4.2. Alnylam Diligence. With respect to each Regional Licensed Product, Alnylam will use Commercially Reasonable Efforts to
(a) Develop such Regional Licensed Product and obtain Regulatory Approval therefor by the FDA in the U.S. or by the EMA in the European Union; (b) perform the Global Development Activities allocated to it under the Global Development Plan
for such Regional Licensed Product; and (c) perform the Development activities set forth in the Alnylam Territory Development Plan for such Regional Licensed Product, as such Alnylam Territory Development Plan may be amended in accordance with
these Regional License Terms. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 33 

 REGIONAL LICENSE TERMS 

 

 2.5. Records; Reports; Information Sharing. 

2.5.1. Development Activities Reports. Each Party will periodically provide to the PJSC responsible for a Regional Licensed Product, but
in no event less than on a Calendar Quarter basis, or more frequently as reasonably requested by the other Party, an update regarding Development activities conducted by or on behalf of such Party with respect to such Regional Licensed Product, as
well as any Secondary Indication Studies and Post-Marketing Studies conducted by or on behalf of such Party with respect to such Regional Licensed Product. The Parties will periodically report to the PJSC responsible for a Regional Licensed Product,
but in no event less than on a Calendar Quarter basis, regarding their respective activities conducted under the Global Development Plan for such Regional Licensed Product. In addition, each Party will promptly share with the other Party all
material developments and information that it comes to possess relating to the Development of any Regional Licensed Products, including Safety Concerns and study reports and data generated from Clinical Studies of such Regional Licensed Product.

 2.5.2. Scientific Records. Each Party will maintain scientific records, in sufficient detail and in sound scientific manner
appropriate for patent and regulatory purposes, which will fully and properly reflect all work done and results achieved in the performance of the Development activities and Secondary Indication Studies with respect to Regional Licensed Products by
such Party. 
 2.5.3. Information Exchange and Development Assistance. Until the expiration or termination of the final Global
Development Plan, upon the reasonable request of the other Party, each Party shall provide to the other Party, without additional compensation (except as provided in Section 6.5 of the Master Agreement (Transfer of Manufacturing Know-How)) and
in a commercially reasonable format, Know-How Controlled by such Party and/or its Related Parties that is licensed to the other Party under these Regional License Terms (i.e. Know-How included in Genzyme Technology for Genzyme and Know-How included
in Alnylam Technology for Alnylam) to the extent that it is reasonably necessary or useful for Developing a Regional Licensed Product in the requesting Party’s Territory or for obtaining or maintaining Regulatory Approval for a Regional
Licensed Product in the requesting Party’s Territory, including copies of (a) all scientific information and data related to such Regional Licensed Product (including all data made, collected or otherwise generated in the conduct of any
pre-clinical studies, Clinical Studies, Secondary Indication Studies or early access/named patient programs for the Regional Licensed Products, as well as CMC information), and (b) protocols and investigator brochures, in each case, that are
reasonably necessary for the other Party (or its Related Parties) to perform its obligations or exploit its rights under these Regional License Terms with respect to such Regional Licensed Product. Notwithstanding the foregoing, Genzyme shall have
no obligation to transfer or disclose to Alnylam any Know-How included in the Genzyme Manufacturing IP; provided, however, that if Genzyme elects, in its sole discretion, to transfer or disclose any such Know-How to Alnylam in writing,
it shall be “Genzyme Disclosed Manufacturing Know-How” under these Regional License Terms and licensed to Alnylam in accordance with Section 6.2.3 (License to Genzyme Disclosed Manufacturing Know-How). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 34 

 REGIONAL LICENSE TERMS 

 

 2.5.4. Personnel. Each Party may request, through the PJSC or the other Party’s
RLP Alliance Manager responsible for a Regional Licensed Product, that the other Party reasonably make available for consultation regarding the Development of such Regional Licensed Product certain of its employees engaged in Development activities
and Secondary Indication Studies with respect to such Regional Licensed Product. The PJSC or the RLP Alliance Managers responsible for a Regional Licensed Product will reasonably coordinate, upon reasonable notice during normal business hours and at
their respective places of employment, consultation between the Parties on the progress of the Development and Secondary Indication Studies for such Regional Licensed Product. 

2.5.5. Confidentiality. All information exchanged by the Parties under this Section 2.5 will be deemed to be Confidential
Information of the disclosing Party and maintained in accordance with Section 7 of the Master Agreement (Confidentiality and Publication). 

2.6. Third Parties. 

2.6.1. The Parties shall be entitled to utilize the services of Third Parties to perform their respective Development and Manufacturing
activities under these Regional License Terms, provided that (a) each Party shall require that such Third Party operates in a manner consistent with these Regional License Terms, (b) each Party shall remain at all times fully liable
for its respective responsibilities and (c) the Parties will make reasonable efforts to share, through the PJSC, information regarding any prior experience with specific CROs that are anticipated to be engaged to perform work under the Global
Development Plan. Each Party shall require that any Third Party agreement entered into pursuant to this Section 2.6.1 include confidentiality and non-use provisions that are no less stringent than those set forth in Section 7 of the Master
Agreement (Confidentiality and Publication) and shall obtain ownership of, and/or a fully sublicensable license under and to, any Know-How and Patent Rights that are developed by such Third Party in the performance of such agreement and are
reasonably necessary or useful to Develop, Manufacture and/or Commercialize Regional Licensed Products in the Field. The Party utilizing the services of a Third Party service provider shall be solely responsible for direction of and communications
with such Third Party, but such Party shall provide the other Party with reasonably detailed updates regarding any such activities from time to time. 

2.6.2. [***]. 
 3.
REGULATORY MATTERS 
 3.1. Regulatory Filings and Interactions. 

3.1.1. Responsibilities. 

3.1.1.1. Pursuant to the Global Development Plan for a Regional Licensed Product and, except as otherwise provided in
such Global Development Plan, except as otherwise set forth in Sections 3.1.1.2 and 3.2 (EMA Regulatory Strategy) below, each Party will be solely responsible for all regulatory matters relating to such Regional Licensed Product in its Territory and
will own all INDs, NDAs and related regulatory documents submitted to the applicable Regulatory 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 35 

 REGIONAL LICENSE TERMS 

 

 
Authorities in its Territory with respect to such Regional Licensed Product, excluding any drug master files maintained by or on behalf of Alnylam, which shall be and remain Alnylam’s sole
responsibility. Notwithstanding the foregoing, the Parties acknowledge that Alnylam shall continue to own all INDs, NDAs and related regulatory documents for ALN-TTR02 in the Genzyme Territory and the provisions of this Section 3.1.1 and
Section 3.1.3 (Regulatory Meetings) shall not apply. Within [***] days after the Implementation Date for ALN-TTR02, the Parties will agree to such other arrangements as are appropriate for such regulatory documents. At Genzyme’s request,
following the Implementation Date for a Regional License Product other than ALN-TTR02, Alnylam will promptly assign and transfer to Genzyme all INDs, NDAs and other regulatory documentation submitted to any Regulatory Authority in the Genzyme
Territory with respect to such Regional Licensed Product that is in the possession and control of Alnylam, and each Party will submit to the applicable Regulatory Authority all filings, letters and other documentation necessary to effect such
assignment and transfer no later than [***] days after such request for such Regional Licensed Product, in each case, excluding any drug master files maintained by or on behalf of Alnylam. Each Party will have the sole right to (i) oversee,
monitor and coordinate all regulatory actions, communications and filings with, and submissions to, each Regulatory Authority in its Territory with respect to such Regional Licensed Product; (ii) interface, correspond and meet with each
Regulatory Authority in its Territory with respect to such Regional Licensed Product, and (iii) seek and maintain all regulatory filings in its Territory with respect to such Regional Licensed Product. 

3.1.1.2. Notwithstanding the foregoing, for every Clinical Study conducted under a Global Development Plan, Alnylam will
draft the protocol, develop the IND strategy, and file INDs globally, including in the Genzyme Territory, after input and review by Genzyme, and Alnylam will use reasonable efforts to address any concerns raised by Genzyme in connection with such
activities. Unless otherwise agreed by the Parties, on a country-by-country basis, following the acceptance or approval of the IND and the first dosing of the first patient in the first Phase III Study of the relevant Regional Licensed Product in
such country, as set forth in Section 3.1.1.1 above, Alnylam will assign the IND in such country in the Genzyme Territory to Genzyme and from that point forward, Genzyme will be primarily responsible for the related regulatory activities with
respect thereto in its Territory. [***] 
 3.1.2. Communications. Each Party will notify the PJSC responsible for each Regional
Licensed Product in writing, including a brief description in English, of the principal issues raised in each material communication with Regulatory Authorities with respect to such Regional Licensed Product within [***] days after receipt thereof.
Upon request, each Party will provide to the other Party: (a) at the providing Party’s expense, a summary translation of such material communications in English, (b) at the providing Party’s expense, complete copies of the

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 36 

 REGIONAL LICENSE TERMS 

 

 
original correspondence in their native language, or (c) at the requesting Party’s expense, a full translation of such material communications in English, in each case (a) through
(c) within a reasonable period of time following such request. For the purposes of this Section 3.1, “material communications” with Regulatory Authorities include meetings with Regulatory Authorities and Regulatory Authority
questions or concerns with respect to significant issues, including any of the following: key product quality attributes (e.g., purity), safety findings affecting the platform (e.g., Serious Adverse Events, emerging safety signals),
clinical or nonclinical findings affecting patient safety, lack of efficacy or receipt or denial of Regulatory Approval. 
 3.1.3.
Regulatory Meetings. Each Party shall provide the other Party with reasonable advance notice of all substantive meetings with the Government Authorities in its Territory pertaining to each Regional Licensed Product, and Alnylam shall provide
Genzyme with reasonable advance notice of all substantive meetings with the Governmental Authorities in the Genzyme Territory pertaining to each Regional Licensed Product, or with as much advance notice as practicable under the circumstances. Each
Party shall use reasonable efforts, to the extent reasonably practicable, to permit the other Party to have, at the other Party’s expense, mutually acceptable representatives of the other Party to attend, solely as a non-participating observer,
material, substantive meetings, including pre-IND and end of Phase II Study meetings, with the Governmental Authorities within such Party’s Territory pertaining to such Regional Licensed Product; provided, however, that neither
Party shall be obligated to change the schedule of such a meeting in order to accommodate the schedule of the other Party’s representatives. Prior to the acceptance or approval of the IND and the first dosing of the first patient in the first
Phase III Study of a Regional Licensed Product by Alnylam in a country in the Genzyme Territory, Alnylam shall provide Genzyme with reasonable advance notice of all substantive meetings with Regulatory Authorities in the Genzyme Territory pertaining
to such Regional Licensed Product, or with as much advance notice as practicable under the circumstances. Alnylam shall use reasonable efforts, to the extent reasonably practicable, to permit Genzyme to have, at Genzyme’s expense, mutually
acceptable representatives of Genzyme to attend, as full and equal participants, material, substantive meetings, including pre-IND and end of Phase II Study meetings, with Regulatory Authorities in the Genzyme Territory pertaining to such Regional
Licensed Product. 
 3.1.4. Submissions. Each Party shall provide the other Party with written notice of each of the following events
with regard to each Regional Licensed Product within a reasonable period of time following the occurrence thereof, to the extent notice was not provided prior to the Implementation Date for such Regional Licensed Product: (a) the filing of any
IND for such Regional Licensed Product; (b) the submission of any filings or applications for Regulatory Approval (including orphan drug applications and designations) of such Regional Licensed Product in such Party’s Territory to any
Regulatory Authority and (c) receipt or denial of Regulatory Approval for such Regional Licensed Product obtained or denied; provided, however, that in all circumstances, each Party shall inform the other Party of such event prior
to public disclosure of such event by such Party. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 37 

 REGIONAL LICENSE TERMS 

 

 3.2. EMA Regulatory Strategy. Within [***] before the anticipated MAA filing
for a Regional Licensed Product, the PJSC will determine an EMA regulatory strategy for such Regional Licensed Product pursuant to which the PJSC will determine (a) whether Alnylam will seek Regulatory Approval for such Regional Licensed
Product in the EU using the EMA centralized or a national authorization procedure and (b) whether Genzyme will file a duplicate license with respect to any MAA held by Alnylam in the Alnylam Territory [***]. In determining the EMA regulatory
strategy, the Parties agree to reasonably consider in good faith each Party’s interests. In the event that Genzyme files a duplicate license in the Genzyme Territory, Alnylam will coordinate communications with EMA, and provide support to
enable Genzyme to efficiently obtain such duplicate license to provide for marketing in Genzyme countries under a separate, Genzyme trade name, to the extent not inconsistent with the Global Branding Strategy for such Regional Licensed Product. 

3.3. Costs of Regulatory Affairs. Except as provided in Section 2.3 (Responsibilities for Development Activities and Costs)
and Section 3.1.1.2, each Party shall be responsible for all costs and expenses incurred in connection with applying for, obtaining and maintaining Regulatory Approval with respect to Regional Licensed Products in its Territory, and related
regulatory affairs activities. 
 3.4. Right of Reference. Each Party hereby grants to the other Party, and at the request of
the other Party will grant to the other Party’s Related Parties, a “Right of Reference,” as that term is defined in 21 C.F.R. § 314.3(b) (or any successor rule or analogous Law recognized outside of the United States), to, and a
right to copy, access, and otherwise use, all information and data (including all CMC information as well as data made, collected or otherwise generated in the conduct of any Clinical Studies or Secondary Indication Studies or early access/named
patient programs for the Regional Licensed Products) included in or used in support of any regulatory filing, Regulatory Approval, drug master file or other regulatory documentation (including orphan drug applications and designations) owned or
controlled by such Party or its Related Parties that relates to (a) any Regional Licensed Product or (b) with respect to such information and data provided to Genzyme, the siRNA Controlled by Alnylam and known as ALN-TTR01, to the extent
necessary or useful to obtain Regulatory Approval of a Regional Licensed Product in the Genzyme Territory, and such Party shall provide a signed statement to this effect, if requested by the other Party, in accordance with 21 C.F.R. §
314.50(g)(3) (or any successor or analogous Law outside of the United States). In addition, upon request of either Party (on behalf of itself or a Sublicensee), the other Party shall obtain and provide to the requesting Party certificates or other
formal or official attestations concerning the regulatory status of the Regional Licensed Products in the Genzyme Territory or the Alnylam Territory, as applicable (e.g., Certificates of Free Sale, Certificates for Export, Certificates to Foreign
Governments). Notwithstanding anything to the contrary in these Regional License Terms, neither Party shall withdraw or inactivate any regulatory filing that the other Party references or otherwise uses pursuant to this Section 3.4. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 38 

 REGIONAL LICENSE TERMS 

 

 4. COMMERCIALIZATION OF THE LICENSED PRODUCTS 

4.1. Responsibility, Cost and Diligence. 

4.1.1. Genzyme. Genzyme shall be solely responsible, at its expense, for all Commercialization activities relating to Regional Licensed
Products in the Field in the Genzyme Territory. [***]. 
 4.1.2. Alnylam. Alnylam shall be solely responsible, at its expense, for all
Commercialization activities relating to Regional Licensed Products in the Field in the Alnylam Territory. 
 4.1.3. Joint
Commercialization. In the event that the Parties mutually agree to conduct any joint Commercialization activities regarding a Regional Licensed Product, the Parties will (a) agree in writing to a written work plan and time table for
conducting such activities; (b) agree in writing to management and governance mechanisms for such joint activities, including coordination of such activities through the PJSC responsible for such Regional Licensed Product; and
(c) negotiate in good faith a budget therefor and an equitable allocation of costs between the Parties. At either Party’s request, the Parties will start discussion regarding beneficial joint Commercialization activities [***] years prior
to the anticipated First Commercial Sale of the Regional Licensed Product, with any agreement to be preferably finalized not less than [***] years prior to the anticipated First Commercial Sale of the Regional Licensed Product. 

4.2. Global Commercial Strategy. Within [***] days after the Implementation Date for a Regional Licensed Product, Alnylam shall
provide and within [***] days after provision the PJSC shall review, update and approve a written summary of the global Commercial strategy for such Regional Licensed Product (the “Global Commercial Strategy”). 

4.3. Genzyme Territory Commercialization Plan. No less than [***] months in advance of the reasonably expected first Regulatory
Approval in the Genzyme Territory with respect to a Regional Licensed Product, and on an annual basis thereafter, Genzyme shall prepare and deliver to the PJSC responsible for such Regional Licensed Product for review a reasonable written plan that
summarizes the Commercialization activities to be undertaken with respect to such Regional Licensed Product in the Genzyme Territory in the next Calendar Year and, to the extent commercially reasonable, Genzyme’s plans to obtain further
Regulatory Approvals and Commercialize such Regional Licensed Product in countries in the Genzyme Territory in which Genzyme is not then Commercializing such Regional Licensed Product, and the dates by which such activities are targeted to be
accomplished (the “Genzyme Territory Commercialization Plan”). Each Genzyme Territory Commercialization Plan shall be consistent with the requirements of the initial Global Commercialization Strategy or the most recently approved by
the PJSC[***]. The Genzyme Territory Commercialization Plan for a Regional Licensed Product shall subsequently be updated and modified by Genzyme, from time to time at its discretion and no less frequently than once per Calendar Year, based upon,
among other things, Genzyme’s Commercialization activities with respect to such Regional Licensed Product in the Genzyme Territory, a copy of which updated plan Genzyme will provide to the PJSC responsible for such Regional Licensed Product.
[***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 39 

 REGIONAL LICENSE TERMS 

 

 4.4. Alnylam Territory Commercialization Plan. No less than [***] months in
advance of the reasonably expected first Regulatory Approval in the Alnylam Territory with respect to a Regional Licensed Product, and on an annual basis thereafter, Alnylam shall prepare and deliver to the PJSC responsible for such Regional
Licensed Product for review a reasonable written plan that summarizes the Commercialization activities to be undertaken with respect to such Regional Licensed Product in the Alnylam Territory in the next Calendar Year and, to the extent commercially
reasonable, Alnylam’s plans to obtain further Regulatory Approvals and Commercialize such Regional Licensed Product in countries in the Alnylam Territory in which Alnylam is not then Commercializing such Regional Licensed Product, and the dates
by which such activities are targeted to be accomplished (the “Alnylam Territory Commercialization Plan”). The Alnylam Territory Commercialization Plan shall at all times remain consistent with the Global Commercialization Strategy.
The Alnylam Territory Commercialization Plan for a Regional Licensed Product shall subsequently be updated and modified by Alnylam, from time to time at its discretion and no less frequently than once per Calendar Year, based upon, among other
things, Alnylam’s Commercialization activities with respect to such Regional Licensed Product in the Alnylam Territory, a copy of which updated plan Alnylam will provide to the PJSC responsible for such Regional Licensed Product. [***]. 

4.5. Advertising and Promotional Materials. 

4.5.1. Global Branding. Alnylam shall have the right, from time to time during the Term, to develop (and thereafter modify and update) a
global branding strategy (including global positioning, colors and other visual branding elements) for each Regional Licensed Product for use in the Field throughout the world (the “Global Branding Strategy”), which the PJSC
responsible for such Regional Licensed Product shall, in accordance with Sections 5.5.2(b) (PJSC Commercialization Responsibilities) and 5.6 (PJSC Decision-Making), review and approve, and which the Parties shall, following such review and approval,
implement. Alnylam will submit the Global Branding Strategy for a Regional Licensed Product to the PJSC responsible for such Regional Licensed Product at least annually (or more frequently if reasonably requested by Genzyme). Alnylam shall consider
in good faith any timely comments Genzyme may have with respect to any Global Branding Strategy, but shall have final decision-making authority with respect to such Global Branding Strategy. Notwithstanding the foregoing, Alnylam shall ensure that
the Global Branding Strategy complies with applicable Laws in the Genzyme Territory, and that any branding elements selected for inclusion in the Global Branding Strategy do not infringe any Third Party trademarks or other intellectual property
rights. If any such Global Branding Strategy infringes Third Party trademarks or other intellectual property rights or otherwise does not comply with applicable Law in the Genzyme Territory, Alnylam shall take action to end such infringement or
other noncompliance (including by modifying such Global Branding Strategy) and Genzyme will not be obligated to implement such Global Branding Strategy in the Genzyme Territory pursuant to this Section 4.5.1 unless and until such infringement
or noncompliance is ended. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 40 

 REGIONAL LICENSE TERMS 

 

 4.5.2. Alnylam A&P. Alnylam will be responsible for the creation, preparation,
production, reproduction and filing with the applicable Regulatory Authorities, of relevant written sales, promotion and advertising materials relating to each Regional Licensed Product (“Promotional Materials”) for use in the
Alnylam Territory. All such Promotional Materials will be compliant with applicable Law and, if applicable, consistent in all material respects with the Global Branding Strategy for such Regional Licensed Product. Alnylam will submit representative
samples of its Promotional Materials developed by it for use in the Alnylam Territory to the PJSC, at least annually (or more frequently if reasonably requested by Genzyme). Alnylam shall consider in good faith any timely comments Genzyme may have
with respect to any such Promotional Materials, but shall have final decision-making authority with respect to such Promotional Materials. Notwithstanding the foregoing, Alnylam will incorporate any changes to Promotional Materials requested by
Genzyme in a timely fashion in cases where Genzyme indicates that believes in good faith based on the advice of counsel that such change is necessary to enable it to comply with any applicable Law. 

4.5.3. Genzyme A&P. Genzyme will be responsible for the creation, preparation, production, reproduction and filing with the
applicable Regulatory Authorities, of relevant Promotional Materials relating to each Regional Licensed Product for use in the Genzyme Territory. All such Promotional Materials will be compliant with applicable Law, consistent in all material
respects with the Genzyme Territory Commercialization Plan and, if applicable, consistent in all material respects with the Global Branding Strategy for such Regional Licensed Product in the Genzyme Territory. Genzyme will submit representative
samples of its Promotional Materials developed by it for use in the Genzyme Territory to the PJSC at least annually thereafter (or more frequently if reasonably requested by Alnylam). Genzyme shall consider in good faith any timely comments Alnylam
may have with respect to any such Promotional Materials, but shall have final decision-making authority in the Genzyme Territory with respect to such Promotional Materials. 

4.5.4. Reporting Obligations. Genzyme shall report to the PJSC responsible for a Regional Licensed Product in writing, by no later than
each [***] following the first Regulatory Approval of such Regional Licensed Product in the Field in the Genzyme Territory (for the period ending December 31 of the prior Calendar Year), summarizing in reasonable detail Genzyme’s
Commercialization activities for such Regional Licensed Product performed to date (or updating such report for activities performed since the last such report was given hereunder, as applicable). In addition, Genzyme shall provide Alnylam with
written notice of the First Commercial Sale of each Regional Licensed Product in the Genzyme Territory within [***] days after such event; provided, however, that in all circumstances, Genzyme shall inform Alnylam of such event prior
to public disclosure of such event by Genzyme. Each Party shall provide such other information to the PJSC responsible for a Regional Licensed Product as the other Party may reasonably request with respect to Commercialization of such Regional
Licensed Product and shall keep such PJSC reasonably informed of such Party’s Commercialization activities with respect to such Regional Licensed Product. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 41 

 REGIONAL LICENSE TERMS 

 

 4.6. Commercialization Reporting Obligations. Each Party and its Related
Parties shall be responsible for booking sales in its Territory. Each Party and its Related Parties may warehouse Regional Licensed Products both inside and outside of such Party’s Territory, provided that any sales with respect to such
Regional Licensed Products are booked in such Party’s Territory. If a Party receives any orders for any Regional Licensed Product in the other Party’s Territory, it shall refer such orders to the other Party, to the extent it is not
prohibited from doing so under applicable Law. Moreover, each Party and its Related Parties shall be solely responsible for handling all returns of any Regional Licensed Product sold in its Territory, as well as all aspects of Regional Licensed
Product order processing, invoicing and collection, distribution, inventory and receivables of Regional Licensed Products sold in its Territory. 

4.7. Recalls, Market Withdrawals or Corrective Actions. In the event that any Regulatory Authority issues or requests a recall or
takes a similar action in connection with a Regional Licensed Product in a Territory, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall or market withdrawal of a
Regional Licensed Product in its Territory, the Party notified of such recall or similar action, or the Party that desires such recall or similar action, shall within [***] hours notify the other Party’s RLP Alliance Manager and PJSC
representatives thereof by telephone or e-mail. Each Party, in consultation with the other Party, shall decide whether to conduct a recall of a Regional Licensed Product in its own Territory and the manner in which any such recall shall be conducted
(except in the case of a government mandated recall, when such Party may act without such advance notice but shall notify the other Party as soon as possible). Except as may otherwise be agreed to by the Parties, each Party shall bear the expense of
any such recall in its own Territory. Each Party will make available all of its pertinent records that may be reasonably requested by the other Party in order to effect a recall of a Regional Licensed Product in the other Party’s Territory. The
Parties’ rights and obligations under this Section 4.7 shall be subject to the terms of any supply agreement(s) entered into between the Parties. In the event of a conflict between the provisions of any such supply agreement and this
Section 4.7, the provisions of such supply agreement shall govern. 
 4.8. [***] 

4.8.1. [***] 
 4.8.2.
[***]. 
 5. COLLABORATION MANAGEMENT 

5.1. Product Joint Steering Committee. The Parties shall establish a product joint steering committee (a “PJSC”)
to facilitate the RLP Collaboration with respect to each Regional Licensed Product as follows: 
 5.1.1. Composition of the Product Joint
Steering Committee. The Development and Commercialization of each Regional Licensed Product pursuant to the RLP Collaboration will be conducted under the oversight of a PJSC, which shall comprise three
(3)

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 42 

 REGIONAL LICENSE TERMS 

 

 
representatives of each Party. The PJSC for ALN-TTR02 shall be established as of the Effective Date. Each Party shall appoint its respective representatives to the PJSC for each other Regional
Licensed Product from time to time following the Implementation Date for such Regional Licensed Product, and may substitute one or more of its representatives on any PJSC, in its sole discretion, effective upon notice to the other Party of such
change. Each Party shall have at least one representative on each PJSC who is a senior employee (vice president level or above), and all representatives on each PJSC shall have appropriate expertise, seniority, decision-making authority and ongoing
familiarity with the RLP Collaboration and the applicable Regional Licensed Product. For the avoidance of doubt, the same representatives from each Party may serve on the PJSC for more than one Regional Licensed Product. Unless otherwise agreed by
the Parties, each Party’s representatives on any PJSC must be employees of such Party. Additional representatives or consultants may from time to time, by mutual consent of the Parties, be invited to attend PJSC meetings, subject to such
representatives and consultants undertaking confidentiality obligations, whether in a written agreement or by operation of law, no less stringent than the requirements of Section 7 of the Master Agreement (Confidentiality and Publication). 

5.1.2. PJSC Chairperson. The chairperson of each PJSC shall rotate every twelve (12) months between a PJSC representative of
Alnylam and a PJSC representative of Genzyme. The initial chairperson of each PJSC shall be a representative of Alnylam. Each PJSC chairperson’s responsibilities shall include chairing meetings, including ensuring that objectives for each
meeting are set and achieved. 
 5.2. Appointment of Subcommittees, Project Teams and RLP Alliance Managers. Each PJSC shall be
empowered to create such subcommittees and project teams as it may deem appropriate or necessary, such as for specific oversight of Development, Manufacturing, Commercialization or intellectual property issues relating to the Regional Licensed
Product for which such PJSC is responsible. Each such project team created by a PJSC shall report to such PJSC, which shall have authority to approve or reject recommendations or actions proposed by such project team, subject to these Regional
License Terms. For the avoidance of doubt, the same representatives from each Party may serve on the project team for more than one Regional Licensed Product. Each Party will designate an alliance manager for each Regional Licensed Product (each, a
“RLP Alliance Manager”) to serve as a primary point of contact for the other Party with respect to all activities under the RLP Collaboration related to such Regional Licensed Product. Each RLP Alliance Manager’s
responsibilities shall include (a) scheduling meetings of the PJSC at least once per Calendar Quarter, but more frequently if the PJSC determines it necessary; (b) setting agendas for PJSC meetings with solicited input from the RLP
Alliance Manager for the other Party and other members of the PJSC; and (c) coordinating the delivery of draft minutes to the PJSC for review and final approval. Beginning with Alnylam’s RLP Alliance Manager, such responsibilities shall
alternate between the RLP Alliance Managers from each Party on a meeting-by-meeting basis after each meeting of the applicable committee. Each Party may change any of its RLP Alliance Managers at any time in its sole discretion with written notice
to the other Party, provided that each RLP Alliance Manager will be individually identified at all times and will have such experience, authority, responsibility and accountability as is reasonably sufficient to enable such person to fulfill
his or her responsibilities as a RLP Alliance Manager under these Regional License Terms on behalf of the applicable Party. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 43 

 REGIONAL LICENSE TERMS 

 

 5.3. PJSC Meetings. Each PJSC shall meet in accordance with a schedule
established by mutual written agreement of the Parties, but no less frequently than once per Calendar Quarter during the Term, with the location for such meetings alternating between Alnylam and Genzyme facilities (or such other locations as are
mutually agreed by the Parties). Alternatively, a PJSC may meet by means of teleconference, videoconference or other similar communications equipment, but at least two (2) meetings of such PJSC per Calendar Year shall be conducted in person.
All proceedings for each PJSC shall take place in English. Where the membership of a PJSC for a Regional Licensed Product is the same as one or more other PJSCs for other Regional Licensed Product(s), such PJSCs may have a single meeting to discuss
each Regional Licensed Product for which they have responsibility. Each Party shall bear its own expenses relating to attendance at such meetings by its representatives. 

5.4. PJSC Minutes. A RLP Alliance Manager shall be appointed secretary for each meeting of each PJSC and shall prepare minutes of
the meeting, which shall provide a description in reasonable detail of the discussions held at the meeting and a list of any actions, decisions or determinations approved by such PJSC. Within [***] days after each meeting, the drafting RLP Alliance
Manager shall provide the draft minutes to the other RLP Alliance Manager for review and comment. The drafting RLP Alliance Manager shall reasonably consider all comments from the other RLP Alliance Manager within [***] days. The drafting RLP
Alliance Manager shall prepare and submit revised minutes within [***] days after receipt of such comments or upon expiration of such [***] day period. 

5.5. PJSC Responsibilities. 

5.5.1. PJSC Development Responsibilities. Each PJSC shall have the following responsibilities with respect to the Development of the
Regional Licensed Product for which it is responsible: 
 (a) developing and approving updates and amendments to the Global
Development Strategy for such Regional Licensed Product in accordance with Section 2.2.1 (Global Development Strategy); 

(b) developing and approving updates and amendments to the Global Development Plan for such Regional Licensed Product in
accordance with Section 2.2.2.3 (Managing and Amending Global Development Plans and Global Development Budgets); 
 (c)
reviewing and approving the initial Genzyme Territory Development Plan and the initial Alnylam Territory Development Plan for such Regional Licensed Product in accordance with Sections 2.2.3 (Alnylam Territory Development Plan) and 2.2.4 (Genzyme
Territory Development Plan); 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 44 

 REGIONAL LICENSE TERMS 

 

 (d) reviewing and discussing updates and amendments to the Genzyme Territory
Development Plan and the Alnylam Territory Development Plan for such Regional Licensed Product in accordance with Sections 2.2.3 (Alnylam Territory Development Plan) and 2.2.4 (Genzyme Territory Development Plan), and providing each Party with
feedback regarding the same; 
 (e) reviewing and discussing updates provided by each Party regarding the Development of such
Regional Licensed Product in such Party’s Territory in accordance with Section 2.5.1 (Development Activities Reports), and providing each Party with feedback regarding the same; 

(f) monitoring and coordinating Development activities in the Genzyme Territory and the Alnylam Territory for such Regional
Licensed Product, and regulatory and pharmacovigilance requirements and matters; 
 (g) reviewing and discussing updates
provided by each Party regarding any Global Development Activities in accordance with the Global Development Plan for such Regional Licensed Product (including the Global Development Budget); 

(h) approving a global list of clinical sites for each Global Clinical Study for such Regional Licensed Product; 

(i) approving the appointment of the global CRO to manage any Phase II Study or Phase III Study for such Regional Licensed
Product; 
 (j) overseeing any manufacturing and supply relationship between the Parties with respect to the Manufacture of
such Regional Licensed Product for Development activities (subject to the provisions of the RLP Clinical Supply Agreement, if any); and 

(k) performing such other activities as the Parties agree in writing shall be the responsibility of such PJSC or that are
otherwise assigned to such PJSC under these Regional License Terms. 
 5.5.2. PJSC Commercialization Responsibilities. Each PJSC shall
have the following responsibilities with respect to the Commercialization of the Regional Licensed Product for which it is responsible, to the extent permissible under applicable Laws: 

(a) reviewing and discussing reports and information provided by each Party regarding the Commercialization of such Regional
Licensed Product in such Party’s Territory in accordance with Section 4.6 (Commercialization Reporting Obligations); 

(b) reviewing and approving, any Global Branding Strategy developed by Alnylam for such Regional Licensed Product in accordance
with Section 4.5.1 (Global Branding); 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 45 

 REGIONAL LICENSE TERMS 

 

 (c) reviewing and discussing the Genzyme Territory Commercialization Plan for
such Regional Licensed Product and updates thereto provided by Genzyme pursuant to Section 4.3 (Genzyme Territory Commercialization Plan); 

(d) reviewing and discussing Promotional Material for such Regional Licensed Product of both Parties in accordance with
Sections 4.5.2 (–Alnylam A&P) and 4.5.3 (–Genzyme A&P); 
 (e) providing a forum for the Parties to discuss
the Commercialization of such Regional Licensed Product in the Field worldwide, including coordination regarding Regional Licensed Product positioning and messaging, key opinion leader relationship management, medical affairs, and marketing and
selling materials; 
 (f) providing a forum for the Parties to discuss collaborating on commercial activities with respect to
such Regional Licensed Product that can be leveraged for both Parties’ respective Territories and how the Parties would share the costs of such mutually agreed joint Commercialization activities; 

(g) overseeing any manufacturing and supply relationship between the Parties with respect to the Manufacture of such Regional
Licensed Product for Commercialization activities (subject to the provisions of the RLP Commercial Supply Agreement, if any); and 

(h) performing such other activities as the Parties agree in writing shall be the responsibility of such PJSC or that are
otherwise assigned to such PJSC under these Regional License Terms. 
 5.6. PJSC Decision-Making. 

5.6.1. PJSC Decisions. With respect to decisions of each PJSC, the representatives of each Party on such PJSC shall have
collectively one vote on behalf of such Party. For each meeting of a PJSC, at least two (2) representatives of each Party shall constitute a quorum. Action on any matter may be taken at a meeting, by teleconference, videoconference or by
written agreement. Each PJSC shall attempt to resolve any and all disputes before it for decision by consensus. For the avoidance of doubt, the phrase “approval by the PJSC” and similar phrases used in these Regional License Terms shall
mean approval in accordance with this Section 5.6 (PJSC Decision-Making), including [***]. 
 5.6.2. Escalation. If
a PJSC is unable to reach a consensus with respect to any dispute for a period in excess of [***] days, then the dispute shall be submitted to the AJSC (as defined in the Master Agreement) at a meeting or meetings (whether in-person or by
teleconference or videoconference). During such meeting(s), each Party shall provide analysis to support its position with respect to such dispute. If the dispute is still unresolved after a further [***] days, such dispute shall be [***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 46 

 REGIONAL LICENSE TERMS 

 

 5.6.3. [***]. If a dispute cannot be resolved under Section 5.6.2 (Escalation),
then, subject to Sections 5.6.4 [***] 
 5.6.3.1. [***] 

5.6.3.2. [***] 

5.6.3.3. [***] 

5.6.4. [***] 

5.6.4.1. [***] 

5.6.4.2. [***] 

5.6.5. [***] 

(i) [***] 

(ii) [***] 

(iii) [***] 

(iv) [***] 

(v) [***] 

5.7. Term of PJSC. With respect to each Regional Licensed Product, after the [***] anniversary of the Implementation Date for
such Regional Licensed Product, Alnylam shall have the right, but not the obligation, to continue its participation in the PJSC responsible for such Regional Licensed Product. 

5.8. Alnylam Third Party Partner. If, at any time during the Term, Alnylam enters into an agreement (a “Third Party
Collaboration Agreement”) with one or more Third Party(ies) (each, a “Third Party Partner”) to Develop and/or Commercialize any Regional Licensed Product in the Field in the Alnylam Territory, Alnylam shall ensure that such
agreement is consistent with these Regional License Terms. 
 5.8.1. Required Terms. Without limitation, Alnylam shall negotiate terms
in the Third Party Collaboration Agreement (a) regarding intellectual property necessary to permit Alnylam to license or sublicense to Genzyme any Patent Rights and Know-How developed in the course of activities pursuant to the Third Party
Collaboration Agreement that are necessary for Genzyme to Develop, Manufacture and Commercialize Regional Licensed Products in accordance with these Regional License Terms, if any; (b) providing Genzyme with a right of reference as set forth in
Section 3.4 (Right of Reference); (c) requiring such Third Party Partner to maintain records substantially as set forth in Section 2.5.2 (Scientific Records); (d) enabling 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 47 

 REGIONAL LICENSE TERMS 

 

 
Alnylam to provide Genzyme with copies of data and reports, including Clinical Study reports, in a commercially reasonable format, made, collected or otherwise generated by or on behalf of the
Third Party Partner in the conduct of any pre-clinical studies, Clinical Studies or early access/named patient programs for any Regional Licensed Products (excluding, for clarity, information generated in Secondary Indication Studies and CMC
information), and protocols and investigator brochures related to any Regional Licensed Product, in each case that are reasonably necessary for Genzyme (or its Related Parties) to Develop and obtain Regulatory Approval for the Regional Licensed
Products in the Genzyme Territory; (e) enabling Alnylam to provide Genzyme with information with respect to matters in the Third Party Partner’s territory as are required to be provided to Genzyme under Sections 2.5.1 (Development
Activities Reports), 3.1.2 (Communications) (to the extent requiring a brief description in English of principal issues raised in material communications from Regulatory Authorities and otherwise to the extent reasonably necessary to assist Genzyme
with obtaining Regulatory Approvals of Regional Licensed Products), and 3.1.4 (Submissions); (f) regarding pharmacovigilance that are consistent with Section 4.6 of the Master Agreement (Pharmacovigilance) and the SDEA; and
(g) regarding recalls that are consistent with Section 4.7 (Recalls, Market Withdrawals or Corrective Actions). 
 5.8.2.
[***]. 
 5.8.3. Global Coordination Committee. Alnylam shall use reasonable efforts to include in any Third Party Collaboration
Agreement relating to rights licensed to a Third Party Partner in the United States and/or major markets in Europe, the discretionary participation by such Third Party Partner with Genzyme and Alnylam in a global coordination committee, which shall
include representatives of Alnylam, Genzyme and the Third Party Partner and which shall be responsible for facilitating discussions between the parties with respect to the global Development, Manufacture and Commercialization of Regional Licensed
Products. 
 5.8.4. Notice. Alnylam shall promptly provide Genzyme with a copy of any fully executed Third Party Collaboration
Agreement, which may be redacted to remove provisions which are not necessary to monitor compliance with this Section 5.8 and such Third Party Collaboration Agreement will be deemed Alnylam Confidential Information for the purposes of
Section 7 of the Master Agreement (Confidentiality and Publication). 
 5.8.5. Sublicenses. If any Third Party Collaboration
Agreement grants the Third Party Partner a sublicense under the Genzyme Technology, Alnylam shall ensure that such Third Party Collaboration agreement complies with Section 6.2.4 (Sublicensing Terms). 

5.8.6. Breach; Responsibility. If Alnylam becomes aware of a material breach of the provisions of any Third Party Collaboration
Agreement by a Third Party Partner, compliance with which is necessary for Alnylam’s compliance with these Regional License Terms, Alnylam shall promptly notify Genzyme of the particulars of the same and use Commercially Reasonable Efforts to
cause the Third Party Partner to comply with all the provisions of the Third Party Collaboration Agreement necessary for Alnylam’s compliance with these Regional License Terms. Notwithstanding any Third Party Collaboration Agreement, Alnylam
shall remain primarily liable to Genzyme for the performance of all of Alnylam’s obligations under, and Alnylam’s compliance with all provisions of, these Regional License Terms with respect to the entire Alnylam Territory. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 48 

 REGIONAL LICENSE TERMS 

 

 6. LICENSES 

6.1. License Grants to Genzyme. 

6.1.1. Development License in the Genzyme Territory. On a Regional Licensed Product-by-Regional Licensed Product basis, subject to these
Regional License Terms (including Section 8.4.1.3(c) (Exclusivity)) and any RLP Clinical Supply Agreement, effective upon the Implementation Date for each Regional Licensed Product, Alnylam hereby grants Genzyme a non-transferable (except as
provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 6.1.4 (Sublicensing Terms)) exclusive (even as to Alnylam) license under Alnylam Technology to Develop such Regional Licensed Product in the
Field in the Genzyme Territory and the Alnylam Territory, in each case solely as and to the extent provided in any approved Genzyme Territory Development Plan or any Global Development Plan, and in each case, solely for Regulatory Approval and
Commercialization in the Genzyme Territory. Notwithstanding the foregoing, Alnylam retains (a) the exclusive right under the Alnylam Technology, with the right to grant licenses through multiple tiers without restriction, to Develop Regional
Licensed Products anywhere in the world for Regulatory Approval and Commercialization in the Alnylam Territory, and (b) the co-exclusive right (with Genzyme) to Develop each Regional Licensed Product anywhere in the world for Regulatory
Approval and Commercialization by Genzyme in the Genzyme Territory in accordance with the Global Development Plan for such Regional Licensed Product. 

6.1.2. Commercialization License in the Genzyme Territory. On a Regional Licensed Product-by-Regional Licensed Product basis, subject to
these Regional License Terms (including Section 8.4.1.3(c) (Exclusivity)) and any RLP Commercial Supply Agreement, effective upon the Implementation Date for each Regional Licensed Product, Alnylam hereby grants Genzyme a non-transferable
(except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 6.1.4 (Sublicensing Terms)) exclusive (even as to Alnylam) license under Alnylam Technology to Commercialize such Regional
Licensed Product in the Field in the Genzyme Territory. Such license shall be royalty-bearing for the Royalty Term applicable to each Regional Licensed Product in each country in the Genzyme Territory, and, after the Royalty Term applicable to such
Regional Licensed Product in such country, shall convert to a fully-paid perpetual exclusive license to Commercialize such Regional Licensed Product in the Field in such country. 

6.1.3. Manufacturing Licenses. On a Regional Licensed Product-by-Regional Licensed Product basis, subject to these Regional License
Terms (including Section 8.4.1.3(c)) and any RLP Clinical Supply Agreement and RLP Commercial Supply Agreement, effective upon the Implementation Date for each Regional Licensed Product, Alnylam hereby grants Genzyme a non-transferable (except
as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 6.1.4(Sublicensing Terms)), worldwide, exclusive (even as to Alnylam) license under Alnylam Technology to Manufacture

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 49 

 REGIONAL LICENSE TERMS 

 

 
such Regional Licensed Product inside or outside of the Genzyme Territory solely for Commercialization in the Genzyme Territory and, to the extent permitted pursuant to Section 2.3.2
(Genzyme Development), for Development for the Alnylam Territory. Notwithstanding the foregoing, Alnylam retains the exclusive right under the Alnylam Technology, with the right to grant licenses through multiple tiers without restriction, to
Manufacture Regional Licensed Products anywhere in the world (a) for Development and Commercialization in the Alnylam Territory and, to the extent permitted pursuant to Section 2 (Development Collaboration) for Development in the Genzyme
Territory, and (b) to supply (or have supplied to) Genzyme pursuant to the RLP Supply Agreements to be agreed by the Parties pursuant to Section 6.2 of the Master Agreement (Collaboration Product Supply Agreements). 

6.1.4. Sublicensing Terms. 

(a) Genzyme shall have the right to sublicense any of its rights under Sections 6.1.1 (Development License in the Genzyme
Territory), 6.1.2 (Commercialization License in the Genzyme Territory) and 6.1.3 (Manufacturing Licenses) to any of its Affiliates or to any Third Party (which sublicensed rights may be further sublicensable through multiple tiers) without the prior
consent of Alnylam, subject to the requirements of this Section 6.1.4. [***]. 
 (b) Each sublicense granted by Genzyme
pursuant to this Section 6.1.4 shall be subject and subordinate to these Regional License Terms and shall contain provisions consistent with those in these Regional License Terms. Genzyme shall promptly provide Alnylam with a copy of the fully
executed sublicense agreement covering any sublicense granted hereunder (which copy may be redacted to remove provisions which are not necessary to monitor compliance with this Section 6.1.4), and each such sublicense agreement shall contain
the following provisions: (i) a requirement that the Sublicensee comply with the confidentiality and non-use provisions of Section 7 of the Master Agreement (Confidentiality and Publication) with respect to Alnylam’s Confidential
Information, (ii) if such sublicense agreement contains a sublicense of Regional Licensed Product Commercialization rights, such sublicense agreement shall also contain the following provisions: (x) a requirement that the Sublicensee
submit applicable sales or other reports to Genzyme to the extent necessary or relevant to the reports required to be made or records required to be maintained under these Regional License Terms; and (y) the audit requirement set forth in
Section 9.2 of the Master Agreement (Audits); and (iii) a requirement that the Sublicensee comply with the applicable provisions under any Alnylam In-License. 

(c) If Genzyme becomes aware of a material breach of the provisions of any sublicense by any Genzyme Sublicensee, compliance
with which is necessary for Genzyme’s compliance with these Regional License Terms, Genzyme shall promptly notify Alnylam of the particulars of the same and use Commercially Reasonable Efforts to cause the Sublicensee to comply with all the
provisions of the sublicense necessary for Genzyme’s compliance with these Regional License Terms. [***]. Notwithstanding any sublicense, Genzyme shall remain primarily liable to Alnylam for the performance of all of Genzyme’s obligations
under, and Genzyme’s compliance with all provisions of, these Regional License Terms. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 50 

 REGIONAL LICENSE TERMS 

 

 6.2. License Grants to Alnylam. 

6.2.1. Commercialization License in the Alnylam Territory. Subject to these Regional License Terms, Genzyme hereby grants Alnylam a
non-transferable (except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 6.2.4 (Sublicensing Terms)), non-exclusive, royalty-free license under Genzyme Collaboration IP to Develop and
Commercialize Regional Licensed Products in the Field in the Alnylam Territory. 
 6.2.2. License to Improvement Manufacturing Patent
Rights. Subject to these Regional License Terms, Genzyme hereby grants Alnylam a non-transferable (except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 6.2.4 (Sublicensing Terms)),
worldwide, non-exclusive license under the Improvement Manufacturing Patent Rights, to Manufacture (a) Alnylam Developed siRNA Products targeting any human gene; and (b) Regional Licensed Products for Development and Commercialization in
the Alnylam Territory and, to the extent permitted pursuant to Section 2.3.3 (Alnylam Development), for Development in the Field in the Genzyme Territory. 

6.2.3. License to Genzyme Disclosed Manufacturing Know-How. Subject to these Regional License Terms, Genzyme hereby grants Alnylam a
non-transferable (except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 6.2.4 (Sublicensing Terms)), worldwide, non-exclusive license under the Genzyme Disclosed Manufacturing Know-How
to Manufacture Regional Licensed Products for Development and Commercialization in the Alnylam Territory and, to the extent permitted pursuant to Section 2.3.3 (Alnylam Development), for Development in the Field in the Genzyme Territory. 

 

	 	6.2.4.	Sublicensing Terms. 

 (a) Subject to Section 6.5 (Alnylam Territory
Right of First Negotiation), Alnylam shall have the right to sublicense any of its rights under Section 6.2.1 (Commercialization License in the Alnylam Territory), 6.2.2 (License to Improvement Manufacturing Patent Rights) and 6.2.3 (License to
Genzyme Disclosed Manufacturing Know-How) to [***]. 
 (b) Each sublicense granted by Alnylam pursuant to this
Section 6.2.4 shall be subject and subordinate to these Regional License Terms and shall contain provisions consistent with those in these Regional License Terms. Alnylam shall promptly provide Genzyme with a copy of the fully executed
sublicense agreement covering any sublicense granted hereunder (which copy may be redacted to remove provisions which are not necessary to monitor compliance with this Section 6.2.4), and each such sublicense

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 51 

 REGIONAL LICENSE TERMS 

 

 
agreement shall contain the following provisions: (i) a requirement that the Sublicensee comply with the confidentiality and non-use provisions of Section 7 of the Master Agreement
(Confidentiality and Publication) with respect to Genzyme’s Confidential Information and (ii) a requirement that the Sublicensee comply with the applicable provisions under any Genzyme In-License. 

(c) If Alnylam becomes aware of a material breach of any sublicense by any Alnylam Sublicensee, compliance with which is
necessary for Alnylam’s compliance with these Regional License Terms, Alnylam shall promptly notify Genzyme of the particulars of the same and use Commercially Reasonable Efforts to cause the Sublicensee to comply with all the provisions of the
sublicense necessary for Alnylam’s compliance with these Regional License Terms. [***]. Notwithstanding any sublicense, Alnylam shall remain primarily liable to Genzyme for the performance of all of Alnylam’s obligations under, and
Alnylam’s compliance with all provisions of, these Regional License Terms. 
 6.3. Joint Collaboration IP. Subject to the
rights and licenses granted to, and the obligations (including royalty obligations) of, each Party under these Regional License Terms, either Party is entitled to practice Joint Collaboration IP for all purposes on a worldwide basis and license
Joint Collaboration IP without consent of and without a duty of accounting to the other Party. Each Party will grant and hereby does grant all permissions, consents and waivers with respect to, and all licenses under, the Joint Collaboration IP,
throughout the world, necessary to provide the other Party with such rights of use and exploitation of the Joint Collaboration IP, and will execute documents as necessary to accomplish the foregoing. 

6.4. Compliance with In-Licenses. All licenses and other rights granted to Genzyme under this Section 6 are subject to the
rights and obligations of Alnylam under the Alnylam In-Licenses. All licenses and other rights granted to Alnylam under this Section 6 are subject to the rights and obligations of Genzyme under the Genzyme In-Licenses. Each Party shall comply
with all applicable provisions of the In-Licenses, and shall perform and take such actions as may be required to allow the Party that is party to such In-License to comply with its obligations thereunder, including obligations relating to
sublicensing, patent matters, confidentiality, reporting, audit rights, indemnification and diligence. Without limiting the foregoing, each Party shall prepare and deliver to the other Party any additional reports required under the applicable
In-Licenses and requested by such other Party, in each case sufficiently in advance to enable the Party that is party to such In-License to comply with its obligations under the applicable In-Licenses. Each Party agrees, upon the other Party’s
request, to provide the other Party with copies of any In-Licenses to which it is a party. Confidential Information of the providing Party or its counterparty may be redacted from such copies, except to the extent that such information is required
in order to enable the other Party to comply with its obligations to the providing Party under these Regional License Terms with respect to such In-License or in order to enable the providing Party to ascertain compliance with these Regional License
Terms. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 52 

 REGIONAL LICENSE TERMS 

 

 6.5. Alnylam Territory Right of First Negotiation. If, at any time during the
Term, Alnylam desires to grant any Third Party rights to Develop and/or Commercialize one or more Regional Licensed Product(s) in any portion of the Alnylam Territory, Alnylam shall notify Genzyme in writing of its intent. Genzyme shall have [***]
days from receipt of such written notice to notify Alnylam in writing as to whether Genzyme desires to negotiate for such rights in such territory, and if Genzyme so notifies Alnylam that it does desire to negotiate for such rights in such
territory, Genzyme shall have the exclusive right for [***] days from the date of such notification to Alnylam to negotiate with Alnylam and to make one or more written non-binding offers to Alnylam concerning the acquisition of such rights in such
territory by Genzyme. Genzyme shall have the exclusive right for [***] days (or such longer period as may be mutually agreed by the Parties) after such [***] day period, to finalize and enter into a definitive agreement with Alnylam for such rights
in such territory, provided that, if either Genzyme does not provide such written notice within such [***] day period or Genzyme does provide such written non-binding offer within such subsequent [***] day period, or Genzyme provides such
notice of interest and such written offer but for any reason Genzyme and Alnylam do not enter into a definitive agreement within the [***] day negotiation period, Alnylam shall be free to enter into an agreement with a Third Party(ies) relating to
such rights in such territory, without further obligation to Genzyme. Alnylam shall not, during the exclusive [***] day negotiating periods described above, enter into discussions, exchange information, or otherwise negotiate with any Third Party
with respect to an agreement with respect to the Development and/or Commercialization of the applicable Regional Licensed Product(s) in the Alnylam Territory. Notwithstanding the foregoing, during the period of [***] months after the termination of
any such negotiation that does not result in a definitive agreement between Alnylam and Genzyme, Alnylam shall not enter into a transaction with respect to such rights in such territory with any Third Party on terms that are, in the aggregate,
materially more favorable to the Third Party than the last terms offered in writing by Genzyme to Alnylam unless Alnylam first re-offers such transaction to Genzyme on such more favorable terms and Genzyme does not accept such offer and enter into
such transaction with Alnylam within [***] days after such re-offer. For clarity, prior to the exclusive negotiating periods described above, Alnylam shall be free to engage in discussions and exchange information with Third Parties with respect to
the applicable Regional Licensed Product(s) rights, but shall not enter into any binding agreement with any Third Party with respect to such rights. 

6.6. Bankruptcy. All rights and licenses granted under or pursuant to these Regional License Terms by a Party to the other,
including those set forth in Sections 6.1 (License Grants to Genzyme), 6.2 (License Grants to Alnylam), and 3.4 (Right of Reference), are and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses
of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties and their respective Sublicensees, as sublicensees of such rights under these Regional License Terms,
shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code and any foreign counterpart thereto. The Parties further agree that upon commencement of a bankruptcy proceeding by or against a Party (the
“Bankrupt Party”) under the Bankruptcy Code, the other Party (the “Non-Bankrupt Party”) will be entitled to a complete duplicate of, or complete access to (as the Non-Bankrupt Party

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 53 

 REGIONAL LICENSE TERMS 

 

 
deems appropriate), all such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments of such intellectual property will be promptly
delivered to the Non-Bankrupt Party (a) upon any such commencement of a bankruptcy proceeding and upon written request by the Non-Bankrupt Party, unless the Bankrupt Party elects to continue to perform all of its obligations under these
Regional License Terms, or (b) if not delivered under (a) above, upon the rejection of these Regional License Terms by or on behalf of the Bankrupt Party and upon written request by the Non-Bankrupt Party. Without limiting the foregoing,
Alnylam hereby grants to Genzyme a right of access to and to obtain possession of (i) copies of research data, (ii) laboratory samples, (iii) samples of Regional Licensed Product, (iv) formulas, (v) laboratory notes and
notebooks, (vi) data and results related to clinical trials, (vii) regulatory filings and approvals, (viii) rights of reference in respect of regulatory filings and approvals, (ix) pre-clinical research data and results, and
(x) marketing, advertising and promotional materials, all of which (in clauses (i) through (x)) constitute “embodiments” of intellectual property pursuant to Section 365(n) of the Bankruptcy Code and (xi) all other
embodiments of such intellectual property, and in respect of each of the foregoing clauses (i) through (xi), solely for the purpose of the exercise of Genzyme’s rights and licenses under these Regional License Terms, whether any of the
foregoing are in Alnylam’s possession or control or in the possession and control of Third Parties. The Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including any trustee) agree not to
interfere with the exercise by the Non-Bankrupt Party or its Related Parties of its rights and licenses to such intellectual property and such embodiments of intellectual property in accordance with these Regional License Terms, and agrees to assist
the Non-Bankrupt Party and its Related Parties in obtaining such intellectual property and such embodiments of intellectual property in the possession or control of Third Parties as are reasonably necessary or desirable for the Non-Bankrupt Party to
exercise such rights and licenses in accordance with these Regional License Terms. The foregoing provisions are without prejudice to any rights the Non-Bankrupt Party may have arising under the Bankruptcy Code or other Laws. 

6.7. No Other Rights. Except as otherwise expressly provided in these Regional License Terms, under no circumstances shall a
Party, as a result of these Regional License Terms, obtain any ownership interest or other right in any Know-How, Patent Rights or other intellectual property rights of the other Party, including items owned, controlled or developed by the other
Party, or provided by the other Party to the receiving Party at any time pursuant to these Regional License Terms. 
 7. CERTAIN
FINANCIAL TERMS 
 7.1. Milestone Fees.  

7.1.1. Development Milestones for Regional Licensed Products. Genzyme shall provide Alnylam with written notice of the achievement by
Genzyme or any of its Related Parties of any development milestone event set forth below in this Section 7.1.1 and Alnylam shall provide Genzyme with written notice of the achievement by Alnylam or any of its Related Parties of any development
milestone event set forth below in this Section 7.1.1, in each case 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 54 

 REGIONAL LICENSE TERMS 

 

 
within [***] days after such event has occurred; provided, however, that the notifying Party shall inform the other Party of such event prior to any public disclosure of such event
by the notifying Party. Alnylam shall invoice Genzyme within [***] days of receipt of such written notice by either Party, and Genzyme shall remit the associated development milestone payment within [***] days of the receipt of such invoice. Each
development milestone payment by Genzyme to Alnylam hereunder shall be payable only once with respect to each Regional Licensed Product, regardless of the number of times a development milestone event is achieved with respect to any Regional
Licensed Product. 
 7.1.1.1. Development Milestones for ALN-TTR02. Genzyme shall pay Alnylam the following
amounts upon achievement of the following development milestone events with respect to ALN-TTR02: 
  

					
	 Development Milestone Event
	  	Development Milestone
Payment	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  

 7.1.1.2. Development Milestones for Regional Licensed Products other than
ALN-TTR02. Genzyme shall pay Alnylam the following amounts upon achievement of the following development milestone events with respect to any Regional Licensed Product other than ALN-TTR02: 

 

					
	 Development Milestone Event
	  	Development Milestone
Payment	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  

 7.1.2. Sales Milestones for Regional Licensed Products other than ALN-TTR02. Genzyme
shall provide Alnylam with written notice of the achievement by Genzyme or any of its Related Parties of any of the sales milestone events set forth below in this Section 7.1.2 within [***] days after such event has occurred. Alnylam shall
invoice Genzyme within [***]days of receipt of such written notice, and Genzyme shall remit the associated sales milestone payment within [***] days of the receipt of such invoice. 

 

					
	 Sales Milestone Event
	  	Sales Milestone Payment	 
	 [***]
	  	 	[***]	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 55 

 REGIONAL LICENSE TERMS 

 

 [***]. 

7.2. Royalties. 

7.2.1. Royalties Payable on Regional Licensed Products. 

7.2.1.1. Royalties Payable on ALN-TTR02. Subject to these Regional License Terms, Genzyme shall pay to Alnylam
royalties on annual Net Sales by Genzyme and its Related Parties of ALN-TTR02 in the Genzyme Territory, as follows: 
  

			
	 Calendar Year

Net Sales of ALN-TTR02 in the Genzyme Territory
	  	Royalty
(as a percentage of Net Sales)
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 Royalties on annual Net Sales of ALN-TTR02 shall be paid at the rate applicable to the portion of Net Sales
within each of the Net Sales levels above during such Calendar Year. By way of example only, if Genzyme receives [***] 
 [***] 

7.2.1.2. Royalties Payable on Other Regional Licensed Products. Subject to these Regional License Terms, Genzyme
shall pay to Alnylam royalties on annual Net Sales by Genzyme and its Related Parties of each Regional Licensed Product other than ALN-TTR02 in the Genzyme Territory, as follows: 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 56 

 REGIONAL LICENSE TERMS 

 

			
	 Calendar Year

Net Sales of a Regional Licensed Product
 other than
ALN-TTR02 in the Genzyme
 Territory
	 	Royalty
(as a percentage of Net Sales of a Regional Licensed
Product)
	 [***]
	 	[***]
	 [***]
	 	[***]
	 [***]
	 	[***]
	 [***]
	 	[***]
	 [***]
	 	[***]

 By way of example only, if Genzyme receives [***] 

[***] 
 [***] 

7.2.2. Royalty Term. Subject to Section 7.2.6 (Royalty Floor), the period during which the royalties set forth in
Section 7.2.1(Royalties Payable on Regional Licensed Products) shall be payable, on a Regional Licensed Product-by-Regional Licensed Product and country-by-country basis, shall commence with the First Commercial Sale of a Regional Licensed
Product in a country and continue until the latest of (a) the expiration of the last Valid Claim of [***] in the country of sale; (b) the expiration of Regulatory Exclusivity for such Regional Licensed Product in such country; or
(c) subject to the last sentence of this Section 7.2.2, the [***] anniversary of the First Commercial Sale of such Regional Licensed Product in such country (each such period, a “Royalty Term”). [***] 

7.2.3. Third Party Royalty Offsets. Genzyme shall be permitted to reduce any royalties payable under Section 7.2.1 (Royalties
Payable on Regional Licensed Products) for a Regional Licensed Product [***]. 
 7.2.4. [***]. 

7.2.5. [***]. 
 7.2.6.
Royalty Floor. Anything in these Regional License Terms to the contrary notwithstanding, in no event during the applicable Royalty Term for a Regional Licensed Product in a country of the Genzyme Territory shall the royalties payable to Alnylam
hereunder for such Regional Licensed Product in such country for any Calendar Quarter be reduced [***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 57 

 REGIONAL LICENSE TERMS 

 

 7.2.7. Validation Information. At Genzyme’s request, Alnylam will provide Genzyme
with such information as Genzyme may reasonably request to validate the amount of the royalty floor described in Section 7.2.6 (Royalty Floor). 

8. REPRESENTATIONS, WARRANTIES AND COVENANTS 

8.1. Representations and Warranties of Alnylam. Except as provided in the Disclosure Schedule to this Section 8.1 (which
Disclosure Schedule with respect to ALN-TTR02 is attached hereto and with respect to any other Regional Licensed Product will be provided by Alnylam to Genzyme as part of the Option Data Package for such Regional Licensed Product), Alnylam
represents and warrants to Genzyme that, with respect to each Regional Licensed Product other than ALN-TTR02, as of the Implementation Date, and, with respect to ALN-TTR02, as of the Execution Date: 

8.1.1. Alnylam is the sole and exclusive owner of, or otherwise Controls pursuant to an Alnylam In-License, the Alnylam Technology, and
all of the Alnylam Technology licensed to Genzyme hereunder in the Genzyme Territory that is solely and exclusively owned by Alnylam is free and clear of liens, charges or encumbrances other than licenses granted to Third Parties that are not
inconsistent with the rights and licenses granted to Genzyme under these Regional License Terms. 
 8.1.2. Alnylam has sufficient
legal and/or beneficial title and ownership of, or sufficient license rights under, the Alnylam Technology to grant the licenses to such Alnylam Technology granted to Genzyme pursuant to these Regional License Terms. 

8.1.3. (a) Schedule 1.2.13 and Schedule 1.2.18 collectively set forth a complete and accurate list of the Alnylam Patents
owned, either solely or jointly, by Alnylam, and to Alnylam’s knowledge, Schedule 1.2.13 and Schedule 1.2.18 collectively set forth a complete and accurate list of the Alnylam Patents licensed, either exclusively or
nonexclusively, to Alnylam, (b) to Alnylam’s knowledge, each issued Alnylam Patent remains in full force and effect and (c) Alnylam or its Affiliates have timely paid all filing and renewal fees payable with respect to such Alnylam
Patents for which Alnylam controls prosecution and maintenance. Schedule 1.2.13 and Schedule 1.2.18 indicate whether each Alnylam Patent is owned exclusively by Alnylam, is owned jointly by Alnylam and one or more Third Parties, or is
licensed to Alnylam. For each Alnylam Patent that is owned, but not owned exclusively, by Alnylam, or that is licensed to Alnylam, Schedule 1.2.13 and Schedule 1.2.18 identify the Third Party owner(s) and, if applicable, the Alnylam
In-License pursuant to which Alnylam Controls such Alnylam Patent. For each Alnylam Product-Specific Patent that is licensed, but not exclusively licensed, to Alnylam, Schedule 1.2.18 indicates the non-exclusive nature of the license. For
each Alnylam Core Technology Patent family (other than Patent Rights licensed from Isis Pharmaceuticals, Inc.) that is licensed, but not exclusively licensed, to Alnylam, Schedule 1.2.13 indicates the non-exclusive nature of the license.
Alnylam is the sole and exclusive owner of all Patent Rights identified in Schedule 1.2.13 and Schedule 1.2.18 as being owned exclusively by Alnylam and Controls all other Patent Rights identified on such schedules. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 58 

 REGIONAL LICENSE TERMS 

 

 8.1.4. To Alnylam’s knowledge, the Alnylam Product-Specific Patents, are, or,
upon issuance, will be, valid and enforceable patents and no Third Party has challenged or threatened to challenge the scope, validity or enforceability of any Alnylam Product-Specific Patent (including, by way of example, through opposition or the
institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority). 

8.1.5. Alnylam has complied with all applicable Laws, including any duties of candor to applicable patent offices, in connection with
the filing, prosecution and maintenance of the Alnylam Patent Rights. 
 8.1.6. Alnylam owns or Controls all Know-How that is or has
been used by Alnylam in the Development and Manufacture of such Regional Licensed Product, and has sufficient legal or beneficial title and ownership of, or sufficient license rights under such Know-How to transfer Know-How to Genzyme as provided in
Section 6.4 of the Master Agreement (Transfer of Manufacturing Know-How). 
 8.1.7. Alnylam Controls all Know-How and Patent
Rights licensed to Alnylam under the Existing Alnylam In-Licenses that is necessary or useful for Genzyme to Develop, Manufacture and/or Commercialize such Regional Licensed Product in the Field in the Genzyme Territory. Without limiting the
generality of the foregoing, Alnylam has obtained all necessary consents and fulfilled all necessary conditions, if any, to sublicense to Genzyme under these Regional License Terms such Know-How and Patent Rights licensed to Alnylam under Existing
Alnylam In-Licenses. 
 8.1.8. To Alnylam’s knowledge, neither Alnylam nor its Affiliates are in breach or default under any
existing Alnylam In-License, and neither Alnylam nor its Affiliates have received any written notice of breach or default with respect to any existing Alnylam In-License. 

8.1.9. Alnylam has obtained from all inventors of Alnylam Technology owned by Alnylam valid and enforceable agreements assigning to
Alnylam each such inventor’s entire right, title and interest in and to all such Alnylam Technology. 
 8.1.10. To Alnylam’s
knowledge, the use, Development, Manufacture or Commercialization by Alnylam or Genzyme (or their respective Related Parties) of such Regional Licensed Product as formulated and manufactured as of the Effective Date, or as intended to be formulated
and manufactured as of the Effective Date (a) does not and will not infringe any issued patent of any Third Party and (b) will not infringe the claims of any published Third Party patent application when and if such claims were to issue in
their current form. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 59 

 REGIONAL LICENSE TERMS 

 

 8.1.11. There is no (a) claim, demand, suit, proceeding, arbitration, inquiry,
investigation or other legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to Alnylam’s knowledge, threatened against Alnylam or any of its Affiliates or (b) judgment or settlement against or owed by Alnylam
or any of its Affiliates, in each case in connection with the Alnylam Technology or such Regional Licensed Product. 
 8.1.12. For
each Regional Licensed Product, other than ALN-TTR02, Schedule 8.1.12(a) (Existing Alnylam In-Licenses) sets forth a complete and accurate list of all agreements between Alnylam and a Third Party entered into prior to the Implementation Date
for a Regional Licensed Product pursuant to which Alnylam Controls Know-How or Patent Rights that are necessary or useful to Develop, Manufacture or Commercialize such Regional Licensed Product in the Field other than Additional Alnylam In-Licenses.
[***]. For the sake of clarity, representations and warranties similar to those made pursuant to this Section 8.1.12 with respect to Regional Licensed Products other than ALN-TTR02 are made with respect to ALN-TTR02 in the Master Agreement.

 8.2. Representations and Warranties of Genzyme. Except as disclosed in Genzyme’s Exercise Notice for a Regional
Licensed Product, Genzyme represents and warrants to Alnylam as of the Implementation Date for such Regional Licensed Product that is not a party to any agreement with a Third Party under which it Controls Know-How or Patent Rights that are
sublicensed to Alnylam under these Regional License Terms with respect to such Regional Licensed Product. 
 8.3. Warranty
Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THESE REGIONAL LICENSE TERMS, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY TECHNOLOGY,
REGIONAL LICENSED PRODUCT, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THESE REGIONAL LICENSE TERMS AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT WITH RESPECT TO ANY AND
ALL OF THE FOREGOING. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY REGIONAL LICENSED PRODUCT PURSUANT TO THESE REGIONAL LICENSE TERMS WILL BE SUCCESSFUL OR THAT ANY
PARTICULAR SALES LEVEL WITH RESPECT TO ANY REGIONAL LICENSED PRODUCT WILL BE ACHIEVED. 
 8.4. Certain Covenants. 

8.4.1. [***] 

8.4.1.1. [***] 

(a) [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 60 

 REGIONAL LICENSE TERMS 

 

 (b) [***] 

(c) [***] 

8.4.1.2. [***] 

(a) [***] 

(b) [***] 

(c) [***] 

8.4.1.3. [***] 

(a) [***] 

(b) [***] 

(c) [***] 

8.4.2. Compliance. Each Party and its Related Parties shall conduct the RLP Collaboration and the Development, Manufacture and
Commercialization of the Regional Licensed Products in accordance with all Laws, including current governmental regulations concerning Good Laboratory Practices (as defined in the Master Agreement), good clinical practices and good manufacturing
practices. In addition, if either Party is or becomes subject to a legal obligation to a Regulatory Authority or other Governmental Authority (such as a corporate integrity agreement or settlement agreement with a Governmental Authority), then the
other Party shall perform such activities as may be reasonably requested by the obligated Party to enable the obligated Party to comply with its legal obligation to such Regulatory Authority with respect to the Regional Licensed Products. 

8.4.3. Conflicting Transactions. During the Term, Alnylam shall not (a) transfer or assign any of its rights, title or interests in
the Alnylam Technology other than as part of a transaction pursuant to which these Regional License Terms are also assigned and assumed in accordance with Section 13.1 of the Master Agreement (Assignment), or (b) enter into any agreement
granting a license or other right under the Alnylam Technology that is inconsistent with these Regional License Terms. 
 8.4.4.
Governmental Authority. If any of the Alnylam Technology is subject to any funding arrangement with any Governmental Authority, at Genzyme’s reasonable request, Alnylam will reasonably cooperate in seeking a waiver or other modification to
such funding arrangement with respect to such Alnylam Technology. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 61 

 REGIONAL LICENSE TERMS 

 

 9. INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS 

9.1. Inventorship. Inventorship for inventions and discoveries first made during the course of the performance of activities
pursuant to these Regional License Terms shall be determined in accordance with United States patent Laws for determining inventorship. 

9.2. Ownership. Alnylam shall own the entire right, title and interest in and to all inventions and discoveries (and Patent
Rights claiming patentable inventions therein) first made or discovered solely by employees or consultants of Alnylam or acquired solely by Alnylam in the course of conducting the Collaboration. Genzyme shall own the entire right, title and interest
in and to all inventions and discoveries (and Patent Rights claiming patentable inventions therein) first made or discovered solely by employees or consultants of Genzyme or acquired solely by Genzyme in the course of conducting the Collaboration.
The Parties shall jointly own any inventions and discoveries (and Patent Rights claiming patentable inventions therein) first made or discovered jointly in the course of conducting the Collaboration. 

9.3. Prosecution and Maintenance of Patent Rights. 

9.3.1. IP Committee. The Parties agree that the IP Committee created pursuant to Section 5.3 of the Master Agreement (IP Committee)
shall be responsible for overseeing and effecting the information sharing and consulting provisions under this Section 9.3.1. 

9.3.2. Genzyme Technology. 

(a) Subject to Section 9.3.2(b) below, Genzyme has the sole responsibility to, at Genzyme’s discretion and at
Genzyme’s sole cost and expense, file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Patent Rights comprising Genzyme Technology (other than Joint Collaboration IP), in Genzyme’s name.

 (b) In the event that Genzyme elects not to seek or continue to seek or maintain patent protection on any Genzyme
Collaboration IP in the Alnylam Territory, Genzyme shall notify Alnylam at least [***] days before any such Patent Rights would become abandoned, no longer available or otherwise forfeited, and subject to the provisions of any applicable Genzyme
In-License, Alnylam shall have the right (but not the obligation), at its sole cost and expense, to seek, prosecute and maintain in any country patent protection on such Genzyme Collaboration IP in the name of Genzyme. Genzyme shall use Commercially
Reasonable Efforts to make available to Alnylam its authorized attorneys, agents or representatives, and/or such of its employees as are reasonably necessary to assist Alnylam in obtaining and maintaining the patent protection described under this
Section 9.3.2(b). Genzyme shall sign or use Commercially Reasonable Efforts to have signed all legal documents as are reasonably necessary to file and prosecute such patent applications or to obtain or maintain such patents. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 62 

 REGIONAL LICENSE TERMS 

 

 9.3.3. Alnylam Technology. The following will apply with respect to Alnylam Patent
Rights during the Term [***]. 
 (a) Subject to Section 9.3.3(c) below, Alnylam has the sole responsibility to, at
Alnylam’s discretion and at Alnylam’s sole cost and expense, file, conduct prosecution, and maintain (including the defense of any interference or opposition proceedings), all Patent Rights comprising Alnylam Technology (other than Joint
Collaboration IP), in Alnylam’s name. Notwithstanding the foregoing, Alnylam shall file Alnylam Product-Specific Rights in the Genzyme Patent Jurisdictions (as defined in the Master Agreement) and shall use commercially reasonable efforts to
prosecute and maintain such Patent Rights in the Genzyme Patent Jurisdictions and shall timely pay all filing and renewal fees payable with respect thereto. 

(b) Notwithstanding the foregoing Section 9.3.3(a), Alnylam shall consult with Genzyme, including through the IP
Committee, on its strategy for the preparation, filing, prosecution, and maintenance of all Alnylam Product-Specific Patents in the Genzyme Territory and the Alnylam Territory. Alnylam shall furnish Genzyme, via electronic mail or such other method
as mutually agreed by the Parties, copies of proposed filings and documents received from outside counsel in the course of filing, prosecution or maintenance of and/or copies of documents filed with the relevant patent offices with respect to
Alnylam Product-Specific Patents and such other documents directly related to the prosecution and maintenance of Alnylam Product-Specific Patents reasonably necessary for Genzyme to exercise its rights under this Section 9.3.3(b), and as
applicable in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by Genzyme and shall consider in good faith timely comments from Genzyme thereon. Alnylam shall furnish to Genzyme, via
electronic mail or such other method as mutually agreed by the Parties, copies of documents received from outside counsel in the course of filing, prosecution or maintenance of and/or copies of documents filed with the relevant national patent
offices with respect to the filing, prosecution, and maintenance of Alnylam Core Technology Patents within a reasonable time after the receipt and/or filing of such documents. 

(c) In the event that Alnylam elects not to seek or continue to seek or maintain patent protection on any Alnylam
Product-Specific Patent in the Genzyme Territory, Alnylam shall notify Genzyme at least [***] days before any such Patent Rights would become abandoned, no longer available or otherwise forfeited, and subject to the provisions of any applicable
Alnylam In-License, Genzyme shall have the right (but not the obligation), at its sole cost and expense, to seek, prosecute and maintain in any country patent protection on any such Alnylam Product-Specific Patent in the Genzyme Territory. If
Genzyme exercises such right, Alnylam shall thereafter and hereby does assign all right, title and interest in and to such Alnylam Product-Specific Patents to Genzyme. Alnylam shall use Commercially Reasonable Efforts to make available to Genzyme
its authorized attorneys, agents or representatives, such of its employees as are reasonably necessary to assist Genzyme in obtaining and maintaining the patent protection described under this Section 9.3.3(b). Alnylam shall sign or use
Commercially Reasonable Efforts to have signed all legal documents as are reasonably necessary to file and prosecute such patent applications or to obtain or maintain such patents. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 63 

 REGIONAL LICENSE TERMS 

 

 (d) [***] 

9.3.4. Joint Collaboration IP. 

(a) [***] shall have the first right to, at [***] discretion, file, prosecute and maintain (including the defense of any
interference or opposition proceedings), all Patent Rights comprising Joint Collaboration IP, in the names of both Alnylam and Genzyme. [***] shall consult with [***] on the filing, prosecution and maintenance of all such Patent Rights. Each Party
shall sign, or use Commercially Reasonable Efforts to have signed, all legal documents as are reasonably necessary to file and prosecute patent applications or to obtain or maintain patents in respect of such Joint Collaboration IP, at its own cost.

 (b) [***] shall furnish [***], via electronic mail or such other method as mutually agreed by the Parties, copies of
documents received from outside counsel in the course of such filing, prosecution or maintenance of Joint Collaboration IP and/or copies of documents relevant to such preparation, filing, prosecution, and maintenance in sufficient time prior to
filing such document or making any payment due thereunder to allow for review and comment by [***] and shall consider in good faith timely comments from [***] thereon. [***] shall furnish to Genzyme, via electronic mail or such other method as
mutually agreed by the Parties, copies of such documents as filed in the relevant patent offices. 
 (c) In the event [***]
elects not to file or continue to prosecute or maintain patent protection on any Joint Collaboration IP, [***]shall have the right (but not the obligation) to file, prosecute and maintain Patent Rights comprising Joint Collaboration IP in the names
of both Alnylam and Genzyme. [***] exercises such right, [***] shall use Commercially Reasonable Efforts to make available to [***] its authorized attorneys, agents or representatives, and/or such of its employees as are reasonably necessary to
assist [***] in obtaining and maintaining the patent protection described under this Section 9.3.4(c). [***] shall sign or use Commercially Reasonable Efforts to have signed all legal documents as are reasonably necessary to file and prosecute
such patent applications or to obtain or maintain such patents. 
 (d) The Parties shall share equally the out-of-pocket
patent filing, prosecution and maintenance expenses incurred with respect to Patent Rights comprising Joint Collaboration IP. 
 9.3.5.
Patent Miscellaneous. Each Party hereby agrees: (a) to make its employees, agents and consultants reasonably available to the other Party (or to the other Party’s authorized attorneys, agents or representatives), to the extent
reasonably necessary to enable such 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 64 

 REGIONAL LICENSE TERMS 

 

 
Party to undertake patent prosecution; (b) to provide the other Party with copies of all material correspondence pertaining to prosecution with the patent offices; (c) to cooperate, if
necessary and appropriate, with the other Party in gaining patent term extensions wherever applicable to Patent Rights licensed under these Regional License Terms; and (d) to endeavor in good faith to coordinate its efforts with the other Party
to minimize or avoid interference with the prosecution and maintenance of the other Party’s patent applications. 
 9.3.6. [***]

 9.3.6.1. [***] 

9.3.6.2. [***] 

9.3.6.3. [***] 

9.4. Third Party Infringement. 

9.4.1. Notices. Each Party shall promptly report in writing to the other Party any (a) known or suspected infringement of any
Alnylam Technology, Genzyme Technology or Joint Collaboration IP or (b) unauthorized use or misappropriation of any Confidential Information or Know-How of a Party by a Third Party of which it becomes aware, in each case to the extent such
infringing, unauthorized or misappropriating activities involve, as to a Regional Licensed Product, a competing product in the Field (a “Competitive Infringement”), and shall provide the other Party with all available evidence of
such infringement, unauthorized use or misappropriation. 
 9.4.2. Rights to Enforce. 

(a) Genzyme Technology. Subject to the provisions of any In-License, Genzyme shall have the sole and exclusive right to
initiate an infringement or other appropriate suit (an “Infringement Action”) anywhere in the world against any Third Party as to any infringement, or suspected infringement, of any Patent Rights, or as to any use or suspected use
without proper authorization of any Know-How comprising Genzyme Patent Rights, Genzyme Know-How or Genzyme Collaboration IP. Genzyme will consider in good faith any request from Alnylam to initiate an Infringement Action against any Third Party with
respect to Competitive Infringement in the Alnylam Territory of Genzyme Patent Rights, Genzyme Know-How or Genzyme Collaboration IP licensed to Alnylam under Section 6 (Licenses); provided, however, that Genzyme shall not be
required to initiate any such Infringement Action or permit Alnylam to initiate any such Infringement Action. 
 (b)
Alnylam Technology. Subject to the provisions of any In-License, Genzyme shall have the first right to initiate an Infringement Action against any Third Party with respect to any Competitive Infringement in the Genzyme Territory of any
Alnylam Product-Specific Patent or Joint Collaboration IP, or, with Alnylam’s prior 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 65 

 REGIONAL LICENSE TERMS 

 

 
written consent, Alnylam Core Technology Patent or Alnylam Know-How. Alnylam will consider in good faith any request from Genzyme to initiate an Infringement Action against any Third Party with
respect to a Competitive Infringement in the Genzyme Territory of any Alnylam Core Technology Patent; provided, however, that Alnylam shall not be required to initiate any such Infringement Action or permit Genzyme to initiate any such
Infringement Action. 
 (c) Step-In Rights. 

(i) If within [***] days (or such shorter period of time as required by applicable Law to avoid loss of material enforcement rights) after
Genzyme’s receipt of a notice of a Competitive Infringement with respect to any Alnylam Product-Specific Patent or Joint Collaboration IP, Genzyme does not initiate any Infringement Action against such Competitive Infringement in the Genzyme
Territory, Alnylam may in its sole discretion, bring and control any Infringement Action in connection therewith at its sole cost and expense. 

(ii) [***] 
 9.4.3. Procedures;
Expenses and Recoveries. The Party having the right to initiate any Infringement Action under Section 9.4.2 (Rights to Enforce) above shall have the sole and exclusive right to select counsel for any such Infringement Action and shall pay
all expenses of the suit, including attorneys’ fees and court costs and reimbursement of the other Party’s reasonable Regional Out-of-Pocket Costs in rendering assistance requested by the initiating Party. If required under applicable Law
in order for the initiating Party to initiate and/or maintain the Infringement Action, or if either Party is unable to initiate or prosecute such Infringement Action solely in its own name or it is otherwise advisable to obtain an effective legal
remedy, in each case, the other Party shall join as a party to such Infringement Action and will execute and cause its Affiliates to execute all documents necessary for the initiating Party to initiate litigation to prosecute and maintain such
action. In addition, at the initiating Party’s request, the other Party shall provide reasonable assistance to the initiating Party in connection with an Infringement Action at no charge to the initiating Party except for reimbursement by the
initiating Party of reasonable Regional Out-of-Pocket Costs incurred in rendering such assistance. The non-initiating Party shall have the right to participate and be represented in any such Infringement Action by its own counsel at its own expense.
If the Parties obtain from a Third Party, in connection with such Infringement Action, any damages, license fees, royalties or other compensation (including any amount received in settlement of such litigation), after payment of any amounts required
under any In-Licenses, the remaining amounts shall be allocated in all cases as follows: 
 (a) first, to reimburse each
Party for all expenses of the Infringement Action incurred by the Parties, including attorneys’ fees and disbursements, court costs and other litigation expenses; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 66 

 REGIONAL LICENSE TERMS 

 

 (b) second, [***] of the balance to be paid to the Party initiating the
Infringement Action; and 
 (c) third, the remainder to the other Party. 

Notwithstanding the foregoing, in the event that Alnylam elects to itself assert an Alnylam Core Technology Patent against a Competitive
Infringement in the Genzyme Territory, the Parties shall each be entitled to [***] of the balance of any recovery therefrom after reimbursement of expenses as described in clause (i) above. 

9.5. Patent Term Extensions. 

9.5.1. Retained Alnylam Product-Specific Patents. Subject to the provisions of any Alnylam In-License, Alnylam shall use Commercially
Reasonable Efforts to obtain all available supplementary protection certificates (“SPCs”) and other extensions of Alnylam Product-Specific Patents in the Genzyme Territory[***]. If more than one such Alnylam Product-Specific Patent
is eligible for extension or patent term restoration in the Genzyme Territory, Genzyme will determine, in its sole discretion, a strategy that will be designed to maximize patent protection and commercial value for the Regional Licensed Product, and
the Parties, subject to the provisions of any In-License, will seek patent term extensions, restorations and SPCs for Alnylam Product-Specific Patents in the Genzyme Territory in accordance with that strategy. Where required under national law, and
subject to the other requirements of this Section 9.5, Alnylam will make the filings for such extensions, restorations and SPCs for Alnylam Product-Specific Patents in the Genzyme Territory as directed by Genzyme. 

9.5.2. Further Assurances for SPCs. Each Party will execute such authorizations and other documents and take such other actions as may
be reasonably requested by the other Party to obtain any such extensions, restorations and SPCs for Alnylam Product-Specific Patents in the Genzyme Territory, in accordance with this Section 9.5. 

9.6. Common Interest. All information exchanged between the Parties representatives regarding the preparation, filing,
prosecution, maintenance, or enforcement of the Patent Rights under this Section 9 will be deemed Confidential Information. In addition, the Parties acknowledge and agree that, with regard to such preparation, filing, prosecution, maintenance,
and enforcement of the Patents Rights under this Section 9, the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent protection possible, and as such, are aligned and are legal in nature. The
Parties agree and acknowledge that they have not waived, and nothing in these Regional License Terms constitutes a waiver of, any legal privilege concerning the Patents Rights under this Section 9, including privilege under the common interest
doctrine and similar or related doctrines. 
 9.7. Trademarks. 

(a) Each Party has the right to use any trademark it owns or controls for Regional Licensed Products in its Territory at its
sole discretion, and each Party and its Affiliates shall retain all right, title and interest in and to its and their respective corporate names and logos. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 67 

 REGIONAL LICENSE TERMS 

 

 (b) Genzyme will develop and propose, and the PJSC shall review and comment
on, one or more Product Trademark(s) for use by Genzyme and its Related Parties throughout the Genzyme Territory. Such Product Trademark(s) considered by the PJSC may include, in Genzyme’s sole discretion, the Product Trademark(s) developed
and/or used by Alnylam with respect to the Commercialization of Regional Licensed Products in the Alnylam Territory (the “Alnylam Trademarks”), but may not include other trademarks owned or controlled by Alnylam. Any Product
Trademark(s) (other than the Alnylam Trademarks) that are used by Genzyme to promote and sell Regional Licensed Products in the Genzyme Territory are hereinafter referred to as the “Genzyme Trademarks.” Alnylam (or its Related
Parties, as appropriate) shall own all rights to Alnylam Trademarks, and all goodwill associated therewith, throughout the Alnylam Territory and the Genzyme Territory. Genzyme (or its Related Parties, as appropriate) shall own all rights to Genzyme
Trademarks and all goodwill associated therewith, throughout the Genzyme Territory. Alnylam shall also own rights to any Internet domain names incorporating the applicable Alnylam Trademarks or any variation or part of such Alnylam Trademarks used
as its URL address or any part of such address; and Genzyme shall also own rights to any Internet domain names incorporating the applicable Genzyme Trademarks or any variation or part of such Genzyme Trademarks used as its URL address or any part of
such address. 
 (c) If Genzyme determines to use Alnylam Trademarks to promote and sell any Regional Licensed Product in the
Genzyme Territory, then Alnylam and Genzyme shall enter into a separate trademark license agreement containing commercially reasonable and customary terms pursuant to which Alnylam will grant Genzyme an exclusive, royalty-free license to use the
applicable Alnylam Trademark(s) to Commercialize Regional Licensed Products in the Genzyme Territory. 
 (d) In the event
either Party becomes aware of any infringement of any Product Trademark by a Third Party, such Party shall promptly notify the other Party and the Parties shall consult with each other and jointly determine the best way to prevent such infringement,
including by the institution of legal proceedings against such Third Party. 
 (e) For the avoidance of doubt, neither Party
shall have any right to use the other Party’s or the other Party’s Affiliates’ corporate names or logos in connection with Commercialization of Regional Licensed Products. 

9.8. Cooperative Research and Technology (CREATE) Act Acknowledgment. It is the intention of the Parties that these Regional
License Terms are a “joint research agreement” as that phrase is defined in Section 35 U.S.C. 103(c). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 68 

 REGIONAL LICENSE TERMS 

 

 10. TERM AND TERMINATION 

10.1. Term. These Regional License Terms shall be effective as of the Effective Date and, unless terminated earlier pursuant to
Section 10.2 (Termination Rights), these Regional License Terms shall continue in effect on a Regional Licensed Product-by-Regional Licensed Product and country-by-country basis until expiration of the last Royalty Term to expire under these
Regional License Terms (“Term”). Upon expiration of the Royalty Term for any particular Regional Licensed Product, all licenses of the Parties under Section 6 (Licenses) with respect to such Regional Licensed Product then in
effect shall become fully paid-up, perpetual licenses. 
 10.2. Termination Rights. These Regional License Terms may be
terminated by the Parties only as set forth in this Section 10.2. 
 10.2.1. Termination of a Regional Licensed Product for
Convenience. Subject to the remainder of this Article 10, Genzyme shall have the right to terminate these Regional License Terms with respect to any particular Regional Licensed Product as follows: 

(a) After initiation of the first Phase II Study for such Regional Licensed Product and prior to completion of such Phase II
Study for such Regional Licensed Product, Genzyme shall have the right to terminate these Regional License Terms with respect to such Regional Licensed Product upon sixty (60) days prior written notice in the event that a Safety Concern occurs,
provided that in the event of such termination Genzyme shall pay to Alnylam [***] of the Global R&D Costs incurred through the effective date of termination (not to exceed [***] wind down any ongoing Phase II Studies with respect to such
Regional Licensed Product in an efficient manner consistent with patient safety, applicable Law and ethical standards. 
 (b)
After initiation of the first Phase II Study for such Regional Licensed Product and prior to completion of such Phase II Study for such Regional Licensed Product, Genzyme shall have the right to terminate these Regional License Terms with respect to
such Regional Licensed Product for any reason upon written notice (in which case, such termination shall become effective immediately upon Alnylam’s receipt of notice of such termination), provided that in the event of such termination
Genzyme shall pay to Alnylam [***] of the Global R&D Costs incurred in any ongoing Phase II Studies for such Regional Licensed Product (not to exceed [***]. 

(c) Within sixty (60) days of Genzyme’s receipt of the Phase 3 Budget and End of Phase II Package, Genzyme shall have
the right to terminate these Regional License Terms with respect to such Regional Licensed Product upon written notice to Alnylam (in which case, such termination shall become effective immediately upon Alnylam’s receipt of notice of such
termination), provided that in the event of such termination Genzyme shall pay to Alnylam [***] of the Global R&D Costs incurred through the effective date of termination (not to exceed [***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 69 

 REGIONAL LICENSE TERMS 

 

 (d) After initiation of the first Phase III Study for such Regional Licensed
Product and prior to completion of such Phase III Study for such Regional Licensed Product, Genzyme shall have the right to terminate these Regional License Terms with respect to such Regional Licensed Product upon sixty (60) days prior written
notice in the event that a Safety Concern occurs, provided that in the event of such termination Genzyme shall pay to Alnylam [***] of the Global R&D Costs incurred through the effective date of termination (not to exceed [***]) to wind
down any ongoing Clinical Studies with respect to such Regional Licensed Product in an efficient manner consistent with patient safety, applicable Law and ethical standards. 

(e) After initiation of the first Phase III Study for such Regional Licensed Product and Genzyme’s payment of the Phase
III Study initiation milestone payment described in Section 7.1.1.2(i) (Development Milestones for Regional Licensed Products other than ALN-TTR02) (if applicable), Genzyme shall have the right to terminate these Regional License Terms with
respect to such Regional Licensed Product at any time upon sixty (60) days prior written notice to Alnylam, provided that in the event of such termination Genzyme shall pay to Alnylam [***] of the Global R&D Costs incurred in
conducting any ongoing Phase III Study with respect to such Regional Licensed Product through filing of the first NDA with respect to such Regional Licensed Product (not to exceed[***]). 

(f) After completion of the first Phase III Study for such Regional Licensed Product, Genzyme shall have the right to terminate
these Regional License Terms with respect to such Regional Licensed Product at any time upon sixty (60) days prior written notice to Alnylam. 

10.2.2. Termination of a Regional Licensed Product for Cause. These Regional License Terms may be terminated with respect to any
particular Regional Licensed Product at any time during the Term upon written notice by either Party if (a) the other Party is in material breach of its obligations hereunder with respect to such Regional Licensed Product and (b) the other
Party has not cured such breach within thirty (30) days in the case of a payment breach, or within ninety (90) days in the case of all other breaches, after notice requesting cure of the breach; provided, however, that if any
breach other than a payment breach is not reasonably curable within ninety (90) days and if a Party is making a bona fide effort to cure such breach, such termination shall be delayed for a time period to be agreed by both Parties, not to
exceed an additional ninety (90) days, in order to permit such Party a reasonable period of time to cure such breach; and provided, further, that in the event that the breach relates to a dispute between the Parties regarding
Genzyme’s obligations to use Commercially Reasonable Efforts in Developing or Commercializing such Regional Licensed Product and Genzyme disputes whether it has breached such obligation or whether such breach gives Alnylam the right to
terminate these Regional License Terms with respect to such Regional Licensed Product and initiates a legal action against Alnylam to resolve such dispute within the foregoing sixty (60) day cure period, then these Regional License Terms shall
not terminate during the pendency of such legal action, provided that if (i) Genzyme is found, in an unappealable decision by a court of competent 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 70 

 REGIONAL LICENSE TERMS 

 

 
jurisdiction or an appealable decision of a court of competent jurisdiction that has not been appealed in the time allowed for an appeal in such legal action, to have materially breached these
Regional License Terms with respect to such Regional Licensed Product, or (ii) Genzyme admits in such legal action or settlement thereof that it has materially breached these Regional License Terms with respect to such Regional Licensed
Product, then these Regional License Terms shall terminate immediately with respect to such Regional Licensed Product following the Parties’ receipt of such decision or immediately following such admission, as applicable. 

10.2.3. Termination of Regional Licensed Product upon Exercise of the Co-Co/Global Option in respect of a Regional Licensed Product.
These Regional License Terms shall automatically be terminated with respect to a Regional Licensed Product if Genzyme exercises the Co-Co/Global Option in respect of such Regional Licensed Product under Section 3.2.2 of the Master Agreement
(Co-Co/Global Option Grant), which termination shall be effective as of the Option Exercise Date for the Co-Co/Global Option. In such event such former Regional Licensed Product shall be a Co-Co Licensed Product or a Global Licensed Product, as
applicable, and shall be governed by either the Co-Co License Terms or the Global License Terms. 
 10.2.4. Challenges of Patent Rights.
If, during the Term, Genzyme or any of its Affiliates (a) commences or participates in any action or proceeding (including any patent opposition or re-examination proceeding), or otherwise asserts any claim, challenging or denying the
validity or enforceability of any Alnylam Product-Specific Patent or any claim thereof or (b) actively assists any other Person or entity in bringing or prosecuting any action or proceeding (including any patent opposition or re-examination
proceeding) challenging or denying the validity or enforceability of any Alnylam Product-Specific Patent for a Regional Licensed Product or any claim thereof (each of (a) and (b), a “Patent Challenge”), then, to the extent
permitted by the applicable Laws, Alnylam shall have the right, exercisable within sixty (60) days following receipt of notice regarding such Patent Challenge, in its sole discretion, to give notice to Genzyme that Alnylam may terminate these
Regional Licensed Terms with respect to the Regional Licensed Product Covered by the Alnylam Product-Specific Patent that is the subject of the Patent Challenge (which termination will be effective ninety (90) days following such notice (or
such longer period as Alnylam may designate in such notice)), and, unless Genzyme or such Affiliate withdraws or causes to be withdrawn all such challenge(s) (or in the case of ex-parte proceedings, multi-party proceedings, or other Patent
Challenges that Genzyme or Genzyme’s Affiliates do not have the power to unilaterally withdraw or cause to be withdrawn, Genzyme and Genzyme’s Affiliates cease actively assisting any other party to such Patent Challenge and, to the extent
Genzyme or a Genzyme Affiliate is a party to such Patent Challenge, it withdraws from such Patent Challenge) within such ninety (90)-day period, Alnylam will have the right to terminate these Regional License Terms with respect to such Regional
Licensed Product by providing written notice thereof to Genzyme. The foregoing sentence shall not apply with respect to (i) any Alnylam Product-Specific Patent that Alnylam first asserts against Genzyme or any of its Affiliates where the Patent
Challenge is made in defense of such assertion or (ii) any Patent Challenge commenced by a Third Party that, after the Effective Date, acquires or is acquired by Genzyme or its Affiliates or its or their business or assets, whether by stock
purchase, merger, asset purchase or otherwise, but only with respect to Patent Challenges commenced prior to the closing of such acquisition. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 71 

 REGIONAL LICENSE TERMS 

 

 10.2.5. Abandonment of Development. At any time on or after [***], either Party may
terminate these Regional License Terms in their entirety (i.e., with respect to all Regional Licensed Products) if (a) no Regional Licensed Product has received Regulatory Approval anywhere in the Genzyme Territory, (b) no Regional
Licensed Product is being Developed for the Genzyme Territory, (c) no Global Development Plan or Genzyme Territory Development Plan is in effect for any Regional Licensed Product, provided that, if Genzyme provides Alnylam with a good
faith Genzyme Territory Development Plan pursuant to Section 2.2.4 (Genzyme Territory Development Plan) during the termination notice period set forth below in this Section 10.2.5, then the condition set forth in this clause (c) shall
be deemed not satisfied at such time and the applicable termination notice shall be deemed not to have effect, and (d) the absence of Development in the Genzyme Territory or a good faith Genzyme Territory Development Plan is not the result of a
breach by the Party seeking to terminate these Regional License Terms of its obligations under Section 2.4 (Diligence). In order to terminate these Regional License Terms pursuant to this Section 10.2.5, the terminating Party must provide
at least six (6) months’ prior written notice to the other Party referencing this Section 10.2.5 and specifying a termination date [***], provided that, with respect to any such termination by Alnylam, such notice must also
include an update regarding the current status of Alnylam’s Development activities with respect to Regional Licensed Products. 

10.3. Effect of Termination. 

10.3.1. Effects of Termination by Genzyme for Cause. 

10.3.1.1. Effects of Termination of Regional Licensed Product by Genzyme for Cause. Without limiting any other
legal or equitable remedies that either Party may have, if these Regional License Terms are terminated by Genzyme with respect to any particular Regional Licensed Product pursuant to Section 10.2.2 (Termination of a Regional Licensed Product
for Cause), then: 
 (a) these Regional License Terms shall continue to survive in all respects with respect to all Regional
Licensed Products other than the terminated Regional Licensed Product; 
 (b) all license grants in these Regional License
Terms with respect to the terminated Regional Licensed Product from either Party to the other shall immediately terminate; 

(c) Genzyme shall as promptly as practicable transfer to Alnylam or Alnylam’s designee (i) possession and ownership
of all Regulatory Approvals and pricing and reimbursement approvals relating to the Development, Manufacture or Commercialization of the terminated Regional Licensed Product, and (ii) copies of all non-clinical and clinical data and material
regulatory correspondence relating to the terminated Regional Licensed Product, provided that Alnylam shall reimburse Genzyme for reasonable out-of-pocket expenses incurred by Genzyme in connection with such transfer; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 72 

 REGIONAL LICENSE TERMS 

 

 (d) Genzyme will assign and transfer to Alnylam, all rights, title and
interests in and to any Alnylam Product-Specific Patents that relate solely to the terminated Regional Licensed Product that were assigned to Genzyme pursuant to Section 9.3.6 (Assignment of Alnylam Product-Specific Patents to Genzyme),
provided that Alnylam shall reimburse Genzyme for reasonable out-of-pocket expenses incurred by Genzyme in connection with such assignment and transfer. In such event, Genzyme will execute and deliver a patent assignment relating to such
Alnylam Product-Specific Patents in the same form used to assign such Patent Rights to Genzyme; and 
 (e) each Party shall
promptly pay any amounts owed to the other Party as of the effective date of such termination. 
 10.3.1.2. Effects
of Termination of Regional Licensed Product upon Exercise of the Co-Co/Global Option in respect of a Regional Licensed Product. Simultaneous with the Option Exercise Date for the Co-Co/Global Option in respect of a Regional Licensed Product that
is ALN-AT3 or ALN-AS1, these Regional License Terms shall automatically be terminated with respect to such Regional Licensed Product pursuant to Section 10.2.2.3 (Termination of Regional Licensed Product upon Exercise of the Co-Co/Global Option
in respect of a Regional Licensed Product), and all license grants in these Regional License Terms from either Party to the other shall immediately terminate with respect to the terminated Regional Licensed Product. In such event such former
Regional Licensed Product shall be a Co-Co Licensed Product or a Global Licensed Product, as applicable, and shall be governed by either the Co-Co License Terms or the Global License Terms. For clarity, notwithstanding any such termination, these
Regional License Terms shall continue to survive in all respects with respect to all Regional Licensed Products other than such terminated Regional Licensed Product. 

10.3.1.3. Effects of Termination of Regional Licensed Product by Alnylam for Cause or by Genzyme for Convenience.
Without limiting any other legal or equitable remedies that either Party may have, if these Regional License Terms are terminated with respect to any particular Regional Licensed Product by Genzyme pursuant to Section 10.2.1 (Termination of
Regional Licensed Product for Convenience), by Alnylam under Section 10.2.2 (Termination of Regional Licensed Product for Cause) or by Alnylam under Section 10.2.4 (Challenges of Patent Rights), then the provisions of this
Section 10.3.1.3 shall apply. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 73 

 REGIONAL LICENSE TERMS 

 

 (a) These Regional License Terms shall continue to survive in all respects
with respect to all Regional Licensed Products other than the terminated Regional Licensed Product. 
 (b) All license grants
in these Regional License Terms with respect to the terminated Regional Licensed Product from either Party to the other shall immediately terminate. 

(c) Any other siRNAs Developed by Alnylam that target the same human gene as the terminated Regional Licensed Product shall not
be considered Option Products for purposes of the Master Agreement; provided, however, that if Alnylam ceases active Development of such terminated Regional Licensed Product upon such termination, then the other siRNAs that target the
same human gene as such Regional Licensed Product shall again be considered Option Products for the purposes of the Master Agreement. [***] 

(d) Genzyme will grant to Alnylam, effective upon the effective date of termination and subject to the provisions of any
applicable Genzyme In-License, a non-transferable, sublicensable (on terms consistent with Section 6.2.4 (Sublicensing Terms)), worldwide, non-exclusive, royalty-free license under any Collaboration IP and Genzyme Patent Rights that Cover the
terminated Regional Licensed Product, in the form that such terminated Regional Licensed Product exists on the effective date of termination (a “Reverted Regional Licensed Product”), solely to the extent necessary to Develop and
Commercialize the Reverted Regional Licensed Product in the Field in the Genzyme Territory. Notwithstanding the foregoing, if (i) any Patent Rights that Cover the Reverted Regional Licensed Product are Controlled by Genzyme pursuant to a
Genzyme In-License and (ii) such Genzyme In-License cannot be assigned to Alnylam or does not relate exclusively to the Reverted Regional Licensed Product, Genzyme shall promptly disclose any payment obligations under such Genzyme In-License to
Alnylam and such Genzyme Patent Rights shall be subject to the license granted in this Section 10.3.1.3(d) only if Alnylam agrees in writing to (A) reimburse Genzyme for one hundred percent (100%) of any amounts that become payable
under such Genzyme In-License as a result of Alnylam’s exercise of the license granted in this Section 10.3.1.3(b), (B) comply with all applicable terms and conditions of such Genzyme In-License and (C) perform and take such
actions as may be required to allow Genzyme to comply with its obligations under such Genzyme In-License. 
 (e) Genzyme will
assign and transfer to Alnylam, all rights, title and interests in and to any Alnylam Product-Specific Patents that relate solely to the Reverted Regional Licensed Product that were assigned to Genzyme pursuant to Section 9.3.6 (Assignment of
Alnylam Product-Specific Patents to Genzyme). In such event, Genzyme will execute and deliver a patent assignment relating to such Alnylam Product-Specific Patents in the same form used to assign such Patent Rights to Genzyme. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 74 

 REGIONAL LICENSE TERMS 

 

 (f) The license grants to Alnylam in Section 6.2 (License Grants to
Alnylam) shall survive and shall be expanded to include the Genzyme Territory with respect to the Reverted Regional Licensed Product. 

(g) Genzyme shall as promptly as practicable transfer to Alnylam or Alnylam’s designee (i) possession and ownership
of all governmental or regulatory correspondence, conversation logs, filings and approvals (including all Regulatory Approvals and pricing and reimbursement approvals) solely relating to the Development, Manufacture or Commercialization of the
Reverted Regional Licensed Product, (ii) copies of all data, reports, records and materials, and other sales and marketing related information in Genzyme’s possession or Control to the extent that such data, reports, records, materials or
other information relate to the Development, Manufacture or Commercialization of the Reverted Regional Licensed Product, including all non-clinical and clinical data relating to the Reverted Regional Licensed Product, and customer lists and customer
contact information and all adverse event data related to the Reverted Regional Licensed Product in Genzyme’s possession or Control, provided that, for a period of [***] months after the effective date of termination with respect to such
Reverted Regional Licensed Product, Genzyme shall use Commercially Reasonable Efforts to obtain for Alnylam the right to access all such data, reports, records, materials, and other sales and marketing related information related to the Reverted
Regional Licensed Product, and (iii) all records and materials in Genzyme’s possession or Control containing Confidential Information of Alnylam solely relating to the Reverted Regional Licensed Product. In addition, Genzyme shall appoint
Alnylam as Genzyme’s and/or Genzyme’s Related Parties’ agent for all matters related to the Reverted Regional Licensed Product involving Regulatory Authorities in the Genzyme Territory until all Regulatory Approvals and other
regulatory filings have been transferred to Alnylam or its designee. 
 (h) If the effective date of termination is after
First Commercial Sale of the Reverted Regional Licensed Product, then Genzyme shall appoint Alnylam as its exclusive distributor of such Reverted Regional Licensed Product in the Genzyme Territory and grant Alnylam the right to appoint
sub-distributors, until such time as all Regulatory Approvals in the Genzyme Territory have been transferred to Alnylam or its designee. 

(i) If Genzyme or its Related Parties are Manufacturing finished product with respect to the Reverted Regional Licensed Product
on the effective date of termination, at Alnylam’s option, Genzyme or its Related Parties shall supply such finished product to Alnylam in the Genzyme Territory on terms no less favorable than those on which Genzyme supplied such finished
product prior to such termination to its most favored distributor in the Genzyme Territory, until the earlier of (i) such time as all Regulatory Approvals in the Genzyme Territory solely related to the Reverted Regional Licensed Product have
been transferred to Alnylam or its designee, Alnylam has obtained all necessary manufacturing approvals and Alnylam has procured or developed its own source of such finished product supply or (ii) [***] months following the effective date of
such termination. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 75 

 REGIONAL LICENSE TERMS 

 

 (j) If Alnylam so requests, and to the extent permitted under Genzyme’s
obligations to Third Parties on the effective date of termination, Genzyme shall transfer to Alnylam any Third Party agreements relating solely and exclusively to the Development, Manufacture or Commercialization of the Reverted Regional Licensed
Product to which Genzyme is a party (including any Genzyme In-License), subject to any required consents of such Third Party, which Genzyme shall use Commercially Reasonable Efforts to obtain promptly; 

(k) Genzyme shall promptly transfer and assign to Alnylam all of Genzyme’s and its Affiliates’ rights, title and
interests in and to the Genzyme Trademark(s) (but not any Genzyme house marks or any trademark containing the word “Genzyme” owned by Genzyme and used for the Reverted Regional Licensed Product in the Field in the Genzyme Territory) owned
by Genzyme and used solely and exclusively for the Reverted Regional Licensed Products in the Field in the Genzyme Territory. 

(l) Genzyme shall transfer to Alnylam any inventory of the Reverted Regional Licensed Products Controlled by Genzyme or its
Affiliates as of the termination date at the actual price paid by Genzyme for such supply. 
 (m) Genzyme shall provide any
other assistance reasonably requested by Alnylam for the purpose of allowing Alnylam or its designee to proceed expeditiously with the Development, Manufacture and Commercialization of the Reverted Regional Licensed Product in the Genzyme Territory,
provided that Genzyme’s obligations under this clause (m) of Section 10.3.1.3 shall expire [***] months after the effective date of termination of such Reverted Regional Licensed Product. 

(n) Genzyme shall execute all documents and take all such further actions as may be reasonably requested by Alnylam in order to
give effect to the foregoing clauses. 
 10.3.2. Effects of Termination for Abandonment of Development. If these Regional License
Terms are terminated in their entirety (i.e., with respect to all Regional Licensed Products) by either Party pursuant to Section 10.2.5 (Abandonment of Development), then the license granted to Alnylam under Section 6.2.2 (License
to Improvement Manufacturing Patent Rights) shall survive and all other licenses granted in these Regional License Terms from either Party to the other shall immediately terminate and: 

(a) Any other siRNAs Developed by Alnylam that target the same human gene as the terminated Regional Licensed Product shall not
be considered Option Products for purposes of the Master Agreement; provided, however, that if Alnylam ceases active Development of such terminated Regional Licensed Product upon such termination, then the other siRNAs that target the
same human gene as such Regional Licensed Product shall again be considered Option Products for the purposes of the Master Agreement. [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 76 

 REGIONAL LICENSE TERMS 

 

 (b) Genzyme shall as promptly as practicable transfer to Alnylam or
Alnylam’s designee (i) possession and ownership of all Regulatory Approvals and pricing and reimbursement approvals relating to the Development, Manufacture or Commercialization of the terminated Regional Licensed Product, and
(ii) copies of all non-clinical and clinical data and material regulatory correspondence relating to the terminated Regional Licensed Product. 

(c) Genzyme will assign and transfer to Alnylam, all rights, title and interests in and to any Alnylam Product-Specific Patents
that relate solely to the terminated Regional Licensed Product that were assigned to Genzyme pursuant to Section 9.3.6 (Assignment of Alnylam Product-Specific Patents to Genzyme). In such event, Genzyme will execute and deliver a patent
assignment relating to such Alnylam Product-Specific Patents in the same form used to assign such Patent Rights to Genzyme. 

(d) each Party shall promptly pay any amounts owed to the other Party as of the effective date of such termination. 

10.4. Fundamental Breach of Alnylam’s Development Obligations. Without limiting Genzyme’s rights under
Section 10.2.2 (Termination of a Regional Licensed Product for Cause) with respect to other material breaches, in the event that Alnylam commits a Fundamental Breach of its Development obligations under Section 2.4.2 (Alnylam Diligence)
with respect to any particular Regional Licensed Product, and Genzyme does not terminate these Regional License Terms in their entirety (i.e., with respect to all Regional Licensed Products) or with respect to such Regional Licensed Product
for cause pursuant to Section 10.2.2 (Termination of a Regional Licensed Product for Cause), then Genzyme may elect to receive the following remedies for such Fundamental Breach: 

10.4.1.1. Genzyme’s obligation to pay development milestone fees under Section 7.1 (Milestone Fees) with
respect to such Regional Licensed Product shall automatically terminate; 
 10.4.1.2. Genzyme will receive a credit,
which Genzyme may offset against royalties and sales milestones due to Alnylam with respect to such Regional Licensed Product pursuant to Section 7 (Certain Financial Terms), in an amount equal to one hundred fifty percent (150%) of all
costs and expenses (i) incurred by Genzyme to Develop such Regional Licensed Product for the Genzyme Territory that are in excess of the costs budgeted by Genzyme in connection with the Genzyme Territory Development Plan for such Regional
Licensed Product in effect at the time of Alnylam’s Fundamental Breach of Section 2.4.2 (Alnylam Diligence) with respect to such Regional Licensed Product and (ii) are incurred by Genzyme as a direct consequence of Alnylam’s
Fundamental Breach of Section 2.4.2 (Alnylam Diligence) with respect to such Regional Licensed Product; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 77 

 REGIONAL LICENSE TERMS 

 

 10.4.1.3. Genzyme may, in its discretion, terminate any or all of the
following provisions of these Regional License Terms (or any subsection thereof) with respect to such Regional Licensed Product: Section 3.1.3 (Regulatory Meetings), Section 4.1.3 (Joint Commercialization), Section 4.3 (Genzyme
Territory Commercialization Plan), Section 4.4 (Alnylam Territory Commercialization Plan), Section 4.5 (Advertising and Promotional Materials), Section 4.6 (Commercialization Reporting Obligations), and Section 5 (Collaboration
Management); and 
 10.4.1.4. Without limiting Genzyme’s remedies under these Regional License Terms or otherwise
with respect to breaches of Alnylam’s Development obligations under clause (a) of Section 2.4.2 (Alnylam Diligence) other than Fundamental Breaches, if Genzyme elects to receive the remedies set forth in this Section 10.4 with
respect to a Fundamental Breach of its Development obligations under clause (a) of Section 2.4.2 (Alnylam Diligence) with respect to such Regional Licensed Product, such remedies shall be Genzyme’s sole and exclusive remedies with
respect to such Fundamental Breach and Genzyme shall have no right to seek any further remedies or damages against Alnylam and its Affiliates with respect to such Fundamental Breach by Alnylam of clause (a) of Section 2.4.2 (Alnylam
Diligence). 
 10.5. Effect of Expiration or Termination; Survival. Any expiration or termination of these Regional License
Terms (a) shall not relieve the Parties of any obligation accruing prior to such expiration or termination and (b) shall be without prejudice to the rights of either Party against the other Party accrued or accruing under these Regional
License Terms prior to such expiration or termination, including the obligation to pay royalties for any Regional Licensed Product sold prior to such expiration or termination. The following provisions shall survive any expiration or termination of
these Regional License Terms in their entirety (i.e., with respect to all Regional Licensed Products) and, if these Regional License Terms expire or are terminated with respect to any particular Regional Licensed Product, shall survive with
respect to such Regional Licensed Product: (a) Sections 1 (Definitions), 8.3 (Warranty Disclaimer), 9.1 (Inventorship), 9.2 (Ownership), 10.3 (Effect of Termination), 10.5 (Effect of Termination or Expiration; Survival) and Section 11
(Performance by Affiliates) of these Regional License Terms and (b) Sections 1 (Definitions), 7 (Confidentiality and Publication), 9 (Royalty Reports; Payments; Audit), 10 (Indemnification; Limitation of Liability; Insurance), 12 (Term and
Termination) and 13 (Miscellaneous) of the Master Agreement. Section 7.2.6 (Royalty Floor) shall survive any termination or expiration of these Regional License Terms with respect to any Regional Licensed Product for royalties accruing prior to
such termination or expiration. Section 9 of the Master Agreement (Royalty Reports; Payments; Audit) will survive for so long as any royalties are due under these Regional License Terms plus three (3) years. Except as otherwise set forth
in this Section 10 or elsewhere in these Regional License Terms, upon termination or 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 78 

 REGIONAL LICENSE TERMS 

 

 
expiration of these Regional License Terms in their entirety, all rights and obligations of the Parties under these Regional License Terms shall cease, but, for clarity, expiration or termination
of these Regional License Terms in their entirety (i.e., with respect to all Regional Licensed Products) shall not result in the termination or expiration of the Master Agreement or any License Terms. Upon termination or expiration of these
Regional License Terms with respect to any particular Regional Licensed Product, all rights and obligations of the Parties under these Regional License Terms with respect to such Regional Licensed Product shall cease except as otherwise set forth in
this Section 10 or elsewhere in these Regional License Terms, but, for clarity, such termination or expiration shall not affect the Parties’ rights and obligations under these Regional License Terms with respect to any other Regional
Licensed Product. 
 11. PERFORMANCE BY AFFILIATES 

11.1. Use of Affiliates. Each Party acknowledges and accepts that the other Party may exercise its rights and perform its
obligations under these Regional License Terms either directly or through one or more of its Affiliates. A Party’s Affiliates will have the benefit of all rights (including all licenses) of such Party under these Regional License Terms.
Accordingly, in these Regional License Terms “Genzyme” will be interpreted to mean “Genzyme and/or its Affiliates” and “Alnylam” will be interpreted to mean “Alnylam and/or its Affiliates” where necessary to
give each Party’s Affiliates the benefit of the rights provided to such Party in these Regional License Terms; provided, however, that in any event each Party will remain responsible for the acts and omissions, including financial
liabilities, of its Affiliates. 
 11.2. Future Acquisition of a Party or its Business. [***] 

11.3. Acquired Programs. 

11.3.1. [***] 
 11.3.2.
[***] 
 11.4. For clarity, upon the closing of the acquisition of the stock and/or assets of Sirna Therapeutics, Inc. by Alnylam
from Merck Sharpe & Dohme Corp., all relevant acquired intellectual property rights acquired in such transaction that may be Controlled by Alnylam (without any further action by Alnylam or Sirna Therapeutics, Inc.) shall become Controlled
by Alnylam for the purposes of these Regional License Terms. 
 [THE REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 79 

 REGIONAL LICENSE TERMS 

 

 Schedule 1.2.13-1 

ALNYLAM CORE TECHNOLOGY PATENTS FOR ALN-TTR02 

See attached. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 80 

 REGIONAL LICENSE TERMS 

 

 Schedule 1.2.18-1 

ALNYLAM PRODUCT-SPECIFIC PATENTS FOR ALN-TTR02 

See attached. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 81 

 REGIONAL LICENSE TERMS 

 

 Schedule 2.2.1-1 

GLOBAL DEVELOPMENT STRATEGY FOR ALN-TTR02 

(To be attached when developed pursuant to Section 2.2.1) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 82 

 REGIONAL LICENSE TERMS 

 

 Schedule 2.2.2.1-1 

GLOBAL DEVELOPMENT PLAN FOR ALN-TTR02 

(To be attached when developed pursuant to Section 2.2.2.1) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 83 

 REGIONAL LICENSE TERMS 

 

 Schedule 2.2.2.6(d)-1 

ALNYLAM TERRITORY DEVELOPMENT PLAN FOR ALN-TTR02 

(To be attached when developed pursuant to Section 2.2.2.6(d).) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 84 

 REGIONAL LICENSE TERMS 

 

 Schedule 2.2.4-1 

GENZYME TERRITORY DEVELOPMENT PLAN FOR ALN-TTR02 

(To be attached when developed pursuant to Section 2.2.4.) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 85 

 REGIONAL LICENSE TERMS 

 

 Schedule 8.1 

DISCLOSURE SCHEDULE 

See attached. 
 Confidential 

  

 REGIONAL LICENSE TERMS 

 

 Confidential Materials omitted and filed separately with the Securities and Exchange
Commission. A total of 2 pages were omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 87 

 REGIONAL LICENSE TERMS 

 

 Schedule 8.1.12 

(A) EXISTING ALNYLAM IN-LICENSES 

(To be attached) 
 (B)
ADDITIONAL ALNYLAM INLICENSES 
 (To be attached) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 88 

 REGIONAL LICENSE TERMS 

 

 Schedule 8.4.1.3(c) 

EXCEPTIONS TO EXCLUSIVITY 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of 1 page was omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 89 

 APPENDIX B 

GLOBAL PRODUCT LICENSE AND COLLABORATION TERMS 

AN APPENDIX TO THE MASTER COLLABORATION AGREEMENT 

dated as of January 11, 2014 

by and between 
 ALNYLAM
PHARMACEUTICALS, INC. 
 and 

GENZYME CORPORATION 
 CERTAIN CONFIDENTIAL
PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL
TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 GLOBAL LICENSE TERMS 

 

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
	 1. RELATIONSHIP WITH MASTER AGREEMENT; DEFINITIONS
	  	 	1	  
		
	 1.1 Relationship with Master Agreement
	  	 	1	  
	 1.2 Definitions
	  	 	2	  
		
	 2. DEVELOPMENT
	  	 	16	  
		
	 2.1 Overview
	  	 	16	  
	 2.2 Transition
	  	 	16	  
	 2.3 Global Development Plan
	  	 	17	  
	 2.4 Development Costs
	  	 	17	  
	 2.5 Diligence
	  	 	18	  
	 2.6 Records; Reports; Information Sharing
	  	 	18	  
	 2.7 Third Parties
	  	 	19	  
		
	 3. REGULATORY MATTERS
	  	 	20	  
		
	 3.1 Regulatory Filings and Interactions
	  	 	20	  
	 3.2 Costs of Regulatory Affairs
	  	 	21	  
	 3.3 Right of Reference
	  	 	21	  
		
	 4. COMMERCIALIZATION OF THE GLOBAL LICENSED PRODUCTS
	  	 	21	  
		
	 4.1 Responsibility, Cost and Diligence
	  	 	21	  
	 4.2 Commercialization Summary
	  	 	21	  
	 4.3 First Commercial Sale Reporting Obligations
	  	 	21	  
	 4.4 Advertising and Promotional Materials
	  	 	21	  
	 4.5 Sales and Distribution
	  	 	22	  
	 4.6 Recalls, Market Withdrawals or Corrective Actions
	  	 	22	  
		
	 5. TRANSITION MANAGEMENT
	  	 	22	  
		
	 5.1 Joint Transition Team
	  	 	22	  
	 5.2 Meetings
	  	 	23	  
	 5.3 Minutes
	  	 	23	  
	 5.4 JTT Responsibilities
	  	 	23	  
	 5.5 Decision-Making
	  	 	23	  
	 5.6 Term of JTT
	  	 	24	  
		
	 6. MANUFACTURE AND SUPPLY OF THE GLOBAL LICENSED PRODUCTS
	  	 	24	  
		
	 6.1 Manufacturing and Supply
	  	 	24	  
		
	 7. LICENSES
	  	 	24	  
		
	 7.1 License Grants to Genzyme
	  	 	24	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -i- 

					
	 7.2 License Grants to Alnylam
	  	 	27	  
	 7.3 Joint Collaboration IP
	  	 	28	  
	 7.4 In-Licenses
	  	 	28	  
	 7.5 Right of First Negotiation
	  	 	28	  
	 7.6 Bankruptcy
	  	 	29	  
	 7.7 No Other Rights
	  	 	30	  
		
	 8. CERTAIN FINANCIAL TERMS
	  	 	30	  
		
	 8.1 Milestone Fees
	  	 	30	  
	 8.2 Royalties
	  	 	32	  
		
	 9. REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	35	  
		
	 9.1 Representations and Warranties of Alnylam
	  	 	35	  
	 9.2 Representations and Warranties of Genzyme
	  	 	37	  
	 9.3 Warranty Disclaimer
	  	 	37	  
	 9.4 Certain Covenants
	  	 	37	  
		
	 10. INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS
	  	 	38	  
		
	 10.1 Inventorship
	  	 	38	  
	 10.2 Ownership
	  	 	38	  
	 10.3 Prosecution and Maintenance of Patent Rights
	  	 	39	  
	 10.4 Third Party Infringement
	  	 	43	  
	 10.5 Patent Term Extensions
	  	 	45	  
	 10.6 Common Interest
	  	 	46	  
	 10.7 Trademarks
	  	 	46	  
	 10.8 Cooperative Research and Technology (CREATE) Act Acknowledgment
	  	 	46	  
		
	 11. TERM AND TERMINATION
	  	 	47	  
		
	 11.1 Term
	  	 	47	  
	 11.2 Termination Rights
	  	 	47	  
	 11.3 Effect of Termination
	  	 	48	  
	 11.4 Effect of Expiration or Termination; Survival
	  	 	51	  
		
	 12. PERFORMANCE BY AFFILIATES
	  	 	52	  
		
	 12.1 Use of Affiliates
	  	 	52	  
	 12.2 Future Acquisition of a Party or its Business
	  	 	52	  
	 12.3 Acquired Programs
	  	 	52	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -ii- 

 GLOBAL LICENSE TERMS 

 

 SCHEDULES 
  

			
	Schedule 1.2.8	  	Alnylam Core Technology Patents
		
	Schedule 1.2.15	  	Alnylam Product-Specific Patents
		
	Schedule 1.2.96	  	Licensed Target
		
	Schedule 9.1	  	Disclosure Schedule
		
	Schedule 9.1.12	  	Existing Alnylam In-Licenses / Additional Alnylam In-Licenses
		
	Schedule 9.4.1(e)	  	Exceptions to Exclusivity

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -iii- 

 GLOBAL LICENSE TERMS 

 

 GLOBAL PRODUCT LICENSE AND COLLABORATION TERMS 

THESE GLOBAL PRODUCT LICENSE AND COLLABORATION TERMS are Appendix B to the Master Collaboration Agreement, dated as of the Execution
Date, by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”), and Genzyme Corporation, a corporation organized and existing under the laws of the
Commonwealth of Massachusetts (“Genzyme”).  
 RECITALS: 

WHEREAS, Alnylam and Genzyme are parties to that certain Master Collaboration Agreement (dated as of the Execution Date) (the
“Master Agreement”) pursuant to which Genzyme has options to receive licenses and other rights with respect to up to two Global Licensed Products from Alnylam in the Licensed Territory;  

WHEREAS, Genzyme may exercise its Co-Co/Global Option pursuant to the Master Agreement for ALN-AS1 and such siRNA will then become a
Global Licensed Product; 
 WHEREAS, Genzyme may exercise its Global Option or Trailing Global Option pursuant to the Master
Agreement for any Global Option Product thereunder and such Global Option Product will then be deemed a Global Licensed Product;  

WHEREAS, if Genzyme does not exercise the Co-Co/Global Option pursuant to the Master Agreement for ALN-AS1 or ALN-AT3, Genzyme may
exercise its Additional Global Option pursuant to the Master Agreement for any Global Option Product thereunder and such Global Option Product will then be deemed a Global Licensed Product; and 

WHEREAS, Alnylam and Genzyme now wish to set forth the terms and conditions under which Genzyme will have the right to Commercialize
such Global Licensed Products in the Licensed Territory. 
 NOW, THEREFORE, in consideration of the foregoing premises and the
mutual covenants herein contained, the Parties hereby agree as follows: 
  

	1.	RELATIONSHIP WITH MASTER AGREEMENT; DEFINITIONS 

 1.1 Relationship
with Master Agreement. These Global License Terms become effective on a Global Licensed Product-by-Global Licensed Product basis on the Implementation Date in accordance with the Master Agreement. The Master Agreement generally governs the
Parties’ relationship with respect to Global Licensed Products during the period of time before Genzyme exercises its Co-Co/Global Option, Global Option or Additional Global Option under the Master Agreement (i.e., before such product
became a Global Licensed Product). The Master Agreement also contains terms that are generally applicable to Global Licensed Products, Regional Licensed Products (as defined in the Master Agreement) and Co-Co Licensed Products (as defined in the
Master Agreement). Accordingly, the following Sections of the Master Agreement are 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
  

 GLOBAL LICENSE TERMS 

 

 
incorporated herein by reference: Section 2.2 (Effectiveness of Licenses to Collaboration Products); Section 5 (Collaboration Management); Section 6 (Manufacture and Supply of the
Collaboration Products); Section 7 (Confidentiality and Publication); Section 9 (Royalty Reports; Payments; Audit); Section 10 (Indemnification; Limitation of Liability; Insurance); Section 12.2.4 (Challenges of Patent Rights);
and Section 13 (Miscellaneous). 
 1.2 Definitions. Unless specifically set forth to the contrary
herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 

1.2.1 “Acquired Business” has the meaning set forth in Section 12.3 (Acquired Programs). 

1.2.2 “Acquirer” has the meaning set forth in Section 12.2 (Future Acquisition of a Party or its
Business). 
 1.2.3 “Additional Alnylam In-Licenses” has the meaning set forth in the Master
Agreement. 
 1.2.4 “Additional Global Option” has the meaning set forth in the Master Agreement.

 1.2.5 “AF11 Lipid Nanoparticle Formulation” has the meaning set forth in the Master Agreement.

 1.2.6 “Affiliate” means, with respect to a Person, any other Person which controls, is controlled
by, or is under common control with the applicable Person. For purposes of this definition, “control” means: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or
shares entitled to vote for the election of directors, or otherwise having the power to control or direct the affairs of such Person; and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent
(50%) of the equity interest or the power to direct the management and policies of such non-corporate entities. 

1.2.7 “AJSC” has the meaning set forth in the Master Agreement. 

1.2.8 “ALN-AS1” has the meaning set forth in the Master Agreement. 

1.2.9 “ALN-AT3” has the meaning set forth in the Master Agreement. 

1.2.10 “Alnylam Core Technology Patents” means Patent Rights Controlled by Alnylam during the Term that
are [***]. The Alnylam Core Technology Patents existing as of the Implementation Date for any Global Licensed Product will be identified as the “Alnylam Core Technology Patents” in the Option Data Package for such Global Licensed Product
provided by Alnylam to Genzyme under the Master Agreement and then attached hereto as Schedules 1.2.8-1 and 1.2.8-2, if applicable. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -2- 

 GLOBAL LICENSE TERMS 

 

 1.2.11 “Alnylam Developed siRNA Product” means an
siRNA with respect to which (a) Alnylam Controls Patent Rights Covering such siRNA, provided that once a product first satisfies the criterion set forth in this clause (a) such criterion shall be deemed satisfied at all times
thereafter as to such product; and (b) Alnylam or an Affiliate of Alnylam plays(ed) a material role in the Development. 

1.2.12 “Alnylam In-License” means any Existing Alnylam In-License or any Collaboration
In-License to which Alnylam is a party.  
 1.2.13 “Alnylam Know-How” means Know-How
Controlled by Alnylam during the Term that is reasonably necessary or useful for Genzyme to Develop, Manufacture and/or Commercialize Global Licensed Products in the Field in the Licensed Territory, other than Alnylam’s interest in Know-How
included in Joint Collaboration IP. 
 1.2.14 “Alnylam Patents” means Alnylam Core Technology Patents
and Alnylam Product-Specific Patents. 
 1.2.15 “Alnylam Product-Specific Patents” means
Patent Rights Controlled by Alnylam during the Term that claim [***]. The Alnylam Product-Specific Patents existing as of the Implementation Date for any Global Licensed Product will be identified as the “Alnylam Product-Specific
Patents” in the Option Data Package for such Global Licensed Product provided by Alnylam to Genzyme under the Master Agreement and then attached hereto as Schedules 1.2.15-2 and 1.2.15-3, if applicable. [***]  

1.2.16 “Alnylam Technology” means, collectively, Alnylam Know-How, Alnylam Patents and Alnylam’s
interest in Joint Collaboration IP. 
 1.2.17 “Alnylam Trademark” has the meaning set forth in
Section 10.7(a) (Trademarks). 
 1.2.18 “ANDA” means an Abbreviated New Drug Application (or any
successor application or procedure) as defined in regulations promulgated by the FDA under the FDCA, which ANDA is filed with or intended to be filed with the FDA (and, as applicable, any other analogous application filed with a Regulatory Authority
in any country other than the U.S. in the Licensed Territory) for Regulatory Approval for marketing and selling a Global Licensed Product in the Licensed Territory. 

1.2.19 “Back-Up Option” has the meaning set forth in Section 7.1.5 (Back-Up Products). 

1.2.20 “Back-Up Option Exercise Notice” has the meaning set forth in Section 7.1.5 (Back-Up
Products). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -3- 

 GLOBAL LICENSE TERMS 

 

 1.2.21 “Back-Up Option Period” means [***]. 

1.2.22 “Back-Up Product” has the meaning set forth in Section 7.1.5 (Back-Up Products). 

1.2.23 “Bankrupt Party” has the meaning set forth in Section 7.6 (Bankruptcy). 

1.2.24 “Calendar Quarter” means the respective periods of three (3) consecutive calendar months
ending on March 31, June 30, September 30 and December 31 of each Calendar Year, provided that (a) the first Calendar Quarter of the Term shall begin on the Effective Date and end on the first to occur of
March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Term shall end on the last day of the Term and (b) the first Calendar Quarter of a Royalty Term for a Global Licensed
Product in a country shall begin on the First Commercial Sale of a Global Licensed Product in such country and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar
Quarter of a Royalty Term shall end on the last day of such Royalty Term. 
 1.2.25 “Calendar Year”
means each successive period of twelve (12) months commencing on January 1 and ending on December 31, provided that (a) the first Calendar Year of the Term shall begin on the Effective Date and end on the first
December 31 thereafter and the last Calendar Year of the Term shall end on the last day of the Term and (b) the first Calendar Year of a Royalty Term for a Global Licensed Product in a country shall begin on the First Commercial Sale of a
Global Licensed Product in such country and end on the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of such Royalty Term. 

1.2.26 “Carbohydrate Conjugate” has the meaning set forth in the Master Agreement. 

1.2.27 “Clinical Study” has the meaning set forth in the Master Agreement. 

1.2.28 “Co-Co/Global Option” has the meaning set forth in the Master Agreement. 

1.2.29 “Co-Co/Global Option Product” has the meaning set forth in the Master Agreement. 

1.2.30 “Collaboration” has the meaning set forth in the Master Agreement. 

1.2.31 “Collaboration In-License” has the meaning set forth in the Master Agreement. 

1.2.32 “Collaboration Product” has the meaning set forth in the Master Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -4- 

 GLOBAL LICENSE TERMS 

 

 1.2.33 “Commercialization” or
“Commercialize” has the meaning set forth in the Master Agreement. 
 1.2.34
“Commercialization Summary” has the meaning set forth in Section 4.2 (Commercialization Summary). 

1.2.35 “Commercially Reasonable Efforts” means [***]. 

1.2.36 “Competing Program” has the meaning set forth in Section 12.3.1 (Acquired Programs). 

1.2.37 “Competitive Infringement” has the meaning set forth in Section 10.4.1 (Notices). 

1.2.38 “Confidential Information” has the meaning set forth in the Master Agreement. 

1.2.39 “Control”, “Controls” or “Controlled by” has the meaning set
forth in the Master Agreement. 
 1.2.40 “Cost of Goods” has the meaning set forth in the Master
Agreement. 
 1.2.41 “Cover,” “Covering” or “Covers” has the
meaning set forth in the Master Agreement. 
 1.2.42 “CPI” means the Consumer Price Index –
Urban Wage Earners and Clerical Workers, U.S. City Average, All Items, 1982-84 = 100, published by the United States Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the United States. 

1.2.43 “Development,” “Developing” or “Develop” has the meaning set
forth in the Master Agreement. 
 1.2.44 “Development Information” has the meaning set forth in
Section 2.2 (Transition). 
 1.2.45 “Effective Date” means the date that the Master Agreement
becomes effective in accordance with its terms. 
 1.2.46 “EMA” means the European Medicines Agency
and any successor Governmental Authority having substantially the same function. 
 1.2.47 “EU” means
the European Union, as its membership may be altered from time to time, and any successor thereto. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -5- 

 GLOBAL LICENSE TERMS 

 

 1.2.48 “Exclusivity Period” means, on a Global
Licensed Product-by-Global Licensed Product and country-by-country basis within the Licensed Territory, the period of time commencing on the Implementation Date for such Global Licensed Product and continuing until the first to occur of
(a) [***]. 
 1.2.49 “Existing Alnylam In-License” has the meaning set forth in the Master
Agreement. 
 1.2.50 “Execution Date” has the meaning set forth in the Master Agreement. 

1.2.51 “Exercise Notice” has the meaning set forth in the Master Agreement. 

1.2.52 “Existing Genzyme In-License” has the meaning set forth in the Master Agreement. 

1.2.53 “FDA” means the United States Food and Drug Administration and any successor Governmental
Authority having substantially the same function. 
 1.2.54 “FDCA” means the United States Federal
Food, Drug, and Cosmetic Act of 1938, as amended from time to time, and the regulations and guidelines promulgated thereunder. 

1.2.55 “Field” means the treatment, diagnosis and/or prevention of all human diseases. 

1.2.56 “First Commercial Sale” means, with respect to a country, the first sale for end use or
consumption of a Global Licensed Product in such country, except for compassionate use or patient access programs, after all Regulatory Approvals legally required for such sale have been granted by the Regulatory Authority of such country. 

1.2.57 “First Regulatory Approval by the EMA” means, with respect to a Global Licensed Product, the
earlier of (i) if Regulatory Approval in the EU is sought through the EMA centralized procedure, receipt of Regulatory Approval for such Global Licensed Product from the EMA or (ii) if Regulatory Approval in the EU is sought through a
national authorization procedure, receipt of Regulatory Approval for such Global Licensed Product in the first (1st) MMC in the EU. 

1.2.58 “First Regulatory Approval in Japan” means, with respect to a Global Licensed Product, receipt
of Regulatory Approval for such Global Licensed Product in Japan. 
 1.2.59 “GalNAc Conjugate” has
the meaning set forth in the Master Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -6- 

 GLOBAL LICENSE TERMS 

 

 1.2.60 “Generic Competition” means, with respect to a
Global Licensed Product in any country in the Licensed Territory in a given Calendar Quarter, that, during such Calendar Quarter, (a) one or more Generic Products with respect to such Global Licensed Product are commercially available in such
country, and (b) Net Sales of such Global Licensed Product in such country in such Calendar Quarter equal less than [***] of the average Net Sales of such Global Licensed Product over the [***] consecutive Calendar Quarters immediately prior to
the Calendar Quarter in which one or more Generic Products first became commercially available in such country. 
 1.2.61
“Generic Product” means, on a Global Licensed Product-by-Global Licensed Product and country-by-country basis, a pharmaceutical product that (a) is sold by a Person that is not a Related Party of Genzyme under a marketing
authorization granted by a Regulatory Authority in such country to a Third Party; (b) [***] and (c) is approved by the Regulatory Authority in such country pursuant to an approval process that relies in part on pivotal safety and/or
efficacy data in such Regulatory Authority’s previous grant of marketing authorization for such Global Licensed Product. 

1.2.62 “Genzyme Collaboration IP” means (a) any Know-How, first identified, discovered or
developed solely by employees of Genzyme or its Affiliates or other persons not employed by Alnylam acting on behalf of Genzyme, in the conduct of the Collaboration and (b) any Patent Rights that claim or cover such Know-How and are Controlled
by Genzyme at any time during the Term. Genzyme Collaboration IP excludes Genzyme’s interest in Joint Collaboration IP, in each case (a) and (b), other than Genzyme Manufacturing IP. 

1.2.63 “Genzyme Disclosed Manufacturing Know-How” means Know-How (a) Controlled by Genzyme at any
time during the Term that is useful in the Manufacture of a Global Licensed Product and (b) that Genzyme, in its sole discretion, discloses in writing to Alnylam in the course of the Collaboration. 

1.2.64 “Genzyme In-License” means any Existing Genzyme In-License, Un-Blocking Genzyme In-License or
any Collaboration In-License to which Genzyme is a party. 
 1.2.65 “Genzyme Know-How” means Know-How
Controlled by Genzyme during the Term that is reasonably necessary or useful for Alnylam to Develop, Commercialize and/or Manufacture Global Licensed Products in the Field in the Licensed Territory (other than Genzyme’s rights in Joint
Collaboration IP, Genzyme Collaboration IP and Genzyme Manufacturing IP). 
 1.2.66 “Genzyme Manufacturing
IP” means (a) any Know-How related to the Manufacture of Global Licensed Products (or oligonucleotides generally) Controlled by Genzyme at any time during the Term, and (b) any Patent Rights that claim or cover such Know-How and
are Controlled by Genzyme at any time during the Term, excluding Improvement Manufacturing Patent Rights and Genzyme Disclosed Manufacturing Know-How. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -7- 

 GLOBAL LICENSE TERMS 

 

 1.2.67 “Genzyme Patent Jurisdictions” has the meaning
set forth in the Master Agreement. 
 1.2.68 “Genzyme Patent Rights” means those Patent Rights
Controlled by Genzyme during the Term that are reasonably necessary or useful to Develop, Commercialize and/or Manufacture Global Licensed Products in the Field in the Licensed Territory. Genzyme Patent Rights excludes Patent Rights included in
Genzyme Collaboration IP, Genzyme’s interest in Joint Collaboration IP and Genzyme Manufacturing IP. 
 1.2.69
“Genzyme Technology” means, collectively, Genzyme Know-How, Genzyme Patent Rights, Genzyme Collaboration IP and Genzyme’s interest in Joint Collaboration IP, but excluding Genzyme Manufacturing IP. 

1.2.70 “Genzyme Trademarks” has the meaning set forth in Section 10.7(a) (Trademarks). 

1.2.71 “Global Branding Strategy” has the meaning set forth in Section 4.4.1 (Global Branding).

 1.2.72 “Global Development Plan” has the meaning set forth in Section 2.3 (Global Development
Plan). 
 1.2.73 “Global License Terms” means this Appendix B to the Master Agreement (Global Product
License and Collaboration Terms) and the provisions of the Master Agreement to the extent applicable to Global Licensed Products. 

1.2.74 “Global Licensed Product” means (i) if Genzyme exercises the Co-Co/Global Options for
ALN-AS1 pursuant to the Master Agreement, then ALN-AS1 as of the applicable Option Exercise Date, (ii) if Genzyme exercises the Global Option or the Trailing Global Option for any Global Option Product pursuant to the Master Agreement, then
such Global Option Product as of the applicable Option Exercise Date, (iii) if Genzyme exercises the Additional Global Option for any Global Option Product pursuant to the Master Agreement, then such Global Option Product as of the applicable
Option Exercise Date, and (iv) if Genzyme exercises a Back-Up Option for any Back-Up Product pursuant to Section 7.1.5 (Back-Up Products), then such Back-Up Product as of the date of delivery of the Back-Up Option Exercise Notice, in each
case (i) through (iv) above, for as long as the Global License Terms apply to ALN-AS1, such Global Option Product or such Back-Up Product. 

1.2.75 “Global Option” has the meaning set forth in the Master Agreement. 

1.2.76 “Global Option Period” has the meaning set forth in the Master Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -8- 

 GLOBAL LICENSE TERMS 

 

 1.2.77 “Global Option Product” has the meaning set
forth in the Master Agreement. 
 1.2.78 “Global Out-of-Pocket Costs” means, with respect to certain
activities hereunder, direct expenses paid or payable by either Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities for a Global Licensed Product, including payments to contract personnel;
provided, however, that amounts paid to contract sales and marketing personnel will not be considered Global Out-of-Pocket Costs. 

1.2.79 “GLP Clinical Supply Agreements” means each clinical supply agreement entered into between
Alnylam and Genzyme as described in Section 6.2 of the Master Agreement (Collaboration Product Supply Agreements) pursuant to which Alnylam will provide clinical supplies of a specified Global Licensed Product to Genzyme. 

1.2.80 “GLP Collaboration” means the collaboration of the Parties in the Development, Manufacture and
Commercialization of Global Licensed Products under these Global License Terms. 
 1.2.81 “GLP Commercial
Supply Agreements” means each commercial supply agreement entered into between Alnylam and Genzyme as described in Section 6.2 of the Master Agreement (Collaboration Product Supply Agreements) pursuant to which Alnylam will provide
commercial supplies of a specified Global Licensed Product to Genzyme. 
 1.2.82 “GLP Supply
Agreements” means, collectively, the GLP Clinical Supply Agreements and the GLP Commercial Supply Agreements. 

1.2.83 “Good Laboratory Practices” has the meaning set forth in the Master Agreement. 

1.2.84 “Governmental Authority” means any applicable government authority, court, tribunal, arbitrator,
agency, department, legislative body, commission or other instrumentality of (a) any government of any country or territory, (b) any nation, state, province, county, city or other political subdivision thereof or (c) any supranational
body. 
 1.2.85 “Human POP Study” has the meaning set forth in the Master Agreement. 

1.2.86 “IFRS” has the meaning set forth in the Master Agreement. 

1.2.87 “Implementation Date” means (i) with respect to ALN-AS1 or each Global Licensed Product
with respect to which Genzyme exercised the Global Option or Additional Global Option, the Option Exercise Date for ALN-AS1 or such Global Licensed Product, as applicable, and (ii) with respect to each Back-Up Product with respect to which
Genzyme exercised the Back-Up Option, the date on which Genzyme sent to Alnylam the Back-Up Option Exercise Notice for such Back-Up Product under Section 7.1.5 (Back-Up Products). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -9- 

 GLOBAL LICENSE TERMS 

 

 1.2.88 “Improvement Manufacturing Patent Right” means
a Patent Right owned exclusively by Genzyme or its Affiliates that claims an invention related to the Manufacture of a Global Licensed Product that was made (a) by Genzyme or its Affiliates after the Effective Date in connection with
Manufacturing Global Licensed Products and (b) using Alnylam Know-How that, at the time such Alnylam Know-How was disclosed to Genzyme or its Affiliates, constituted Alnylam’s Confidential Information under Section 7 of the Master
Agreement (Confidentiality and Publication). 
 1.2.89 “IND” has the meaning set forth in the Master
Agreement. 
 1.2.90 “In-License” has the meaning set forth in the Master Agreement. 

1.2.91 “Infringement Action” has the meaning set forth in Section 10.4.2(a) (Rights to Enforce
– Genzyme Technology). 
 1.2.92 “Joint Collaboration IP” means, collectively, (a) any
Know-How first identified, discovered or developed jointly by employee(s), agent(s) or consultant(s) acting on behalf of Alnylam or its Affiliates, on the one hand, and employee(s), agent(s) or consultant(s) acting on behalf of Genzyme or its
Affiliates, on the other hand, in the conduct of the Collaboration that is Controlled by Alnylam and Genzyme, and (b) any Patent Rights that Cover such Know-How and are Controlled by Alnylam and Genzyme. 

1.2.93 “Joint Transition Team” or “JTT” means the transition team as more fully
described in Section 5.1 (Joint Transition Team). 
 1.2.94 “Know-How” has the meaning set forth
in the Master Agreement. 
 1.2.95 “Laws” has the meaning set forth in the Master Agreement. 

1.2.96 “Licensed Target” means, for each Global Licensed Product, the human gene that is targeted by
such Global Licensed Product, as identified in the Option Data Package for such Global Licensed Product and then attached hereto as Schedules 1.2.96-1 and 1.2.96-2, if applicable. 

1.2.97 “Licensed Territory” means worldwide. 

1.2.98 “Lipid Nanoparticle Formulation” has the meaning set forth in the Master Agreement. 

1.2.99 “Manufacturing” or “Manufacture” has the meaning set forth in the Master
Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -10- 

 GLOBAL LICENSE TERMS 

 

 1.2.100 “Manufacturing Claim” means a claim within a
Patent Right directed solely to Manufacturing a Global Licensed Product. 
 1.2.101 “MMC” means
[***]. 
 1.2.102 “NDA” has the meaning set forth in the Master Agreement. 

1.2.103 “Net Sales” means, with respect to a Global Licensed Product, the aggregate gross invoiced
sales prices from sales of all units of such Global Licensed Product sold by Genzyme and its Related Parties to independent Third Parties (other than a Sublicensee) after deducting, if not previously deducted, from the amount invoiced or received:

 (a) trade, quantity and cash discounts, credits or allowances actually given; 

(b) returns, rejections or recalls (due to spoilage, damage, expiration of useful life or otherwise); 

(c) Third Party rebates, chargebacks, hospital buying group/group purchasing organization administration fees or managed care
organization rebates actually given; 
 (d) rebates and similar payments made with respect to sales paid for by any
governmental or regulatory authority such as Federal or state Medicaid, Medicare or similar state program; 
 (e)
distribution fees and sales commissions paid to Third Parties; 
 (f) retroactive price reductions or billing corrections;

 (g) value added, sales and use, excise and other similar taxes and surcharges, customary transportation and insurance,
custom duties, and other governmental charges; and 
 (h) amounts previously included in Net Sales of such Global Licensed
Product that are adjusted or written-off by Genzyme or its Related Parties as bad debt or otherwise uncollectible in accordance with the standard practices of Genzyme or its Related Parties for writing off uncollectible amounts consistently applied;
provided, however, if any such written-off amounts are subsequently collected, such collected amounts shall be included in Net Sales in the period in which they are subsequently collected. 

Such amounts shall be determined from the books and records of Genzyme or its Related Parties, maintained in accordance with IFRS. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -11- 

 GLOBAL LICENSE TERMS 

 

 In the case of any sale or other disposal for value, such as barter or counter-trade, of a
Global Licensed Product, or part thereof, other than in an arm’s length transaction exclusively for cash, Net Sales shall be calculated as above on the value of the non-cash consideration received or the fair market price (if higher) of such
Global Licensed Product in the country of sale or disposal, as determined in accordance with IFRS. 
 Notwithstanding the foregoing, the
following will not be included in Net Sales: (1) sales between or among Genzyme and its Related Parties (but Net Sales shall include sales to the first Third Party (other than a Sublicensee) by Genzyme or its Related Parties); (2) samples
of Global Licensed Product used to promote additional Net Sales, in amounts consistent with normal business practices of Genzyme; and (3) disposal or use of Global Licensed Products in Clinical Studies or under compassionate use, patient
assistance, named patient use, or test marketing programs or non-registrational studies or other similar programs or studies where the Global Licensed Product is supplied without charge or at the actual manufacturing cost thereof (without allocation
of indirect costs or any mark-up). 
 In the case where a Global Licensed Product is sold as part of a Combination Product in a country in
the Licensed Territory, Net Sales for the Global Licensed Product included in such Combination Product in such country shall be calculated as follows: 
  

	 	(i)	if the Global Licensed Product is sold separately in such country and the other active ingredient or ingredients in the Combination Product are sold separately in such country, Net Sales for the Global Licensed Product
shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the fraction A/(A+B), where A is the invoice price of the Global Licensed Product when sold separately in such country and B is the total invoice
price of the other active ingredient or ingredients in the Combination Product when sold separately in such country; 

  

	 	(ii)	if the Global Licensed Product is sold separately in such country but the other active ingredient or ingredients in the Combination Product are not sold separately in such country, Net Sales for the Global Licensed
Product shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the fraction A/D, where A is the invoice price of the Global Licensed Product when sold separately in such country and D is the invoice price
of the Combination Product in such country; 

  

	 	(iii)	if the Global Licensed Product is not sold separately in such country but the other active ingredient or ingredients in the Combinations Product are sold separately in such country, Net Sales for the Global Licensed
Product shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction 1 – (B/D), where B is the invoice price of the other active ingredient or ingredients in the Combination Product when sold separately in
such country and D is the invoice price of the Combination Product; or 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -12- 

 GLOBAL LICENSE TERMS 

 

	 	(iv)	if neither the Global Licensed Product nor the other active ingredient or ingredients in the Combination Product are sold separately in such country, the Parties shall determine Net Sales for the Global Licensed Product
in such Combination Product by mutual agreement based on the relative contribution of the Global Licensed Product and each other active ingredient to the Combination Product, and shall take into account in good faith any applicable allocations and
calculations that may have been made for the same period in other countries. 

 For purposes of this Section,
“Combination Product” means a product that includes at least one active ingredient other than a Global Licensed Product. Drug delivery vehicles, adjuvants, and excipients shall not be deemed to be “active ingredients”,
except in the case where such delivery vehicle, adjuvant, or excipient is recognized by the FDA as an active ingredient in accordance with 21 C.F.R. 210.3(b)(7). 

1.2.104 “Non-Bankrupt Party” has the meaning set forth in Section 7.6 (Bankruptcy). 

1.2.105 “Option Data Package” has the meaning set forth in the Master Agreement. 

1.2.106 “Option Exercise Date” has the meaning set forth in the Master Agreement. 

1.2.107 “Party” means Genzyme and/or Alnylam. 

1.2.108 “Patent Rights” has the meaning set forth in the Master Agreement. 

1.2.109 “Person” means any natural person, corporation, unincorporated organization, partnership,
association, sole proprietorship joint stock company, joint venture, limited liability company, trust or government, or any Governmental Authority, or any other similar entity. 

1.2.110 “Phase III Study” has the meaning set forth in the Master Agreement. 

1.2.111 “PJSC” has the meaning set forth in the Regional License Terms (as defined in the Master
Agreement) and the meaning set forth in the Co-Co License Terms (as defined in the Master Agreement). 
 1.2.112
“Product Trademark(s)” means the Trademarks used, or intended for use, in connection with the distribution, marketing, promotion and sale of the Global Licensed Products. Product Trademarks specifically exclude the corporate names and
logos of the Parties and their Affiliates. Product Trademark includes both the Alnylam Trademarks and the Genzyme Trademarks. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -13- 

 GLOBAL LICENSE TERMS 

 

 1.2.113 “Promotional Materials” has the meaning set
forth in Section 4.4.2 (Promotional Materials). 
 1.2.114 “R&D Cost Opt-In Date” has the
meaning set forth in Section 2.4(a) (Development Costs). 
 1.2.115 “R&D Costs” means, with
respect to a Global Licensed Product, costs and expenses incurred in connection with the performance of any Development activity for such Global Licensed Product, including [***]. 

1.2.116 “R&D FTE” means [***] hours of work per annum devoted to or in support of the Development
or Manufacture of a Global Licensed Product that is carried out by one or more qualified scientific or technical employees (excluding Third Party contractors) of a Party or its Affiliates. 

1.2.117 “R&D FTE Cost” means, for any period, the R&D FTE Rate multiplied by the number of
R&D FTEs in such period. 
 1.2.118 “R&D FTE Rate” means [***] per FTE, increased annually
beginning on January 1, 2015 and thereafter on January 1 of each succeeding year by the percentage increase in the CPI as of December 31 of the then most recently ended calendar year over the level of the CPI on December 31,
2013. 
 1.2.119 “Regulatory Approval” has the meaning set forth in the Master Agreement. 

1.2.120 “Regulatory Authority” has the meaning set forth in the Master Agreement. 

1.2.121 “Regulatory Exclusivity” means, with respect to a Global Licensed Product in a country, any
exclusive marketing right, data exclusivity right, orphan drug designation or other country-wide exclusive right or status conferred by any Governmental Authority with respect to such Global Licensed Product in such country, other than a Patent
Right, that limits or prohibits a Person [***]. 
 1.2.122 “Related Party” means a Party’s
Affiliates and permitted Sublicensees. 
 1.2.123 “Reverted Global Licensed Product” has the meaning
set forth in Section 11.3.2(b) (Effects of Termination of Global Licensed Product by Alnylam for Cause or by Genzyme for Convenience). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -14- 

 GLOBAL LICENSE TERMS 

 

 1.2.124 “Royalty Term” has the meaning set forth in
Section 8.2.2 (Royalty Term). 
 1.2.125 “Serious Adverse Event” has the meaning set forth in
the Master Agreement. 
 1.2.126 “siRNA” has the meaning set forth in the Master Agreement. 

1.2.127 “SPCs” has the meaning set forth in Section 10.5 (Patent Term Extensions). 

1.2.128 “Sublicensee” means a Third Party to whom a Party grants a sublicense under any Alnylam
Technology or Genzyme Technology, as the case may be, pursuant to Section 7.1.4 (Sublicensing Terms) or Section 7.2.3 (Sublicensing Terms). 

1.2.129 “Term” has the meaning set forth in Section 11.1 (Term). 

1.2.130 “Third Party” has the meaning set forth in the Master Agreement. 

1.2.131 “Third Party License Payment” has the meaning set forth in the Master Agreement. 

1.2.132 “Trademark” has the meaning set forth in the Master Agreement. 

1.2.133 “Trailing Global Option” has the meaning set forth in the Master Agreement. 

1.2.134 “Transition Activities” has the meaning set forth in Section 2.2 (Transition). 

1.2.135 “Transition Period” means with respect to a Global Licensed Product, the period beginning on
the Implementation Date for such Global Licensed Product and ending on the date that such period is terminated by Genzyme pursuant to Section 5.6 (Term of JTT). 

1.2.136 “Transition Plan” has the meaning set forth in Section 2.2 (Transition). 

1.2.137 “Un-Blocking Genzyme In-License” has the meaning set forth in the Master Agreement. 

1.2.138 “United States” means the United States of America and its territories, possessions and
commonwealths. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -15- 

 GLOBAL LICENSE TERMS 

 

 1.2.139 “Valid Claim” means a claim of: (a) an
issued and unexpired patent, which claim has not been withdrawn, cancelled, abandoned, disclaimed, revoked or held unenforceable or invalid by an unappealable decision of a court or other governmental agency of competent jurisdiction, or has not
been appealed within the time allowed for appeal, or by an appealed decision of a court or other governmental agency of competent jurisdiction where the appeal has been pending for more than [***] years (unless and until such decision is
subsequently overturned on appeal) and which has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise; or (b) a patent application that has been pending
less than [***] years from the date of filing of the earliest patent application from which such patent application claims priority, which claim has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action
from which no appeal can be taken. 
 2. DEVELOPMENT 

2.1 Overview. Genzyme will have the sole right to Develop Global Licensed Products in the Licensed Territory.

 2.2 Transition. Within [***] days after the Implementation Date for a Global Licensed Product, Alnylam shall
prepare and provide to Genzyme a draft plan for the transition of the Development of such Global Licensed Product from Alnylam to Genzyme (a “Transition Plan”). Promptly following the delivery of such draft Transition Plan to
Genzyme (and in any event no later than [***] days following such delivery), the JTT responsible for such Global Licensed Product shall finalize the Transition Plan for such Global Licensed Product. The Transition Plan for each Global Licensed
Product will require Alnylam to, as soon as reasonably practicable following the Implementation Date with respect to such Global Licensed Product: (a) assign the Alnylam Product-Specific Patents to Genzyme pursuant to Section 10.3.6.1
(Assignment of Alnylam Product-Specific Patents); (b) transfer to Genzyme all Know-How Controlled by Alnylam that is reasonably necessary or useful for Developing such Global Licensed Product, or obtaining or maintaining Regulatory Approval for
such Global Licensed Product in the Licensed Territory, including information and materials reasonably requested by Genzyme, in a format reasonably acceptable to Genzyme (which shall be specified in such Transition Plan, along with the process of
transferring such Know-How); (c) assign to Genzyme all INDs and other regulatory filings submitted to, or filed with, any Regulatory Authority with respect to such Global Licensed Product, as well as any related regulatory documents submitted
to any Regulatory Authority with respect to such Global Licensed Product, excluding any drug master files maintained by or on behalf of Alnylam; (d) transfer to Genzyme all written correspondence with any Regulatory Authority with respect to
such Global Licensed Product and all written minutes of meetings and memoranda of oral communications with any Regulatory Authority with respect to such Global Licensed Product; (e) assign to Genzyme any Third Party agreements relating solely
and exclusively to the Development of such Global Licensed Product to which Alnylam is a party (including any Alnylam In-License), subject to any required consents of such Third Party, which Alnylam shall use reasonable

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -16- 

 GLOBAL LICENSE TERMS 

 

 
efforts to obtain; and (f) transfer to Genzyme any other information or materials reasonably requested by Genzyme that are reasonably necessary or useful for Development of such Global
Licensed Product in the Licensed Territory (the items described in clauses (a) through (f) collectively, “Development Information”). The Transition Plan for each Global Licensed Product will also describe any Development
activities with respect to such Global Licensed Product that Alnylam is required to perform as requested by Genzyme and mutually agreed upon by the Parties (“Transition Activities”). [***]. With respect to each of Alnylam’s
employees who were engaged in the Development of a Global Licensed Product prior to the Implementation Date for such Global Licensed Product, Alnylam shall (i) commit a sufficient portion of such employee’s working hours to enable the
completion of the activities set forth in the Transition Plan for such Global Licensed Product in accordance with the timeline set forth in such Transition Plan and (ii) make such employee available to Genzyme at Genzyme’s reasonable
request until the obligations in such Transition Plan with respect to which such employee has or had relevant experience or knowledge are completed. 

2.3 Global Development Plan. Within [***] days following the Implementation Date with respect to a Global
Licensed Product, Genzyme shall provide the JTT responsible for such Global Licensed Product with a work plan and time table for the Development activities and Clinical Studies to be undertaken with respect to such Global Licensed Product in the
Licensed Territory (a “Global Development Plan”). During the Transition Period with respect to a Global Licensed Product, Genzyme shall update the Global Development Plan for such Global Licensed Product annually and shall provide
such updated Global Development Plan to the JTT responsible for such Global Licensed Product. Each JTT shall review and comment on each Global Development Plan submitted to it by Genzyme and Genzyme shall consider such JTT’s comments;
provided, however, that Genzyme will have sole discretion and control over the contents of such Global Development Plan. 

2.4 Development Costs.  

                (a) With respect to any Global
Licensed Product, if Genzyme exercised the Co-Co/Global Option, Global Option or Additional Global Option with respect to such Global Licensed Product, Genzyme shall be responsible for one-hundred percent (100%) of all R&D Costs that occur
after the later of (i) [***] (such later date, the “R&D Cost Opt-In Date”) and amounts specified in clauses (ii) and (iii) in Section 2.4(b) below, if any. Alnylam shall be responsible for one-hundred percent
(100%) of R&D Costs for such Global Licensed Product that occur prior to the R&D Cost Opt-In Date, except for amounts specified in clauses (ii) and (iii) of Section 2.4(b) below, if any. 

                (b) The Global R&D Costs to
be shared by the Parties pursuant to Section 2.4(a) above shall only include amounts that are within one or more of the following four (4) categories: 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -17- 

 GLOBAL LICENSE TERMS 

 

	 	(i)	[***] 

  

	 	(ii)	[***] 

  

	 	(iii)	[***] 

  

	 	(iv)	[***] 

 (c) For clarity, R&D Costs to be paid by Genzyme pursuant to
Section 2.4(a) shall exclude any amounts paid after the R&D Cost Opt-In Date to Third Parties with respect to services rendered or services procured in connection with the conduct of any Clinical Study or Development activity that, in
either case, is completed prior to the R&D Cost Opt-In Date. 
 (d) The amount of all R&D Costs to be paid by Genzyme
pursuant to Section 2.4(a) and incurred by Alnylam prior to the delivery of the Option Data Package for a Global Licensed Product will be set forth therein. 

(e) Alnylam will invoice Genzyme for the R&D Costs to be paid by Genzyme pursuant to Section 2.4(a) and incurred by
Alnylam. Alnylam will provide copies of invoices from vendors and other supporting documentation as reasonably requested by Genzyme. Genzyme shall reimburse Alnylam within [***] days after receipt by Genzyme of such invoice. Genzyme shall reimburse
Alnylam on a quarterly basis for R&D FTE Costs, Global Out-of-Pocket Costs and Cost of Goods incurred by Alnylam in the performance of Transition Activities, within [***] days after receipt by Genzyme of an invoice for such amounts from Alnylam.

 2.5 Diligence. Genzyme will use Commercially Reasonable Efforts to [***]. 

2.6 Records; Reports; Information Sharing. 

2.6.1 Development Activities. Following the Transition Period with respect to a Global Licensed Product, [***] Genzyme
will provide to Alnylam, through the AJSC, an update regarding Development activities conducted by or on behalf of Genzyme with respect to such Global Licensed Product, as well as any Clinical Studies with respect to such Global Licensed Product
conducted by Genzyme. 
 2.6.2 Scientific Records. Genzyme will maintain scientific records, in sufficient
detail and in sound scientific manner appropriate for patent and regulatory purposes and in compliance with Good Laboratory Practices with respect to activities intended to be submitted in regulatory filings (including INDs and NDAs), which will
fully and properly reflect all work done and results achieved in the performance of the Development activities and Clinical Studies with respect to Global Licensed Products. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -18- 

 GLOBAL LICENSE TERMS 

 

 2.6.3 Information Exchange and Development Assistance. Following the
completion of the Transition Plan with respect to a Global Licensed Product, Alnylam shall deliver to Genzyme, [***] and in a commercially reasonable format, any Development Information with respect to such Global Licensed Product that comes into
Alnylam’s Control or possession. If, following the completion of the Transition Plan with respect to a Global Licensed Product, Alnylam discovers that it Controls or possesses any Development Information with respect to such Global Licensed
Product that should have been transferred by Alnylam to Genzyme under the Transition Plan but that was not so transferred, Alnylam will promptly provide such Development Information to Genzyme. 

2.6.4 Personnel. Genzyme may request that Alnylam reasonably make available for consultation regarding the
Development of a Global Licensed Product certain of its employees engaged in Development activities with respect to such Global Licensed Product. 

2.6.5 Confidentiality. All information exchanged by the Parties under this Section 2 will be deemed to be
Confidential Information of the disclosing Party and maintained in accordance with Section 7 of the Master Agreement (Confidentiality and Publication); provided, however, that all Development Information with respect to a Global
Licensed Product delivered by Alnylam to Genzyme pursuant to Section 2.2 (Transition) or 2.6.3 (Information Exchange and Development Assistance) shall be deemed to be Confidential Information of Genzyme. 

2.7 Third Parties. The Parties shall be entitled to utilize the services of Third Parties to perform their
respective Development and Manufacturing activities under these Global License Terms, provided that (a) each Party shall require that such Third Party operates in a manner consistent with the terms of these Global License Terms and
(b) each Party shall remain at all times fully liable for its respective responsibilities. Each Party shall require that any such Third Party agreement include confidentiality and non-use provisions that are no less stringent than those set
forth in Section 7 of the Master Agreement (Confidentiality and Publication) and shall obtain ownership of, and/or a fully sublicensable license under and to, any Know-How and Patent Rights that are developed by such Third Party in the
performance of such agreement and are reasonably necessary or useful to Develop, Manufacture and/or Commercialize Global Licensed Products in the Field. The Party utilizing the services of a Third Party service provider shall be solely responsible
for direction of and communications with such Third Party. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -19- 

 GLOBAL LICENSE TERMS 

 

	3.	REGULATORY MATTERS 

 3.1 Regulatory Filings and
Interactions. 
 3.1.1 Ownership of Regulatory Filings. Genzyme will own all INDs, NDAs and related regulatory
documentation submitted to any Regulatory Authority in the Licensed Territory with respect to any Global Licensed Product, excluding any drug master files maintained by or on behalf of Alnylam. At Genzyme’s request following the Implementation
Date for a Global Licensed Product, Alnylam will promptly assign and transfer to Genzyme all INDs, NDAs and other regulatory documentation submitted to any Regulatory Authority in the Licensed Territory with respect to such Global Licensed Product
that is in the possession or control of Alnylam, excluding any drug master files maintained by or on behalf of Alnylam, and each Party will submit all filings, letters and other documentation necessary to effect such assignment and transfer to the
applicable Regulatory Authority no later than [***] days after such request for such Global Licensed Product. Alnylam hereby appoints Genzyme as Alnylam’s agent for all matters related to each Global Licensed Product involving Regulatory
Authorities in the Licensed Territory during the period beginning on the Implementation Date for such Global Licensed Product and ending on the date that the transfer of all INDs, NDAs and related regulatory documents filed with or submitted to any
Regulatory Authority in the Licensed Territory that relate to such Global Licensed Product, excluding any drug master files maintained by or on behalf of Alnylam, becomes effective, and Genzyme hereby accepts such appointment. 

3.1.2 Responsibilities for Regulatory Matters. Genzyme will be solely responsible for all regulatory matters relating to
Global Licensed Products in the Licensed Territory, including (i) overseeing, monitoring and coordinating all regulatory actions, communications and filings with, and submissions to, each Regulatory Authority in the Licensed Territory with
respect to Global Licensed Products; (ii) interfacing, corresponding and meeting with each Regulatory Authority in the Licensed Territory with respect to Global Licensed Products; and (iii) seeking and maintaining all regulatory filings in
the Licensed Territory with respect to Global Licensed Products. 
 3.1.3 Communications with Regulatory Authorities.
Genzyme will provide Alnylam, through the AJSC, as part of the quarterly updates regarding Development activities described in Section 2.6.1 (Development Activities), with a brief description in English, of the principal issues raised in
any material communication with any Regulatory Authority in the Licensed Territory with respect to any Global Licensed Product during the preceding Calendar Quarter. For purposes of this Section 3.1.3, “material communication” with
Regulatory Authorities include meetings with Regulatory Authorities and Regulatory Authority questions or concerns regarding significant issues, including any of the following: key product quality attributes (e.g., purity), safety findings
affecting the platform (e.g., Serious Adverse Events, emerging safety signals), clinical or nonclinical findings affecting patient safety, or lack of efficacy. 

3.1.4 Submissions. With respect to each Global Licensed Product, Genzyme shall provide Alnylam with prompt written
notice of each of the following events (but in any event within [***] days) after the occurrence of such event in the Licensed Territory: (i) the filing of any IND for such Global Licensed Product; (ii) the submission of any filings or
applications for Regulatory Approval (including orphan drug applications and designations) of such Global Licensed Product to any Regulatory Authority; and (iii) receipt or denial of Regulatory Approval for such Global Licensed Product;
provided, however, that in all circumstances, Genzyme shall inform Alnylam of such event prior to public disclosure of such event by Genzyme. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -20- 

 GLOBAL LICENSE TERMS 

 

 3.2 Costs of Regulatory Affairs. Genzyme shall be responsible
for all costs and expenses incurred in connection with applying for Regulatory Approval with respect to Global Licensed Products in the Licensed Territory, and related regulatory affairs activities. 

3.3 Right of Reference. Alnylam hereby grants to Genzyme, and at the request of Genzyme will grant to
Genzyme’s Related Parties, a “Right of Reference,” as that term is defined in 21 C.F.R. § 314.3(b) (or any successor rule or analogous Law recognized outside of the United States), to, and a right to copy, access, and otherwise
use, all information and data (including all CMC information as well as data made, collected or otherwise generated in the conduct of any Clinical Studies or early access/named patient programs for the Global Licensed Products) included in or used
in support of any drug master file maintained by or on behalf of Alnylam or its Related Parties that relates to any Global Licensed Product to the extent necessary or useful to Develop, Manufacture or Commercialize Global Licensed Products in the
Licensed Territory. Notwithstanding anything to the contrary in these Global License Terms, Alnylam shall not withdraw or inactivate any regulatory filing that the other Party references or otherwise uses pursuant to this Section 3.3. 

 

	4.	COMMERCIALIZATION OF THE GLOBAL LICENSED PRODUCTS 

 4.1
Responsibility, Cost and Diligence. Genzyme shall be solely responsible, at its expense, for all Commercialization activities relating to Global Licensed Products in the Field in the Licensed Territory. Genzyme shall use Commercially
Reasonable Efforts to [***]. 
 4.2 Commercialization Summary. No less [***] months in advance of the
reasonably expected first Regulatory Approval in the Licensed Territory with respect to a Global Licensed Product, and annually thereafter, Genzyme shall prepare and deliver to Alnylam, through the AJSC, [***] (the “Commercialization
Summary”). 
 4.3 First Commercial Sale Reporting Obligations. Genzyme shall provide Alnylam with
written notice of the First Commercial Sale of each Global Licensed Product. 
 4.4 Advertising and Promotional
Materials. 
 4.4.1 Global Branding. Genzyme shall have the sole right, from time to time during the Term, to
develop (and thereafter modify and update) a global branding strategy (including global positioning, messages, logo, colors and other visual branding elements) for each Global Licensed Product for use in the Field throughout the Licensed

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -21- 

 GLOBAL LICENSE TERMS 

 

 
Territory (the “Global Branding Strategy”) for review by the AJSC. Except as prohibited by applicable Law, the labeling for each Global Licensed Product shall include a
reasonably prominent reference to such Global Licensed Product as being sold under license from Alnylam and, if applicable, a reasonably prominent reference to Alnylam as the manufacturer of such Global Licensed Product. 

4.4.2 Promotional Materials. Genzyme will be responsible for the creation, preparation, production, reproduction and
filing with the applicable Regulatory Authorities, of relevant written sales, promotion and advertising materials relating to each Global Licensed Product (“Promotional Materials”) for use in the Licensed Territory. All such
Promotional Materials will be compliant with applicable Law. 
 4.5 Sales and Distribution. Genzyme and its
Related Parties shall be solely responsible for booking sales and shall warehouse and distribute Global Licensed Products in the Licensed Territory. 

4.6 Recalls, Market Withdrawals or Corrective Actions. In the event that any Regulatory Authority issues or
requests a recall or takes a similar action in connection with a Global Licensed Product, Genzyme shall have the sole right to decide whether to conduct a recall and the manner in which any such recall shall be conducted. Genzyme shall bear the
expense of any such recall. 
  

	5.	TRANSITION MANAGEMENT 

 5.1 Joint Transition Team. The Parties
shall establish a joint transition team (a “JTT”) to facilitate the transition of each Global Licensed Product from Alnylam to Genzyme as follows: 

5.1.1 Composition of the Joint Transition Team. The transition of each Global Licensed Product from Alnylam to Genzyme
shall be conducted under the oversight of a JTT, which shall comprise three (3) representatives of each Party. Each Party shall appoint its respective representatives to the JTT for a Global Licensed Product within [***] days following the
Implementation Date for such Global Licensed Product, and may substitute one or more of its representatives, in its sole discretion, effective upon notice to the other Party of such change. Each representative on a JTT shall have appropriate
expertise and ongoing familiarity with the applicable Global Licensed Product and the GLP Collaboration generally. Additional representatives or consultants may from time to time, by mutual consent of the Parties, be invited to attend JTT meetings,
subject to such representatives and consultants undertaking confidentiality obligations, whether in a written agreement or by operation of law, no less stringent than the requirements of Section 7 of the Master Agreement (Confidentiality and
Publication). 
 5.1.2 JTT Chairperson. The JTT chairperson shall be a JTT representative of Genzyme. The JTT
chairperson’s responsibilities shall include (a) scheduling meetings; (b) setting agendas for meetings with solicited input from other members; (c) coordinating the delivery of draft minutes to the JTT for review and final
approval; and (d) conducting meetings, including ensuring that objectives for each meeting are set and achieved. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -22- 

 GLOBAL LICENSE TERMS 

 

 5.2 Meetings. Each JTT shall meet in accordance with a schedule
established by mutual written agreement of the Parties, but no less frequently than once per Calendar Quarter, with the location for such meetings alternating between Alnylam and Genzyme facilities (or such other locations as are mutually agreed by
the Parties). Alternatively, a JTT may meet by means of teleconference, videoconference or other similar communications equipment. All proceedings for each JTT shall take place in English. Where the membership of a JTT for a Global Licensed Product
is the same as one or more other JTTs for other Global Licensed Products or PJSCs for other Collaboration Products, such JTTs and PJSCs may have a single meeting to discuss each Global Licensed Product and other Collaboration Product for which they
have responsibility. Each Party shall bear its own expenses relating to attendance at such meetings by its representatives. 

5.3 Minutes. A secretary shall be appointed for each meeting of each JTT and shall prepare minutes of the
meeting, which shall provide a description in reasonable detail of the discussions held at the meeting and a list of any actions, decisions or determinations approved by such JTT. 

5.4 JTT Responsibilities. The JTT with respect to a Global Licensed Product shall have the following
responsibilities with respect to such Global Licensed Product: 
 (a) finalizing and approving a Transition Plan for such
Global Licensed Product that meets the requirements set forth in Section 2.2 (Transition), including any Transition Activities that Alnylam will be obligated to perform under such Transition Plan; 

(b) reviewing and commenting on the initial Global Development Plan for such Global Licensed Product, and reviewing and
commenting on updates to the Global Development Plan provided by Genzyme; 
 (c) overseeing any manufacturing and supply
relationship between the Parties with respect to the Manufacture of such Global Licensed Product for Development activities (subject to the terms of the GLP Clinical Supply Agreement, if any); and 

(d) performing such other activities as the Parties agree in writing shall be the responsibility of such JTT. 

5.5 Decision-Making. Each JTT shall not have any decision-making authority with respect to any matters under
these Global License Terms; provided, however, that each JTT shall have the authority to approve the Transition Plan for the Global Licensed Product for which such JTT is responsible. With respect to approving a

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -23- 

 GLOBAL LICENSE TERMS 

 

 
Transition Plan, the representatives of each Party on a JTT shall have collectively one vote on behalf of such Party and such JTT shall attempt to approve such Transition Plan by consensus. If
the applicable JTT fails to approve a Transition Plan for a Global Licensed Product within [***] days following the Implementation Date with respect to such Global Licensed Product, then the matter shall be submitted to the AJSC. If the matter is
still unresolved after a further [***] days, then such matter shall be submitted to [***]. 
 5.5.1 [***] 

(a) [***] 

(b) [***] 

(c) [***] 

(d) [***] 

(e) [***] 

5.6 Term of JTT. After the commencement of a Phase III Study for a Global Licensed Product, either Party shall
have the right to terminate the Transition Period with respect to such Global Licensed Product which will relieve the Parties’ obligations to participate in the JTT for such Global Licensed Product. 

 

	6.	MANUFACTURE AND SUPPLY OF THE GLOBAL LICENSED PRODUCTS 

 6.1
Manufacturing and Supply. The Manufacturing of each Global Licensed Product will be addressed in the Master Agreement and breach of such Manufacturing terms as applied to a Global Licensed Product shall be treated as a breach under these
Global License Terms, and not under the Master Agreement. 
  

	7.	LICENSES 

 7.1 License Grants to Genzyme. 

7.1.1 Development License. On a Global Licensed Product-by-Global Licensed Product basis, subject to the provisions of
these Global License Terms (including Section 9.4.1(e) (Exclusivity)) and any GLP Clinical Supply Agreement, effective upon the Implementation Date for such Global Licensed Product, Alnylam hereby grants Genzyme a non-transferable (except as
provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 7.1.4 (Sublicensing Terms)), exclusive (even as to Alnylam) license under Alnylam Technology other than Patent Rights assigned to Genzyme
pursuant to Section 10.3.6.1 (Assignment of Alnylam Product-Specific Patents) to Develop such Global Licensed Product in the Field in the Licensed Territory. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -24- 

 GLOBAL LICENSE TERMS 

 

 7.1.2 Commercialization License. On a Global Licensed
Product-by-Global Licensed Product basis, subject to the provisions of these Global License Terms (including Section 9.4.1(e) (Exclusivity)) and any GLP Commercial Supply Agreement, effective upon the Implementation Date for such Global
Licensed Product, Alnylam hereby grants Genzyme a non-transferable (except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 7.1.4 (Sublicensing Terms)), exclusive (even as to Alnylam)
license under Alnylam Technology other than Patent Rights assigned to Genzyme pursuant to Section 10.3.6.1 (Assignment of Alnylam Product-Specific Patents) to Commercialize such Global Licensed Product in the Field in the Licensed Territory.
Such license shall be royalty-bearing for the Royalty Term applicable to each Global Licensed Product in each country in the Licensed Territory, and, after the Royalty Term applicable to such Global Licensed Product in such country, shall convert to
a fully-paid, perpetual license to Commercialize such Global Licensed Product in the Field in such country. 
 7.1.3
Manufacturing License. On a Global Licensed Product-by-Global Licensed Product basis, subject to the provisions of these Global License Terms (including Section 9.4.1(e) (Exclusivity)), any GLP Supply Agreement and any Third Party Supply
Agreement, effective upon the Implementation Date for such Global Licensed Product, Alnylam hereby grants Genzyme a non-transferable (except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to
Section 7.1.4 (Sublicensing Terms)), worldwide, exclusive (even as to Alnylam) license under Alnylam Technology other than Patent Rights assigned to Genzyme pursuant to Section 10.3.6.1 (Assignment of Alnylam Product-Specific Patents) to
Manufacture such Global Licensed Product. Notwithstanding the foregoing, Alnylam retains the right under the Alnylam Technology, with the right to grant licenses through multiple tiers without restriction, to Manufacture Global Licensed Products
anywhere in the world to supply (or have supplied) Genzyme pursuant to any GLP Supply Agreement. 
 7.1.4 Sublicensing
Terms. 
 (a) Subject to Section 7.5 (Right of First Negotiation), Genzyme shall have the right to sublicense any of
its rights under Sections 7.1.1 (Development License), 7.1.2 (Commercialization License) and 7.1.3 (Manufacturing License) to any of its Affiliates or to any Third Party (which sublicensed rights may be further sublicensable through multiple
tiers) without the prior consent of Alnylam, subject to the requirements of this Section 7.1.4. [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -25- 

 GLOBAL LICENSE TERMS 

 

 (b) Each sublicense granted by Genzyme pursuant to this Section 7.1.4
shall be subject and subordinate to the provisions of these Global License Terms and shall contain provisions consistent with those in these Global License Terms. Genzyme shall promptly provide Alnylam with a copy of the fully executed sublicense
agreement covering any sublicense granted hereunder (which copy may be redacted to remove provisions which are not necessary to monitor compliance with this Section 7.1.4), and each such sublicense agreement shall contain the following
provisions: (i) a requirement that the Sublicensee comply with the confidentiality and non-use provisions of Section 7 of the Master Agreement (Confidentiality and Publication) with respect to Alnylam’s Confidential Information,
(ii) if such sublicense agreement contains a sublicense of Global Licensed Product Commercialization rights, such sublicense agreement shall also contain the following provisions: (x) a requirement that the Sublicensee submit applicable
sales or other reports to Genzyme to the extent necessary or relevant to the reports required to be made or records required to be maintained under these Global License Terms; and (y) the audit requirement set forth in Section 9.2 of the
Master Agreement (Audits); and (iii) a requirement that the Sublicensee comply with the applicable provisions under any Alnylam In-License. 

(c) If Genzyme becomes aware of a material breach of the terms of any sublicense by any Genzyme Sublicensee, compliance with
which is necessary for Genzyme’s compliance with the terms of these Global License Terms, Genzyme shall promptly notify Alnylam of the particulars of the same and use Commercially Reasonable Efforts to cause the Sublicensee to comply with all
the terms of the sublicense necessary for Genzyme’s compliance with the terms of these Global License Terms. [***] Notwithstanding any sublicense, Genzyme shall remain primarily liable to Alnylam for the performance of all of Genzyme’s
obligations under, and Genzyme’s compliance with all provisions of, these Global License Terms. 
 7.1.5 Back-Up
Products. Subject to Sections 12.2 (Future Acquisition of a Party or its Business), 12.3.1 (Acquired Programs), and 12.3.2 (Acquired Programs), Alnylam hereby grants to Genzyme a series of exclusive options (each, a “Back-Up
Option”), under each of which Genzyme shall have the right, but not the obligation, to take a license on the terms set forth in the these Global License Terms to any siRNA that targets the same Licensed Target as a Global Licensed Product
(a “Back-Up Product”) and for which Alnylam has determined the siRNA composition for which GLP toxicology studies will be conducted during the Back-Up Option Period. Genzyme may exercise the Back-Up Option with respect to such
Back-Up Product by delivering written notice to Alnylam at any time during the Back-Up Option Period (the “Back-Up Option Exercise Notice”). Upon delivery of the Back-Up Option Exercise Notice to Alnylam, the applicable Back-Up
Product shall automatically be deemed to be a Global Licensed Product for all purposes under the Collaboration Agreement and the license from Alnylam to Genzyme for such Global Licensed Product shall automatically, with no further action by any
Party, go into full force and effect and all obligations of Alnylam and Genzyme set forth in these Global License Terms, including the payment obligations set forth herein, shall become the binding obligations of the applicable Party in respect of
such Global Licensed Product. Upon the expiration of the Back-Up Option Period, all Back-Up Options not previously exercised shall automatically terminate. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -26- 

 GLOBAL LICENSE TERMS 

 

 7.2 License Grants to Alnylam.  

7.2.1 License to Improvement Manufacturing Patent Rights. Subject to the provisions of these Global License Terms,
Genzyme hereby grants Alnylam a non-transferable (except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 7.2.3 (Sublicensing Terms)), worldwide, non-exclusive license under the
Improvement Manufacturing Patent Rights, to Manufacture (a) Alnylam Developed siRNA Products targeting any human gene; and (b) Global Licensed Products for Development and Commercialization in the Licensed Territory by Genzyme. 

7.2.2 License to Genzyme Disclosed Manufacturing Know-How. Subject to the provisions of these Global License Terms,
Genzyme hereby grants Alnylam a non-transferable (except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 7.2.3 (Sublicensing Terms)), worldwide, non-exclusive license under the Genzyme
Disclosed Manufacturing Know-How to Manufacture Global Licensed Products for Development and Commercialization in the Licensed Territory by Genzyme. 

7.2.3 Sublicensing Terms. 

(a) Subject to Section 7.5 (Right of First Negotiation), Alnylam shall have the right to sublicense any of its rights
under Sections 7.2.1 (License to Improvement Manufacturing Patent Rights) and 7.2.2 (License to Genzyme Disclosed Manufacturing Know-How) (which sublicensed rights may be further sublicensable through multiple tiers) to [***]. 

(b) Each sublicense granted by Alnylam pursuant to this Section 7.2.3 shall be subject and subordinate to the provisions
of these Global License Terms and shall contain provisions consistent with those in these Global License Terms. Alnylam shall promptly provide Genzyme with a copy of the fully executed sublicense agreement covering any sublicense granted hereunder
(which copy may be redacted to remove provisions which are not necessary to monitor compliance with this Section 7.2.3), and each such sublicense agreement shall contain the following provisions: (i) a requirement that the Sublicensee
comply with the confidentiality and non-use provisions of Section 7 of the Master Agreement (Confidentiality and Publication) with respect to Genzyme’s Confidential Information and (ii) a requirement that the Sublicensee comply with
the applicable provisions under any Genzyme In-License. 
 (c) If Alnylam becomes aware of a material breach of any
sublicense by any Alnylam Sublicensee, compliance with which is necessary for Alnylam’s compliance with the provisions of these Global License Terms, Alnylam shall promptly notify Genzyme of the particulars of the same and use Commercially
Reasonable Efforts to cause the Sublicensee to comply with all the terms of the sublicense necessary for Alnylam’s compliance with the provisions of these Global License Terms. [***]. Notwithstanding any sublicense, Alnylam shall remain
primarily liable to Genzyme for the performance of all of Alnylam’s obligations under, and Alnylam’s compliance with all provisions of, these Global License Terms. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -27- 

 GLOBAL LICENSE TERMS 

 

 7.3 Joint Collaboration IP. Subject to the rights and licenses
granted to, and the obligations (including royalty obligations) of, each Party under these Global License Terms, either Party is entitled to practice Joint Collaboration IP for all purposes on a worldwide basis and license Joint Collaboration IP
without consent of and without a duty of accounting to the other Party. Each Party will grant and hereby does grant all permissions, consents and waivers with respect to, and all licenses under, the Joint Collaboration IP, throughout the world,
necessary to provide the other Party with such rights of use and exploitation of the Joint Collaboration IP, and will execute documents as necessary to accomplish the foregoing. 

7.4 In-Licenses.  

7.4.1 Compliance with In-Licenses. All licenses and other rights granted to Genzyme under this Section 7 are
subject to the rights and obligations of Alnylam under the Alnylam In-Licenses. All licenses and other rights granted to Alnylam under this Section 7 are subject to the rights and obligations of Genzyme under the Genzyme In-Licenses. Each Party
shall comply with all applicable terms and conditions of the In-Licenses, and shall perform and take such actions as may be required to allow the Party that is party to such In-License to comply with its obligations thereunder, including obligations
relating to sublicensing, patent matters, confidentiality, reporting, audit rights, indemnification and diligence. Without limiting the foregoing, each Party shall prepare and deliver to the other Party any additional reports required under the
applicable In-Licenses and requested by such other Party, in each case sufficiently in advance to enable the Party that is party to such In-License to comply with its obligations under the applicable In-Licenses. Each Party agrees, upon the other
Party’s request, to provide the other Party with copies of any In-Licenses to which it is a party. Confidential Information of the providing Party or its counterparty may be redacted from such copies, except to the extent that such information
is required in order to enable the other Party to comply with its obligations to the providing Party under these Global License Terms with respect to such In-License or in order to enable the providing Party to ascertain compliance with the
provisions of these Global License Terms. 
 7.5 Right of First Negotiation. If, at any time during the Term,
Genzyme desires to grant any Third Party rights to Develop and/or Commercialize one or more Global Licensed Product(s) in the Field in any portion of the Licensed Territory (excluding customary distribution arrangements entered into in the ordinary
course of business by Genzyme), Genzyme shall notify Alnylam in writing of its intent. Alnylam shall have [***] days from receipt of such written notice to notify Genzyme in writing as to whether Alnylam desires to negotiate for such rights in such
territory, and if Alnylam so notifies Genzyme that it does desire to negotiate for such rights in such territory, Alnylam shall have the exclusive right for [***] days from the date of such notification to

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -28- 

 GLOBAL LICENSE TERMS 

 

 
Genzyme to negotiate with Genzyme and to make one or more written non-binding offers to Genzyme concerning the acquisition of such rights in such territory by Alnylam. Alnylam shall have the
exclusive right for [***] days (or such longer period as may be mutually agreed by the Parties) after such [***] day period, to finalize and enter into a definitive agreement with Genzyme for such rights in such territory, provided that if
either Alnylam does not provide such written notice within such [***] day period or Alnylam does provide such written non-binding offer within such subsequent [***] day period, or Alnylam provides such notice of interest and such written offer but
for any reason Genzyme and Alnylam do not enter into a definitive agreement within the [***] day negotiation period, Genzyme shall be free to enter into an agreement with a Third Party(ies) relating to such rights in such territory, without further
obligation to Alnylam. Genzyme shall not, during the exclusive [***] and [***] day negotiating periods described above, enter into discussions, exchange information, or otherwise negotiate with any Third Party with respect to an agreement with
respect to the Development and/or Commercialization of the applicable Global Licensed Product(s) in the Field in the Licensed Territory. Notwithstanding the foregoing, during the period of [***] months after the termination of any such negotiation
that does not result in a definitive agreement between Alnylam and Genzyme, Genzyme shall not enter into a transaction with respect to such rights in such territory with any Third Party on terms that are, in the aggregate, materially more favorable
to the Third Party than the last terms offered in writing by Alnylam to Genzyme unless Genzyme first re-offers such transaction to Alnylam on such more favorable terms and Alnylam does not accept such offer and enter into such transaction with
Genzyme within [***] days after such re-offer. For clarity, prior to the exclusive negotiating periods described above, Genzyme shall be free to engage in discussions and exchange information with Third Parties with respect to the applicable Global
Licensed Product(s) rights, but shall not enter into any binding agreement with any Third Party with respect to such rights. 

7.6 Bankruptcy. All rights and licenses granted under or pursuant to these Global License Terms by a Party to the
other, including those set forth in Sections 3.3 (Right of Reference), 7.1 (License Grants to Genzyme), 7.2 (License Grants to Alnylam), and 11.3.2(b) (Effects of Termination of Global Licensed Product by Alnylam for Cause or by Genzyme for
Convenience), are and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties
agree that the Parties and their respective Sublicensees, as sublicensees of such rights under these Global License Terms, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code and any foreign
counterpart thereto. The Parties further agree that upon commencement of a bankruptcy proceeding by or against a Party (the “Bankrupt Party”) under the Bankruptcy Code, the other Party (the “Non-Bankrupt Party”)
will be entitled to a complete duplicate of, or complete access to (as the Non-Bankrupt Party deems appropriate), all such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments of
such intellectual property will be promptly delivered to the Non-Bankrupt Party (a) upon any 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -29- 

 GLOBAL LICENSE TERMS 

 

 
such commencement of a bankruptcy proceeding and upon written request by the Non-Bankrupt Party, unless the Bankrupt Party elects to continue to perform all of its obligations under these Global
License Terms, or (b) if not delivered under (a) above, upon the rejection of these Global License Terms by or on behalf of the Bankrupt Party and upon written request by the Non-Bankrupt Party. Without limiting the foregoing, Alnylam
hereby grants to Genzyme a right of access to and to obtain possession of (i) copies of research data, (ii) laboratory samples, (iii) samples of Global Licensed Product, (iv) formulas, (v) laboratory notes and notebooks,
(vi) data and results related to clinical trials, (vii) regulatory filings and approvals, (viii) rights of reference in respect of regulatory filings and approvals, (ix) pre-clinical research data and results, (x) marketing,
advertising and promotional materials, all of which (in clauses (i) through (x)) constitute “embodiments” of intellectual property pursuant to Section 365(n) of the Bankruptcy Code and (xi) all other embodiments of such
intellectual property, and in respect of each of the foregoing clauses (i) through (xi), solely for the purpose of the exercise of Genzyme’s rights and licenses under these Global License Terms, whether any of the foregoing are in
Alnylam’s possession or control or in the possession and control of Third Parties. The Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including any trustee) agrees not to interfere with the
exercise by Non-Bankrupt Party or its Related Parties of its rights and licenses to such intellectual property and such embodiments of intellectual property in accordance with these Global License Terms, and agrees to assist the Non-Bankrupt Party
and its Related Parties in obtaining such intellectual property and such embodiments of intellectual property in the possession or control of Third Parties as reasonably necessary or desirable for the Non-Bankrupt Party to exercise such rights and
licenses in accordance with these Global License Terms. The foregoing provisions are without prejudice to any rights the Non-Bankrupt Party may have arising under the Bankruptcy Code or other Laws. 

7.7 No Other Rights. Except as otherwise expressly provided in these Global License Terms, under no circumstances
shall a Party, as a result of these Global License Terms, obtain any ownership interest or other right in any Know-How, Patent Rights or other intellectual property rights of the other Party, including items owned, controlled or developed by the
other Party, or provided by the other Party to the receiving Party at any time pursuant to these Global License Terms. 
  

	8.	CERTAIN FINANCIAL TERMS 

 8.1 Milestone Fees. 

8.1.1 Development Milestones for Global Licensed Products. Genzyme shall provide Alnylam with written notice of the
achievement by Genzyme or any of its Related Parties of any development milestone event set forth below in this Section 8.1.1 within [***] days after such event has occurred; provided, however, that Genzyme shall inform Alnylam of
such event prior to any public disclosure of such event by Genzyme. Alnylam shall invoice Genzyme within [***] days of receipt of such written notice by 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -30- 

 GLOBAL LICENSE TERMS 

 

 
Alnylam, and Genzyme shall remit the associated development milestone payment within [***] days of the receipt of such invoice. Each development milestone payment by Genzyme to Alnylam hereunder
shall be payable only once with respect to each Global Licensed Product, regardless of the number of times a development milestone event is achieved with respect to such Global Licensed Product.  

8.1.1.1 Development Milestones for ALN-AS1. Genzyme shall pay Alnylam the following amounts upon achievement of
the following development milestone events with respect to ALN-AS1: 
  

			
	 Development Milestone Event
	  	Development Milestone
Payment
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 8.1.1.2 Development Milestones for Global Licensed Products other than ALN-AS1.
Genzyme shall pay Alnylam the following amounts upon the first achievement of the following development milestone events with respect to each Global Licensed Product other than ALN-AS1: 

 

			
	 Development Milestone Event
	  	Development Milestone
Payment
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 8.1.2 Sales Milestones for Global Licensed Products. Genzyme shall provide Alnylam with
written notice of the achievement by Genzyme or any of its Related Parties of any sales milestone event set forth below in this Section 8.1.2 within [***] days after such event has occurred. Alnylam shall invoice Genzyme within [***] days of receipt
of such written notice by Alnylam, and Genzyme shall remit the associated milestone payment within [***] days of the receipt of such invoice. Notwithstanding the foregoing, in the event that more than one of the sales milestone events is achieved
simultaneously by a Global Licensed Product, Genzyme will make only one sales milestone payment at such time, which will be for the sales milestone event requiring the highest sales milestone payment; and further, payment for achievement of the
lower sales milestone shall be due in the next Calendar Year. Each sales milestone payment by Genzyme to Alnylam hereunder shall be payable only once with respect to each Global Licensed Product, regardless of the number of times a sales milestone
event is achieved with respect to such Global Licensed Product. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -31- 

 GLOBAL LICENSE TERMS 

 

 8.1.2.1 Sales Milestones for ALN-AS1. Genzyme shall pay Alnylam
the following amounts upon achievement of the following sales milestone events with respect to ALN-AS1: 
  

					
	 Sales Milestone Event
	  	Sales Milestone Payment	 
	 (i) First Calendar Year in which Net Sales for ALN-AS1 exceeds [***]
	  	 	[	***] 
	 (ii) First Calendar Year in which Net Sales for ALN-AS1 exceeds [***]
	  	 	[	***] 
	 (i) First Calendar Year in which Net Sales for ALN-AS1 exceeds [***]
	  	 	[	***] 
	 (ii) First Calendar Year in which Net Sales for ALN-AS1 exceeds[***]
	  	 	[	***] 

 8.1.2.2 Sales Milestones for Global Licensed Products other than ALN-AS1. Genzyme
shall pay Alnylam the following amounts upon achievement of the following sales milestone events with respect to each Global Licensed Product other than ALN-AS1: 
  

					
	 Sales Milestone Event
	  	Sales Milestone Payment	 
	 (i) First Calendar Year in which Net Sales for a Global Licensed Product (other than ALN-AS1) exceeds [***]
	  	 	[	***] 
	 (ii) First Calendar Year in which Net Sales for a Global Licensed Product (other than ALN-AS1) exceeds [***]
	  	 	[	***] 
	 (iii) First Calendar Year in which Net Sales for a Global Licensed Product (other than ALN-AS1) exceeds [***]
	  	 	[	***] 

 8.2 Royalties. 

8.2.1 Royalties Payable on Licensed Products. Subject to the provisions of these Global License Terms, Genzyme shall pay
to Alnylam royalties on annual Net Sales of each Global Licensed Product by Genzyme and its Related Parties, as calculated on a Global Licensed Product-by-Global Licensed Product basis, in the Licensed Territory, as follows: 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -32- 

 GLOBAL LICENSE TERMS 

 

			
	 Calendar Year
 Net Sales of a
Global Licensed Product
 in the Licensed Territory
	  	Royalty
(as a percentage of Net Sales of
such Global Licensed Product)
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 Royalties on annual Net Sales of each Global Licensed Product shall be paid at the rate applicable to [***]:

 [***] 
 Royalties on annual
Net Sales shall be paid at the rate applicable to the portion of such Net Sales within each of the Net Sales levels above during such Calendar Year. 

8.2.2 Royalty Term. Subject to Section 8.2.6 (Royalty Floor), the period during which the royalties set forth in
Section 8.2.1 (Royalties Payable on Licensed Products) shall be payable, on a Global Licensed Product-by-Global Licensed Product and country-by-country basis, shall commence with the First Commercial Sale of a Global Licensed Product in a
country and continue until the latest of (a) the expiration of the last Valid Claim of [***] in the country of sale; (b) the expiration of Regulatory Exclusivity for such Global Licensed Product in such country; or (c) subject to the
last sentence of this Section 8.2.2, the [***] anniversary of the First Commercial Sale of such Global Licensed Product in such country (each such period, a “Royalty Term”). [***]. 

8.2.3 Third Party Royalty Offsets. Genzyme shall be permitted to reduce any royalties payable under Section 8.2.1
(Royalties Payable on Licensed Products) for a Global Licensed Product by [***] percent ([***]) of any amounts for which Genzyme is responsible under Collaboration In-Licenses for such Global Licensed Product pursuant to Section 11.3 of the
Master Agreement (In-Licenses) or under an Un-Blocking Genzyme In-License, but only to the extent that the relevant Third Party License Payment under such Collaboration In-License or Un-Blocking Genzyme In-License constitutes either royalties or a
milestone payment based on sales of such Global Licensed Product; provided, however, that the royalties payable under Section 8.2.1 (Royalties Payable on Licensed Products) with respect to such Global Licensed Product shall not be
reduced in any such event below [***]percent ([***]) of the amounts set forth in Section 8.2.1 (Royalties Payable on Licensed Products) and; provided, further, that if any of such 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -33- 

 GLOBAL LICENSE TERMS 

 

 
amounts cannot be offset against royalties due with respect to such Global Licensed Product for any given royalty period due to the preceding proviso, such unused amount may be carried forward
and offset against royalties due with respect to such Global Licensed Product in future royalty periods. 
 8.2.4 No
Alnylam Patents or Regulatory Exclusivity. The royalties to be paid by Genzyme to Alnylam pursuant to Section 8.2.1 (Royalties Payable on Licensed Products) with respect to any Global Licensed Product shall be reduced to [***]percent
([***]) of the amounts otherwise payable pursuant to Section 8.2.1 (Royalties Payable on Licensed Products) with respect to Net Sales of such Global Licensed Product in a country of the Licensed Territory as to which both (a) the
Manufacture, use, offer for sale, sale or importation of which is not Covered by any Valid Claim in any Alnylam Patent or in any Patent Right included in the Joint Collaboration IP in such country and (b) there is no applicable Regulatory
Exclusivity in such country. 
 8.2.5 Royalty Adjustments for Generic Products. If, during a given Calendar Quarter
when a Global Licensed Product is being Commercialized by or on behalf of Genzyme in a particular country in the Licensed Territory, there is Generic Competition in such country with respect to such Global Licensed Product, then, subject to
Section 8.2.6 (Royalty Floor), the royalties payable pursuant to Section 8.2.1 (Royalties Payable on Licensed Products) on the Net Sales of such Global Licensed Product in such country shall thereafter be reduced to [***] percent ([***])
of the amounts otherwise payable pursuant to Section 8.2.1 (Royalties Payable on Licensed Products) with respect to such Global Licensed Product in such country for such Calendar Quarter for so long as such Generic Competition remains. 

8.2.6 Royalty Floor. Anything in these Global License Terms to the contrary notwithstanding, in no event during the
applicable Royalty Term for a Global Licensed Product in a country of the Licensed Territory shall the royalties payable to Alnylam hereunder for such Global Licensed Product in such country for any Calendar Quarter be reduced (a) by the
application of the reductions or credits described in Sections 8.2.3 (Third Party Royalty Offsets) or 8.2.4 (No Alnylam Patents or Regulatory Exclusivity), whether taken together or separately, to less than [***]percent ([***]) of the royalties
payable pursuant to Section 8.2.1 (Royalties Payable on Licensed Products) as to such Global Licensed Product in such country for such Calendar Quarter, or (b) by the application of the reductions or credits described in Sections 8.2.3
(Third Party Royalty Offset), 8.2.4 (No Alnylam Patents or Regulatory Exclusivity), 8.2.5 (Royalty Adjustments for Generic Products) and/or 10.4.2 (Rights to Enforce), whether taken together or separately, to less than the greater of (1) [***]
percent ([***]) of the royalties payable pursuant to Section 8.2.1 (Royalties Payable on Licensed Products) as to such Global Licensed Product in such country for such Calendar Quarter, and (2) [***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -34- 

 GLOBAL LICENSE TERMS 

 

 8.2.7 Validation Information. At Genzyme’s request, Alnylam will
provide Genzyme with such information as Genzyme may reasonably request to validate the amount of the royalty floor described in Section 8.2.6 (Royalty Floor). 
  

	9.	REPRESENTATIONS, WARRANTIES AND COVENANTS 

 9.1 Representations and
Warranties of Alnylam. Except as provided in the Disclosure Schedule to this Section 9.1 (which Disclosure Schedule with respect to any Global Licensed Product will be provided by Alnylam to Genzyme as part of the Option Data Package
for such Global Licensed Product), with respect to each Global Licensed Product, Alnylam represents and warrants to Genzyme that as of the Implementation Date for such Global Licensed Product: 

9.1.1 Alnylam is the sole and exclusive owner of, or otherwise Controls pursuant to an Alnylam In-License, the Alnylam
Technology, and all of the Alnylam Technology licensed to Genzyme hereunder in the Licensed Territory that is solely and exclusively owned by Alnylam is free and clear of liens, charges or encumbrances other than licenses granted to Third Parties
that are not inconsistent with the rights and licenses granted to Genzyme under these Global License Terms. 
 9.1.2
Alnylam has sufficient legal and/or beneficial title and ownership of, or sufficient license rights under, the Alnylam Technology to grant the licenses to such Alnylam Technology granted to Genzyme pursuant to these Global License Terms. 

9.1.3(a) Schedule 1.2.8 and Schedule 1.2.15 collectively set forth a complete and accurate list
of the Alnylam Patents owned, either solely or jointly, by Alnylam, and to Alnylam’s knowledge, Schedule 1.2.8 and Schedule 1.2.15 collectively set forth a complete and accurate list of the Alnylam Patents licensed,
either exclusively or nonexclusively, to Alnylam, (b) to Alnylam’s knowledge, each issued Alnylam Patent remains in full force and effect and (c) Alnylam or its Affiliates have timely paid all filing and renewal fees payable with
respect to such Alnylam Patents for which Alnylam controls prosecution and maintenance. Schedule 1.2.8 and Schedule 1.2.15 indicate whether each Alnylam Patent is owned exclusively by Alnylam, is owned jointly by Alnylam and
one or more Third Parties, or is licensed to Alnylam. For each Alnylam Patent that is owned, but not owned exclusively, by Alnylam, or that is licensed to Alnylam, Schedule 1.2.8 and Schedule 1.2.15 identify the Third Party
owner(s) and, if applicable, the Alnylam In-License pursuant to which Alnylam Controls such Alnylam Patent. For each Alnylam Product-Specific Patent that is licensed, but not exclusively licensed, to Alnylam, Schedule 1.2.15 indicates
the non-exclusive nature of the license. For each Alnylam Core Technology Patent family (other than Patent Rights licensed from Isis Pharmaceuticals, Inc.) that is licensed, but not exclusively licensed, to Alnylam, Schedule 1.2.8
indicates the non-exclusive nature of the license. Alnylam is the sole and exclusive owner of all Patent Rights identified in Schedule 1.2.8 and Schedule 1.2.15 as being owned exclusively by Alnylam and Controls all other
Patent Rights identified on such schedules. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -35- 

 GLOBAL LICENSE TERMS 

 

 9.1.4 To Alnylam’s knowledge, the Alnylam Product-Specific
Patents, are, or, upon issuance, will be, valid and enforceable patents and no Third Party has challenged or threatened to challenge the scope, validity or enforceability of any Alnylam Product-Specific Patent (including, by way of example, through
opposition or the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority). 

9.1.5 Alnylam has complied with all applicable Laws, including any duties of candor to applicable patent offices, in
connection with the filing, prosecution and maintenance of the Alnylam Patent Rights. 
 9.1.6 Alnylam owns or
Controls all Know-How that is or has been used by Alnylam in the Development and Manufacture of such Global Licensed Products, and has sufficient legal or beneficial title and ownership of, or sufficient license rights under such Know-How to
transfer Know-How to Genzyme as provided in Section 6.4 of the Master Agreement (Transfer of Manufacturing Know-How). 

9.1.7 Alnylam Controls all Know-How and Patent Rights licensed to Alnylam under the Existing Alnylam In-Licenses that is
necessary or useful for Genzyme to Develop, Manufacture and/or Commercialize such Global Licensed Product in the Field in the Licensed Territory. Without limiting the generality of the foregoing, Alnylam has obtained all necessary consents and
fulfilled all necessary conditions, if any, to sublicense to Genzyme under these Global License Terms such Know-How and Patent Rights licensed to Alnylam under Existing Alnylam In-Licenses. 

9.1.8 To Alnylam’s knowledge, neither Alnylam nor its Affiliates are in breach or default under any existing
Alnylam In-License, and neither Alnylam nor its Affiliates have received any written notice of breach or default with respect to any existing Alnylam In-License. 

9.1.9 Alnylam has obtained from all inventors of Alnylam Technology owned by Alnylam valid and enforceable agreements
assigning to Alnylam each such inventor’s entire right, title and interest in and to all such Alnylam Technology. 

9.1.10 To Alnylam’s knowledge, the use, Development, Manufacture or Commercialization by Alnylam or Genzyme (or
their respective Related Parties) of such Global Licensed Product as formulated and manufactured as of the Effective Date, or as intended to be formulated and manufactured as of the Effective Date (a) does not and will not infringe any issued
patent of any Third Party and (b) will not infringe the claims of any published Third Party patent application when and if such claims were to issue in their current form. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -36- 

 GLOBAL LICENSE TERMS 

 

 9.1.11 There is no (a) claim, demand, suit, proceeding,
arbitration, inquiry, investigation or other legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to Alnylam’s knowledge, threatened against Alnylam or any of its Affiliates or (b) judgment or settlement
against or owed by Alnylam or any of its Affiliates, in each case in connection with the Alnylam Technology or such Global Licensed Product. 

9.1.12 For each Global Licensed Product, Schedule 9.1.12(a) sets forth a complete and accurate list of all
agreements between Alnylam and a Third Party entered into prior to the Implementation Date for a Global Licensed Product pursuant to which Alnylam Controls Know-How or Patent Rights that are necessary or useful to Develop, Manufacture or
Commercialize such Global Licensed Product in the Field other than Additional In-Licenses. [***]. 
 9.2
Representations and Warranties of Genzyme. Except as disclosed in Genzyme’s Exercise Notice, Genzyme represents and warrants to Alnylam as of the Implementation Date for such Global Licensed Product that it is not a party to any
agreement with a Third Party under which it Controls Know-How or Patent Rights that are sublicensed to Alnylam under these Global License Terms with respect to such Global Licensed Products. 

9.3 Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THESE GLOBAL LICENSE TERMS, NEITHER PARTY
MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY TECHNOLOGY, GLOBAL LICENSED PRODUCT, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THESE GLOBAL LICENSE TERMS AND
HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT,
MANUFACTURE OR COMMERCIALIZATION OF ANY GLOBAL LICENSED PRODUCT PURSUANT TO THESE GLOBAL LICENSE TERMS WILL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY GLOBAL LICENSED PRODUCT WILL BE ACHIEVED. 

9.4 Certain Covenants. 

9.4.1 [***].  

(a) [***] 
 (b)
[***]  
 (c) [***] 

(d) [***] 
 (e)
[***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -37- 

 GLOBAL LICENSE TERMS 

 

 9.4.2 Compliance. Each Party and its Related Parties shall conduct the
GLP Collaboration and the Development, Manufacture and Commercialization of the Global Licensed Products in accordance with all Laws, including current governmental regulations concerning Good Laboratory Practices (as defined in the Master
Agreement), good clinical practices and good manufacturing practices. In addition, if either Party is or becomes subject to a legal obligation to a Regulatory Authority or other Governmental Authority (such as a corporate integrity agreement or
settlement agreement with a Governmental Authority), then the other Party shall perform such activities as may be reasonably requested by the obligated Party to enable the obligated Party to comply with its legal obligation to such Regulatory
Authority with respect to the Global Licensed Products. 
 9.4.3 Conflicting Transactions. During the Term, Alnylam
shall not (a) transfer or assign any of its rights, title or interests in the Alnylam Technology other than as part of a transaction pursuant to which these Global License Terms is also assigned and assumed in accordance with Section 13.1
of the Master Agreement (Assignment), or (b) enter into any agreement granting a license or other right under the Alnylam Technology that is inconsistent with the terms of these Global License Terms. 

9.4.4 Governmental Authority. If any of the Alnylam Technology is subject to any funding arrangement with any
Governmental Authority, at Genzyme’s reasonable request, Alnylam will reasonably cooperate in seeking a waiver or other modification to such funding arrangement with respect to such Alnylam Technology. 

 

	10.	INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS 

 10.1
Inventorship. Inventorship for inventions and discoveries first made during the course of the performance of activities pursuant to these Global License Terms shall be determined in accordance with United States patent Laws for
determining inventorship. 
 10.2 Ownership. Alnylam shall own the entire right, title and interest in and to
all inventions and discoveries (and Patent Rights claiming patentable inventions therein) first made or discovered solely by employees or consultants of Alnylam or acquired solely by Alnylam in the course of conducting the Collaboration. Genzyme
shall own the entire right, title and interest in and to all inventions and discoveries (and Patent Rights claiming patentable inventions therein) first made or discovered solely by employees or consultants of Genzyme or acquired solely by Genzyme
in the course of conducting the Collaboration. The Parties shall jointly own any inventions and discoveries (and Patent Rights claiming patentable inventions therein) first made or discovered jointly in the course of conducting the Collaboration.

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -38- 

 GLOBAL LICENSE TERMS 

 

 10.3 Prosecution and Maintenance of Patent Rights.  

10.3.1 IP Committee. The Parties agree that the IP Committee created pursuant to Section 5.3 of the Master
Agreement (IP Committee) shall be responsible for overseeing and effecting the information sharing and consulting provisions under this Section 10.3. 

10.3.2 Genzyme Technology. 

(a) Subject to Section 10.3.1(b) below, Genzyme has the sole responsibility, at Genzyme’s discretion and at
Genzyme’s sole cost and expense, to file, prosecute and maintain (including the defense of any interference or opposition proceedings), all Patent Rights comprising Genzyme Technology (other than Joint Collaboration IP and Alnylam
Product-Specific Patents assigned by Alnylam to Genzyme pursuant to Section 10.3.6.1 (Assignment of Alnylam Product-Specific Patents)), in Genzyme’s name. 

(b) In the event that Genzyme elects not to seek or continue to seek or maintain patent protection on any Genzyme Collaboration
IP in the Licensed Territory, Genzyme shall notify Alnylam at least [***] days before any such Patent Rights would become abandoned, no longer available or otherwise forfeited, and subject to the terms and conditions of any applicable Genzyme
In-License, Alnylam shall have the right (but not the obligation), at its expense, to seek, prosecute and maintain in any country patent protection on such Genzyme Collaboration IP in the name of Genzyme. Genzyme shall use Commercially Reasonable
Efforts to make available to Alnylam its authorized attorneys, agents or representatives, and such of its employees as are reasonably necessary to assist Alnylam in obtaining and maintaining the patent protection described under this
Section 10.3.1(b). Genzyme shall sign or use Commercially Reasonable Efforts to have signed, all legal documents necessary to file and prosecute such patent applications or to obtain or maintain such patents. 

10.3.3 Alnylam Technology and Alnylam Product-Specific Patents. 

(a) Subject to Sections 10.3.3(b) and 10.3.3(c), Alnylam has the sole responsibility, at Alnylam’s discretion and at
Alnylam’s sole cost and expense, to file, conduct prosecution and maintain (including the defense of any interference or opposition proceedings), all Patent Rights comprising Alnylam Technology (other than Alnylam Product-Specific Patents
assigned to Genzyme and Joint Collaboration IP), in Alnylam’s name. 
 (b) Notwithstanding the foregoing
Section 10.3.3(a), subject to the terms and conditions of any applicable Alnylam In-License, as between the Parties Genzyme shall have the first right, at its expense, to file, conduct prosecution and maintain (including the defense of any
interference or opposition proceedings) all Alnylam Product-Specific Patents (regardless of whether such Alnylam Product-Specific Patents are Controlled by Alnylam or Genzyme). Genzyme shall consult with Alnylam, including through the IP 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -39- 

 GLOBAL LICENSE TERMS 

 

 
Committee, on the preparation, filing, prosecution and maintenance of all Alnylam Product-Specific Patents but shall retain final decision making authority on such preparation, filing,
prosecution and maintenance. Genzyme shall furnish Alnylam via electronic mail or other such method as mutually agreed by the Parties with copies of proposed filings and documents received from outside counsel in the course of such filing,
prosecution or maintenance of and/or copies of documents filed with the relevant patent offices with respect to Alnylam Product-Specific Patents and such other documents directly related to the prosecution and maintenance of Alnylam Product-Specific
Patents reasonably necessary for Alnylam to exercise its rights under this Section 10.3.3(b), and as applicable in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by Alnylam.
Genzyme shall consider in good faith timely input from Alnylam thereon, but Genzyme will make all decisions relating to the prosecution and maintenance of Alnylam Product-Specific Patents. Alnylam shall make available to Genzyme its authorized
attorneys, agents or representatives, and such of its employees as are reasonably necessary to assist Genzyme in obtaining and maintaining the patent protection described under this Section 10.3.3(b). Alnylam shall sign, or have signed, all
legal documents necessary to file and prosecute such patent applications or to obtain or maintain such patents. 
 (c) In the
event that Genzyme elects not to seek or continue to seek or maintain patent protection on any Alnylam Product-Specific Patent in any country in the Licensed Territory, Genzyme shall notify Alnylam at least [***] days before such Alnylam
Product-Specific Patent would become abandoned, no longer available or otherwise forfeit (including any decision by Genzyme not to continue to file and prosecute at least one patent application claiming priority to an Alnylam Product-Specific Patent
issuing in any particular country). Alnylam shall have the right (but not the obligation), at its expense, to seek, prosecute and maintain in any country patent protection on any such Alnylam Product-Specific Patent (including the defense of any
interference or opposition proceedings). If Alnylam exercises such right, the applicable Alnylam Product-Specific Patent (and all Patent Rights thereafter filed by or on behalf of Alnylam claiming priority thereto) shall no longer be treated as a
“Alnylam Product-Specific Patent” hereunder, and if Controlled by Genzyme, Genzyme shall assign and transfer such Alnylam Product-Specific Patent to Alnylam. Genzyme shall make available to Alnylam its authorized attorneys, agents or
representatives, such of its employees as are reasonably necessary to assist Alnylam in obtaining and maintaining the patent protection described under this Section 10.3.3(c). Genzyme shall sign, or have signed, all legal documents as are
reasonably necessary to assist Alnylam in obtaining and maintaining the patent protection described under this Section 10.3.3(c). 

10.3.4 Joint Collaboration IP. 

(a) [***] shall have the first right to, at [***] discretion, file, prosecute and maintain (including the defense of any
interference or opposition proceedings), all Patent Rights comprising Joint Collaboration IP, in the names of both Alnylam and Genzyme. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -40- 

 GLOBAL LICENSE TERMS 

 

 
[***] shall consult with [***] on the filing, prosecution and maintenance of all such Patent Rights. Each Party shall sign, or use Commercially Reasonable Efforts to have signed, all legal
documents as are reasonably necessary to file and prosecute patent applications or to obtain or maintain patents in respect of such Joint Collaboration IP, at its own cost. 

(b) [***] shall furnish to [***] via electronic mail or other such method as mutually agreed by the Parties copies of documents
received from outside counsel in the course of such filing, prosecution or maintenance of Joint Collaboration IP and/or copies of documents relevant to such preparation, filing, prosecution, and maintenance in sufficient time prior to filing such
document or making any payment due thereunder to allow for review and comment [***] and shall consider in good faith timely comments from [***] thereon. [***] shall furnish to [***] via electronic mail or other such method as mutually agreed by the
Parties copies of such documents as filed in the relevant patent offices. 
 (c) In the event that [***] elects not to file
or continue to prosecute or maintain patent protection on any Joint Collaboration IP, Alnylam shall have the right (but not the obligation) to file, prosecute and maintain Patent Rights comprising Joint Collaboration IP in the names of both Alnylam
and Genzyme at [***] sole cost and expense. If [***] exercises such right, [***] shall make available to [***] its authorized attorneys, agents or representatives, and such of its employees as are reasonably necessary to assist [***] in obtaining
and maintaining the patent protection described under this Section 10.3.4(c). [***] shall sign, or use Commercially Reasonable Efforts to have signed, all legal documents as are reasonably necessary to file and prosecute such patent
applications or to obtain or maintain such patents. 
 (d) [***] shall bear all out-of-pocket patent filing, prosecution and
maintenance expenses incurred with respect to Patent Rights comprising Joint Collaboration IP. 
 10.3.5 Patent
Miscellaneous. Each Party hereby agrees: (a) to make its employees, agents and consultants reasonably available to the other Party (or to the other Party’s authorized attorneys, agents or representatives), to the extent reasonably
necessary to enable such Party to undertake patent prosecution; (b) to provide the other Party with copies of all material correspondence pertaining to prosecution with the patent offices; (c) to cooperate, if necessary and appropriate,
with the other Party in gaining patent term extensions wherever applicable to Patent Rights licensed under these Global License Terms; and (d) to endeavor in good faith to coordinate its efforts with the other Party to minimize or avoid
interference with the prosecution and maintenance of the other Party’s patent applications. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -41- 

 GLOBAL LICENSE TERMS 

 

 10.3.6 Alnylam Product-Specific Patents. 

10.3.6.1 Assignment of Alnylam Product-Specific Patents. On the Implementation Date with respect to a Global Licensed
Product, Alnylam will assign and transfer to Genzyme, all rights, title, and interests in and to the Alnylam Product-Specific Patents with respect to such Global Licensed Product that are owned by Alnylam on the Implementation Date, and all claims
and causes of action arising from or relating to such Alnylam Product-Specific Patents, including all rights to recovery for damages from infringement arising prior to, on or after the Implementation Date. On the Implementation Date for a Global
Licensed Product, Alnylam will execute and deliver a confirmatory assignment relating to all Alnylam Product-Specific Patents with respect to such Global Licensed Product assigned to Genzyme under this Section 10.3.6.1 in a mutually agreed
form. 
 10.3.6.2 Disclosure of Future Alnylam Product-Specific Patents. Upon becoming aware of any potentially
patentable invention Controlled by Alnylam that would, if patented, be included within the definition of Alnylam Product-Specific Patents with respect to any Global Licensed Product, Alnylam will promptly disclose such invention to Genzyme in
writing in reasonable detail via the IP Committee. 
 10.3.6.3 Covenants in Support of Assignment. Alnylam will
provide all further cooperation which Genzyme reasonably determines is necessary to accomplish the complete transfer of the Alnylam Product-Specific Patents with respect to a Global Licensed Product, and all associated rights, to Genzyme on or after
the Implementation Date for such Global Licensed Product, including executing and delivering further assignments, consents, releases and other commercially reasonable documentation, and providing good faith testimony by affidavit, declaration,
deposition, in-person or other proper means and otherwise assisting Genzyme in support of any effort by Genzyme to establish, perfect, defend or enforce its rights in such Alnylam Product-Specific Patents through filing and prosecution of such
Alnylam Product-Specific Patents, interferences, oppositions, other regulatory proceedings, litigation or other means. Alnylam will obtain the cooperation of the individual inventors of any inventions disclosed in such Alnylam Product-Specific
Patents assigned to Genzyme pursuant to this Section 10.3.6, including (a) obtaining signatures of such inventors on any patent applications or other documentation reasonably necessary to obtain patent protection for such inventions and
(b) procuring (at Genzyme’s expense) such inventors’ good faith testimony by affidavit, declaration, deposition in-person or other proper means in support of Genzyme’s efforts in establishing, perfecting, defending or enforcing
patent rights to such inventions. To the extent Alnylam cannot transfer and assign the Alnylam Product-Specific Patents with respect to a Global Licensed Product, or any portion thereof, on the Implementation Date for such Global Licensed Product,
then Alnylam will transfer and assign such Alnylam Product-Specific Patents to Genzyme at its first opportunity to do so 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -42- 

 GLOBAL LICENSE TERMS 

 

 
and, pending such transfer and assignment, such Alnylam Product-Specific Patents will be deemed to be Alnylam Patents for all purposes under these Global License Terms. To the extent further
transfer or assignment of such Alnylam Product-Specific Patents is required or permitted, and Alnylam has not executed and returned to Genzyme the form of assignment reasonably requested by Genzyme within [***] business days of the delivery of such
assignment to Alnylam at the address for notices set forth in Section 13.11 of the Master Agreement (Notices), then Alnylam hereby irrevocably appoints Genzyme as its attorney-in-fact with the right, authority and ability to execute and enter
into such assignment on behalf of Alnylam. Alnylam stipulates and agrees that such appointment is a right coupled with an interest and will survive the unavailability of Alnylam at any future time. 

10.3.6.4 Grant-Back License. Subject to the provisions of these Global License Terms, Genzyme hereby grants
Alnylam a non-exclusive, non-transferable license (with no right to sublicense) under the Alnylam Product-Specific Patents to the extent necessary to perform Alnylam’s obligations under these Global License Terms and any GLP Supply Agreement.

 10.4 Third Party Infringement. 

10.4.1 Notices. Each Party shall promptly report in writing to the other Party any (a) known or suspected
infringement of any Alnylam Technology, Genzyme Technology, Genzyme Manufacturing IP or Joint Collaboration IP or (b) unauthorized use or misappropriation of any Confidential Information or Know-How of a Party by a Third Party of which it
becomes aware, in each case to the extent such infringing, unauthorized or misappropriating activities involve, as to a Global Licensed Product, a competing product in the Field (a “Competitive Infringement”), and shall provide the
other Party with all available evidence of such infringement, unauthorized use or misappropriation. 
 10.4.2 Rights to
Enforce. 
 (a) Genzyme Technology. Subject to the provisions of any In-License, Genzyme shall have the
sole and exclusive right to initiate an infringement or other appropriate suit (an “Infringement Action”) anywhere in the world against any Third Party as to any infringement, or suspected infringement of, any Patent Rights, or as
to any use or suspected use without proper authorization of any Know-How, comprising Genzyme Patent Rights, Genzyme Know-How, Genzyme Collaboration IP or Genzyme Manufacturing IP. 

(b) Alnylam Technology. Subject to the provisions of any In-License, Genzyme shall have the first right to
initiate an Infringement Action anywhere in the world against any Third Party with respect to any Competitive Infringement in the Licensed Territory of any Alnylam Product-Specific Patent or Joint Collaboration IP, or, with Alnylam’s prior
written consent, Alnylam Core Technology Patent or Alnylam 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -43- 

 GLOBAL LICENSE TERMS 

 

 
Know-How. Alnylam will consider in good faith any request from Genzyme to initiate an Infringement Action against any Third Party with respect to a Competitive Infringement in the Licensed
Territory of any Alnylam Core Technology Patent; provided, however, that Alnylam shall not be required to initiate any such Infringement Action or permit Genzyme to initiate any such Infringement Action. 

 

	 	(c)	Step-In Right. 

  

	 	(i)	If, within [***] days (or such shorter period of time as required by applicable Law to avoid loss of material enforcement rights) after Genzyme’s receipt of a notice of a Competitive Infringement with respect to
any Alnylam Product-Specific Patent or Joint Collaboration IP, Genzyme does not initiate any Infringement Action permitted hereunder against such Competitive Infringement in the Licensed Territory, Alnylam may elect, in its sole discretion, to bring
and control an Infringement Action in connection therewith at its sole cost and expense by providing written notice of such election to Genzyme. 

  

	 	(ii)	If (A) there are no Alnylam Product-Specific Patents or Patent Rights included in Joint Collaboration IP that can be asserted against a Competitive Infringement in the Licensed Territory, for any reason other than
the unwillingness of Genzyme to consent to such assertion of any Patent Rights included in the Joint Collaboration IP; (B) there are Alnylam Core Technology Patent(s) that can reasonably be asserted, but Alnylam refuses to either permit Genzyme
to assert or itself assert at least one of such Alnylam Core Technology Patent(s) that can reasonably be asserted against a Competitive Infringement in the Licensed Territory; and (C) Genzyme and Alnylam are unable to stop the Competitive
Infringement through enforcement of any other Patent Rights or Know-How Controlled by either Party, then the royalties to be paid by Genzyme to Alnylam pursuant to Section 8.2 (Royalties), with respect to the applicable Global Licensed Product
in the countries in the Licensed Territory where such Competitive Infringement exists, shall be reduced by [***] during the period when the conditions in the foregoing clauses (A), (B) and (C) exist and such Competitive Infringement
continues, subject to the limitations set forth in Section 8.2 (Royalties). 

 10.4.3 Procedures;
Expenses and Recoveries. The Party having the right to initiate any Infringement Action under Section 10.4.2 (Rights to Enforce) above shall have the sole and exclusive right to select counsel for any such Infringement Action and shall pay
all expenses of such Infringement Action, including attorneys’ fees and court costs and reimbursement of the other Party’s reasonable Global Out-of-Pocket Costs in rendering assistance requested by the initiating Party. If required under
applicable Law in order for the initiating Party to initiate and/or maintain such Infringement Action, or if 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -44- 

 GLOBAL LICENSE TERMS 

 

 
either Party is unable to initiate or prosecute such Infringement Action solely in its own name or it is otherwise advisable to obtain an effective legal remedy, in each case, the other Party
shall join as a party to such Infringement Action and will execute, and cause its Affiliates to execute, all documents necessary for the initiating Party to initiate litigation to prosecute and maintain such Infringement Action. In addition, at the
initiating Party’s request, the other Party shall provide reasonable assistance to the initiating Party in connection with an Infringement Action at no charge to the initiating Party except for reimbursement by the initiating Party of
reasonable Global Out-of-Pocket Costs incurred in rendering such assistance. The non-initiating Party shall have the right to participate and be represented in any such Infringement Action by its own counsel at its own expense. If the Parties obtain
from a Third Party, in connection with such Infringement Action, any damages, license fees, royalties or other compensation (including any amount received in settlement of such litigation), after payment of any amounts required under any
In-Licenses, the remaining amounts shall be allocated in all cases as follows: 
  

	 	(i)	first, to reimburse each Party for all expenses of such Infringement Action incurred by the Parties, including attorneys’ fees and disbursements, court costs and other litigation expenses; 

 

	 	(ii)	second [***] of the balance to be paid to the Party initiating such Infringement Action; and 

  

	 	(iii)	third, the remainder to the other Party. 

 Notwithstanding the foregoing, in the event that
Alnylam elects to itself assert an Alnylam Core Technology Patent against a Competitive Infringement in the Licensed Territory, the Parties shall each be entitled to [***] of the balance of any recovery therefrom after reimbursement of
expenses as described in clause (i) above. 
 10.5 Patent Term Extensions. 

10.5.1 Retained Alnylam Product-Specific Patent Rights. Subject to the provisions of any Alnylam In-License, Alnylam
shall use Commercially Reasonable Efforts to obtain all available supplementary protection certificates (“SPCs”) and other extensions of Alnylam Product-Specific Patents in the Licensed Territory that are not assigned to Genzyme
pursuant to Section 10.3.5. If more than one Alnylam Product-Specific Patent is eligible for extension or patent term restoration in the Licensed Territory, Genzyme will determine, in its sole discretion, a strategy that will be designed to
maximize patent protection and commercial value for the Global Licensed Product, and the Parties, subject to the provisions of any In-License, will seek patent term extensions, restorations and SPCs for Alnylam Product-Specific Patents in the
Licensed Territory in accordance with that strategy. Where required under national law, and subject to the other requirements of this Section 10.5, Alnylam will make the filings for such extensions, restorations and SPCs for Alnylam
Product-Specific Patents in the Licensed Territory as directed by Genzyme. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -45- 

 GLOBAL LICENSE TERMS 

 

 10.5.2 Further Assurances for SPCs. Each Party will execute such
authorizations and other documents and take such other actions as may be reasonably requested by the other Party to obtain any such extensions, restorations and SPCs for Alnylam Product-Specific Patents in the Licensed Territory, in accordance with
this Section 10.5. 
 10.6 Common Interest. All information exchanged between the Parties’
representatives regarding the preparation, filing, prosecution, maintenance, or enforcement of the Patent Rights under this Section 10 will be deemed Confidential Information. In addition, the Parties acknowledge and agree that, with regard to
such preparation, filing, prosecution, maintenance and enforcement of the Patent Rights under this Section 10, the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent protection possible, and
as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in these Global License Terms constitutes a waiver of, any legal privilege concerning the Patent Rights under this
Section 10, including privilege under the common interest doctrine and similar or related doctrines. 
 10.7
Trademarks.  
 (a) Genzyme has the sole and exclusive right to select and develop one or more Product
Trademark(s) for use by Genzyme and its Related Parties throughout the Licensed Territory. Such Product Trademark(s) may not include trademarks owned or Controlled by Alnylam (“Alnylam Trademarks”) and no right or license to any
Alnylam Trademarks are conveyed hereunder to Genzyme. Any Product Trademark(s) that are used by Genzyme to promote and sell Licensed Products in the Licensed Territory are hereinafter referred to as the “Genzyme Trademarks.” Genzyme
(or its Related Parties, as appropriate) shall own all rights to Genzyme Trademarks and all goodwill associated therewith, throughout the Licensed Territory. Genzyme shall also own rights to any Internet domain names incorporating the applicable
Genzyme Trademarks or any variation or part of such Genzyme Trademarks used as its URL address or any part of such address. 

(b) In the event that Alnylam becomes aware of any infringement of any Product Trademark by a Third Party, Alnylam shall
promptly notify Genzyme and the Parties shall consult with each other and jointly determine the best way to prevent such infringement, including by the institution of legal proceedings against such Third Party. 

10.8 Cooperative Research and Technology (CREATE) Act Acknowledgment. It is the intention of the Parties that
these Global License Terms are a “joint research agreement” as that phrase is defined in Section 35 U.S.C. 103(c). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -46- 

 GLOBAL LICENSE TERMS 

 

	11.	TERM AND TERMINATION 

 11.1 Term. These Global License
Terms shall be effective as of the Implementation Date and, unless terminated earlier pursuant to Section 11.2 (Termination Rights), these Global License Terms shall continue in effect on a Global Licensed Product-by-Global Licensed Product and
country-by-country basis until expiration of the last Royalty Term to expire under these Global License Terms (“Term”). Upon expiration of the Royalty Term for a Global Licensed Product, all licenses of the Parties under
Section 7 (Licenses) with respect to such Global Licensed Product then in effect shall become fully paid-up, perpetual, exclusive licenses. 

11.2 Termination Rights. These Global License Terms may be terminated by the Parties only as set forth in this
Section 11.2. 
 11.2.1 Termination of Global Licensed Product for Convenience. Subject to the remainder
of this Article 11, Genzyme shall have the right to terminate these Global License Terms with respect to any particular Global Licensed Product at any time after the Implementation Date on six (6) months prior written notice to Alnylam. 

11.2.2 Termination of Global Licensed Product for Cause. These Global License Terms may be terminated with
respect to any Global Licensed Product at any time during the Term upon written notice by either Party if (a) the other Party is in material breach of its obligations hereunder with respect to such Global Licensed Product, (b) such
material breach relates to such Global Licensed Product and (c) the other Party has not cured such breach within thirty (30) days in the case of a payment breach, or within ninety (90) days in the case of all other breaches, after
notice requesting cure of the breach; provided, however, that if any breach other than a payment breach is not reasonably curable within ninety (90) days and if a Party is making a bona fide effort to cure such breach, such
termination shall be delayed for a time period to be agreed by both Parties, not to exceed an additional ninety (90) days, in order to permit such Party a reasonable period of time to cure such breach; provided, further, that in
the event that the breach relates to a dispute between the Parties regarding Genzyme’s obligations to use Commercially Reasonable Efforts in Developing or Commercializing such Global Licensed Product and Genzyme disputes whether it has breached
such obligation or whether such breach gives Alnylam the right to terminate these Global License Terms with respect to such Global Licensed Product and initiates a legal action against Alnylam to resolve such dispute within the foregoing sixty
(60) day cure period, then these Global License Terms shall not terminate during the pendency of such legal action, provided that if (i) Genzyme is found, in an unappealable decision by a court of competent jurisdiction or an
appealable decision of a court of competent jurisdiction that has not been appealed in the time allowed for an appeal in such legal action, to have materially breached these Global License Terms with respect to such Global Licensed Product, or
(ii) Genzyme admits in such legal action or settlement thereof that it has materially breached these Global License Terms with respect to such Global Licensed Product, then these Global License Terms shall terminate immediately with respect to
such Global Licensed Product following the Parties’ receipt of such decision or immediately following such admission, as applicable. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -47- 

 GLOBAL LICENSE TERMS 

 

 11.3 Effect of Termination. 

11.3.1 Effects of Termination of Global Licensed Product by Genzyme for Cause. Without limiting any other legal or
equitable remedies that either Party may have, if these Global License Terms are terminated by Genzyme with respect to any Global Licensed Product pursuant to Section 11.2.2 (Termination of Global Licensed Product for Cause), then the
provisions of this Section 11.3.1 shall apply: 
 (a) These Global License Terms shall terminate with respect to the
rights and licenses granted to Genzyme for such terminated Global Licensed Product but shall continue to survive in all respects with respect to all Global Licensed Products other than the terminated Global Licensed Product. 

(b) All License grants in these Global License Terms from either Party to the other with respect to the terminated Global
Licensed Product shall immediately terminate. 
 (c) The Back-Up Option shall terminate with respect to all Back-Up Products
for the terminated Global Licensed Product; provided, however, that such Back-Up Products shall, as of such date, be considered Option Products for the purposes of the Master Agreement, and the Options granted under the Master
Agreement to siRNA that targets the same gene as the terminated Global Licensed Product shall again apply in accordance with the terms and conditions set forth in the Master Agreement; 

(d) Genzyme shall as promptly as practicable transfer to Alnylam or Alnylam’s designee (i) possession and ownership
of all Regulatory Approvals and pricing and reimbursement approvals relating to the Development, Manufacture or Commercialization of the terminated Global Licensed Product, and (ii) copies of all non-clinical and clinical data and material
regulatory correspondence relating to the terminated Global Licensed Product, provided that Alnylam shall reimburse Genzyme for any reasonable out-of-pocket expenses incurred by Genzyme in connection with such transfer; 

(e) Genzyme will assign and transfer to Alnylam, all rights, title and interests in and to any Alnylam Product Specific
Patents that relate solely to the terminated Global Licensed Product that were assigned to Genzyme pursuant to Section 10.3.5 (Alnylam Product-Specific Patents), provided that Alnylam shall reimburse Genzyme for any reasonable
out-of-pocket expenses incurred by Genzyme in connection with such assignment and transfer. In such event, Genzyme will execute and deliver a patent assignment relating to such Alnylam Product-Specific Patents in the form reasonably requested by
Alnylam; and 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -48- 

 GLOBAL LICENSE TERMS 

 

 (f) each Party shall promptly pay any amounts owed to the other Party as of
the effective date of such termination. 
 11.3.2 Effects of Termination of Global Licensed Product by Alnylam for Cause
or by Genzyme for Convenience. Without limiting any other legal or equitable remedies that either Party may have, if these Global License Terms are terminated with respect to any Global Licensed Product by Genzyme pursuant to Section 11.2.1
(Termination of Global Licensed Product for Convenience) or by Alnylam pursuant to Section 11.2.2 (Termination of Global Licensed Product for Cause), then the provisions of this Section 11.3.2 shall apply: 

(a) These Global License Terms shall terminate with respect to the rights and licenses granted to Genzyme for such terminated
Global Licensed Product but shall continue to survive in all respects with respect to all Global Licensed Products other than the terminated Global Licensed Product. 

(b) The license grants to Alnylam in Section 7.2 (License Grants to Alnylam) shall survive such termination with respect
to the Reverted Global Licensed Product. 
 (c) Genzyme will grant to Alnylam, effective upon the effective date of
termination and subject to the terms of any applicable Genzyme In-License, a non-transferable, sublicensable (on terms consistent with Section 7.1.4 (Sublicensing Terms)), worldwide, non-exclusive, royalty-free license under any Genzyme
Collaboration IP and Genzyme Patent Rights that Cover any Global Licensed Product that is being Developed or Commercialized by Genzyme pursuant to these Global License Terms on the effective date of termination, in the form that such Global Licensed
Product exists on the effective date of termination (a “Reverted Global Licensed Product”), solely to the extent necessary to Develop and Commercialize the Reverted Global Licensed Product in the Field in the Licensed Territory.
Notwithstanding the foregoing, if (i) any Patent Rights that Cover any Reverted Global Licensed Product are Controlled by Genzyme pursuant to a Genzyme In-License and (ii) such Genzyme In-License cannot be assigned to Alnylam or does not
relate exclusively to the Reverted Global Licensed Product, Genzyme shall promptly disclose any payment obligations under such Genzyme In-License to Alnylam and such Genzyme Patent Rights shall be subject to the license granted in this
Section 11.3.2(b) only if Alnylam agrees in writing to (A) reimburse Genzyme for one hundred percent (100%) of any amounts that become payable under such Genzyme In-License as a result of Alnylam’s exercise of the license granted
in this Section 11.3.2(b), (B) comply with all applicable terms and conditions of such Genzyme In-License and (C) perform and take such actions as may be required to allow Genzyme to comply with its obligations under such Genzyme
In-License. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -49- 

 GLOBAL LICENSE TERMS 

 

 (d) The Back-Up Option shall terminate with respect to all Back-Up Products
for the terminated Global Licensed Product and such Back-Up Product shall be treated as an Option Product for which Genzyme has not exercised an Option for purposes of Section 3.5 of the Master Agreement; 

(e) Genzyme will assign and transfer to Alnylam, all rights, title and interests in and to any Alnylam Product Specific Patents
that relate solely to the terminated Global Licensed Product that were assigned to Genzyme pursuant to Section 10.3.5 (Alnylam Product-Specific Patents). In such event, Genzyme will execute and deliver a patent assignment relating to such
Alnylam Product-Specific Patents in the form reasonably requested by Alnylam; 
 (f) Genzyme shall as promptly as practicable
transfer to Alnylam or Alnylam’s designee (i) possession and ownership of all governmental or regulatory filings and approvals (including all Regulatory Approvals and pricing and reimbursement approvals) and material correspondence and
conversation logs relating to the Development, Manufacture or Commercialization of the Reverted Global Licensed Product and all Genzyme Trademarks, (ii) copies of all data, reports, records and materials, and other sales and marketing related
information in Genzyme’s possession or Control to the extent that such data, reports, records, materials or other information relate to the Development, Manufacture or Commercialization of the Reverted Global Licensed Product, including all
non-clinical and clinical data relating to the Reverted Global Licensed Product, and customer lists and customer contact information and all adverse event data related to the Reverted Global Licensed Product in Genzyme’s possession or Control,
provided that for a period of [***] months after the effective date of termination with respect to such Reverted Global Licensed Product, Genzyme shall use Commercially Reasonable Efforts to obtain for Alnylam the right to access all such
data, reports, records, materials, and other sales and marketing related information), and (iii) all records and materials in Genzyme’s possession or Control containing Confidential Information of Alnylam exclusively related to the
Reverted Global Licensed Product. In addition, Genzyme shall appoint Alnylam as Genzyme’s and/or Genzyme’s Related Parties’ agent for all Reverted Global Licensed Product-related matters involving Regulatory Authorities in the
Licensed Territory until all Regulatory Approvals and other regulatory filings have been transferred to Alnylam or its designee. 

(g) If the effective date of termination is after First Commercial Sale of the Reverted Global Licensed Product, then Genzyme
shall appoint Alnylam as its exclusive distributor of the Reverted Global Licensed Product in the Licensed Territory and grant Alnylam the right to appoint sub-distributors, until such time as all Regulatory Approvals in the Licensed Territory have
been transferred to Alnylam or its designee. 
 (h) If Genzyme or its Related Parties are Manufacturing finished product with
respect to the Reverted Global Licensed Product on the effective date of termination, at Alnylam’s option, Genzyme or its Related Parties shall supply such finished product to 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -50- 

 GLOBAL LICENSE TERMS 

 

 
Alnylam in the Licensed Territory on terms no less favorable than those on which Genzyme supplied such finished product prior to such termination to its most favored distributor in the Licensed
Territory, until the earlier of (i) such time as all Regulatory Approvals in the Licensed Territory related to the Reverted Global Licensed Product have been transferred to Alnylam or its designee, Alnylam has obtained all necessary
manufacturing approvals and Alnylam has procured or developed its own source of such finished product supply or (ii) [***] months following the effective date of termination. 

(i) If Alnylam so requests, and to the extent permitted under Genzyme’s obligations to Third Parties on the effective date
of termination, Genzyme shall transfer to Alnylam any Third Party agreements relating solely and exclusively to the Development, Manufacture or Commercialization of the Reverted Global Licensed Product to which Genzyme is a party (including any
Genzyme In-License), subject to any required consents of such Third Party, which Genzyme shall use Commercially Reasonable Efforts to obtain promptly. 

(j) Genzyme shall promptly transfer and assign to Alnylam all of Genzyme’s and its Affiliates’ rights, title and
interests in and to the Genzyme Trademark(s) exclusively used in connection with the Reverted Global Licensed Product (but not any Genzyme house marks or any trademark containing the word “Genzyme”) owned by Genzyme and used for the
Reverted Global Licensed Product in the Field in the Licensed Territory. 
 (k) Genzyme shall transfer to Alnylam any
inventory of the Reverted Global Licensed Product Controlled by Genzyme or its Affiliates as of the termination date at the actual price paid by Genzyme for such supply. 

(l) Genzyme shall provide any other assistance reasonably requested by Alnylam for the purpose of allowing Alnylam or its
designee to proceed expeditiously with the Development, Manufacture and Commercialization of the Reverted Global Licensed Product in the Licensed Territory; provided that Genzyme’s obligations under this clause shall expire [***] months after
the effective date of termination of such Reverted Global Licensed Product. 
 (m) Genzyme shall execute all documents and
take all such further actions as may be reasonably requested by Alnylam in order to give effect to the foregoing clauses. 

11.4 Effect of Expiration or Termination; Survival. Any expiration or termination of these Global License Terms
(a) shall not relieve the Parties of any obligation accruing prior to such expiration or termination and (b) shall be without prejudice to the rights of either Party against the other Party accrued or accruing under these Global License
Terms prior to such expiration or termination, including the obligation to pay royalties for any Global Licensed Product sold prior to such expiration or termination. If these Global License Terms expire or are terminated with respect to any Global
Licensed Product, the following provisions shall survive with respect to such 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -51- 

 GLOBAL LICENSE TERMS 

 

 
Global Licensed Product: (a) Sections 1 (Definitions), 9.3 (Warranty Disclaimer), 10.1 (Inventorship), 10.2 (Ownership), 11.3 (Effect of Termination), and 11.4 (Effect of Expiration or
Termination; Survival), 12 (Performance of Affiliates) of these Global License Terms, and (b) Sections 1 (Definitions), 7 (Confidentiality and Publication), 9 (Royalty Reports; Payments; Audits), 10 (Indemnification; Limitation of Liability;
Insurance), 12 (Term and Termination) and 13 (Miscellaneous) of the Master Agreement. Section 8.2.6 (Royalty Floor) shall survive any termination or expiration of these Global License Terms with respect to royalties accruing prior to such
termination or expiration. Section 9 of the Master Agreement (Royalty Reports; Payments; Audit) shall survive for so long as any royalties are due under these Global License Terms plus three (3) years. Except as otherwise set forth in this
Section 11, upon termination or expiration of these Global License Terms in their entirety (i.e., with respect to all Global Licensed Products), all rights and obligations of the Parties under these Global License Terms shall cease, but,
for clarity, such expiration or termination of these Global License Terms shall not result in the termination or expiration of the Master Agreement or any License Terms. Upon termination or expiration of these Global License Terms with respect to
any particular Global Licensed Product, all rights and obligations of the Parties under these Global License Terms with respect to such Global Licensed Product shall cease, but such termination or expiration shall not affect the Parties’ rights
and obligations under these Global License Terms with respect to any other Global Licensed Product. 
  

	12.	PERFORMANCE BY AFFILIATES 

 12.1 Use of Affiliates. Each
Party acknowledges and accepts that the other Party may exercise its rights and perform its obligations under these Global License Terms either directly or through one or more of its Affiliates. A Party’s Affiliates will have the benefit of all
rights (including all licenses) of such Party under these Global License Terms. Accordingly, in these Global License Terms “Genzyme” will be interpreted to mean “Genzyme and/or its Affiliates” and “Alnylam” will be
interpreted to mean “Alnylam and/or its Affiliates” where necessary to give each Party’s Affiliates the benefit of the rights provided to such Party in these Global License Terms; provided, however, that in any event
each Party will remain responsible for the acts and omissions, including financial liabilities, of its Affiliates. 
 12.2
Future Acquisition of a Party or its Business. [***]  
 12.3 Acquired Programs. 

12.3.1 [***]  

12.3.2 [***]. 

12.3.3 For clarity, upon the closing of the acquisition of the stock and/or assets of Sirna Therapeutics, Inc. by
Alnylam from Merck Sharpe & Dohme Corp., all relevant acquired intellectual property rights acquired in such transaction that may be Controlled by Alnylam (without any further action by Alnylam or Sirna Therapeutics, Inc.) shall become
Controlled by Alnylam for the purposes of these Global License Terms. 
 [Remainder of page intentionally left blank] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -52- 

 GLOBAL LICENSE TERMS 

 

 SCHEDULE 1.2.8 

ALNYLAM CORE TECHNOLOGY PATENTS 

SCHEDULE 1.2.8-1: 
 [To be added
from the applicable Option Data Package] 
 SCHEDULE 1.2.8-2: 

[To be added from the applicable Option Data Package] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -1- 

 GLOBAL LICENSE TERMS 

 

 SCHEDULE 1.2.15 

ALNYLAM PRODUCT-SPECIFIC PATENTS 

SCHEDULE 1.2.15-1: 
 [To be added
from the applicable Option Data Package] 
 SCHEDULE 1.2.15-2: 

[To be added from the applicable Option Data Package] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -2- 

 GLOBAL LICENSE TERMS 

 

 SCHEDULE 1.2.96 

LICENSED TARGET 
 SCHEDULE
1.2.96-1: 
 [To be added from the applicable Option Data Package] 

SCHEDULE 1.2.96-2: 
 [To be added
from the applicable Option Data Package] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -1- 

 GLOBAL LICENSE TERMS 

 

 SCHEDULE 9.1 

DISCLOSURE SCHEDULE 
 SCHEDULE
9.1-1: 
 [To be added from the applicable Option Data Package] 

SCHEDULE 9.1-2: 
 [To be added from
the applicable Option Data Package] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -1- 

 GLOBAL LICENSE TERMS 

 

 SCHEDULE 9.1.12 

(A) EXISTING ALNYLAM IN-LICENSES 

[To be added from the applicable Option Data Package] 

(B) ADDITIONAL ALNYLAM IN-LICENSES 

[To be added from the applicable Option Data Package] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -1- 

 GLOBAL LICENSE TERMS 

 

 SCHEDULE 9.4.1(e) 

EXCEPTIONS TO EXCLUSIVITY 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of 1 page was omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -1- 

 EXECUTION VERSION 

 

 APPENDIX C 

CO-CO PRODUCT LICENSE AND COLLABORATION TERMS 

AN APPENDIX TO THE MASTER COLLABORATION AGREEMENT 

dated as of January 11, 2014 

by and between 
 ALNYLAM
PHARMACEUTICALS, INC. 
 and 

GENZYME CORPORATION 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 CO-CO LICENSE TERMS 

 

 TABLE OF CONTENTS 

 

					
	 1. RELATIONSHIP WITH MASTER AGREEMENT; DEFINITIONS
	  	 	1	  
		
	 2. DEVELOPMENT COLLABORATION
	  	 	20	  
		
	 2.1. Overview
	  	 	20	  
		
	 2.2. Development Plans
	  	 	20	  
		
	 2.3. Joint Responsibilities for Development Activities and Costs
	  	 	26	  
		
	 2.4. Diligence
	  	 	29	  
		
	 2.5. Records; Reports; Information Sharing
	  	 	29	  
		
	 2.6. Third Parties
	  	 	31	  
		
	 3. REGULATORY MATTERS
	  	 	31	  
		
	 3.1. Regulatory Filings and Interactions in the Genzyme Territory
	  	 	31	  
		
	 3.2. Regulatory Filings and Interactions in the Co-Co Territory
	  	 	33	  
		
	 3.3. EMA Regulatory Strategy
	  	 	35	  
		
	 3.4. Costs of Regulatory Affairs
	  	 	35	  
		
	 3.5. Right of Reference
	  	 	35	  
		
	 4. COMMERCIALIZATION OF THE LICENSED PRODUCTS
	  	 	36	  
		
	 4.1. Responsibility, Cost and Diligence
	  	 	36	  
		
	 4.2. Co-Co Territory Commercialization
	  	 	36	  
		
	 4.3. Genzyme Territory Commercialization Plan
	  	 	39	  
		
	 4.4. Advertising and Promotional Materials
	  	 	39	  
		
	 4.5. Commercialization Reporting Obligations
	  	 	41	  
		
	 4.6. Recalls, Market Withdrawals or Corrective Actions
	  	 	42	  
		
	 4.7. Export Monitoring
	  	 	42	  
		
	 5. COLLABORATION MANAGEMENT
	  	 	42	  
		
	 5.1. Product Joint Steering Committee
	  	 	42	  
		
	 5.2. Appointment of Subcommittees, Project Teams and CLP Alliance Managers
	  	 	43	  
		
	 5.3. PJSC Meetings
	  	 	44	  
		
	 5.4. PJSC Minutes
	  	 	44	  
		
	 5.5. PJSC Development Responsibilities
	  	 	44	  
		
	 5.6. PJSC Commercialization Responsibilities
	  	 	45	  
		
	 5.7. PJSC Decision-Making
	  	 	46	  
		
	 5.8. Term of PJSC
	  	 	47	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -i- 

 CO-CO LICENSE TERMS 

 

					
	 6. MANUFACTURE AND SUPPLY OF CO-CO LICENSED PRODUCTS
	  	 	48	  
		
	 6.1. Supply Agreements
	  	 	48	  
		
	 7. LICENSES
	  	 	48	  
		
	 7.1. License Grants to Genzyme
	  	 	48	  
		
	 7.2. License Grants to Alnylam
	  	 	51	  
		
	 7.3. Joint Collaboration IP
	  	 	52	  
		
	 7.4. In-Licenses
	  	 	52	  
		
	 7.5. Bankruptcy
	  	 	53	  
		
	 7.6. No Other Rights
	  	 	53	  
		
	 8. FINANCIAL TERMS FOR GENZYME TERRITORY
	  	 	54	  
		
	 8.1. Milestone Fees
	  	 	54	  
		
	 8.2. Royalties
	  	 	55	  
		
	 9. FINANCIAL TERMS FOR CO-CO TERRITORY
	  	 	56	  
		
	 10. REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	56	  
		
	 10.1. Representations and Warranties of Alnylam
	  	 	56	  
		
	 10.2. Representations and Warranties of Genzyme
	  	 	58	  
		
	 10.3. Warranty Disclaimer
	  	 	58	  
		
	 10.4. Certain Covenants
	  	 	59	  
		
	 11. INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS
	  	 	60	  
		
	 11.1. Inventorship
	  	 	60	  
		
	 11.2. Ownership
	  	 	60	  
		
	 11.3. Prosecution and Maintenance of Patent Rights
	  	 	60	  
		
	 11.4. Third Party Infringement
	  	 	63	  
		
	 11.5. Patent Term Extensions
	  	 	66	  
		
	 11.6. Common Interest
	  	 	67	  
		
	 11.7. Trademarks
	  	 	67	  
		
	 11.8. Cooperative Research and Technology (CREATE) Act Acknowledgment
	  	 	68	  
		
	 12. TERM AND TERMINATION
	  	 	68	  
		
	 12.1. Term
	  	 	68	  
		
	 12.2. Termination Rights
	  	 	68	  
		
	 12.3. Effect of Termination
	  	 	71	  
		
	 12.4. Fundamental Breach of Alnylam’s Development Obligations
	  	 	76	  
		
	 12.5. Effect of Expiration or Termination; Survival
	  	 	76	  
		
	 13. PERFORMANCE BY AFFILIATES
	  	 	77	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -ii- 

 CO-CO LICENSE TERMS 

 

 SCHEDULES 
  

			
	Schedule 1.2.14-1	  	Alnylam Core Technology Patents for ALN-TTRsc
		
	Schedule 1.2.19-1	  	Alnylam Product-Specific Patents for ALN-TTRsc
		
	Schedule 2.2.1-1	  	Global Development Strategy for ALN-TTRsc
		
	Schedule 2.2.2-1	  	Global Development Plan for ALN-TTRsc
		
	Schedule 2.2.3-1	  	Genzyme Territory Development Plan for ALN-TTRsc
		
	Schedule 2.7	  	TTRsc/02 Arbitration Criteria
		
	Schedule 4.2-1	  	Co-Co Territory Commercialization Plan for ALN-TTRsc
		
	Schedule 10.1-1	  	Disclosure Schedule
		
	Schedule 10.1.12	  	Existing Alnylam In-Licenses / Additional Alnylam In-Licenses
		
	Schedule 10.4.1.4	  	Exceptions to Exclusivity

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -iii- 

 CO-CO LICENSE TERMS 

 

 CO-CO PRODUCT LICENSE AND COLLABORATION TERMS 

THESE CO-CO PRODUCT LICENSE AND COLLABORATION TERMS are Appendix C to the Master Agreement, dated as of the Execution Date, by and
between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Alnylam”) and, Genzyme Corporation, a corporation organized and existing under the laws of the Commonwealth of
Massachusetts (“Genzyme”). 
 RECITALS: 

WHEREAS, Alnylam and Genzyme are parties to that certain Master Collaboration Agreement (dated as of the Execution Date) (the
“Master Agreement”) pursuant to which Genzyme has an option to receive licenses and other rights with respect to Co-Co Licensed Products from Alnylam in the Genzyme Territory;  

WHEREAS, the Parties have agreed that ALN-TTRsc is a Co-Co Licensed Product;  

WHEREAS, Genzyme may exercise its Co-Co/Global Option pursuant to the Master Agreement for the siRNA known as ALN-AT3 (or a successor
siRNA Controlled by Alnylam that targets Antithrombin) and such siRNA will then become a Co-Co Licensed Product; 
 WHEREAS,
the Parties desire for Alnylam to continue to develop such Co-Co Licensed Products for the Co-Co Territory and the Genzyme Territory; and 

WHEREAS, Alnylam and Genzyme now wish to set forth the terms and conditions under which Genzyme will have the right to Develop and
Commercialize such Co-Co Licensed Products in the Genzyme Territory and co-Commercialize with Alnylam such Co-Co Licensed Products in the Co-Co Territory. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the Parties hereby agree as
follows: 
 1. RELATIONSHIP WITH MASTER AGREEMENT; DEFINITIONS 

1.1. Relationship with Master Agreement. These Co-Co License Terms become effective on a Co-Co Licensed Product-by-Co-Co Licensed
Product basis on the Implementation Date in accordance with the Master Agreement. The Master Agreement generally governs the Parties’ relationship with respect to Co-Co Licensed Products during the period of time before Genzyme exercises its
Co-Co/Global Option under the Master Agreement (i.e., before such product became a Co-Co Licensed Product). The Master Agreement also contains terms that are generally applicable to Co-Co Licensed Products, Global Licensed Products (as
defined in the Master Agreement) and Regional Licensed Products (as defined in the Master Agreement). Accordingly, the following Sections of the Master Agreement are incorporated herein by reference: Section 2.2 (Effectiveness of Licenses to
Collaboration Products); Section 5 (Collaboration Management); Section 6 (Manufacture and Supply of the Collaboration Products); Section 7 (Confidentiality and Publication); Section 9 (Royalty Reports; Payments; Audit); Section 10
(Indemnification; Limitation of Liability; Insurance); Section 12.2.4 (Challenges of Patent Rights); and Section 13 (Miscellaneous). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -1- 

 CO-CO LICENSE TERMS 

 

 1.2. Definitions. Unless specifically set forth to the contrary herein, the
following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 
 1.2.1.
“Acquired Business” has the meaning set forth in Section 13.3 (Acquired Programs). 
 1.2.2.
“Acquirer” has the meaning set forth in Section 13.2 (Future Acquisition of a Party or its Business). 

1.2.3. “Additional Development Activities” has the meaning set forth in Section 2.2.2.5(a) (Additional Development
Proposals). 
 1.2.4. “Additional Development Opt-In Date” has the meaning set forth in
Section 2.2.2.5(d)(i) (Opt-In for Additional Development Activities). 
 1.2.5. “Additional Development Opt-In
Notice” has the meaning set forth in Section 2.2.2.5(d)(i) (Opt-In for Additional Development Activities). 
 1.2.6.
“Additional Development Proposal” has the meaning set forth in Section 2.2.2.5(a) (Additional Development Proposals). 

1.2.7. “AF11 Lipid Nanoparticle Formulation” has the meaning set forth in the Master Agreement. 

1.2.8. “Affiliate” means, with respect to a Person, any other Person which controls, is controlled by, or is under
common control with the applicable Person. For purposes of this definition, “control” shall mean: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled
to vote for the election of directors, or otherwise having the power to control or direct the affairs of such Person; and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity
interest or the power to direct the management and policies of such non-corporate entities.  
 1.2.9. “AJSC”
has the meaning set forth in the Master Agreement.  
 1.2.10. “ALN-AT3” has the meaning set forth in the
Master Agreement. 
 1.2.11. “ALN-TTR02” has the meaning set forth in the Master Agreement. 

1.2.12. “ALN-TTRsc” has the meaning set forth in the Master Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -2- 

 CO-CO LICENSE TERMS 

 

 1.2.13. “ALN-TTRsc Global R&D Cost Opt-In Date” has the meaning
set forth in Section 2.3.1.2(a) (Global R&D Costs).  
 1.2.14. “Alnylam Core Technology Patents”
means Patent Rights Controlled by Alnylam during the Term that are [***]. The Alnylam Core Technology Patents existing as of the Effective Date for ALN-TTRsc are those Patent Rights identified on Schedule 1.2.14-1. The Alnylam Core Technology
Patents existing as of the Implementation Date for ALN-AT3 will be identified as the “Alnylam Core Technology Patents” in the Option Data Package for ALN-AT3 provided by Alnylam to Genzyme under the Master Agreement and then attached
hereto as Schedule 1.2.14-2. 
 1.2.15. “Alnylam Developed siRNA Product” means an siRNA with respect to which
(a) Alnylam Controls Patent Rights Covering such siRNA, provided that once a product first satisfies the criterion set forth in this clause (a) such criterion shall be deemed satisfied at all times thereafter as to such product, and
(b) Alnylam or an Affiliate of Alnylam plays(ed) a material role in the Development. 
 1.2.16. “Alnylam
In-License” means any Existing Alnylam In-License or any Collaboration In-License to which Alnylam is a party.  
 1.2.17.
“Alnylam Know-How” means Know-How Controlled by Alnylam during the Term that is reasonably necessary or useful for Genzyme to Develop, Manufacture and/or Commercialize Co-Co Licensed Products in the Field in the Genzyme
Territory, other than Alnylam’s interest in Know-How included in Joint Collaboration IP.  
 1.2.18. “Alnylam
Patents” means Alnylam Core Technology Patents and Alnylam Product-Specific Patents.  
 1.2.19. “Alnylam
Product-Specific Patents” means Patent Rights Controlled by Alnylam during the Term [***]. The Alnylam Product-Specific Patents existing as of the Effective Date for ALN-TTRsc are those Patent Rights identified on Schedule 1.2.19-1.
The Alnylam Product-Specific Patents existing as of the Implementation Date for ALN-AT3 will be identified as the “Alnylam Product-Specific Patents” in the Option Data Package for ALN-AT3 provided by Alnylam to Genzyme under the Master
Agreement and then attached hereto as Schedule 1.2.19-2. [***]  
 1.2.20. “Alnylam Technology” means,
collectively, Alnylam Know-How, Alnylam Patents and Alnylam’s interest in Joint Collaboration IP.  
 1.2.21.
“Alnylam Trademark” has the meaning set forth in Section 11.7(b) (Trademarks). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -3- 

 CO-CO LICENSE TERMS 

 

 1.2.22. “ANDA” means an Abbreviated New Drug Application (or any
successor application or procedure) as defined in regulations promulgated by the FDA under the FDCA, which ANDA is filed with or intended to be filed with the FDA (and, as applicable, any other analogous application filed with a Regulatory Authority
in any country other than the U.S. in the Genzyme Territory) for Regulatory Approval for marketing and selling a Co-Co Licensed Product in the Genzyme Territory. 

1.2.23. “Antithrombin” has the meaning set forth in the Master Agreement. 

1.2.24. “Appendix” means this Appendix B (Co-Co License and Collaboration Terms). 

1.2.25. “ATTR” means the human disease TTR-mediated amyloidosis. 

1.2.26. “Back-Up Option” has the meaning set forth in Section 7.1.5 (Back-Up Products). 

1.2.27. “Back-Up Option Exercise Notice” has the meaning set forth in Section 7.1.5 (Back-Up Products). 

1.2.28. “Back-Up Option Period” means (i) with respect to a Back-Up Product for ALN-TTRsc, the period beginning
with the Implementation Date for ALN-TTRsc and ending on [***] and (ii) with respect to a Back-Up Product for ALN-AT3, the period beginning with the Implementation Date for ALN-AT3 and ending on [***].  

1.2.29. 
 1.2.30.
“Back-Up Product” has the meaning set forth for in Section 7.1.5 (Back-Up Products). 
 1.2.31.
“Bankrupt Party” has the meaning set forth in Section 7.5 (Bankruptcy). 
 1.2.32. “Budget
Adjustment Triggers” has the meaning set forth in Section 2.2.2.3 (Managing and Amending Global Development Plans and Global Development Budgets). 

1.2.33. “Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on
March 31, June 30, September 30 and December 31 of each Calendar Year, provided that (a) the first Calendar Quarter of the Term shall begin on the Effective Date and end on the first to occur of
March 31, June 30, September 30 or December 31 thereafter and the last Calendar Quarter of the Term shall end on the last day of the Term and (b) the first Calendar Quarter of a Royalty Term for a Co-Co Licensed
Product in a country shall begin on the First Commercial Sale of a Co-Co Licensed Product in such country and end on the first to occur of March 31, June 30, September 30 or December 31 thereafter and the last Calendar
Quarter of a Royalty Term shall end on the last day of such Royalty Term. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -4- 

 CO-CO LICENSE TERMS 

 

 1.2.34. “Calendar Year” means each successive period of twelve
(12) months commencing on January 1 and ending on December 31, provided that (a) the first Calendar Year of the Term shall begin on the Effective Date and end on the first December 31 thereafter and the last Calendar
Year of the Term shall end on the last day of the Term and (b) the first Calendar Year of a Royalty Term for a Co-Co Licensed Product in a country shall begin on the First Commercial Sale of a Co-Co Licensed Product in such country and end on
the first December 31 thereafter and the last Calendar Year of the Term shall end on the last day of such Royalty Term. 

1.2.35. “Carbohydrate Conjugate” has the meaning set forth in the Master Agreement. 

1.2.36. “Clinical Study” has the meaning set forth in the Master Agreement. 

1.2.37. “CLP Alliance Manager” has the meaning set forth in Section 5.2 (Appointment of Subcommittees, Project
Teams and CLP Alliance Managers). 
 1.2.38. “Co-Co Clinical Supply Agreements” means, collectively, the
ALN-TTRsc Clinical Supply Agreement and the ALN-AT3 Clinical Supply Agreement entered into between Alnylam and Genzyme as described in Section 6.2 of the Master Agreement (Collaboration Product Supply Agreements) pursuant to which Alnylam will
provide clinical supplies of the specified Co-Co Licensed Product to Genzyme.  
 1.2.39. “Co-Co
Collaboration” means the collaboration of the Parties in the Development, Manufacture and Commercialization of a Co-Co Licensed Product under these Co-Co License Terms. 

1.2.40. “Co-Co Commercial Supply Agreements” means, collectively, the ALN-TTRsc Commercial Supply Agreement and the
ALN-AT3 Commercial Supply Agreement entered into between Alnylam and Genzyme as described in Section 6.2 of the Master Agreement (Collaboration Product Supply Agreements) pursuant to which Alnylam will provide commercial supplies of the
specified Co-Co Licensed Product to Genzyme. 
 1.2.41. “Co-Co/Global Option” has the meaning set forth in the
Master Agreement.  
 1.2.42. “Co-Co License Terms” means this Appendix and the terms of the Master Agreement
to the extent applicable to Co-Co Licensed Products. 
 1.2.43. “Co-Co Licensed Product” means
(i) ALN-TTRsc as of the Effective Date, (ii) if Genzyme exercises the Co-Co/Global Options for ALN-AT3 pursuant to the Master Agreement, then ALN-AT3 as of the applicable Option Exercise Date, and (iii) if Genzyme exercises a Back-Up
Option for any Back-Up Product pursuant to Section 7.1.5 (Back-Up Products), then such Back-Up Product as of the date of delivery of the Back-Up Option Exercise Notice, in each case (i) through (iii) above, for as long as the Co-Co
License Terms apply to ALN-TTRsc, ALN-AT3, or such Back-Up Product. For the sake of clarity (but not for purposes of interpretation of the Collaboration Agreement), each Co-Co Licensed Product that becomes subject to the Co-Co License Terms will be
exclusively licensed to Genzyme in the Genzyme Territory in much the same way that each Regional Licensed Product will be exclusively 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -5- 

 CO-CO LICENSE TERMS 

 

 
licensed to Genzyme in the Genzyme Territory under the Regional License Terms, but also will be licensed to Genzyme in the Alnylam Territory to the extent necessary to enable Genzyme to
co-Commercialize such Co-Co Licensed Product in the Alnylam Territory as contemplated by these Co-Co License Terms. 
 1.2.44.
“Co-Co Out-of-Pocket Costs” means, with respect to certain activities hereunder, direct expenses paid or payable by either Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such
activities for a Co-Co Licensed Product, including payments to contract personnel; provided, however, that amounts paid to contract sales and marketing personnel will not be considered Co-Co Out-of-Pocket Costs. 

1.2.45. “Co-Co Supply Agreements” means, collectively, the Co-Co Clinical Supply Agreements and the Co-Co Commercial
Supply Agreements. 
 1.2.46. “Co-Co Territory” means the United States, Canada, Austria, Belgium, Denmark,
Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden, the United Kingdom, Norway, Switzerland, Liechtenstein, Andorra, Iceland and Greenland. 

1.2.47. “Co-Co Territory Commercialization Budget” has the meaning set forth in Section 4.2.3 (Co-Co Territory
Commercialization Budget).  
 1.2.48. “Co-Co Territory Commercialization Plan” has the meaning set forth in
Section 4.2.1 (Co-Co Territory Commercialization Plan). 
 1.2.49. “Co-Co Territory Development Milestone
Payments” means any Third Party License Payment that is payable as a result of the achievement of a Development milestone in the Co-Co Territory.  

1.2.50. “Co-Co Territory MMC” means [***].  

1.2.51. “Collaboration In-License” has the meaning set forth in the Master Agreement. 

1.2.52. “Commercialization” or “Commercialize” has the meaning set forth in the Master Agreement. 

 1.2.53. “Commercially Reasonable Efforts” means [***].  

1.2.54. “Competing Program” has the meaning set forth in Section 13.3 (Acquired Programs).  

1.2.55. “Competitive Infringement” has the meaning set forth in Section 11.4.1 (Notices).  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -6- 

 CO-CO LICENSE TERMS 

 

 1.2.56. “Confidential Information” has the meaning set forth in the
Master Agreement. 
 1.2.57. “Control,” “Controls” or “Controlled by” has
the meaning set forth in the Master Agreement. 
 1.2.58. “Cost of Goods” has the meaning set forth in the
Master Agreement.  
 1.2.59. “Cover,” “Covering” or “Covers” has the
meaning set forth in the Master Agreement. 
 1.2.60. “CPI” shall mean the Consumer Price Index – Urban
Wage Earners and Clerical Workers, U.S. City Average, All Items, 1982-84 = 100, published by the United States Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the United States. 

1.2.61. “CRO” means a contract research organization. 

1.2.62. “Development,” “Developing” or “Develop” has the meaning set forth in the
Master Agreement.  
 1.2.63. “Development Plan” means, with respect to each Co-Co Licensed Product,
(a) with respect to Genzyme, the Genzyme Territory Development Plan for such Co-Co Licensed Product and (b) with respect to both Parties, the Global Development Plan for such Co-Co Licensed Product. 

1.2.64. “Disputing Party” has the meaning set forth in Section 2.3.1.2 (Global R&D Costs). 

1.2.65. “Effective Date” means the date that the Master Agreement becomes effective in accordance with its terms. 

 1.2.66. “EMA” means the European Medicines Agency and any successor Governmental Authority having
substantially the same function.  
 1.2.67. “End of Phase II Package” has the meaning set forth in Section
2.2.2.4(c)(ii). 
 1.2.68. “EU” means the European Union, as its membership may be altered from time to time,
and any successor thereto.  
 1.2.69. “Excess Global R&D Costs” has the meaning set forth in
Section 2.3.1.2 (Global R&D Costs). 
 1.2.70. “Exclusivity Period” means, on a Co-Co Licensed
Product-by-Co-Co Licensed Product and country-by-country basis within the Genzyme Territory [***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -7- 

 CO-CO LICENSE TERMS 

 

 1.2.71. “Execution Date” has the meaning set forth in the Master
Agreement. 
 1.2.72. “Existing Alnylam In-License” has the meaning set forth in the Master Agreement.

 1.2.73. “Existing Genzyme In-License” has the meaning set forth in the Master Agreement. 

1.2.74. “FAP” has the meaning set forth in Section 2.7 (ALN-TTRsc/ALN-TTR02).  

1.2.75. “FDA” means the United States Food and Drug Administration and any successor Governmental Authority having
substantially the same function. 
 1.2.76. “FDCA” means the United States Federal Food, Drug, and Cosmetic
Act of 1938, as amended from time to time, and the regulations and guidelines promulgated thereunder. 
 1.2.77.
“Field” means the treatment, diagnosis and/or prevention of all human diseases.  
 1.2.78. “First
Commercial Sale” means, with respect to a country, the first sale for end use or consumption of a Co-Co Licensed Product in such country, except for compassionate use or patient access programs, after all Regulatory Approvals legally
required for such sale have been granted by the Regulatory Authority of such country.  
 1.2.79. “First Regulatory
Approval by the EMA” means, with respect to a Co-Co Licensed Product, the earlier of (i) if Regulatory Approval in the EU is sought through the EMA centralized procedure, receipt of Regulatory Approval for such Co-Co Licensed Product
from the EMA or (ii) if Regulatory Approval in the EU is sought through a national authorization procedure, receipt of Regulatory Approval for such Co-Co Licensed Product in the first (1st) MMC in the EU.  

1.2.80. “First Regulatory Approval in Japan” means, with respect to a Co-Co Licensed Product, receipt of Regulatory
Approval for such Co-Co Licensed Product in Japan.  
 1.2.81. “Force Majeure” means embargoes, war, acts of
war (whether war be declared or not), terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods or other acts of God.  

1.2.82. “Fundamental Breach” [***]. 

1.2.83. “GAAP” has the meaning set forth in the Master Agreement. 

1.2.84. “GalNAc Conjugate” has the meaning set forth in the Master Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -8- 

 CO-CO LICENSE TERMS 

 

 1.2.85. “Generic Competition” means, with respect to a Co-Co Licensed
Product in any country in the Genzyme Territory in a given Calendar Quarter, that, during such Calendar Quarter, (a) one or more Generic Products with respect to such Co-Co Licensed Product are commercially available in such country, and
(b) Net Sales of such Co-Co Licensed Product in such country in such Calendar Quarter equal less than [***] of the average Net Sales of such Co-Co Licensed Product over the [***] consecutive Calendar Quarters immediately prior to the Calendar
Quarter in which one or more Generic Products first became commercially available in such country.  
 1.2.86. “Generic
Product” means, on a Co-Co Licensed Product-by-Co-Co Licensed Product and country-by-country basis, a pharmaceutical product that (a) is sold by a Person that is not a Related Party of Genzyme under a marketing authorization granted by
a Regulatory Authority in such country to a Third Party; (b) [***]; and (c) is approved by the Regulatory Authority in such country pursuant to an approval process that relies in part on pivotal safety and/or efficacy data in such
Regulatory Authority’s previous grant of marketing authorization for such Co-Co Licensed Product.  
 1.2.87.
“Genzyme Collaboration IP” means (a) any Know-How, first identified, discovered or developed solely by employees of Genzyme or its Affiliates or other persons not employed by Alnylam acting on behalf of Genzyme, in the
conduct of the Collaboration and (b) any Patent Rights that claim or Cover such Know-How and are Controlled by Genzyme at any time during the Term. Genzyme Collaboration IP excludes Genzyme’s interest in Joint Collaboration IP, in each
case (a) and (b), other than Genzyme Manufacturing IP. 
 1.2.88. “Genzyme Disclosed Manufacturing
Know-How” means Know-How (a) Controlled by Genzyme at any time during the Term that is useful in the Manufacture of a Co-Co Licensed Product and (b) that Genzyme, in its sole discretion, discloses in writing to Alnylam in the
course of the Collaboration. 
 1.2.89. “Genzyme In-License” means any Existing Genzyme In-License,
Un-Blocking Genzyme In-License, or any Collaboration In-License to which Genzyme is a party. 
 1.2.90. “Genzyme
Know-How” means Know-How Controlled by Genzyme during the Term that is reasonably necessary or useful for Alnylam to Develop, Commercialize and/or Manufacture Co-Co Licensed Products in the Field in the Co-Co Territory (other than
Genzyme’s rights in Joint Collaboration IP, Genzyme Collaboration IP and Genzyme Manufacturing IP). 
 1.2.91.
“Genzyme Manufacturing IP” means (a) any Know-How related to the Manufacture of Co-Co Licensed Products (or oligonucleotides generally) Controlled by Genzyme at any time during the Term, and (b) any Patent Rights that
claim or cover such Know-How and are Controlled by Genzyme at any time during the Term, excluding Improvement Manufacturing Patent Rights and Genzyme Disclosed Manufacturing Know-How.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -9- 

 CO-CO LICENSE TERMS 

 

 1.2.92. “Genzyme Patent Jurisdictions” has the meaning set forth in
the Master Agreement. 
 1.2.93. “Genzyme Patent Rights” means those Patent Rights Controlled by Genzyme
during the Term that are reasonably necessary or useful to Develop, Commercialize and/or Manufacture Co-Co Licensed Products in the Field in the Co-Co Territory. Genzyme Patent Rights excludes Patent Rights included in Genzyme Collaboration IP,
Genzyme’s interest in Joint Collaboration IP and Genzyme Manufacturing IP. 
 1.2.94. “Genzyme
Technology” means, collectively, Genzyme Know-How, Genzyme Patent Rights, Genzyme Collaboration IP and Genzyme’s interest in Joint Collaboration IP, but excluding Genzyme Manufacturing IP.  

1.2.95. “Genzyme Territory” means all countries and territories of the world other than the Co-Co Territory. 

 1.2.96. “Genzyme Territory Commercialization Plan” has the meaning set forth in Section 4.3 (Genzyme
Territory Commercialization Plan).  
 1.2.97. “Genzyme Territory Development Plan” has the meaning set forth
in Section 2.2.3 (Genzyme Territory Development Plan). 
 1.2.98. “Genzyme Territory MMC” [***].

 1.2.99. “Genzyme Trademark” has the meaning set forth in Section 11.7(b) (Trademarks). 

1.2.100. “Global Branding Strategy” has the meaning set forth in Section 4.4.1 (Global Branding). 

1.2.101. “Global Clinical Study” has the meaning set forth in Section 5.5.5 (PJSC Development
Responsibilities). 
 1.2.102. “Global Development Activity(ies)” has the meaning set forth in
Section 2.2.2.1 (Global Development Plans).  
 1.2.103. “Global Development Budget” has the meaning set
forth in Section 2.2.2.2 (Global Development Budgets). 
 1.2.104. “Global Development Plan” has the
meaning set forth in Section 2.2.2.1 (Global Development Plans). 
 1.2.105. “Global Development
Strategy” has the meaning set forth in Section 2.2.1 (Global Development Strategy). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -10- 

 CO-CO LICENSE TERMS 

 

 1.2.106. “Global Option Period” has the meaning set forth in the
Master Agreement. 
 1.2.107. “Global R&D Cost Opt-In Date” has the meaning set forth in
Section 2.3.1.2 (Global R&D Costs).  
 1.2.108. “Global R&D Costs” means, with respect to a
Co-Co Licensed Product, R&D Costs incurred in connection with any Global Development Activity for such Co-Co Licensed Product. 

1.2.109. “Global R&D Costs Report” has the meaning set forth in Section 2.3.1.2 (Global R&D Costs).

 1.2.110. “Global Regulatory Costs” has the meaning set forth in Section 2.2.2.2 (Global Development
Budgets). 
 1.2.111. “Governmental Authority” means any applicable government authority, court, tribunal,
arbitrator, agency, department, legislative body, commission or other instrumentality of (a) any government of any country or territory, (b) any nation, state, province, county, city or other political subdivision thereof or (c) any
supranational body. 
 1.2.112. “Gross Margin” means, with respect to a Co-Co Licensed Product in the Co-Co
Territory, [***].  
 1.2.113. “Human POP Study” has the meaning set forth in the Master Agreement.

 1.2.114. “IFRS” has the meaning set forth in the Master Agreement. 

1.2.115. “Implementation Date” means (i) with respect to ALN-TTRsc, the Effective Date,
(ii) with respect to ALN-AT3, the Option Exercise Date for ALN-AT3, and (iii) with respect to each Back-Up Product with respect to which Genzyme exercised the Back-Up Option, the date on which Genzyme sent to Alnylam the Back-Up Option
Exercise Notice for such Back-Up Product under Section 7.1.5 (Back-Up Products). 
 1.2.116. “Improvement Manufacturing
Patent Right” means a Patent Right owned exclusively by Genzyme or its Affiliates that claims an invention related to the Manufacture of a Co-Co Licensed Product that was made (a) by Genzyme or its Affiliates after the Effective Date
in connection with Manufacturing Co-Co Licensed Products and (b) using Alnylam Know-How that, at the time such Alnylam Know-How was disclosed to Genzyme or its Affiliates, constituted Alnylam’s Confidential Information under Section 7
of the Master Agreement (Confidentiality and Publication).  
 1.2.117. “IND” has the meaning set forth in the
Master Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -11- 

 CO-CO LICENSE TERMS 

 

 1.2.118. “In-License” has the meaning set forth in the Master
Agreement. 
 1.2.119. “Infringement Action” has the meaning set forth in Section 11.4.2(a) (Genzyme
Technology).  
 1.2.120. “Joint Collaboration IP” means, collectively, (a) any Know-How first
identified, discovered or developed jointly by employee(s), agent(s) or consultant(s) acting on behalf of Alnylam or its Affiliates, on the one hand, and employee(s), agent(s) or consultant(s) acting on behalf of Genzyme or its Affiliates, on the
other hand, in the conduct of the Collaboration that is Controlled by Alnylam and Genzyme, and (b) any Patent Rights that Cover such Know-How and are Controlled by Alnylam and Genzyme.  

1.2.121. “Know-How” has the meaning set forth in the Master Agreement. 

1.2.122. “Laws” has the meaning set forth in the Master Agreement. 

1.2.123. “Licensed Target” means, for ALN-TTRsc, TTR, and, if the Co-Co/Global Option is exercised for ALN-AT3, then
Antithrombin.  
 1.2.124. “Lipid Nanoparticle Formulation” has the meaning set forth in the Master
Agreement. 
 1.2.125. “Litigation Expenses” has the meaning set forth in Section 11.4.3 (Procedures;
Expenses and Recoveries). 
 1.2.126. “Manufacturing” or “Manufacture” has the meaning set
forth in the Master Agreement.  
 1.2.127. “Manufacturing Claim” means a claim within a Patent Right directed
solely to Manufacturing a Co-Co Licensed Product.  
 1.2.128. “MMC” means any Co-Co Territory MMC or Genzyme
Territory MMC. 
 1.2.129. “NDA” has the meaning set forth in the Master Agreement. 

1.2.130. “Net Sales” means, with respect to a Co-Co Licensed Product, the aggregate gross invoiced sales prices from
sales of all units of such Co-Co Licensed Product sold by a Party and its Related Parties to independent Third Parties (other than a Sublicensee) after deducting, if not previously deducted, from the amount invoiced or received: 

(a) trade, quantity and cash discounts, credits or allowances actually given; 

(b) returns, rejections or recalls (due to spoilage, damage, expiration of useful life or otherwise); 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -12- 

 CO-CO LICENSE TERMS 

 

 (c) Third Party rebates, chargebacks, hospital buying group/group purchasing
organization administration fees or managed care organization rebates actually given; 
 (d) rebates and similar payments
made with respect to sales paid for by any governmental or regulatory authority such as Federal or state Medicaid, Medicare or similar state program; 

(e) distribution fees and sales commissions paid to Third Parties; 

(f) retroactive price reductions or billing corrections; 

(g) value added, sales and use, excise and other similar taxes and surcharges, customary transportation and insurance, custom
duties, and other governmental charges; and 
 (h) amounts previously included in Net Sales of such Co-Co Licensed Product
that are adjusted or written-off by such Party or its Related Parties as bad debt or otherwise uncollectible in accordance with the standard practices of such Party or its Related Parties for writing off uncollectible amounts consistently applied;
provided, however, if any such written-off amounts are subsequently collected, such collected amounts shall be included in Net Sales in the period in which they are subsequently collected. 

For Genzyme, such amounts shall be determined from the books and records of Genzyme or its Related Parties, maintained in accordance with
IFRS. For Alnylam, such amounts shall be determined from the books and records of Alnylam or its Related Parties, maintained in accordance with GAAP. 

In the case of any sale or other disposal for value, such as barter or counter-trade, of a Co-Co Licensed Product, or part thereof, other than
in an arm’s length transaction exclusively for cash, Net Sales shall be calculated as above on the value of the non-cash consideration received or the fair market price (if higher) of such Co-Co Licensed Product in the country of sale or
disposal, as determined in accordance with IFRS or GAAP, as applicable. 
 Notwithstanding the foregoing, the following will not be included
in Net Sales for a Party: (1) sales between or among such Party and its Related Parties (but Net Sales shall include sales to the first Third Party (other than a Sublicensee) by such Party or its Related Parties); (2) samples of Co-Co
Licensed Product used to promote additional Net Sales, in amounts consistent with normal business practices of such Party; and (3) disposal or use of Co-Co Licensed Products in Clinical Studies or under compassionate use, patient assistance,
named patient use, or test marketing programs or non-registrational studies or other similar programs or studies where the Co-Co Licensed Product is supplied without charge or at the actual manufacturing cost thereof (without allocation of indirect
costs or any mark-up). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -13- 

 CO-CO LICENSE TERMS 

 

 In the case where a Co-Co Licensed Product is sold as part of a Combination Product in a
country in the Licensed Territory, Net Sales for the Co-Co Licensed Product included in such Combination Product in such country shall be calculated as follows: 
  

	 	(i)	if the Co-Co Licensed Product is sold separately in such country and the other active ingredient or ingredients in the Combination Product are sold separately in such country, Net Sales for the Co-Co Licensed Product
shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the fraction A/(A+B), where A is the invoice price of the Co-Co Licensed Product when sold separately in such country and B is the total invoice price
of the other active ingredient or ingredients in the Combination Product when sold separately in such country; 

  

	 	(ii)	if the Co-Co Licensed Product is sold separately in such country but the other active ingredient or ingredients in the Combination Product are not sold separately in such country, Net Sales for the Co-Co Licensed
Product shall be calculated by multiplying actual Net Sales of such Combination Product in such country by the fraction A/D, where A is the invoice price of the Co-Co Licensed Product when sold separately in such country and D is the invoice price
of the Combination Product in such country; 

  

	 	(iii)	if the Co-Co Licensed Product is not sold separately in such country but the other active ingredient or ingredients in the Combinations Product are sold separately in such country, Net Sales for the Co-Co Licensed
Product shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction 1 – (B/D), where B is the invoice price of the other active ingredient or ingredients in the Combination Product when sold separately in
such country and D is the invoice price of the Combination Product in such country; or 

  

	 	(iv)	if neither the Co-Co Licensed Product nor the other active ingredient or ingredients in the Combination Product are sold separately in such country, the Parties shall determine Net Sales for the Co-Co Licensed Product
in such Combination Product by mutual agreement based on the relative contribution of the Co-Co Licensed Product and each other active ingredient to the Combination Product, and shall take into account in good faith any applicable allocations and
calculations that may have been made for the same period in other countries. 

 For purposes of this Section, “Combination
Product” means a product that includes at least one active ingredient other than a Co-Co Licensed Product. Drug delivery vehicles, adjuvants, and excipients shall not be deemed to be “active ingredients”, except in the case where
such delivery vehicle, adjuvant, or excipient is recognized by the FDA as an active ingredient in accordance with 21 C.F.R. § 210.3(b)(7). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -14- 

 CO-CO LICENSE TERMS 

 

 1.2.131. “Non-Bankrupt Party” has the meaning set forth in Section 7.5
(Bankruptcy).  
 1.2.132. “Non-Disputing Party” has the meaning set forth in Section 2.3.1.2 (Global R&D
Costs).  
 1.2.133. “Option Data Package” has the meaning set forth in the Master Agreement. 

1.2.134. “Option Exercise Date” has the meaning set forth in the Master Agreement.  

1.2.135. “Option Exercise Notice” has the meaning set forth in the Master Agreement.  

1.2.136. “Party” means Genzyme and/or Alnylam. 

1.2.137. “Patent Challenge” has the meaning set forth in Section 12.2.3 (Challenges of Patent Rights). 

1.2.138. “Patent Rights” has the meaning set forth in the Master Agreement.  

1.2.139. “Person” means any natural person, corporation, unincorporated organization, partnership, association, sole
proprietorship joint stock company, joint venture, limited liability company, trust or government, or any Governmental Authority, or any other similar entity. 

1.2.140. “Phase 2 Budget” has the meaning set forth in Section 2.2.2.4 (Budget Caps; Adjustment and
Compensation). 
 1.2.141. [***]. 

1.2.142. “Phase 3 Budget” has the meaning set forth in Section 2.2.2.4 (Budget Caps; Adjustment and
Compensation). 
 1.2.143. [***]. 

1.2.144. “Phase I Study” has the meaning set forth in the Master Agreement.  

1.2.145. “Phase II Study” has the meaning set forth in the Master Agreement. 

1.2.146. “Phase III Study” has the meaning set forth in the Master Agreement.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -15- 

 CO-CO LICENSE TERMS 

 

 1.2.147. “Post-Marketing Study” has the meaning set forth in the
Master Agreement. 
 1.2.148. “Post-Phase 3 Budget” has the meaning set forth in Section 2.2.2.4 (Budget
Caps; Adjustment and Compensation). 
 1.2.149. [***]. 

1.2.150. “Product Joint Steering Committee” or “PJSC” means the joint steering committee as more fully
described in Section 5.1 (Product Joint Steering Committee). 
 1.2.151. “Product Trademark(s)” means the
Trademarks used, or intended for use, in connection with the distribution, marketing, promotion and sale of the Co-Co Licensed Products. Product Trademarks specifically exclude the corporate names and logos of the Parties and their Affiliates.
Product Trademark includes both the Alnylam Trademarks and the Genzyme Trademarks. 
 1.2.152. “Promotional
Materials” has the meaning set forth in Section 4.4.2 (Alnylam A&P). 
 1.2.153. “Proposing
Party” has the meaning set forth in Section 2.2.2.5(a) (Additional Development Proposals). 
 1.2.154.
“R&D Costs” means, with respect to a Co-Co Licensed Product, costs and expenses incurred in connection with the performance of any Development activity for such Co-Co Licensed Product, including [***].
 
 1.2.155. “R&D FTE” means [***] of work per annum devoted to or in support of the Development
or Manufacture of a Co-Co Licensed Product that is carried out by one or more qualified scientific or technical employees (excluding Third Party contractors) of a Party or its Affiliates. 

1.2.156. “R&D FTE Cost” means, for any period, the R&D FTE Rate multiplied by the number of R&D FTEs in
such period. 
 1.2.157. “R&D FTE Rate” means [***] per FTE, increased annually beginning on
January 1, 2015 and thereafter on January 1 of each succeeding year by the percentage increase in the CPI as of December 31 of the then most recently ended Calendar Year over the level of the CPI on December 31, 2013. 

 1.2.158. “Regulatory Approval” has the meaning set forth in the Master Agreement.  

1.2.159. “Regulatory Authority” has the meaning set forth in the Master Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -16- 

 CO-CO LICENSE TERMS 

 

 1.2.160. “Regulatory Exclusivity” means, with respect to a Co-Co
Licensed Product in a country, any exclusive marketing right, data exclusivity right, orphan drug designation or other country-wide exclusive right or status conferred by any Governmental Authority with respect to such Co-Co Licensed Product in such
country, other than a Patent Right, that limits or prohibits a Person [***].  
 1.2.161. “Related Party”
means a Party’s Affiliates, permitted Sublicensees and, with respect to Alnylam, licensees in the Co-Co Territory.  

1.2.162. “Reverted Co-Co Licensed Product” has the meaning set forth in Section 12.3.2(b) (Effects of Termination
by Alnylam for Cause or by Genzyme for Convenience).  
 1.2.163. “Royalty Term” has the meaning set forth in
Section 8.2.2 (Royalty Term).  
 1.2.164. “S&M Activities” means, with respect to a
Co-Co Licensed Product in the Co-Co Territory, all sales and marketing activities in the Co-Co Territory Commercialization Budget for such Co-Co Licensed Product. 

1.2.165. “S&M Costs” means, with respect to a Co-Co Licensed Product, costs and expenses incurred in connection
with the performance of any S&M Activities for such Co-Co Licensed Product in the Co-Co Territory, including S&M FTE Costs and fees charged by Third Party service providers and other Co-Co Out-of-Pocket Costs.  

1.2.166. “S&M FTE” means [***] of work per annum devoted to or in support of S&M Activities for a Co-Co Licensed
Product that is carried out by one or more qualified employees of, or contract sales and marketing personnel engaged by, a Party or its Affiliates. For purposes of calculating S&M FTEs with respect to S&M Activities for a Co-Co Licensed
Product: 
 (a) [***] 

(b) [***] 

1.2.167. “S&M FTE Costs” means, on a Co-Co Licensed Product-by-Co-Co Licensed Product and country-by-country basis,
the S&M FTE Rate for such country multiplied by the total number of S&M FTEs allocated to a Party in such country pursuant to the Co-Co Territory Commercialization Budget for such Co-Co Licensed Product in such Calendar Year. 

 1.2.168. “S&M FTE Rate” means, on a country-by-country basis, the then-current FTE rate for a Genzyme
S&M FTE in such country. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -17- 

 CO-CO LICENSE TERMS 

 

 1.2.169. “Safety Concern” has the meaning set forth in the Master
Agreement. 
 1.2.170. “Secondary Indication” has the meaning set forth in the Master Agreement.  

1.2.171. “Secondary Indication Study” has the meaning set forth in the Master Agreement. 

1.2.172. “Serious Adverse Event” has the meaning set forth in the Master Agreement. 

1.2.173. “siRNA” has the meaning set forth in the Master Agreement. 

1.2.174. “SPCs” has the meaning set forth in Section 11.5 (Patent Term Extensions). 

1.2.175. “Sublicensee” means a Third Party to whom a Party grants a sublicense under any Alnylam Technology or Genzyme
Technology, as the case may be, to Develop, Manufacture or Commercialize a Co-Co Licensed Product in the Field pursuant to Section 7.1.4 (Sublicensing Terms) or Section 7.2.4 (Sublicensing Terms).  

1.2.176. “Term” has the meaning set forth in Section 12.1 (Term). 

1.2.177. “Territory” means (a) with respect to Alnylam, the Co-Co Territory and (b) with respect to Genzyme,
the Genzyme Territory.  
 1.2.178. “Third Party” has the meaning set forth in the Master Agreement. 

1.2.179. “Third Party License Payment” has the meaning set forth in the Master Agreement.  

1.2.180. “Trademark” has the meaning set forth in the Master Agreement. 

1.2.181. “TTR” has the meaning set forth in the Master Agreement.  

1.2.182. “Un-Blocking Genzyme In-License” has the meaning set forth in the Master Agreement.  

1.2.183. “United States” means the United States of America and its territories, possessions and commonwealths. 

1.2.184. “Valid Claim” means a claim of: (a) an issued and unexpired patent, which claim has not been withdrawn,
cancelled, abandoned, disclaimed, revoked or held unenforceable or invalid by an unappealable decision of a court or other governmental agency of competent jurisdiction, or has not been appealed within the time allowed for appeal, or by an

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -18- 

 CO-CO LICENSE TERMS 

 

 
appealed decision of a court or other governmental agency of competent jurisdiction where the appeal has been pending for more than [***] years (unless and until such decision is subsequently
overturned on appeal) and which has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise; or (b) a patent application that has been pending less than [***]
years from the date of filing of the earliest patent application from which such patent application claims priority, which claim has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no
appeal can be taken. 
 1.2.185. “[***]” has the meaning set forth in Section 2.2.2.3(a) (Managing and Amending Global
Development Plans and Global Development Budgets). 
 1.2.186. “[***] Budget” has the meaning set forth in
Section 2.2.2.3(a) (Managing and Amending Global Development Plans and Global Development Budgets). 
 1.2.187.
“[***]” has the meaning set forth in Section 2.2.2.3(a) (Managing and Amending Global Development Plans and Global Development Budgets).  

1.2.188. “[***] Budget” has the meaning set forth in Section 2.2.2.3(a) (Managing and Amending Global Development
Plans and Global Development Budgets). 
 2. DEVELOPMENT COLLABORATION 

2.1. Overview. The Parties will collaborate in the Development of each Co-Co Licensed Product pursuant to the applicable Global
Development Plan and Genzyme Territory Development Plan. The PJSC will have primary responsibility for the oversight of the Global Development Plans, with Alnylam having primary responsibility for execution of those Global Development Plans, and
Genzyme will have sole responsibility for the Genzyme Territory Development Plans, as described below. 
 2.2. Development Plans.

 2.2.1. Global Development Strategy. For each Co-Co Licensed Product, the key Development principles for such Co-Co Licensed
Product will be set forth in a written summary of the global Development strategy for such Co-Co Licensed Product, including the indication(s) (including Secondary Indications), for which Regulatory Approval will be sought (each, a “Global
Development Strategy”). The initial Global Development Strategy for ALN-TTRsc will be provided by Alnylam to Genzyme within [***] days after the Effective Date, agreed upon by the PJSC within [***] days after the Effective Date, and then
attached hereto as Schedule 2.2.1-1. The initial Global Development Strategy for ALN-AT3 will be included in the Option Data Package, mutually agreed upon by the Parties prior to Genzyme’s exercise of the Co-Co/Global Option with respect
to ALN-AT3 in accordance with the Master Agreement, and then attached hereto as Schedule 2.2.1-2. Any Global Development Strategy may be amended from time to time only by the PJSC responsible for the applicable Co-Co Licensed Product. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -19- 

 CO-CO LICENSE TERMS 

 

 2.2.2. Global Development Plan. 

2.2.2.1. Global Development Plans. For each Co-Co Licensed Product, the Development activities that are necessary
or useful to be undertaken for such Co-Co Licensed Product to achieve initial Regulatory Approval for each of the indications to be sought pursuant to the Global Development Strategy in at least all of the MMCs in a proximal fashion (including the
design of necessary or useful Clinical Studies) will be set forth in reasonable detail in a written work plan and time table (each, a “Global Development Plan”). Alnylam will provide a draft of the initial Global Development Plan
for ALN-TTRsc to Genzyme on or before March 31, 2014, and within [***] days thereafter the PJSC will review, update and approve such Global Development Plan and it will be attached hereto as Schedule 2.2.2-1. The initial Global Development
Plan for ALN-AT3 will be prepared by Alnylam and included in the Option Data Package for ALN-AT3 provided by Alnylam to Genzyme under the Master Agreement, and if Genzyme exercises the Co-Co/Global Option for ALN-AT3, within [***] days of the
Implementation Date for ALN-AT3 the PJSC responsible for ALN-AT3 will review, update and approve such Global Development Plan and it will be attached hereto as Schedule 2.2.2-2. Each Global Development Plan must, at all times, be consistent
with the Global Development Strategy and include all Development activities that (i) are reasonably necessary to obtain initial Regulatory Approval of the applicable Co-Co Licensed Product in at least each MMC for each of the indications, including
Secondary Indications, to be sought pursuant to the Global Development Strategy in a proximal fashion, (ii) Post-Marketing Studies for the Co-Co Territory and (iii) Secondary Indication Studies included in the initial Global Development Plan or
added pursuant to Section 2.2.2.5 (Secondary Indications) (all such Development activities, collectively, the “Global Development Activities”); provided, however, that, unless otherwise agreed by the Parties, in no
event will any Global Development Plan include (a) any Post-Marketing Study in the Genzyme Territory, (b) any Secondary Indication Study, except for Secondary Indication Studies included in the initial Global Development Plan or added to a Global
Development Plan pursuant to Section 2.2.2.4 (Secondary Indications) or (c) after the last Regulatory Approval in all MMCs, any Development activity that is useful solely to achieve initial Regulatory Approval in a country in the Genzyme Territory
that is not a Genzyme Territory MMC, except for Secondary Indication Studies included in the initial Global Development Plan or added to a Global Development Plan pursuant to Section 2.2.2.5 (Secondary Indications). In addition, for the period
following the first Regulatory Approval in an MMC of a Co-Co Licensed Product, the Global Development Plan (and the Global Development Activities thereunder) must be established by the PJSC in a manner that reconciles the Parties’ preferences
regarding short- and long-term profitability of such Co-Co Licensed Product. Each Global Development Plan will allocate responsibility for the performance of each Global Development Activity to one of the Parties. The time table for the

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -20- 

 CO-CO LICENSE TERMS 

 

 
completion of the Global Development Activities included in each Global Development Plan will be designed to obtain initial Regulatory Approval of the applicable Co-Co Licensed Product in each
MMC in a proximal fashion and as soon as reasonably possible. The terms of, and Development activities set forth in, each Global Development Plan will at all times be designed to be in compliance with all applicable Laws and in accordance with
professional and ethical standards customary in the pharmaceutical industry. 
 2.2.2.2. Global Development
Budgets. Each Global Development Plan will contain a [***] year rolling budget for the probable Global Regulatory Costs and probable Global Development Activities to be performed during the [***], and a forecast of the budgets for each
subsequent Calendar Year thereafter through completion of all Global Development Activities set forth in any such Global Development Plan, provided that each initial Global Development Plan will also include such a budget for the partial
Calendar Year commencing as of the date of such Global Development Plan and ending December 31 of such Calendar Year (each such [***] budget plus any such partial Calendar Year is a “Global Development Budget”). Each Global
Development Budget will be updated annually by the PJSC responsible for the applicable Co-Co Licensed Product in accordance with Section 2.2.2.3 (Managing and Amending Global Development Plans and Global Development Budgets). The initial Global
Development Budget for a Co-Co Licensed Product, and each update thereto, will be prepared by the PJSC in accordance with [***]: 

(a) [***] 

(b) [***] 

(c) [***] 

(d) [***] 

Alnylam will enter such Global Development Budget in a template that the Parties agree is efficient for both Parties to communicate such
information. 
 2.2.2.3. Managing and Amending Global Development Plans and Global Development Budgets. The
PJSC responsible for a Co-Co Licensed Product will update and amend the applicable Global Development Plan from time-to-time as it deems necessary and, until such time as no further Global Development Activities are occurring or expected to occur
with respect to such Co-Co Licensed Product, the PJSC will update such Global Development Plan annually as follows: 

(a) No later than [***] of each Calendar Year, the applicable PJSC will prepare an updated draft of the Global Development
Plan, which shall contain a proposed Global Development Budget[***]. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -21- 

 CO-CO LICENSE TERMS 

 

 (b) No later than [***] of each Calendar Year, the applicable PJSC will
review and tentatively approve an updated Global Development Plan and Global Development Budget, and such updated Global Development Plan and Global Development Budget will become effective upon such tentative approval by the PJSC, provided
that the Parties acknowledge and agree that each Party’s internal process for receiving final approval of such Global Development Plan and Global Development Budget from its Board of Directors and/or senior management may occur after [***]
(but, in any event, before [***]) and such Global Development Plan and Global Development Budget will not become final unless and until such approvals are obtained [***]. 

2.2.2.4. [***]; Adjustments and Compensation. In addition to the Global Development Budget for each Co-Co
Licensed Product, Alnylam shall prepare, and submit to the PJSC for approval, three (3) Development budget(s) for each Co-Co Licensed Product, the first of which shall cover the period commencing as of the Implementation Date for such Co-Co
Licensed Product and ending on the anticipated date of initiation of the first Phase III Study for such Co-Co Licensed Product (as further described below, each a “Phase 2 Budget”), the second of which shall cover the period
commencing as of the anticipated date of initiation of the first Phase III Study for such Co-Co Licensed Product and ending on the anticipated date of filing of an application for Regulatory Approval of such Co-Co Licensed Product in the first MMC
(as further described below, each a “Phase 3 Budget”) and the third of which shall cover the period commencing as of the anticipated date of filing of an application for Regulatory Approval for such Co-Co Licensed Product in the
first MMC and ending on the date that there are no further Development activities to be performed under the Global Development Plan for such Co-Co Licensed Product (as further described below, each a “Post-Phase 3 Budget”),
provided that if the period covered by the Post-Phase 3 Budget is longer than three (3) years, Alnylam shall prepare a new Post-Phase 3 Budget to cover each subsequent three (3) year period. Each Phase 2 Budget, Phase 3 Budget and
Post-Phase 3 Budget [***]. 
 (a) Preparation of Phase 2 Budget, Phase 3 Budget and Post-Phase 3 Budget.
Each Phase 2 Budget, Phase 3 Budget and Post-Phase 3 Budget submitted to the PJSC will be prepared by Alnylam in accordance with [***].  

(b) [***] 

(c) Delivery and Effectiveness of Phase 2 Budget, Phase 3 Budget and Post-Phase 3 Budget.  

 

	 	(i)	Alnylam shall include a Phase 2 Budget [***] with the initial Global Development Plan for each Co-Co Licensed Product. Such Phase 2 Budget [***] shall become effective, subject to adjustment in accordance with the
foregoing Section 2.2.2.4(b), upon the Implementation Date for the relevant Co-Co Licensed Product. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -22- 

 CO-CO LICENSE TERMS 

 

	 	(ii)	Alnylam shall provide to the PJSC for approval a Phase 3 Budget [***] for each Co-Co Licensed Product no less than [***] days prior to the anticipated initiation of the first Phase III Study for each Co-Co Licensed
Product, along with the top line data and data tables from any completed Phase II Studies and other completed non-clinical studies (including all Serious Adverse Event and Safety Concern data), as well as a draft of the end of Phase II briefing
package, in each case to the extent not previously provided or made available to Genzyme (such budget, data and draft, collectively the “End of Phase II Package”). Such Phase 3 Budget [***] shall become effective at the end of such
[***] day period. 

  

	 	(iii)	Alnylam shall provide to the PJSC for approval a Post-Phase 3 Budget [***] for each Co-Co Licensed Product no less than [***] days prior to the anticipated completion of the first Phase III Study for each Co-Co Licensed
Product. Such Post-Phase 3 Budget [***] shall become effective upon approval by the PJSC. 

  

	 	(d)	[***] 

 2.2.2.5. Secondary Indications.  

(a) Additional Development Proposals. If a Party desires to conduct a Secondary Indication Study of a Co-Co Licensed
Product for the purpose of seeking Regulatory Approval to market such Co-Co Licensed Product for a Secondary Indication, such Party (the “Proposing Party”) will submit to the PJSC responsible for such Co-Co Licensed Product a
proposal to add such Secondary Indication Study to the applicable Global Development Plan (an “Additional Development Proposal”). Each Additional Development Proposal will describe in reasonable detail the Secondary Indication
Study(ies) that the Proposing Party desires to conduct, including a synopsis of the trial, the proposed enrollment criteria, number of patients to be included, endpoints to be measured, and statistical design and powering (the “Additional
Development Activities”), as well as a proposed timeline and budget and an analysis of the business opportunity and revenue potential for such Additional Development Activities and Secondary Indication. 

(b) PJSC Decision Regarding Additional Development Activities. The PJSC shall approve or reject an Additional
Development Proposal within [***] days after receipt thereof from the Proposing Party as set forth in this Section 2.2.2.5. 
  

	 	(i)	 If the PJSC approves an Additional Development Proposal, upon such an approval, the applicable Global Development Plan will be amended to include the
Additional Development Activities, including the proposed 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -23- 

 CO-CO LICENSE TERMS 

 

	 	
timeline and budget for such Additional Development Activities, set forth in such Additional Development Proposal (as may be amended by the PJSC) upon such approval. Any Additional Development
Activities included in a Global Development Plan pursuant to this Section 2.2.2.5(b) shall be deemed to be Global Development Activities for all purposes under these Co-Co License Terms (including the definition of Global R&D Costs).

  

	 	(ii)	If the PJSC fails to approve an Additional Development Proposal, upon such a failure, the Secondary Indication Study proposed in the Additional Development Proposal will not be deemed a Global Development Activity for
any purpose under these Co-Co License Terms, and Sections 2.2.2.5(c) (Independent Performance of Additional Development Activities) and Section 2.2.2.5(d) (Opt-In for Additional Development Activities) shall apply. 

 

	 	(c)	Independent Performance of Additional Development Activities. 

  

	 	(i)	If the PJSC fails to approve for inclusion in the Global Development Plan an Additional Development Proposal proposed by Alnylam for a Secondary Indication Study(ies) for a Co-Co Licensed Product, Alnylam may, upon
notice to Genzyme, conduct the proposed Secondary Indication Study(ies) at its own expense [***]. 

  

	 	(ii)	If the PJSC fails to approve for inclusion in the Global Development Plan an Additional Development Proposal proposed by Genzyme for a Secondary Indication Study(ies) for such Co-Co Licensed Product, Genzyme may, upon
notice to Alnylam, conduct the proposed Secondary Indication Study(ies) at its own expense [***]. 

  

	 	(iii)	Notwithstanding anything in Section 3.5 (Right of Reference) to the contrary, the Non-Proposing Party with respect to an Additional Development Activity that is permitted to be conducted in accordance with this
Section 2.2.2.5 will not have any rights under Section 3.5 (Right of Reference) with respect to any information or data generated from such Additional Development Activity, except as described in Section 2.2.2.5(d) (Opt-In for
Additional Development Activities). 

  

	 	(d)	Opt-In for Additional Development Activities.  

  

	 	(i)	 In the event that the Proposing Party conducts Secondary Indication Study(ies) pursuant to Section 2.2.2.5(c) (Independent Performance of Additional
Development Activities), the Non-Proposing Party may elect, in its discretion and upon written notice to the Proposing Party prior to the date on which [***] (an “Additional Development Opt-In Notice”), to

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -24- 

 CO-CO LICENSE TERMS 

 

	 	
opt in with respect to any Secondary Indication Study that was the subject of such Additional Development Proposal that the Proposing Party elected to conduct in accordance with
Section 2.2.2.5(c) (Independent Performance of Additional Development Activities), and then (i) such Secondary Indication Study shall be deemed to be a Global Development Activity under the Global Development Plan for the applicable Co-Co
Licensed Product from and after the date on which such Additional Development Opt-In Notice is received by the Proposing Party (the “Additional Development Opt-In Date”); (ii) the then-current plan and budget of the Proposing
Party with respect to such Secondary Indication Study shall be deemed to be included within, and part of, the Global Development Plan for such Co-Co Licensed Product as of the Additional Development Opt-In Date, and shall control with respect to
such Secondary Indication Study unless and until an amendment to the Global Development Plan providing for a different or modified plan and budget is approved by the applicable PJSC; and (iii) the Non-Proposing Party will have all rights
granted to it under Section 3.5 (Right of Reference) with respect to the information and data generated from such Secondary Indication Study as if such Secondary Indication Study was conducted under the Global Development Plan for such Co-Co
Licensed Product, [***]. 

  

	 	(ii)	If the Non-Proposing Party does not provide an Additional Development Opt-In Notice to the Proposing Party prior to the date on which Regulatory Approval for the applicable Co-Co Licensed Product is granted by a
Regulatory Authority in an MMC for the Secondary Indication proposed by such Proposing Party, then, as of the date of such Regulatory Approval, the Non-Proposing Party shall be deemed to have opted in and the Non-Proposing Party will have all rights
granted to it under Section 3.5 (Right of Reference) with respect to the information and data generated from such Secondary Indication Study as if such Secondary Indication Study was conducted under the Global Development Plan for such Co-Co
Licensed Product, [***]. 

 2.2.2.6. Additional Clinical Study Sites in Genzyme Territory. With
respect to any Clinical Study in a Global Development Plan, at Genzyme’s request, Alnylam will add a study site in a country in the Genzyme Territory [***]. If Alnylam adds such a study site at Genzyme’s request, Genzyme will reimburse
Alnylam for any incremental R&D FTE Costs or Co-Co Out-of-Pocket Costs required as a result of adding such study site. Genzyme will pay Alnylam such reimbursement within [***] days of receipt of an invoice from Alnylam. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -25- 

 CO-CO LICENSE TERMS 

 

 2.2.3. Genzyme Territory Development Plan. Other than Global Development Activities,
all Development activities to be undertaken with respect to each Co-Co Licensed Product by or on behalf of Genzyme with respect to the Genzyme Territory, including Secondary Indication Studies and Post-Marketing Studies, will be set forth in a
written work plan and time table (each, a “Genzyme Territory Development Plan”). Each Genzyme Territory Development Plan shall be consistent with the requirements of the then-current Global Development Strategy. The Genzyme
Territory Development Plan for ALN-TTRsc will be prepared by Genzyme and delivered to the applicable PJSC by [***] and, following review and approval by the PJSC, will then be attached to the PJSC meeting minutes and deemed to be attached hereto as
Schedule 2.2.3-1. If Genzyme exercises the Co-Co/Global Option with respect to ALN-AT3, the initial Genzyme Territory Development Plan for ALN-AT3 (if any) will be prepared by Genzyme and following review and approval by the PJSC, will then
be attached to the PJSC meeting minutes and deemed to be attached hereto as Schedule 2.2.3-2. Each Genzyme Territory Development Plan will set forth a rolling written work plan and time table with respect to the Development of and Secondary
Indication Studies for the applicable Co-Co Licensed Product from the Implementation Date until such time as no further Development or Secondary Indication Studies are occurring or expected to occur with respect to the applicable Co-Co Licensed
Product. Genzyme will update each such Genzyme Territory Development Plan from time-to-time but at least annually on or before [***]. Genzyme will present each Genzyme Territory Development Plan and any proposed amendments thereto to the applicable
PJSC at least [***] days in advance of implementation of the Genzyme Territory Development Plan, and following review and approval by the PJSC, will then be attached to the PJSC meeting minutes and deemed to be attached hereto as the applicable
Schedule.  
 2.3. Joint Responsibilities for Development Activities and Costs. 

2.3.1. Global Development. 

2.3.1.1. Generally. With respect to each Co-Co Licensed Product, the PJSC will have overall responsibility for
oversight of the global Development of each Co-Co Licensed Product and all Development activities under such Global Development Plan. Alnylam shall have overall responsibility for execution under the Global Development Plan and each Party, in turn,
shall be responsible for execution of the activities allocated to it under the Global Development Plan. Each Party and its Affiliates shall conduct each Global Development Activity for which it is responsible solely in accordance with the Global
Development Plan (as such Global Development Plan may be amended from time to time in accordance with these Co-Co License Terms) in sound scientific manner and in compliance with applicable Law. Notwithstanding anything to the contrary in these
Co-Co License Terms, neither Party will be obligated to undertake or continue any Global Development Activity if (a) such Party reasonably determines that performance of such Global Development Activity would violate applicable Law; or
(b) with respect to any Global Clinical Study, (i) a Regulatory Authority or independent safety data review board for such Global Clinical Study has required or recommended termination or suspension of such Global Clinical Study or
(ii) such Party believes in good faith that termination or suspension of such Global 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -26- 

 CO-CO LICENSE TERMS 

 

 
Clinical Study is warranted because of safety or tolerability risks or the lack of suitable risk benefit ratio to the study subjects. In the event that a Party determines not to undertake or
continue any Global Development Activity in accordance with the immediately preceding sentence, such Party shall promptly notify the other Party of such determination, and shall use all reasonable efforts to notify and consult with the other Party
prior to making such determination. 
 2.3.1.2. Global R&D Costs.  

(a) With respect to ALN-TTRsc, each Party shall be responsible for fifty percent (50%) of all Global Regulatory Costs and
Global R&D Costs for Global Development Activities that occur after the later of (i) [***] and (ii) [***] (such later date, the “ALN-TTRsc Global R&D Cost Opt-In Date”), and amounts specified in clauses
(ii) and (iii) of Section 2.3.1.2(c) below, if any. Alnylam shall be responsible for one-hundred percent (100%) of Global Regulatory Costs and Global R&D Costs for Global Development Activities for ALN-TTRsc that occur prior
to the ALN-TTRsc Global R&D Cost Opt-In Date, except for amounts specified in clauses (ii) and (iii) of Section 2.3.1.2(c) below, if any. 

(b) With respect to ALN-AT3, if Genzyme exercises the Co-Co/Global Option, each Party shall be responsible for fifty
percent (50%) of all Global Regulatory Costs and Global R&D Costs for Global Development Activities that occur after the later of (i) [***] and (ii) [***] (such later date, the “ALN-AT3 Global R&D Cost Opt-In
Date,” and together with the ALN-TTRsc Global R&D Cost Opt-In Date, the “Global R&D Cost Opt-In Date”), and amounts specified in clauses (ii) and (iii) in Section 2.3.1.2(c) below, if any. Alnylam
shall be responsible for one-hundred percent (100%) of Global Regulatory Costs and Global R&D Costs for Global Development Activities for such Co-Co Licensed Product that occur prior to the ALN-AT3 Global R&D Cost Opt-In Date, except
for amounts specified in clauses (ii) and (iii) of Section 2.3.1.2(c) below, if any. 
 (c) The Global
R&D Costs to be shared by the Parties pursuant to Sections 2.3.1.2(a) and 2.3.1.2(b) above shall only include amounts that are within one or more of the following four (4) categories: 

(i) [***] 

(ii) [***] 

(iii) [***] 

(iv) [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -27- 

 CO-CO LICENSE TERMS 

 

 (d) For clarity, Global Regulatory Costs and Global R&D Costs to be
shared by the Parties pursuant to Section 2.3.1.2(a) and Section 2.3.1.2(b) shall exclude any amounts paid after the Global R&D Cost Opt-In Date to Third Parties with respect to services rendered or materials procured in connection
with the conduct of any Clinical Study or other Development activity that, in either case, is completed prior to the Global R&D Cost Opt-In Date. 

(e) Global R&D Costs and Global Regulatory Costs for each Co-Co Licensed Product shall initially be borne by the
Party incurring the cost or expense. Each Party will calculate and maintain records of Global R&D Costs and Global Regulatory Costs incurred by it and its Affiliates with respect to each Co-Co Licensed Product and, within [***] days following
the end of each Calendar Quarter, each Party shall submit to the other a report detailing the Global R&D Costs and Global Regulatory Costs incurred by it and its Affiliates during such Calendar Quarter, and, if requested, reasonable supporting
documentation will be provided (a “Global R&D Costs Report”). In addition, each Party shall use good faith efforts to notify the other Party of any material Global R&D Costs and Global Regulatory Costs incurred by such Party
during such Calendar Quarter within [***] days after the end of such Calendar Quarter. The Party that incurs more than its share of the total actual Global R&D Costs and Global Regulatory Costs with respect to a Co-Co Licensed Product during any
Calendar Quarter shall be paid by the other Party an amount of cash sufficient to reconcile to its agreed percentage of Global R&D Costs and Global Regulatory Costs for such Co-Co Licensed Product, which payment shall be made within [***] days
after delivery of the Global R&D Cost Reports for such Calendar Quarter. Notwithstanding the foregoing, if following receipt of a Global R&D Costs Report a Party (the “Disputing Party”) disputes any Global R&D Costs or
Global Regulatory Costs under such Global R&D Costs Report, it shall have [***] days to notify the other Party (the “Non-Disputing Party”). Upon receiving such notice from the Disputing Party, the Non-Disputing Party shall, at
the reasonable request of the Disputing Party, provide to the Disputing Party supporting documentation relating to any such disputed Global R&D Costs or Global Regulatory Costs. The Parties agree to use reasonable efforts to resolve any such
dispute as soon as reasonably practicable, and any undisputed portion of Global R&D Costs or Global Regulatory Costs in such Global R&D Costs Report shall be paid within [***] days after delivery of such Global R&D Costs Report. Once the
Parties have resolved such dispute, any disputed amounts still owed by either Party will be paid within [***] days of resolution of such dispute.  

(f) [***] 

(g) Notwithstanding anything to the contrary in these Co-Co License Terms, the Parties shall not share Global R&D Costs
incurred in a Calendar Year with respect to Global Development Activities for a Co-Co Licensed Product to the extent such Global R&D Costs exceed [***] of the amounts included in the final [***] Budget that was applicable to such Current
Calendar Year (the amount in excess of such [***] limit is the “Excess Global R&D Costs”). One hundred percent (100%) of any Excess Global R&D Costs for such Co-Co Licensed Product will be borne by the Party that
incurred such Excess Global R&D Costs. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -28- 

 CO-CO LICENSE TERMS 

 

 2.3.2. Genzyme Development. Except with respect to Global R&D Costs (which shall
be shared by the Parties in accordance with Section 2.3.1.2 (Global R&D Costs)), Genzyme shall be responsible for one hundred percent (100%) of all costs and expenses incurred with respect to Development activities that are conducted
by Genzyme pursuant to any Genzyme Territory Development Plan. Genzyme will conduct all Development of each Co-Co Licensed Product for the Genzyme Territory solely in accordance with the applicable Global Development Plan and Genzyme Territory
Development Plan, as such Global Development Plan and Genzyme Territory Development Plan may be amended in accordance with these Co-Co License Terms, and in sound scientific manner and in compliance with applicable Law. 

2.3.3. Alnylam Development. Alnylam will conduct all Development of each Co-Co Licensed Product for the Co-Co Territory solely in
accordance with the applicable Global Development Plan, as such Global Development Plan may be amended in accordance with these Co-Co License Terms, and in sound scientific manner and in compliance with applicable Law.  

2.4. Diligence. 

2.4.1. Genzyme Diligence. With respect to each Co-Co Licensed Product, Genzyme will use Commercially Reasonable Efforts to [***]. 

 2.4.2. Alnylam Diligence. With respect to each Co-Co Licensed Product, Alnylam will use Commercially Reasonable Efforts to
(a) Develop such Co-Co Licensed Product and obtain Regulatory Approval therefor in (i) each Co-Co Territory MMC, and (ii) any other country(ies) within the Co-Co Territory where the PJSC determines that it is commercially reasonable
to seek Regulatory Approval (taking into account all relevant factors as provided in the definition of Commercially Reasonable Efforts); and (b) perform the Global Development Activities allocated to it under the Global Development Plan for
such Co-Co Licensed Product in accordance with the Global Development Plan.  
 2.5. Records; Reports; Information Sharing.

 2.5.1. Development Activities Reports. Each Party will periodically provide to the PJSC responsible for a Co-Co Licensed
Product, but in no event less than on a Calendar Quarter basis, or more frequently as reasonably requested by the other Party, an update regarding Development activities conducted by or on behalf of such Party with respect to such Co-Co Licensed
Product, as well as any Secondary Indication Studies and Post-Marketing Studies conducted by or on behalf of such Party with respect to such Co-Co Licensed Product. The Parties will periodically report to the PJSC responsible for a Co-Co Licensed
Product, but in no event less than on a Calendar Quarter basis, regarding their respective activities conducted under the Global Development Plan for such Co-Co Licensed Product. In addition, each Party will promptly share with the other Party all
material developments and information that it comes to possess relating to the Development of any Co-Co Licensed Products, including Safety Concerns and study reports and data generated from Clinical Studies of such Co-Co Licensed Product.

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -29- 

 CO-CO LICENSE TERMS 

 

 2.5.2. Scientific Records. Each Party will maintain scientific records, in sufficient
detail and in sound scientific manner appropriate for patent and regulatory purposes, which will fully and properly reflect all work done and results achieved in the performance of the Development activities and Secondary Indication Studies with
respect to Co-Co Licensed Products by such Party.  
 2.5.3. Information Exchange and Development Assistance. Until the
expiration or termination of the final Global Development Plan, upon the reasonable request of the other Party, each Party shall provide to the other Party, without additional compensation (except as provided in Section 6.5 (Transfer of
Manufacturing Know-How) of the Master Agreement) and in a commercially reasonable format, Know-How Controlled by such Party and/or its Related Parties that is licensed to the other Party under these Co-Co License Terms (i.e.,
Know-How included in Genzyme Technology for Genzyme and Know-How included in Alnylam Technology for Alnylam) to the extent that it is reasonably necessary or useful for Developing a Co-Co Licensed Product in the requesting Party’s Territory or
for obtaining or maintaining Regulatory Approval for a Co-Co Licensed Product in the requesting Party’s Territory, including copies of (a) all scientific information and data related to such Co-Co Licensed Product (including all data made,
collected or otherwise generated in the conduct of any pre-clinical studies, Clinical Studies, Secondary Indication Studies or early access/named patient programs for the Co-Co Licensed Products, as well as CMC information), and (b) protocols
and investigator brochures, in each case, that are reasonably necessary for the other Party (or its Related Parties) to perform its obligations or exploit its rights under these Co-Co License Terms with respect to such Co-Co Licensed Product.
Notwithstanding the foregoing, Genzyme shall have no obligation to transfer or disclose to Alnylam any Know-How included in the Genzyme Manufacturing IP; provided, however, that if Genzyme elects, in its sole discretion, to transfer or
disclose any such Know-How to Alnylam in writing, it shall be “Genzyme Disclosed Manufacturing Know-How” under these Co-Co License Terms and licensed to Alnylam in accordance with Section 7.2.3 (License to Genzyme Disclosed
Manufacturing Know-How).  
 2.5.4. Personnel. Each Party may request, through the PJSC or the other Party’s CLP Alliance
Manager responsible for a Co-Co Licensed Product, that the other Party reasonably make available for consultation regarding the Development of such Co-Co Licensed Product certain of its employees engaged in Development activities and Secondary
Indication Studies with respect to such Co-Co Licensed Product. The PJSC or the CLP Alliance Managers responsible for a Co-Co Licensed Product will reasonably coordinate, upon reasonable notice during normal business hours and at their respective
places of employment, consultation between the Parties on the progress of the Development and Secondary Indication Studies for such Co-Co Licensed Product. 

2.5.5. Confidentiality. All information exchanged by the Parties under this Section 2.5 will be deemed to be Confidential
Information of the disclosing Party and maintained in accordance with Section 7 of the Master Agreement (Confidentiality and Publication). 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -30- 

 CO-CO LICENSE TERMS 

 

 2.6. Third Parties. 

2.6.1. Use of Third Parties. The Parties shall be entitled to utilize the services of Third Parties to perform their respective
Development and Manufacturing activities under these Co-Co License Terms, provided that (a) each Party shall require that such Third Party operates in a manner consistent with these Co-Co License Terms, (b) each Party shall remain
at all times fully liable for its respective responsibilities and (c) the Parties will make reasonable efforts to share, through the PJSC, information regarding any prior experience with specific CROs that are anticipated to be engaged to
perform work under the Global Development Plan. Each Party shall require that any Third Party agreement entered into pursuant to this Section 2.6.1 include confidentiality and non-use provisions that are no less stringent than those set forth
in Section 7 of the Master Agreement (Confidentiality and Publication) and shall obtain ownership of, and/or a fully sublicensable license under and to, any Know-How and Patent Rights that are developed by such Third Party in the performance of
such agreement and are reasonably necessary or useful to Develop, Manufacture and/or Commercialize Co-Co Licensed Products in the Field. The Party utilizing the services of a Third Party service provider shall be solely responsible for direction of
and communications with such Third Party, but such Party shall provide the other Party with reasonably detailed updates regarding any such activities from time to time. 

2.6.2. [***].  

2.7. [***]. 
 3.
REGULATORY MATTERS 
 3.1. Regulatory Filings and Interactions in the Genzyme Territory. 

3.1.1. Ownership of Regulatory Filings. 

3.1.1.1. Genzyme will own all INDs, NDAs and related regulatory documentation submitted to any Regulatory Authority in
the Genzyme Territory with respect to any Co-Co Licensed Product. At Genzyme’s request following the Implementation Date for a Co-Co Licensed Product, Alnylam will promptly assign and transfer to Genzyme all INDs, NDAs and other regulatory
documentation submitted to any Regulatory Authority in the Genzyme Territory with respect to such Co-Co Licensed Product that is in the possession or control of Alnylam, and each Party will submit all filings, letters and other documentation
necessary to effect such assignment and transfer to the applicable Regulatory Authority no later than [***] days after such request for such Co-Co Licensed Product, in each case, excluding any drug master files maintained by or on behalf of Alnylam,
which shall be and remain Alnylam’s sole responsibility. Alnylam hereby appoints Genzyme as Alnylam’s agent for all matters related to each Co-Co Licensed Product involving Regulatory Authorities in the Genzyme Territory during the period
beginning on the Implementation Date for such Co-Co Licensed 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -31- 

 CO-CO LICENSE TERMS 

 

 
Product and ending on the date that the transfer of all INDs, NDAs and related regulatory documents filed with or submitted to any Regulatory Authority in the Genzyme Territory that relate to
such Co-Co Licensed Product becomes effective, and Genzyme hereby accepts such appointment, excluding any drug master files maintained by or on behalf of Alnylam, which shall be and remain Alnylam’s sole responsibility. 

3.1.1.2. Notwithstanding the foregoing, for every Clinical Study conducted under a Global Development Plan, Alnylam will
draft the protocol, develop the IND strategy, and file INDs globally, including in the Genzyme Territory, after input and review by Genzyme and Alnylam will use reasonable efforts to address any concerns raised by Genzyme in connection with such
activities. Unless otherwise agreed by the Parties, on a country-by-country basis, following the acceptance or approval of the IND and the first dosing of the first patient in the first Phase III Study of the relevant Co-Co Licensed Product in such
country, Alnylam will assign the IND in such country, as set forth in Section 3.1.1.1, in the Genzyme Territory to Genzyme and from that point forward, Genzyme will be primarily responsible for the related regulatory activities with respect
thereto in its Territory. [***] 
 3.1.2. Responsibilities for Regulatory Matters. Pursuant to the Global Development Plan for
a Co-Co Licensed Product and, except as otherwise provided in such Global Development Plan, Genzyme will be solely responsible for all regulatory matters relating to such Co-Co Licensed Product in the Genzyme Territory, including
(i) overseeing, monitoring and coordinating all regulatory actions, communications and filings with, and submissions to, each Regulatory Authority in the Genzyme Territory with respect to such Co-Co Licensed Product; (ii) interfacing,
corresponding and meeting with each Regulatory Authority in the Genzyme Territory with respect to such Co-Co Licensed Product; and (iii) seeking and maintaining all regulatory filings in the Genzyme Territory with respect to such Co-Co Licensed
Product, excluding any drug master files maintained by or on behalf of Alnylam, which shall be and remain Alnylam’s sole responsibility. 

3.1.3. Communications with Regulatory Authorities. Genzyme will promptly (and in any event no later than [***] days) notify the Alnylam
representatives on the PJSC responsible for a Co-Co Licensed Product in writing, including a brief description in English, of the principal issues raised in any material communication with any Regulatory Authority in the Genzyme Territory with
respect to such Co-Co Licensed Product. Upon Alnylam’s reasonable request after receiving a notice from Genzyme in accordance with the immediately preceding sentence, Genzyme will provide to Alnylam: (i) at Genzyme’s expense, a summary
translation of the applicable material communication in English; (ii) at Genzyme’s expense, complete copies of the original correspondence with the applicable Regulatory Authority in their native language; or (iii) at Alnylam’s expense, a
full translation of the applicable material communication in English, in each case (i) through (iii) within a reasonable period of time following such request. For purposes of this Section 3.1.3, “material communication” will include any
meetings with 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -32- 

 CO-CO LICENSE TERMS 

 

 
Regulatory Authorities, or questions or concerns from Regulatory Authorities, regarding significant issues, such as key product quality attributes (e.g., purity), safety findings affecting
the platform (e.g., Serious Adverse Events, emerging safety signals), clinical or nonclinical findings affecting patient safety or lack of efficacy, or receipt or denial of Regulatory Approval. 

3.1.4. Meetings with Regulatory Authorities. Genzyme shall provide Alnylam with reasonable advance notice of all substantive meetings
with Regulatory Authorities in the Genzyme Territory pertaining to each Co-Co Licensed Product, or with as much advance notice as practicable under the circumstances. Genzyme shall use reasonable efforts, to the extent reasonably practicable, to
permit Alnylam to have, at Alnylam’s expense, mutually acceptable representatives of Alnylam attend, solely as a non-participating observers, material, substantive meetings (including pre-IND and end of Phase II Study meetings) with Regulatory
Authorities in the Genzyme Territory pertaining to such Co-Co Licensed Product; provided, however, that Genzyme shall not be obligated to change or re-schedule any such meeting in order to accommodate the schedule of Alnylam’s
representatives. Prior to the acceptance or approval of the IND and the first dosing of the first patient in the first Phase III Study of a Co-Co Licensed Product in a country in the Genzyme Territory, Alnylam shall provide Genzyme with reasonable
advance notice of all substantive meetings with Regulatory Authorities in the Genzyme Territory pertaining to such Co-Co Licensed Product, or with as much advance notice as practicable under the circumstances. Alnylam shall use reasonable efforts,
to the extent reasonably practicable, to permit Genzyme to have, at Genzyme’s expense, mutually acceptable representatives of Genzyme attend, as full and equal participants, material, substantive meetings (including pre-IND and end of Phase II
Study meetings) with Regulatory Authorities in the Genzyme Territory pertaining to such Co-Co Licensed Product. 
 3.1.5. Submissions.
With respect to each Co-Co Licensed Product, Genzyme shall provide Alnylam with prompt written notice of each of the following events (but in any event within [***] days) after the occurrence of such event in the Genzyme Territory: (i) the
filing of any IND for such Co-Co Licensed Product; and (ii) the submission of any filings or applications for Regulatory Approval (including orphan drug applications and designations) of such Co-Co Licensed Product to any Regulatory Authority;
provided, however, that in all circumstances, Genzyme shall inform Alnylam of such event prior to public disclosure of such event by Genzyme. 

3.2. Regulatory Filings and Interactions in the Co-Co Territory. 

3.2.1. Ownership of Regulatory Filings. Alnylam will own all INDs, NDAs and related regulatory documentation submitted to any Regulatory
Authority in the Co-Co Territory with respect to any Co-Co Licensed Product. 
 3.2.2. Responsibilities for Regulatory Matters.
Pursuant to the Global Development Plan for a Co-Co Licensed Product and, except as otherwise provided in such Global Development Plan, Alnylam will be primarily responsible for all regulatory matters relating to such Co-Co Licensed Product in the
Co-Co Territory, including (i) overseeing, monitoring and coordinating all regulatory actions, communications and filings with, and 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -33- 

 CO-CO LICENSE TERMS 

 

 
submissions to, each Regulatory Authority in the Co-Co Territory with respect to such Co-Co Licensed Product; (ii) interfacing, corresponding and meeting with each Regulatory Authority in
the Co-Co Territory with respect to such Co-Co Licensed Product; and (iii) seeking and maintaining all regulatory filings in the Co-Co Territory with respect to such Co-Co Licensed Product; provided, however, that Alnylam and
Genzyme may have roles of varying responsibility for such activities in respect of the Co-Co Licensed Products in the Co-Co Territory as is set forth in the applicable Global Development Plan. 

3.2.3. Communications with Regulatory Authorities. Alnylam will notify the Genzyme representatives on the PJSC responsible for a Co-Co
Licensed Product in writing, including a brief description in English, of the principal issues raised in any material communication with any Regulatory Authority in the Co-Co Territory with respect to such Co-Co Licensed Product within [***] days
after receipt of such material communication. Alnylam will allow Genzyme a reasonable opportunity to review and comment on Alnylam’s proposed response to any such material communications in advance of the transmission of any such response, and
Alnylam will reasonably consider all comments timely provided by Genzyme in connection therewith. Upon Genzyme’s reasonable request after receiving a notice from Alnylam in accordance with the immediately preceding sentence, Alnylam will
provide to Genzyme: (i) at Alnylam’s expense, a summary translation of the applicable material communication in English; (ii) at Alnylam’s expense, complete copies of the original correspondence with the applicable Regulatory
Authority in their native language; or (iii) at Genzyme’s expense, a full translation of the applicable material communication in English, in each case (i) through (iii) within a reasonable period of time following such request.
For purposes of this Section 3.2.3, “material communication” will include any meetings with Regulatory Authorities, or questions or concerns from Regulatory Authorities, regarding significant issues, such as key product quality
attributes (e.g., purity), safety findings affecting the platform (e.g., Serious Adverse Events, emerging safety signals), clinical or nonclinical findings affecting patient safety, lack of efficacy, or receipt or denial of Regulatory
Approval. 
 3.2.4. Meetings with Regulatory Authorities. Alnylam shall provide Genzyme with reasonable advance notice of all
substantive meetings with Regulatory Authorities in the Co-Co Territory pertaining to each Co-Co Licensed Product, or with as much advance notice as practicable under the circumstances. Alnylam shall use Commercially Reasonable Efforts, to the
extent reasonably practicable, to permit Genzyme to have, at Genzyme’s expense, mutually acceptable representatives of Genzyme attend the following: (i) solely as non-participating observers, material, substantive meetings (including
pre-IND and end of Phase II Study meetings) with Regulatory Authorities in the Co-Co Territory pertaining to such Co-Co Licensed Product, and (ii) any internal Alnylam meetings held in preparation for such material, substantive meetings with
Regulatory Authorities in the Co-Co Territory. 
 3.2.5. Submissions. With respect to each Co-Co Licensed Product, Alnylam will
allow Genzyme a reasonable opportunity to review and comment on all regulatory filings and other submissions to Regulatory Authorities or other Governmental Authorities in the Co-Co Territory in advance of the submission of any such filing, and
Alnylam will reasonably consider 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -34- 

 CO-CO LICENSE TERMS 

 

 
all comments timely provided by Genzyme in connection therewith. In addition, Alnylam shall provide Genzyme with prompt written notice of each of the following events (but in any event within
[***] days) after the occurrence of such event in the Co-Co Territory: (i) the filing of any IND for such Co-Co Licensed Product; (ii) the submission of any filings or applications for Regulatory Approval (including orphan drug
applications and designations) of such Co-Co Licensed Product to any Regulatory Authority; and (iii) receipt or denial of Regulatory Approval for such Co-Co Licensed Product; provided, however, that in all circumstances, Alnylam
shall inform Genzyme of such event prior to public disclosure of such event by Alnylam. 
 3.3. EMA Regulatory Strategy. Within
[***] year before the anticipated MAA filing for a Co-Co Licensed Product, the PJSC will determine an EMA regulatory strategy for such Co-Co Licensed Product pursuant to which the PJSC will determine (a) whether Alnylam will seek Regulatory
Approval for such Co-Co Licensed Product in the EU using the EMA centralized or a national authorization procedure and (b) whether Genzyme will file a duplicate license with respect to any MAA held by Alnylam in the Co-Co Territory [***]. In
determining the EMA regulatory strategy, the Parties agree to reasonably consider in good faith each Party’s interests. In the event that Genzyme files a duplicate license in the Genzyme Territory, Alnylam will coordinate communications with
EMA, and provide support to enable Genzyme to efficiently obtain such duplicate license to provide for marketing in Genzyme countries under a separate, Genzyme trade name, to the extent not inconsistent with the Global Commercial Strategy or Global
Branding Strategy for such Co-Co Licensed Product. 
 3.4. Costs of Regulatory Affairs. Except as provided in Sections 2.3
(Joint Responsibilities for Development Activities and Costs) and 3.1.1.2 (Ownership of Regulatory Filings), each Party shall be responsible for all costs and expenses incurred in connection with applying for, obtaining and maintaining Regulatory
Approval with respect to Co-Co Licensed Products, and related regulatory affairs activities. 
 3.5. Right of Reference. Each
Party hereby grants to the other Party, and at the request of the other Party will grant to the other Party’s Related Parties, a “Right of Reference,” as that term is defined in 21 C.F.R. § 314.3(b) (or any successor rule or
analogous Law recognized outside of the United States), to, and a right to copy, access, and otherwise use, all information and data (including all CMC information as well as data made, collected or otherwise generated in the conduct of any Clinical
Studies or Secondary Indication Studies or early access/named patient programs for the Co-Co Licensed Products) included in or used in support of any regulatory filing, Regulatory Approval, drug master file or other regulatory documentation
(including orphan drug applications and designations) owned or controlled by such Party or its Related Parties that relates to (a) any Co-Co Licensed Product or (b) with respect to such information and data provided to Genzyme, the siRNA Controlled
by Alnylam and known as ALN-TTR01, to the extent necessary or useful to obtain Regulatory Approval of a Co-Co Licensed Product in the Genzyme Territory, and such Party shall provide a signed statement to this effect, if requested by the other Party,
in accordance with 21 C.F.R. § 314.50(g)(3) (or any successor or analogous Law outside of the United States). In addition, upon request of either Party (on behalf of itself or a Sublicensee), the other Party shall obtain and

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -35- 

 CO-CO LICENSE TERMS 

 

 
provide to the requesting Party certificates or other formal or official attestations concerning the regulatory status of the Co-Co Licensed Products in the Genzyme Territory or the Co-Co
Territory, as applicable (e.g., Certificates of Free Sale, Certificates for Export, Certificates to Foreign Governments). Notwithstanding anything to the contrary in these Co-Co License Terms, neither Party shall withdraw or inactivate any
regulatory filing that the other Party references or otherwise uses pursuant to this Section 3.5. 
 4. COMMERCIALIZATION OF THE
LICENSED PRODUCTS 
 4.1. Responsibility, Cost and Diligence. 

4.1.1. Global Commercial Strategy. For each Co-Co Licensed Product, the key Commercialization principles will be set forth in a written
summary of the global Commercialization strategy for such Co-Co Licensed Product (each, a “Global Commercial Strategy”). Alnylam shall provide the initial draft of such Global Commercial Strategy to the PJSC responsible for the
applicable Co-Co Licensed Product within [***] days after the Implementation Date for such Co-Co Licensed Product, and within [***] days after provision, such PJSC shall review, update and approve such Global Commercial Strategy. The PJSC for such
Co-Co Licensed Product will update and amend the Global Commercial Strategy not later than the initiation of the first Phase III Study for such Co-Co Licensed Product, and then annually thereafter. Amendments to any Global Commercial Strategy will
become effective following review and approval by the applicable PJSC. In no event, however, may any Global Commercial Strategy be amended with the result that it fails to satisfy the requirements for Commercialization of Co-Co Licensed Products set
forth in this Section 4.  
 4.1.2. Co-Co Territory. The PJSC will lead responsibility for all Commercialization
activities relating to Co-Co Licensed Products in the Field in the Co-Co Territory. The Parties, under the direction of the PJSC, will participate in the planning and conduct of such Commercialization activities as and to the extent set forth in
these Co-Co License Terms, including without limitation, Section 4.2 (Co-Co Territory Commercialization).  
 4.1.3. Genzyme
Territory. Genzyme shall be solely responsible, at its expense, for all Commercialization activities relating to Co-Co Licensed Products in the Field in the Genzyme Territory.  

4.1.4. Genzyme Commercial Diligence. Genzyme shall use Commercially Reasonable Efforts to [***]. 

4.2. Co-Co Territory Commercialization. 

4.2.1. Co-Co Territory Commercialization Plan. For each Co-Co Licensed Product, the Commercialization activities that are necessary or
useful to be undertaken for such Co-Co Licensed Product in the Co-Co Territory will be set forth in reasonable detail in a written work plan (each, a “Co-Co Territory Commercialization Plan”). Each Co-Co Territory Commercialization
Plan must, at all times, include a detailed description of the S&M Activities 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -36- 

 CO-CO LICENSE TERMS 

 

 
to be undertaken in each country in the Co-Co Territory with respect to the applicable Co-Co Licensed Product during the then-current Calendar Year and the next Calendar Year. Each Co-Co
Territory Commercialization Plan shall be consistent with the requirements of the applicable Global Commercialization Strategy, as such Global Commercialization Strategy may be updated as reasonably necessary. Any amendment to a Global
Commercialization Strategy shall take into account the then-current deployment of resources and time required to realign resources consistent with the Global Commercialization Strategy in a reasonable manner, and with this Section 4.2.1. The
Commercialization Activities set forth in each Co-Co Territory Commercialization Plan will at all times be designed to be in compliance with all applicable Laws and in accordance with professional and ethical standards customary in the
pharmaceutical industry. 
 4.2.1.1. ALN-TTRsc Co-Co Territory Commercialization Plan. Within [***] year after
the Effective Date, Alnylam will provide a draft of the initial Co-Co Territory Commercialization Plan for ALN-TTRsc to the PJSC, and within [***] days thereafter, the PJSC will review, update and approve such Co-Co Territory Commercialization Plan
and it will be attached hereto as Schedule 4.2-1. 
 4.2.1.2. ALN-AT3 Co-Co Territory Commercialization
Plan. The initial Co-Co Territory Commercialization Plan for ALN-AT3 will be prepared and approved by the PJSC no later than [***] years prior to the anticipated date of the First Commercial Sale of ALN-AT3 in any country in the Co-Co Territory
and, upon approval, it will be attached hereto as Schedule 4.2-2. 
 4.2.1.3. Allocation of S&M
Activities. Promptly following the approval of any Co-Co Territory Commercialization Plan in accordance with this Section 4.2.1 or Section 4.2.4, the Parties shall allocate responsibility for each S&M Activity to be performed in
the next Calendar Year between the Parties in an equitable manner mutually agreed by the Parties, which allocation shall be made on an activity-by-activity or S&M FTE-by-S&M FTE basis, as applicable, and subject to the following: 

(a) each Party will have the right to provide up to [***] in each country in the Co-Co Territory in such Calendar Year; and

 (b) [***] 

4.2.2. Diligence. If the PJSC agrees upon the allocation of responsibility for the S&M Activities in a Co-Co Territory
Commercialization Plan [***].  
 4.2.3. Co-Co Territory Commercialization Budget. Each Co-Co Territory Commercialization Plan
will contain a budget for the S&M Activities (and no other activities) to be performed during the then-current Calendar Year with respect to the applicable Co-Co Licensed Product in the Co-Co Territory (a “Co-Co Territory
Commercialization Budget”), which budget will allocate expenditures equitably across the countries in the Co-Co Territory, 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -37- 

 CO-CO LICENSE TERMS 

 

 
taking into account the allocation of activities described in Section 4.2.1.3 (Allocation of S&M Activities) and the then-current and future commercial opportunities for such Co-Co
Licensed Product. Each Co-Co Territory Commercialization Budget will be updated annually by the PJSC responsible for the applicable Co-Co Licensed Product in accordance with Section 4.2.4 (Managing and Amending Co-Co Territory Commercialization
Plans and Co-Co Territory Commercialization Budgets). The initial Co-Co Territory Commercialization Budget for a Co-Co Licensed Product, and each update thereto, will be prepared by the PJSC [***]. Alnylam will enter such Co-Co Commercialization
Budget in a template that the Parties agree is efficient for both Parties to communicate such information. [***] 
 4.2.4. Managing and
Amending Co-Co Territory Commercialization Plans and Co-Co Territory Commercialization Budgets. For each Co-Co Licensed Product, Alnylam will update and amend, and the PJSC will approve, the applicable Co-Co Territory Commercialization Plan from
time-to-time as it deems necessary and, until such time as no further S&M Activities are occurring or expected to occur with respect to such Co-Co Licensed Product, the Co-Co Territory Commercialization Plan will be updated as follows:

 (a) No later than [***] of each Calendar Year, Alnylam shall prepare, and the applicable PJSC will approve, an updated
draft of the Co-Co Territory Commercialization Plan, which shall contain a proposed Co-Co Territory Commercialization Budget covering the next Calendar Year. The proposed Co-Co Territory Commercialization Budget will satisfy the requirements set
forth in Section 4.2.3 (Co-Co Territory Commercialization Budget). 
 (b) No later than [***] of each Calendar Year,
Alnylam shall prepare, and the applicable PJSC will review and tentatively approve an updated Co-Co Territory Commercialization Plan and Co-Co Territory Commercialization Budget for such Co-Co Licensed Product, and such updated Co-Co Territory
Commercialization Plan and Co-Co Territory Commercialization Budget will become effective upon such tentative approval by the PJSC, provided that the Parties acknowledge and agree that each Party’s internal process for receiving final approval
of such Co-Co Territory Commercialization Plan and Co-Co Territory Commercialization Budget from its Board of Directors may occur after [***] (but, in any event, before [***]) and Co-Co Territory Commercialization Plan and Co-Co Territory
Commercialization Budget will not become final unless and until such approvals are obtained. In no event may any Co-Co Territory Commercialization Plan be amended with the result that it fails to satisfy the requirements for Co-Co Territory
Commercialization Plans set forth in Section 4.2.1 (Co-Co Territory Commercialization Plan). 
 4.2.5. Responsibility for Co-Co
Territory Commercialization Costs. With respect to each Co-Co Licensed Product, unless otherwise agreed to by the Parties in writing [***]. On the first day of each Calendar Year, the PJSC responsible for a Co-Co Licensed Product will determine
the total S&M Costs allocated to each Party for such Calendar Year under the applicable Co-Co Territory Commercialization Budget, which S&M Costs shall be calculated by [***].  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -38- 

 CO-CO LICENSE TERMS 

 

 4.2.6. Verification. With respect to each Co-Co Licensed Product, promptly following
the end of each Calendar Year, the Head of the Rare Disease Business of Genzyme and an appropriate officer of Alnylam shall certify to one another in writing whether or not such Party has spent the S&M Costs allocated to such Party in the
applicable Co-Co Territory Commercialization Budget during such Calendar Year in performing the S&M Activities allocated to such Party in the applicable Co-Co Territory Commercialization Plan. If either Party did not spend all of the S&M
Costs or perform all of the S&M Activities allocated to such Party in the applicable Co-Co Territory Commercialization Plan, then such Party shall pay the other Party an amount equal to [***] of the difference between the S&M Costs and
S&M Activities allocated to such Party in the applicable Co-Co Territory Commercialization Plan and the S&M Costs and S&M Activities certified as being spent or performed by such Party. The certification mechanism and true-up payment
provided for in this Section 4.2.6 shall be in lieu of auditing the Parties’ S&M Costs and S&M Activities for Co-Co Licensed Products in the Co-Co Territory.  

4.3. Genzyme Territory Commercialization Plan. No less than [***] months in advance of the reasonably expected first Regulatory
Approval in the Genzyme Territory with respect to a Co-Co Licensed Product, and on an annual basis thereafter, Genzyme shall prepare and deliver to the PJSC responsible for such Co-Co Licensed Product for review a reasonable written plan that
summarizes the Commercialization activities to be undertaken with respect to such Co-Co Licensed Product in the Genzyme Territory in the next Calendar Year and, to the extent commercially reasonable, Genzyme’s plans to obtain further Regulatory
Approvals and Commercialize such Co-Co Licensed Product in countries in the Genzyme Territory in which Genzyme is not then Commercializing such Co-Co Licensed Product, and the dates by which such activities are targeted to be accomplished (the
“Genzyme Territory Commercialization Plan”). Each Genzyme Territory Commercialization Plan shall be consistent with the requirements of the initial Global Commercialization Strategy approved by the PJSC pursuant to
Section 4.1.1 (Global Commercial Strategy) or the most recently approved by the PJSC without the use of tie-break authority pursuant to Section 5.7.3 (Tie-Breaking). The Genzyme Territory Commercialization Plan for a Co-Co Licensed Product
shall subsequently be updated and modified by Genzyme, from time to time at its discretion and no less frequently than once per Calendar Year, based upon, among other things, Genzyme’s Commercialization activities with respect to such Co-Co
Licensed Product in the Genzyme Territory, a copy of which updated plan Genzyme will provide to the PJSC responsible for such Co-Co Licensed Product. [***]. 

4.4. Advertising and Promotional Materials. 

4.4.1. Global Branding. Alnylam shall have the right, from time to time during the Term, to develop (and thereafter to modify and
update) a global branding strategy (including global positioning, colors and other visual branding elements) for each Co-Co Licensed Product for use in the Field throughout the world (the “Global Branding Strategy”), which the PJSC
responsible for such Co-Co Licensed Product shall, in accordance with Sections 5.6 (PJSC 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -39- 

 CO-CO LICENSE TERMS 

 

 
Commercialization Responsibilities) and 5.7 (PJSC Decision-Making), review and approve, and which the Parties shall, following such review and approval, implement. Alnylam will submit the Global
Branding Strategy for a Co-Co Licensed Product to the PJSC responsible for such Co-Co Licensed Product at least annually (or more frequently if reasonably requested by Genzyme). Alnylam shall consider in good faith any timely comments Genzyme may
have with respect to any Global Branding Strategy, but shall have final decision-making authority with respect to such Global Branding Strategy. Notwithstanding the foregoing, Alnylam shall ensure that the Global Branding Strategy complies with
applicable Laws in the Genzyme Territory, and that any branding elements selected for inclusion in the Global Branding Strategy do not infringe any Third Party trademarks or other intellectual property rights. If any such Global Branding Strategy
infringes Third Party trademarks or other intellectual property rights or otherwise does not comply with applicable Law in the Genzyme Territory, Alnylam shall take action to end such infringement or other noncompliance (including by modifying such
Global Branding Strategy) and Genzyme will not be obligated to implement such Global Branding Strategy in the Genzyme Territory pursuant to this Section 4.4.1 unless and until such infringement or noncompliance is ended. 

4.4.2. Alnylam A&P. Alnylam will be responsible for the creation, preparation, production, reproduction and filing with the
applicable Regulatory Authorities, of relevant written sales, promotion and advertising materials relating to each Co-Co Licensed Product (“Promotional Materials”) for use in the Co-Co Territory. All such Promotional Materials will
be compliant with applicable Law and, if applicable, consistent in all material respects with the Global Branding Strategy for such Co-Co Licensed Product. Alnylam will submit representative samples of its Promotional Materials developed by it for
use in the Co-Co Territory to the PJSC, at least annually (or more frequently if reasonably requested by Genzyme). Alnylam shall consider in good faith any timely comments Genzyme may have with respect to any such Promotional Materials, but shall
have final decision-making authority with respect to such Promotional Materials. Notwithstanding the foregoing, Alnylam will incorporate any changes to Promotional Materials requested by Genzyme in a timely fashion in cases where Genzyme indicates
that believes in good faith based on the advice of counsel that such change is necessary to enable it to comply with any applicable Law. 

4.4.3. Genzyme A&P. Genzyme will be responsible for the creation, preparation, production, reproduction and filing with the
applicable Regulatory Authorities, of relevant Promotional Materials relating to each Co-Co Licensed Product for use in the Genzyme Territory. All such Promotional Materials will be compliant with applicable Law, consistent in all material respects
with the Genzyme Territory Commercialization Plan and, if applicable, consistent in all material respects with the Global Branding Strategy for such Co-Co Licensed Product. Genzyme will submit representative samples of its Promotional Materials
developed by it for use in the Genzyme Territory to the PJSC at least annually thereafter (or more frequently if reasonably requested by Alnylam). Genzyme shall consider in good faith any timely comments Alnylam may have with respect to any such
Promotional Materials, but shall have final decision-making authority with respect to such Promotional Materials. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -40- 

 CO-CO LICENSE TERMS 

 

 4.4.4. Reporting Obligations. 

4.4.4.1. Genzyme Territory. Genzyme shall report to the PJSC responsible for a Co-Co Licensed Product in writing,
by no later than each [***] following the first Regulatory Approval of such Co-Co Licensed Product in the Field in the Genzyme Territory (for the period ending December 31 of the prior Calendar Year), summarizing in reasonable detail
Genzyme’s Commercialization activities for such Co-Co Licensed Product in the Genzyme Territory performed to date (or updating such report for activities performed since the last such report was given hereunder, as applicable). In addition,
Genzyme shall provide Alnylam with written notice of the First Commercial Sale of each Co-Co Licensed Product in the Genzyme Territory within [***] days after such event; provided, however, that in all circumstances, Genzyme shall
inform Alnylam of such event prior to public disclosure of such event by Genzyme. Genzyme shall provide such other information to the PJSC responsible for a Co-Co Licensed Product as Alnylam may reasonably request with respect to Commercialization
of such Co-Co Licensed Product and shall keep such PJSC reasonably informed of Genzyme’s Commercialization activities in the Genzyme Territory with respect to such Co-Co Licensed Product. 

4.4.4.2. Co-Co Territory. Each Party shall report to the PJSC responsible for a Co-Co Licensed Product in
writing, by no later than each [***] following the first Regulatory Approval of such Co-Co Licensed Product in the Field in the Co-Co Territory (for the period ending December 31 of the prior Calendar Year), summarizing in reasonable detail
such Party’s Commercialization activities for such Co-Co Licensed Product in the Co-Co Territory performed to date (or updating such report for activities performed since the last such report was given hereunder, as applicable). Each Party
shall provide such other information to the PJSC responsible for a Co-Co Licensed Product as the other Party may reasonably request with respect to Commercialization of such Co-Co Licensed Product and shall keep such PJSC reasonably informed of such
Party’s Commercialization activities in the Co-Co Territory with respect to such Co-Co Licensed Product. 
 4.5. Commercialization
Reporting Obligations. Each Party and its Related Parties shall be responsible for booking sales in its Territory (for avoidance of doubt, meaning, with respect to the Co-Co Territory, Alnylam, and with respect to the Genzyme Territory,
Genzyme). Each Party and its Related Parties may warehouse Co-Co Licensed Products both inside and outside of such Party’s Territory, provided that any sales with respect to such Co-Co Licensed Products are booked in such Party’s
Territory. If a Party receives any orders for any Co-Co Licensed Product in the other Party’s Territory, it shall refer such orders to the other Party, to the extent it is not prohibited from doing so under applicable Law. Moreover, each Party
and its Related Parties shall be solely responsible for handling all returns of any Co-Co Licensed Product sold in its Territory, as well as all aspects of Co-Co Licensed Product order processing, invoicing and collection, distribution, inventory
and receivables of Co-Co Licensed Products sold in its Territory.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -41- 

 CO-CO LICENSE TERMS 

 

 4.6. Recalls, Market Withdrawals or Corrective Actions. In the event that any
Regulatory Authority issues or requests a recall or takes a similar action in connection with a Co-Co Licensed Product in the Co-Co Territory or Genzyme Territory, or in the event either Party determines that an event, incident or circumstance has
occurred that may result in the need for a recall or market withdrawal of a Co-Co Licensed Product in the Co-Co Territory or Genzyme determines that an event, incident or circumstance has occurred that may result in the need for a recall or market
withdrawal of a Co-Co Licensed Product in the Genzyme Territory, the Party notified of such recall or similar action, or the Party that desires such recall or similar action, shall within [***] hours notify the other Party’s CLP Alliance
Manager and PJSC representatives thereof by telephone or e-mail. The Parties shall mutually agree whether to conduct a recall of a Co-Co Licensed Product in the Co-Co Territory and the manner in which any such recall shall be conducted (except in
the case of a government mandated recall, when the Party subject to such mandate may act without such advance notice but shall notify the other Party as soon as possible). Genzyme shall determine whether to conduct a recall of a Co-Co Licensed
Product in the Genzyme Territory and the manner in which any such recall shall be conducted (except in the case of a government mandated recall, when Genzyme may act without such advance notice but shall notify Alnylam as soon as possible). Except
as may be otherwise agreed by the Parties, each Party shall share equally the expense of any such recall in the Co-Co Territory and Genzyme shall bear the expense of any such recall in the Genzyme Territory. Each Party will make available all of its
pertinent records that may be reasonably requested by the other Party in order to effect a recall of a Co-Co Licensed Product in the Co-Co Territory or Genzyme Territory. The Parties’ rights and obligations under this Section 4.6 shall be
subject to the terms of any supply agreement(s) entered into between the Parties and, in the event of any conflict between the provisions of any such supply agreement and this Section 4.6, the provisions of such supply agreement shall
govern. 
 4.7. Export Monitoring. 

4.7.1. [***] 

4.7.2. [***]  

5. COLLABORATION MANAGEMENT 

5.1. Product Joint Steering Committee. The Parties shall establish a product joint steering committee (a “PJSC”)
to facilitate the Co-Co Collaboration with respect to each Co-Co Licensed Product as follows: 
 5.1.1. Composition of the Product
Joint Steering Committee. The Development and Commercialization of each Co-Co Licensed Product pursuant to the Co-Co Collaboration will be conducted under the oversight of a PJSC, which shall be comprised of three (3) representatives of each
Party. The PJSC for ALN-TTRsc shall be established as of the 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -42- 

 CO-CO LICENSE TERMS 

 

 
Effective Date. Each Party shall appoint its respective representatives to each PJSC from time to time following the Implementation Date for ALN-AT3, and may substitute one or more of its
representatives on any PJSC, in its sole discretion, effective upon notice to the other Party of such change. Each Party shall have at least one representative on each PJSC who is a senior employee (vice president level or above), and all
representatives on each PJSC shall have appropriate expertise, seniority, decision-making authority and ongoing familiarity with the Co-Co Collaboration and the applicable Co-Co Licensed Product. Unless otherwise agreed by the Parties, each
Party’s representatives on any PJSC must be employees of such Party or any of its Affiliates. For the avoidance of doubt, the same representatives from each Party may serve on the PJSC for more than one Co-Co Licensed Product. Additional
representatives or consultants may from time to time, by mutual consent of the Parties, be invited to attend PJSC meetings, subject to such representatives and consultants undertaking confidentiality obligations, whether in a written agreement or by
operation of law, no less stringent than the requirements of Section 7 of the Master Agreement (Confidentiality and Publication). 

5.1.2. PJSC Chairperson. The chairperson of each PJSC shall rotate every twelve (12) months between a PJSC representative of
Alnylam and a PJSC representative of Genzyme. The initial chairperson of each PJSC shall be a representative of Alnylam. Each PJSC chairperson’s responsibilities shall include chairing meetings, including ensuring that objectives for each
meeting are set and achieved. 
 5.2. Appointment of Subcommittees, Project Teams and CLP Alliance Managers. Each PJSC
shall be empowered to create such subcommittees and project teams as it may deem appropriate or necessary, such as for specific oversight of Development, Manufacturing, Commercialization or intellectual property issues relating to the Co-Co Licensed
Product for which such PJSC is responsible. Each such project team created by a PJSC shall report to such PJSC, which shall have authority to approve or reject recommendations or actions proposed by such project team, subject to these Co-Co License
Terms. For the avoidance of doubt, the same representatives from each Party may serve on the project team for more than one Co-Co Licensed Product. Each Party will designate an alliance manager for each Co-Co Licensed Product (each, a “CLP
Alliance Manager”) to serve as a primary point of contact for the other Party with respect to all activities under the CLP Collaboration related to such Co-Co Licensed Product. Each CLP Alliance Manager’s responsibilities shall include
(a) scheduling meetings of the PJSC at least once per Calendar Quarter, but more frequently if the PJSC determines it necessary; (b) setting agendas for PJSC meetings with solicited input from the CLP Alliance Manager for the other Party
and other members of the PJSC; and (c) coordinating the delivery of draft minutes to the PJSC for review and final approval. Beginning with Alnylam’s CLP Alliance Manager, such responsibilities shall alternate between the CLP Alliance
Managers from each Party on a meeting-by-meeting basis after each meeting of the applicable committee. Each Party may change any of its CLP Alliance Managers at any time in its sole discretion with written notice to the other Party, provided
that each CLP Alliance Manager will be individually identified at all times and will have such experience, authority, responsibility and accountability as is reasonably sufficient to enable such person to fulfill his or her responsibilities as a CLP
Alliance Manager under these Co-Co License Terms on behalf of the applicable Party. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -43- 

 CO-CO LICENSE TERMS 

 

 5.3. PJSC Meetings. Each PJSC shall meet in accordance with a schedule
established by mutual written agreement of the Parties, but no less frequently than once per Calendar Quarter during the Term, with the location for such meetings alternating between Alnylam and Genzyme facilities (or such other locations as are
mutually agreed by the Parties). Alternatively, a PJSC may meet by means of teleconference, videoconference or other similar communications equipment, but at least two (2) meetings of such PJSC per Calendar Year shall be conducted in person.
All proceedings for each PJSC shall take place in English. Where the membership of a PJSC for a Co-Co Licensed Product is the same as one or more other PJSCs for the other Co-Co Licensed Product, such PJSCs may have a single meeting to discuss each
Co-Co Licensed Product for which they have responsibility. Each Party shall bear its own expenses relating to attendance at such meetings by its representatives. 

5.4. PJSC Minutes. A CLP Alliance Manager shall be appointed secretary for each meeting of each PJSC and shall prepare minutes of
the meeting, which shall provide a description in reasonable detail of the discussions held at the meeting and a list of any actions, decisions or determinations approved by such PJSC. Within [***] days after each meeting, the drafting CLP Alliance
Manager shall provide the draft minutes to the other CLP Alliance Manager for review and comment. The drafting CLP Alliance Manager shall reasonably consider all comments from the other CLP Alliance Manager within [***] days. The drafting CLP
Alliance Manager shall prepare and submit revised minutes for approval within [***] days after receipt of such comments or upon expiration of such [***] day period. 

5.5. PJSC Development Responsibilities. Each PJSC shall have the following responsibilities with respect to the Development of
the Co-Co Licensed Product for which it is responsible: 
 5.5.1. reviewing, commenting on and approving updates and amendments
to the Global Development Strategy for such Co-Co Licensed Product in accordance with Section 2.2.2.3 (Managing and Amending Global Development Plans and Global Development Budgets); 

5.5.2. reviewing, commenting on and approving updates and amendments to the Global Development Plan for such Co-Co Licensed Product in
accordance with Section 2.2.2.3 (Managing and Amending Global Development Plans and Global Development Budgets); 
 5.5.3.
monitoring the implementation of the Global Development Plan for such Co-Co Licensed Product, including the Global Development Activities set forth in such Global Development Plan; 

5.5.4. reviewing, commenting on and approving the design of any Phase III Study for such Co-Co Licensed Product; 

5.5.5. monitoring any Clinical Study included in such Global Development Activities (a “Global Clinical Study”)
performed by a CRO retained by a Party to perform such Global Clinical Study, against the criteria and timelines in such Global Development Plan; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -44- 

 CO-CO LICENSE TERMS 

 

 5.5.6. reviewing, commenting on and approving the initial Genzyme Territory
Development Plan for such Co-Co Licensed Product in accordance with Section 2.2.3 (Genzyme Territory Development Plan); 

5.5.7. reviewing, commenting on and approving updates and amendments to the Genzyme Territory Development Plan in accordance with
Section 2.2.3 (Genzyme Territory Development Plan), and providing Genzyme with feedback regarding the same; 
 5.5.8.
reviewing and discussing updates provided by each Party regarding the Development of such Co-Co Licensed Product in either Territory in accordance with Section 2.5.1 (Development Activities Reports), and providing each Party with feedback
regarding the same; 
 5.5.9. monitoring and coordinating Development activities in the Genzyme Territory and the Co-Co
Territory for such Co-Co Licensed Product, and regulatory and pharmacovigilance requirements and matters; 
 5.5.10. reviewing
and discussing updates provided by each Party regarding any Global Development Activities in accordance with the Global Development Plan for such Co-Co Licensed Product (including the Global Development Budget);  

5.5.11. overseeing any manufacturing and supply relationship between the Parties with respect to the Manufacture of such Co-Co Licensed
Product for Development activities (subject to the provisions of the CLP Clinical Supply Agreement); 
 5.5.12. approving a global
list of clinical sites for each Global Clinical Study for such Co-Co Licensed Product; 
 5.5.13. approving the appointment of the
global CRO to manage any Phase II Study or Phase III Study for such Co-Co Licensed Product; and 
 5.5.14. performing such
other activities as the Parties agree in writing shall be the responsibility of such PJSC or that are otherwise assigned to such PJSC under these Co-Co License Terms. 

5.6. PJSC Commercialization Responsibilities. Each PJSC shall have the following responsibilities with respect to the
Commercialization of the Co-Co Licensed Product for which it is responsible, to the extent permissible under applicable Laws: 

5.6.1. reviewing, commenting on and approving updates and amendments to the Global Commercial Strategy for such Co-Co Licensed Product
in accordance with Section 4.1.1 (Global Commercial Strategy); 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -45- 

 CO-CO LICENSE TERMS 

 

 5.6.2. reviewing and discussing reports and information provided by each Party
regarding the Commercialization of such Co-Co Licensed Product in both Territories in accordance with Section 4.5 (Commercialization Reporting Obligations); 

5.6.3. reviewing, commenting on and approving any Global Branding Strategy developed by Alnylam for such Co-Co Licensed Product in
accordance with Section 4.4.1 (Global Branding); 
 5.6.4. reviewing, commenting on and approving the Genzyme Territory
Commercialization Plan for such Co-Co Licensed Product and updates thereto provided by Genzyme to the extent provided in Section 4.3 (Genzyme Territory Commercialization Plan); 

5.6.5. reviewing, commenting on and approving the Co-Co Territory Commercialization Plan for such Co-Co Licensed Product and updates
thereto provided by Genzyme to the extent provided in Section 4.2 (Co-Co Territory Commercialization Plan); 
 5.6.6.
reviewing, commenting on and discussing Promotional Material for such Co-Co Licensed Product of both Parties in accordance with Sections 4.4.2 (Alnylam A&P) and 4.4.3 (Genzyme A&P); 

5.6.7. providing a forum for the Parties to discuss the Commercialization of such Co-Co Licensed Product in the Field worldwide,
including coordination regarding Co-Co Licensed Product positioning and messaging, key opinion leader relationship management, medical affairs, and marketing and selling materials; 

5.6.8. providing a forum for the Parties to discuss collaborating on commercial activities with respect to such Co-Co Licensed Product
that can be leveraged for both Territories and how the Parties would share the costs of such mutually agreed joint Commercialization activities;  

5.6.9. overseeing any manufacturing and supply relationship between the Parties with respect to the Manufacture of such Co-Co Licensed
Product for Commercialization activities (subject to the provisions of the CLP Commercial Supply Agreement); and 
 5.6.10.
performing such other activities as the Parties agree in writing shall be the responsibility of such PJSC or that are otherwise assigned to such PJSC under these Co-Co License Terms. 

5.7. PJSC Decision-Making. 

5.7.1. PJSC Decisions. With respect to decisions of each PJSC, the representatives of each Party on such PJSC shall have collectively
one vote on behalf of such Party. For each meeting of a PJSC, at least two (2) representatives of each Party shall constitute a quorum. Action on any matter may be taken at a meeting, by teleconference, videoconference or by written agreement.
Each PJSC shall attempt to resolve any and all disputes before it for decision by consensus. [***]. For the avoidance of doubt, the phrase “approval by the PJSC” and similar phrases used in these Co-Co License Terms shall mean approval in
accordance with this Section 5.7 (PJSC Decision-Making), including [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -46- 

 CO-CO LICENSE TERMS 

 

 5.7.2. Escalation. If a PJSC is unable to reach a consensus with respect to any
dispute for a period in excess of [***] days, then the dispute shall be submitted to the AJSC (as defined in the Master Agreement) at a meeting or meetings (whether in-person or by teleconference or videoconference). During such meeting(s), each
Party shall provide analysis to support its position with respect to such dispute. If the dispute is still unresolved after a further [***] days, such dispute shall be [***].  

5.7.3. [***]. If a PJSC dispute cannot be resolved under Section 5.7.2 (Escalation), then, subject to Sections 5.7.4 ([***])
and 5.7.5 (No Deciding Vote): 
 5.7.3.1. [***] 

5.7.3.2. [***]  

5.7.3.3. [***]  

[***] 
 5.7.4. [***]  

5.7.4.1. [***]r 

5.7.4.2. [***] 

[***] 
 5.7.5. [***] 

5.7.5.1. [***] 

5.7.5.2. [***] 

5.7.5.3. [***] 

5.7.5.4. [***] 

5.7.5.5. [***]  

5.8. Term of PJSC. With respect to each Co-Co Licensed Product, after the [***] of the Implementation Date for such Co-Co
Licensed Product, Alnylam shall have the right, but not the obligation, to continue its participation on the PJSC responsible for such Co-Co Licensed Product. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -47- 

 CO-CO LICENSE TERMS 

 

 6. MANUFACTURE AND SUPPLY OF CO-CO LICENSED PRODUCTS 

6.1. Supply Agreements. The Manufacturing of each Co-Co Licensed Product, including ALN-TTRsc, will be addressed in the Master
Agreement and breach of such Manufacturing terms as applied to a Co-Co Licensed Product shall be treated as a breach under this Agreement, and not under the Master Agreement. 

7. LICENSES 
 7.1.
License Grants to Genzyme. 
 7.1.1. Development License. On a Co-Co Licensed Product-by-Co-Co Licensed Product basis,
subject to the provisions of these Co-Co License Terms (including Section 10.4.1.4 (Exception to Exclusivity)), and any Co-Co Clinical Supply Agreement, effective upon the Implementation Date for such Co-Co Licensed Product, Alnylam hereby
grants Genzyme (i) a non-transferable (except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 7.1.4 (Sublicensing Terms)), exclusive (even as to Alnylam) license under Alnylam
Technology to Develop such Co-Co Licensed Product in the Field in the Genzyme Territory and Co-Co Territory, in each case (x) solely as and to the extent provided in any approved Genzyme Territory Development Plan or any Global Development Plan
and (y) solely for Regulatory Approval and Commercialization in the Genzyme Territory; and (ii) a non-transferable, non-sublicensable, co-exclusive (with Alnylam) license under Alnylam Technology to Develop such Co-Co Licensed Product in
the Field for Regulatory Approval and Commercialization in the Co-Co Territory, solely as and to the extent provided in any approved Global Development Plan. Notwithstanding the foregoing: (a) Alnylam retains the right under the Alnylam
Technology to Develop each Co-Co Licensed Product in the Field anywhere in the world for Regulatory Approval and Commercialization by Genzyme in the Genzyme Territory, in accordance with the Global Development Plan for such Co-Co Licensed Product
and (b) Alnylam retains the co-exclusive right (with Genzyme) under the Alnylam Technology to Develop such Co-Co Licensed Product anywhere in the world for Commercialization in the Co-Co Territory.  

7.1.2. Commercialization License. On a Co-Co Licensed Product-by-Co-Co Licensed Product basis, subject to the provisions of these Co-Co
License Terms (including Section 10.4.1.4 (Exception to Exclusivity)), and any Co-Co Commercial Supply Agreement, effective upon the Implementation Date for such Co-Co Licensed Product, Alnylam hereby grants Genzyme (i) a non-transferable
(except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 7.1.4 (Sublicensing Terms)), exclusive (even as to Alnylam) license under Alnylam Technology to Commercialize such Co-Co Licensed
Products in the Field in the Genzyme Territory and (ii) a non-transferable, non-sublicensable, co-exclusive (with Alnylam) license under Alnylam Technology to Commercialize such Co-Co Licensed Product in the Field in the Co-Co Territory.

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -48- 

 CO-CO LICENSE TERMS 

 

 
The license granted under the foregoing clause (i) shall be royalty-bearing for the Royalty Term applicable to each Co-Co Licensed Product in each country in the Genzyme Territory, and,
after the Royalty Term applicable to such Co-Co Licensed Product in such country, shall convert to a fully-paid, exclusive, perpetual license to Commercialize such Co-Co Licensed Product in the Field in such country in the Genzyme Territory. 

7.1.3. Manufacturing Licenses. On a Co-Co Licensed Product-by-Co-Co Licensed Product basis, subject to the provisions of these Co-Co
License Terms (including Section 10.4.1.4 (Exception to Exclusivity)), and any Co-Co Clinical Supply Agreement and Co-Co Commercial Supply Agreement, effective upon the Implementation Date for such Co-Co Licensed Product, Alnylam hereby grants
Genzyme (i) a non-transferable (except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 7.1.4 (Sublicensing Terms)), worldwide, non-exclusive license under Alnylam Technology to
Manufacture such Co-Co Licensed Product inside or outside the Genzyme Territory solely for Development or Commercialization in the Genzyme Territory and, to the extent permitted pursuant to Section 2.3.2 (Genzyme Development), for Development
in the Co-Co Territory for the purpose of obtaining Regulatory Approval and Commercialization in the Genzyme Territory and (ii) a non-transferable, non-sublicensable, non-exclusive license under Alnylam Technology to Manufacture such Co-Co
Licensed Product inside or outside the Genzyme Territory for Development and Commercialization in the Co-Co Territory solely as and to the extent required for Genzyme to act as a second source Manufacturer as described in Section 6 of the
Master Agreement (Manufacture and Supply of the Collaboration Products) or to Manufacture Co-Co Licensed Products on the terms and conditions set forth in the Co-Co Supply Agreements. Notwithstanding the foregoing exclusive license: Alnylam retains
the exclusive right under the Alnylam Technology, with the right to grant licenses through multiple tiers without restriction, to Manufacture Co-Co Licensed Products anywhere in the world (a) for Development and Commercialization in the Co-Co
Territory and, to the extent permitted pursuant to Section 2 (Development Collaboration) for Development in the Genzyme Territory, and (b) to supply Genzyme pursuant to the Co-Co Supply Agreements to be agreed by the Parties pursuant to
Section 6.1 (Supply Agreements). 
 7.1.4. Sublicensing Terms. 

(a) Genzyme shall have the right to sublicense any of its rights under (i) Section 7.1.1 (Development License),
(ii) the license granted in clause (i) (but not clause (ii)) of Section 7.1.2 (Commercialization License), and (iii) Section 7.1.3 (Manufacturing License) to any of its Affiliates or to any Third Party (which sublicensed rights
may be further sublicensable through multiple tiers) without the prior consent of Alnylam, subject to the requirements of this Section 7.1.4. [***] 

(b) Each sublicense granted by Genzyme pursuant to this Section 7.1.4 shall be subject and subordinate to the provisions
of these Co-Co License Terms and shall contain terms and conditions consistent with those in these Co-Co License Terms. Genzyme shall promptly provide Alnylam with a copy of the fully executed sublicense

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -49- 

 CO-CO LICENSE TERMS 

 

 
agreement covering any sublicense granted hereunder (which copy may be redacted to remove terms and conditions which are not necessary to monitor compliance with this Section 7.1.4), and
each such sublicense agreement shall contain the following provisions: (i) a requirement that the Sublicensee comply with the confidentiality and non-use provisions of Section 7 of the Master Agreement (Confidentiality and Publication)
with respect to Alnylam’s Confidential Information; (ii) if such sublicense agreement contains a sublicense of Co-Co Licensed Product Commercialization rights, such sublicense agreement shall also contain the following provisions:
(x) a requirement that the Sublicensee submit applicable sales or other reports to Genzyme to the extent necessary or relevant to the reports required to be made or records required to be maintained under these Co-Co License Terms; and
(y) the audit requirement set forth in Section 9.2 of the Master Agreement (Audits); and (iii) a requirement that the Sublicensee comply with the applicable provisions under any Alnylam In-License. 

(c) If Genzyme becomes aware of a material breach of the terms of any sublicense by any Genzyme Sublicensee, compliance with
which is necessary for Genzyme’s compliance with the provisions of these Co-Co License Terms, Genzyme shall promptly notify Alnylam of the particulars of the same and use Commercially Reasonable Efforts to cause the Sublicensee to comply with
all the terms of the sublicense necessary for Genzyme’s compliance with the provisions of these Co-Co License Terms. [***] Notwithstanding any sublicense, Genzyme shall remain primarily liable to Alnylam for the performance of all of
Genzyme’s obligations under, and Genzyme’s compliance with all provisions of, these Co-Co License Terms. 
 7.1.5. Back-Up
Products. Subject to Sections 13.2 (Future Acquisition of a Party or its Business), 13.3.1 (Acquired Programs) and 13.3.2 (Acquired Programs), Alnylam hereby grants to Genzyme a series of exclusive options (each, a “Back-Up
Option”), under each of which Genzyme shall have the right, but not the obligation, to take a license on the terms set forth in these Co-Co License Terms, to any siRNA that targets the same Licensed Target as a Co-Co Licensed Product (a
“Back-Up Product”) and for which Alnylam has determined the GLP toxicology studies will be conducted during the Back-Up Option Period. Genzyme may exercise the Back-Up Option with respect to such Back-Up Product by delivering
written notice to Alnylam at any time during the Back-Up Option Period (the “Back-Up Option Exercise Notice”). Upon delivery of the Back-Up Option Exercise Notice to Alnylam, the applicable Back-Up Product shall automatically be
deemed to be a Co-Co Licensed Product for all purposes under the Collaboration Agreement and the license from Alnylam to Genzyme for such Co-Co Licensed Product shall automatically, with no further action by any Party, go into full force and effect
and all obligations of Alnylam and Genzyme set forth in these Co-Co License Terms, including the payment obligations set forth herein, shall become the binding obligations of the applicable Party in respect of such Co-Co Licensed Product. Upon the
expiration of the Back-Up Option Period, all Back-Up Options not previously exercised shall automatically terminate.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -50- 

 CO-CO LICENSE TERMS 

 

 7.2. License Grants to Alnylam. 

7.2.1. Commercialization License in the Co-Co Territory. Genzyme hereby grants Alnylam a non-transferable (except as provided in
Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 7.2.4 (Sublicensing Terms)), non-exclusive, royalty-free license under Genzyme Collaboration IP to Develop and Commercialize Co-Co Licensed Products in
the Field in the Co-Co Territory.  
 7.2.2. License to Improvement Manufacturing Patent Rights. Subject to the provisions of
these Co-Co License Terms, Genzyme hereby grants Alnylam a non-transferable (except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 7.2.4 (Sublicensing Terms)), worldwide, non-exclusive
license under the Improvement Manufacturing Patent Rights, to Manufacture (a) Alnylam Developed siRNA Products targeting any human gene; and (b) Co-Co Licensed Products for Commercialization in the Co-Co Territory, Development in either
the Co-Co Territory or Genzyme Territory in accordance with the Global Development Plan for such Co-Co Licensed Product, and for sale to Genzyme under any Co-Co Clinical Supply Agreement or Co-Co Commercial Supply Agreement. 

7.2.3. License to Genzyme Disclosed Manufacturing Know-How. Subject to the provisions of these Co-Co License Terms, Genzyme hereby
grants Alnylam a non-transferable (except as provided in Section 13.1 of the Master Agreement (Assignment)), sublicensable (subject to Section 7.2.4 (Sublicensing Terms)), worldwide, non-exclusive license under the Genzyme Disclosed
Manufacturing Know-How to Manufacture Co-Co Licensed Products for Commercialization in the Co-Co Territory, Development in either the Co-Co Territory or Genzyme Territory in accordance with the Global Development Plan for such Co-Co Licensed
Product, and for sale to Genzyme under any Co-Co Clinical Supply Agreement or Co-Co Commercial Supply Agreement. 
 7.2.4.
Sublicensing Terms. 
 (a) Alnylam shall have the right to sublicense any of its rights under Section 7.2.1
(Commercialization License in the Co-Co Territory), 7.2.2 (License to Improvement Manufacturing Patent Rights) and 7.2.3 (License to Genzyme Disclosed Manufacturing Know-How) to [***]. 

(b) Each sublicense granted by Alnylam pursuant to this Section 7.2.4 shall be subject and subordinate to the provisions
of these Co-Co License Terms and shall contain terms and conditions consistent with those in these Co-Co License Terms. Alnylam shall promptly provide Genzyme with a copy of the fully executed sublicense agreement covering any sublicense granted
hereunder (which copy may be redacted to remove terms and conditions which are not necessary to monitor compliance with this Section 7.2.4), and each such sublicense agreement shall contain the following provisions: (i) a requirement that
the Sublicensee comply with the confidentiality and non-use provisions of Section 7 of the Master Agreement (Confidentiality and Publication) with respect to Genzyme’s Confidential Information and (ii) a requirement that the
Sublicensee comply with the applicable provisions under any Genzyme In-License. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -51- 

 CO-CO LICENSE TERMS 

 

 (c) If Alnylam becomes aware of a material breach of any sublicense by any
Alnylam Sublicensee, compliance with which is necessary for Alnylam’s compliance with the provisions of these Co-Co License Terms, Alnylam shall promptly notify Genzyme of the particulars of the same and use Commercially Reasonable Efforts to
cause the Sublicensee to comply with all the terms of the sublicense necessary for Alnylam’s compliance with the provisions of these Co-Co License Terms. [***] Notwithstanding any sublicense, Alnylam shall remain primarily liable to Genzyme for
the performance of all of Alnylam’s obligations under, and Alnylam’s compliance with all terms and conditions of, these Co-Co License Terms. 

7.3. Joint Collaboration IP. Subject to the rights and licenses granted to, and the obligations (including royalty obligations)
of, each Party under these Co-Co License Terms, either Party is entitled to practice Joint Collaboration IP for all purposes on a worldwide basis and license Joint Collaboration IP without consent of and without a duty of accounting to the other
Party. Each Party will grant and hereby does grant all permissions, consents and waivers with respect to, and all licenses under, the Joint Collaboration IP, throughout the world, necessary to provide the other Party with such rights of use and
exploitation of the Joint Collaboration IP, and will execute documents as necessary to accomplish the foregoing. 
 7.4.
In-Licenses. 
 All licenses and other rights granted to Genzyme under this Section 7 are subject to the rights and
obligations of Alnylam under the Alnylam In-Licenses. All licenses and other rights granted to Alnylam under this Section 7 are subject to the rights and obligations of Genzyme under the Genzyme In-Licenses. Each Party shall comply with all
applicable terms and conditions of the In-Licenses, and shall perform and take such actions as may be required to allow the Party that is party to such In-License to comply with its obligations thereunder, including obligations relating to
sublicensing, patent matters, confidentiality, reporting, audit rights, indemnification and diligence. Without limiting the foregoing, each Party shall prepare and deliver to the other Party any additional reports required under the applicable
In-Licenses and requested by such other Party, in each case sufficiently in advance to enable the Party that is party to such In-License to comply with its obligations under the applicable In-Licenses. Each Party agrees, upon the other Party’s
request, to provide the other Party with copies of any In-Licenses to which it is a party. Confidential Information of the providing Party or its counterparty may be redacted from such copies, except to the extent that such information is required
in order to enable the other Party to comply with its obligations to the providing Party under these Co-Co License Terms with respect to such In-License or in order to enable the providing Party to ascertain compliance with the provisions of these
Co-Co License Terms. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -52- 

 CO-CO LICENSE TERMS 

 

 7.5. Bankruptcy. All rights and licenses granted under or pursuant to these
Co-Co License Terms by a Party to the other, including those set forth in Sections 7.1 (License Grants to Genzyme), 7.2 (License Grants to Alnylam), and 3.5 (Right of Reference), are and shall otherwise be deemed to be, for purposes of
Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties and their respective Sublicensees, as
sublicensees of such rights under these Co-Co License Terms, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code and any foreign counterpart thereto. The Parties further agree that upon commencement
of a bankruptcy proceeding by or against a Party (the “Bankrupt Party”) under the Bankruptcy Code, the other Party (the “Non-Bankrupt Party”) will be entitled to a complete duplicate of, or complete access to (as
the Non-Bankrupt Party deems appropriate), all such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments of such intellectual property will be promptly delivered to the Non-Bankrupt
Party (a) upon any such commencement of a bankruptcy proceeding and upon written request by the Non-Bankrupt Party, unless the Bankrupt Party elects to continue to perform all of its obligations under these Co-Co License Terms, or (b) if
not delivered under (a) above, upon the rejection of these Co-Co License Terms by or on behalf of the Bankrupt Party and upon written request by the Non-Bankrupt Party. Without limiting the foregoing, Alnylam hereby grants to Genzyme a right of
access to and to obtain possession of (i) copies of research data, (ii) laboratory samples, (iii) samples of Co-Co Licensed Product, (iv) formulas, (v) laboratory notes and notebooks, (vi) data and results related to
clinical trials, (vii) regulatory filings and approvals, (viii) rights of reference in respect of regulatory filings and approvals, (ix) pre-clinical research data and results, and (x) marketing, advertising and promotional
materials, all of which (in clauses (i) through (x)) constitute “embodiments” of intellectual property pursuant to Section 365(n) of the Bankruptcy Code and (xi) all other embodiments of such intellectual property, and in
respect of each of the foregoing clauses (i) through (xi), solely for the purpose of the exercise of Genzyme’s rights and licenses under these Co-Co License Terms, whether any of the foregoing are in Alnylam’s possession or control or
in the possession and control of Third Parties. The Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including any trustee) agree not to interfere with the exercise by the Non-Bankrupt Party or its
Related Parties of its rights and licenses to such intellectual property and such embodiments of intellectual property in accordance with these Co-Co License Terms, and agrees to assist the Non-Bankrupt Party and its Related Parties in obtaining
such intellectual property and such embodiments of intellectual property in the possession or control of Third Parties as are reasonably necessary or desirable for the Non-Bankrupt Party to exercise such rights and licenses in accordance with these
Co-Co License Terms. The foregoing provisions are without prejudice to any rights the Non-Bankrupt Party may have arising under the Bankruptcy Code or other Laws. 

7.6. No Other Rights. Except as otherwise expressly provided in these Co-Co License Terms, under no circumstances shall a Party,
as a result of these Co-Co License Terms, obtain any ownership interest or other right in any Know-How, Patent Rights or other intellectual property rights of the other Party, including items owned, controlled or developed by the other Party, or
provided by the other Party to the receiving Party at any time pursuant to these Co-Co License Terms. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -53- 

 CO-CO LICENSE TERMS 

 

 8. FINANCIAL TERMS FOR GENZYME TERRITORY 

8.1. Development Milestone Fees. Genzyme shall provide Alnylam with written notice of the achievement by Genzyme or any of its
Related Parties of any development milestone event set forth below in this Section 8.1 and Alnylam shall provide Genzyme with written notice of the achievement by Alnylam or any of its Related Parties of any development milestone event set
forth below in this Section 8.1, in each case within [***] days after such event has occurred; provided, however, that the notifying Party shall inform the other Party of such event prior to any public disclosure of such event by
the notifying Party. Alnylam shall invoice Genzyme within [***] days of receipt of such written notice by either Party, and Genzyme shall remit the associated development milestone payment within [***] days of the receipt of such invoice. Each
development milestone payment by Genzyme to Alnylam hereunder shall be payable only once with respect to each Co-Co Licensed Product, regardless of the number of times a development milestone event is achieved with respect to such Co-Co Licensed
Product. 
 8.1.1. Development Milestones for ALN-TTRsc. Genzyme shall pay Alnylam the following amounts upon achievement of
the following development milestone events with respect to ALN-TTRsc: 
  

					
	 Development Milestone Event
	  	Development Milestone Payment	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  

 8.1.2. Development Milestones for ALN-AT3. Genzyme shall pay Alnylam the following amounts upon
achievement of the following development milestone events with respect to ALN-AT3: 
  

					
	 Development Milestone Event
	  	Development Milestone Payment	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -54- 

 CO-CO LICENSE TERMS 

 

 8.2. Royalties. 

8.2.1. Royalties Payable on Co-Co Licensed Products. Subject to the provisions these Co-Co License Terms, Genzyme shall pay to Alnylam
royalties on annual Net Sales by Genzyme and its Related Parties of each Co-Co Licensed Product in the Genzyme Territory, as follows: 
  

					
	 Calendar Year

Net Sales of a Co-Co Licensed Product in
 the Genzyme
Territory
	  	Royalty
(as a percentage of Net Sales of such Co-Co
Licensed Product)	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  

 [***] 

[***] 
 Royalties on annual Net Sales of a Co-Co
Licensed Product shall be paid at the rate applicable to the portion of Net Sales within each of the Net Sales levels above during such Calendar Year. 

8.2.2. Royalty Term. Subject to Section 8.2.6 (Royalty Floor), the period during which the royalties set forth in
Section 8.2.1 (Royalties Payable on Co-Co Licensed Products) shall be payable, on a Co-Co Licensed Product-by-Co-Co Licensed Product and country-by-country basis, shall commence with the First Commercial Sale of a Co-Co Licensed Product in a
country and continue until the latest of (a) the expiration of the last Valid Claim of [***] in the country of sale; (b) the expiration of Regulatory Exclusivity for such Co-Co Licensed Product in such country; or (c) subject to the
last sentence of this Section 8.2.2, the [***] anniversary of the First Commercial Sale of such Co-Co Licensed Product in such country (each such period, a “Royalty Term”). [***].  

8.2.3. Third Party Royalty Offsets. Genzyme shall be permitted to reduce any royalties payable under Section 8.2.1 (Royalties
Payable on Co-Co Licensed Products) for a Co-Co Licensed Product by [***].  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -55- 

 CO-CO LICENSE TERMS 

 

 8.2.4. [***].  

8.2.5. [***]. 

8.2.6. Royalty Floor. Anything in these Co-Co License Terms to the contrary notwithstanding, in no event during the applicable Royalty
Term for a Co-Co Licensed Product in a country of the Genzyme Territory shall the royalties payable to Alnylam hereunder for such Co-Co Licensed Product in such country for any Calendar Quarter be reduced [***] In-Licenses). 

8.2.7. Validation Information. At Genzyme’s request, Alnylam will provide Genzyme with such information as Genzyme may reasonably
request to validate the amount of the royalty floor described in Section 8.2.6 (Royalty Floor). 
 9. FINANCIAL TERMS FOR
CO-CO TERRITORY 
 9.1. [***].  

9.2. Third Party License Payments Paid By Genzyme. Genzyme shall provide Alnylam with written notice of any Third Party License
Payments made by Genzyme with respect to a Co-Co Licensed Product in the Co-Co Territory. [***]. 
 10. REPRESENTATIONS,
WARRANTIES AND COVENANTS 
 10.1. Representations and Warranties of Alnylam. Except as provided in the Disclosure Schedule
to this Section 10.1 (which Disclosure Schedule with respect to ALN-TTRsc is attached hereto as Schedule 10.1-1 and with respect to ALN-AT3 will be provided by Alnylam to Genzyme as part of the Option Data Package for ALN-AT3), Alnylam
represents and warrants to Genzyme that, with respect to ALN-AT3, as of the Implementation Date, and, with respect to ALN-TTRsc, as of the Execution Date:  

10.1.1. Alnylam is the sole and exclusive owner of, or otherwise Controls pursuant to an Alnylam In-License, the Alnylam Technology, and
all of the Alnylam Technology licensed to Genzyme hereunder in the Genzyme Territory and the Co-Co Territory that is solely and exclusively owned by Alnylam is free and clear of liens, charges or encumbrances other than licenses granted to Third
Parties that are not inconsistent with the rights and licenses granted to Genzyme under these Co-Co License Terms. 
 10.1.2.
Alnylam has sufficient legal and/or beneficial title and ownership of, or sufficient license rights under, the Alnylam Technology to grant the licenses to such Alnylam Technology granted to Genzyme pursuant to these Co-Co License Terms. 

 10.1.3. (a) Schedule 1.2.14 and Schedule 1.2.19 collectively set forth a complete and accurate list of the
Alnylam Patents owned, either solely or jointly, by Alnylam, and to Alnylam’s knowledge, Schedule 1.2.14 and Schedule 1.2.19 collectively set forth a complete and accurate list of the Alnylam Patents licensed, either exclusively
or nonexclusively, to Alnylam, (b) to Alnylam’s knowledge, each issued Alnylam Patent remains in full force and effect and 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -56- 

 CO-CO LICENSE TERMS 

 

 
(c) Alnylam or its Affiliates have timely paid all filing and renewal fees payable with respect to such Alnylam Patents for which Alnylam controls prosecution and maintenance. Schedule
1.2.14 and Schedule 1.2.19 indicate whether each Alnylam Patent is owned exclusively by Alnylam, is owned jointly by Alnylam and one or more Third Parties, or is licensed to Alnylam. For each Alnylam Patent that is owned, but not owned
exclusively, by Alnylam, or that is licensed to Alnylam, Schedule 1.2.14 and Schedule 1.2.19 identify the Third Party owner(s) and, if applicable, the Alnylam In-License pursuant to which Alnylam Controls such Alnylam Patent. For each
Alnylam Product-Specific Patent that is licensed, but not exclusively licensed, to Alnylam, Schedule 1.2.19 indicates the non-exclusive nature of the license. For each Alnylam Core Technology Patent family (other than Patent Rights licensed
from Isis Pharmaceuticals, Inc.) that is licensed, but not exclusively licensed, to Alnylam, Schedule 1.2.14 indicates the non-exclusive nature of the license. Alnylam is the sole and exclusive owner of all Patent Rights identified in
Schedule 1.2.14 and Schedule 1.2.19 as being owned exclusively by Alnylam and Controls all other Patent Rights identified on such schedules. 

10.1.4. To Alnylam’s knowledge, the Alnylam Product-Specific Patents, are, or, upon issuance, will be, valid and enforceable
patents and no Third Party has challenged or threatened to challenge the scope, validity or enforceability of any Alnylam Product-Specific Patent (including, by way of example, through opposition or the institution or written threat of institution
of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority). 

10.1.5. Alnylam has complied with all applicable Laws, including any duties of candor to applicable patent offices, in connection with
the filing, prosecution and maintenance of the Alnylam Patent Rights.  
 10.1.6. Alnylam owns or Controls all Know-How that is
or has been used by Alnylam in the Development and Manufacture of such Co-Co Licensed Product, and has sufficient legal or beneficial title and ownership of, or sufficient license rights under such Know-How to transfer Know-How to Genzyme as
provided in Section 6.4 of the Master Agreement (Transfer of Manufacturing Know-How). 
 10.1.7. Alnylam Controls all
Know-How and Patent Rights licensed to Alnylam under the Existing Alnylam In-Licenses that is necessary or useful for Genzyme to Develop, Manufacture and/or Commercialize such Co-Co Licensed Product in the Field in the Genzyme Territory and the
Co-Co Territory. Without limiting the generality of the foregoing, Alnylam has obtained all necessary consents and fulfilled all necessary conditions, if any, to sublicense to Genzyme under these Co-Co License Terms such Know-How and Patent Rights
licensed to Alnylam under Existing Alnylam In-Licenses.  
 10.1.8. To Alnylam’s knowledge, neither Alnylam nor its
Affiliates are in breach or default under any existing Alnylam In-License, and neither Alnylam nor its Affiliates have received any written notice of breach or default with respect to any existing Alnylam In-License.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -57- 

 CO-CO LICENSE TERMS 

 

 10.1.9. Alnylam has obtained from all inventors of Alnylam Technology owned by Alnylam
valid and enforceable agreements assigning to Alnylam each such inventor’s entire right, title and interest in and to all such Alnylam Technology. 

10.1.10. To Alnylam’s knowledge, the use, Development, Manufacture or Commercialization by Alnylam or Genzyme (or their respective
Related Parties) of such Co-Co Licensed Product as formulated and manufactured as of the Effective Date, or as intended to be formulated and manufactured as of the Effective Date (a) does not and will not infringe any issued patent of any Third
Party and (b) will not infringe the claims of any published Third Party patent application when and if such claims were to issue in their current form. 

10.1.11. There is no (a) claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature,
civil, criminal, regulatory or otherwise, pending or, to Alnylam’s knowledge, threatened against Alnylam or any of its Affiliates or (b) judgment or settlement against or owed by Alnylam or any of its Affiliates, in each case in connection
with the Alnylam Technology or such Co-Co Licensed Product. 
 10.1.12. For each Co-Co Licensed Product, other than ALN-TTRsc,
Schedule 10.1.12(a) (Existing Alnylam In-Licenses) sets forth a complete and accurate list of all agreements between Alnylam and a Third Party entered into prior to the Implementation Date for a Co-Co Licensed Product pursuant to which
Alnylam Controls Know-How or Patent Rights that are necessary or useful to Develop, Manufacture or Commercialize such Co-Co Licensed Product in the Field other than Additional Alnylam In-Licenses. [***]. For the sake of clarity, representations and
warranties similar to those made pursuant to this Section 10.1.12 with respect to Regional Licensed Products other than ALN-TTRsc are made with respect to ALN-TTRsc in the Master Agreement.  

10.2. Representations and Warranties of Genzyme. Except as disclosed in Genzyme’s Option Exercise Notice for a Co-Co
Licensed Product, Genzyme represents and warrants to Alnylam as of the Implementation Date that it is not a party to any agreement with a Third Party under which it Controls Know-How or Patent Rights that are sublicensed to Alnylam under these Co-Co
License Terms with respect to such Co-Co Licensed Product.  
 10.3. Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY
PROVIDED IN THESE CO-CO LICENSE TERMS, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY TECHNOLOGY, CO-CO LICENSED PRODUCT, GOODS, SERVICES, RIGHTS OR OTHER
SUBJECT MATTER OF THESE CO-CO LICENSE TERMS AND HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. EACH PARTY HEREBY DISCLAIMS ANY
REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY CO-CO LICENSED PRODUCT PURSUANT TO THESE CO-CO LICENSE TERMS WILL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY CO-CO LICENSED PRODUCT
WILL BE ACHIEVED. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -58- 

 CO-CO LICENSE TERMS 

 

 10.4. Certain Covenants. 

10.4.1. [***]. 

10.4.1.1. [***] 
  

	 	(i)	[***] 

  

	 	(ii)	[***] 

  

	 	(iii)	[***] 

 10.4.1.2. [***] 

 

	 	(i)	[***] 

  

	 	(ii)	[***] 

  

	 	(iii)	[***] 

 10.4.1.3. [***]  

 

	 	(i)	[***] 

  

	 	(ii)	[***] 

  

	 	(iii)	[***] 

 10.4.1.4. [***] 

10.4.2. No Third Party Collaboration Agreements in the Co-Co Territory. During the Term, Alnylam shall not enter into any agreement with
any Third Party granting it rights to Develop or Commercialize any Co-Co Licensed Product in the Field in any portion of the Co-Co Territory except for the benefit, and at the direction, of Alnylam.  

10.4.3. Compliance. Each Party and its Related Parties shall conduct the Co-Co Collaboration and the Development, Manufacture and
Commercialization of the Co-Co Licensed Products in accordance with all Laws, including current governmental regulations concerning Good Laboratory Practices (as defined in the Master Agreement), good clinical practices and good manufacturing
practices. In addition, if either Party is or becomes subject to a legal obligation to a Regulatory Authority or other Governmental Authority (such as a corporate integrity agreement or settlement agreement with a Governmental Authority), then the
other Party shall perform such activities as may be reasonably requested by the obligated Party to enable the obligated Party to comply with its legal obligation to such Regulatory Authority with respect to the Co-Co Licensed Products.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -59- 

 CO-CO LICENSE TERMS 

 

 10.4.4. Conflicting Transactions. During the Term, Alnylam shall not (a) transfer
or assign any of its rights, title or interests in the Alnylam Technology other than as part of a transaction pursuant to which these Co-Co License Terms are also assigned and assumed in accordance with Section 13.1 of the Master Agreement
(Assignment), or (b) enter into any agreement granting a license or other right under the Alnylam Technology that is inconsistent with the provisions of these Co-Co License Terms. 

10.4.5. Governmental Authority. If any of the Alnylam Technology is subject to any funding arrangement with any Governmental Authority,
at Genzyme’s reasonable request, Alnylam will reasonably cooperate in seeking a waiver or other modification to such funding arrangement with respect to such Alnylam Technology. 

11. INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS 

11.1. Inventorship. Inventorship for inventions and discoveries first made during the course of the performance of activities
pursuant to these Co-Co License Terms shall be determined in accordance with United States patent Laws for determining inventorship. 

11.2. Ownership. Alnylam shall own the entire right, title and interest in and to all inventions and discoveries (and Patent
Rights claiming patentable inventions therein) first made or discovered solely by employees or consultants of Alnylam or acquired solely by Alnylam in the course of conducting the Collaboration. Genzyme shall own the entire right, title and interest
in and to all inventions and discoveries (and Patent Rights claiming patentable inventions therein) first made or discovered solely by employees or consultants of Genzyme or acquired solely by Genzyme in the course of conducting the Collaboration.
The Parties shall jointly own any inventions and discoveries (and Patent Rights claiming patentable inventions therein) first made or discovered jointly in the course of conducting the Collaboration. 

11.3. Prosecution and Maintenance of Patent Rights. 

11.3.1. IP Committee. The Parties agree that the IP Committee created pursuant to Section 5.3 of the Master Agreement (IP
Committee) shall be responsible for overseeing and effecting the information sharing and consulting provisions under this Section 11.3.  

11.3.2. Genzyme Technology. 

(a) Subject to Section 11.3.2(b) below, Genzyme has the sole responsibility to, at Genzyme’s discretion and at
Genzyme’s sole cost and expense, file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Patent Rights comprising Genzyme Technology (other than Joint Collaboration IP), in Genzyme’s name.

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -60- 

 CO-CO LICENSE TERMS 

 

 (b) In the event that Genzyme elects not to seek or continue to seek or
maintain patent protection on any Genzyme Collaboration IP in the Co-Co Territory, Genzyme shall notify Alnylam at least [***] days before any such Patent Rights would become abandoned, no longer available or otherwise forfeited, and subject to the
terms and conditions of any applicable Genzyme In-License, Alnylam shall have the right (but not the obligation), at its sole cost and expense, to seek, prosecute and maintain in any country patent protection on such Genzyme Collaboration IP in the
name of Genzyme. Genzyme shall use Commercially Reasonable Efforts to make available to Alnylam its authorized attorneys, agents or representatives, and/or such of its employees as are reasonably necessary to assist Alnylam in obtaining and
maintaining the patent protection described under this Section 11.3.2(b). Genzyme shall sign or use Commercially Reasonable Efforts to have signed all legal documents as are reasonably necessary to file and prosecute such patent applications or
to obtain or maintain such patents. 
 11.3.3. Alnylam Technology. The following will apply with respect to Alnylam Patent Rights
during the Term, [***]. 
 (a) Subject to Section 11.3.3(c) below, Alnylam has the sole responsibility to, at
Alnylam’s discretion and at Alnylam’s sole cost and expense, file, conduct prosecution, and maintain (including the defense of any interference or opposition proceedings), all Patent Rights comprising Alnylam Technology (other than Joint
Collaboration IP), in Alnylam’s name. Notwithstanding the foregoing, Alnylam shall file such Alnylam Product-Specific Patents in the Genzyme Patent Jurisdictions (as defined in the Master Agreement) and shall use commercially reasonable efforts
to prosecute and maintain such Patent Rights in the Genzyme Patent Jurisdictions and shall timely pay all filing and renewal fees payable with respect thereto. 

(b) Notwithstanding the foregoing Section 11.3.3(a), Alnylam shall consult with Genzyme, including through the IP
Committee, on its strategy for the preparation, filing, prosecution, and maintenance of all Alnylam Product-Specific Patents in the Genzyme Territory and the Co-Co Territory. Alnylam shall furnish to Genzyme, via electronic mail or such other method
as mutually agreed by the Parties, copies of proposed filings and documents received from outside counsel in the course of such filing, prosecution or maintenance of and/or copies of documents filed with the relevant patent offices with respect to
Alnylam Product-Specific Patents and such other documents directly related to the prosecution and maintenance of Alnylam Product-Specific Patents reasonably necessary for Genzyme to exercise its rights under this Section 11.3.3(b), and as
applicable in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by Genzyme and shall consider in good faith timely comments from Genzyme thereon. Alnylam shall furnish to Genzyme, via
electronic mail or such other method as mutually agreed by the Parties, copies of documents received from outside counsel in the course of filing, prosecution or maintenance of and/or copies of documents filed with the relevant national patent
offices with respect to the filing, prosecution, and maintenance of Alnylam Core Technology Patents within a reasonable period of time after the receipt and/or filing of such documents. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -61- 

 CO-CO LICENSE TERMS 

 

 (c) In the event that Alnylam elects not to seek or continue to seek or
maintain patent protection on any Alnylam Product-Specific Patent in the Genzyme Territory or the Co-Co Territory, Alnylam shall notify Genzyme at least [***] days before any such Patent Rights would become abandoned, no longer available or
otherwise forfeited, and subject to the provisions of any applicable Alnylam In-License, Genzyme shall have the right (but not the obligation), at its sole cost and expense, to seek, prosecute and maintain in any country patent protection on such
Alnylam Product-Specific Patent in the Genzyme Territory. If Genzyme exercises such right, Alnylam shall thereafter and hereby does assign all right, title and interest in and to such Alnylam Product-Specific Patent Rights to Genzyme. Alnylam shall
use Commercially Reasonable Efforts to make available to Genzyme its authorized attorneys, agents or representatives, and/or such of its employees as are reasonably necessary to assist Genzyme in obtaining and maintaining the patent protection
described under this Section 11.3.3(c). Alnylam shall sign or use Commercially Reasonable Efforts to have signed all legal documents as are reasonably necessary to file and prosecute such patent applications or to obtain or maintain such
patents. 
 (d) [***] 

11.3.4. Joint Collaboration IP. 

(a) [***]shall have the first right to, at [***]discretion, file, prosecute and maintain (including the defense of any
interference or opposition proceedings), all Patent Rights comprising Joint Collaboration IP, in the names of both Alnylam and Genzyme. [***]shall consult with [***] on the filing, prosecution and maintenance of all such Patent Rights. Each Party
shall sign, or use Commercially Reasonable Efforts to have signed, all legal documents as are reasonably necessary to file and prosecute patent applications or to obtain or maintain patents in respect of such Joint Collaboration IP, at its own cost.

 (b) [***] shall furnish [***], via electronic mail or such other method as mutually agreed by the Parties, copies of
documents received from outside counsel in the course of such filing, prosecution or maintenance of Joint Collaboration IP and/or copies of documents relevant to such preparation, filing, prosecution, and maintenance in sufficient time prior to
filing such document or making any payment due thereunder to allow for review and comment by [***] and shall consider in good faith timely comments from [***] thereon. Alnylam shall furnish to[***], via electronic mail or such other method as
mutually agreed by the Parties, copies of such documents as filed in the relevant patent offices. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -62- 

 CO-CO LICENSE TERMS 

 

 (c) In the event that [***] elects not to file or continue to prosecute or
maintain patent protection on any Joint Collaboration IP, [***] shall have the right (but not the obligation) to file, prosecute and maintain Patent Rights comprising Joint Collaboration IP in the names of both Alnylam and Genzyme. If Genzyme
exercises such right, [***] shall use Commercially Reasonable Efforts to make available to [***] its authorized attorneys, agents or representatives, and/or such of its employees as are reasonably necessary to assist [***] in obtaining and
maintaining the patent protection described under this Section 11.3.4(c). [***] shall sign or use Commercially Reasonable Efforts to have signed all legal documents as are reasonably necessary to file and prosecute such patent applications or
to obtain or maintain such patents. 
 (d) The Parties shall share equally the out-of-pocket patent filing, prosecution and
maintenance expenses incurred with respect to Patent Rights comprising Joint Collaboration IP. 
 11.3.5. Patent Miscellaneous. Each
Party hereby agrees: (a) to make its employees, agents and consultants reasonably available to the other Party (or to the other Party’s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable such
Party to undertake patent prosecution; (b) to provide the other Party with copies of all material correspondence pertaining to prosecution with the patent offices; (c) to cooperate, if necessary and appropriate, with the other Party in
gaining patent term extensions wherever applicable to Patent Rights licensed under these Co-Co License Terms; and (d) to endeavor in good faith to coordinate its efforts with the other Party to minimize or avoid interference with the
prosecution and maintenance of the other Party’s patent applications.  
 11.3.6. [***]. 

11.3.6.1. [***]  

11.3.6.2. [***] 

11.3.6.3. [***] 

11.4. Third Party Infringement. 

11.4.1. Notices. Each Party shall promptly report in writing to the other Party any (a) known or suspected infringement of any
Alnylam Technology, Genzyme Technology or Joint Collaboration IP or (b) unauthorized use or misappropriation of any Confidential Information or Know-How of a Party by a Third Party of which it becomes aware, in each case to the extent such
infringing, unauthorized or misappropriating activities involve, as to a Co-Co Licensed Product, a competing product in the Field (a “Competitive Infringement”), and shall provide the other Party with all available evidence of such
infringement, unauthorized use or misappropriation.  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -63- 

 CO-CO LICENSE TERMS 

 

 11.4.2. Rights to Enforce. 

(a) Genzyme Technology. Subject to the provisions of any In-License, Genzyme shall have the sole and exclusive right to
initiate an infringement or other appropriate suit (an “Infringement Action”) anywhere in the world against any Third Party as to any infringement, or suspected infringement, of any Patent Rights, or as to any use or suspected use
without proper authorization of any Know-How comprising Genzyme Patent Rights, Genzyme Know-How or Genzyme Collaboration IP. Genzyme will consider in good faith any request from Alnylam to initiate an Infringement Action against any Third Party with
respect to Competitive Infringement in the Co-Co Territory of Genzyme Patent Rights, Genzyme Know-How or Genzyme Collaboration IP licensed to Alnylam under Section 7 (Licenses); provided, however, that Genzyme shall not be
required to initiate any such Infringement Action or permit Alnylam to initiate any such Infringement Action. 
 (b)
Alnylam Technology. 
  

	 	(i)	Genzyme Territory. Subject to the provisions of any In-License, Genzyme shall have the first right to initiate an Infringement Action anywhere in the world against any Third Party with respect to any Competitive
Infringement in the Genzyme Territory of any Alnylam Product-Specific Patent, Joint Collaboration IP or Alnylam Collaboration IP, or, with Alnylam’s prior written consent, Alnylam Core Technology Patent or Alnylam Know-How. Alnylam will
consider in good faith any request from Genzyme to initiate an Infringement Action against any Third Party with respect to a Competitive Infringement in the Genzyme Territory of any Alnylam Core Technology Patent Right or Alnylam Know-How;
provided, however, that Alnylam shall not be required to initiate any such Infringement Action or permit Genzyme to initiate any such Infringement Action.  

 

	 	(ii)	Co-Co Territory. Subject to the provisions of any In-License, Alnylam shall have the first right to initiate an Infringement Action anywhere in the world against any Third Party with respect to any Competitive
Infringement in the Co-Co Territory of any Alnylam Product-Specific Patent, Joint Collaboration IP, Alnylam Collaboration IP, Alnylam Core Technology Patent or Alnylam Know-How. Alnylam will consider in good faith any request from Genzyme to
initiate an Infringement Action against any Third Party with respect to such Competitive Infringement in the Co-Co Territory; provided, however, that Alnylam shall not be required to initiate any such Infringement Action.

  

	 	(c)	Step-In Rights. 

  

	 	(i)	 Alnylam Step-In Right for Alnylam Technology in Genzyme Territory. If within [***] days (or such shorter period of time as required by
applicable Law to avoid loss of material enforcement rights) after Genzyme’s receipt 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -64- 

 CO-CO LICENSE TERMS 

 

	 	
of a notice of a Competitive Infringement with respect to any Alnylam Product-Specific Patent or Joint Collaboration IP, Genzyme does not initiate any Infringement Action against such Competitive
Infringement in the Genzyme Territory, Alnylam may in its sole discretion, bring and control any Infringement Action in connection therewith at its sole cost and expense. 

 

	 	(ii)	Genzyme Step-In Right for Alnylam Technology in Co-Co Territory. If within [***] days (or such shorter period of time as required by applicable Law to avoid loss of material enforcement rights) after
Alnylam’s receipt of a notice of a Competitive Infringement with respect to any Alnylam Product-Specific Patent, Joint Collaboration IP or Alnylam Collaboration IP, Alnylam does not initiate any Infringement Action against such Competitive
Infringement in the Co-Co Territory, Genzyme may in its sole discretion, bring and control any Infringement Action in connection therewith at its sole cost and expense.  

 

	 	(iii)	[***] 

 11.4.3. Procedures; Expenses and Recoveries. The Party having the right to
initiate any Infringement Action under Section 11.4.2 (Rights to Enforce) above shall have the sole and exclusive right to select counsel for any such Infringement Action and shall pay all expenses of the suit, including attorneys’ fees
and court costs and reimbursement of the other Party’s reasonable Co-Co Out-of-Pocket Costs in rendering assistance requested by the initiating Party. If required under applicable Law in order for the initiating Party to initiate and/or
maintain such Infringement Action, or if either Party is unable to initiate or prosecute such Infringement Action solely in its own name or it is otherwise advisable to obtain an effective legal remedy, in each case, the other Party shall join as a
party to the Infringement Action and will execute and cause its Affiliates to execute all documents necessary for the initiating Party to initiate litigation to prosecute and maintain such action. In addition, at the initiating Party’s request,
the other Party shall provide reasonable assistance to the initiating Party in connection with an Infringement Action at no charge to the initiating Party except for reimbursement by the initiating Party of reasonable Co-Co Out-of-Pocket Costs
incurred in rendering such assistance. The non-initiating Party shall have the right to participate and be represented in any such Infringement Action by its own counsel at its own expense. If the Parties obtain from a Third Party, in connection
with such Infringement Action, any damages, license fees, royalties or other compensation (including any amount received in settlement of such litigation), after payment of any amounts required under any In-Licenses, the remaining amounts shall be
allocated in all cases as follows: 
 (a) first, to reimburse each Party for all expenses of the Infringement Action
incurred by the Parties, including attorneys’ fees and disbursements, court costs and other litigation expenses; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -65- 

 CO-CO LICENSE TERMS 

 

 (b) second, [***] of the balance to be paid to the Party initiating the
Infringement Action, with respect to Infringement Actions in the Genzyme Territory, and [***] of the balance to be paid to the Party initiating the Infringement Action, with respect to Infringement Actions in the Co-Co Territory; and 

(c) third, the remainder to the other Party. 

Notwithstanding the foregoing, in the event that Alnylam elects to itself assert an Alnylam Core Technology Patent against a Competitive
Infringement in the Genzyme Territory, the Parties shall each be entitled to [***] of the balance of any recovery therefrom after reimbursement of expenses as described in clause (i) above. In addition, with respect to Infringement Actions
brought in the Co-Co Territory, the Parties shall share evenly the expenses of the suit, including attorneys’ fees of each Party, court costs, and both Parties’ reasonable Co-Co Out-of-Pocket expenses in rendering assistance related to the
Infringement Action (“Litigation Expenses”). For such Infringement Actions brought in the Co-Co Territory, Litigation Expenses shall initially be borne by the Party incurring the expense. Each Party will calculate and maintain
records of Litigation Expenses incurred by it and its Affiliates with respect to any such Infringement Action, and, within thirty (30) days following the end of each Calendar Quarter, each Party shall submit to the other a report detailing the
Litigation Expenses incurred by it and its Affiliates during such Calendar Quarter. Unless otherwise agreed by the Parties, the Party that incurs more than its share of the total Litigation Expenses with respect to such an Infringement Action in the
Co-Co Territory during any Calendar Quarter shall be paid by the other Party an amount of cash sufficient to reconcile to its fifty percent (50%) share of Litigation Expenses.  

11.5. Patent Term Extensions. 

11.5.1. Retained Alnylam Product-Specific Patent Rights. Subject to the provisions of any Alnylam In-License, Alnylam shall use
Commercially Reasonable Efforts to obtain all available supplementary protection certificates (“SPCs”) and other extensions of Alnylam Product-Specific Patents in the Genzyme Territory[***]. If more than one Alnylam Product-Specific
Patent is eligible for extension or patent term restoration in the Genzyme Territory, Genzyme will determine, in its sole discretion, a strategy that will be designed to maximize patent protection and commercial value for the Co-Co Licensed Product,
and the Parties, subject to the provisions of any In-License, will seek patent term extensions, restorations and SPCs for Alnylam Product-Specific Patents in the Genzyme Territory in accordance with that strategy. Where required under national law,
and subject to the other requirements of this Section 11.5, Alnylam will make the filings for such extensions, restorations and SPCs for Alnylam Product-Specific Patents in the Genzyme Territory as directed by Genzyme. 

11.5.2. Further Assurances for SPCs. Each Party will execute such authorizations and other documents and take such other actions as may
be reasonably requested by the other Party to obtain any such extensions, restorations and SPCs for Alnylam Product-Specific Patents in the Genzyme Territory, in accordance with this Section 11.5. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -66- 

 CO-CO LICENSE TERMS 

 

 11.6. Common Interest. All information exchanged between the
Parties’ representatives regarding the preparation, filing, prosecution, maintenance, or enforcement of the Patent Rights under this Section 11 will be deemed Confidential Information. In addition, the Parties acknowledge and agree that,
with regard to such preparation, filing, prosecution, maintenance, and enforcement of the Patents Rights under this Section 11, the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent
protection possible, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in these Co-Co License Terms constitutes a waiver of, any legal privilege concerning the Patents Rights
under this Section 11, including privilege under the common interest doctrine and similar or related doctrines. 
 11.7.
Trademarks.  
 (a) Each Party has the right to use any trademark it owns or controls for Co-Co Licensed Products
in its Territory at its sole discretion, and each Party and its Affiliates shall retain all right, title and interest in and to its and their respective corporate names and logos. 

(b) Genzyme will develop and propose, and the PJSC shall review and comment on, one or more Product Trademark(s) for use by
Genzyme and its Related Parties throughout the Genzyme Territory. Such Product Trademark(s) considered by the PJSC may include, in Genzyme’s sole discretion, the Product Trademark(s) developed and/or used by Alnylam with respect to the
Commercialization of Co-Co Licensed Products in the Co-Co Territory (the “Alnylam Trademarks”), but may not include other trademarks owned or controlled by Alnylam. Any Product Trademark(s) (other than the Alnylam Trademarks) that
are used by Genzyme to promote and sell Co-Co Licensed Products in the Genzyme Territory are hereinafter referred to as the “Genzyme Trademarks.” Alnylam (or its Related Parties, as appropriate) shall own all rights to Alnylam
Trademarks, and all goodwill associated therewith, throughout the Co-Co Territory and the Genzyme Territory. Genzyme (or its Related Parties, as appropriate) shall own all rights to Genzyme Trademarks and all goodwill associated therewith,
throughout the Genzyme Territory. Alnylam shall also own rights to any Internet domain names incorporating the applicable Alnylam Trademarks or any variation or part of such Alnylam Trademarks used as its URL address or any part of such address; and
Genzyme shall also own rights to any Internet domain names incorporating the applicable Genzyme Trademarks or any variation or part of such Genzyme Trademarks used as its URL address or any part of such address. 

(c) If Genzyme determines to use Alnylam Trademarks to promote and sell any Co-Co Licensed Product in the Genzyme Territory,
then Alnylam and Genzyme shall enter into a separate trademark license agreement containing commercially reasonable and customary terms pursuant to which Alnylam will grant Genzyme an exclusive, royalty-free license to use the applicable Alnylam
Trademark(s) to Commercialize Co-Co Licensed Products in the Genzyme Territory. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -67- 

 CO-CO LICENSE TERMS 

 

 (d) In the event either Party becomes aware of any infringement of any
Product Trademark by a Third Party, such Party shall promptly notify the other Party and the Parties shall consult with each other and jointly determine the best way to prevent such infringement, including by the institution of legal proceedings
against such Third Party. 
 (e) For the avoidance of doubt, neither Party shall have any right to use the other Party’s
or the other Party’s Affiliates’ corporate names or logos in connection with Commercialization of Co-Co Licensed Products. 

11.8. Cooperative Research and Technology (CREATE) Act Acknowledgment. It is the intention of the Parties that these Co-Co
License Terms are a “joint research agreement” as that phrase is defined in Section 35 U.S.C. 103(c). 
 12. TERM
AND TERMINATION 
 12.1. Term. These Co-Co License Terms shall be effective as of the Effective Date and, unless terminated
earlier pursuant to Section 12.2 (Termination Rights), these Co-Co License Terms shall continue in effect on a Co-Co Licensed Product-by-Co-Co Licensed Product and country-by-country basis until no further payments are due under Section 8
(Financial Terms for Genzyme Territory) or Section 9 (Financial Terms for Co-Co Territory) of these Co-Co License Terms (“Term”). Upon expiration of the Royalty Term for any particular Co-Co Licensed Product, all licenses of
the Parties under Section 7 (Licenses) with respect to such Co-Co Licensed Product then in effect shall become fully paid-up, perpetual licenses. 

12.2. Termination Rights. These Co-Co License Terms may be terminated by the Parties only as set forth in this Section 12.2.

 12.2.1. Termination for Convenience. Subject to the remainder of this Article 12, Genzyme shall have the right to terminate
these Co-Co License Terms with respect to any particular Co-Co Licensed Product as follows: 
 (a) After initiation of
the first Phase II Study for such Co-Co Licensed Product and prior to completion of such Phase II Study for such Co-Co Licensed Product, Genzyme shall have the right to terminate these Co-Co License Terms with respect to such Co-Co Licensed Product
upon sixty (60) days prior written notice in the event that a Safety Concern occurs, provided that in the event of such termination Genzyme shall pay to Alnylam [***] of the Global R&D Costs and Global Regulatory Costs incurred
through the effective date of termination (not to exceed [***]) to wind down any ongoing Phase II Studies with respect to such Co-Co Licensed Product in an efficient manner consistent with patient safety, applicable Law and ethical standards. 

(b) After initiation of the first Phase II Study for such Co-Co Licensed Product and prior to completion of such Phase II Study
for such Co-Co Licensed Product, Genzyme shall have the right to terminate these Co-Co License Terms with respect to 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -68- 

 CO-CO LICENSE TERMS 

 

 
such Co-Co Licensed Product for any reason upon written notice (in which case, such termination shall become effective immediately upon Alnylam’s receipt of notice of such termination),
provided that in the event of such termination Genzyme shall pay to Alnylam [***] of the Global R&D Costs and Global Regulatory Costs incurred in any ongoing Phase II Studies for such Co-Co Licensed Product (not to exceed [***]. 

(c) Within sixty (60) days of Genzyme’s receipt of the Phase 3 Budget and End of Phase II Package, Genzyme shall have
the right to terminate these Co-Co License Terms with respect to such Co-Co Licensed Product upon written notice to Alnylam (in which case, such termination shall become effective immediately upon Alnylam’s receipt of notice of such
termination), provided that in the event of such termination Genzyme shall pay to Alnylam [***] of the Global R&D Costs and Global Regulatory Costs incurred through the effective date of termination (not to exceed [***]. 

(d) After initiation of the first Phase III Study for such Co-Co Licensed Product and prior to completion of such Phase III
Study for such Co-Co Licensed Product, Genzyme shall have the right to terminate these Co-Co License Terms with respect to such Co-Co Licensed Product upon sixty (60) days prior written notice in the event that a Safety Concern occurs,
provided that in the event of such termination Genzyme shall pay to Alnylam [***] of the Global R&D Costs and Global Regulatory Costs incurred through the effective date of termination (not to exceed [***]) to wind down any ongoing
Clinical Studies with respect to such Co-Co Licensed Product in an efficient manner consistent with patient safety, applicable Law and ethical standards. 

(e) After initiation of the first Phase III Study for such Co-Co Licensed Product and Genzyme’s payment of the Phase III
Study initiation milestone payment described in Section 8.1.1(i) (Development Milestones for ALN-TTRsc) or 8.1.2(i) (Development Milestones for ALN-AT3), Genzyme shall have the right to terminate these Co-Co License Terms with respect to such
Co-Co Licensed Product at any time upon sixty (60) days prior written notice to Alnylam, provided that in the event of such termination Genzyme shall pay to Alnylam [***] of the Global R&D Costs and Global Regulatory Costs incurred
in conducting any ongoing Phase III Study with respect to such Co-Co Licensed Product through filing of the first NDA with respect to such Co-Co Licensed Product (not to[***]). 

(f) After completion of the first Phase III Study for such Co-Co Licensed Product, Genzyme shall have the right to terminate
these Co-Co License Terms with respect to such Co-Co Licensed Product at any time upon sixty (60) days prior written notice to Alnylam. 

12.2.2. Termination for Cause. These Co-Co License Terms may be terminated with respect to any particular Co-Co Licensed Product at any
time during the Term upon written notice by either Party if (a) the other Party is in material breach of its obligations hereunder with respect to such Co-Co Licensed Product and (b) the other Party has not cured such breach within thirty (30) days
in the case of a payment breach, or within ninety (90) days in the case of all 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -69- 

 CO-CO LICENSE TERMS 

 

 
other breaches, after notice requesting cure of the breach; provided, however, that if any breach other than a payment breach is not reasonably curable within ninety (90) days
and if a Party is making a bona fide effort to cure such breach, such termination shall be delayed for a time period to be agreed by both Parties, not to exceed an additional ninety (90) days, in order to permit such Party a reasonable period
of time to cure such breach; and provided, further, that in the event that the breach relates to a dispute between the Parties regarding Genzyme’s obligations to use Commercially Reasonable Efforts in Developing or Commercializing
such Co-Co Licensed Product and Genzyme disputes whether it has breached such obligation or whether such breach gives Alnylam the right to terminate these Co-Co License Terms with respect to such Co-Co Licensed Product and initiates a legal action
against Alnylam to resolve such dispute within the foregoing sixty (60) day cure period, then these Co-Co License Terms shall not terminate during the pendency of such legal action, provided that if (i) Genzyme is found, in an
unappealable decision by a court of competent jurisdiction or an appealable decision of a court of competent jurisdiction that has not been appealed in the time allowed for an appeal in such legal action, to have materially breached these Co-Co
License Terms with respect to such Co-Co Licensed Product, or (ii) Genzyme admits in such legal action or settlement thereof that it has materially breached these Co-Co License Terms with respect to such Co-Co Licensed Product, then these Co-Co
License Terms shall terminate immediately with respect to such Co-Co Licensed Product following the Parties’ receipt of such decision or immediately following such admission, as applicable. 

12.2.3. Challenges of Patent Rights. If, during the Term, Genzyme or any of its Affiliates (a) commences or participates in any action
or proceeding (including any patent opposition or re-examination proceeding), or otherwise asserts any claim, challenging or denying the validity or enforceability of any Alnylam Product-Specific Patent or any claim thereof or (b) actively assists
any other Person or entity in bringing or prosecuting any action or proceeding (including any patent opposition or re-examination proceeding) challenging or denying the validity or enforceability of any Alnylam Product-Specific Patent for a Co-Co
Licensed Product or any claim thereof (each of (a) and (b), a “Patent Challenge”), then, to the extent permitted by the applicable Laws, Alnylam shall have the right, exercisable within sixty (60) days following receipt of notice
regarding such Patent Challenge, in its sole discretion, to give notice to Genzyme that Alnylam may terminate these Co-Co Licensed Terms with respect to the Co-Co Licensed Product Covered by the Alnylam Product-Specific Patent that is the subject of
the Patent Challenge (which termination will be effective ninety (90) days following such notice (or such longer period as Alnylam may designate in such notice)), and, unless Genzyme or such Affiliate withdraws or causes to be withdrawn all such
challenge(s) (or in the case of ex-parte proceedings, multi-party proceedings, or other Patent Challenges that Genzyme or Genzyme’s Affiliates do not have the power to unilaterally withdraw or cause to be withdrawn, Genzyme and Genzyme’s
Affiliates cease actively assisting any other party to such Patent Challenge and, to the extent Genzyme or a Genzyme Affiliate is a party to such Patent Challenge, it withdraws from such Patent Challenge) within such ninety (90)-day period, Alnylam
will have the right to terminate these Co-Co License Terms with respect to such Co-Co Licensed Product by providing written notice thereof to Genzyme. The foregoing sentence shall not apply with respect to (i) any Alnylam Product-Specific Patent
that Alnylam first asserts against Genzyme or any of its 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -70- 

 CO-CO LICENSE TERMS 

 

 
Affiliates where the Patent Challenge is made in defense of such assertion or (ii) any Patent Challenge commenced by a Third Party that, after the Effective Date, acquires or is acquired by
Genzyme or its Affiliates or its or their business or assets, whether by stock purchase, merger, asset purchase or otherwise, but only with respect to Patent Challenges commenced prior to the closing of such acquisition. 

12.2.4. Abandonment of Development. At any time on or after [***], either Party may terminate these Co-Co License Terms in their
entirety (i.e., with respect to all Co-Co Licensed Products) if (a) no Co-Co Licensed Product has received Regulatory Approval anywhere in the Genzyme Territory, (b) no Co-Co Licensed Product is being Developed for the
Genzyme Territory, (c) no Global Development Plan or Genzyme Territory Development Plan is in effect for any Co-Co Licensed Product, provided that if Genzyme provides Alnylam with a good faith Genzyme Territory Development Plan pursuant
to Section 2.2.3 (Genzyme Territory Development Plan) during the termination notice period set forth below in this Section 12.2.4, then the condition set forth in this clause (c) shall be deemed not satisfied at such time and the
applicable termination notice shall be deemed not to have effect, and (d) the absence of Development in the Genzyme Territory or a good faith Genzyme Territory Development Plan is not the result of a breach by the Party seeking to terminate
these Co-Co License Terms of its obligations under Section 2.4 (Diligence). In order to terminate these Co-Co License Terms pursuant to this Section 12.2.4, the terminating Party must provide at least six (6) months’ prior
written notice to the other Party referencing this Section 12.2.4 and specifying a termination date on or after [***], provided that, with respect to any such termination by Alnylam, such notice must also include an update regarding the
current status of Alnylam’s Development activities with respect to Co-Co Licensed Products. 
 12.3. Effect of
Termination. 
 12.3.1. Effects of Termination by Genzyme for Cause. Without limiting any other legal or equitable remedies
that either Party may have, if these Co-Co License Terms are terminated by Genzyme with respect to any particular Co-Co Licensed Product pursuant to Section 12.2.2 (Termination for Cause), then: 

(a) these Co-Co License Terms shall continue to survive in all respects with respect to all Co-Co Licensed Products other than
the terminated Co-Co Licensed Product; 
 (b) all license grants in these Co-Co License Terms with respect to the terminated
Co-Co Licensed Product from either Party to the other shall immediately terminate; 
 (c) the Back-Up Option shall terminate
with respect to all Back-Up Products for the terminated Co-Co Licensed Product; provided, however, that such Back-Up Products shall, as of such date, be considered Option Products for the purposes of the Master Agreement, and the
Options granted under the Master Agreement to siRNA that targets the same gene as the terminated Co-Co Licensed Product shall again apply in accordance with the terms and conditions set forth in the Master Agreement; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -71- 

 CO-CO LICENSE TERMS 

 

 (d) Genzyme shall as promptly as practicable transfer to Alnylam or
Alnylam’s designee (i) possession and ownership of all Regulatory Approvals and pricing and reimbursement approvals relating to the Development, Manufacture or Commercialization of the terminated Co-Co Licensed Product, and
(ii) copies of all non-clinical and clinical data and material regulatory correspondence relating to the terminated Co-Co Licensed Product, provided that Alnylam shall reimburse Genzyme for any reasonable out-of-pocket expenses incurred
by Genzyme in connection with such transfer; 
 (e) Genzyme will assign and transfer to Alnylam all rights, title and
interests in and to any Alnylam Product-Specific Patents that relate solely to the terminated Co-Co Licensed Product that were assigned to Genzyme pursuant to Section 11.3.6 (Assignment of Alnylam Product-Specific Patents to Genzyme),
provided that Alnylam shall reimburse Genzyme for any reasonable out-of-pocket expenses incurred by Genzyme in connection with such assignment and transfer. In such event, Genzyme will execute and deliver a patent assignment relating to such
Alnylam Product-Specific Patents in the same form used to assign such Patent Rights to Genzyme; and 
 (f) each Party shall promptly pay any
amounts owed to the other Party as of the effective date of such termination. 
 12.3.2. Effects of Termination by Alnylam for Cause or by
Genzyme for Convenience. Without limiting any other legal or equitable remedies that either Party may have, if these Co-Co License Terms are terminated with respect to any particular Co-Co Licensed Product by Genzyme pursuant to
Section 12.2.1 (Termination for Convenience) or by Alnylam under Section 12.2.2 (Termination for Cause) or Section 12.2.3 (Challenges of Patent Rights), then: 

(a) these Co-Co License Terms shall continue to survive in all respects with respect to all Co-Co Licensed Products other than
the terminated Co-Co Licensed Product; 
 (b) all licenses granted by Alnylam to Genzyme in these Co-Co License Terms with
respect to the terminated Co-Co Licensed Product shall immediately terminate; 
 (c) the Back-Up Option shall terminate with
respect to all Back-Up Products for the terminated Co-Co Licensed Product and such Back-Up Products shall be treated as Option Products for which Genzyme has not exercised an Option for purposes of Section 3.5 of the Master Agreement; 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -72- 

 CO-CO LICENSE TERMS 

 

 (d) Genzyme will assign and transfer to Alnylam, all rights, title and
interests in and to any Alnylam Product Specific Patents that relate solely to the terminated Co-Co Licensed Product that were assigned to Genzyme pursuant to Section 11.3.6 (Assignment of Alnylam Product-Specific Patents to Genzyme). In such
event, Genzyme will execute and deliver a patent assignment relating to such Alnylam Product-Specific Patents in the same form used to assign such Patent Rights to Genzyme; 

(e) Genzyme will grant to Alnylam, effective upon the effective date of termination and subject to the provisions of any
applicable Genzyme In-License, a non-transferable, sublicensable (on terms consistent with Section 7.2.4 (Sublicensing Terms)), worldwide, non-exclusive, royalty-free license under any Genzyme Collaboration IP and Genzyme Patent Rights that
Cover the terminated Co-Co Licensed Product, in the form that such terminated Co-Co Licensed Product exists on the effective date of termination (the “Reverted Co-Co Licensed Product”), solely to the extent necessary to Develop and
Commercialize the Reverted Co-Co Licensed Product in the Field in the Genzyme Territory. Notwithstanding the foregoing, if (i) any Patent Rights that Cover the Reverted Co-Co Licensed Product are Controlled by Genzyme pursuant to a Genzyme
In-License and (ii) such Genzyme In-License cannot be assigned to Alnylam or does not relate exclusively to the Reverted Co-Co Licensed Product, Genzyme shall promptly disclose any payment obligations under such Genzyme In-License to Alnylam
and such Genzyme Patent Rights shall be subject to the license granted in this Section 12.3.2(e) only if Alnylam agrees in writing to (A) reimburse Genzyme for one hundred percent (100%) of any amounts that become payable under such
Genzyme In-License as a result of Alnylam’s exercise of the license granted in this Section 12.3.2(e), (B) comply with all applicable terms and conditions of such Genzyme In-License and (C) perform and take such actions as may be
required to allow Genzyme to comply with its obligations under such Genzyme In-License. 
 (f) The license grants to Alnylam
in Section 7.2 (License Grants to Alnylam) shall survive and shall be expanded to include the Genzyme Territory with respect to the Reverted Co-Co Licensed Product. 

(g) Genzyme shall as promptly as practicable transfer to Alnylam or Alnylam’s designee (i) possession and ownership
of all governmental or regulatory correspondence, conversation logs, filings and approvals (including all Regulatory Approvals and pricing and reimbursement approvals) solely relating to the Development, Manufacture or Commercialization of the
Reverted Co-Co Licensed Product, (ii) copies of all data, reports, records and materials, and other sales and marketing related information in Genzyme’s possession or Control, to the extent that such data, reports, records, materials or
other information relate to the Development, Manufacture or Commercialization of the Reverted Co-Co Licensed Product, including all non-clinical and clinical data relating to the Reverted Co-Co Licensed Product, and customer lists and customer
contact information and all adverse event data relating to the Reverted Co-Co Licensed Product in Genzyme’s possession or Control, provided that for a period of [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -73- 

 CO-CO LICENSE TERMS 

 

 
months after the effective date of termination with respect to such Reverted Co-Co Licensed Product, Genzyme shall use Commercially Reasonable Efforts to obtain for Alnylam the right to access
all such data, reports, records, materials, and other sales and marketing related information related to the Reverted Co-Co Licensed Product, and (iii) all records and materials in Genzyme’s possession or Control containing Confidential
Information of Alnylam solely relating to the Reverted Co-Co Licensed Product. In addition, Genzyme shall appoint Alnylam as Genzyme’s and/or Genzyme’s Related Parties’ agent for all matters related to the Reverted Co-Co Licensed
Product involving Regulatory Authorities in the Genzyme Territory until all Regulatory Approvals and other regulatory filings have been transferred to Alnylam or its designee. 

(h) If the effective date of termination is after First Commercial Sale of the Reverted Co-Co Licensed Product, then Genzyme
shall appoint Alnylam as its exclusive distributor of the Reverted Co-Co Licensed Product in the Genzyme Territory and grant Alnylam the right to appoint sub-distributors, until such time as all Regulatory Approvals in the Genzyme Territory have
been transferred to Alnylam or its designee. 
 (i) If Genzyme or its Related Parties are Manufacturing finished product with
respect to the Reverted Co-Co Licensed Product on the effective date of termination, at Alnylam’s option, Genzyme or its Related Parties shall supply such finished product to Alnylam in the Genzyme Territory on terms no less favorable than
those on which Genzyme supplied such finished product prior to such termination to its most favored distributor in the Genzyme Territory, until the earlier of (i) such time as all Regulatory Approvals in the Genzyme Territory solely related to
the Reverted Co-Co Licensed Product have been transferred to Alnylam or its designee, Alnylam has obtained all necessary manufacturing approvals and Alnylam has procured or developed its own source of such finished product supply or (ii) [***]
months following the effective date of such termination. 
 (j) If Alnylam so requests, and to the extent permitted under
Genzyme’s obligations to Third Parties on the effective date of termination, Genzyme shall transfer to Alnylam any Third Party agreements relating solely and exclusively to the Development, Manufacture or Commercialization of the Reverted Co-Co
Licensed Product to which Genzyme is a party (including any Genzyme In-License), subject to any required consents of such Third Party, which Genzyme shall use Commercially Reasonable Efforts to obtain promptly. 

(k) Genzyme shall promptly transfer and assign to Alnylam all of Genzyme’s and its Affiliates’ rights, title and
interests in and to the Genzyme Trademark(s) (but not any Genzyme house marks or any trademark containing the word “Genzyme” owned by Genzyme and used for the Reverted Co-Co Licensed Product in the Field in the Genzyme Territory) owned by
Genzyme and used solely and exclusively for the Reverted Co-Co Licensed Product in the Field in the Genzyme Territory. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -74- 

 CO-CO LICENSE TERMS 

 

 (l) Genzyme shall transfer to Alnylam any inventory of the Reverted Co-Co
Licensed Products Controlled by Genzyme or its Affiliates as of the termination date at the actual price paid by Genzyme for such supply. 

(m) Genzyme shall provide any other assistance reasonably requested by Alnylam for the purpose of allowing Alnylam or its
designee to proceed expeditiously with the Development, Manufacture and Commercialization of the Reverted Co-Co Licensed Product in the Genzyme Territory, provided that Genzyme’s obligations under this clause (m) of
Section 12.3.2 shall expire [***] months after the effective date of termination of such Reverted Co-Co Licensed Product. 

(n) Genzyme shall execute all documents and take all such further actions as may be reasonably requested by Alnylam in order to
give effect to the foregoing clauses. 
 12.3.3. Effects of Termination for Abandonment of Development. If these Co-Co License Terms
are terminated in their entirety (i.e., with respect to all Co-Co Licensed Products) by either Party pursuant to Section 12.2.4 (Abandonment of Development), then the license granted to Alnylam under Section 7.2.2
(License to Improvement Manufacturing Patent Rights) shall survive and all other licenses granted in these Co-Co License Terms from either Party to the other shall immediately terminate and: 

(a) the Back-Up Option shall terminate with respect to all Back-Up Products for the terminated Co-Co Licensed Products ; 

(b) Genzyme shall as promptly as practicable transfer to Alnylam or Alnylam’s designee (i) possession and ownership
of all Regulatory Approvals and pricing and reimbursement approvals relating to the Development, Manufacture or Commercialization of the terminated Co-Co Licensed Product, and (ii) copies of all non-clinical and clinical data and material
regulatory correspondence relating to the terminated Co-Co Licensed Product; 
 (c) Genzyme will assign and transfer to
Alnylam, all rights, title and interests in and to any Alnylam Product Specific Patents that relate solely to the terminated Co-Co Licensed Product that were assigned to Genzyme pursuant to Section 11.3.6 (Assignment of Alnylam Product-Specific
Patents to Genzyme). In such event, Genzyme will execute and deliver a patent assignment relating to such Alnylam Product-Specific Patents in the same form used to assign such Patent Rights to Genzyme; and 

(d) each Party shall promptly pay any amounts owed to the other Party as of the effective date of such termination. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -75- 

 CO-CO LICENSE TERMS 

 

 12.4. Fundamental Breach of Alnylam’s Development Obligations. Without
limiting Genzyme’s rights under Section 12.2.2 (Termination for Cause) with respect to other material breaches, in the event that Alnylam commits a Fundamental Breach of its Development obligations under Section 2.4.2 (Alnylam
Diligence) with respect to any particular Co-Co Licensed Product, and Genzyme does not terminate these Co-Co License Terms in their entirety (i.e., with respect to all Co-Co Licensed Products) or with respect to such Co-Co
Licensed Product for cause pursuant to Section 12.2.2 (Termination for Cause), then Genzyme may elect to receive the following remedies for such Fundamental Breach: 

12.4.1. Genzyme’s obligation to pay development milestone fees under Section 8.1 (Development Milestone Fees) with respect to
such Co-Co Licensed Product shall automatically terminate; 
 12.4.2. Genzyme will receive a credit, which Genzyme may offset
against royalties and other amounts payable under these Co-Co License Terms due to Alnylam with respect to such Co-Co Licensed Product pursuant to Section 8 (Financial Terms for Genzyme Territory), in an amount equal to one hundred fifty
percent (150%) of all costs and expenses (i) incurred by Genzyme to Develop such Co-Co Licensed Product for the Genzyme Territory that are in excess of the costs budgeted by Genzyme in connection with the Genzyme Territory Development Plan
for such Co-Co Licensed Product in effect at the time of Alnylam’s Fundamental Breach of Section 2.4.2 (Alnylam Diligence) with respect to such Co-Co Licensed Product and (ii) are incurred by Genzyme as a direct consequence of
Alnylam’s Fundamental Breach of Section 2.4.2 (Alnylam Diligence) with respect to such Co-Co Licensed Product; 
 12.4.3.
Genzyme may, in its discretion, terminate any or all of the following provisions of these Co-Co License Terms (or any subsection thereof) with respect to such Co-Co Licensed Product: Section 3.1.4 (Meetings with Regulatory Authorities),
Section 4.1.2 (Co-Co Territory), Section 4.2.1 (Co-Co Territory Commercialization Plan), Section 4.3 (Genzyme Territory Commercialization Plan), Section 4.4 (Advertising and Promotional Materials), Section 4.5
(Commercialization Reporting Obligations) and Section 5 (Collaboration Management); and 
 12.4.4. Without limiting
Genzyme’s remedies under these Co-Co License Terms or otherwise with respect to breaches of Alnylam’s Development obligations under clause (a) of Section 2.4.2 (Alnylam Diligence) other than Fundamental Breaches, if Genzyme
elects to receive the remedies set forth in this Section 12.4 with respect to a Fundamental Breach of its Development obligations under clause (a) of Section 2.4.2 (Alnylam Diligence) with respect to any Co-Co Licensed Product, such
remedies shall be Genzyme’s sole and exclusive remedies with respect to such Fundamental Breach and Genzyme shall have no right to seek any further remedies or damages against Alnylam and its Affiliates with respect to such Fundamental Breach
by Alnylam of clause (a) of Section 2.4.2 (Alnylam Diligence). 
 12.5. Effect of Expiration or Termination;
Survival. Any expiration or termination of these Co-Co License Terms (a) shall not relieve the Parties of any obligation accruing prior to such expiration or termination and (b) shall be without prejudice to the rights of either
Party against the other accrued or accruing under these Co-Co License Terms prior to expiration or termination, including the obligation to pay royalties for any Co-Co Licensed Product sold prior to such expiration or termination. The following
provisions shall survive any expiration or 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -76- 

 CO-CO LICENSE TERMS 

 

 
termination of these Co-Co License Terms in their entirety (i.e., with respect to all Co-Co Licensed Products) and, if these Co-Co License Terms expire or are terminated with respect
to any particular Co-Co Licensed Product, shall survive with respect to such Co-Co Licensed Product: (a) Sections 1 (Definitions), 9 (Financial Terms for Co-Co Territory), 10.3 (Warranty Disclaimer), 11.1 (Inventorship), 11.2 (Ownership), 12.3
(Effect of Termination), 12.5 (Effect of Termination or Expiration; Survival), Section 13 (Performance by Affiliates) of these Co-Co License Terms and (b) Sections 1 (Definitions), 7 (Confidentiality and Publication), 10 (Indemnification;
Limitation of Liability; Insurance), 12 (Term and Termination) and 13 (Miscellaneous) of the Master Agreement. Section 8.2.6 (Royalty Floor) shall survive any termination or expiration of these Co-Co License Terms with respect to any Co-Co
Licensed Product for royalties accruing prior to such termination or expiration. Section 9 of the Master Agreement (Royalty Reports; Payments; Audit) will survive for so long as any royalties are due under these Co-Co License Terms plus three
(3) years. Except as otherwise set forth in this Section 12 or elsewhere in these Co-Co License Terms, upon termination or expiration of these Co-Co License Terms in their entirety, all rights and obligations of the Parties under these
Co-Co License Terms shall cease, but, for clarity, expiration or termination of these Co-Co License Terms in their entirety (i.e., with respect to all Co-Co Licensed Products) shall not result in the termination or expiration of the Master
Agreement or any other License Terms. Upon termination or expiration of these Co-Co License Terms with respect to any particular Co-Co Licensed Product, all rights and obligations of the Parties under these Co-Co License Terms with respect to such
Co-Co Licensed Product shall cease except as otherwise set forth in this Section 12 or elsewhere in these Co-Co License Terms, but, for clarity, such termination or expiration shall not affect the Parties’ rights and obligations under
these Co-Co License Terms with respect to the other Co-Co Licensed Product.  
 13. PERFORMANCE BY AFFILIATES 

13.1. Use of Affiliates. Each Party acknowledges and accepts that the other Party may exercise its rights and perform its
obligations under these Co-Co License Terms either directly or through one or more of its Affiliates. A Party’s Affiliates will have the benefit of all rights (including all licenses) of such Party under these Co-Co License Terms. Accordingly,
in these Co-Co License Terms “Genzyme” will be interpreted to mean “Genzyme and/or its Affiliates” and “Alnylam” will be interpreted to mean “Alnylam and/or its Affiliates” where necessary to give each
Party’s Affiliates the benefit of the rights provided to such Party in these Co-Co License Terms; provided, however, that in any event each Party will remain responsible for the acts and omissions, including financial liabilities,
of its Affiliates.  
 13.2. Future Acquisition of a Party or its Business. [***] 

13.3. Acquired Programs. 

13.3.1. [***] 

13.3.2. [***]  

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -77- 

 CO-CO LICENSE TERMS 

 

 13.3.3. For clarity, upon the closing of the acquisition of the stock and/or assets of
Sirna Therapeutics, Inc. by Alnylam from Merck Sharpe & Dohme Corp., all relevant acquired intellectual property rights acquired in such transaction that may be Controlled by Alnylam (without any further action by Alnylam or Sirna
Therapeutics, Inc.) shall become Controlled by Alnylam for the purposes of these Co-Co License Terms. 
 [THE REMAINDER OF THIS PAGE HAS
BEEN LEFT INTENTIONALLY BLANK] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -78- 

 CO-CO LICENSE TERMS 

 

 Schedule 1.2.14-1 

ALNYLAM CORE TECHNOLOGY PATENTS FOR ALN-TTRsc 

See attached. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -79- 

 CO-CO LICENSE TERMS 

 

 Schedule 1.2.19-1 

ALNYLAM PRODUCT-SPECIFIC PATENTS FOR ALN-TTRsc 

See attached. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -80- 

 CO-CO LICENSE TERMS 

 

 Schedule 2.2.2.1-1 

GLOBAL DEVELOPMENT STRATEGY FOR ALN-TTRsc 

(To be attached when developed pursuant to Section 2.2.2.1.) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -81- 

 CO-CO LICENSE TERMS 

 

 Schedule 2.2.2-1 

GLOBAL DEVELOPMENT PLAN FOR ALN-TTRsc 

(To be attached when developed pursuant to Section 2.2.2.) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -82- 

 CO-CO LICENSE TERMS 

 

 Schedule 2.2.3-1 

GENZYME TERRITORY DEVELOPMENT PLAN FOR ALN-TTRsc 

(To be attached when developed pursuant to Section 2.2.3.) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -83- 

 CO-CO LICENSE TERMS 

 

 Schedule 2.7 

TTRSC/02 ARBITRATION CRITERIA 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 1 page was omitted. 

[***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -84- 

 CO-CO LICENSE TERMS 

 

 Schedule 4.2-1 

CO-CO TERRITORY COMMERCIALIZATION PLAN FOR ALN-TTRsc 

(To be attached when developed pursuant to Section 4.2.) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -85- 

 CO-CO LICENSE TERMS 

 

 Schedule 10.1-1 

DISCLOSURE SCHEDULE 

See attached. 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -86- 

 CO-CO LICENSE TERMS 

 

 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 2
pages were omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -87- 

 CO-CO LICENSE TERMS 

 

 Schedule 10.1.12 

(A) EXISTING ALNYLAM IN-LICENSES 

(To be attached) 
 (B)
ADDITIONAL ALNYLAM IN-LICENSES 
 (To be attached) 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -88- 

 CO-CO LICENSE TERMS 

 

 Schedule 10.4.1.4 

EXCEPTIONS TO EXCLUSIVITY 
 Confidential
Materials omitted and filed separately with the Securities and Exchange Commission. A total of 1 page was omitted. 
 [***] 

  
 CERTAIN CONFIDENTIAL PORTIONS OF THIS
EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 
 -89-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]